cluster,concept,cuis
1399,enzyme inducing,C0014442;C4521602
1399,non - enzyme inducing,C0014442;C1518422;C4521602
1398,dual ii - end of trial hbanmbrc,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
1398,dual iv - end of trial hbanmbrc,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
1397,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
1397,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
1396,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
1396,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
1396,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
1395,placebo - famotidine nmbr,C0015620;C0032042;C1696465;C1706408
1395,placebo - famotidine nmbr - famotidine nmbr,C0015620;C0032042;C1696465;C1706408
1394,febuxostat - febuxostat / lesinurad nmbr - febuxostat / lesinurad nmbr,C0249529;C3886073
1394,febuxostat - febuxostat / lesinurad nmbr,C0249529;C3886073
1393,placebo - vonoprazan nmbr,C0032042;C1696465;C1706408;C4080009
1393,placebo - vonoprazan nmbr - vonoprazan nmbr,C0032042;C1696465;C1706408;C4080009
1392,zoledronic acid ( n = nmbr ),C0257685
1392,zoledronic acid,C0257685
1391,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1391,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1390,week nmbr czp dose combined ( n   =   nmbr ),C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1390,week nmbr czp dose combined,C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
1389,walk for exercise ( % ),C0015259;C0080331;C1522704
1389,walk for exercise,C0015259;C0080331;C1522704
1388,voiding subscore,C0042034;C4067975
1388,voided volume,C0042034;C0449468;C1552835;C1690016;C1705102;C2700258
1387,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1387,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1387,vascular risk score — no . { % ) ^,C0005847;C0035647;C1558950;C1801960;C4552904
1386,valve replacement / repair with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
1386,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
1386,valve repair / replacement with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
1385,ustekinumab ® ( n = nmbr ),C1608841
1385,ustekinumab,C1608841
1385,ustekinumab ' ’ ( n = nmbr ),C1608841
1385,ustekinumab combined,C1608841
1384,verapamil ( n,C0042523
1384,use of verapamil or quinidine,C0042523;C1524063
1383,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0456389
1383,weekly number of hives scorenmbr,C0042109;C0237753;C0332174;C0449788
1383,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788
1383,urticaria,C0042109;C1559188
1382,upa nmbr mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
1382,upa nmbrmg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
1381,trandolapril ( n = nmbr ),C0076891
1381,trandolapril,C0076891
1380,total bleeds,C0232100
1380,total bleeding,C0232100
1379,total bilirubin,C0005437;C0368753
1379,total bilirubin > nmbr x ulnnmbr,C0005437;C0368753;C1519815
1378,topical prescription,C0033080;C0332237;C1521941
1378,topical non - prescription,C0033080;C0332237;C1518422;C1521941
1377,tolvaptan,C1176308
1377,tolvaptan ( n = nmbr ),C1176308
1376,tj ( nmbr % ),C0039247
1376,tj ( nmbr - nmbr ),C0039247
1375,tiotropium nmbr . nmbr pg,C0030827;C0072225;C0213771;C1266240
1375,tiotropium nmbr pg,C0030827;C0072225;C0213771;C1266240
1374,time from index acs event to randomisation ( days ),C0040223;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
1374,time between index acs and randomization — days,C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1374,time between index acs and randomization ( days ),C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
1373,teriparatide ( n   =   nmbr ),C0070093
1373,teriparatide n / n ( % ),C0070093
1372,tanezumab nmbr . nmbr mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1372,tanezumab nmbr mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1371,tanezumab nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1371,tanezumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1370,tanezumab ( all doses combined ) + nsaida,C2346819
1370,tanezumab ( all doses combined ),C2346819
1369,tamsulosin nmbr . nmbrmg vs . nmbr . nmbrmg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1369,tamsulosin nmbr . nmbr mg vs . placebo,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1369,tamsulosin nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1368,tamsulosin ( w = nmbr ),C0257343
1368,with tamsulosin,C0257343
1368,tamsulosin ( n = nmbr ),C0257343
1368,tamsulosin,C0257343
1368,without tamsulosin,C0257343
1367,tadalafil nmbr mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
1367,tadalafil nmbr . nmbr mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1367,tadalafil nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1367,tadalafil nmbr mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1367,tadalafil nmbr . nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1367,tadalafil nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1367,tadalafil nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1366,table nmbr . characteristics of patients treated with losartan and atenolol *,C0039224;C0815172;C1706074
1366,table nmbr . characteristics of the patients at baseline . *,C0039224;C0815172;C1706074
1366,table nmbr . selected baseline characteristics of the study patients . *,C0039224;C1706074
1365,ta,C0039297;C1506978;C1705538;C3272501;C4553364
1365,ta ( n = nmbr ),C0039297;C1506978;C1705538;C3272501;C4553364
1364,symptomatic hypotension with sbp < nmbr mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
1364,symptomatic hypotension ( sbp < nmbr mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
1363,table nmbr baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0168634;C0370003;C0947343;C1315074;C1442488;C1706074;C2347026;C4684572
1363,supplementary table nmbr . change from baseline in urine albumin - to - creatinine ratio by hbanmbrc at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0039224;C0168634;C0392747;C0443172;C1442488;C1705241;C1706074;C4319952
1362,subgroup statistics,C0038215;C0600673;C1079230;C1515021
1362,statistics,C0038215;C0600673
1361,spirometry,C0037981
1361,spirometry after bronchodilation §,C0037981;C1371299;C3537072
1360,spain,C0037747
1360,spain ( n = nmbr ),C0037747
1359,sotagliflozin,C3896939
1359,sotagliflozin ( n = nmbr ),C3896939
1358,so,C0037640
1358,so nmbr %,C0037640
1357,semaglutide ( n = nmbr ),C3885068
1357,semaglutide,C3885068
1357,semaglutide exposure,C0274281;C0332157;C3885068
1356,sample size,C0242618
1356,sample size ( n ),C0242618
1355,rotigotine ( n = nmbr ),C1700683;C4318637
1355,rotigotine n = nmbr,C1700683;C4318637
1354,rosiglitazone nmbr mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1354,rosiglitazone nmbr mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
1353,risedronate ( n = nmbr ),C0246719
1353,risedronate n / n ( % ),C0246719
1353,risedronate ( n   =   nmbr ),C0246719
1352,right ventricular dysfunction,C0242707;C1556315
1352,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C1556315
1351,relative risk ( nmbr % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0039798;C0087111;C0242492;C0596019;C1363945;C1707455
1351,relative risk comparing icd therapy and placebo,C0021122;C0039798;C0087111;C0242492;C1363945;C1707455
1350,pvr volume,C0242852;C0449468;C0456261;C1419141;C1690016;C1705102;C2700258
1350,pvr,C0242852;C0456261;C1419141
1349,previous exposure to non - biologic systemic psoriasis therapyb ( yes ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
1349,previous exposure to biologic systemic psoriasis therapyb ( yes ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
1348,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
1348,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
1347,pre - bd fvc snmbr % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
1347,pre - bd fvc < nmbr % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
1346,postprandial indices,C0376674;C4033634
1346,ppg post - meal test,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C3831328;C4318744
1345,spine,C0037949;C2752558
1345,spine *,C0037949;C2752558
1345,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
1344,platelet aggregation inhibitors,C0032177
1344,platelet aggregation inhibitors excluding heparin,C0032177
1343,placebo + insulin ( n = nmbr ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
1343,placebo + insulin ( n   = nmbr ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
1342,phototherapy previous systemic treatment,C0031765;C0205156;C0678812;C1552607
1342,phototherapy,C0031765
1341,patients with pneumonia resulting in death,C0030705;C0032285
1341,patients with pneumonia event,C0030705;C0032285;C0441471;C4019010
1341,patients with pneumonia events,C0030705;C0032285;C0441471;C3541888
1340,patients with glycated hemoglobin < nmbr . nmbr % and no severe hypoglycemia or diabetic ketoacidosis,C0017853;C0030705
1340,patients with glycated hemoglobin > nmbr . nmbr % and > nmbr episode of severe hypoglycemia *,C0017853;C0030705
1340,patients with glycated hemoglobin > nmbr . nmbr % and > nmbr episode ofdiabetic ketoacidosis *,C0017853;C0030705
1339,patients with no prior cvd ( primary,C0007222;C0030705;C0332152;C2826257
1339,patients with established cv disease aged > nmbr years .,C0007222;C0030705;C0443211;C1272684;C1510829
1338,patients with early cd ( n = nmbr ),C0007928;C0030705;C0034283;C1279919;C4552032
1338,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
1337,patients without dm ( n = nmbr,C0011816;C0030705;C3250443
1337,patients with possible new dm at randomization ( fpg > nmbr - nmbr ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
1337,patients with dm ( n = nmbr ),C0011816;C0030705;C3250443
1337,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
1337,patients without dm ( n = nmbr ),C0011816;C0030705;C3250443
1337,patients with possible new dm at randomization ( hbanmbrc > nmbr . nmbr - nmbr % ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
1336,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
1336,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
1335,randomised patients with > nmbr % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1335,patients with > nmbr % bsa psoriasis skin involvement,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
1334,patients with > nmbr co - aeds,C0030705;C0180309;C3245499
1334,patients with nmbr co - aeds,C0030705;C0180309;C3245499
1333,patients in analysis,C0002778;C0030705;C0936012;C1524024
1333,patients ( full analysis sety ),C0002778;C0030705;C0443225;C0936012;C1524024
1332,pnd,C1417807;C1956415;C4552608
1332,paroxysmal nocturnal dyspnea,C1956415
1331,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
1331,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
1330,pah - ssc,C0030123;C3203102;C3897657;C4284467
1330,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
1329,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0242960;C0289313;C1709380
1329,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0019409;C0242960;C0289313;C1709380
1328,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
1328,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
1327,other plain vitamin preparations,C0042890
1327,vitamins,C0042890;C3540032;C3714649
1326,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
1326,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
1326,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
1325,on bp medication,C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
1325,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
1324,om nmbr / aml nmbr / hctz nmbr . nmbr mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1324,om nmbr / aml nmbr / hctz nmbr mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1324,om nmbr / aml nmbr / hctz nmbr . nmbr mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1323,olodaterol nmbr | ig tiotropium n = nmbr non - tiotropium n = nmbr,C0021027;C0305052;C0360506;C1518422;C4032878
1323,olodaterol nmbr nmbr | ig tiotropium n = nmbr non - tiotropium n = nmbr,C0021027;C0305052;C0360506;C1518422;C4032878
1322,olmesartan / ccb - olmesartan / diuretic,C0006684;C1098320
1322,olmesartan along with ccb ( n - nmbr ),C0006684;C1098320
1321,oat ( n   =   nmbr ),C0028753;C0331496;C0939905;C3539067;C3897364
1321,oma / oat ( n   =   nmbr ),C0028753;C0331496;C0939905;C3539067;C3897364
1321,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
1321,oat,C0028753;C0331496;C0939905;C3539067;C3897364
1320,subjects with prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
1320,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
1320,prevalent vertebral fracture,C0033105;C0080179;C0220900
1320,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
1319,np tercile nmbr ( bnp > nmbr pg / ml,C0054015;C0065827;C0439297;C1095989;C1417808;C1706141;C2982014;C3887659
1319,np tercile nmbr ( bnp < nmbr pg / ml,C0054015;C0065827;C0439297;C1095989;C1417808;C1706141;C2982014;C3887659
1318,spondylitis with peripheral arthritis,C0038012;C0238694
1318,spondylitis,C0038012
1318,non - spondylitis,C0038012;C1518422
1317,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1317,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
1316,with ckd intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453;C1561643
1316,no - ckd intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453;C1561643
1315,nintedanib ( n   =   nmbr ),C2930789
1315,nintedanib ( n = nmbr ),C2930789
1314,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
1314,net adverse clinical events at day nmbr,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
1314,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
1314,net ep nmbr,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
1313,necrosis,C0027540;C1334928
1313,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
1312,nc group ( n = nmbr ),C0027964;C0028407;C0067895;C0265987;C0441848
1312,nc,C0027964;C0028407;C0067895;C0265987
1311,nail involvement,C0027342;C1314939;C1432728;C3538766
1311,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
1311,target nail napsi score ( nmbr – nmbr scale ),C0027342;C1432728;C1521840;C2986546;C3538766
1310,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
1310,nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
1310,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
1309,multivariate logistic modelb,C0242415
1309,univariate logistic modela,C0242415
1308,sustained mucosal healingc,C0026724;C0443318
1308,sustained mucosal healingc n / n ( % ),C0026724;C0443318
1308,mucosal healingf,C0026724
1308,mucosal healingc n / n ( % ),C0026724
1307,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
1307,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
1306,severe cord * : qvainmbr - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
1306,moderate cord * : qvanmbr - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
1305,metformin + su,C0025598;C0038642;C1705534
1305,metformin ? su,C0025598;C0038642;C1705534
1305,metformin + su + tzd,C0025598;C0038642;C1705534
1304,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
1304,mesalamine use,C0042153;C0127615;C0457083;C1947944
1303,mental activities updrs subscore ( baseline ),C0168634;C0229992;C0441655;C1442488;C3639721
1303,motor updrs subscore ( baseline ),C0168634;C1442488;C1513492;C1705994;C3639721
1302,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1302,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1302,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1302,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1301,sbp ( mean over nmbr h ),C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1301,mean nmbr - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1300,mean ( se ) auc^p l,C0036919;C0376690;C0444504;C2347634;C2348143
1300,mean ( se ) aucnmbr - nmbr,C0036919;C0376690;C0444504;C2347634;C2348143
1299,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
1299,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
1299,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
1298,maintenance use — no . ( % ),C0024501
1298,maintenance ocs use,C0024501
1298,pnmbrynmbr inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
1297,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
1297,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
1296,lvh by echocardiogram,C0013516;C0149721;C2243117
1296,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
1296,lvh by echocardiography,C0013516;C0149721
1295,lv function > nmbr . nmbr and < nmbr . nmbr,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1295,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
1294,luts = lower urinary tract symptoms  is =,C0574785
1294,luts severity,C0439793;C0522510;C0574785
1293,lumbar,C0024090
1293,t - score categories lumbar spineb,C0024090;C0683312;C3854607
1292,ls mean [nmbr % ci] treatment difference vs placebo,C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1292,ls mean treatment difference ( nmbr % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1292,ls - mean difference between treatment groups ( nmbr % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1291,low renin ( pra < nmbr . nmbr ng / ml / h ) ( n = nmbr ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
1291,pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
1291,normal - high renin ( pra > nmbr . nmbr ng / ml / h ) ( n = nmbr ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
1290,lixisenatide,C2973895
1290,lixisenatide ( n = nmbr ),C2973895
1290,lixisenatide ( n = nmbro ),C2973895
1289,lipid trial participantss,C0008976;C0023779
1289,lipid trial participantsk,C0008976;C0023779
1288,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
1288,lipid concentrations,C0023779;C0086045
1287,lifestyle behaviors,C0004927;C0023676;C0677505
1287,lifestyle behaviours,C0004927;C0023676;C0677505
1286,lei > nmbr ( n = nmbr ),C0023401;C0428209
1286,leinmbr,C0023401;C0428209
1286,lei,C0023401;C0428209
1285,lebrikizumab nmbr - nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1285,lebrikizumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1285,lebrikizumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1285,lebrikizumab nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1284,ldlc : hdlc,C1416822;C1704429
1284,non - hdlc,C1518422;C1704429
1283,lathosterol ( jimol / l ),C0064673
1283,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
1282,previous labd alone,C0205156;C0396059;C1552607
1282,labd alone,C0396059
1282,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
1281,itch nrs nmbr - nmbr ( . \ ' = nmbr ),C0033774;C1422257;C2240043;C4050142
1281,itch nrs nmbr - nmbr ( at = nmbr ),C0033774;C1422257;C2240043;C4050142
1281,itch nrs nmbr - nmbr ( a ' = nmbr ),C0033774;C1422257;C2240043;C4050142
1281,itch nrs nmbr - nmbr ( v = nmbr ),C0033774;C1422257;C2240043;C4050142
1281,itch nrs nmbr ( v = nmbr ),C0033774;C1422257;C2240043;C4050142
1281,itch nrs,C0033774;C1422257;C2240043;C4050142
1280,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
1280,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
1279,proximal gl tract,C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
1279,involved gl areas,C0018229;C1423073;C1427674;C1879646
1278,intracranial bleed,C0151699
1278,intracranial bleeding,C0151699
1278,intracranial hemorrhage †,C0151699;C4554169
1278,intracranial hemorrhage,C0151699;C4554169
1277,insulins and analogs,C0021641;C3537244;C4049919
1277,insulins,C0021641;C3537244;C4049919
1276,insulin lispro mix nmbr,C0205430;C0293359;C1421951;C1720722;C4553942
1276,insulin lispro mix nmbr / lispro mix nmbr - insulin glargine / insulin lispro,C0293359
1275,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C2344255;C4050145
1275,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C2344255;C4050145
1274,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
1274,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
1273,injection - site reaction,C0151735;C4551923
1273,potential injection site reactions,C0151735;C3245505
1272,serious infections,C0205404;C3714514
1272,infections and infestations,C3714514
1272,infections,C3714514
1271,individuals with prediabetes,C0027361;C0237401;C0362046
1271,individuals with pre - diabetes,C0027361;C0237401;C0362046
1270,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
1270,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
1269,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
1269,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
1268,inadequate response ( > nmbr months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
1268,mmf ( n = nmbr ),C0083765;C0209368;C3848524
1267,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
1267,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0802604;C1510665;C2598133;C4284232
1266,impaired cognitive function ( spmsq > nmbr ) . n - nmbr n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
1266,normal cognitive function ( spmsq < nmbr ) . n - nmbr . nmbr n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
1265,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
1265,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
1264,ideglira - ideg,C4308663
1264,ideglira,C4308663
1264,ideglira - ideg - lira,C1555441;C4308663
1263,ics / labd,C0396059;C0815320;C4551720
1263,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
1262,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1262,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
1261,ics dose of stable maintenance treatment ( μ g ) ∗,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
1261,ics / laba therapy,C0039798;C0087111;C0815320;C1363945;C4551720
1260,ics ( tiotropium n = nmbr,C0213771;C0815320;C4551720
1260,laba plus ics ( tiotropium n = nmbr,C0213771;C0332287;C0815320;C4551720
1259,ich,C0019191;C3272597;C3281105
1259,symptomatic ich,C0019191;C0231220;C3272597;C3281105
1258,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
1258,i vitamin e ( n = nmbr ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
1257,i placebo ( n = nmbr ),C0021966;C0032042;C0221138;C1696465;C1706408
1257,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
1256,i lisinopril ( n = nmbr ),C0021966;C0065374;C0221138
1256,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
1255,i - nmbr mg / d ( n = nmbr ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
1255,mean daily dose ( range ) — mg  i ,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
1254,hypovolaemia,C0546884
1254,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
1253,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
1253,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
1252,history of lvh on electrocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
1252,history of lvh on echocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
1251,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
1251,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
1250,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1250,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1249,high trs : nmbr - nmbr ( n = nmbr,C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1249,moderate trs : nmbr - nmbr ( n = nmbr,C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
1249,low trs : nmbr - nmbr ( n = nmbr,C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
1248,low nafld fibrosis score ( nfs < - nmbr . nmbr ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
1248,high nafld fibrosis score ( nfs > nmbr . nmbr ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
1247,liver disorder,C0023895
1247,hepatic disorders,C0023895
1246,heparin ± tirofiban ( n = nmbr ),C0019134;C0247025;C0770546
1246,heparin plus tirofiban ( n = nmbr ),C0019134;C0247025;C0332287;C0770546
1246,heparin + tirofiban ( n = nmbr ),C0019134;C0247025;C0770546
1245,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
1245,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
1244,nateglinide and repaglinide,C0903898
1244,nateglinide ( n = nmbr ),C0903898
1244,hazard ratio ( nmbr % cl ) nateglinide vs . placebo,C0596019;C0903898;C2985465
1244,nateglinide n / n,C0903898
1243,hand,C0018563;C1552914
1243,total hands score,C0018563;C0439175;C0439810;C1552914
1243,psa ‐ modified shs of hands and feet,C0018563;C0392747;C1552914;C3810537;C3813209;C3889737
1243,hands,C0018563;C1552914
1242,gt,C1435727;C1704693;C2697657
1242,p value by gt,C1435727;C1704693;C1709380;C2697657
1241,golimumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1241,golimumab nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1241,golimumab nmbr mg / nmbr mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1241,golimumab nmbr mg ( n = nmbr ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1240,glycopyrrolate / eflow cs nmbr meg ( n = nmbr ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
1240,glycopyrrolate / glycopyrrolate / eflow cs nmbr meg eflow cs nmbr meg ( n = nmbr ) ( n = nmbr ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
1239,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
1239,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
1238,glunmbrasp g . t,C0125690;C0439267
1238,nosnmbr glunmbrasp g . t,C0125690;C0326287;C0439267;C1518425
1237,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
1237,gastrointestinal disorders,C0017178
1236,fgf - nmbr low / egfr < nmbr,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
1236,fgf - nmbr high / egfr > nmbr,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
1236,fgf - nmbr high / egfr < nmbr,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
1236,fgf - nmbr low / egfr > nmbr,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
1235,fgf - nmbr high / < nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1235,fgf - nmbr high / > nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1235,fgf - nmbr low / < nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1235,fgf - nmbr low / > nmbr elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1234,ff / vi nmbr % ( nmbr % ci nmbr – nmbr % ),C0008107;C0205999;C3259781;C4554348
1234,vi – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781
1234,vi nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781
1234,vi nmbr % ( nmbr % ci nmbr – nmbr % ),C0008107;C0205999;C3259781
1234,ff / vi – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C0205999;C3259781;C4554348
1233,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
1233,ff mdi,C0993596;C1839839;C4049613;C4554348
1233,gff mdi,C0993596;C1839839;C4049613
1233,mdi,C0993596;C1839839;C4049613
1232,fevnmbr / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
1232,fevnmbr   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
1231,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
1231,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
1230,febuxostat nmbr mg daily n = nmbr,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1230,febuxostat nmbr mg n = nmbr,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
1230,febuxostat nmbr mg daily n = nmbr % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1230,febuxostat nmbr mg daily n = nmbr n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1230,febuxostat nmbr mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
1230,febuxostat nmbr mg ( n = nmbr ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
1229,fdc nmbr / nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1229,fdc nmbr / nmbr pg vs aclidinium nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1229,fdc nmbr / nmbr pg vs formoterol nmbr pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1229,fdc nmbr / nmbr pg vs placebo,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1228,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
1228,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
1227,idiopathic / familial,C0015576;C0241888;C0332240
1227,familial,C0015576;C0241888
1226,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
1226,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
1226,extent of index pe ' ( n,C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
1225,evolocumab,C3529352
1225,evolocumab ( n = nmbr ),C3529352
1225,evolocumab + soc ( n = nmbr ),C3529352
1224,estradiol ( enmbr ) ( pmol / l ),C0014912;C0439284
1224,estradiol ( pmol / l ),C0014912;C0439284
1224,estradiol quartiles,C0014912;C2828255
1223,esophageal hiatal hernia *,C3489393
1223,hiatus hernia,C3489393
1223,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
1222,eq - nmbrd mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1222,eq - nmbrdprofile - mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
1221,eligibility stratum,C0013893;C1548635
1221,eligibility strata,C0013893;C1548635
1220,elevated natriuretic peptides in previous nmbr days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1220,elevated natriuretic peptide level ( n = nmbr ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
1220,elevated natriuretic peptides in previous nmbr days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1219,electrocardiography,C0013798;C1623258
1219,electrocardiogram,C0013798;C1547122;C1623258
1218,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
1218,elective surgery,C0206058
1217,egfr by creatinine ( ml / min per nmbr · nmbr mnmbr,C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
1217,egfr by creatinine ( ml / min per nmbr · nmbr mnmbr ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
1216,e major non - vertebral fragility fractures ( fas ),C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
1216,morphometric vertebral,C0200760;C0549207
1215,dutasteride ( n = nmbr ),C0754659
1215,dutasteride ( w = nmbr ),C0754659
1215,dutasteride,C0754659
1214,dulaglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1214,dulaglutide nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1214,dulaglutide nmbr · nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1214,dulaglutide nmbr . nmbr mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1213,dihydropyridine ccbs,C0006684;C0012315;C0220821
1213,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
1212,ratio mepo / pbo ( nmbr % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
1212,rate ratio mepo / pbo ( nmbr % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
1212,difference mepo - pbo ( nmbr % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
1211,difference ( n - nmbr fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
1211,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
1210,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
1210,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
1209,systoiic biood pressure,C0033095;C0460139;C1306345;C4284008
1209,diastoiic biood pressure,C0033095;C0460139;C1306345;C4284008
1209,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
1209,pressure,C0033095;C0460139;C1306345;C4284008
1208,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
1208,diabetic therapy use,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
1207,iga mod nmbr score,C0011860;C0449820;C2825347;C4050231
1207,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1207,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
1207,diabetes type ii,C0011860
1207,type ii diabetes,C0011860
1206,dexlansoprazole mr nmbr mg,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1206,dexlansoprazole mr nmbr mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1205,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1205,dexlansoprazole mr ( n = nmbr ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1204,delayed - eptifibatide group ( n = nmbr ),C0205421;C0253563;C0441848;C1545665;C3272602
1204,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
1204,early eptifibatide,C0253563;C1279919
1204,early - eptifibatide group ( n = nmbr ),C0253563;C0441848;C1279919
1203,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1203,death due to renal failure or sustained esrd,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1202,de ( n = nmbr ),C0011198;C0017480;C3541240
1202,denmbr n = nmbr,C0011198;C0017480;C3541240
1202,de,C0011198;C0017480;C3541240
1201,mean nmbr - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
1201,dbp ( mean over nmbr h ),C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
1200,dapagliflozin nmbr mg + insulin ( n   = nmbr ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
1200,dapagliflozin nmbr mg + insulin ( n = nmbr ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
1199,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
1199,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
1198,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
1198,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
1197,favors dabigatran,C0309049;C2348066
1197,dabigatran,C2348066
1197,dabigatran nmbr mg nmbr mg % per yr,C0439234;C1319635;C2348066
1197,dabigatran ( n = nmbr ),C2348066
1197,factors dabigatran,C1521761;C2348066;C2827422
1197,dabigatran nmbr vs dabigatran nmbr mg bid,C2348066
1197,dabigatrannmbr vs . warfarin p ( inter ),C2348066
1197,hazard ratio with dabigatran,C2348066;C2985465
1196,dnmbr vs warfarin rr ( nmbr % ci,C0073187;C0332173;C4484261
1196,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
1196,d includes cardiac glycosides,C0073187;C0332173;C4484261
1196,d,C0073187;C0332173;C4484261
1196,dnmbr % ( n / n ),C0073187;C0332173;C4484261
1196,dnmbr vs warfarin,C0073187;C0332173;C4484261
1195,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
1195,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
1195,cvd / stroke / see,C0007222;C0038454;C4554100
1194,cvd mortality,C0007222;C0026565;C0026566
1194,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
1193,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
1193,hormones,C0019932
1192,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
1192,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
1191,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
1191,duration alendronate use,C0042153;C0102118;C0449238;C0457083;C1947944;C2926735
1190,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1190,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
1189,x cr nmbr . nmbr x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1189,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
1188,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
1188,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
1187,time from end of fit,C0036572;C1522314;C2349186;C4048158;C4553125
1187,convulsion,C0036572;C4048158
1186,continued use of gpa,C0549178;C1524063;C3495801;C4553145
1186,new use of gpa,C0205314;C1524063;C3495801;C4553145
1185,concomitant treatments at randomization,C0034656;C0087111;C0521115
1185,randomized treatments,C0034656;C0087111;C3815594
1185,treatments at randomisation,C0034656;C0087111
1184,oral anti - dm drug status,C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
1184,concomitant oral anti - dm drugs,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
1183,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
1183,participated in a previous febuxostat studyb,C0205156;C0249529;C1552607
1183,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
1183,febuxostat,C0249529
1182,combined therapy vsdutasteride,C0033972
1182,combined therapy ( / v = nmbr ),C0033972
1181,golimumab combined ( n = nmbr ),C0205195;C2353893
1181,combined golimumab groups,C0205195;C2353893
1181,golimumab,C2353893
1180,no colchicine ( n = nmbr ),C0009262
1180,colchicine ( n = nmbr ),C0009262
1179,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
1179,non cns embolism,C0013922;C1518422;C1704212;C3714787
1178,ck > nmbr x ulnnmbr,C0009212;C0010287;C1519815;C1872855
1178,ck > nmbrxuln,C0009212;C0010287;C1872855
1177,lung,C0024109
1177,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
1177,pulmonary embolismb,C0024109;C2707265;C2709248;C4522268
1177,pulmonary embolisma,C0024109;C2707265;C2709248;C4522268
1176,characteristic_name,C0027365;C1521970;C1547383;C4522128
1176,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
1176,subgoup_name,C0027365;C1547383;C4522128
1175,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
1175,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
1175,central / south america and mexico,C0007674;C0037713;C0205099;C1710133;C1879652
1174,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0149871;C1314792;C2926618;C3899446
1174,causes of dvt or pe,C0015127;C0149871;C1314792;C2926618;C3899446
1173,caucasian race,C0007457
1173,caucasian race ( % ),C0007457
1172,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
1172,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
1171,cardiogenic shock during first nmbr hr after randomization,C0036980;C0205435;C1279901
1171,cardiogenic shock,C0036980
1170,by gfr stratum tor all participants,C0017654;C0076836;C1199517;C1419603;C1424601;C3539732
1170,by gfr stratum tor diabetic participants,C0017654;C0076836;C0241863;C0679646;C1199517;C1419603;C1424601;C3539732
1169,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
1169,fdc nmbr / nmbr   μ g ( n   =   nmbr ),C0340427;C0439267;C1413520;C3539652
1168,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
1168,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
1167,bp goal,C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
1167,bp goal at week nmbr,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
1166,both iv vasodilator and inotrope,C0022326;C0042402;C3537240;C4265176
1166,iv vasodilator,C0022326;C0042402;C3537240;C4265176
1165,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1165,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
1164,body mass index group ( ≥ nmbr kg / mnmbr ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
1164,body mass index group ( kg / mnmbr ) ≥ nmbr kg / mnmbr — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
1163,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1163,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1162,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
1162,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
1161,blood eosinophil count cells / mmnmbr no .,C0005773;C0200638;C0750879;C4330985;C4554674
1161,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
1160,biomarker low,C0005516
1160,elevated biomarkers and st - segment changes,C0005516;C0205250;C3163633
1160,biomarker high,C0005516
1160,biomarker levels,C0005516;C0441889
1159,benralizumab,C2982078
1159,benralizumab qnmbrw ( n = nmbr ),C2982078
1159,benralizumab qnmbrw ( n - nmbr ),C2982078
1158,without baseline vertebral fracture,C0080179;C0168634;C1442488
1158,vertebral fractures at baseline,C0080179;C0168634;C1442488
1158,baseline vertebral fracture,C0080179;C0168634;C1442488
1158,with baseline vertebral fracture,C0080179;C0168634;C1442488
1157,baseline t - score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
1157,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
1157,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
1156,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
1156,baseline spirometry,C0037981;C0168634;C1442488
1155,baseline serum mg < nmbr . nmbr mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
1155,baseline serum mg > = nmbr . nmbr mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
1154,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
1154,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
1153,baseline use of adm,C0168634;C0215825;C1442488;C1524063;C4521767
1153,baseline numberf of adm classes,C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
1152,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
1152,baseline luts severity,C0168634;C0439793;C0522510;C0574785;C1442488
1151,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
1151,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
1151,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
1150,baseline fasting tgs,C0015663;C0168634;C1156212;C1442488;C1537574
1150,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
1149,baseline creatinine,C0010294;C0168634;C1442488;C1561535
1149,creatinine > nmbr x baseline,C0010294;C0168634;C1442488;C1561535
1149,creatinine > nmbr . nmbrx baseline and above uln,C0010294;C0168634;C1442488;C1561535
1148,baseline ckd egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
1148,baseline ckd egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
1147,patientswith bp $ nmbr / nmbr mmhg ( abpm ) at baseline,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
1147,baseline bp,C0037623;C0168634;C1415692;C1442488;C1708288;C4318478
1146,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541
1146,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
1145,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828
1145,aunivariate logistic regression .,C0206031
1145,logistic regression,C0206031
1144,atm - locus,C1708726;C3711796
1144,atm - locm,C3711796
1143,atherosclerotic vascular disease history,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1143,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1142,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
1142,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
1141,aspartate aminotransferase increased,C0004002
1141,aspartate aminotransferase,C0004002
1140,ard per nmbr nmbr patient - years ( nmbr % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
1140,event rates per nmbr patient - years ( nmbr % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
1139,apoe   ε nmbr carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
1139,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
1138,apixaban nmbr mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1138,apixaban nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1137,nutraceuticals,C1518478
1137,any llt other than nutraceuticals,C1518478;C2347090
1136,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1136,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1136,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1135,antihypertensive agents ( n per patient ),C0003364;C0030705
1135,patients on antihypertensive medications,C0003364;C0030705
1134,tnf - ir,C0022065;C0022071;C1448132;C1448177
1134,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
1133,anti ‐ tnf ‐ na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1133,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,anti - histamines,C0019590
1132,histamine - nmbr - receptor antagonist,C0019590;C4521896
1131,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
1131,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
1130,angioedema present,C0002994;C0150312;C0449450
1130,proportion of angioedema - free days from week nmbr to week nmbrx,C0002994;C0332296;C0439228;C1709707;C1880497;C1996904
1130,presence of angioedema at baseline,C0002994;C0150312;C0392148;C3854307
1130,angioedema ( adjudicated ),C0002994
1129,analgesic medication,C0002771
1129,previous analgesic products n ( % ),C0002771;C0205156;C1552607
1129,prior analgesic products,C0002771;C0332152;C2826257
1128,ii nmbr amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
1128,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
1128,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
1127,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
1127,amiodarone use at baseline yes nmbr,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
1126,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
1126,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
1125,alprostadil n / n,C0002335
1125,alprostadil n / n %,C0002335
1125,alprostadil ( n = nmbr ),C0002335
1124,alogliptin ( n = nmbr ),C1958126
1124,alogliptin,C1958126
1123,allopurinol nmbr / nmbr mg daily n = nmbr,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1123,allopurinol nmbr mg ( n = nmbr ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1123,allopurinol nmbr / nmbr mg n = nmbr,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1122,recent use of allopurinol ( within nmbr days of,C0002144;C0332185;C1524063
1122,allopurinol,C0002144
1121,allergic rhinitis duration,C0449238;C1334103;C2607914;C2926735;C4552864
1121,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
1121,allergic rhinitis,C1334103;C2607914;C4552864
1120,sensitive responders ( n = nmbr ),C0020517;C0332324;C1522640
1120,hypersensitivity,C0020517;C0520946
1120,sensitive responder ( n = nmbr ),C0020517;C0332324;C1522640
1120,allergic disease by historyb,C0020517;C0851444
1120,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
1120,sensitive,C0020517;C0332324;C1522640
1119,high - dose edoxaban,C0444956;C2975435
1119,low - dose edoxaban ( n = nmbr ),C0445550;C1708745;C2975435
1119,low - dose edoxaban vs warfarin,C0445550;C1708745;C2975435
1119,high - dose edoxaban ( n = nmbr ),C0444956;C2975435
1119,higher - dose edoxaban vs warfarin,C0444956;C2975435
1119,high - dose edoxaban vs warfarin,C0444956;C2975435
1119,higher - dose edoxaban ( n = nmbr ),C0444956;C2975435
1119,edoxaban ( n = nmbr ),C2975435
1119,edoxaban,C2975435
1119,higher dose edoxaban regimen,C0205250;C2348331;C2975435
1119,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
1119,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
1119,edoxaban dose adjusted at randomisation,C0178602;C0869039;C1114758;C2975435
1119,low - dose edoxaban,C0445550;C1708745;C2975435
1119,edoxaban n = nmbr,C2975435
1119,edoxaban vs . warfarin,C2975435
1119,all others eteed for nmbr mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
1119,edoxaban higher dose vs warfarin,C0444956;C2975435
1119,edoxaban lower dose vs warfarin,C2975435
1119,hd edoxaban vs warfarin,C2975435
1119,edoxaban n = nmbr n / n ( % ),C2975435
1119,ld edoxaban vs warfarin,C0694649;C2975435
1118,alirocumab nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
1118,alirocumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
1117,duration of prior alendronate use,C0102118;C0332152;C1881378;C2826257;C2826775
1117,alendronate ( n = nmbr ),C0102118
1117,alendronate,C0102118
1117,duration of alendronate use,C0102118;C1881378;C2826775
1116,progression of albuminuria,C0001925;C0242656;C0449258
1116,albuminuria progression,C0001925;C0242656;C0449258
1115,baseline albuminuria,C0001925;C0168634;C1442488
1115,albuminuria ( acr > nmbr m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
1114,not on an aha,C0050451;C0772110;C1518422
1114,aha status at screeningb,C0050451;C0449438;C0772110
1113,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
1113,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
1112,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1112,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1112,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
1111,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
1111,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
1110,add - on to met + sunmbr,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1110,su / tzd,C0038642;C1705534
1110,su / met,C0038642;C1705534
1110,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
1110,su monotherapy,C0038642;C1705534
1110,su,C0038642;C1705534
1110,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1109,acute reperfusion,C0035124;C0205178;C0684253
1109,no reperfusion,C0035124;C0684253
1108,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
1108,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
1108,acr response by baseline mtx use,C0025677;C0042153;C0168634;C0457083;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C1947944;C2911692
1108,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
1108,pasi response by baseline mtx use,C0025677;C0042153;C0168634;C0457083;C0871261;C1417487;C1442488;C1704632;C1706817;C1947944;C2911692;C4528685
1107,aclidinium / formoterol nmbr / nmbr pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
1107,formoterol nmbr pg vs placebo,C0030827;C0060657;C0072225;C1266240
1107,formoterol nmbr pg,C0030827;C0060657;C0072225;C1266240
1106,absolute risk reductions,C3179139
1106,absolute risk reduction ( nmbr % cl ) *,C0596019;C3179139
1105,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
1105,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
1104,ga,C0016993
1104,ga / a,C0016993
1104,a / ga,C0016993
1103,reslizumab nmbr . nmbr   mg / kg ( n   = nmbr ),C0439272;C1869620
1103,reslizumab,C1869620
1103,reslizumab nmbr . nmbr mg / kg ( n = nmbr ),C0439272;C1869620
1103,b reslizumab nmbr . nmbr mg / kg n / n,C0439272;C1869620
1103,a reslizumab nmbr . nmbr mg / kg n / n,C0439272;C1869620
1103,reslizumab ( n = nmbr ),C1869620
1102,a compared wi,C0043193;C1520135;C1707455
1102,active pso winmbr bsa > nmbr %,C0043193;C0205177;C1520135;C3853793;C3888249
1102,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
1101,snmbr years ( n = nmbr ),C0439234;C2986823
1101,nmbr < nmbrs ) n nmbr ( nmbr . nmbr ),C2986823
1101,snmbr ( n = nmbr ),C2986823
1100,dabigatran nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbrmg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg bid ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
1100,dabigatran nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,nmbr mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,nmbr mg dabigatran ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1100,dabigatran nmbr mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1099,nmbr % ( ito nmbr ),C0022283
1099,nmbr % ( - ito nmbr ),C0022283
1098,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
1098,lisinopril - chlorthalidone,C0008294;C0065374
1098,nmbr lisinopril - chlorthalidone,C0008294;C0065374
1098,lisinopril / chlorthalidone,C0008294;C0065374
1097,lisinopril vs chlorthalidone normal,C0065374
1097,nmbr lisinopril,C0065374
1097,lisinopril,C0065374
1097,lisinopril vs amlodipineb,C0065374
1097,lisinopril ( n = nmbr ),C0065374
1097,lisinopril vs chlorthalidone,C0065374
1097,ii lisinopril,C0065374;C1710602;C4082587
1097,lisinopril vs chlorthalidone overweight,C0065374
1097,lisinopril vs chlorthalidone obese,C0065374
1096,chlorthalidone vs doxazosin,C0008294
1096,chlorthalidone vs lisinopril,C0008294
1096,chlorthalidone nmbr,C0008294
1096,chlorthalidone ( n = nmbr ),C0008294
1096,chlorthalidone,C0008294
1096,nmbr chlorthalidone,C0008294
1096,nmbr chlorthalidone ( n = nmbr ),C0008294
1096,chlorthalidone vs amlodipine,C0008294
1096,amlodipione - chlorthalidone,C0008294
1095,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
1095,nmbr chlorthalidone amlodipine,C0008294;C0051696
1095,nmbr amlodipine - chlorthalidone,C0008294;C0051696
1095,amlodipine / chlorthalidone,C0008294;C0051696
1094,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
1094,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
1094,nmbr . nmbr ( nmbr . nmbr - nmbr . os ),C0229090;C0230028;C0262950;C0393706;C1561953
1093,nonobese ( < nmbr kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
1093,> nmbr kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
1093,bmi : < nmbr kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
1093,> nmbr kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
1092,< nmbr y ears,C0013443;C0521421
1092,less than nmbr y ears,C0013443;C0439092;C0521421
1091,> = nmbr kg / manmbr,C0022718;C0024443;C0439209;C3887485;C4054209
1091,< nmbr kg / manmbr,C0022718;C0024443;C0439209;C3887485;C4054209
1090,“ on ” without troublesome dyskinesia,C0013384
1090,“ on ” with troublesome dyskinesia,C0013384
1089,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
1089,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
1089,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
1089,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
1089,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
1089,* eligibility risk factors,C0013893;C0035648;C1548635;C1553898
1089,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
1088,nmbr . nmbr ( ne,C0027608;C0028219;C3538705
1088,( ne,C0027608;C0028219;C3538705
1088,ne,C0027608;C0028219;C3538705
1087,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1087,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1087,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
1086,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
1086,( nmbr - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
1085,percent stenosis [investigator],C0035173;C0439165;C0678234;C1261287;C2632116
1085,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
1084,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
1084,% asthma control days {,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
1083,- oil,C0028908;C0032085;C1517288;C3541397
1083,oil,C0028908;C0032085;C1517288;C3541397
1082,- nmbr . nmbr < flex fn f - score < - nmbr,C0016327;C0449820;C1570610;C4050231
1082,- nmbr < flex fn f - score,C0016327;C0449820;C1570610;C4050231
1082,flex fn f - score < - nmbr . nmbr,C0016327;C0449820;C1570610;C4050231
1081,bb,C0004739;C0332297
1081,- < — ■ bb — - ►,C0004739;C0332297
1080,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
1080,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
1079,paroxysmal af,C0235480
1079,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
1078,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1078,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1078,patient assessment of pain ( nmbr - nmbr cm,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
1078,patient assessment of pain ( nmbr - nmbr mm ),C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
1077,nonischemic cardiomyopathy,C0878544
1077,nonischemic cardiomyopathy — no . ( % ),C0878544
1077,cardiomyopathy,C0878544
1076,patients with psoriasis ( bsa ≥   nmbr % ),C0030705;C0033860
1076,patients without psoriasis ( n = nmbr ),C0030705;C0033860
1076,dlqi ( patients with £ nmbr % bsa psoriasis ),C0030705;C0033860;C3899393
1076,patients with psoriasis ( n = nmbr ),C0030705;C0033860
1075,gp iib / iiia inhibitors,C0016011;C0243077
1075,gpiib - iiia inhibitors,C0016011;C0243077
1075,glycoprotein iib / iiia inhibitors,C0016011;C0243077
1074,low tt < nmbr . nmbr ( n = nmbr ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
1074,estimated glomerular filtration rate - ml / min / nmbr . nmbrmnmbrtt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
1074,tt,C1452561;C4554543
1074,high tt > nmbr . nmbr ( n = nmbr ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
1073,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
1073,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
1072,median ( minimum – maximum ) focal seizure frequency / nmbr   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
1072,baseline focal seizure frequency / nmbr days,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0751495;C0871396;C1442488;C1561548;C1705502;C3898838;C4321352
1071,hawaiian / pacific islander,C0242191;C0337920
1071,native hawaiian / pacific islander,C0242191;C0337920
1071,hawaiian pacific islander,C0242191;C0337920
1070,karnofsky score < nmbr,C0206065
1070,karnofsky score 竺 nmbr,C0206065
1069,respiratory rate,C0231832;C0489258
1069,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
1068,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
1068,standing after nmbr minutes change from baseline,C0231472;C0439232;C0700321;C0702093;C1282918;C2347166
1068,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
1068,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
1068,standing after nmbr minute change from baseline,C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1705241;C2347166;C4319952
1067,proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr,C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1067,proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr,C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
1066,established renal disease *,C0022658;C0443211;C1272684
1066,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
1066,previous renal disease,C0022658;C0205156;C1552607
1066,renal disease ),C0022658
1066,renal disease,C0022658
1066,nephropathy,C0022658
1066,kidney disease ( usrds ),C0022658
1065,relative risk ( nmbr % cl ),C0242492;C0596019
1065,relative risk ® ( nmbr % cl ),C0242492;C0596019
1065,relative risk vs . placebo ( nmbr % cl ),C0242492
1065,relative risk * ( nmbr % cl ),C0242492;C0596019
1065,relative risk ® ' ( nmbr % cl ),C0242492;C0596019
1065,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age,C0242492;C1274040
1064,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
1064,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
1063,menopause and ht,C0025320;C0567312
1063,menopause and hrt,C0025320;C0567312
1062,hip fracture + > nmbr,C0019557;C0149531;C4552776
1062,hip fracture,C0019557;C0149531;C4552776
1062,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
1061,< nmbr % blood eosinophils at baseline,C0014467;C0168634;C1442488
1061,> nmbr % blood eosinophils at baseline,C0014467;C0168634;C1442488
1060,odds ratio ( nmbr % ci ),C0008107;C0028873;C3259781
1060,odds ratios ( nmbr % ci ),C0008107;C0028873;C3259781
1060,odds ‐ ratio ( nmbr % ci ),C0008107;C0028873;C3259781
1059,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1059,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
1059,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
1058,^ ≥ nmbr % incidence in any treatment group in the overall safety population .,C0021149;C0220856;C0374505
1058,incidence^,C0021149;C0220856
1058,incidence of each outcome,C0021149;C0220856;C1274040
1058,cumulative incidence nmbr years,C0021149;C0220856;C0439234;C1511559
1058,cumulative incidence nmbryears,C0021149;C0220856;C0439234;C1511559
1058,cumulative incidence lyear,C0021149;C0220856;C1511559
1058,event incidence / n,C0021149;C0220856;C0441471;C4019010
1058,nmbr - year cumulative incidence,C0021149;C0220856;C0439234;C0439508;C1511559
1058,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
1058,incidence *,C0021149;C0220856
1058,incidence,C0021149;C0220856
1057,baseline su dose > nmbr / nmbr maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1057,baseline su dose < nmbr / nmbr maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
1056,sjc ( nmbr joints ),C0022417;C0392905
1056,tjc ( nmbr joints ),C0022417;C0392905
1056,tjc ( / nmbr joints ),C0022417;C0392905
1056,primary study joint,C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
1056,sjc ( / nmbr joints ),C0022417;C0392905
1055,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1055,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
1054,> = nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),C0032042;C0439234;C1611934;C1696465;C1706408
1054,< nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),C0032042;C0439234;C1611934;C1696465;C1706408
1053,anterior circulation,C0005775;C0205094;C1516559
1053,posterior circulation,C0005775;C0205095;C1516559
1052,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes ( n = nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
1052,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes { p = nmbr * nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,diabetes history,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1052,no history of diabetes ( n = nmbr ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1051,timi minor bleeding,C0019080;C0026193;C0205165
1051,minor bleed,C0019080;C0026193;C0205165
1051,minor bleeding,C0019080;C0026193;C0205165
1050,om nmbr mg / hctz nmbr mg ( n = nmbr ),C0020261;C0028971;C1319635;C1705272
1050,om nmbr mg / hctz nmbr mg,C0020261;C0028971;C1319635;C1705272
1049,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
1049,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
1049,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
1048,hypokalaemia,C0020621;C4553966
1048,hypokalemia,C0020621;C4553966
1047,white ethnic origin,C0007457;C0015031;C0043157;C0220938
1047,ethnic origin white,C0007457;C0015031;C0043157;C0220938
1046,hospital stay,C3489408
1046,hospital stay ( days ),C0439228;C3489408
1045,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
1045,seated dbp,C0277814;C0536221;C1283233;C3813197;C4281799
1044,tiotropium + olodaterol nmbr / nmbr pg,C0030827;C0072225;C1266240;C4032878
1044,tiotropium + olodaterol nmbr . nmbr / nmbr pg,C0030827;C0072225;C1266240;C4032878
1043,not hispanie / latino,C0086528;C1518422
1043,hispanie / latino,C0086528
1043,non - hispanic / latino,C0086528;C1518424
1043,not hispanic / latino ( n = nmbr,C0086528;C1518424
1043,latino,C0086528
1043,not hispanic / latino,C0086528;C1518424
1042,troponin i ( pg / ml ),C0077401;C0439297
1042,positive troponin i or t,C0077401;C0439178;C1446409;C1514241;C2825490;C3812269
1042,tni ultrapositive,C0077401
1042,tni ultrapositive ≥ nmbr . nmbr µ g / l,C0077401;C0439294;C0456615
1041,other forms of atherosclerosis^,C0003850;C0004153;C0348078;C0376315
1041,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
1040,other anti - platelet agents,C0005821;C0040616
1040,anti ‐ platelet agents,C0005821;C0040616
1039,difference from placebo * ( nmbr % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
1039,difference from placebo ( nmbr % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
1038,anatomy,C0002808;C0700276;C1384516
1038,noncomplex anatomy ( n - nmbr,C0002808;C0700276;C1384516
1038,complex anatomy ( n - nmbr,C0002808;C0439855;C0700276;C1384516;C1704241
1037,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all - cause mortality ( n = nmbr ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all - cause mortality at nmbr year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
1037,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all cause mortality or hosp . for worsening hf hs - crp < nmbr . nmbr mg / l,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all - cause mortality or hf hospitalization^,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1037,all - cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
1036,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
1036,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1036,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1036,depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1036,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1035,with corticosteroid treatment > nmbr,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1035,with corticosteroid treatment < nmbr,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
1034,thiazolidinediones,C1257987;C3541957
1034,thiazolidinediones *,C1257987;C3541957
1033,at clinic systolic pressure > nmbr mm hg,C0002424;C0439475;C0442592;C0871470
1033,at clinic systolic pressure < nmbr mm hg,C0002424;C0439475;C0442592;C0871470
1032,at clinic diastolic pressure > nmbr mm hg,C0002424;C0428883;C0439475;C0442592
1032,at clinic diastolic pressure < nmbr mm hg,C0002424;C0428883;C0439475;C0442592
1031,mean systolic blood pressure ( sd ),C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1031,mean ( s . d . ) systolic blood pressure,C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
1031,mean systolic blood pressure,C0039155;C0428886;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
1030,mean ( s . d . ) diastolic blood pressure,C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143
1030,mean diastolic blood pressure ( sd ),C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
1030,mean diastolic blood pressure,C0012000;C0428883;C0428886;C0444504;C0488053;C1305849;C2347634;C2348143
1029,furosemide,C0016860
1029,furosemide equivalent,C0016860;C0205163;C0439185
1028,vildagliptin nmbr mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1028,vildagliptin nmbr mg qd n = nmbr,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1028,vildagliptin nmbr mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1028,vildagliptin nmbr mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1028,vildagliptin nmbr mg bid n = nmbr,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1027,abdominal obesity,C0311277
1027,abdominal obesity *,C0311277
1026,gender - male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1026,gender ( male ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1026,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1026,gender : male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1025,upper limb,C1140618
1025,upper limb fractures,C1140618
1025,upper limbs,C1140618
1024,troponin nmbr at baseline *,C0041199;C0168634;C1442488
1024,troponin nmbr at baseline,C0041199;C0168634;C1442488
1023,patients with baseline crp concentration £ nmbr mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1023,patients with baseline crp concentration < nmbr mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
1022,ertugliflozin nmbr mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,week nmbr ertugliflozin nmbr mg vs placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,week nmbr ertugliflozin nmbr mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg vs placebo / giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,week nmbr ertugliflozin nmbr   mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr   mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg vs placebo / glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1022,ertugliflozin nmbr mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1021,nmbr mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1021,empagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1021,empagliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1020,bare metal,C0025552
1020,bare - metal,C0025552
1019,elevated creatine kinase mb ( > nmbr u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
1019,elevated creatine kinase - mb ( > nmbr u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
1018,salmeterol ( n [nmbr ),C0073992
1018,salmeterol,C0073992
1018,salmeterol ( n = nmbr ),C0073992
1018,salmeterol ( n[nmbr ),C0073992
1017,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
1017,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
1016,everolimus - eluting,C0541315
1016,everolimus,C0541315
1015,sirolimus - eluting,C0072980
1015,sirolimus,C0072980
1014,aldosterone receptor antagonists,C1579268
1014,mineralocorticoid receptor antagonists,C1373021;C1579268
1014,mineralocorticoid receptor antagonist,C1579268
1014,mineralocorticoid receptor antagonist n ( % ),C1579268
1013,proton - pump inhibitors,C0358591;C1384478;C3540020
1013,proton - pump inhibitor,C0358591;C3536754;C4521480
1013,proton pump inhibitor ( n,C0358591;C3536754;C4521480
1013,proton pump inhibitor,C0358591;C3536754;C4521480
1013,proton pump inhibitors,C0358591;C1384478;C3540020
1012,total ho population ( n = nmbr ),C0019905;C1832110;C3258257;C3889614
1012,ho,C0019905;C1832110;C3889614
1011,la grade a,C0023031;C0023749;C0230347;C2346906;C4553351
1011,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
1011,usual care ( n = nmbrla ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
1010,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1010,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1009,olodaterol nmbr m g,C0456715;C2934193
1009,olodaterol,C2934193
1009,olodaterol sgg,C2934193
1009,olodaterol nmbr jig,C2934193
1008,angiotensin ii receptor blockers,C0521942;C2757003
1008,angiotensin ii receptor blocker,C0521942;C3536793
1007,anacetrapib nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1007,anacetrapib nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1007,anacetrapib nmbr mg ( n - nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1007,anacetrapib nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1006,alirocumab ( n = nmbr ),C3491162
1006,alirocumab n = nmbr,C3491162
1006,alirocumab,C3491162
1005,ezetimibe nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1005,ezetimibe nmbr mg ( n — nmbr ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1005,ezetimibe nmbr mg ( n = nmbr * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1005,eze = ezetimibe nmbr mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1004,native american,C0282204;C1515945
1004,native american or alaska native,C0282204;C1515945
1004,native american or alaskan native,C0282204;C1515945
1003,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1003,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
1003,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
1003,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
1003,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
1003,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
1003,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
1003,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
1002,rectal bleeding subscore,C0018932;C0267596
1002,rectal bleeding subscore {,C0018932;C0267596
1001,body weiqht,C0242821;C0460148;C1268086;C4082212
1001,body massindex,C0242821;C0460148;C1268086;C4082212
1001,body weighta,C0242821;C0460148;C1268086;C4082212
1000,total cholesterol > nmbr - nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1000,total cholesterol < nmbr - nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1000,total cholesterol > nmbr ' nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1000,total cholesterol < nmbr nmbr mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
1000,nmbr . nmbr ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
999,baseline pav - > = median ( n = nmbr,C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
999,baseline pav - < median ( n = nmbr,C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
998,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
998,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
998,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
998,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
998,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
997,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
997,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
996,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
996,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
995,batellna c - reective protein,C0033684
995,high - sensitivityc - reactive protein,C0033684;C0205250;C0205332;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
994,leukotriene receptor antagonists,C0595726;C2757015;C3542962
994,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
993,cs use : no,C0010182;C0271160;C3540510;C4085345
993,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
993,no cs and imm,C0010182;C0271160;C3540510;C4085345
993,cs and is,C0010182;C0271160;C3540510;C4085345
993,no cs and is,C0010182;C0271160;C3540510;C4085345
993,cs and imm,C0010182;C0271160;C3540510;C4085345
993,cs and im,C0010182;C0271160;C3540510;C4085345
993,neither cs nor imm,C0010182;C0271160;C3540510;C4085345
993,cs,C0010182;C0271160;C3540510;C4085345
992,symptomatic hypotension,C0020649;C0231220;C3163620
992,hypotension,C0020649;C3163620
991,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
991,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
990,who fc ii symptoms at baselinenmbr,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
990,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
990,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
989,without psoriasis ( zi = nmbr,C0033860;C0043476
989,without psoriasis ( zi = nmbr ),C0033860;C0043476
989,with psoriasis ( zi = nmbr ),C0033860;C0043476
988,czp + mtx n = nmbr,C0025677;C0054841;C1417487;C1861828;C1872109
988,czp + mtx^mtx,C0025677;C0054841;C1417487;C1861828;C1872109
988,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
988,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
987,pbo + mtx^mtx,C0025677;C0031962;C1417487
987,pbo + mtx,C0025677;C0031962;C1417487
987,pbo + mtx to mtx,C0025677;C0031962;C1417487
987,pbo + mtx n = nmbr,C0025677;C0031962;C1417487
986,hispanic / latino,C0086409;C0086528
986,hispanic / latino ( n = nmbr ),C0086409;C0086528
985,mmp - nmbr,C0623362;C0919336
985,mmp - nmbr ( ng / ml ) *,C0439275;C0623362;C0919336
985,mmp - nmbr ( ng / ml ),C0439275;C0623362;C0919336
984,aml / hctz ( n = nmbr ),C0020261;C0023465;C0023467
984,aml nmbr mg + hctz nmbr mg ( n = nmbr ),C0020261;C0023465;C0023467;C1319635
984,aml nmbr mg + hctz nmbr mg,C0020261;C0023465;C0023467;C1319635
984,aml nmbr mg / hctz nmbr mg,C0020261;C0023465;C0023467;C1319635
983,vildagliptin,C1570906
983,vildagliptin ( n = nmbr ),C1570906
982,isehemie heart disease,C0018799
982,cardiac disorders ( soc ),C0018799
982,cardiac disorder,C0018799
982,cardiac disease,C0018799
982,no cardiac disease,C0018799
982,no apparent heart disease,C0018799;C0750489
981,history of tia,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
981,history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
981,history of tia or stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
981,no history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
980,laba ( tiotropium n = nmbr  placebo n = nmbr ),C0032042;C0213771;C1696465;C1706408
980,( tiotropium n = nmbr  placebo n =,C0032042;C0213771;C1696465;C1706408
980,placebo tiotropium n = nmbr non - tiotropium n = nmbr,C0032042;C0213771;C1518422;C1696465;C1706408
980,tiotropium + placebo ( n[nmbr ),C0032042;C0213771;C1696465;C1706408
979,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
979,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
978,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
978,baseline sbp { p = o - nmbr ),C0085805;C0168634;C1442488
978,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
978,baseline sbp,C0085805;C0168634;C1442488
978,baseline mean ambulatory sbp,C0085805;C0168634;C0439841;C0444504;C1442488;C2347634;C2348143
978,baseline nmbr - hour mean sbp,C0085805;C0168634;C0439227;C0444504;C0564385;C1442488;C2347634;C2348143
978,sbp at baseline,C0085805;C0168634;C1442488
977,bl h / y : unilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
977,bl h / y : bilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
976,sitagliptin nmbrmg n = nmbr,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
976,sitagliptin nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
975,south america,C0037713
975,south america ( n = nmbr ),C0037713
975,south america ( % ),C0037713
974,post - menopausal without hormone replacement,C0019930
974,post - menopausal with hormone replacement,C0019930
973,pre - menopausal with hormone replacement,C0206158;C0282402
973,pre - menopausal without hormone replacement,C0206158;C0282402
972,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
972,imt ( nmbr ),C0334121;C1704614;C4318736
972,carotid imt,C0334121;C0741968;C1704614;C4318736
971,baseline insulin dose ( u = kg ) [lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
971,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
971,baseline anmbrc ( % ) [lsm ( se ) ],C0036919;C0168634;C1442488
971,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
971,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
971,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
970,azl - ma,C0024443;C3887485
970,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
969,unadjusted irr,C1439367;C4082285
969,irr = nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ) nmbr . nmbr,C4082285
968,systolic ( mmhg ),C0039155;C0439475
968,systolic — mm hg,C0039155;C0439475
968,mean systolic pressure gradient,C0039155;C4687744
968,systolic,C0039155
968,peak systolic pressure gradient,C0039155;C4687747
968,systolic ( mm hg ),C0039155;C0439475
968,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
968,systolic ( mean,C0039155;C0444504;C2347634;C2348143
967,sal ( n = nmbr ),C0036140;C0037494;C0206136
967,sal ( n   = nmbr,C0036140;C0037494;C0206136
966,fair / poor,C0032854;C0542537;C2700379;C2911689
966,poor,C0032854;C0542537;C2700379
965,ng,C0017887;C0028074
965,ng ( n = nmbr,C0017887;C0028074
964,ua,C0041580;C0042014
964,ua ( n = nmbr ),C0041580;C0042014
963,china,C0008115
963,china / tjapan,C0008115
962,hip,C0019552;C0022122;C1505163;C3538851;C4284725
962,standardized total hip bmd ( g / cmnmbr ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
962,hip + other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725
962,total hip ( n = nmbr,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
962,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
962,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
962,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
962,total hip bmd ( g / cmnmbr ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
962,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
962,waist - to - hip,C0019552;C0022122;C0230097;C1505163;C3538851;C4284725
962,total hip or knee replacement,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
962,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
961,nausea and / or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
961,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
960,canada or united states,C0006823
960,canada,C0006823
959,african descent,C0027567
959,african,C0027567
958,niacin ( n = nmbr ),C0027996;C1142562
958,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1524063;C1552607
958,niacin,C0027996;C1142562
957,glipizide,C0017642
957,glipizide ( n = nmbr ),C0017642
956,australia,C0004340
956,australia and new zealand,C0004340
955,russia and georgia,C0035970
955,rs - breathlessnessb,C0035970;C3714753;C3813325
955,rs - totala,C0035970;C3714753;C3813325
955,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
955,rsnmbr,C0035970;C3714753;C3813325
955,rsnmbr & rsnmbr,C0035970;C3714753;C3813325
955,russia,C0035970
955,enrolled in russia or georgia,C0035970;C4684790
954,sys : ns dia : < nmbr . nmbr,C0038944;C1112705;C1425041;C1705982;C1706546
954,ns,C0038944;C1112705;C1705982
953,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
953,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
953,cvd deaths,C0007222;C0011065;C1306577
952,aml ( n = nmbr ),C0023465;C0023467
952,aml vs . chl,C0023465;C0023467
952,aml,C0023465;C0023467
952,aml vs . lis,C0023465;C0023467
952,aml nmbr /,C0023465;C0023467
952,a / aml ( n = nmbr ),C0023465;C0023467
951,ni,C0028075;C2348274;C3869926;C3869927
951,< nmbr ml / min / nmbr . nmbrni -,C0028075;C0439445;C2348274;C3869926;C3869927
951,> nmbr ml / niin / lnmbrni -,C0028075;C1635169;C2348274;C3869926;C3869927
950,pt,C0032743;C0699718
950,pt . years = nmbr,C0032743;C0439234;C0699718
949,fp ( n [nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
949,fp ( n = nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
949,fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412
949,fp ( n[nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412
949,fp,C0016704;C1419068;C1419906;C3541238;C3541412
949,fp ( n   = nmbr,C0016704;C1419068;C1419906;C3541238;C3541412
949,fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412
948,( id,C0009450;C0600091;C1441613
948,id ( n = nmbr ),C0009450;C0600091;C1441613
948,id,C0009450;C0600091;C1441613
947,( gm ),C0017480;C3854019
947,gm,C0017480;C3854019
946,italy ( n = nmbr ),C0022277
946,italy,C0022277
945,taci ( n = nmbr ),C0666480;C1425349;C4284230
945,taci,C0666480;C1425349;C4284230
944,no betablocker use,C0001645;C0042153;C0457083;C1947944
944,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
944,beta blocker use,C0001645;C0042153;C0457083;C1947944
944,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
944,beta - blocker use,C0001645;C0042153;C0457083;C1947944
944,betablocker use,C0001645;C0042153;C0457083;C1947944
943,hdl - cd,C0007928;C0034283;C3715113;C4552032
943,previous cd related surgery ( ref ) a,C0007928;C0034283;C0205156;C1552607;C4552032
943,prior surgery for cd,C0007928;C0034283;C0455610;C4552032
943,no previous cd related surgerynmbr,C0007928;C0034283;C0205156;C1552607;C4552032
943,ses - cd,C0007928;C0034283;C4552032
943,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
943,cd duration,C0007928;C0034283;C0449238;C2926735;C4552032
943,cd [gemini nmbr] * ’,C0007928;C0034283;C4552032
942,prior om,C0028971;C0332152;C1705272;C2826257
942,new om,C0028971;C0205314;C1705272
942,om nmbr /,C0028971;C1705272
941,chadsnmbrscoref,C0007928;C1413373
941,chads score,C0007928;C1413373
941,chadsnmbr score nmbr,C0007928;C1413373
941,chadsnmbr,C0007928;C1413373
941,chadsnmbr   score,C0007928;C1413373
941,chadsnmbr score > nmbr,C0007928;C1413373
941,chadsnmbr^,C0007928;C1413373
941,chads - nmbr score,C0007928;C1413373
941,chadsnmbr score per outcome stroke or systemic embolism,C0007928;C1413373
941,chadnmbr > nmbr,C0007928;C1413373
941,chadsnmbr < nmbr,C0007928;C1413373
941,chadsnmbr scoreb,C0007928;C1413373
941,chadsnmbr score *,C0007928;C1413373
941,chadsnmbrcomponents,C0007928;C0449432;C1413373
941,chadsnmbr score,C0007928;C1413373
941,chadsnmbr scoret,C0007928;C1413373
941,chadsnmbr score nmbr - nmbr,C0007928;C1413373
940,japanese subgroup ( n = nmbr ),C0376247;C1079230;C1515021;C1556094
940,no . japanese,C0376247;C1556094
940,japanese,C0376247;C1556094
939,acs presentation,C0449450;C0742343;C4318612
939,acs event,C0441471;C0742343;C4019010;C4318612
939,acs ( n = nmbr,C0742343;C4318612
939,days from acs to randomization,C0439228;C0742343;C4318612
939,days between acs and rand,C0439228;C0742343;C4318612
939,acs type,C0332307;C0742343;C1547052;C4318612
939,nste acs,C0742343;C4318612
939,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
939,acs ( n - nmbr,C0742343;C4318612
939,no acs,C0742343;C4318612
939,nste - acs,C0742343;C4318612
939,acs,C0742343;C4318612
939,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
938,phi ( n = nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801
938,phi ( n - nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801
938,pgi - s,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
937,icd / crt - d,C0021122
937,icd vs . placebo,C0021122
937,icd or crt - d,C0021122
937,icd,C0021122
936,> nmbr beds,C0004916
936,< nmbr beds,C0004916
935,pm,C0030266;C4049155
935,lta ( max response to nmbr pm adp ) defined hpr ( % patients ),C0030266;C0523452;C2611142;C4049155
934,cough ( leading to study drug discontinuation ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
934,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
934,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
933,female n ( % ),C0043210;C0086287;C1705497;C1705498
933,female ( n   = nmbr,C0043210;C0086287;C1705497;C1705498
933,female : ≥ nmbr years postmenopausal,C0043210;C0086287;C0439234;C1705497;C1705498
933,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
933,female subjects ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
933,female simva ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
933,female : perimenopausal or < nmbr years postmenopausal,C0043210;C0086287;C1705497;C1705498
933,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
933,nmbr ( except for female alone ),C0043210;C0086287;C1705497;C1705498
933,female participants who are ≥ nmbr years postmenopausal,C0043210;C0086287;C0679646;C1705497;C1705498
933,female ( n — nmbr ),C0043210;C0086287;C1705497;C1705498
933,female eze / simva ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
933,female acr definition,C0043210;C0086287;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C3539107;C3888054
933,female nmbr,C0043210;C0086287;C1705497;C1705498
933,female ( n = lllnmbr ),C0043210;C0086287;C1261077;C1705497;C1705498
933,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
933,female ( n = nmbr,C0043210;C0086287;C1705497;C1705498
933,female : premenopausal,C0043210;C0086287;C1705497;C1705498
933,femalenmbr,C0043210;C0086287;C1705497;C1705498
933,female simva,C0043210;C0086287;C1705497;C1705498
933,female ( n = nmbr ),C0043210;C0086287;C1705497;C1705498
933,female,C0043210;C0086287;C1705497;C1705498
933,female simva ( „ = nmbr },C0043210;C0086287;C1705497;C1705498
933,female ( n z nmbr ),C0043210;C0086287;C1705497;C1705498
933,female eze / simva,C0043210;C0086287;C1705497;C1705498
933,female eze / simva ( „ = nmbr },C0043210;C0086287;C1705497;C1705498
933,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
933,female - n ( % ),C0043210;C0086287;C1705497;C1705498
933,female ( % ),C0043210;C0086287;C1705497;C1705498
932,atvnmbr mg ( n = nmbr ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
932,atv nmbr mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
931,simvastatin nmbr mg ( n = nmbr ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
931,simvastatin nmbr mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
931,simvastatin nmbr mg ( n = nmbr ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
931,simvastatin nmbr mg ( n = nmbr,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
930,thrombolytic agents,C0016018
930,fibrinolytic agents before or after entry,C0016018
930,fibrinolytic agent — no . ( % ) : t,C0016018
930,types of fibrinolytic agent,C0016018;C0332307
930,fibrinolytic agent given,C0016018
929,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
929,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
929,copd medication taken for at least nmbr months before study entry,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
929,copd medication taken for at least nmbr months before st,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
929,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
928,pbo ( n   =   nmbr ),C0031962
928,pbo ( n nmbr nmbr ),C0031962
928,pbo n ( % ),C0031962
928,ifg pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C1334085;C1708411
928,pbo,C0031962
928,pbo ( n = nmbr ),C0031962
928,pbo ( nnmbr nmbr ),C0031962
928,mets pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C0812270;C1705694;C2939420
928,vdz / pbo [n = nmbr],C0031962
928,type nmbr diabetes pbo ( n = nmbr ) vs evomab ( n = nmbr ),C0031962;C1320657
928,ind + pbo ( n = nmbr ),C0031962;C4049864
928,pbo ( nnmbr ),C0031962
928,pbo ( n = nmbr ) vs,C0031962
928,flex pbo ®,C0031962
928,pbo n = nmbr,C0031962
928,pbo ( n - nmbr ),C0031962
927,rank based on treatment   =   placebo,C0667477;C0699794
927,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
927,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
927,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
927,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
927,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
927,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
927,log - rank,C0667477;C0699794;C1708728;C2986775
926,bowel function,C0011135
926,daily bowel movements,C0011135;C0332173
925,mtx use at randomization,C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
925,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
925,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
924,tiotropium nmbr . nmbr mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbr mg ( n = nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbrmg ( n = nmbr,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbr mg respimat ® ( n = nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbr mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbrmg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
924,tiotropium nmbr mg respimat ® ( n z nmbr ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
923,esrd or death,C0022661;C0035078;C2316810
923,esrd or nmbr % dedine in gfr,C0022661;C0035078;C2316810
923,esrd ',C0022661;C0035078;C2316810
923,esrd or nmbr % decline in gfr,C0022661;C0035078;C2316810
923,sustained esrd,C0022661;C0035078;C0443318;C2316810
923,esrd,C0022661;C0035078;C2316810
923,esrd *,C0022661;C0035078;C2316810
922,losartan plus lisinopril ( n = nmbr ),C0065374;C0126174;C0332287
922,losartan + lisinopril,C0065374;C0126174
921,diet ( n = nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
921,diet nmbr / nmbr ( nmbr . nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
921,diet group ( n = nmbr ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
921,diet ( n 二 nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949
921,diet,C0012155;C0012159;C1519433;C2983588;C3668949
921,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
921,diet alone,C0012155;C0012159;C1519433;C2983588;C3668949
921,diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949
920,era,C1521863;C3495919
920,era and pde - nmbri,C1521863;C3495919
920,era and pdenmbr inhibitors,C1521863;C3495919
920,era monotherapy,C1521863;C3495919
919,onset nmbr [nmbr],C0206132;C0332162
919,age at onset,C0206132;C3870509
919,age of onset nmbr years ( n = nmbr ),C0206132;C0439234;C3175530
919,age of onset < nmbr years ( n = nmbr ),C0206132;C0439234;C3175530
919,age of onset,C0206132;C3175530
918,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
918,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
917,medications during hospitalization or at discharge,C0013227;C0019993;C0802604;C2598133;C4284232
917,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
917,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
916,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
916,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
915,rheumatoid arthritis,C0003873
915,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
915,duration of rheumatoid arthritis,C0003873;C0449238;C2926735
915,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
914,immobilization — no . ( % ),C0020944;C4048292
914,immobilization,C0020944;C4048292
913,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
913,difference in ls meannmbr ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
913,ls t - score < — nmbr . nmbr,C0023668;C0449820;C4050231
913,ls mean,C0023668;C0444504;C2347634;C2348143
913,ls - mean difference ® ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
913,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
913,ls mean difference ( nmbr % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
913,ls mean difference vs placebo ( nmbr % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
913,ls / ul nmbr nmbr,C0023668;C1300557
913,- nmbr . nmbr < ls t - score < — nmbr . nmbr,C0023668;C0449820;C4050231
913,ssed as ls means,C0023668;C1704970
913,- nmbr . nmbr < ls t - score,C0023668;C0449820;C4050231
913,difference in ls mean vs placebo ( nmbr % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
912,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
912,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
912,nonsevere hypoglycemia,C0020615;C4553659
912,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
912,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
912,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
912,no nonsevere hypoglycemia,C0020615;C4553659
912,hypoglycemia^,C0020615;C4553659
912,hypoglycemia,C0020615;C4553659
912,b nonsevere hypoglycemia,C0020615;C4553659
912,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
911,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
911,converting enzyme inhibitor,C0014432;C0919438;C4521603
910,time in therapeutic range before inclusion,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
910,median time in therapeutic range for warfarin recipients,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
910,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
910,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C1547707;C1554109;C2946261;C3541383;C3810851
909,insulin - dependent diabetes mellitus,C0011854
909,insulin - dependent diabetes,C0011854
908,linagliptin ( n z nmbr ),C2746078
908,linagliptin,C2746078
908,linagliptin ( n = nmbr ),C2746078
908,linagliptin ( n = nmbr ) ',C2746078
908,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
907,budesonide,C0054201
907,budesonide ( symptom days a week ),C0054201;C0439228;C1457887;C3854129
907,budesonide { symptom days a week ),C0054201;C0439228;C1457887;C3854129
907,budesonide nmbr ^g ( n = nmbr ),C0054201;C0439267
907,budesonide — no . ( % ),C0054201
907,budesonide ( n = nmbr ),C0054201
906,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
906,function subscale,C0031843;C0542341;C0700205;C1705273
906,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
905,known prothrombotic genotype,C0017431;C0205309
905,genotype,C0017431
904,asa > nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
904,aspirin nmbr mg ( n = nmbr ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
904,asa < nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
904,aspirin nmbr mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
903,nice secondary prevention onlyb,C0679699;C4087029
903,secondary prevention subgroup,C0679699;C1079230;C1515021
902,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
902,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
902,fracture history ( predefined ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
901,beyond popliteal pedal,C0016504;C0442037;C0687080
901,feet,C0016504;C0347981
901,total feet score,C0016504;C0347981;C2964552
900,syndrome,C0039082
900,specific syndromes,C0039082;C0205369;C1552740;C1558916
900,nonmetabolic syndrome ( n = nmbr ),C0039082
900,cardiometabolic syndrome,C0039082
899,quality of life,C0034380;C0518214
899,european quality of life - nmbr dimensions - nmbr level ( eq - nmbrd ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
898,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
898,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C1524063;C3540777;C3540778
898,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C1524063;C3540777;C3540778
897,utis,C0042029
897,urinary tract infection,C0042029;C0262655;C4554638
896,hemoglobin anmbrc,C0019020;C3889898
896,hemoglobin anmbrc ( % ),C0019020;C3889898
896,hemoglobin a^c,C0019020;C3889898
896,hemoglobin - anmbrc ( % ) ' • ■ * *,C0019020;C3889898
895,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
895,pcs score,C1864389;C1882368
895,pcs score ( nmbr – nmbr scale ),C1864389;C1882368
894,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
894,mra use,C0243032;C1609165;C3891069
894,mra,C0243032;C1609165;C3891069
893,hospitalization in previous year with management of heart failure,C0019993;C0205156;C0439234;C0439508;C1552607
893,hospitalisation related to exacerbation,C0019993
893,symptom onset to hospitalization,C0019993;C4086878
893,exacerbations in previous year requiring hospitalization,C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
893,hospitalization,C0019993
893,exacerbations in previous year requiring hospitalization and / or ed visit,C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
893,hospitalisation,C0019993
893,hospitalization for,C0019993
893,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
893,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
893,hospitalization for / due to,C0019993
893,no hospitalization in the past nmbr months prior to baseline ( ref ),C0019993;C4331910
893,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
893,hospitalization stratum,C0019993
893,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
893,hospitalization in the past nmbr months prior to baseline,C0019993;C4331910
893,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
893,prior hospitalizations,C0019993;C0332152;C2826257
893,hospitalizations,C0019993
892,dapagliflozin nmbr mg / day ( n = nmbr ),C0439422;C2353951
892,dapagliflozin ( n = nmbr ),C2353951
892,dapagliflozin,C2353951
891,amlodipine - amlodipine / valsartan,C1962523
891,amlodipine / valsartan nmbr / nmbr vs nmbr / nmbr mg,C1962523
890,atorvastatin nmbr mg ( n = nmbr,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
890,atorvastatin nmbr mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
890,atorvastatin nmbrmg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
890,atorvastatin nmbr mg ( n = nmbr ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
890,atorvastatin nmbr mg and simvastatin nmbr - nmbr mg ( zi = nmbr ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
889,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
889,mean fecal calprotectin level,C0015733;C0441889;C0444504;C0456079;C0950624;C1335798;C1366582;C1547707;C2347634;C2348143;C2946261
889,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
888,regadenoson,C1698215
888,regadenoson ( n = nmbr ),C1698215
887,fasting triglycerides,C0015663;C0041004
887,fasting triglycerides > nmbr mg / dl *,C0015663;C0041004;C0439269
887,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
886,estimated creatinine clearance < nmbr ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
886,estimated creatinine clearance < nmbr rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
885,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
885,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
884,body weight at randonization { ixrs ),C0005910;C1305866
884,body weight *,C0005910;C1305866
884,mean body weight ( sd ),C0005910;C0444504;C1305866;C2347634;C2348143;C2699239
884,bodyweight,C0005910;C1305866
884,mean body weight,C0005910;C0444504;C1305866;C2347634;C2348143
884,per body weight,C0005910;C1305866
884,body weight,C0005910;C1305866
883,smoker at baseline,C0168634;C0337664;C1442488
883,smokers ( at baseline ),C0168634;C0337664;C1442488
882,diclofenac nmbr mg,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
882,diclofenac nmbr mg ( n nmbr nmbr ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
882,diclofenac nmbr mg ( n = nmbr ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
881,physician,C0031831;C0804815
881,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1511726;C1709908;C3245479;C3714741
881,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1709908
880,anacetrapib ( n = nmbr,C2604745
880,anacetrapib ( n = nmbr ),C2604745
879,tdi total score ( week nmbr,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
879,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
878,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
878,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
877,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
877,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
877,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
876,high density lipoprotein ( mg / dl ),C0023821;C0439269
876,high - density lipoprotein,C0023821
876,high - density lipoprotein],C0023821
875,il - nmbr,C0020898;C0021764;C0022271
875,il - nmbr ( pg / ml ),C0020898;C0021764;C0022271;C0439297
875,il - nmbr range,C0020898;C0021764;C0022271;C1514721;C2348147;C3542016
874,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
874,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
874,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
873,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
873,cataract removal,C0007389
872,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
872,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
872,ib ( nmbr . nmbr ),C2744579;C3890035;C4283819
872,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
871,alcohol drinker,C0001962;C0001975;C0556338
871,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0521116;C1705970
871,alcohol useb,C0001962;C0001975
871,alcohol usef,C0001962;C0001975
871,alcohol,C0001962;C0001975
871,alcohol > nmbr / wk,C0001962;C0001975;C0332174;C0439230
871,alcohol < = nmbr / wk,C0001962;C0001975;C0332174;C0439230
871,alcohol^,C0001962;C0001975
871,current alcohol,C0001962;C0001975;C0521116;C1705970
870,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
870,inflammatory bowel disease,C0021390
869,alanine aminotransferase or aspartate aminotransferase > nmbrx upper limit of normal ( n = nmbr ),C0001899;C0057041;C1415274;C3887708
869,alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708
869,alanine aminotransferase,C0001899;C0057041;C1415274;C3887708
868,olodaterol nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
868,olodaterol nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
867,infarct on brain imaging 丰,C0751955
867,infarct on brain imaging^,C0751955
866,antihypertensive medication use,C0003364;C0042153;C0457083;C1947944
866,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
866,antihypertensive use,C0003364;C0042153;C0457083;C1947944
866,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
865,glucagon - like peptide - nmbr receptor agonist,C0014361;C4543206
865,glucagon - like peptide - nmbr agonist,C0014361;C2987634
864,contrast volume > nmbr ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
864,contrast volume > nmbr ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
864,contrast used ( ml ) *,C0009924;C1979874
864,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
864,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
863,prediabetes,C0362046
863,ifg / prediabetes^,C0362046;C1334085;C1708411
863,prediabetes — no . ( % ) nmbr,C0362046
863,pre – diabetes mellitus,C0362046
862,biguanides ¶,C0005382;C0360396;C3540012
862,biguanides,C0005382;C0360396;C3540012
862,biguanide,C0005382;C3537187;C4317165
861,back pain,C0004604;C1963071;C4553945
861,total back pain,C0004604;C0439175;C0439810;C1963071;C4553945
860,thiazide diuretic,C0012802;C3536861
860,thiazide diuretic *,C0012802;C3536861
860,thiazide diuretics,C0012802
860,any thiazide diuretic,C0012802;C3536861
860,diuretic thiazide,C0012802
859,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
859,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
859,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415
858,baseline nmbr - asa,C0004057;C0168634;C1442488;C3853627
858,no aspirin at baseline,C0004057;C0168634;C1442488
858,aspirin at baseline,C0004057;C0168634;C1442488
858,on aspirin at baseline,C0004057;C0168634;C1442488
857,valvular heart disease — no . ( % ),C0018824;C1963123
857,cardiac valvular disease,C0018824
857,valvular heart disease,C0018824;C1963123
856,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
856,other forms of,C0348078;C0376315
856,before a change to the enrollment form was implemented in august nmbr . bnp,C0348078;C0376315;C0392747;C0443172;C1516879;C1522492;C1696073;C1705241;C3888021;C4255237;C4319952
855,irbesartan ( n = nmbr ),C0288171
855,irbesartan,C0288171
854,americas ( n = nmbr ),C0002454;C0596070
854,n america,C0002454;C0369718;C0441922
854,americas * *,C0002454;C0596070
854,america,C0002454
854,americas,C0002454;C0596070
854,enrolled in the americas,C0002454;C0596070;C4684790
853,bisphosphonates,C0012544;C3541401
853,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
852,gissi prevention nmbr / nmbr - nmbr / nmbr,C0199176;C1706420;C2700409
852,prevention ),C0199176;C1706420;C2700409
851,use of loop diuretics,C0354100;C1524063
851,total intravenous loop diuretics,C0348016;C0354100;C0439175;C0439810
851,intravenous loop diuretics !,C0348016;C0354100
851,loop diuretic,C0354100;C3536704
851,loop diuretics,C0354100
850,whole cohort,C0009247;C0444667;C0599755
850,entire cohort,C0009247;C0439751;C0444667;C0599755
850,total cohort,C0009247;C0439175;C0439810;C0599755
850,cohort,C0009247;C0599755
850,itt cohort,C0009247;C0599755
850,cohort nmbr ( uacr > nmbr . nmbr mg / g ),C0009247;C0599755;C1300563
850,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
850,full cohort,C0009247;C0443225;C0599755
850,cohort nmbr ( n = nmbr ),C0009247;C0599755
850,cohort nmbr ( uacr < nmbr . nmbr mg / g ),C0009247;C0599755;C1300563
849,prednisone - equivalent dose,C0032952;C0178602;C0205163;C0439185;C0869039;C1114758
849,prednisone or equivalent dose ( mg / day ),C0032952
849,prednisone,C0032952
849,< median prednisone dose,C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
849,smedian prednisone dose,C0032952;C0178602;C0869039;C1114758
848,b - agonists ( long - acting ) a,C0243192;C2987634
848,jsnmbr - agonists,C0243192;C1552154;C2987634
848,b - agonists ( short - acting ) a,C0243192;C2987634
847,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
847,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
847,sbp / dbp $ nmbr / $ nmbr mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
846,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
846,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
846,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
846,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
845,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C1514463;C2349943;C3539704;C3713294
845,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
844,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
844,week nmbr overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
844,overall vero population,C0032659;C0282416;C1257890;C1561607
844,overall population ( n = nmbr nmbr ) : non - cana ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
844,overall population ( n - nmbr ),C0032659;C0282416;C1257890;C1561607
844,overall population,C0032659;C0282416;C1257890;C1561607
844,overall population ( n = nmbr ),C0032659;C0282416;C1257890;C1561607
843,nmbr - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
843,nmbr - year mortality,C0026565;C0026566;C0439234;C0439508
843,all - causa mortality,C0026565;C0026566;C3903827
843,total mortality all,C0026565;C0026566;C0439175;C0439810
843,mortality,C0026565;C0026566
843,mortality outcomes,C0026565;C0026566;C1274040
843,shfm annual mortality,C0026565;C0026566;C0332181
843,total mortality,C0026565;C0026566;C0439175;C0439810
842,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
842,levetiracetam,C0377265;C3693636
841,duration of assigned regimen before surgery post - randomisation characteristic * *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
841,duration of assigned regimen before surgery post - randomisation characteristic *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
841,duration of assigned regimen before surgery,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
840,glucosamine + chondroitin sulfate ( n = nmbr ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
840,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
839,anterior myocardial infarction — no . / total no . ( % ),C0340293
839,anterior myocardial infarction — no . ( % ),C0340293
838,colon or rectum,C0009368;C3888384
838,colon only,C0009368;C0205171;C1720467;C3888384
838,colon,C0009368;C3888384
838,all of the colon,C0009368;C3888384
837,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
837,cigarette smoking,C0239059;C0700219
837,cigarette smoking in the past year,C0239059;C0700219;C4086728
836,glucosamine,C0017718
836,glucosamine ( n = nmbr ),C0017718
835,chinese,C0008120;C0152035
835,chinese subgroup,C0008120;C0152035;C1079230;C1515021
834,cardiac catheterisation or pci for index event,C0018795
834,cardiac catheterization,C0018795
833,brv overall,C0155502
833,brv overalla ( n = nmbr ),C0155502
833,brv nmbr mg / day ( n = nmbr ),C0155502;C0439422
833,brv dosage,C0155502;C0178602;C2986497
833,brv nmbr mg / day ( n =,C0155502;C0439422
833,brv nmbr   mg / day,C0155502;C0439422
833,brv > nmbr mg / day,C0155502;C0439422
832,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
832,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
831,mean ( sd ) [range] duration of epilepsy,C0014544;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
831,duration of epilepsy,C0014544;C0449238;C2926735
830,myocardial infarction / cabg / pci < nmbr years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
830,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
829,baseline mdrd egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
829,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
829,baseline egfr < nmbr,C0168634;C1442488;C1739039;C3811844;C3812682
829,baseline egfr ≥ nmbr to < nmbr,C0168634;C1442488;C1739039;C3811844;C3812682
829,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
829,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
829,baseline egfr ( ml / min per nmbr « nmbr m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
829,egfr at baseline,C0168634;C1442488;C1739039;C3811844;C3812682
829,baseline mdrd egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
829,baseline egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
828,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
828,history of htn,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
827,om nmbrmg / aml nmbr mg,C0023465;C0023467;C0028971;C1319635;C1705272
827,om nmbr mg / aml nmbr mg ( n = nmbr ),C0023465;C0023467;C0028971;C1319635;C1705272
827,om nmbr mg / aml nmbr mg,C0023465;C0023467;C0028971;C1319635;C1705272
827,om nmbr / aml nmbr /,C0023465;C0023467;C0028971;C1705272
826,edema peripheral,C0013604;C1717255
826,edema,C0013604;C1717255
825,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C1622890
825,heart rate at rest — beats / min,C0018810;C0035253;C1622890
824,om nmbr mg + aml nmbr mg + hctz nmbr mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
824,om nmbr mg / aml nmbr mg / hctz nmbr mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
824,om nmbr mg + aml nmbr mg + hctz nmbr mg ( n = nmbr ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
823,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
823,hrt use,C0042153;C0282402;C0457083;C1947944
822,minor,C0026193;C0205165
822,minor ischaemic stroke,C0026193;C0205165;C0948008
822,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
821,aspirin + dipyridamole ( n = nmbr ),C0732279
821,aspirin + dipyridamole,C0732279
820,improving anemia bsl hb < nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
820,no anemia bsl hb > nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
820,new anemia bsl hb > nmbrg i - nmbr  yr nmbr < nmbrg i - nmbr,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
819,• hospitalization for unstable angina,C0002965;C0019993
819,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
819,hospitalization for unstable angina,C0002965;C0019993
819,unstable angina requiring hospitalization,C0002965;C0019993
818,africa,C0001737
818,africa *,C0001737
818,africa or near east,C0001737
818,africa ! near east,C0001737;C1707877
817,r ight coronary,C0205090;C0684010;C2603358
817,rnmbr,C0205090;C0684010;C2603358
817,canvas - r,C0205090;C0684010;C2603358;C3281223
817,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
817,hemoglobin ( g rnmbr ),C0205090;C0684010;C1319312;C2603358
817,r,C0205090;C0684010;C2603358
816,belimumab nmbr mg sc ( n nmbr ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
816,sc belimumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
815,nmbr % confidence interval,C0009667
815,hazard ratio ( nmbr % confidence interval ) *,C0009667;C2985465
815,hazard ratio ( nmbr % confidence interval ),C0009667;C2985465
814,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
814,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
814,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
814,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
814,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
813,psoriatic arthropathy,C0003872
813,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
813,psoriatic arthritis,C0003872
812,ecg left ventricular,C1623258
812,ecg changes ( % ) t,C1623258
812,ecg abnormality ( resting ),C1623258;C1704258
812,minutes from prehospital ecg to pci,C0439232;C0700321;C0702093;C1282918;C1623258;C2347166
812,ecg,C1623258
812,si . gni . fi . canr ecg changes,C1623258;C4050619
812,ecg and imaging data,C1623258
812,due to ecg changes,C1623258
811,myocardial infarction without st - segment elevation — no . ( % ),C1536220
811,no prior stemi,C0332152;C1536220;C2826257;C3538872
811,prior stemi,C0332152;C1536220;C2826257;C3538872
811,stemi ( % ),C1536220;C3538872
811,stemi,C1536220;C3538872
811,st - segment — elevation myocardial infarction,C1536220
811,st - elevation myocardial infarction,C1536220;C3538872
811,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
811,st - segment elevation myocardial infarction,C1536220
811,st - segment - elevation myocardial infarction — no . ( % ),C1536220
810,reversible to bronchodilator,C0006280;C0205343
810,bronchodilator response,C0006280;C0871261;C1704632;C1706817;C2911692
809,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
809,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
808,patients without diabetes,C0011847;C0011849;C0030705
808,patients with diabetes,C0011847;C0011849;C0030705
808,patients with diabetes mellitus,C0011849;C0030705
808,patients without diabetes mellitus ( n = nmbr ),C0011849;C0030705
808,patients with diabetes mellitus ( n = nmbr ),C0011849;C0030705
807,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
807,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
807,prior use of conventional dmards only ( biologic - nai ' ve ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
806,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
806,prior biologic therapeutic failures,C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
805,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
805,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
805,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
805,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
805,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
804,amputation,C0002688;C0332840;C1546539
804,major amputations at week nmbr,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
804,amputations,C0002688
804,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
804,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
804,amputation — no . ( % ),C0002688;C0332840;C1546539
803,rituximab ( nmbrxnmbr mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
803,rituximab ( nmbrxnmbr mg ) + mtx ( n = nmbr ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
802,inhaled jnmbr - agonist §,C0004048;C2987634
802,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
802,inhaled^,C0004048
802,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
802,inhaled §,C0004048
801,mercaptopurine,C0000618
801,nmbr - mercaptopurine,C0000618
800,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
800,family history of premature,C0151526;C0205252;C0241889;C4018905
800,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
800,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
799,indacaterol / glycopyrronium nmbr / nmbr   μ g o . d .,C0439417;C1722260;C3814772
799,indacaterol - glycopyrronium group ( n = nmbr ),C0441848;C1722260;C3814772
799,indacaterol group ( n = nmbr ),C0441848;C1722260
799,indacaterol n = nmbr,C1722260
798,ckd at baseline,C0168634;C1442488;C1561643
798,change from baseline stage nmbr ckd,C0168634;C0597205;C0679846;C1442488;C1561643
797,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
797,visit nmbr dbp,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
797,dbp ( mmghg ),C0536221;C3813197;C4281799
797,daytime mean dbp ( abpm ) at week nmbr,C0332169;C0332174;C0439230;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
797,dbp ( office measurement ),C0242485;C0442603;C0536221;C3813197;C4281799
797,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
797,dbp < nmbr mmhg,C0439475;C0536221;C3813197;C4281799
797,dbp ≥ nmbr mmhg,C0439475;C0536221;C3813197;C4281799
797,dbp > nmbr or sbp > nmbr mm hg laboratory determinations,C0536221;C3813197;C4281799
797,dbp at visit nmbr,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
797,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
797,dbp mm hg,C0439475;C0536221;C3813197;C4281799
797,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
797,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
797,dbp,C0536221;C3813197;C4281799
797,mean change in dbp from baseline,C0392747;C0443172;C0444504;C0536221;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952
797,nighttime mean dbp ( abpm ) at week nmbr,C0240526;C0332174;C0439230;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
796,first hospitalization for chf or cv death,C0018802;C0019993;C0205435;C1279901
796,hospitalisation for chf within nmbr years of randomisation,C0018802;C0019993
795,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C1704675;C1709380
795,new vertebral fracture at nmbr months,C0080179;C0205314;C0439231
795,clinical vertebral fractures,C0080179;C0205210
795,vertebral fracture and / or t score - nmbr . nmbr,C0080179
795,vertebral fracture,C0080179
795,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
795,spinal fractures,C0080179;C0518450
795,vertebral fracture and / or t score s - nmbr . nmbr,C0080179
794,on antihypertensive medication at baseline,C0003364;C0168634;C1442488
794,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
793,first co - primary,C0205435;C1279901;C3245499
793,colombia,C3245499
793,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
793,second co - primary,C0205436;C0457385;C0565930;C1561503;C1705190;C3245499
793,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
792,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
792,thiazolidinedione,C0289779;C1257987;C3537039
792,thiazolidinedione no,C0289779;C1257987;C3537039
792,any thiazolidinedione,C0289779;C1257987;C3537039
792,thiazolidinedione based,C0289779;C1257987;C3537039
792,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
792,thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039
791,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
791,method used to diagnose the incident pulmonary embolism,C0025663;C0449851;C0871511
791,method of insulin administration,C0025663;C0199782;C0449851;C0871511
790,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
790,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
790,gastrointestinal bleeding,C0017181
790,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
789,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
789,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
789,estrogen ( ' % ? ),C0014939;C2936882;C4542544
789,estrogen,C0014939;C2936882;C4542544
789,no estrogen,C0014939;C2936882;C4542544
789,estrogens,C0014939;C3537250;C3541386;C3714615
788,type ic,C0020750;C0332307;C1547052;C4554818
788,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
788,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
787,ckd ( egfr < nmbr ),C1561643;C1739039;C3811844;C3812682
787,ckd ( egfr < nmbrb ),C1561643;C1739039;C3811844;C3812682
786,hla - bnmbr positive,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
786,hla - bnmbr,C0019737;C0550853;C1415561
786,positive hla - bnmbr status,C0019737;C0439178;C0449438;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
786,positive for hla - bnmbr,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
786,hla ‐ bnmbr positive,C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
785,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
785,iu,C0049272;C0439453;C0694756
785,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
784,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
784,on steroid at baseline,C0038317;C0168634;C1442488
784,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
784,baseline steroids,C0038317;C0168634;C1442488
783,neuraxial alonee,C3714787
783,central nervous system,C3540014;C3714787
782,previous aorta - femoral or lower extremity bypass surgery,C0003483;C0205156;C1552607
782,aortic,C0003483
781,ez / simva nmbr / nmbr mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
781,ez / simva nmbr mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
780,vte / vte - related deathsb,C0439849;C0445223;C0630906
780,vte / vte - related deathsa,C0439849;C0445223;C0630906
780,any vte - related death,C0425043;C0630906
780,previous vte,C0205156;C0630906;C1552607
780,any vte or vte - related death — no . ( % ),C0630906
780,previous vte n ( % ),C0205156;C0630906;C1552607
780,unprovoked vte n ( % ),C0630906
780,previous vte — no . ( % ),C0205156;C0630906;C1552607
780,vte at day nmbr +,C0332173;C0439228;C0439505;C0630906
780,clinical presentation of vte at initial diagnosis — no . ( % ),C0630906;C2708283
779,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
779,• ii : death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1710602;C1956346;C4082313;C4082587;C4552775
779,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
778,osteoarthritis,C0029408
778,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
778,severe oa symptoms at baselined,C0029408;C0436345;C3887876
778,oa,C0029408;C3887876
778,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
777,seated sbp,C0085805;C0277814;C1283233
777,seated sbp at nmbr weeks,C0085805;C0277814;C0439230;C1283233
777,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
776,black / african american *,C0085756
776,african - american,C0085756
776,african america,C0085756
776,african - american / african heritage ( n = nmbr ),C0085756;C2986513
776,african american n = nmbr,C0085756
776,black / african - american,C0085756
776,african - latin american,C0085756
776,black / african - american ( nmbr . nmbr % ),C0085756
776,black / african american,C0085756
776,african americans,C0085756
776,african american,C0085756
776,black / af rican american,C0085756;C0344434;C4049859
775,sirukumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
775,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
774,inhaled corticosteroid,C0001617;C0004048;C3536709
774,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
774,inhaled corticosteroid - yes,C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
773,reduction in risk % ( nmbr % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
773, ( nmbr % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
772,no extensive colitis,C0009319;C0205231;C1963084
772,extensive colitis or pancolitis,C0009319;C0205231;C1963084
772,extensive colitis,C0009319;C0205231;C1963084
771,metoprolol group ( n = nmbr ),C0025859;C0441848
771,metoprolol ( n = nmbr nmbr ),C0025859
770,normoglycaemic individuals,C0027361;C0237401;C0580545
770,no . ( % ) of individuals *,C0027361;C0237401
770,other individual and exploratory end points,C0027361;C0237401
770,no . of cardiovascular events ( cardiovascular events / nmbr person - years ),C0027361;C0439234;C1320716;C2347489
770,incidence rate per nmbr person years,C0027361;C0439234;C1708485;C2347489
770,person - years,C0027361;C0439234;C2347489
770,event rate ( per nmbr person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
770,incidence rate ( per nmbr person - yr ),C0027361;C0439234;C1708485;C2347489
770,event rate ( per nmbr person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
770,incidence rate per nmbr person - years,C0027361;C0439234;C1708485;C2347489
770,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
770,individual endpoints,C0027361;C0237401;C2349179
770,individuals with normoglycaemia,C0027361;C0237401;C0580545
770,individuals with type nmbr diabetes,C0027361;C0237401;C1320657
770,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C1709707
770,teaes in anmbr % of individuals,C0027361;C0237401
770,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0237401;C1709707
770,number of people ( n ),C0027361;C0237753;C0449788
770,no . / nmbr person - yr,C0027361;C0439234;C2347489
770,incidence [n / n ( rate per nmbr person - years ) ],C0027361;C0439234;C1708485;C2347489
769,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
769,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
769,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
769,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
769,[cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
769,[cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
768,liraglutide nmbr . nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
768,liraglutide nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
768,liraglutide nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
768,liraglutide nmbr - nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
768,liraglutide ( nmbr . nmbr mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
768,liraglutide nmbr . nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
768,liraglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
767,coronary intervention,C0018787;C0184661;C0886296;C1273869
767,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
767,prior coronary intervention or coronary artery bypass grafting,C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
766,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
766,no worsening in pga,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
766,pga score,C0016410;C0449820;C3541266;C4050231;C4050369
766,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
766,pga,C0016410;C3541266;C4050369
766,pga subscore,C0016410;C3541266;C4050369
765,pdqol scale,C0175659;C0349674;C1947916
765,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
765,jsn score ( nmbr – nmbr scale ),C0175659;C0349674;C0449820;C1947916;C4050231
765,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
765,pasi score ( nmbr – nmbr scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
765,dactylitis score ( nmbr – nmbr scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
765,total score ( nmbr – nmbr scale ),C0175659;C0349674;C1947916;C2964552
765,erosion score ( nmbr – nmbr scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
765,geometric mean blood eosinophil count on loge scale — cells / ^ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
765,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mmnmbr,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
765,scale — cognitive portion  ldl — low -,C0175659;C0349674;C0449719;C1516691;C1947916
764,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
764,dha ( n = nmbr ),C0142831;C2348308
763,family history of chd ( n = nmbr,C0241889;C0280604;C3542407
763,no family history of chd ( n = nmbr,C0241889;C0280604;C3542407
763,family history^,C0241889
763,family history of cancera,C0241889
763,family history,C0241889
763,family history of cancerf,C0241889
762,low - density lipoprotein,C0023823
762,low - density lipoprotein^,C0023823
762,low - density lipoprotein choles -,C0023823
761,duration of ulcerative colitis,C0009324;C0449238;C2926735
761,ulcerative colitis,C0009324
760,drug therapy,C0013216;C0013217
760,drug therapy at admission — no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
760,drug therapy at admission 一 no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
760,pharmacotherapy,C0013216;C0013217
760,other drug therapy,C0013216;C0013217
759,mean ( se ),C0036919;C0444504;C2347634;C2348143
759,crp median ( se ),C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
759,( se ),C0036919
759,nmbr - y incidence rate ( se ) per nmbr participants,C0036919;C0679646;C1708485
759,( se]tf,C0036919;C4048299;C4048587
759,se,C0036919
759,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
759,( se]tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
759,( se]tf hdl - c,C0036919;C3715113;C4048299;C4048587
759,adjusted mean ( se ) fevi auco_nmbr,C0036919;C0429706;C0444504;C0456081;C0849974;C1561566;C2347634;C2348143;C4528367
759,difference ( se ),C0036919;C1705241;C1705242
759,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
759,% ( se ),C0036919
759,s / se,C0036919;C0565930;C2603362
759,adjusted mean ( se ) trough fevi,C0036919;C0444504;C0444506;C0456081;C0849974;C1561566;C2347634;C2348143;C4528367
759,( se]t,C0036919
759,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
759,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
759,mean ( se ) nmbr - year rates per nmbr population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
759,( se] +,C0036919
759,( se ) t *,C0036919
759,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
759,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
759,mean ( se ) trough,C0036919;C0444504;C0444506;C2347634;C2348143
759,mean ± se,C0036919;C0444504;C2347634;C2348143
759,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
759,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
759,( se]t *,C0036919
759,week nmbr mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
758,overweight,C0497406
758,overweight ( nmbr to < nmbr kg / mnmbr ),C0497406;C1532718
758,nmbr - nmbr . nmbr : overweight,C0497406
758,overweight ( bmi £ nmbr to < nmbr ),C0497406;C0578022
758,bmi nmbr – nmbr overweight,C0497406;C0578022
758,overweight ( bmi = nmbr - nmbr . nmbr ),C0497406;C0578022
757,indacaterol + tiotropium ( n[nmbr ),C0213771;C1722260
757,differences between indacaterol + tiotropium versus tiotropium + placebo,C0213771;C1705241;C1705242;C1722260
756,extent of index dvt ' ( n,C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
756,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
756,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
756,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
755,poor compliance / noncompliance,C0032646;C0376405;C0457432
755,non - compliance,C0376405;C0457432
754,lvh by echo or ecg,C0058928;C0149721;C1655045
754,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
753,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
753,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
752,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
752,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
752,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
752,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
752,placebo patients with events / total,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
751,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
751,latvia,C0023128
750,demographic characteristic,C0011298;C1521970
750,demographics age ( years ),C0011298;C1510829;C1704791
750,demographic and clinical,C0011298
750,demographic and medical variables,C0011298
750,demographics age,C0001779;C0011298;C1704791
750,demographic,C0011298
750,demographics,C0011298;C1704791
750,demographics and clinical characteristics,C0011298;C1704791
750,demographic nmbr . nmbr ( nmbr . nmbr ),C0011298
750,demographic variable,C0011298;C0439828;C4553760
750,demography,C0011298
750,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
750,demographic and clinical characteristics,C0011298
750,( a ) demographics,C0011298;C1704791
749,pvd,C0085096;C4521226
749,peripheral vascular disease,C0085096
748,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
748,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
748,< nmbr cells / pl,C0007584;C0007634;C3897966;C4049765
748,< nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
748,nmbr to < nmbr cells,C0007584;C0007634
748,> nmbr cells / pl,C0007584;C0007634;C3897966;C4049765
748,> nmbr to < nmbr cells / mm ’,C0007584;C0007634;C4330985;C4554674
748,> nmbr to < nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
748,> nmbr cells / mm^,C0007584;C0007634;C4330985;C4554674
748,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
748,eosinophil count ( cells / pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
748,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
748,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
747,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
747,omalizumab ( lsm ),C0966225
747,omalizumab,C0966225
746,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
746,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
746,background lipid therapy per acc / aha definition,C0023779;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
746,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
745,blood glucose - lowering drugs,C0005802;C0013227;C0017725;C0018938;C0441994;C2003888;C3687832
745,oral blood glucose - lowering drug nmbr ( nmbr . nmbr ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
744,nonvertebral fractures,C0016658
744,fracture,C0016658
744,nonvertebral fracture,C0016658
744,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
744,fractures ( site not specified ),C0016658
744,clinical fracture,C0016658;C0205210
744,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
744,bone fracture,C0016658
744,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
744,prior nonvertebral fracture,C0016658;C0332152;C2826257
744,fractures,C0016658
744,c clinical fractures ( fas ),C0016658;C0205210
744,prior clinical fracture ( since age nmbr ),C0016658;C0205210;C0332152;C2826257
744,prior nonvertebral fracture at age > nmbr years,C0016658;C0332152;C1510829;C2826257
743,r nmbr mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
743,r nmbr mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
743,r nmbr mg ( « = nmbr ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
743,r nmbr mg + fa ( « = nmbr ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
742,with alogliptin nmbr . nmbr mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
742,with alogliptin nmbr mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
742,with alogliptin nmbr . nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
742,with alogliptin nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
741,waist - hip ratio,C0205682
741,waisthip ratio,C0205682;C0456603;C1547037
741,waist : hip ratio,C0205682
741,waist - to - hip ratio,C0205682
740,secukinumab nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab nmbr   mg no load ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab intravenous nmbr mg ( n = nmbr ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
740,secukinumab nmbr   mg ( n   =   nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
739,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
739,thrombus aspiration done per lesion †,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
739,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
739,anti - thrombotics,C0087086
739,increased risk for thrombotic cardiovascular event^,C0087086;C0205217;C0442805;C1273410
738,placebo + statin,C0032042;C0360714;C1696465;C1706408
738,placebo plus statin ( n = nmbr ),C0032042;C0332287;C0360714;C1696465;C1706408
738,statin + placebo ( n = nmbr ),C0032042;C0360714;C1696465;C1706408
738,placebo + statin ( n = nmbr,C0032042;C0360714;C1696465;C1706408
737,xanthinesnmbr,C0043318;C3541955
737,xanthines,C0043318;C3541955
736,evolocumab nmbr mg every nmbrweeks ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
736,evolocumab nmbr mg monthly ( n = nmbr ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
736,evolocumab ( nmbr mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
735,arrhythmias,C0003811
735,prior arrhythmias,C0003811;C0332152;C2826257
735,arrhythmia,C0003811
735,arrhythmia !,C0003811
734,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
734,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
734,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
733,safety,C0036043;C1705187
733,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
733,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
733,safety variable,C0036043;C0439828;C1705187;C4553760
732,other cardiac surgery,C0018821;C0524727
732,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
731,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
731,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
731,bl bmioo kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
731,bl alc < nmbr . nmbr %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
731,bl,C0005918;C0006413;C1552663;C2827109
731,bl bml > nmbr kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
731,bl bml < nmbr kg / m^,C0005918;C0006413;C1532718;C1552663;C2827109
731,bl mean,C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
730,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
730,tpm subgroup,C0076829;C1079230;C1515021
730,tpm - naive,C0076829
730,topiramate,C0076829
730,tpm - exposed,C0076829
729,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
729,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
728,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
728,treatment groups,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1552839;C1705169;C1705428;C1705429;C3538994;C3887704
727,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
727,nmbr - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
726,cardiac medications during indexhospitalization and / or discharge,C0013227;C0018787;C0802604;C1522601;C2598133;C4284232
726,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
725,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
725,hyperlipidaemia,C0020473;C0428465;C4555212
725,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
725,hyperlipidemia ( % ),C0020473;C0428465;C4555212
725,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
725,hyperlipidemia | |,C0020473;C0428465;C4555212
725,hyperlipidemia §,C0020473;C0428465;C4555212
725,hyperlipidemia^,C0020473;C0428465;C4555212
725,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
725,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
725,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C4555212
725,hyperlipidemia,C0020473;C0428465;C4555212
724,bmnmbr,C0006416
724,bmnmbr ( kg / mnmbr ),C0006416;C1532718
724,mean bmnmbr ± s . d .,C0006416;C0444504;C2347634;C2348143
723,dpp ‐ nmbr inhibitors,C0243077;C1414174
723,dpp - nmbr inhibitors,C0243077;C1414174
723,inhibitors — no . { % ) se - nmbr physical functioning score^^,C0243077
723,cypnmbranmbr inhibitors,C0243077;C1418793;C2634343
723,gp llb / llla inhibitors,C0243077;C1705010;C3811116
723,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
723,raas inhibitors,C0243077
723,ilb / iiia inhibitors,C0243077;C4697913
723,no ilb / iiia inhibitors,C0243077;C4697913
722,diclofenac ( n = nmbr nmbr ),C0012091
722,diclofenac ( n = nmbr,C0012091
722,diclofenac,C0012091
722,diclofenac ( n = nmbr ),C0012091
722,diclofenac group ( n = nmbr nmbr ),C0012091;C0441848
721,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death or hospitalized hf,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death ( n = nmbr ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
721,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
721,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
721,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
720,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0032790;C3536840
720,postoperative nsaid or glucocorticoid use,C0003211;C0032790;C3536840
719,dapagliflozin nmbr mg group ( n = nmbr ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
719,dapagliflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
719,dapagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
719,dapagliflozin nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
718,with tiotropium,C0213771
718,( tiotropium n = nmbr,C0213771
718,lama ( tiotropium ),C0213771;C0999593;C1416775
718,tiotropium group ( n = nmbr ),C0213771;C0441848
718,( tiotropium n = nmbr non - tiotropium n = nmbr ),C0213771;C1518422
718,( tiotropium n = nmbr non - tiotropium n = nmbr nmbr,C0213771;C1518422
718,tiotropium ( n = nmbr ),C0213771
718,tiotropium nmbr m g,C0213771;C0456715
718,tiotropium + placeb ( n[nmbr ),C0213771
718,tiotropium ( n z nmbr ),C0213771
718,tiotropium vs . salmeterol,C0213771
718,non - tiotropium,C0213771;C1518422
718,tiotropium nmbr . nmbr μ g ( n   = nmbr ),C0213771;C0439267
718,tiotropium nmbr   μ g ( n   =   nmbr ),C0213771;C0439267
718,tiotropium,C0213771
718,tiotropium nmbr . nmbr   μ g ( n   =   nmbr ),C0213771;C0439267
717,sitagliptin no . / total no .,C1565750
717,sitagliptin ( n = nmbr ),C1565750
717,sitagliptin ± oad,C1565750
717,sitagliptin,C1565750
717,sitagliptin n = nmbr,C1565750
717,sitagliptin nmbr,C1565750
716,sulfonylureas,C0038766;C3653359
716,any sulfonylurea,C0038766;C3536898
716,sulfonylurea — no . ( % ),C0038766;C3536898
716,duration of sulphonylurea use ( months ),C0038766;C0439231;C1881378;C2826775;C3536898
716,other sulfonylurea 一 no . ( % ),C0038766;C3536898
716,sulfonylurea based,C0038766;C3536898
716,sulfonylurea derivatives,C0038766
716,sulphonylureas,C0038766
716,sulphonylureas only,C0038766;C0205171;C1720467
716,sulphonylurea,C0038766;C3536898
716,sulfonylurea,C0038766;C3536898
716,on sulfonylurea,C0038766;C3536898
715,urine qmax,C0042036;C0042037;C2963137
715,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
715,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
715,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
715,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
715,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
714,primary angioplasty ( n = nmbr ),C0162577;C0205225;C0439612;C0439631;C1548817
714,prior angioplasty,C0162577;C0332152;C1548817;C2826257
714,previous angioplasty,C0162577;C0205156;C1548817;C1552607
714,peripheral angioplasty,C0162577;C0205100;C1548817
714,angioplasty,C0162577;C1548817
713,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
713,ras antagonist,C0034678;C0231491;C0525678
713,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
712,placebo - abatacept nmbr / nmbr - abatacept nmbr / nmbr,C0032042;C1619966;C1696465;C1706408
712,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
711,fondaparinux,C1098510
711,fondaparinux ( n = nmbr ),C1098510
711,fondaparinux ( n = nmbr,C1098510
711,fondaparinux — no . ( % ),C1098510
711,commercially available fondaparinux,C0470187;C1098510
710,lamotrigine,C0064636;C0524166
710,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
709,n - nmbr pufa ( n = nmbr ),C0032615;C0369718;C0441922
709,n - nmbr - pufa ( n = nmbr ),C0032615;C0369718;C0441922
709,n - nmbr pufa,C0032615;C0369718;C0441922
708,social functioning,C0037395
708,daily activities / social functioning,C0037395;C0871707
708,social function,C0037395
707,qrs > nmbr ms,C2349943;C3539704;C3713294
707,qrs > nmbr ms *,C2349943;C3539704;C3713294
707,ms,C2349943;C3539704;C3713294
707,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
707,qrs duration > nmbr ms,C0429025;C0488377;C2349943;C3539704;C3713294
707,ms nmbr - nmbr,C2349943;C3539704;C3713294
707,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
707,nmbrms score †,C0449820;C2349943;C3539704;C3713294;C4050231
707,qrs < nmbr ms ( nmbr % cl ) ( n - nmbr,C0596019;C2349943;C3539704;C3713294
707,ms < nmbr,C2349943;C3539704;C3713294
707,qrs $ nmbr ms ( nmbr % cl ) ( n - nmbr ),C0596019;C2349943;C3539704;C3713294
706,parental history of mi before age nmbr y,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
706,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
706,parental history of ml before age nmbr y yes,C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
705,glycoprotein ilb / iiia inhibitor before pci],C0017968;C1999216;C4049621;C4697913
705,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
705,glycoprotein llb / llia inhibitor,C0017968;C1999216
705,glycoprotein llb / illa inhibitor,C0017968;C1999216
705,glycoprotein iib / iiiareceptorinhibitor,C0017968
704,oral antidiabetes combination therapy without insulina,C0009429;C0442027;C0556895;C4521986
704,combination therapy ( n = nmbr ),C0009429;C0556895
704,combination therapy * *,C0009429;C0556895
704,combination therapy,C0009429;C0556895
704,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
703,albumin ( mg / dl ),C0001924;C0439269
703,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
703,albumin,C0001924
702,relative risk ( nmbr % ci ),C0008107;C0242492;C3259781
702,relative risk ( nmbr % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
702,relative risk { nmbr % ci ),C0008107;C0242492;C3259781
701,history of stroke or transient ischemic attack,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
701,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke at baseline,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of strokenmbr,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke or tia - n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke / see / tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke or tia — no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke or tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
701,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
700,immunosuppressant use,C0021081;C0042153;C0457083;C1947944
700,immunosuppressive use,C0021081;C0042153;C0457083;C1947944
699,self - reported disease severity,C0521117;C0681906;C2700446
699,self - reported descent,C0681906;C2700446
698,baseline gfr < nmbr ml / min / nmbr . nmbrmnmbr,C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
698,estimated gfr at baseline,C0017654;C0168634;C0750572;C1424601;C1442488
698,baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr,C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
698,mildlydecreased baseline gfr ( nmbr - nmbr ml / min / nmbr . nmbrmnmbr ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
697,ratio of hrs ( nmbr % cl ),C0456603;C0596019;C1547037;C1568891
697,> nmbr : nmbr hrs : min ( n = nmbr ),C0702093;C1524029;C1568891;C3813700
697,> nmbr hrs,C1568891
697,> l : nmbrhrs : min ( n = nmbr ),C0439393;C1568891
697,< nmbr hrs,C1568891
697,^nmbr hrs,C1568891
696,renal insufficiency,C0035078;C1565489
696,renal insufficiency *,C0035078;C1565489
696,renal insufficiency or failure,C0035078;C1565489
696,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
696,renal insufficiencynmbr,C0035078;C1565489
696,renal insufficiency — no . ( % ),C0035078;C1565489
695,active smoker,C0205177;C0337664;C3853793;C3888249
695,active smokers,C0205177;C0337664;C3853793;C3888249
695,noncurrent smoker,C0337664
695,smoking history : ex - smoker,C0337664;C1519384
695,smokers,C0337664
695,past smoker,C0337664;C1444637;C4284302
695,ever - smoker,C0337664;C3887636
695,smokers : qvanmbr - nmbrfc,C0337664;C2983605
695,present smoker,C0150312;C0337664;C0449450
695,smoker or ex - smoker,C0337664
695,smoker ( % ) a,C0337664
695,currently smoker,C0337664;C0521116
695,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
695,smoker,C0337664
695,smoker ( % ),C0337664
695,> nmbr kg / mnmbr smokers,C0337664;C1532718
694,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1959907;C3541383
694,time from hospital admission to pci,C0019994;C0040223;C1510665;C1959907;C3541383
693,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450
693,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392
692,beta - carotene,C0053396;C0696105
692,beta - carotene ( n = nmbr,C0053396;C0696105
691,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
691,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
690,compression stockings,C0038348
690,use of compression stockings,C0038348;C1524063
689,mitral insufficiency,C0026266
689,mitral regurgitation,C0026266
688,pneumonia events,C0032285;C0441471;C3541888
688,adjusted rate of pneumonia events ( per patient - year ),C0032285;C0441471;C0456081;C0871208;C1521828;C3541888
688,hospitalized pneumonia events,C0032285;C0441471;C0701159;C3541888
688,previous pneumonia,C0032285;C0205156;C1552607
688,patients with hospitalized pneumonia events,C0032285;C0441471;C0870668;C3541888
688,pneumonia in past year,C0032285;C4086728
688,adjusted rate of hospitalized pneumonia events ( per patient - year ),C0032285;C0441471;C0456081;C0701159;C0871208;C1521828;C3541888
688,pneumonia,C0032285
687,baseline laboratory values,C0022877;C0042295;C0168634;C1442488;C3244292;C4283904
687,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
686,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
686,ischemic cause,C0015127;C0475224;C1524003
686,pah origin / cause,C0015127;C1418251;C1524003
686,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
686,all - cause mortalitv,C0015127;C1524003
686,ischaemic cause,C0015127;C0475224;C1524003
686,all - cause,C0015127;C1524003
686,any cause,C0015127;C1524003
686,other cause,C0015127;C1524003
685,black ( n   = nmbr ),C0005680;C0027567;C0085756;C0439541
685,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
685,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
685,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
685,black or asian,C0005680;C0027567;C0085756;C0439541
685,black or african heritage,C0005680;C0027567;C0085756;C0439541
685,nmbrfe black *,C0005680;C0027567;C0085756;C0439541;C3848561
685,non - black ( n = nmbr ),C0005680;C0027567;C0085756;C0439541;C1518422
685,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
685,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
685,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
685,black ( n = nmbr )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
685,black or african,C0005680;C0027567;C0085756;C0439541
685,black /,C0005680;C0027567;C0085756;C0439541
685,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
685,black or african american,C0005680;C0027567;C0085756;C0439541
685,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541
685,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
685,black and other,C0005680;C0027567;C0085756;C0439541
685,african american / black,C0005680;C0027567;C0085756;C0439541
685,black race — no . / total no . ( % ) f,C0005680;C0027567;C0085756;C0439541
685,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
685,black or african - american,C0005680;C0027567;C0085756;C0439541
685,black,C0005680;C0027567;C0085756;C0439541
685,black ( n = nmbr ),C0005680;C0027567;C0085756;C0439541
685,black or african america,C0005680;C0027567;C0085756;C0439541
685,black ( n — nmbr ),C0005680;C0027567;C0085756;C0439541
685,black *,C0005680;C0027567;C0085756;C0439541
685,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
685,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
684,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
684,canagliflozin,C2974540
684,canagliflozin ( n = nmbr ),C2974540
683,rolofylline,C0166128
683,rolofylline dose,C0166128;C0178602;C0869039;C1114758
683,rolofylline n,C0166128
683,rolofylline ( n = nmbr,C0166128
683,rolofylline rx,C0166128;C1425688;C1521941;C2709207
683,rolofylline ( n = nmbr ),C0166128
682,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
682,crp ( normal range : nmbr - nmbr . nmbr ),C0086715;C3890735;C4048285
682,% of predicted normal value *,C0086715;C0681842;C1882327
681,calima japan ( n = nmbr ),C0022341
681,japan and south korea,C0022341
681,japan n = nmbr,C0022341
681,not - japan,C0022341;C1518422
681,not - japan n = nmbr,C0022341;C1518422
681,japan,C0022341
680,hazard ratio ( nmbr % cl ) valsartan vs . placebo,C0216784;C0596019;C2985465
680,valsartan ( n = nmbr ),C0216784
680,valsartan,C0216784
680,valsartan n / n,C0216784
679,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
679,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3887460
679,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
678,patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr,C0030705;C1739039;C3811844;C3812682
678,patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
678,patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
678,patients with egfr < nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
677,non - tnf inhibitors,C0243077;C1448177;C1518422
677,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
677,tnf inhibitors,C0243077;C1448177
676,dyslipidaemia,C0242339
676,dyslipidaemia and hypertension,C0242339
676,dyslipidemia,C0242339
676,dyslipidaemia and hypertensiont,C0242339
676,dyslipidaemia — no . ( % ),C0242339
676,dyslipidaemia including hypercholesterol — no . ( % ),C0242339
676,dyslipidemia — no . ( % ),C0242339
676,dyslipidemia — no . { % ),C0242339
676,dyslipidaemia 本,C0242339
676,dyslipidemia — no . ( % ) |,C0242339
676,dyslipidemianmbr,C0242339
675,knee,C0022742;C0022745;C1963703
675,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
674,baricitinib nmbr mg qd ( n = nmbr ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
674,baricitinib nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
674,baricitinib nmbr mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
674,baricitinib nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
674,baricitinib nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
673,age group ( ≥ nmbr years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
673,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
672,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
672,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
672,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
672,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
672,> nmbr glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
672,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
671,tenecteplase and pci ( n = nmbr ),C0872913
671,tenecteplase,C0872913
670,ab / ff nmbr / nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240;C4554348
670,ff nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240;C4554348
670,ab nmbr pg ( n = nmbr ),C0030827;C0072225;C1266240
670,sfc nmbr / nmbr pg twice daily ( n = nmbr ),C0030827;C0072225;C0585361;C1266240;C4521536
670,gly ( nmbr . nmbr pg b . i . d . ) n = nmbr,C0030827;C0072225;C0152277;C1266240;C1415124
670,nmbr - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
670,qvanmbr / nmbr pg once daily ( n = nmbr ),C0030827;C0072225;C0332173;C1266240
670,aclidinium nmbr pg,C0030827;C0072225;C1266240;C2699757
670,aclidinium nmbr pg vs placebo,C0030827;C0072225;C1266240;C2699757
669,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
669,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
669,anthropometric characteristics,C0003188;C1521970
668,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
668,agi,C1299007
668,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
667,nmbr - mercaptopurine / azathioprine,C0000618;C0004482
667,azathioprine / nmbr - mercaptopurine,C0000618;C0004482
666,rest of world,C0035253;C1622890;C2700280
666,paonmbr at rest,C0035253;C0232555;C1423784;C1427155;C1622890;C4318615
666,rest - of - world ( n = nmbr ),C0035253;C1622890;C2700280
666,aaponmbr at rest,C0035253;C1622890
666,intensity of rest pain ( mmvas ),C0035253;C0234253;C0522510;C1320357;C1622890;C4085211
666,rest ofthe world,C0035253;C1622890;C2700280
666,rest of the world,C0035253;C1622890;C2700280
666,rest ofworld,C0035253;C1622890
666,rest of world n z nmbr,C0035253;C1622890;C2700280
665,ls mean difference ( nmbr % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
665,ls mean ( nmbr % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
665,difference in ls means ( nmbr % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,ls means difference ( nmbr % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,difference in ls means ( nmbr % ci ) versus placebo,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,difference in ls means ( nmbr % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,ls means difference ( nmbr % ci ) nmbr,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,difference in ls means ( nmbr % ci ) nmbr,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
665,ls mean ( nmbr % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
665,ls - mean between - group difference ( nmbr % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
664,multiple diagnoses,C0011900;C0439064
664,history of diagnosed hypertension prior to randomization,C0011900;C0455527
664,history of diagnosed hypertension n ( % ),C0011900;C0455527
664,diagnosed,C0011900
663,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
663,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
662,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
662,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
662,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
661,anti - tnf - naive patientsnmbr,C0030705;C1448177
661,anti - tnf - experienced patients,C0030705;C1448177
661,anti - tnf - naive patients,C0030705;C1448177
660,ambulance ( % ),C0002422;C3846685
660,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
660,ambulance,C0002422;C3846685
660,in ambulance,C0002422;C3846685
660,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685;C4086878
659,high - dose statin use,C0042153;C0360714;C0444956;C0457083;C1947944
659,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
659,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
659,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
659,statin use,C0042153;C0360714;C0457083;C1947944
659,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
659,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
659,statin use ( % ),C0042153;C0360714;C0457083;C1947944
659,no statin use,C0042153;C0360714;C0457083;C1947944
659,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
659,prior statin use ( n = nmbr ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
658,vedolizumab,C2742797
658,vedolizumab n = nmbr,C2742797
657,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
657,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
657,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
657,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
656,carbamazepine,C0006949;C0006950;C0682993
656,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
656,cbz - naive,C0006949
656,cbz - exposed,C0006949
655,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
655,thiazides,C0541746
655,thiazide users,C0541746;C1706077
655,thiazide,C0541746
655,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
654,biochemical measures,C0079809;C0205474;C1879489
654,ipeated - measures state examinatioi,C0079809;C1879489
654,measure,C0079809;C0242485
654,measures,C0079809;C1879489
654,measures ( % ),C0079809;C1879489
654,physiological measures,C0079809;C0205463;C1879489
654,measures ( mmol / l ),C0079809;C0242485;C1879489
653,pre - hospital ticagrelor ( n = nmbr ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
653,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
653,in - hospital ticagrelor ( n = nmbr ),C0019994;C1510665;C1999375
653,in hospital ticagrelor,C0019994;C1510665;C1999375
652,no previous ischemic stroke / tia ( n = nmbr nmbr  nmbr . nmbr % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
652,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
652,previous ischemic stroke / tia ( n = nmbr  nmbr . nmbr % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
652,previous tia or stroke,C0007787;C0205156;C0917805;C1054154;C1552607
652,transient ischaemic attack — no . ( % ),C0007787;C0917805
652,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
652,hemispheric tia n = nmbr,C0007787;C0205139;C0917805;C1054154
652,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
652,transient ischaemic attack,C0007787;C0917805
652,transient ischemic attack,C0007787;C0917805
652,tia,C0007787;C0917805;C1054154
652,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
651,cfb at week nmbr,C0009002;C0332174;C0439230;C1824728
651,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
651,mtss cfb,C0009002;C1824728
650,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
650,revascularization during index hospitalization,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
650,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
649,asthma symptoms in the past nmbr weeks,C0004096;C0683368;C1457887;C2984299;C2987125
649,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
648,blood transfusion,C0005841;C0281867
648,transfusions,C0005841;C0199960;C1879316
648,transfusion,C0005841;C0199960;C1879316
648,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
648,any blood transfusion,C0005841;C0281867
647,mean ( sd ) periostin,C0219433;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
647,periostin high,C0219433;C1424662;C3812270
647,low periostin subgroup (,C0205251;C0219433;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
647,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
647,periostin,C0219433;C1424662;C3812270
647,high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
647,periostin low,C0219433;C1424662;C3812270
646,lv diastolic dysfunction,C0023128;C0520863;C0731033;C1881413
646,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
646,lv systolic dysfunction,C0023128;C0731033;C0749225;C1881413
646,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
646,lv ejection fraction > nmbr % and < nmbr %,C0023128;C0489482;C0731033;C1881413;C2700378
646,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
645,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
645,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419
644,pravastatin ( n = nmbr >,C0085542
644,pravastatin vs usual care,C0085542
644,pravastatin ( n = nmbr ),C0085542
644,pravastatin,C0085542
644,pravastatin n = nmbr,C0085542
643,a . overall and subgroups bv statin potency - -,C0282416;C1561607
643,overall hr ( nmbr % cl ),C0282416;C0596019;C1561607
643,overall nmbr,C0282416;C1561607
643,overall ( n = nmbr ),C0282416;C1561607
643,overall ( n = unmbr ),C0282416;C0439148;C1561607
643,overall n = nmbr,C0282416;C1561607
643,overall,C0282416;C1561607
643,overall a phase population,C0282416;C1561607
643,overall study population,C0282416;C1561607;C2348561
643,overall n ( n / loopy ),C0282416;C1561607
643,overall efficacy,C0282416;C1280519;C1561607;C1707887
643,overall pad,C0282416;C1561607
643,overall dlqi scorenmbr,C0282416;C1561607;C3899393
643,overall dlqi score,C0282416;C1561607;C3899393
643,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
643,overall ctd,C0282416;C1335071;C1442905;C1561607
643,event during overall,C0282416;C0441471;C1561607;C4019010
643,overall ( w = nmbr ),C0282416;C1561607
643,overall ( per protocol ) ( n = nmbr ),C0282416;C1561607;C1698058
643,overall ( itt ) ( n = nmbr ),C0282416;C1561607
643,overall ( nmbr,C0282416;C1561607
643,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
643,subgroup overall,C0282416;C1079230;C1515021;C1561607
643,overall ( n = nmbr vs nmbr ),C0282416;C1561607
643,overall study period,C0282416;C1561607
643,overall ( n = nmbr,C0282416;C1561607
643,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
643,p - value ( overall ),C0282416;C1561607;C1709380
643,overall  qvainmbr - sfc,C0282416;C1561607;C4521536
643,overall ® nmbr . nmbr,C0282416;C1561607
643,overall treatment effect,C0282416;C1518681;C1561607
643,calima overall ( n = nmbr ),C0282416;C1561607
642,not at goal,C0018017;C1518422;C1571704
642,distance to ldl - c goal,C0012751;C0018017;C1571704
642,at goal,C0018017;C1571704
642,goal,C0018017;C1571704
642,% to goal,C0018017;C1571704
641,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
641,ex - smokers nmbr,C0337671;C4555205
641,ex - smoker,C0337671;C4555205
641,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
641,ex - smokers : qvainmbr - sfc,C0337671;C4521536;C4555205
641,ex - smokers ( n = nmbr ),C0337671;C4555205
641,ex - smokers ( itt ) ( n = nmbr ),C0337671;C4555205
641,ex - smokers,C0337671;C4555205
641,ex - smoker ( n z nmbr ),C0337671;C4555205
641,exsmoker,C0337671;C4555205
641,ex - smoker / smoker,C0337671;C4555205
640,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
640,probable stent thrombosis,C0033204;C0332148;C3897493
640,"probability "" of event %",C0033204;C0441471;C4019010
640,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
640,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
640,probable,C0033204;C0332148
639,patient ' s preference not to take vka,C0376409
639,patient ' s preference not to take,C0376409
638,randomization to angiography,C0002978;C0034656
638,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
638,randomization - to - angiography,C0002978;C0034656
637,rosuvastatin nmbr mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
637,rosuvastatin nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
636,events / control group,C0009932;C0441471;C3541888
636,control group,C0009932
635,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
635,iduration of symptoms > nmbr min,C0683368;C0702093;C1457887;C1524029;C3813700
635,time from symptoms onset to nmbrst balloon inflation ( h ),C0449244;C0683368;C1457887
635,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
635,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
635,symptoms,C0683368;C1457887
635,no symptoms,C0683368;C1457887
635,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
635,systemic symptoms,C0205373;C0683368;C1457887
635,daytime symptoms more than twice per week,C0332169;C0683368;C1457887;C1720725;C1948050
635,symptoms and feelings,C0683368;C1457887
635,nmbr = no symptoms,C0683368;C1457887
634,abciximab vs . primary,C0288672
634,nmbr abciximab ( n = nmbr ),C0288672
634,abciximab,C0288672
634,abciximab - facilitated pci ( n = nmbr ),C0288672;C4049621
634,abciximab ( n = nmbr ),C0288672
634,abciximab no . / total ( % ),C0288672
634,abciximab - facilitated pci,C0288672;C4049621
633,fluticasone - salmeterol ( n = nmbr ),C0939232
633,fluticasone - fluticasone / salmeterol,C0939232
633,salmeterol - fluticasone group ( n = nmbr ),C0441848;C0939232
632,saxagliptin ( n = nmbr,C1611934
632,saxagliptin ( n = nmbr ),C1611934
632,saxagliptin ( % ),C1611934
632,saxagliptin,C1611934
631,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
631,high - sensitivity c - reactive protein,C0006560;C1413716;C1441604;C4048285
631,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
631,c - reactive protein,C0006560;C1413716;C4048285
631,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
631,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
631,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
631,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
631,median c - reactive protein — mg / dl^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
630,placebo + nmbr mg / d of simvastatin ( n = nmbr ),C0032042;C0074554;C0439422;C1696465;C1706408
630,placebo + nmbr mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
630,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
629,cox bsl onlyc,C1549954;C1565830
629,cox bsl + yr nmbr hbd,C0439234;C1549954;C1565830
628,chronic renal disease — no . ( % ),C0022661;C1561643
628,chronic renal disease,C0022661;C1561643
628,chronic renal failure,C0022661;C1561643;C2316810
627,gastroesophageal reflux disease,C0017168;C4553201
627,gastrooesophageal reflux disease,C0017168;C4553201
626,stable angina ( n = nmbr,C0340288
626,stable angina — no . ( % ),C0340288
626,histor y of stable angina,C0340288
626,stable angina ( n - nmbr,C0340288
626,chronic stable angina,C0340288
626,stable angina,C0340288
625,serum,C0229671;C1546774;C1550100
625,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
625,serum mg > nmbr . nmbr mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
625,serum gastrint,C0229671;C1546774;C1550100
625,serum values^,C0042295;C0229671;C1546774;C1550100
625,mean total serum ige ( sd ),C0229671;C0439175;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
625,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
625,serum values,C0042295;C0229671;C1546774;C1550100
624,low risk ( ri = nmbr - nmbr ),C0035487;C1826843;C3272281;C3538919
624,( ri = nmbr ),C0035487;C1826843
624,intermediate risk ( ri = nmbr ),C0035487;C1826843;C3640764
624,high risk ( ri ≥ nmbr ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
623,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
623,urinary acr,C0042027;C1412134;C1515941;C1524119
623,categories of urinary acr,C0042027;C0683312;C1412134;C1515941;C1524119
623,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
622,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
622,associated with transient or reversible risk factor,C0040704;C0205374;C0332281
622,transient,C0040704;C0205374
622,transient st elevation,C0040704;C0205374;C0520886
621,rnmbr ( n = nmbr ),C0687673
621,rnmbr + ezio ( n = nmbr ),C0687673
620,ind / gly nmbr / nmbr mg once daily ( n = nmbr,C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
620,ind / gly nmbr / nmbr mg once daily ( n = nmbr ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
619,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
619,with baseline crp level of > nmbr mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
619,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
619,baseline aspirin dose < nmbr mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
618,af first diagnosis > nmbr years,C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
618,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
618,diagnosis ( y ),C0011900;C1704338;C1704656
618,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
618,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
618,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
618,diagnosis of hefh,C0011900;C1704338;C1704656
618,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
618,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
618,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
618,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
617,proteinuria ( > nmbr g / nmbr h ),C0033687;C0560020;C1962972;C4554346
617,proteinurianmbr ( g / day ),C0033687;C0439417;C1962972;C4554346
617,protein in urine,C0033687
616,platelets xlooo / mm^,C0005821;C0443116;C1963076;C4330985;C4554674
616,platelet,C0005821
615,perianal gi tract,C0017189;C0442158
615,proximal gi tract,C0017189;C0205107;C4489236
615,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
614,baseline antihyperglycemic medications,C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
614,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
613,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
613,non - cortical,C0001613;C0007776;C0022655;C1518422
612,graft occlusionsa,C0181074;C0332835;C1961139
612,graft,C0181074;C0332835;C1961139
611,meglitinide,C0065880
611,meglitinides ( glinides ),C0065880;C1579432;C3537178
610,white - cell count — xnmbr_nmbr / liter,C0023508;C0427512;C0475211
610,white blood cell count,C0023508;C0427512
609,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
609,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
608,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
608,dm - ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
608,dm + ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
608,aliskiren dm = nmbr non - dm = nmbr,C0011816;C1120110;C3250443
607,both adalimumab groups ( n = nmbr ) baseline cd - related antibiotic use,C1122087
607,both adalimumab groups ( n = nmbr ) baseline immunosuppressant use,C1122087
607,both adalimumab groups ( n = nmbr ) no baseline cd - related antibiotic use,C1122087
607,both adalimumab groups ( n = nmbr ),C1122087
607,adalimumab ( n = nmbr ),C1122087
607,adalimumab,C1122087
606,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
606,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
606,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
605,bw at nmbr weeks,C0005910;C0006041;C0439230;C2986891
605,bw,C0005910;C0006041;C2986891
604,ileum,C0020885
604,ileum and colon,C0020885
604,ileum or colon,C0020885
604,ileum only,C0020885;C0205171;C1720467
603,alcohol consumption,C0001948
603,regular alcohol consumption per week,C0001948;C0205272;C0332174;C0439230
603,alcohol use,C0001948
603,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
603,alcohol use ( % ),C0001948
603,alcohol consumption ( % ),C0001948
603,alcohol intake ( + ) ( % ),C0001948
603,current alcohol use,C0001948;C0521116;C1705970
603,alcohol intake ( a ),C0001948
603,no alcohol consumption,C0001948
603,alcohol consumption !,C0001948
603,alcohol consumption > once weekly,C0001948
603,alcohol consumption *,C0001948
603,current alcohol drinking,C0001948;C0521116;C0556297;C1705970
603,alcohol intake,C0001948
603,alcohol use ( %,C0001948
603,alcohol intake never / rarely,C0001948;C0522498;C2003901
603,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
602,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
602,digoxin scd,C0012265
602,digoxin,C0012265
602,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
602,digoxin or digitalis preparations,C0012265
602,digoxin or digitalis preparation,C0012265
602,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
602,no digoxin n = nmbr nmbr ( nmbr % ),C0012265
602,digoxin n ( % ),C0012265
602,digoxin n = nmbr ( nmbr % ),C0012265
602,digoxin or digitalis glycoside,C0012265
602,no digoxin scd,C0012265
601,apolipoprotein a - i,C0085201;C1677784
601,apo a - i,C0085201;C1677784
601,apolipoprotein a - i *,C0085201;C1677784
601,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
601,apoa - i,C0085201;C1677784
600,fluticasone furoate,C1948374
600,fluticasone furoate and vilanterol ( n = nmbr ),C1948374
599,vasodilator,C0042402;C3537240
599,other vasodilators §,C0042402
599,other vasodilator,C0042402;C3537240
598,ethnicity - - hispanic or latino,C0015031;C0086409;C0243103
598,hispanic ethnicity,C0015031;C0086409;C0243103
597,pulse pressure,C0949236
597,pulse pressure ( mm hg ),C0439475;C0949236
597,pulse pressure ( median nmbr . nmbr],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
597,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
597,pulse pressure ( mmhg ),C0439475;C0949236
596,aerobic activity,C0001701
596,aerobic exercise,C0001701
595,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
595,pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703
595,prior pacemaker,C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
595,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
594,calcium channel,C0006685
594,calcium - channel inhibitor,C0006685;C1999216
594,calcium - channel blockerf,C0006685
594,calcium - channel blockersubgroup,C0006685
593,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
593,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
592,bivalirudin used,C0168273
592,bivalirudin ( n = nmbr ),C0168273
592,bivalirudin used during pci,C0168273
592,bivalirudin ( n = nmbr,C0168273
592,bivalirudin alone ( n = nmbr ),C0168273;C0205171;C0439044;C0679994
592,bivalirudin only,C0168273;C0205171;C1720467
592,bivalirudin,C0168273
591,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
591,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
591,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
591,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
591,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
591,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
591,ls mean difference ( se ) vs placebo,C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
590,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
590,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
589,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
589,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
588,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
588,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
588,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
587,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
587,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
587,bdi focal scorenmbr,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
586,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
586,baseline dmard use,C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
585,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
585,age group 一 ％,C0027362;C2348001
585,age group ( ≥ nmbr ) — no . ( % ),C0027362;C2348001
585,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
585,age group nmbr,C0027362;C2348001
585,age groups,C0027362
585,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
585,severe ( ipss > nmbr ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
585,age group,C0027362;C2348001
585,age group — no . ( % ),C0027362;C2348001
585,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
584,drug - eluting stent implanted ( at least one ),C1322815
584,drug - eluting stent — no . ( % ),C1322815
584,received drug - eluting stent,C1322815;C1514756
584,non - drug - eluting stent,C1322815;C1518422
584,drug - eluting stent implanted,C1322815
584,drug - eluting stent implanted — no . ( % ),C1322815
584,drug - eluting stent,C1322815
584,drug eluting stent,C1322815
584,at least one drug - eluting stent,C0205447;C1322815
583,north america ( plus australia and new zealand ),C0004340;C0028405;C0332287
583,north america plus australia and new zealand,C0004340;C0028405;C0332287
582,rerapamil - sr strategy ( n = nmbr ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
582,sr ii b nmbr - cjl nmbr,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
581,tiotropium + olodaterol nmbr . nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
581,tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
581,tiotropium / olodaterol nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
581,tiotropium + olodaterol nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
581,tiotropium / olodaterol nmbr . nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
580,symptoms of atrial fibrillation in the nmbr months before randomiza -,C0004238;C0344434;C0683368;C1457887;C1963067
580,symptoms of atrial fibrillation in the nmbr months before randomization — no . ( % ),C0004238;C0344434;C0683368;C1457887;C1963067
579,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
579,pe and dvt,C0070939;C1880476;C4284304
579,pe with / without dvt,C0070939;C1880476;C4284304
579,pe associated with dvt at diagnosis,C0070939;C1880476;C4284304
579,pe ( with or without dvt ),C0070939;C1880476;C4284304
579,symptomatic pe,C0070939;C0231220;C1880476;C4284304
579,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
579,pe,C0070939;C1880476;C4284304
579,neither pe nor dvt,C0070939;C1880476;C4284304
579,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
578,sulfasalazine,C0036078
578,sulfasalazine ( mean dose : nmbr . nmbr g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
577,nmbr carotid artery sites,C0007272;C0162859;C0205145
577,carotid artery — no . ( % ),C0007272;C0162859
577,common carotid artery sites,C0007272;C0162859;C0205145
577,carotid artery diseaset,C0007272;C0162859
576,prior migraine,C0149931;C0332152;C2826257
576,migraine severity score,C0149931;C0457451
576,prior migraine *,C0149931;C0332152;C2826257
576,migraine — no . ( % ) $,C0149931
575,ularitide n / n ( % ),C0077910
575,ularitide ( n = nmbr ),C0077910
574,long - acting bnmbr - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
574,short - acting bnmbr - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
574,with long - acting jnmbr - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
573,arterial blood pressure,C1272641
573,visit nmbr blood pressures :,C0545082;C1272641;C1512346;C2826704
572,embolism,C0013922;C1704212
572,peripheral embolism,C0013922;C0205100;C1704212
572,systemic embolism,C0013922;C0205373;C1704212
571,dronedarone ( n = nmbr ),C0766326
571,dronedarone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0766326
571,dronedarone,C0766326
570,nmbr . nmbr % vi,C0205999
570,nmbr . nmbr % vi . nmbr . nmbr %,C0205999
570,vi nmbr % ( - nmbr %,C0205999
570,favors ff / vi favors placebo,C0205999;C0309049;C4554348
570,ff / vi nmbr % ( nmbr %,C0205999;C4554348
570,ff / vi,C0205999;C4554348
570,umec / vi nmbr . nmbr / nmbr ( n nmbr nmbr ),C0205999
570,ff / vi nmbr mg / nmbr mg ( n = nmbr ),C0205999;C1319635;C4554348
570,ff / vi nmbr / nmbr   µ g,C0205999;C0439267;C4554348
570,vi - nmbr % ( - nmbr %,C0205999
570,ff / vi ( n   =   nmbr ),C0205999;C4554348
570,ff / vi nmbr % ( - nmbr %,C0205999;C4554348
570,vi nmbr   µ g,C0205999;C0439267
570,umec / vi nmbr . nmbr / nmbr,C0205999
570,difference ff / vi versus uc,C0205999;C1705241;C1705242;C4554348
570,ff / vi nmbr . nmbr,C0205999;C4554348
569,baseline triglycerides < nmbr mg / dl,C0041004;C0168634;C0439269;C1442488
569,triglycerides at baseline,C0041004;C0168634;C1442488
569,baseline triglycerides > nmbr mg / dl and,C0041004;C0168634;C0439269;C1442488
569,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
569,baseline triglycerides,C0041004;C0168634;C1442488
569,baseline triglycerides in nmbr classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
568,serum ctx - nmbr,C0010377;C0229671;C0631180;C1546774;C1550100;C3539598
568,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
567,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
567,diastolic fmmhff ' ),C0012000
567,diastolic,C0012000
567,diastolic ( mean,C0012000;C0444504;C2347634;C2348143
567,diastolic — mm hg,C0012000;C0439475
567,diastolic ( mm hg ),C0012000;C0439475
567,diastolic ( mmhg ),C0012000;C0439475
566,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
566,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
565,alpha blockers,C0001641
565,alpha - blockers,C0001641
565,alpha nmbr blockers,C0001641
565,alpha - blocker,C0001641
565,alpha - blocker / other vasodilator,C0001641
564,egfr ( ml / min / nmbr - nmbr mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
564,egfr < nmbr ml / min / nmbr . nmbr mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
564,egfr > nmbr ml / min / nmbr . nmbr mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
563,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
563,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
562,hypercholesterolemia *,C0020443;C1522133
562,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
562,hypercholesterolaemia ( % ),C0020443;C1522133
562,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
562,hypercholesterolemia ( % ),C0020443;C1522133
562,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
562,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
562,hypercholesterolemia — no . ( % ),C0020443;C1522133
562,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
562,hypercholesterolemia,C0020443;C1522133
562,elevated cholesterol,C0020443
562,hypercholesterolemia ( > nmbr mg / dl ),C0020443;C0439269;C1522133
562,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than nmbr mg per deciliter ( nmbr . nmbr mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as nmbr or more consecutive ventricular beats at a heart rate of more than nmbr beats per minute . ‡ to convert weight to kilograms  divide by nmbr . nmbr . § to convert values for creatinine to micromoles per liter  multiply by nmbr . nmbr . ¶ data for follow - up medication were available for nmbr patients ( amiodarone  nmbr  placebo  nmbr  and icd  nmbr ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < nmbr . nmbr for the comparison among the groups,C0020443;C1522133
562,hypercholesterolaemia,C0020443;C1522133
561,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
561,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
560,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
560,taking calcium supplements at baseline,C0006675;C0006726;C1515187;C2936886;C3540037;C3714611
560,calcium,C0006675;C0006726;C2936886;C3540037;C3714611
560,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
560,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
560,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
560,calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611
559,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
559,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
559,blood glucose,C0005802
559,glycemic characteristics,C0005802;C1521970
559,glycemic variability,C0005802;C2827666
559,glycemia,C0005802
559,glycaemic parameters,C0005802;C0449381
558,rectum and sigmoid colon only,C0034896
558,rectum,C0034896
557,secondary outcomes,C0027627;C0175668;C0205436;C1274040
557,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
557,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
557,secondary pci,C0027627;C0175668;C0205436;C4049621
557,key secondary end points,C0027627;C0175668;C0205436;C2349179
557,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
557,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
557,secondary # nmbr,C0027627;C0175668;C0205436
557,secondary p,C0027627;C0175668;C0205436
557,metastatic disease,C0027627;C2939419;C2939420
557,secondary *,C0027627;C0175668;C0205436
557,secondary nonresponse,C0027627;C0175668;C0205436
557,secondary end points,C0027627;C0175668;C0205436;C2349179
557,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
557,secondary outcome,C0027627;C0175668;C0205436;C1274040
557,secondary end points nmbr,C0027627;C0175668;C0205436;C2349179
556,glycated hemoglobin - % ’,C0017853
556,glycated hemoglobin ( % ),C0017853
556,glycated haemoglobin ( % ),C0017853
556,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
556,glycated hemoglobin — % -,C0017853
556,glycosylated hemoglobin,C0017853
556,glycated hemoglobin,C0017853
556,glycated haemoglobin,C0017853
556,glycated hemoglobin — %,C0017853
556,mean glycated hemoglobin reduction during characteristic follow - up ( nmbr % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
556,glycated hemoglobin | |,C0017853
555,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
555,vein bypass stented,C0042449;C0741847
555,venous,C0042449;C0348013
554,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
554,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
553,metformin use,C0025598;C0042153;C0457083;C1947944
553,previous metformin use,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
553,no metformin use,C0025598;C0042153;C0457083;C1947944
552,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
552,time to treatment,C3494202
552,time to treatment initiation ( min ,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
552,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
551,perindopril,C0136123
551,treatment with open - label perindopril,C0136123;C3640652
550,albuterol use ( sd ),C0001927;C0042153;C0457083;C1947944;C2699239
550,days without albuterol use,C0001927;C0042153;C0439228;C0457083;C1947944
550,albuterol use,C0001927;C0042153;C0457083;C1947944
549,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
549,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
548,standard bp lowering,C0037623;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
548,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
548,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
548,any bp - lowering agents^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
548,bp < nmbr / nmbr,C0037623;C1415692;C1708288;C4318478
548,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
548,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
548,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
548,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
548,bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478
548,bp in pre - treated patients,C0037623;C1415692;C1708288;C4318478
548,bp variable,C0037623;C0439828;C1415692;C1708288;C4318478;C4553760
548,patientswith bp,C0037623;C1415692;C1708288;C4318478
547,measured at clinic visit with usual device,C0008952;C0444706;C3541902
547,measured at clinic visit with automated device §,C0008952;C0444706;C3541902
546,ace / arb use,C1452534;C3888198;C4284014
546,ace / arb users,C1452534;C1706077;C3888198;C4284014
546,arb / ace,C1452534;C3888198;C4284014
546,ace - l / arbs,C1452534;C3888198;C4284014
546,ace - lorarb,C1452534;C4284014
546,ace,C1452534;C4284014
546,ace / arb,C1452534;C3888198;C4284014
546,ace or arb,C1452534;C4284014
545,arm,C0446516;C3715044;C4553528
545,three arm,C0205449;C0446516;C3715044;C4553528
545,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
545,two arm,C0205448;C0446516;C3715044;C4553528
544,no nadroparin ( n = nmbr ),C0206232
544,nadroparin vs control,C0206232
544,nadroparin,C0206232
544,nadroparin ( n = nmbr ),C0206232
543,physical activity §,C0015259;C0026606
543,some physical activity,C0015259;C0026606
543,intense physical activity,C0015259;C0026606;C0522510
543,physical activity,C0015259;C0026606
543,physical activity ( hours walking / wk ),C0015259;C0026606;C0439227
542,hf duration,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
542,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
542,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
542,ischemic hf,C0018488;C0475224;C1313497;C1538440;C3273279
542,no prior hf ( n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
542,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
542,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
542,participants without hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
542,participants with hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
542,no prior hf n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
542,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
542,duration of hf,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
542,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
542,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
542,hf symptom unchanged,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
542,hosp . for hf,C0018488;C1313497;C1538440;C3273279
542,no hx of hf ( n = nmbr ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
542,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
542,hf,C0018488;C1313497;C1538440;C3273279
542,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
542,hf or lvef < nmbr % associated with index event,C0018488;C1313497;C1538440;C3273279
542,hf hosp .,C0018488;C1313497;C1538440;C3273279
542,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
542,hf without known reduced ef ( n = nmbr ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
542,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
542,admission for hf in previous year,C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
542,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
542,prior hf n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
542,prior hf ( n = nmbr,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
542,hf symptom worsened,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
542,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
541,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
541,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
540,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
540,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
540,no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
540,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
540,subpopulation,C1257890
540,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
540,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,indian subpopulation,C1257890;C1524069
540,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
540,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
540,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
540,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
540,group dif . ( nmbr ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
539,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
539,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
539,amlodipine / valsartan nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
539,amlodipine / valsartan nmbr to nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
539,amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
538,non - smokers receiving lipid lowering drugs,C0337672;C4554605
538,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
538,non - smoker ( n = nmbr,C0337672;C0425293;C4554605
538,nonsmoker,C0337672;C0425293;C4554605
538,non - smoker,C0337672;C0425293;C4554605
538,non - smokers receiving lipid - lowering drugs,C0337672;C4554605
538,current nonsmokers,C0337672;C0521116;C1705970;C4554605
537,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
537,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
537,mtx at baseline,C0025677;C0168634;C1417487;C1442488
536,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
536,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
536,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
536,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
535,baseline diabetes,C0011847;C0011849;C0168634;C1442488
535,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
535,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
534,lebrikizumab ( n = nmbr ),C2981360
534,rate ratio ( lebrikizumab vs placebo,C0456603;C0871208;C1521828;C1547037;C2981360
533,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
533,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
532,other dmard use,C0042153;C0242708;C0457083;C1947944
532,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
531,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
531,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
531,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
531,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
530,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
530,systemic glucocorticoid use at randomization,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
529,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
529,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
529,cat > nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
529,cat total scorenmbr,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
529,comparison : cat . nmbr vs . cat . nmbr,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
529,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
529,cat . nmbr n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
529,cat > = nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
529,cat > = nmbr ( n = nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
529,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
529,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
529,cat < nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
528,troponin t,C0077404;C1420827
528,troponin t ( pg / ml ),C0077404;C0439297;C1420827
527,symptom onset to hospital arrival,C0019994;C1510665;C1555577;C1706079;C4086878
527,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
527,in - hospital,C0019994;C1510665
527,hospital factor # nmbr,C0019994;C1510665;C1521761;C2827422
527,median ( range ) duration of hospital stayi,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
527,duration from hospital admission to pci,C0019994;C0449238;C1510665;C1959907;C2926735
527,pci - hospital,C0019994;C1510665;C4049621
526,older des ( n = nmbr ),C0011702;C0580836;C4551552
526,in - stent restenosis of des,C0011702;C3272317;C4551552
526,des,C0011702;C4551552
526,des type,C0011702;C0332307;C1547052;C4551552
526,> nmbr des type,C0011702;C0332307;C1547052;C4551552
526,type of des at index procedure,C0011702;C0332307;C1547052;C4551552
526,with des,C0011702;C4551552
526,type of des,C0011702;C0332307;C1547052;C4551552
526,no des,C0011702;C4551552
526,new des ( n = nmbr ),C0011702;C0205314;C4551552
525,coronary artery treated,C0205042
525,native coronary - artery lesions,C0205042;C0221198;C0302891
525,coronary artery,C0205042
524,nmbr - nmbr with cv risk but not disease ( n = nmbr ),C0035647;C3538987;C4048877;C4318503;C4552904
524,framingham nmbr - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
523,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
523,cad history and risk factors,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
523,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
522,upper gastrointestinal,C3203348
522,upper gastrointestinal tract,C3203348
521,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
521,anemia ( % ),C0002871;C1000483;C4554633
521,anemia,C0002871;C1000483;C4554633
520,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
520,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
519,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
519,criterion,C0243161
519,clinical criterianmbr,C0205210;C0243161
519,entry criteria ( % ),C0243161;C1705654
519,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
519,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
519,entry criteria,C0243161;C1705654
519,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
519,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
519,by who / simon broome criteria,C0243161;C0443058
519,criterion reached first,C0243161
518,known thrombophilia,C0205309;C0398623
518,known thrombophilia — no . ( % ),C0205309;C0398623
518,thrombophilia,C0398623
517,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
517,history of hf or lvef bnmbr % with index event,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
517,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
517,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
516,rhabdomyolysis,C0035410;C4552660
516,rhabdomyolysis or myopathy,C0035410;C4552660
516,rhabdomyolysis ( n = nmbr ),C0035410;C4552660
515,europe ( eu ),C0015176;C0015179;C3665627
515,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
514,post - salbutamol fevnmbr / fvcb,C0001927;C0687676;C1704687;C3469826;C3714541
514,fevnmbr reversibilityz ( pre / post salbutamol ),C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
514,fevnmbr / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
514,post - salbutamol fevnmbr ( l ) b,C0001927;C0687676;C1704687;C3469826;C3714541
514,fevnmbr ( pre - albuterol ),C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
513,hemorrhagic stroke,C0553692
513,haemorrhagic stroke — no . ( % ),C0553692
513,haemorrhagic stroke,C0553692
513,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
513,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
513,• hemorrhagic stroke,C0553692
513,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
513,hemorrhagic stroke ( n = nmbr ),C0553692
512,baseline hbanmbrc < nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
512,baseline hbanmbrc subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
512,low ( < nmbr % ) baseline hbanmbrc,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
512,hbanmbrc at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc ≥ nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
512,hbanmbrc   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hba^c,C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc^,C0019016;C0168634;C1442488;C1825777;C3538758
512,mean ( s . d . ) baseline hbanmbrc,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
512,baseline hbanmbrc ≥ nmbr . nmbr % to < nmbr . nmbr % ( nmbr – nmbr mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
512,hbanmbrc at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc > median nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
512,hbanmbrc ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
512,baseline hbanmbrc ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc in nmbr classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
512,baseline hbanmbrc < nmbr . nmbr %,C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc > nmbr . nmbr %,C0019016;C0168634;C1442488;C1825777;C3538758
512,baseline hbanmbrc ≥ nmbr mmol / mol ( ≥ nmbr . nmbr % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
512,baseline hbanmbrc ≤ median nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
512,baseline hbanmbrc,C0019016;C0168634;C1442488;C1825777;C3538758
511,femoral,C0015811
511,femoral neckc,C0015811
511,femoral access,C0015811;C0444454;C1554204
511,femoral access — no . / total no . ( % ),C0015811
510,obese ( > nmbr kg / m^nmbr ),C0028754;C1532718
510,obesity ( bmi £ nmbr kg / mnmbr ),C0028754;C0578022;C1532718;C1963185
510,obesity ( bmi > nmbr kg / mnmbr ),C0028754;C0578022;C1532718;C1963185
510,obese ( > nmbr kg / mnmbr ),C0028754;C1532718
510,obesity *,C0028754;C1963185
510,obese ( bmi > nmbrkg / mnmbr ),C0028754;C0578022;C1532718
510,obesity ( % ) §,C0028754;C1963185
510,obese ( bmi £ nmbr ),C0028754;C0578022
510,obese ( > nmbr kg / mnmbr ) b,C0028754;C1532718
510,obesity,C0028754;C1963185
510,obesity t,C0028754;C1963185
510,> nmbr kg / m^ ( obesity ),C0028754;C1532718;C1963185
510,obese,C0028754
509,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
509,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1547111;C3714652;C4321495
508,hazard ratio glp - nmbr analogue vs placebo [nmbr % cl],C0018301;C0243071;C1422069;C1425391;C1539338;C2350813;C2985465
508,glp - nmbr analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
508,other glp - nmbr receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
508,glp - nmbr receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
508,glp - nmbr receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
507,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
507,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
507,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
506,arthritis characteristics,C0003864;C1521970;C4552845
506,arthritis type *,C0003864;C0332307;C1547052;C4552845
506,arthritis,C0003864;C4552845
506,dip joint arthritis,C0003864;C0932510;C4552845
505,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
505,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
505,ls mean change from baselinenmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
504,enalapril ( n = nmbr ),C0014025
504,enalapril lcznmbr ( n = nmbr ) ( n = nmbr ),C0014025
504,enalapril,C0014025
503,on statins at baseline,C0168634;C0360714;C1442488
503,baseline statin,C0168634;C0360714;C1442488
503,baseline statin usec,C0168634;C0360714;C0439224;C1442488
503,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
502,adl,C0001288;C1420005
502,adl subscale ( range,C0001288;C1420005;C1514721;C2348147;C3542016
501,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
501,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
501,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
501,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
501,atherosclerotic vascular disease — no .,C0004153
501,atherosclerotic cardiovascular disease *,C0004153
501,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
501,atherosclerotic cardiovascular disease,C0004153
501,atherosclerotic vascular disease,C0004153
500,immunosuppressants,C0021081
500,immunosuppressant^^,C0021081
500,immunosuppressive agents only,C0021081;C0205171;C1720467
500,"prior immunosuppressant failure """,C0021081;C0231174;C0332152;C0680095;C2826257
500,immunosuppressant ( with or without corticosteroid ),C0021081
500,prior immunosuppressive exposure,C0021081;C0274281;C0332152;C0332157;C2826257
500,any immunosuppressive agent,C0021081
500,immunosuppressants and antimalarials only,C0021081
500,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
500,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
500,immunosuppressant^,C0021081
500,immunosuppressants onlyff,C0021081
500,prior immunosuppressant failurec,C0021081;C0332152;C2826257
500,immunosuppressants only,C0021081;C0205171;C1720467
500,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
499,d - dimer ( ng / ml ),C0060323;C0439275
499,d - dimer levelsatinclusion,C0060323
499,d - dimer level,C0060323;C0441889;C0456079;C1547707;C2946261
498,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
498,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
497,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
497,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
497,fenofibric acid - nmbr - low - dose statin,C0060179;C0360714;C0445550;C1708745
496,cerebral infarction,C0007785
496,chd plus cerebral infarction,C0007785;C0280604;C3542407
496,chd + cerebral infarction,C0007785;C0280604;C3542407
495,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
495,fibrinolytic therapy — no . ( % ),C0040044
495,fibrinolytics,C0040044
495,thrombolytic therapy,C0040044
495,fibrinolytic,C0040044
494,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
494,glycoprotein iib / iiia inhibitor,C0016011;C1999216
494,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
494,glycoprotein iib / iiia inhibitort,C0016011
494,gp iib / iiia inhibitor used,C0016011;C1999216
493,men,C0025266
493,men ( n = nmbr ),C0025266
493,men : qvainmbr - sfc,C0025266;C4521536
493,no . men,C0025266
493,all men,C0025266
493,low hdl - c ( for men < nmbr   mg / dl / for women < nmbr   mg / dl ),C0025266;C0151691;C0439269
493,nmbr - nmbr ( men ),C0025266
493,chd men,C0025266;C0280604;C3542407
493,men ( % ),C0025266
493,men : < nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0025266;C0439269;C1532563
493,men with ed ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0025266;C3538926
493,men ( n = nmbr nmbr ),C0025266
493,men ( n,C0025266
493,men ( n = nmbr vs nmbr ),C0025266
493,men ( n 二 nmbr ),C0025266
493,high hdl - c ( for men ≥ nmbr   mg / dl / for women ≥ nmbr   mg / dl ),C0025266;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
493,men ( n [ % ] ),C0025266
493,p value ( men versus women ),C0025266;C1709380
493,gmi ( men ),C0025266
493,men without ed ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0025266;C3538926
492,lipid - lowering drug,C0086440
492,other lipid lowering drugs,C0086440
492,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
492,lipid - lowering drug * *,C0086440
492,lipid lowering agent n ( % ),C0086440
492,without lipid - lowering agents,C0086440
492,lipid lowering drugs,C0086440
492,lipid - lowering agent §,C0086440
492,lipid - lowering agents ( % ),C0086440
492,lipid lowering agents,C0086440
492,any lipid - lowering agent,C0086440
492,lipid - lowering agents,C0086440
492,lipid - lowering drugs,C0086440
492,lipid - lowering agent,C0086440
492,with lipid - lowering agents,C0086440
491,syncope,C0039070;C3541349;C4554644
491,syncope — no . ( % ),C0039070;C3541349;C4554644
490,non – small - cell lung cancer,C0007131;C2984258;C3539721
490,nsclc,C0007131
489,associated with connective tissue disease,C0009782;C0332281
489,connective - tissue disease,C0009782
489,connective tissue disease,C0009782
488,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
488,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
488,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
488,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
488,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
488,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
488,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
488,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
488,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
488,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
487,retinopathy,C0035309;C1962966
487,retinopathy — no . ( % ),C0035309;C1962966
487,retinopathy ( stage nmbr / nmbr / nmbr / nmbr ),C0035309;C0205390;C1300072;C1306673;C1962966
487,retinopathy — %,C0035309;C1962966
486,glucose,C0017725
486,glucose — mg / dl,C0017725;C0439269
486,concomitant oral glucose - lowering agents,C0017725;C0441994;C0442027;C2003888;C2347852;C4521986
486,glucose ( mg / dl ),C0017725;C0439269
486,glucose — mmol / liter,C0017725;C0439190;C0475211
486,nmbr - hour postload glucose,C0017725;C0439227;C0564385
486,previous oral glucose - lowering agents,C0017725;C0205156;C0441994;C0442027;C0450442;C1254351;C1521826;C1552607;C2003888;C4521986
486,other glucose status,C0017725;C0449438
486,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
485,heparin plus gpi ( n = nmbr,C0019134;C0332287;C0770546;C1415351
485,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
485,heparins and fondaparinux,C0019134
485,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = nmbr ),C0019134;C2825026
485,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1555582;C1705685
485,unfractionated heparin within nmbr hr before randomization — no . / total no . ( % ),C0019134;C2825026
485,unfractionated heparin ( n = nmbr ),C0019134;C2825026
485,initial heparin treatment duration on or after randomization,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
485,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C2825026
485,unfractionated heparin ( n = nmbr,C0019134;C2825026
485,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
485,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
485,bolus of heparin given,C0019134;C0770546;C1186706;C1511237;C1705509;C3812160
485,additional heparin,C0019134;C0770546;C1524062
485,unfractionated heparin — no . ( % ),C0019134;C2825026
485,heparin plus a gpi ( n = nmbr ),C0019134;C0770546;C1415351
485,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
485,both unfractionated heparin and low - molecular - weight heparin,C0019134;C2825026
485,heparin dose regimen,C0019134;C0770546;C2348331
485,> = nmbr day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
485,heparin,C0019134;C0770546
485,unfractionated heparin,C0019134;C2825026
485,> = nmbr^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
485,heparin only,C0019134;C0205171;C0770546;C1720467
485,heparin alone ( n = nmbr ),C0019134;C0205171;C0439044;C0679994;C0770546
484,st - segment depression > nmbr . nmbr mv on admission,C0520887;C1454484;C1705503;C4281602
484,st - segment depression > nmbr . nmbr mv,C0520887;C1454484;C1705503;C4281602
484,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
484,st - segment depression < nmbr . nmbr mv,C0520887;C1454484;C1705503;C4281602
483,time from randomization to coronary angiography — hr,C0034656;C0040223;C3541383
483,time to randomisation [hours] ( interaction : p = nmbr . nmbr ),C0034656;C0040223;C0439227;C1704675;C3541383
483,on oac at time of randomisation,C0034656;C0040223;C3541383
483,time of randomization,C0034656;C0040223;C3541383
483,time from randomization to pci ( st - elevation mi ),C0034656;C0040223;C3541383
483,time from randomization to pci — hr,C0034656;C0040223;C3541383
483,time to randomization from symptom onset,C0034656;C0040223;C3541383
483,time from randomization to cabg — hr,C0034656;C0040223;C3541383
483,time from randomization to pci ( non - st - elevation mi ),C0034656;C0040223;C3541383
483,time to randomisation from symptom onset ( h ),C0034656;C0040223;C3541383
483,time from randomisation to nmbrst balloon inflation ( h ),C0034656;C0040223;C3541383
483,time to randomization,C0034656;C0040223;C3541383
483,time of randomization ( interaction : p = nmbr . nmbr ),C0034656;C0040223;C1704675;C3541383
482,ivabradine ( n = nmbr ),C0257190
482,ivabradine group ( n = nmbr ),C0257190;C0441848
482,ivabradine,C0257190
481,intensive control ( n = nmbr ) no . of patients ( percent ),C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
481,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
480,blood eosinophil count > nmbr / mmnmbr in nmbr months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0229664;C0439231;C0750480;C0750879;C1705566;C4330985;C4554674
480,blood eosinophil count,C0005767;C0005768;C0014467;C0200638;C0229664;C0750480;C0750879;C1705566
480,median blood eosinophil count,C0005767;C0005768;C0014467;C0200638;C0229664;C0549183;C0750480;C0750879;C0876920;C1705566;C2347635;C2348144;C2939193
479,tobacco abuse,C0040336
479,current tobacco abuse,C0040336;C0521116;C1705970
478,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
478,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
477,ipf,C0034069;C1800706
477,ipf - related,C0034069;C1800706
476,haematological,C0018943;C0200627
476,hematologic,C0018943;C0205488
475,methotrexate use,C0025677;C0042153;C0457083;C1947944
475,concomitant mtx use,C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
475,concomitant methotrexate use,C0025677;C0042153;C0457083;C0521115;C1947944
474,baseline cardiovascular medication,C0007220;C0168634;C1442488
474,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
474,baseline cardiovascular medications,C0007220;C0168634;C1442488
473,qualifying nstemi,C1514624;C3537184;C4255010
473,nstemi ( % ),C3537184;C4255010
473,nstemi,C3537184;C4255010
473,nstemi ( n = nmbr,C3537184;C4255010
473,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
473,nste - mi,C3537184;C4255010
472,ticlopidine,C0040207
472,ticlopidine ( n = nmbr ),C0040207
471,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
471,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
470,previous therapies,C0087111;C0205156;C1552607
470,main concomitant treatments,C0087111;C0205225;C0521115;C1542147
470,diabetic treatments !,C0087111;C0241863
470,therapies,C0087111
470,all treatments,C0087111
469,cor revasc,C0018787;C0056331;C0378365
469,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
468,losartan + placebo,C0032042;C0126174;C1696465;C1706408
468,losartan plus placebo ( n = nmbr ),C0032042;C0126174;C0332287;C1696465;C1706408
467,pacific islander,C0242191
467,other pacific islander,C0242191
466,fasting glucose > nmbr mg / dl *,C0015663;C0017725;C0439269
466,fasting glucose *,C0015663;C0017725
466,fasting glucose — mg / dl,C0015663;C0017725;C0439269
466,fasting glucose > nmbr mg / dl,C0015663;C0017725;C0439269
466,fasting glucose,C0015663;C0017725
466,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
466,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
465,paclitaxel - eluting,C0144576
465,paclitaxel,C0144576
464,fibrin - specific,C0015982
464,non - fibrin - specific,C0015982;C0205370
464,fibrin - specilic,C0015982
463,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
463,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
462,certolizumab pegol ( n = nmbr ),C1872109
462,certolizumab group ( n = nmbr ),C0441848;C1872109
461,pulse in beats / minute,C0232117;C0391850;C0439385;C1947910
461,pulse rate ( bpm ),C0232117
461,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910
461,pulse — beats / min,C0232117;C0391850;C1947910
461,pulse,C0232117;C0391850;C1947910
461,pulse rate,C0232117
460,rosuvastatin n ( rate ) nmbr,C0871208;C0965129;C1521828
460,rosuvastatin n = nmbr,C0965129
460,rosuvastatin ( n = nmbr ),C0965129
460,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
460,rosuvastatin +,C0965129
460,rosuvastatin ( n = nmbr . nmbr ),C0965129
460,rosuvastatin ( n = nmbr,C0965129
460,rosuvastatin   n   =   nmbr,C0965129
460,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
460,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
460,rosuvastatin,C0965129
459,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
459,low - medium microalbuminuria ( n = nmbr ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
459,low to medium microalbuminuria ( n = nmbr ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
459,medium normal ( n = nmbr ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
459,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
459,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
458,thienopyridine at baseline,C0168634;C1120149;C1442488
458,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
457,gender n ( % ),C0079399;C1522384
457,eze / simva gender,C0079399;C1522384
457,gender,C0079399;C1522384
457,gender :,C0079399;C1522384
457,gender [n ( % ) ],C0079399;C1522384
457,gender ( m / f ),C0079399;C1306057;C1522384
457,gender - n ( % ),C0079399;C1522384
456,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
456,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
456,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
455,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
455,therapy ( asa nmbr,C0004057;C0039798;C0087111;C1363945;C3853627
454,impaired glucose tolerance or impaired fasting glucose,C0271650
454,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
454,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0271650
453,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0039798;C0087111;C1363945
453,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
452,baseline lp ( a ) in nmbr classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
452,baseline lp ( a ),C0065058;C0168634;C1439335;C1442488;C4553379
451,coronary artery disease — %,C0010054;C0010068;C1956346
451,coronary artery disease^,C0010054;C0010068;C1956346
451,previous coronary artery disease,C0010054;C0010068;C0205156;C1552607;C1956346
451,coronary heart disease,C0010054;C0010068;C1956346
451,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
451,multivessel coronary artery disease,C0010054;C0010068;C1956346
451,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
451,any coronary artery disease,C0010054;C0010068;C1956346
451,coronary artery disease,C0010054;C0010068;C1956346
451,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
451,coronary artery disease ( % ),C0010054;C0010068;C1956346
451,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
451,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
451,coronary heart disease ( % ),C0010054;C0010068;C1956346
451,coronary artery disease §,C0010054;C0010068;C1956346
451,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
451,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
451,coronary artery disease ( n = nmbr nmbr ),C0010054;C0010068;C1956346
451,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
451,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
451,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
451,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
451,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
451,coronary artery disease *,C0010054;C0010068;C1956346
450,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
450,number of previous anti - tnf treatments for psa,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
449,australia / new zealand / south africa,C0037712;C4289954
449,sf - nmbr bodily pain,C0037712;C3890602
449,south africa,C0037712
449,sf - nmbr mcs,C0037712
449,sf - nmbr summary scores,C0037712;C1552616;C1706244
449,short form nmbr ( sf - nmbr ),C0037712;C2964478
449,sf - nmbrvnmbr mcs,C0037712
449,sf - nmbr score,C0037712;C0449820;C4050231
449,sf - nmbr mcs score,C0037712
449,sf - nmbrvnmbr domain scores,C0037712;C1880389;C1883221;C3541951
448,denosumab ( n = nmbr ) n ( % ),C1690432
448,denosumab,C1690432
448,denosumab ( n = nmbr ),C1690432
447,recent cardioversion ( within nmbr days before randomization ) —,C0013778;C0332185;C0439228
447,prior electrical cardioversion for af ( n = nmbr nmbr ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
447,cardioversion in previous nmbr wk,C0013778;C0205156;C0332174;C0439230;C1552607
447,recent cardioversion ( within nmbr days before randomization ) — no . ( % ),C0013778;C0332185;C0439228
446,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
446,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
445,patient global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
445,vas ( nmbr - nmbr ),C0042815;C3536884;C3827561
445,patient ' s global assessment of disease activity ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
445,physician ' s global assessment of disease activity ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
445,( nmbr - nmbr - cm vas ),C0042815;C3536884;C3827561
445,activity ( nmbr - nmbr vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
445,general health vas,C0042815;C0424575;C3536884;C3827561;C4018875
445,ptga ( nmbr - nmbr cm vas ),C0042815;C3536884;C3827561
445,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
445,patient global assessment ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
445,physician global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
445,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
445,physician global assessment ( nmbr - nmbr mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
445,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
444,not on metformin,C0025598;C1518422
444,metformin ( n = nmbr ),C0025598
444,metformin : no / yes,C0025598
444,metformin open - label *,C0025598
444,metformin only,C0025598;C0205171;C1720467
444,metformin monotherapy,C0025598
444,metformin alone,C0025598
444,metformin ± other oral anti - dm drugs,C0025598
444,metformin ( n nmbr nmbr ),C0025598
444,metformin - dose,C0025598;C0178602;C0869039;C1114758
444,no metformin,C0025598
444,metformin,C0025598
444,plus metformin,C0025598;C0332287
444,metformin ( hdm ),C0025598
444,metformin dose,C0025598;C0178602;C0869039;C1114758
444,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
444,metformin — no . ( % ),C0025598
444,metformin 一 no . ( % ),C0025598
444,mean ( s . d . ) metformin dose †,C0025598;C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
443,bdmard - ir,C0022065;C0022071;C1448132
443,tnfi - ir,C0022065;C0022071;C1448132
443,homa_ir,C0022065;C0022071;C1448132
443,homa - ir ( % ) b,C0022065;C0022071;C1448132
443,homa . ir,C0022065;C0022071;C1448132
443,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
443,homa - ir,C0022065;C0022071;C1448132
443,homa - ir ( mu / l^mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
442,empagliflozin ( n   =   nmbr ),C3490348
442,empagliflozin,C3490348
442,pooled empagliflozin ( n = nmbr ),C1709595;C2349200;C3490348;C4522255
442,empagliflozin pooled ( n = nmbr ),C1709595;C2349200;C3490348;C4522255
442,empagliflozin ( n = nmbr ),C3490348
442,empagliflozin ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C3490348
442,empagliflozin nmbr mg / day ( n = nmbr ),C0439422;C3490348
442,empagliflozin n with event / n,C0441471;C3490348;C4019010
441,infliximab - naive ( n = nmbr ),C0666743
441,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0205156;C0413234;C0666743;C1552607
441,infliximab monotherapy,C0666743
441,infliximab nmbr mg / kg,C0439272;C0666743
441,infliximab,C0666743
441,infliximab - experienced ( n = nmbr ),C0666743
441,combined infliximab,C0205195;C0666743
441,previous intolerance of infliximab,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
441,infliximab ( combined nmbr mg / kg and nmbr mg / kg ),C0205195;C0439272;C0666743
441,inflix,C0666743
441,infliximab ( n = nmbr ),C0666743
440,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
440,prior tobacco use,C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
440,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
440,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
440,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
440,tobacco use,C0040335;C0543414;C0841002;C3853727
439,spironolactone ( n = nmbr ),C0037982
439,spironolactone,C0037982
438,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
438,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
437,saxagliptin nmbrmg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr . nmbr mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr . nmbr mg ( n z nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbrmg ( n z nmbr ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
437,saxagliptin nmbr . nmbr mg ( n = nmbr,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
436,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
436,use of parenteral antithrombotic,C0030547;C1524063;C4522267
435,histor y of unstable angina,C0002965
435,unstable angina §,C0002965
435,unstable angina — no . ( % ),C0002965
435,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
435,no rest angina,C0002965;C0152172
435,worsening angina,C0002965
435,• unstable angina,C0002965
435,* * * unstable angina,C0002965
435,unstable angina age,C0001779;C0002965
435,unstable angina ( n = nmbr,C0002965
435,rest angina but not past nmbr h,C0002965;C0152172
435,unstable angina *,C0002965
435,rest angina,C0002965;C0152172
435,unstable angina,C0002965
435,due worsening angina,C0002965;C0678226;C3146286
435,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
434,limb ( sd ),C0015385;C2699239
434,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
434,limb,C0015385
434,previous limb or foot amputation,C0015385;C0205156;C1552607
433,depressed only,C0344315;C0549249
433,depressed and low perceived social support,C0344315;C0549249
432,liraglutide nmbr . nmbr mg / day ( n = nmbr ),C0439422;C1456408
432,liraglutide n ( % ),C1456408
432,liraglutide ( « = nmbr ),C1456408
432,liraglutide ( n = nmbr,C1456408
432,liraglutide,C1456408
432,liraglutide ( n = nmbr ),C1456408
431,baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
431,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
431,baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
430,rosiglitazone versus metformin,C0289313
430,rosiglitazone,C0289313
430,rosiglitazone ( n = nmbr ),C0289313
430,rosiglitazone versus glyburide,C0289313
429,lp ( a ) ( week nmbr ),C0065058;C0332174;C0439230;C1439335;C4553379
429,lp ( a ) §,C0065058;C1439335;C4553379
429,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
429,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
429,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
429,lp ( a ),C0065058;C1439335;C4553379
429,median ( qnmbr : qnmbr ) lp ( a ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
428,non - black race and ss > nmbr ( n = nmbr vs nmbr ),C0005680;C1518422
428,non - black race and ss < nmbr ( n = nmbr vs nmbr ),C0005680;C1518422
428,black race ( n = nmbr vs nmbr ),C0005680
428,non - black race ( n = nmbr vs nmbr ),C0005680;C1518422
428,black race and ss > nmbr ( n = nmbr vs nmbr ),C0005680
428,black race,C0005680
428,black race and ss < nmbr ( n = nmbr vs nmbr ) ■ -,C0005680
427,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
427,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
426,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
426,any cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
426,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
425,hrqol,C4279947;C4300252
425,health - related quality of life,C4279947
424,hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ),C0019016;C0030705;C0168634;C1442488;C1825777;C3538758
424,hbanmbrc in patients with baseline hbanmbrc < nmbr % ( < nmbr mmol / l ),C0019016;C0030705;C0168634;C1442488;C1532563;C1825777;C3538758
424,hbanmbrc in patients with baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ),C0019016;C0030705;C0168634;C1442488;C1825777;C3538758;C3829066
423,rivaroxaban + aspirin,C0004057;C1739768
423,rivaroxaban plus aspirin ( n = nmbr ),C0004057;C0332287;C1739768
423,rivaroxaban plus aspirin ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0004057;C0332287;C1739768
423,rivaroxaban plus aspirin ( nmbr % cl ),C0004057;C0332287;C0596019;C1739768
422,albuterol reversibility,C0001927;C0449261
422,mean ( sd ) number of albuterol per day,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
422,post - albuterol % predicted fevnmbr mean ( sd ) e,C0001927;C0687676;C1704687;C3469826
422,salbutamol,C0001927
422,use of rescue albuterol,C0001927;C1524063
421,peripheral artery disease,C1704436;C4025272
421,peripheral artery disease details,C1704436;C4025272
421,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
421,peripheral - artery disease ( % ),C1704436;C4025272
421,peripheral artery disease 一 no . ( % ),C1704436;C4025272
421,peripheral - artery disease,C1704436;C4025272
421,peripheral artery disease *,C1704436;C4025272
421,peripheral artery disease - -,C1704436;C4025272
421,peripheral artery disease — no . ( % ),C1704436;C4025272
421,peripheral - artery disease — no . ( % ),C1704436;C4025272
420,calcification,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
420,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
419,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
419,intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828
419,intent of early invasive strategy,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
419,intent - to - treatb,C0162425;C1283828;C1550453
419,intention to treat,C0162425;C1283828
419,intent to use direct thrombin,C0162425;C1283828;C1550453
419,intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828
419,intent to use dti,C0162425;C1283828;C1550453
419,intent to use glycoprotein iib / iiia inhibitor,C0162425;C1283828;C1550453
419,intention - to - treat,C0162425;C1283828
419,intensive ( n = nmbr ),C0162425;C0522510;C1283828;C1550453
419,intent to use gp iib / iiia,C0162425;C1283828;C1550453
419,intent of conservative strategy,C0162425;C0679199;C1283828;C1550453
418,usa ( n = nmbr,C0041703
418,united states ( n   = nmbr,C0041703
418,united states and canada,C0041703
418,usa and canada,C0041703
418,united states,C0041703
418,non usa,C0041703;C1518422
418,> nmbr yr from the united states,C0041703;C0439234
418,u . s . site,C0041703;C0205145;C1515974;C2825164
418,u . s . sites,C0041703;C0205145
418,non - united states,C0041703;C1518422
418,united states or canada,C0041703
418,usa,C0041703
418,usa ( n = nmbr ),C0041703
417,rerandomization to placebo ( n = nmbr ) f,C0016327;C0032042;C1696465;C1706408
417,placebo group ( n = nmbr ) f,C0016327;C0032042;C0441848;C1696465;C1706408
416,use of ticagrelor,C1524063;C1999375
416,ticagrelor,C1999375
416,prehospital ticagrelor ( n = nmbr ),C1999375
416,ticagrelor in ‐ hosp ( n = nmbr ),C1999375
416,ticagrelor pre ‐ hosp ( n = nmbr ),C0332152;C0740175;C1999375;C2257086;C3669034
415,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
415,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
415,time from onset of pain to randomization — hr,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
415,time from onset of pain to randomization,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
414,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
414,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
414,aa,C0282379;C1235746;C1882141;C4554792
413,chronic bronchitis,C0008677
413,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
413,chronic bronchitis ( % ),C0008677
413,chronic bronchitis !,C0008677
413,chronic bronchitis ( itt ) ( n = nmbr ),C0008677
413,chronic bronchitis ( n = nmbr ),C0008677
412,nmbro - inmbr mm hg,C0021966;C0221138;C0439475;C0483204
412,i with mets ( n = nmbr ),C0021966;C0221138;C0812270;C1705694;C2939420
412,pasi^i,C0021966;C0221138;C4528685
412,inmbri,C0021966;C0221138
412,i without mets ( n = nmbr ),C0021966;C0221138;C0812270;C1705694;C2939420
412,igehigh ( > inmbrku / l  n = i  nmbr ),C0021966;C0221138;C0439340
412,igelow ( < inmbrku / l  n = i  nmbr ),C0021966;C0221138;C0439340
412,nmbr . nmbrinmbr . nmbr ( n = nmbr ),C0021966;C0221138
412,i u - uj,C0021966;C0221138;C0439148
412,nmbr nmbr ( o - nmbr - i - onmbr ),C0021966;C0221138;C0483204
412,i / ii,C0021966;C0221138;C1710602;C4082587
412,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
412,i . nmbr ( nmbr . nmbr - i . nmbr ),C0021966;C0221138
412,inmbrinmbr ± nmbr,C0021966;C0221138
412,aqe inmbr,C0021966;C0221138
412,nmbr - nmbr ( o - nmbrs - i - nmbr ),C0021966;C0221138;C0483204
412,inmbri ± inmbr,C0021966;C0221138
412,nmbr t i,C0021966;C0221138;C2603360
412,inmbr ( inmbr . i ),C0021966;C0221138
412,inmbr ( inmbr . nmbr ),C0021966;C0221138
412,nmbr - nmbr ( onmbro - i - inmbr ),C0021966;C0221138;C0483204
412,nmbr . inmbr ( nmbr . nmbri - nmbr . nmbr ),C0021966;C0221138
412,nmbr - nmbr fo - nmbr - o - q^i,C0021966;C0221138
412,nmbr - nmbr ( o - nmbri - o - nmbr ),C0021966;C0221138;C0483204
412,l . i ( nmbr . nmbr ),C0021966;C0221138;C0439394;C1706495;C3642217
412,nmbr - nmbr ( o - nmbr - i - onmbr ),C0021966;C0221138;C0483204
412,nmbr - nmbr ( o - nmbr - i - nmbr ),C0021966;C0221138;C0483204
412,other ' i ',C0021966;C0221138
412,inmbr ± nmbri,C0021966;C0221138
412,i . nmbri ( nmbr . nmbr - i . nmbr ),C0021966;C0221138
412,inmbr ± nmbrii,C0021966;C0221138;C1710602;C4082587
412,"median pasi score { range ) ' i "" i '",C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
412,inmbri ( inmbr . nmbr ),C0021966;C0221138
412,inmbr ± inmbr,C0021966;C0221138
412,pde - nmbri monotherapy,C0021966;C0221138
412,pde - nmbri,C0021966;C0221138
412,p for i,C0021966;C0221138;C0369773;C2603361
412,iinmbr ( inmbr . nmbr ),C0021966;C0221138;C1710602;C4082587
412,stratum i,C0021966;C0221138
412,inmbr years of age,C0021966;C0221138;C1510829
412,nmbr . nmbr ( nmbr . nmbr - nmbr . inmbri ),C0021966;C0221138
412,period i,C0021966;C0221138;C0439531;C1948053
412,i - ^w « - i - nmbr,C0021966;C0221138
412,i nmbr . nmbr vs nmbr . nmbr,C0021966;C0221138
412,( i - blocker,C0021966;C0221138
412,nmbr . nmbrinmbr . nmbr ( n = nmbr ) a,C0021966;C0221138
412,> i,C0021966;C0221138
412,nmbr - i,C0021966;C0221138
412,nmbr ( nmbri . i ),C0021966;C0221138
412,"nmbr - aminosalicylates ’ i "" i ‘",C0021966;C0221138;C0368663
412,> o - nmbr - i - i,C0021966;C0221138;C0483204
412,nmbrinmbr ( nmbri . nmbr ),C0021966;C0221138
412,- b - i -,C0021966;C0221138
412,- b - i —,C0021966;C0221138
412,"albumin - to - creatinine ratio ' i "" /",C0021966;C0221138;C0486293;C1318293
412,nmbr . nmbr ( io . i ),C0021966;C0221138;C1046794;C3146236
412,nmbr . i ± ii . nmbr,C0021966;C0221138;C1710602;C4082587
412,ciass i,C0021966;C0221138
412,i ( nmbr . i ),C0021966;C0221138
412,tio inmbr mcg ( n = nmbr ),C0021966;C0221138;C0439211;C3463985
412,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
412,infliiimab i,C0021966;C0221138
412,antithrombotic ! i,C0021966;C0221138
412,i or ii,C0021966;C0221138
412,i,C0021966;C0221138
412,nmbr . nmbr ( inmbr . s ),C0021966;C0221138
412,i % nmbr,C0021966;C0221138
412,total score on the sgrq - c  i ,C0021966;C0221138;C2964552;C3826872
412,i no . of events,C0021966;C0221138
411,homa_ % b tx difference vs pbo,C0041403;C1705241;C1705242
411,txnmbr,C0041403
411,fpg tx difference vs pbo,C0041403;C1705241;C1705242
411,homajr tx difference vs pbo,C0041403;C1705241;C1705242
411,hbalc tx difference vs pbo,C0041403;C1705241;C1705242
411,tx,C0041403
410,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
410,estimated creatinine clearance — ml / min  i ,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
409,indacaterol nmbr mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
409,indacaterol nmbr mg[n z nmbr],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
408,community hospital,C0020003
408,community hospital ( % ),C0020003
407,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
407,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
407,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
406,nmbr baricitinib nmbr mg ■ baricitinib nmbr mg,C1319635;C4044947
406,baricitinib,C4044947
406,all - baricitinib ra ( n = nmbr ) *,C3538806;C4044947;C4048756
405,etanercept,C0717758
405,etanercept ( n = nmbr ),C0717758
404,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
404,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
403,ffa ( mmol / l ),C0015688;C1532563
403,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
403,free fatty acids ( mmol / l ),C0015688;C1532563
402,central / eastern europe and russia hr ( nmbr % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
402,eastern europe ( n   = nmbr,C0015177
402,eastern europe and africa,C0015177
402,eastern europe ( n = nmbr ),C0015177
402,eastern europe,C0015177
402,eastern europe ( % ),C0015177
401,asia,C0003980
401,asia / pacific ( % ),C0003980
401,asia / australia / new zealand,C0003980;C4289954
401,asia / pacific,C0003980
401,asia - pacific,C0003980
401,asia ( n = nmbr ),C0003980
401,residence in asia,C0003980;C0237096
401,asia pacific,C0003980
401,getgoal - l - asia,C0003980
401,asia pacific or other,C0003980
401,asia / pacific / other,C0003980
401,asia pacific and south africa,C0003980
401,asia - pacific and south africa,C0003980
401,asia pacific and africa,C0003980
401,asia #,C0003980
401,asia pacific and other,C0003980
401,asia ( n = nmbr,C0003980
401,asia pacific ( n = nmbr ),C0003980
401,asia and pacific islands,C0003980
401,asia - pacific hr ( nmbr % cl ),C0003980;C0596019
400,etoricoxib nmbr mg,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
400,etoricoxib nmbr mg n = nmbr n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
400,etoricoxib nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
399,aldosterone antagonists,C0002007;C2757004
399,aldosterone inhibitor,C0002007
399,aldosterone antagonist,C0002007;C2757004;C3536833
399,aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004
398,extracranial carotid stenosis,C0007282;C0580586
398,carotid stenosis,C0007282
398,carotid artery stenosis,C0007282
397,fn t - score < — nmbr . nmbr,C0449820;C1570610;C4050231
397,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
397,— nmbr . nmbr < fn t - score,C0449820;C1570610;C4050231
397,current ( nmbr + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
397,fn t - score < = - nmbr . nmbr ( % ),C0449820;C1570610;C4050231
397,nmbr - nmbr months fn = nmbr . nmbr ),C0439231;C1570610
397,— nmbr . nmbr < fn t - score < — nmbr . nmbr,C0449820;C1570610;C4050231
396,mucolytic agent,C0026698
396,mucolytics,C0026698
395,systolic bp at baseline :,C0168634;C0871470;C1442488
395,baseline systolic bp,C0168634;C0871470;C1442488
394,( _ > nmbr . nmbr mmol / l ) hdl - c women : < nmbr mg / dl ( < nmbr . nmbr mmol / l ) men : < nmbr mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
394,men / women,C0025266;C0043210
394,women / men [ % ],C0025266;C0043210
394,women men,C0025266;C0043210
394,£ nmbr ( men ) / £ nmbr ( women ),C0025266;C0043210
394,men : women ( % ),C0025266;C0043210
394,women / men,C0025266;C0043210
394,< nmbr ( men ) / < nmbr ( women ),C0025266;C0043210
394,no of events women men *,C0025266;C0043210;C0441471;C3541888
394,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
393,treatment before randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
393,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
393,treatment after randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
393,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
392,profound thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0392386;C0439808
392,moderate thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
392,thrombocytopenia,C0040034;C0392386
391,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
391,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
391,copd severity ( gold nmbr ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
390,nmbr vitamin e,C0042874;C3714803
390,nmbr vitamin e ( n = nmbr nmbr ),C0042874;C3714803
390,vitamin e,C0042874;C3714803
389,rivastigmine,C0649350
389,rivastigmine ( n = nmbr ),C0649350
388,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
388,gall bladder adverse event ( n = nmbr ),C0016976;C0877248
387,diuretic drugs,C0012798;C0013227;C3687832
387,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
386,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
386,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
385,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
385,lipoprotein ( a ),C0065058;C0125953;C1096202;C1439335
385,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
385,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
384,biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl ),C0005516;C0205251;C0219433;C0439275;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
384,biomarker high ( periostin > nmbr ng / ml or blood eosinophils > nmbr cells per pl ) t,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
384,biomarker high ( periostin > nmbrng / ml or blood eosinophils > nmbrcells per pl ),C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
383,comorbidity score,C0009488;C0449820;C4050231
383,comorbid diseasesa diabetesb,C0009488
383,comorbidities,C0009488
383,comorbidity,C0009488
383,co - morbidities,C0009488
383,comorbid illnesses,C0009488;C0221423
383,comorbidities and concomitant medications,C0009488
383,comorbid conditionsb,C0009488
383,comorbidities ( % ),C0009488
382,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
382,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
382,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
382,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
381,amlodipine ( n = nmbr ),C0051696
381,amlodipine vs chlorthalidone obese,C0051696
381,amlodipine vs chlorthalidone overweight,C0051696
381,amlodipine,C0051696
381,amlodipine / vaisartan ( n = nmbr ),C0051696
381,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
381,! amlodipine,C0051696
381,amlodipine vs chlorthalidone normal,C0051696
381,amlodipine and valsartan,C0051696
380,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
380,gold nmbr groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
379,lo ( lo - lo ),C0206579;C1232424
379,nmbr . nmbr ( lo - nmbr . nmbr ),C0206579;C1232424
379,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
378,celecoxib,C0538927
378,celecoxib ( n = nmbr ),C0538927
377,placebo + mtx ( n = nmbr ),C0025677;C0032042;C1417487;C1696465;C1706408
377,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
377,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
376,week nmbr mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
376,endoscopic disease severity,C0014245;C0442418;C0521117
376,patients with evaluable endoscopy,C0014245;C2986511
376,endoscopy subscore,C0014245
375,lower limbs,C0023216
375,lower limb fractures,C0023216
375,lower - limb arterial — no . ( % ),C0023216
375,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
374,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
374,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
374,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
373,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
373,baseline lipids,C0023779;C0168634;C1442488
373,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
373,baseline lipid profile,C0023779;C0168634;C1442488;C1979963;C2003903
373,baseline lipids  mean ± sd ( mmol / nmbr ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
373,baseline lipid and apolipoprotein levels,C0023779;C0168634;C1442488
373,baseline lipid parameters,C0023779;C0168634;C0449381;C1442488
373,baseline lipid and lipoprotein values,C0023779;C0168634;C1442488
372,mean blood pressure,C0428886;C0488053
372,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
372,mean arterial pressure,C0428886
371,acute coronary syndrome,C0948089
371,acute coronary syndrome nmbr,C0948089
370,fenofibric acid nmbr = nmbr,C0060179
370,fenofibric acid   n   =   nmbr,C0060179
370,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179
370,rosuvastain + fenofibric acid nmbr = nmbr,C0060179
370,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
370,fenofibric acid,C0060179
370,rosuvastain + fenofibric acid   n   =   nmbr,C0060179
369,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
369,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
369,randomization groups nmbr and nmbr,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
368,sf - nmbr pcs,C0037712;C1864389;C1882368
368,sf - nmbr pcs score,C0037712;C1864389;C1882368
368,sfnmbr - pcs,C0037712;C1864389;C1882368
368,sf ‐ nmbr pcs,C0037712;C1864389;C1882368
368,sf - nmbrvnmbr pcs,C0037712;C1864389;C1882368
367,creatinine ≥ nmbr . nmbr mg / dl,C0010294;C0439269;C1561535
367,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
367,creatinine ( mg / dl ),C0010294;C0439269;C1561535
367,creatinine — mg / dl,C0010294;C0439269;C1561535
367,creatinine,C0010294;C1561535
367,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
367,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
367,creatinine clearanceb,C0010294;C1561535
367,creatinine ( ^mol / l ) ( median,C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
367,creatinine ( p,C0010294;C1561535
367,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
367,creatinine ciearance,C0010294;C1561535
367,creatinine ratio nmbr - nmbr,C0010294;C0456603;C1547037;C1561535
367,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
367,estimated creatinine clearancet,C0010294;C0750572;C1561535
367,increase creatinine,C0010294;C0442805;C1561535
367,creatinine ratio,C0010294;C0456603;C1547037;C1561535
366,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
366,etiology,C0015127;C1314792;C1524003
366,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
366,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
366,aetiology,C0015127;C1314792;C1524003
366,etiology ( % ),C0015127;C1314792;C1524003
366,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
366,ischemic etiology,C0015127;C0475224;C1314792;C1524003
366,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
366,other determined etiology,C0015127;C0521095;C1314792;C1524003
366,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
366,ed etiology,C0015127;C1314792;C1524003;C3538926
365,blood eosinophils,C0014467
365,eosinophils > nmbr . nmbrxnmbr ' ' nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
365,low eosinophil subgroup (,C0014467;C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
365,eosinophils < nmbr . nmbrxnmbr ' ' nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils nmbr % ( n - nmbr ),C0014467;C0200638
365,eosinophils < nmbr nmbrxnmbr * nmbr / l ( n = nmbr ),C0014467;C0200638
365,eosinophils £ nmbr % ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr . nmbrxnmbr ' ^ ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr . nmbrxnmbr^^ ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils nmbr . nmbrxnmbr ' ' nmbr ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr % ( n = nmbr ),C0014467;C0200638
365,blood eosinophils count,C0014467
365,eosinophils £ nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils,C0014467;C0200638
365,blood eosinophil proportion ( % ),C0014467;C1709707
365,eosinophil low,C0014467
365,eosinophils < nmbr . nmbrxnmbr ' ' nmbr ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr . nmbrxnmbr * nmbr ( n = nmbr ),C0014467;C0200638
365,eosinophils < nmbr % ( n = nmbr ),C0014467;C0200638
365,eosinophil high,C0014467
365,eosinophils < nmbr . nmbrxnmbr * nmbr ( n = nmbr ),C0014467;C0200638
365,eosinophils < nmbr % ( itt ) ( n = nmbr ),C0014467;C0200638
365,eosinophils > nmbr nmbrxnmbr * nmbr / nmbr ( n = nmbr ),C0014467;C0200638
365,blood eosinophil,C0014467
365,eosinophils < nmbr . nmbrxnmbr * nmbr ( itt ) ( n = nmbr ),C0014467;C0200638
364,apoa - nmbr,C0003592;C0523508;C4553344;C4553379
364,apo anmbr ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
364,apo anmbr,C0003592;C0523508;C4553344;C4553379
364,apoanmbr,C0003592;C0523508;C4553344;C4553379
364,apolipoprotein anmbr ( mg / dl ),C0003592;C0439269;C0523508
364,apolipoprotein anmbr ( g / l ),C0003592;C0439294;C0456615;C0523508
364,apolipoprotein a,C0003592;C0523508
364,apo a - nmbr,C0003592;C0523508;C4553344;C4553379
364,apo anmbr ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
363,exenatide lar,C0167117
363,exenatide no . of events / total no . ( % ),C0167117
363,exenatide,C0167117
363,exenatide n = nmbr,C0167117
363,exenatide er,C0167117;C3810541;C3811131
363,exenatide ± oad,C0167117
362,fish oil,C0016157
362,fish oil ( n = nmbr ),C0016157
361,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
361,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
360,eu,C0015179;C3665627
360,european union,C0015179
360,western eu,C0015179;C1705493;C3665627
360,eastern eu,C0015179;C1707877;C3665627
359,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
359,baseline copd exacerbation history,C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
358,gly nmbr μ g bid,C0017890;C0439267;C0523677
358,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
358,ind / glynmbr / nmbr pg o . d . n = nmbr,C0017890;C0523677;C2827928;C4049864
358,ind / gly,C0017890;C0523677;C4049864
358,ind + gly ( n = nmbr ),C0017890;C0523677;C4049864
358,ind / gly n = nmbr,C0017890;C0523677;C4049864
358,gly,C0017890;C0523677
358,ind / gly ( n = nmbr ),C0017890;C0523677;C4049864
357,elevated troponin — %,C0041199;C0205250;C3163633
357,troponin negative ( n = nmbr ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
357,elevated troponin ( > nmbr . nmbr pg / l ),C0041199;C0205250;C0439278;C3163633
357,positive troponin or ck - mb,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
357,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439775;C0441889;C0702240
357,troponin ( - ),C0041199
357,troponin positive ( n = nmbr ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
357,troponin or ckmb value,C0041199
357,elevated troponin ( > nmbr . nmbr mg / l ),C0041199;C0205250;C0439268;C3163633
357,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
357,troponin ( + ),C0041199
357,elevated troponin,C0041199;C0205250;C3163633
357,troponin,C0041199
357,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
356,ace - i or angiotensin receptor blocker,C0021966;C0221138;C1452534;C4284014
356,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
356,ace ‐ i or arb,C0021966;C0221138;C1452534;C4284014
356,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
356,ace - i ( n,C0021966;C0221138;C1452534;C4284014
356,neither ace - i nor arb use,C0021966;C0221138;C1452534;C4284014
356,ace - i or arb,C0021966;C0221138;C1452534;C4284014
356,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
356,ace - i or arb use at baseline,C0021966;C0221138;C1452534;C4284014
355,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
355,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
355,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
355,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
355,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
355,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
355,mean ± sd fasting insulin,C0015663;C0021641;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
354,abi < nmbr . nmbr,C1328319;C3888326
354,abi > nmbr . nmbr,C1328319;C3888326
354,abi # nmbr . nmbr,C1328319;C3888326
354,abi,C1328319;C3888326
354,ankle - brachial index < nmbr . nmbr — no . ( % ),C1328319;C3888326
354,ankle - brachial index < nmbr . nmbr,C1328319;C3888326
354,ankle / brachial index,C1328319;C3888326
354,ankle - brachial index £ nmbr . nmbr,C1328319;C3888326
353,standard therapy ( n = nmbr ),C2936643
353,standard therapy,C2936643
352,risk factors,C0035648;C1553898
352,risk factors only,C0035648;C0205171;C1553898;C1720467
352,no . of risk factors for venous thromboembolism,C0035648;C1553898
352,risk factors bmi ( kg / mnmbr ),C0035648;C0578022;C1532718;C1553898
352,risk factors specified as inclusion criteria — no . ( % ) f,C0035648;C1553898
352,any risk factor for stent thrombosis,C0035648;C3897493
352,risk factor ( predefined ) for falling at screening,C0035648
352,high ( > nmbr risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
352,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
352,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
352,risk factors and immobility level,C0035648;C1553898
352,qualifying risk factor — no . ( % ),C0035648;C1514624
352,chd risk factors #,C0035648;C0280604;C1553898;C3542407
352,temporary risk factor,C0035648;C0205374;C1548539;C3245481
352,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
352,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
352,qualifying risk factor,C0035648;C1514624
352,no . of risk factors ( % ) | |,C0035648;C1553898
352,risk factors and diabetes status ( % ),C0035648;C1553898
352,outcome according to no . of risk factors for vte,C0035648;C0680240;C1274040;C1553898
352,multiple risk factors,C0035648;C0439064;C1553898
352,risk factor,C0035648
352,> nmbr chd risk factors,C0035648;C0280604;C1553898;C3542407
352,other risk factors,C0035648;C1553898
352,risk factors ( % ),C0035648;C1553898
352,risk factors and medical history,C0035648;C1553898
352,moderate ( nmbr risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
352,multiple ( > nmbr ) chd risk factors that confer a nmbr - year risk of chd > nmbr %,C0035648;C0280604;C0439064;C1553898;C3542407
352,risk factors — no . ( % ),C0035648;C1553898
351,st / t wave,C0036056;C0429103;C3272372
351,nmbr st < nmbr . nmbr,C0036056;C3272372
351,st - nmbr ( ng / ml ),C0036056;C0439275;C3272372
351,nmbr days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
351,> nmbrst and < nmbrnd quartile,C0036056;C3272372
351,omega - nmbr fa intake nmbrst third,C0036056;C0205437;C1512806;C1719844;C3272372
351,st ‐ str ≥ nmbr % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
351,st - segment deviation > nmbr mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
351,st - t wavett,C0036056;C3272372
351,< nmbrst quartile,C0036056;C2828255;C3272372
351,st - t wave abnormality d,C0036056;C1839341;C3272372
351,st - t waveft,C0036056;C3272372
351,st - t wave changes,C0036056;C0429103;C3272372
351,st,C0036056;C3272372
351,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
351,st change > nmbr mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
351,st +,C0036056;C3272372
351,key secondary end point : st,C0036056;C3272372;C4528314
351,st -,C0036056;C3272372
351,nmbrst tertile ( < = nmbr mg / dl [ < = nmbr . nmbr mmol / l] ) b,C0036056;C0439269;C1532563;C3272372
351,nmbrst : nmbr - nmbr . nmbr pmol / l,C0036056;C0439284;C3272372
351,st - t wave,C0036056;C0429103;C3272372
350,intermittent claudication,C0021775
350,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
350,claudication ( fontaine class > nmbr ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
350,claudication,C0021775;C0311395;C1456822
349,pulmonary rales,C0034642
349,eze / simva - nmbryr km rale ( % ),C0034642;C0439234;C3887676
349,rales,C0034642;C0240859
348,atherosclerosis^,C0003850;C0004153
348,atherosclerosis,C0003850;C0004153
348,large vessel atherosclerosis,C0003850;C0004153;C0225990
348,large - artery atherosclerosis,C0003850;C0004153;C0226003
348,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
348,qualifying atherosclerosis,C0003850;C0004153;C1514624
348,qualifying type of atherosclerosis,C0003850;C0004153;C0332307;C1514624;C1547052
347,native hawaiian or other pacific islander,C0337920
347,native hawaiian or other pacific,C0337920
347,hawaiian / pacific,C0337920
347,native hawaiian or,C0337920
347,native hawaiian / other,C0337920
346,angiotensin - receptor,C0034787;C1622222
346,angiotensin receptor,C0034787;C1622222
346,angiotensin receptor blocker,C0034787;C1622222
346,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
346,angiotensin receptor blocker and / or ace,C0034787;C1622222
346,angiotensin - receptor blocker,C0034787;C1622222
345,leflunomide ( mean dose : nmbr . nmbr mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
345,leflunomide,C0063041
344,peak creatine kinase - mb,C0010290;C0444505;C0523584
344,ck - mb,C0010290
343,warfarin n = nmbr,C0043031
343,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
343,warfarin ( n - nmbr,C0043031
343,in therapeutic range for warfarin subjects,C0043031;C0460097
343,warfarin ( n = nmbr ),C0043031
343,> nmbr yr warfarin experience,C0043031;C0237607;C0439234;C0596545
343,warfarin n = nmbr n / n ( % ),C0043031
343,> nmbr days warfarin,C0043031;C0439228
343,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
343,warfarin naive,C0043031
343,warfarin ( % ),C0043031
343,warfarin ( snmbr % cl ),C0043031;C0596019
343,warfarin,C0043031
343,warfarin group ( n = nmbr ),C0043031;C0441848
343,warfarin % ( n / n ),C0043031
343,warf,C0043031
343,long - term warfarin ( n = nmbr ),C0043031;C0443252
343,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
343,long - term warfarin ( n - nmbr ),C0043031;C0443252
343,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
342,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
342,medication at randomization,C0013227;C0034656;C3244316;C4284232
342,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
342,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
341,hyperkalaemia ( serum potassium > nmbr . nmbr mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
341,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
341,hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C0439375;C4552983
341,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
341,hyperkalemia * ’,C0020461;C4552983
341,hyperkalaemia,C0020461;C4552983
341,hyperkalemia,C0020461;C4552983
340,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
340,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight # nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
340,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
340,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
340,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight ( kg },C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
340,weight $ nmbr . nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight < nmbr . nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight in kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,yes ( % ) weight [kg] ( interaction : p = nmbr . nmbr ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
340,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
340,weight < nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight [kg],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight of < nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
340,weight > nmbr kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
340,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
339,rivaroxaban alone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0205171;C0439044;C0679994;C1739768
339,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
339,rivaroxaban,C1739768
339,rivaroxaban +,C1739768
339,low - dose rivaroxaban plus aspirin ( n = nmbr ),C0332287;C1739768;C2608320
339,rivaroxaban alone ( n = nmbr ),C0205171;C0439044;C0679994;C1739768
339,rivaroxaban ( n = nmbr ),C1739768
339,rivaroxaban plus,C1739768
339,rivaroxaban ( n   = nmbr ),C1739768
338,exercise > once weekly,C0015259;C1522704
338,exercise,C0015259;C1522704
338,exercise status,C0015259;C0449438;C1522704
338,exercise > once weekly ?,C0015259;C1522704
338,exercise times per week,C0015259;C0456698;C1522704
338,exercise at least weekly ( a ),C0015259;C1522704
338,exercise ( % ),C0015259;C1522704
337,diastolic bp ( mm hg ),C0428883;C0439475
337,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
337,diastolic blood pressure mmhg,C0428883;C0439475;C1305849
337,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
337,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
337,diastolic blood pressure  and lp ( a ) ,C0428883;C1305849
337,at home diastolic pressure > nmbr mm hg,C0428883;C0439475;C4534363
337,at home diastolic pressure < nmbr mm hg,C0428883;C0439475;C4534363
337,diastolic bp ( mmhg ) *,C0428883;C0439475
337,diastolic pressure,C0428883
337,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
337,diastolic bp,C0428883
337,diastolic bp ( mmhg ),C0428883;C0439475
337,mean diastolic bp,C0428883;C0444504;C2347634;C2348143
337,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
337,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
337,diastolic blood pressure > nmbr mm hg,C0428883;C0439475;C1305849
337,diastolic blood pressure,C0428883;C1305849
337,< nmbr . nmbr mm hg diastolic blood pressure,C0428883;C0439475;C1305849
336,abatacept nmbr mg / kg ( n = nmbr ),C0439272;C1619966
336,abatacept nmbr / — nmbr mg / kg ( n = nmbr ),C0439272;C1619966
336,abatacept ‡,C1619966
336,abatacept,C1619966
336,abatacept / open - label abatacept,C1619966;C1709323
336,abatacept monotherapy ( n = nmbr ),C1619966
336,abatacept ~ nmbr mg / kg ( n = nmbr ),C0439272;C1619966
336,abatacept ( n = nmbr * ),C1619966
336,abatacept nmbr / nmbr ( n = nmbr ),C1619966
335,glyburide,C0017628
335,glyburide ( n = nmbr ),C0017628
334,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0149871
334,deep - vein thrombosis,C0149871
334,residual deep - vein thrombosis,C0149871;C1609982
334,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
334,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
334,deep vein thrombosis only,C0149871;C0205171;C1720467
334,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
334,without dvt dvt alone,C0149871;C2926618;C3899446
334,dvt,C0149871;C2926618;C3899446
334,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
334,neither deep - vein thrombosis nor pulmonary embolism^,C0149871
334,deep - vein thrombosis only,C0149871;C0205171;C1720467
334,neither deep - vein thrombosis nor pulmonary embolism §,C0149871
334,both deep - vein thrombosis and pulmonary embolism,C0149871
334,concomitant dvt,C0149871;C0521115;C2926618;C3899446
334,symptomatic deep - vein thrombosis,C0149871;C0231220
334,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0521115;C2926618;C3899446
334,deep - vein thrombosis ( % ),C0149871
334,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
333, abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0030705;C0168634;C0332293;C1442488
333,normoalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C1442488
333,macroalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C1442488
333,microalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0168634;C0730345;C1442488
332,parental history of myocardial infarction before age nmbr y yes,C0030551;C1275835
332,parental history of myocardial infarction before age nmbr y,C0030551;C1275835
332,parental history of myocardial infarction before nmbr yr of age ( % ),C0030551;C1275835
331,candesartan nmbr / nmbr,C0717550
331,other - candesartan,C0717550
331,candesartan group ( n = nmbr ),C0441848;C0717550
331,candesartan,C0717550
330,score distribution :,C0449820;C0520511;C1704711;C4050231
330,distribution — no . ( % ),C0520511;C1704711
330,bmi distribution,C0520511;C0578022;C1704711
330,distribution — no . { % ),C0520511;C1704711
330,score distribution : < nmbr,C0449820;C0520511;C1704711;C4050231
330,anmbrc distribution ( % ),C0520511;C1704711
329,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
329,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
329,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
329,potassium ( meql ),C0032821;C0202194;C0304475;C0597277;C3714637
329,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
329,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
329,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
329,potassium at admission,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C3714637
329,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
329,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
328,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
328,rec . ischemia,C0022116;C1424025;C2606415;C4321499
328,rec . ischemia leading to hosp,C0022116;C1424025;C2606415;C4321499
327,concomitant anticoagulant,C0003280;C0521115;C0848112;C3536711
327,any anticoagulant,C0003280;C0848112;C3536711
327,anticoagulant group ( n = nmbr ),C0003280;C0441848;C0848112;C3536711
327,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
327,anticoagulant,C0003280;C0848112;C3536711
327,anticoagulants,C0003280
327,other anticoagulant,C0003280;C0848112;C3536711
327,periprocedural anticoagulant,C0003280;C0848112;C3536711
326,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
326,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
325,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
325,hispanic ethnic group,C0015031;C0086409;C1879937
325,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C1879937
325,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937
325,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0086409;C1879937
324,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
324,act total score   ≥   nmbr and / or improvement from baseline   ≥   nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
324,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
324,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
324,act . nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
324,act total score ≥   nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
324,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
324,long - acting^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
324,act - nmbr,C0079613;C1704930;C1869853;C3890007;C4048375
323,lmwh,C0019139;C3536766
323,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
323,lmwh within nmbr days before randomization — no . / total no . ( % ),C0019139;C0439228;C3536766
323,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
323,low molecular weight heparin,C0019139;C3536766
323,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
323,low - molecular - weight heparin,C0019139;C3536766
323,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766
323,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
322,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
322,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
321,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
321,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
321,csdmard use at baseline^,C0042153;C0168634;C0457083;C1442488;C1947944
321,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
320,congestive heart failure ( definite ),C0018802
320,congestive heart failure ( chf ) ( in past nmbr weeks ),C0018802;C2987125
320,chf ( % ),C0018802
320,prior chf,C0018802;C0332152;C2826257
320,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
320,histor y of congestive heart failure — no . ( % ),C0018802
320,congestive heart failure — no . ( % ),C0018802
320,new york heart association congestive heart failure class,C0018802;C1882083
320,congestive heart failure — %,C0018802
320,chronic heart failure,C0018802;C0264716
320,congestive heart failure — no . ( % ) | |,C0018802
320,chf score ( u ),C0018802;C0439148;C0449820;C4050231
320,congestive heart failure ( < nmbr wk ),C0018802;C0332174;C0439230
320,previous chf,C0018802;C0205156;C1552607
320,previous chf — no . ( % ),C0018802;C0205156;C1552607
320,nyha chf class,C0018802;C1882083
320,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
320,congestive heart failure †,C0018802
320,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
320,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
320,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
320,prior congestive heart failure,C0018802;C0332152;C2826257
320,congestive heart failure §,C0018802
320,congestive heart failure,C0018802
320,previous congestive heart failure,C0018802;C0205156;C1552607
320,congestive heart failure — no . ( % ) |,C0018802
320,chf,C0018802
319,prasugrel or ticagrelor,C1620287
319,prasugrel,C1620287
318,angiographic data and treatment :,C0002978;C1511726;C3245479;C3714741
318,prior angiography showing stenosis > nmbr %,C0002978;C0332152;C2826257
318,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
318,angiography,C0002978
318,angiography and revascularization,C0002978
318,additional angiography,C0002978;C1524062
318,minutes from pre - pci angiography to post - pci angiography,C0002978;C0332152;C0439232;C0700321;C0702093;C0740175;C1282918;C2257086;C2347166;C3669034;C4049621
318,> nmbr ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
318,prior angiography showing stenosis ≥ nmbr %,C0002978;C0332152;C2826257
318,diagnostic angiography,C0002978
318,angiographic data,C0002978;C1511726;C3245479;C3714741
318,angiography — no . ( % ),C0002978
318,angiographic extent of disease,C0002978;C0449279;C4553144
318,angiographic characteristics,C0002978;C1521970
317,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C2826257
317,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205191;C0679831
317,current angina ( % ),C0002962;C0521116;C1705970
317,no prior angina ( n = nmbr,C0002962;C0332152;C2826257
317,previous angina,C0002962;C0205156;C1552607
317,angina status — no . ( % ),C0002962;C0449438
317,current angina,C0002962;C0521116;C1705970
317,prior angina ( n = nmbr,C0002962;C0332152;C2826257
317,angina,C0002962
317,angina pectoris 本,C0002962
317,angina pectoris *,C0002962
317,angina pectorisf,C0002962
317,angina pectoris,C0002962
317,prior angina pectoris,C0002962;C0332152;C2826257
317,angina ( past nmbr weeks ),C0002962;C2987125
317,angina or positive stress test,C0002962
317,prior angina,C0002962;C0332152;C2826257
317,hospitalized angina,C0002962;C0701159
317,angina pectoris — no . ( % ),C0002962
317,angina or acute mi,C0002962
317,previous angina pectoris,C0002962;C0205156;C1552607
317,hospitaiization for angina,C0002962
317,angina .,C0002962
316,balloon angioplasty — no . ( % ),C0002996;C0002997
316,balloon angioplasty,C0002996;C0002997
316,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
315,aspirin use ( p = nmbr . nmbrt ),C0004057;C0042153;C0457083;C1947944
315,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
315,use nmbr - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
315,aspirin use ( p = nmbr - nmbr 十 ),C0004057;C0042153;C0457083;C1947944
315,aspirin use,C0004057;C0042153;C0457083;C1947944
315,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
315,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
315,aspirin use ( p = nmbr - nmbrt ),C0004057;C0042153;C0457083;C1947944
315,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
315,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
315,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
315,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
314,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
314,number of concomitant aeds,C0180309;C0237753;C0449788;C0521115
314,no . of prior aeds,C0180309;C0332152;C2826257
314,prior aeds,C0180309;C0332152;C2826257
314,concomitant aeds,C0180309;C0521115
314,most common concomitant aeds,C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
313,vorapaxar nmbr - y,C2974521
313,vorapaxar ( n = nmbr,C2974521
313,vorapaxar ( n = nmbr nmbr ),C2974521
313,vorapaxar ( n = nmbr . nmbr ),C2974521
313,vorapaxar,C2974521
313,vorapaxar n = nmbr,C2974521
313,vorapaxar group ( n = nmbr ),C0441848;C2974521
313,vorapaxar event rate ( n = nmbr ),C0441471;C0871208;C1521828;C2974521;C4019010
313,vorapaxar ( n = nmbr ),C2974521
313,vorapaxar no . ( nmbr - y km % ),C2974521
312,heart rate ( beats / min ),C0018810
312,< nmbr mm hg heart rate,C0018810;C0439475
312,heart rate ( beats per minute ),C0018810
312,heart rate — beats / min,C0018810
312,heart rate ( bpm ),C0018810
312,heart rate ( beats per min ),C0018810
312,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
312,heart rates ( beats / minutes ),C0018810
312,nmbr - lead ecg heart rate,C0018810;C0179504
312,heart rate ( bpm ) *,C0018810
312,heart rate ( bpmnmbr ) *,C0018810
312,heart rate,C0018810
312,heart rate ( median nmbr . nmbr },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
312,preoperative heart rate ( beats per minute ),C0018810;C0445204
312,heart rate ( min − nmbr ),C0018810;C0702093;C1524029;C3813700
312,heart rate < nmbr bpm,C0018810
312,heart rate > nmbr bpm,C0018810
312,heart rate ( sd ),C0018810;C2699239
312,heart rate 一 beats / min,C0018810
312,heart rate — bpm,C0018810
311,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
311,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
310,nt - probnp,C0669479;C0754710
310,nt - probnpnmbr pmol - l - nmbr,C0439284;C0669479;C0754710
310,< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
310,change in nt - probnp at nmbr,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
310,nt - probnp values were reported in nmbr of nmbr patients enrolled in this stratum,C0042295;C0669479;C0754710
310,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
310,nt - probnp — pg / ml,C0439297;C0669479;C0754710
310,nt - pro bnp,C0669479;C0754710
310,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
310,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
310,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
310,nt - probnp ( pg / ml ) ( qnmbr - qnmbr ),C0439297;C0669479;C0754710
310,change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
310,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
310,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
310,nt - pro - bnp,C0669479;C0754710
309,zotarolimus - eluting,C1700035
309,zotarolimus,C1700035
308,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
308,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
308,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
308,concomitant pd medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
308,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
308,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
308,medications at baseline,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
308,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
307,baseline heart failure severity amongthose with priorheartfailure,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
307,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
306,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
306,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
306,no . of background glucose - lowering therapies,C0017725;C0087111;C0441994;C1706907;C2003888
305,mean lumbar spine t score,C0024091;C3533236;C3887615
305,lumbar spine bmd t -,C0024091;C3887615
305,lumbar spine,C0024091;C3887615
305,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
304,cancer §,C0006826;C0998265;C1306459
304,cancer ( n = nmbr ),C0006826;C0998265;C1306459
304,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
304,all cancer,C0006826;C0998265;C1306459
304,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
304,cancer,C0006826;C0998265;C1306459
304,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
304,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
304,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
304,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
304,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
304,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
304,cancer *,C0006826;C0998265;C1306459
304,cancer n ( % ),C0006826;C0998265;C1306459
304,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
304,cancer — no . ( % ),C0006826;C0998265;C1306459
304,cancer * *,C0006826;C0998265;C1306459
304,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
303,pbo + statin nmbr,C0031962;C0360714
303,pbo + statin,C0031962;C0360714
303,pbo + statin n = nmbr,C0031962;C0360714
303,neither pbo + statin eze + statin,C0031962;C0360714
302,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744;C0205195
302,ischemic heart disease *,C0010054;C0151744
302,ischaemic heart disease,C0010054;C0151744
302,ischemic heart disease ( % ),C0010054;C0151744
302,myocardial ischaemia,C0010054;C0151744
302,ischaemic heart disease or cerebrovascular disorder,C0010054;C0151744
302,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
302,ischemic heart disease,C0010054;C0151744
301,pdenmbr inhibitors,C0031638
301,phosphodiesterase type nmbr inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
301,pdenmbr inhibitor monotherapy,C0031638
301,previous pdenmbr inhibitors,C0031638;C0205156;C1552607
300,sbp ( mmhg ) *,C0085805;C0439475
300,sbp ( mmghg ),C0085805
300,sbp ( office measurement ),C0085805;C0242485;C0442603
300,mean change in sbp from baseline,C0085805;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
300,sbp > nmbr mmhg and / or dbp > nmbr mmhg,C0085805;C0439475
300,sbp ( mmhg ),C0085805;C0439475
300,nmbr < sbp < nmbr mmhg n = nmbr,C0085805;C0439475
300,nmbr < sbp < nmbrmmhg n = nmbr,C0085805;C0439475
300,daytime mean sbp ( abpm ) at week nmbr,C0085805;C0332169;C0332174;C0439230;C0444504;C2347634;C2348143
300,sbp < nmbr mmhg and dbp < nmbr mmhg,C0085805;C0439475
300,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
300,sbp ( sd ),C0085805;C2699239
300,ambulatory sbp,C0085805;C0439841
300,difference in sbp between treatment,C0085805;C1705241;C1705242
300,sbp ( mmhg ) < nmbr,C0085805;C0439475
300,range of sbp,C0085805;C1514721;C2348147;C3542016
300,nighttime mean sbp ( abpm ) at week nmbr,C0085805;C0240526;C0332174;C0439230;C0444504;C2347634;C2348143
300,sbp < nmbrmmhg n = nmbr,C0085805;C0439475
300,sbp > nmbr mmhg or dbp > nmbr mmhg,C0085805;C0439475
300,sbp > median ( n = nmbr ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
300,sbp > nmbrmmhg,C0085805;C0439475
300,sbp < nmbrmm hg,C0085805;C0439475
300,sbp ( mm hg ),C0085805;C0439475
300,sbp,C0085805
300,sbp < median ( n = nmbronmbr ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
300,sbp < nmbrmmhg,C0085805;C0439475
300,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
300,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
300,sbp > nmbrmm hg,C0085805;C0439475
300,sd of sbp,C0085805;C2699239
300,sbp at visit nmbr,C0085805;C0545082;C1512346;C2826704
300,visit nmbr sbp,C0085805;C0545082;C1512346;C2826704
300,sbp > nmbr mmhg,C0085805;C0439475
300,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0085805
300,sbp < nmbr mmhg,C0085805;C0439475
300,sbp > nmbr mm hg and / or dbp > nmbr mm hg nmbr / nmbr,C0085805;C0439475
300,sbp < nmbr mm hg and dbp < nmbr mm hg nmbr / nmbr,C0085805;C0439475
300,change in sbp ( nmbr months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
300,sbp ≥ nmbr mmhg,C0085805;C0439475
300,sbp > nmbrmmhg n = nmbr,C0085805;C0439475
299,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
299,> nmbr at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,screening absolute reversibility fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
299,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
299,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
299,> nmbr per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
299,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
299,screening ( visit nmbr ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
299,current smoker at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
299,oad at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,screening bmi ( kg / mnmbr ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
299,screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
299,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
299,modified rankin scale at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
298,adjusted mean change from baseline ( nmbr % ci ),C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
298,from baseline ( nmbr % ci ),C0008107;C0168634;C1442488;C3259781
297,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
297,one vessel,C0005847;C0205447
297,nmbr vessels or left main,C0005847
297,nmbr vessel pci,C0005847;C4049621
297,vessel size,C0005847;C0456389
297,more than nmbr vessels stented,C0005847;C0205172
297,timi flow grade nmbr of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
297,any vascular diasease,C0005847;C1558950;C1801960
297,timi flow grade nmbr of mi culprit vessel pre ‐ pci,C0005847;C0441800;C0919553;C3244287;C3272266;C3810814
297,> nmbr diseased vessels,C0005847
297,nmbr vessels,C0005847
297,vascular territory # nmbr,C0005847;C1301808;C1558950;C1801960;C2983136
297,> nmbr lesions per vessel,C0005847;C0221198
297,number of diseased vessels,C0005847;C0237753;C0449788
297,vascular,C0005847;C1558950;C1801960
297,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
297,nmbr vessel,C0005847
297,single vessel coronary artery diseasea,C0005847;C0265903
297,number of vessels treated,C0005847;C0237753;C0449788
297,no . of vessels,C0005847
297,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
297,culprit vessel,C0005847
297,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
297,no . of treated vessels,C0005847;C1522326
297,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
297,restenotic vessel,C0005847;C0333186
297,treated vessel ( s ),C0005847;C1522326
297,no . of vessels treated,C0005847
297,vascular disordersb,C0005847;C1558950;C1801960
297,treated vessel,C0005847;C1522326
297,treated vessel !,C0005847;C1522326
297,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
297,> nmbr vessels treated,C0005847
297,no culprit vessel identified,C0005847
297,no . of vessels with > nmbr % stenosis,C0005847
297,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
297,number of treated vessels,C0005847;C0237753;C0449788;C1522326
297,vessel treated,C0005847
296,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx > nmbr – nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx ≥ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx £ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx > nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx ≤ nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,mtx < nmbr mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
296,nmbr mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
295,losmapimod,C3272847
295,losmapimod ( n = nmbr ),C3272847
294,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
294,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
294,concomitant antihyperglycaemic drugs,C0013227;C0020616;C0521115;C3687832
293,use of ics,C0815320;C1524063;C4551720
293,calima japandhigh - dosage ics / laba and baseline blood eosinophils > nmbr cells / ml ( n = nmbr ) y,C0178602;C0815320;C2986497;C4551720
293,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > nmbr cells / ml ( n = nmbr ),C0178602;C0815320;C2986497;C4551720
293,previous ics alone,C0205156;C0815320;C1552607;C4551720
293,other ics,C0815320;C4551720
293,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
293,other ics versus no ics,C0815320;C4551720
293,ics non - users,C0815320;C1518422;C1706077;C4551720
293,without concomitant ics,C0521115;C0815320;C4551720
293,ics  no laba ( tiotropium n = nmbr  placebo n = nmbr ),C0815320;C4551720
293,total ics dose at entry,C0815320;C1705654;C2986497;C4551720
293,use of ics at baseline,C0815320;C1524063;C4551720
293,ics / laba subset,C0815320;C1515021;C4551720
293,laba + ics,C0815320;C4551720
293,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
293,ics + laba,C0815320;C4551720
293,ics / laba,C0815320;C4551720
293,ics / lama,C0815320;C0999593;C1416775;C4551720
293,laba plus ics,C0815320;C4551720
293,mean ics use at enrolment ( pg ) *,C0444504;C0815320;C2347634;C2348143;C4551720
293,laba / ics #,C0815320;C4551720
293,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
293,ics use at screeningg,C0815320;C4551720
293,ics users : qvainmbr - sfc,C0815320;C1706077;C4521536;C4551720
293,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
293,laba   +   ics,C0815320;C4551720
293,non - ics +,C0815320;C1518422;C4551720
293,ics alone,C0815320;C4551720
293,high - dosage ics plus laba with baseline blood eosinophils anmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
293,ics users,C0815320;C1706077;C4551720
293,neither ics nor laba,C0815320;C4551720
293,ics use yes,C0815320;C4551720
293,ics use no,C0815320;C4551720
293,ics use at screening,C0815320;C4551720
293,ics use at enrollment,C0815320;C4551720
293,ics,C0815320;C4551720
293,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
293,ics use at baseline : no,C0815320;C4551720
293,with ics,C0815320;C4551720
293,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
293,ics non - users : qvainmbr - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
293,ics nonusers,C0815320;C4551720
293,ics ? laba ( free or fdc ),C0815320;C4551720
293,with concomitant ics,C0521115;C0815320;C4551720
293,ics use yes / no,C0815320;C4551720
293,ics subset,C0815320;C1515021;C4551720
293,ics only,C0205171;C0815320;C1720467;C4551720
293,+ ics / + laba n z nmbr,C0815320;C4551720
293,laba + ics n = nmbr,C0815320;C4551720
293,laba / ics use at screening,C0815320;C4551720
293,ics no laba,C0815320;C4551720
293,total daily dose of ics,C0815320;C2348070;C4551720
293,- ics / + laba n z nmbr,C0815320;C4551720
293,discontinuation of ics / laba prior to baseline,C0457454;C0815320;C1444662;C4551720;C4552847
293,ics usage,C0457083;C0815320;C4551720
293,ics # #,C0815320;C4551720
293,high - dosage ics plus laba with baseline blood eosinophils > nmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
293,high - dosage ics plus laba with baseline blood eosinophils < nmbr cells per pl ( n = nmbr ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
293,no ics,C0815320;C4551720
293,ics use,C0815320;C4551720
293,ics plus laba,C0815320;C4551720
293,ics use at baseline,C0815320;C4551720
293,ics : no,C0815320;C4551720
293,ics use at baseline : yes,C0815320;C4551720
293,laba + ics versus indzgly lsm difference ( nmbr % cl ),C0815320;C4551720
293,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
293,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
292,p ( losartan versus placebo ),C0126174;C0369773;C2603361
292,losartan,C0126174
292,losartan n = nmbr,C0126174
292,losartan ( n = nmbr,C0126174
292,treated with losartan ( n = nmbr ),C0126174;C0332293
292,adjusted hr losartan vs atenolol *,C0126174;C0456081
292,losartan ( n = nmbr ),C0126174
291,cangrelor,C1121991
291,p value ( cangrelor versus clopidogrel in men ),C1121991;C1709380
291,cangrelor n / n ( % ),C1121991
291,p value ( cangrelor versus clopidogrel in women ),C1121991;C1709380
291,cangrelor ( n = nmbr ) n / n ( % ),C1121991
291,cangrelor ( n = nmbr ),C1121991
290,umec nmbr . nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506
290,tio nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506
290,ff nmbr | ig ( n = nmbr ),C0021027;C0305052;C0360506;C4554348
290,sfc nmbr / nmbr | ig bid n = nmbr,C0021027;C0305052;C0360506;C4521536
290,ig ( n = nmbr ),C0021027;C0305052;C0360506
289,other vascular disease,C0042373
289,vessel disease,C0042373
289,vascular disease,C0042373
289,clinically evident vascular disease,C0042373;C3887511
289,any vascular disease,C0042373
289,double - vessel disease,C0042373;C0205173;C1705764;C1705765
289,number of vessels disease,C0042373;C0237753;C0449788
289,previous vascular disease,C0042373;C0205156;C1552607
289,other vascular disease — no . ( % ),C0042373
288,incident dm or change in,C0011816;C1551358;C3250443
288,non - dm,C0011816;C1518422;C3250443
288,with dm,C0011816;C3250443
288,no incident dm or change in fg > nmbr,C0011816;C1551358;C3250443
288,tnmbrdm,C0011816;C2603360;C3250443
288,mean ( s . d . ) duration of tnmbrdm,C0011816;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
288,duration of tnmbrdm,C0011816;C0449238;C2926735;C3250443
288,no dm ( n = nmbr,C0011816;C3250443
288,duration of tnmbrdm > nmbr years,C0011816;C0439234;C0449238;C2926735;C3250443
288,no dm,C0011816;C3250443
288,mean ( sd ) duration of tnmbrdm,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
288,of tnmbrdm ( years ),C0011816;C0439234;C2603360;C3250443
288,tnmbrdm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
288,dm absent,C0011816;C3250443
288,dm present,C0011816;C0150312;C0449450;C3250443
288,no prior dm,C0011816;C0332152;C2826257;C3250443
288,duration of tnmbrdm < nmbr years,C0011816;C0439234;C0449238;C2926735;C3250443
288,mets w / o tnmbrdm,C0011816;C0812270;C1705694;C2939420;C3250443
288,dm,C0011816;C3250443
288,neither tnmbrdm nor mets,C0011816;C2603360;C3250443
288,no dm ( n = nmbr ),C0011816;C3250443
288,prior dm,C0011816;C0332152;C2826257;C3250443
288,without tnmbrdm n = nmbr,C0011816;C2986835;C3250443
288,new dm,C0011816;C0205314;C3250443
288,dm ( n = nmbr,C0011816;C3250443
288,dm duration,C0011816;C0449238;C2926735;C3250443
288,dm or ckd *,C0011816;C3250443
288,duration of tnmbrdm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
288,known duration of tnmbrdm,C0011816;C0205309;C0449238;C2926735;C3250443
288,duration of tnmbrdm ( % ),C0011816;C0449238;C2926735;C3250443
288,dm ( n = nmbr ),C0011816;C3250443
288,with tnmbrdm n = nmbr,C0011816;C2986835;C3250443
288,without dm ( n = nmbrinmbr * ),C0011816;C3250443
288,dm or diabetic complications,C0011816;C3250443
288,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
288,tnmbrdm duration,C0011816;C0449238;C2603360;C2926735;C3250443
288,without dm,C0011816;C3250443
288,previous dm,C0011816;C0205156;C1552607;C3250443
288,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
287,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
287,in - clinic uasnmbr,C0002424;C0150312;C0332285;C0442592;C1707101
287,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
287,mayo clinic score,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
287,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
287,complete mayo clinic score,C0002424;C0205197;C0442592;C0449820;C0454788;C0725685;C1077578;C3853530;C4050231;C4283785
287,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
286,years of education,C0013621;C0013622;C0013658;C0039401;C0439234
286,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
286,age of completion of highest education,C0001779;C0013621;C0013622;C0013658;C0039401;C0205197;C1522410;C1554962
286,education,C0013621;C0013622;C0013658;C0039401
286,education nmbr - nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
286,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
286,education ( % ),C0013621;C0013622;C0013658;C0039401
286,> nmbr years education,C0013621;C0013622;C0013658;C0039401;C0439234
286,education *,C0013621;C0013622;C0013658;C0039401
286,education < nmbr y,C0013621;C0013622;C0013658;C0039401
286,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
286,education > nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
286,education > nmbr y,C0013621;C0013622;C0013658;C0039401
286,education > nmbr yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
286,education nmbr to nmbr y,C0013621;C0013622;C0013658;C0039401
286,< nmbr yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
286,education < nmbr years,C0013621;C0013622;C0013658;C0039401;C0439234
286,education in years,C0013621;C0013622;C0013658;C0039401;C0439234
285,relative risk reduction ( nmbr % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
285,relative risk reduction ( nmbr % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
284,cardiovascular hospitalization,C0007226;C0019993;C3887460
284,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
283,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
283,nmbr prior tnf antagonist failures,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
283,type of tnf antagonist failure,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
283,tnf - naive patientsa,C1448177
283,tnf antagonist - naive ' ’,C0231491;C1448177
283,tnf antagonist - exposed,C0231491;C1448177
283,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
283,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
283,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
283,prior tnf antagonist,C0231491;C0332152;C1448177;C2826257
283,prior anti - tnf treatment,C1448177;C1514463
283,prior tnf antagonist failure,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
283,tnf - failurea,C1448177
283,tnf inhibitor,C1448177;C1999216
283,nmbr prior tnf antagonist failure,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
283,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
283,prior therapy with tnf antagonist,C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
283,tnf antagonist - naive subgroup ( n - nmbr ),C0231491;C1079230;C1448177;C1515021
283,previous tnf antagonist exposure,C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
283,anti - tnf - naive,C1448177
283,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
283,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
283,tnf antagonist - naive ®,C0231491;C1448177
283,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
283,anti - tnf,C1448177
283,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
283,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
283,tnf - naivea,C1448177
283,tnf antagonist,C0231491;C1448177
283,tnf - failure patientsa,C0231174;C0680095;C1448177
283,type of tnf failure,C0231174;C0332307;C0680095;C1448177;C1547052
282,pulmonary embolism only,C0034065;C0205171;C1720467
282,isolated pulmonary embolism,C0034065;C0205409;C1548221
282,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
282,pulmonary embolism,C0034065
281,hispanic / latin american,C0019576
281,hispanic american,C0019576
280,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
280,pfor heterogeneity,C0019409;C0242960;C1151635
280,heterogeneity p value,C0019409;C0242960;C1709380
280,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
280,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
280,p value for heterogeneity,C0019409;C0242960;C1709380
280,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
280,* p for heterogeneity of treatment effect between tertiles > nmbr . nmbr .,C0019409;C0242960;C0369773;C1518681;C2603361
280,heterogeneity or trend p value,C0019409;C0242960
280,pvalue for heterogeneity,C0019409;C0242960
280,heterogeneity or trend p vaiue,C0019409;C0242960
279,theophylline compound,C0039771;C0205198;C1706082
279,theophyllines,C0039771
278,uric acid ( mg / dl ),C0041980;C0439269
278,uric acid tertile nmbr ( < nmbr . nmbr mg / dl ),C0041980;C0439269
278,uric acid tertile nmbr ( nmbr . nmbr to < nmbr . nmbr mg / dl ),C0041980;C0439269
278,uric acid tertile nmbr ( > nmbr . nmbr mg / dl ),C0041980;C0439269
277,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
277,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
276,first disease - progression outcome to occur §,C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1947900;C3542417;C4552808
276,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
276,radiographic progression based on change from baseline > sdc,C0242656;C0444708;C0449258
275,no nasal polyps,C0027430
275,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430
275,nasal polyps,C0027430
274,antimalarials only,C0003374;C0205171;C1720467
274,antimalarial,C0003374;C3536844;C4552582
273,no corticosteroid,C0001617;C3536709
273,corticosteroid or immunosuppressant,C0001617;C3536709
273,no corticosteroid + no imm,C0001617;C3536709
273,refractory to corticosteroids,C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
273,no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
273,oral corticosteroid use,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
273,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
273,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
273,corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727
273,imm + corticosteroid,C0001617;C0205470;C3536709
273,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
273,immy ( without corticosteroid ),C0001617;C3536709
273,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C1514873;C3536709
273,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
273,> nmbr corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
273,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
273,corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727
273,corticosteroids ( excluding budesonide ),C0001617;C3539185;C3540725;C3540726;C3540727
273,corticosteroids ' nmbr,C0001617;C3539185;C3540725;C3540726;C3540727
273,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
273,imm ( without corticosteroid ),C0001617;C0205470;C3536709
273,corticosteroid and immunosuppressant,C0001617;C3536709
273,corticosteroid or azathioprine / nmbr - mercaptopurine,C0001617;C3536709
273,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
273,corticosteroid + imm,C0001617;C0205470;C3536709
273,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
273,neither corticosteroid nor immunosuppressant,C0001617;C3536709
273,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
273,prior corticosteroid treatment,C0001617;C1514463;C3536709
273,corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
273,concomitant oral corticosteroids,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
273,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
273,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
273,corticosteroid ( with or without immunosuppressants ),C0001617;C3536709
273,corticosteroid ( without imm ),C0001617;C0205470;C3536709
273,corticosteroid,C0001617;C3536709
272,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex ( p = nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
272,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
272,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,> nmbr yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
272,> nmbr yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
272,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
271,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
271,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
271,body - mass index — no . ( % ) : i :,C0005893;C0578022;C1305855
271,body - mass index ”,C0005893;C0578022;C1305855
271,body - mass index ( kg / mnmbr ) *,C0005893;C0578022;C1305855;C1532718
271,body - mass index^ :,C0005893;C0578022;C1305855
271,body - mass index^ ,C0005893;C0578022;C1305855
271,body - mass index ( kg / cmnmbr ),C0005893;C0578022;C1305855;C4054689
271,body - mass index ( kg / m   nmbr ),C0005893;C0578022;C1305855;C1532718
271,body - mass index^,C0005893;C0578022;C1305855
271,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
271,body - mass index ) ',C0005893;C0578022;C1305855
271,mean ( sd ) body mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
271,body - mass index ( kg / mnmbr ) ( mean,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
271,body mass index ( kg / m^ ),C0005893;C0578022;C1305855;C1532718
271,body mass index ( bmi ),C0005893;C0578022;C1305855
271,body mass index ( kg / m^ ) ^,C0005893;C0578022;C1305855;C1532718
271,mean body mass index ( kg / mnmbr ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
271,body mass index > nmbr kg / mnmbr,C0005893;C0578022;C1305855;C1532718
271,body mass index category,C0005893;C0578022;C0683312;C1305855;C3889287
271,body mass index^,C0005893;C0578022;C1305855
271,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
271,body mass index mean kg / mnmbr ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
271,body mass index  mean ± sd ( kg / mnmbr ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
271,body mass index > nmbrt,C0005893;C0578022;C1305855
271,body mass index > nmbr kg / m,C0005893;C0578022;C1305855;C1532718
271,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
271,body mass index [kg / mnmbr],C0005893;C0578022;C1305855;C1532718
271,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
271,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
271,body mass index ( kgm _nmbr ),C0005893;C0578022;C1305855
271,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
271,body mass index ( kg / mnmbr ) ∗,C0005893;C0578022;C1305855;C1532718
271,body - mass index - kg / mnmbr,C0005893;C0578022;C1305855;C1532718
271,body mass index > nmbr — no . ( % ) f,C0005893;C0578022;C1305855
271,body mass index ( kg / mnmbr ) * ',C0005893;C0578022;C1305855;C1532718
271,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
271,mean body - mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143
271,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
271,mean body mass index,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143
271,mean body mass index ( kg / mnmbr ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
271,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
271,body - mass index \ kg / mnmbr,C0005893;C0578022;C1305855;C1532718
271,bodymass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
271,body mass index *,C0005893;C0578022;C1305855
271,median body mass index,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
271,"body - mass index ) """,C0005893;C0578022;C1305855
271,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
271,body mass index ( kg / mnmbr ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
271,body - mass index ),C0005893;C0578022;C1305855
271,body - mass index > nmbr,C0005893;C0578022;C1305855
271,body - mass index *,C0005893;C0578022;C1305855
271,body - mass index §,C0005893;C0578022;C1305855
271,body - mass index $,C0005893;C0578022;C1305855
271,body mass index > nmbr,C0005893;C0578022;C1305855
271,mean body - mass index ( = sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
271,body mass index ( range ) ( kg / mnmbr ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
271,sd = standard deviation  bmi = body mass index  ed = erectile,C0871420;C1305855;C2699239;C3538926
271,body mass index > nmbr kg / mnmbr *,C0005893;C0578022;C1305855;C1532718
271,body mass index +,C0005893;C0578022;C1305855
271,body mass index :,C0005893;C0578022;C1305855
271,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
271,body - mass index,C0005893;C0578022;C1305855
271,body - mass index ) -,C0005893;C0578022;C1305855
271,body mass index < nmbr kg / mnmbr,C0005893;C0578022;C1305855;C1532718
271,body - mass index ( kg / mnmbr ) t,C0005893;C0578022;C1305855;C1532718
271,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
271,body mass index,C0005893;C0578022;C1305855
271,body mass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
271,body mass indexnmbr,C0005893;C0578022;C1305855
271,body - mass index - ! ',C0005893;C0578022;C1305855
271,body - mass index  ! ,C0005893;C0578022;C1305855
271,body - mass index : ! :,C0005893;C0578022;C1305855
271,body mass index - kg / mnmbrt,C0005893;C0578022;C1305855;C1532718
271,body - mass index ( kg / mnmbr ),C0005893;C0578022;C1305855;C1532718
271,mean body mass index ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
270,gemfibrozil,C0017245
270,gemfibrozil ( n = nmbr,C0017245
269,% risk reduction ( nmbr % ci ),C0008107;C1137094;C3259781
269,risk reduction ( %  nmbr % ci ),C0008107;C1137094;C3259781
268,vorapaxar placebo nmbr - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
268,vorapaxar placebo nmbr - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
268,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
268,vorapaxar placebo nmbr - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
267,c peptide,C0006558
267,c - peptide,C0006558
266,diet + pravastatin nmbr / nmbr ( nmbr . nmbr ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
266,diet plus pravastatin group ( n = nmbr ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
266,diet + pravastatin ( n = nmbr ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
266,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
266,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
265,median serum periostin,C0219433;C0229671;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
265,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
264,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
264,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
264,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
263,oral hypoglycemics hormone replacement,C0282402;C0359086
263,hormone replacement ! !,C0282402
263,use of hormone replacement therapy ( a ),C0282402;C1524063
263,hormone replacement,C0282402
263,hormone replacement therapy,C0282402
263,hrt,C0282402
262,patients with fistulas at baseline,C0016169;C0030705
262,all patients with fistulas ( n = nmbr ),C0016169;C0030705
261,region north america,C0017446;C0028405;C0205147
261,region - north america,C0017446;C0028405;C0205147
261,geographic region - north america,C0017446;C0028405
260,odds ratio versus placebo ( nmbr % ci ),C0028873
260,odds ratio,C0028873
260,odds ratio ( nmbr % cl ),C0028873;C0596019
260,odds ratio and nmbr % cl,C0028873
260,estimated odds ratio,C0028873;C0750572
259,p value ( aged > nmbr vs . < nmbr years ),C0001779;C0001792;C1709380;C1999167
259,aged ≥ nmbr years,C0001779;C0001792;C0439234;C1999167
259,aged nmbr y or older,C0001779;C0001792;C1999167
259,aged a nmbr years,C0001779;C0001792;C1999167
259,non ‐ elderly,C0001792;C1518422;C1999167
259,non - elderly ( < nmbr years ),C0001792;C0439234;C1518422;C1999167
259,aged < nmbr years,C0001779;C0001792;C0439234;C1999167
259,elderly ( > nmbr years ),C0001792;C0439234;C1999167
259,aged ^nmbr years,C0001779;C0001792;C0439234;C1999167
259,elderly,C0001792;C1999167
258,physical examinations,C0031809
258,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
258,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
258,physical examination,C0031809;C1744699
258,physical and cognitive examination : ! :,C0031809;C0205485;C1509143
258,physical characteristics,C0031809;C0205485;C1509143;C1521970
257,selexipag,C2000145
257,selexipag vs placebo hazard ratio ( nmbr % cl ),C2000145
257,selexipag ( n = nmbr ),C2000145
256,mild to moderate renal impairment *,C1299392;C1565489
256,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
256,renal impairment,C1565489
256,severe renal impairment,C0205082;C1565489;C4050465;C4050466
256,renal impairment ( crcl < nmbr ml / min ),C0439445;C1565489;C1846718
256,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
256,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
256,no renal dysfunction,C1565489;C3279454
256,renal dysfunction,C1565489;C3279454
256,renal impairment *,C1565489
256,impaired renal function †,C1565489
256,impaired renal function §,C1565489
256,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
255,hgb,C0019029;C0019046;C0518015;C1424337
255,missing hb at yr nmbr,C0019046;C0439234;C1551393;C1705492;C3272743
255,hb,C0019046
255,bsl hb,C0019046;C1549954
255,hemoglobin,C0019046
255,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
255,hb decrease ≥ nmbr g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
255,haemoglobin ( mg / dl ),C0019046;C0439269
255,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
255,hemoglobin ale *,C0019046;C0678386;C2632076
255,for combined hemoglobin groups,C0019046;C0205195
255,haemoglobin,C0019046
255,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
255,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
255,hemoglobin category,C0019046;C0683312;C3889287
255,glyeated haemoglobin,C0019046
255,hemoglobin ale,C0019046;C0678386;C2632076
254,tocilizumab ( n = nmbr ),C1609165
254,tocilizumab,C1609165
253,randomized patients,C0030705;C0034656;C3815594
253,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
253,all randomized patients,C0030705;C0034656;C3815594
252,pef,C0030771;C1518922;C1542834
252,pef !,C0030771;C1518922;C1542834
251,mean duration of surgery ± sd,C0038894;C0038895;C0444504;C0449238;C0543467;C1274039;C2347634;C2348143;C2699239;C2926735
251,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
251,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
251,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
251,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
251,valve surgery,C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
251,surgery,C0038894;C0038895;C0543467;C1274039
251,planned valve surgery,C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
250,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
250,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
250,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
249,insulin glargine vs standard care least - squares mean ( nmbr % cl ),C0907402
249,number insulin glargine,C0237753;C0449788;C0907402
249,insulin glargine,C0907402
249,insulin glargine allocation,C0907402;C1706778
249,iglar ( insulin glargine lnmbr u ),C0439148;C0907402
249,insulin glargine ( n = nmbr ),C0907402
249,insulin glargine n ( x ),C0907402
249,glargine allocation,C0907402;C1706778
249,glargine n ( n / loopy ),C0907402
249,insulin glargine   ±   oad,C0907402
249,glargine nmbr,C0907402
249,insulin glargine ( n = nmbrll ),C0907402
249,glargine,C0907402
248,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
248,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
248,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
248,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1442488
247,urgency episodes / nmbrh,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
247,first dose admin . nmbr - nmbrh / nmbr - nmbrh post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
247,nmbr - h pmg,C0033727;C0369286;C0441932;C0564385;C4528284
247,within nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,b + h ( n = nmbr ),C0033727;C0369286;C0441932;C0564385;C4528284
247,mean sd nmbr - h asbp,C0033727;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
247,within nmbr h after,C0033727;C0369286;C0441932;C0564385;C4528284
247,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
247,> nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
247,hnmbr - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
247,< nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,> nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,< nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
247,nmbr — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
247,hnmbr blocker ( n,C0033727;C0369286;C0441932;C0564385;C4528284
247,hnmbr receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
247,nmbr to < nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
247,> nmbr to < nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
247,after nmbr h,C0033727;C0369286;C0441932;C0564385;C4528284
247,use of hnmbr bloekers,C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
247,nmbr - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
247,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
247,nmbr - nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
247,incontinence episodes / nmbrh,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
247,h,C0033727;C0369286;C0441932;C0564385;C4528284
247,> = nmbrh,C0033727;C0369286;C0441932;C0564385;C4528284
246,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
246,intervention .,C0184661;C0886296;C1273869
246,intervention ( n = nmbr ),C0184661;C0886296;C1273869
246,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
246,intervention,C0184661;C0886296;C1273869
246,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
246,interventional or surgical procedures,C0184661;C3274035
246,procedure,C0184661;C2700391;C3274430;C3539779
246,procedure * *,C0184661;C2700391;C3274430;C3539779
246,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
246,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
246,multivessel intervention,C0184661;C0886296;C1273869
246,proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869
246,intervention group ( n = nmbr ),C0184661;C0441848;C0886296;C1273869
246,experimental intervention group ( n = nmbr ),C0184661;C0441848;C0886296;C1273869;C1517586
246,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
246,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
246,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
245,post - bronchodilator fev i reversibility,C0021966;C0221138;C0449261;C2599594;C3714541
245,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
245,i & ii : fevnmbr > nmbr % predicted,C0021966;C0221138;C1710602;C3714541;C4082587
244,day nmbr oral glucocorticoid use — no . { % ),C0017710;C0332173;C0439228;C0439505;C0442027;C4521986
244,glucocorticoid,C0017710
244,use of systemic glucocorticoid at random -,C0017710;C0205373;C1524063
244,glucocorticoids,C0017710;C3540777;C3540778
244,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
244,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
244,glucocorticoids *,C0017710;C3540777;C3540778
244,oral glucocorticoid use,C0017710;C1527415
244,no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778
244,any glucocorticoid *,C0017710
244,glucocorticoid],C0017710
244,glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778
244,oral glucocorticoid dose,C0017710;C0178602;C0442027;C0869039;C1114758;C4521986
244,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
244,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
243,niacin + statin,C0027996;C0360714;C1142562
243,statin + er niacin ( n = nmbr ),C0027996;C0360714;C1142562;C3810541;C3811131
243,extended - release niacin plus statin ( n = nmbr ),C0027996;C0332287;C0360714;C1142562;C1707968
243,statin with niacin,C0027996;C0360714;C1142562
242,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
242,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
242,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
242,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
242,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
242,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
242,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
242,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
242,myocardial infarction within the previous nmbr yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
242,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
242,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
242,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
242,no previous myocardial infarction nmbr / nmbr,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
242,myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959
242,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
242,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
242,no myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
242,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
242,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
242,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
242,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
242,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
242,myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
241,oriental,C0078988;C0699027
241,asian ( n   = nmbr ),C0078988
241,asian *,C0078988
241,asian,C0078988
241,non - east asian §,C0078988;C1518422;C1707877
241,east asian,C0078988;C1707877
241,other asian,C0078988
241,asian / oriental,C0078988;C0699027
241,asians ( n = nmbr ),C0078988
241,asian or oriental,C0078988
241,asian ( n = nmbr ),C0078988
241,asian ( n = nmbr,C0078988
241,p - value for east asian versus non - east asian *,C0078988;C1707877;C1709380
241,asian ( nmbr . nmbr % ),C0078988
241,non - asian ( n = nmbr nmbr ),C0078988;C1518422
241,non - asian,C0078988;C1518422
241,asian or pacific islander,C0078988
241,asian ( n — nmbr ),C0078988
240,controls ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,control group ( n = nmbr ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
240,control n = nmbr,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
240,control ( n - nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,control ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,control ( nznmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,control ( n z nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,standard control ( n = nmbr ) no . of patients ( percent ),C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
240,( % ) control ( nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
240,good control ( < nmbr ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
240,fair control ( nmbr - nmbr . nmbr ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
240,control nmbr months ( n - nmbr ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
240,rhythm - control group ( n = nmbr ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
239,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
239,femoral neck ( n = nmbr,C0015815
239,femoral neck bmd t - score,C0015815;C0449820;C4050231
239,femoral neck,C0015815
239,at femoral neck,C0015815
239,femoral neck bmd ( g / cmnmbr ),C0015815;C0439267
239,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0392747;C0443172;C1705241;C4319952
239,t - score at femoral neck,C0015815;C3854607
239,mean femoral neck t score,C0015815;C3533236
239,femoral neck t - score,C0015815;C0449820;C4050231
238,nyha iv,C0022326;C1275491;C4265176
238,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
238,iii / iv,C0022326;C0439070;C1705160;C4265176
238,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
238,killip class ii - iv,C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
238,ii - iv,C0022326;C1710602;C4082587;C4265176
238,lll / iv,C0022326;C1261077;C4265176
238,iii - iv,C0022326;C0439070;C1705160;C4265176
238,iv,C0022326;C4265176
238,iv nitrates,C0022326;C4265176
238,lll - iv,C0022326;C1261077;C4265176
238,dual iv,C0022326;C0205173;C1554184;C4265176
238,iv ( nmbr ),C0022326;C4265176
238,iii & iv,C0022326;C0439070;C1705160;C4265176
238,dyspnea at rest ( nyha iv ),C0022326;C0743330;C1275491;C4265176
238,iv ( n z nmbr ),C0022326;C4265176
238,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
237,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
237,aspirin plus placebo ( n = nmbr ),C0004057;C0032042;C0332287;C1696465;C1706408
236,p nmbr interaction women vs men,C0043210;C0369773;C1704675;C2603361
236,women  qvanmbr - sfc,C0043210;C4521536
236,woman,C0043210;C4281745
236,women < nmbr years,C0043210;C0439234
236,no . women,C0043210
236,ratio of women to men — %,C0043210;C0456603;C1547037
236,women ( n = nmbr ) events,C0043210;C0441471;C3541888
236,"women t """,C0043210
236,women - no . ( % ),C0043210
236,women ( n = nmbr vs nmbr ),C0043210
236,women ( % ),C0043210
236,women ( n ( % ) ),C0043210
236,p interaction women vs men,C0043210;C0369773;C1704675;C2603361
236,women > nmbr years,C0043210;C0439234
236,nmbr - nmbr ( women ),C0043210
236,( women only ),C0043210;C0205171;C1720467
236,women — no . ( % ),C0043210
236,women : < nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0043210;C0439269;C1532563
236,women ( n = nmbr ),C0043210
236,gmi ( women ),C0043210
236,women taking estrogen,C0043210
236,p ( women vs men ),C0043210;C0369773;C2603361
236,all women,C0043210
236,women,C0043210
235,north america ( plus america and new zealand ),C0028405;C0332287
235,north america *,C0028405
235,north america ( n = nmbr ),C0028405
235,north america,C0028405
235,north america hr ( nmbr % cl ),C0028405;C0596019
235,north america n z nmbr,C0028405
235,north america ( % ),C0028405
234,anticholinergic drug,C0242896
234,anticholinergic,C0242896;C3537004
234,anticholinergics,C0242896;C3537307;C3540711
234,anti - cholinergics ( short - acting ) a,C0242896
234,anti - cholinergics ( long - acting ),C0242896
233,interleukin nmbr ( pg / ml ),C0021764;C0439297;C1527200
233,interleukin - nmbr ( ng / l ),C0021764;C0439297;C1527200
232,diuretic — no . / total no . ( % ),C0012798
232,diuretics,C0012798
232,diuretic — no . ( % ) surgery,C0012798
232,diuretic ( any ),C0012798
232,diuretics group ( n = nmbr ),C0012798;C0441848
232,use of diuretics,C0012798;C1524063
232,diuretic agents,C0012798;C0450442;C1254351;C1521826
232,no - diuretics group ( n = nmbr ),C0012798;C0441848
232,diuretic agents ( excluding antialdosterone ),C0012798;C0450442;C1254351;C1521826
232,diuretic n ( % ),C0012798
232,diuretic subgroup,C0012798;C1079230;C1515021
232,diuretics^,C0012798
232,diuretics * *,C0012798
232,diuretic,C0012798
232,non diuretics,C0012798;C1518422
232,diuretic agent,C0012798;C0450442;C1254351;C1521826
232,other diuretic,C0012798
232,diuretics ( % ),C0012798
231,investigator - defined drug - related aes,C0035173
231,investigator - determined myocardial infarction,C0035173
231,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > nmbr x uln with associated muscle symptoms with no other plausible etiology ^consecutive defined as two or more measurements at least one week apart or one measurement < nmbr days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0035173;C0521095
231,investigator - reported hypoglycaemia,C0035173
231,investigator - reported hypoglycaemia *,C0035173
231,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0868945
230,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
230,ischemia on cecg ( n = nmbr,C0022116;C4321499
230,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
230,ischemia on cecg ( % ),C0022116;C4321499
230,ischemia,C0022116;C4321499
230,ischemia driven revascularization,C0022116;C4321499
230,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
230,global ischemia,C0022116;C0205246;C2348867;C4321499
230,no ischemia ( n = nmbr,C0022116;C4321499
230,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
230,ischemia - driven revascularization,C0022116;C4321499
229,prior cardiac resynchronization therapy,C0332152;C1167956;C2826257
229,cardiac resynchronization therapy,C1167956
229,cardiac resynchronization therapy n ( % ),C1167956
228,statins / ezetimibe,C0360714;C1142985
228,statin with ezetimibe,C0360714;C1142985
228,statin + ezetimibe,C0360714;C1142985
228,statin + ezetimibe ( n = nmbr . nmbr ),C0360714;C1142985
228,statin + ezetimibe { n = nmbr,C0360714;C1142985
227,pulmonary disease — no . ( % ),C0024115
227,pulmonary disease,C0024115
226,> nmbr % coronary stenosis,C0242231
226,coronary artery stenosis > nmbr %,C0242231
226,> nmbr % stenosis of coronary,C0242231
225,ct,C0007673;C3540513;C3813556;C3888140
225,ct ratio > nmbr . nmbr,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
225,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
225,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
224,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
224,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
224,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
224,tc level,C0039411;C0040642;C0041405;C0041698;C0441889;C0456079;C1547707;C1824670;C2946261;C3272447;C4522122
224,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
224,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
224,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
223,ezetimibe + simvastatin ( n = nmbr,C1532737
223,ezetimibe / simvastatin,C1532737
223,ezetimibe + simvastatin ( n = nmbr * ),C1532737
222,history of chd at baseline d,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
222,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
222,prior treatment historynmbr,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
222,type nmbr diabetes history,C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
222,history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,history of chd at baseline §,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
222,prior history ml or stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
222,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
222,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
222,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
222,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of atrial arrhythmia,C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
222,history mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
222,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
222,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
222,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
222,history coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,oad history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
222,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
222,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
222,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
222,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
222,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
222,history of mi ( n = nmbr,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,no history of mi ( n = nmbr,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,copd exacerbation history in the previous year,C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
222,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
222,history ol mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
222,history of upper gi events ( perforations,C0019664;C0019665;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
222,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
222,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
222,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
222,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,history of macroalbuminuriat,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
222,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
222,history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
222,history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
222,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
222,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
222,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,history of more than nmbr prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
222,history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
222,ed history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538926
222,presenting history or diagnosis — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0449450;C1705255;C2004062
222,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
222,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
222,chd history,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
222,copd exacerbation history,C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
221,systolic blood pressure > nmbr mm hg,C0439475;C0488055;C0871470;C1306620
221,at home systolic pressure > nmbr mm hg,C0439475;C0871470;C4534363
221,at home systolic pressure < nmbr mm hg,C0439475;C0871470;C4534363
221,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
221,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
221,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
221,systolic blood pressure > nmbr mm hg or diastolic,C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0439475;C0488055;C0871470;C1306620;C1704675
221,systolic blood pressure ( median nmbr . nmbr ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
221,systolic bp ( mmhg ) *,C0439475;C0871470
221,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure > nmbr mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure < nmbr mm hg and diastolic,C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
221,systolic pressure — mm hg,C0439475;C0871470
221,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure > nmbr mm hg or diastolic blood pressure > nmbr mm hg,C0439475;C0488055;C0871470;C1306620
221,systolic pressure,C0871470
221,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure mmhg,C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure < nmbr mm hg and diastolic blood pressure < nmbr mm hg,C0439475;C0488055;C0871470;C1306620
221,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
221,systolic bp ( mmhg ),C0439475;C0871470
221,mean systolic bp,C0444504;C0871470;C2347634;C2348143
221,systolic bp ( mm hg ),C0439475;C0871470
221,systolic bp,C0871470
221,systolic blood pressure,C0488055;C0871470;C1306620
221,systolic blood pressure^,C0488055;C0871470;C1306620
220,aspirin plus clopidogrel ( n = nmbr ),C0004057;C0070166;C0332287
220,aspirin nmbr clopidogrel,C0004057;C0070166
220,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
220,clopidogrel plus aspirin ( n = nmbr ),C0004057;C0070166;C0332287
220,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057;C0070166
220,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0070166
220,clopidogrel plus aspirin,C0004057;C0070166;C0332287
220,clopidogrel + aspirin ( n = nmbr ),C0004057;C0070166
219,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
219,other biologic agent,C0005515
219,biologic naive,C0005515;C0205460
219,biologic,C0005515;C0205460
219,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
219,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607
219,biologic agents,C0005515
218,western europe and other,C0043129
218,western europe ( n = nmbr ),C0043129
218,western europe and lebanon,C0043129
218,western europe ( n   = nmbr,C0043129
218,western europe and israel,C0043129
218,western europe ( including south africa ),C0043129
218,western europe,C0043129
218,western europe hr ( nmbr % cl ),C0043129;C0596019
218,western europe and australia,C0043129
218,western europe plus other,C0043129
218,western europe ( % ),C0043129
217,apolipoprotein b nmbr,C0003593
217,apolipoprotein b,C0003593
217,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
217,apolipoprotein b^,C0003593
217,apolipoprotein b ( mg / dl ),C0003593;C0439269
216,sex : male ( n = nmbr ),C0086582
216,male ( n - nmbr ),C0086582;C1706180;C1706428;C1706429
216,male sex — no . ( % ) weight — no . ( % ),C0086582
216,male gender ( % ),C0086582;C1706180
216,males [n ( % ) ],C0086582
216,male sex — no . ( % ) f,C0086582
216,male ( n = nmbr,C0086582;C1706180;C1706428;C1706429
216,sex ( male ),C0086582
216,genital mycotic infections malenmbr,C0086582;C0740330;C1706180;C1706428;C1706429
216,male gender,C0086582;C1706180
216,males ( % ),C0086582
216,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
216,male eze / simva,C0086582;C1706180;C1706428;C1706429
216,male sex 一 no . ( % ),C0086582
216,sex ( male ) - no . ( % ),C0086582
216,male eze / simva ( „ = nmbr },C0086582;C1706180;C1706428;C1706429
216,male,C0086582;C1706180;C1706428;C1706429
216,sex : male,C0086582
216,male ( % ),C0086582;C1706180;C1706428;C1706429
216,male sex — no . ( % ),C0086582
216,male ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
216,male subjects ( n = nmbr,C0086582;C1706180;C1706428;C1706429
216,sexa male,C0086582;C1706180;C1706428;C1706429
216,male sex — no . / total no . ( % ),C0086582
216,male sex^,C0086582
216,male sex \ no . ( % ),C0086582
216,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582
216,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
216,male ( n z nmbr ),C0086582;C1706180;C1706428;C1706429
216,male sex — no . { % ),C0086582
216,male eze / simva ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
216,male acr definition,C0086582;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C3539107;C3888054
216,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
216,male ( n   = nmbr,C0086582;C1706180;C1706428;C1706429
216,sex ( male,C0086582
216,male simva ( „ = nmbr },C0086582;C1706180;C1706428;C1706429
216,male sex — no . of patients ( % ),C0086582
216,male vs . female,C0086582;C1706180;C1706428;C1706429
216,male sex — %,C0086582
216,male sex,C0086582
216,male simva ( n = nmbr ),C0086582;C1706180;C1706428;C1706429
216,males ( n = nmbr ),C0086582
216,male simva,C0086582;C1706180;C1706428;C1706429
216,males ( itt ) ( n = nmbr ),C0086582
216,years male gender,C0086582;C0439234;C1706180
216,male sex ( % ),C0086582
216,male sex — no . ( % ) risk factors,C0086582
216,male *,C0086582;C1706180;C1706428;C1706429
216,males,C0086582
216,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
215,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
215,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
215,asthma - related health -,C0004096;C2984299
215,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
215,hospitalized for asthma,C0004096;C0701159;C2984299
215,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
215,asthma duration ( sd ),C0004096;C0449238;C2699239;C2926735;C2984299
215,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
215,total asthma symptom score,C0004096;C2984299;C3533163
215,duration of asthma,C0004096;C0449238;C2926735;C2984299
215,asthma,C0004096;C2984299
215,total asthma symptom score :,C0004096;C2984299;C3533163
215,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
215,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
215,duration of asthma > nmbr years,C0004096;C0439234;C0449238;C2926735;C2984299
214,ethnic group ( % ),C0015031;C1879937
214,ethnic group,C0015031;C1879937
214,ethnic origin,C0015031
214,ethnic origin *,C0015031
214,ethnic group — no . ( % ) ',C0015031;C1879937
214,ethnic background,C0015031
213,amlodipine nmbrtonmbrmg ( n = nmbr ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
213,amlodipine nmbrmg / v = nmbr,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
212,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
212,prior use of biologics,C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
211,cvd risk factors ( age > nmbr ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
211,cvd risk factors ( age > nmbr ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
210,aliskiren,C1120110
210,aliskiren ( n = nmbr ),C1120110
209,upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912
209,upper respiratory tract infection,C0041912
208,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302
208,angiotensin -,C0003018;C4521302
208,angiotensin receptive blocker,C0003018;C0544683;C4521302
208,angiotensin ll - receptor blocker,C0003018;C4521302
208,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
207,diabetes with no use of diabetes drugs,C0020616;C1524063
207,antihyperglycemic,C0020616
207,other hypoglycemic agent,C0020616
207,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
207,other antihyperglycemic agents,C0020616
207,hypoglycemic agent,C0020616
207,hypoglycaemic agents,C0020616
206,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
206,body mass index ( bmi  kg / mnmbr )  n ( % ) < nmbr kg / mnmbr,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
206,body - mass index > nmbr kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
205,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
205,vein graft stented,C0042449;C0181074;C0332835;C1961139
204,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
204,neoplasia,C0027651;C1882062
203,sita nmbr + pio nmbr,C0030800;C2347712
203,pio nmbr,C0030800;C2347712
203,sita / pio nmbr / nmbr,C0030800;C2347712
202,crusade bleeding score,C0019080;C0449820;C4050231
202,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
202,fatal bleeding,C0019080;C1302234;C1705232
202,fatal bleed,C0019080;C1302234;C1705232
202,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
202,bleeding events during first nmbr days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
202,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
202,bleeding end points,C0019080;C2349179
202,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
202,life - threatening bleeding,C0019080;C1546953;C2826244;C3537125
202,bleeding,C0019080
202,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
202,timi major / minor bleeding,C0019080;C4441842
202,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
202,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
202,major bleeding nmbr to nmbr,C0019080;C0205082;C0205164;C4318856;C4521762
202,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
202,any overt bleed,C0019080
202,any gusto bleeding,C0019080
202,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
202,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
202,bleeding outcomes,C0019080;C1274040
201,nmbr to < nmbr . nmbr %,C0040363;C0041260;C1883351
201,$ nmbr to,C0040363;C0041260;C1883351
201,nmbr to < nmbr bpm ( n = nmbr ),C0040363;C0041260;C1883351
201,≥ nmbr to < nmbr %,C0040363;C0041260;C1883351
201,> nmbr to nmbr,C0040363;C0041260;C1883351
201,nmbr . nmbr to < nmbr . nmbr % ( nmbr to < nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
201,> nmbr % to < nmbr % ( > nmbr to nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
201,> nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ),C0040363;C0041260;C1883351;C3829066
201,> - nmbr . nmbr to < - nmbr . nmbr,C0040363;C0041260;C1883351
201,nmbr to < nmbr ( % ),C0040363;C0041260;C1883351
201,> nmbr to s nmbr yrs,C0040363;C0041260;C1883351
201,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) ],C0040363;C0041260;C1883351
201,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) ],C0040363;C0041260;C1883351
201,nmbr . nmbr to nmbr . nmbr ( % ),C0040363;C0041260;C1883351
201,nmbr to less than nmbr,C0040363;C0041260;C1883351
201,nmbr to < nmbr,C0040363;C0041260;C1883351
201,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) [ - nmbr . nmbr ( - nmbr . nmbr to - nmbr . nmbr ) ] - nmbr . nmbr ( nmbr . nmbr ) [ - nmbr . nmbr ( nmbr . nmbr ) ],C0040363;C0041260;C1883351
201,> nmbr . nmbr to < nmbr . nmbr,C0040363;C0041260;C1883351
201,> nmbr % to < nmbr %,C0040363;C0041260;C1883351
201,> nmbr . nmbrto < nmbr . nmbr %,C0040363;C0041260;C1883351
201,> nmbr to < nmbr,C0040363;C0041260;C1883351
201,nmbr . nmbr to nmbr . nmbr,C0040363;C0041260;C1883351
201,三 nmbr to < nmbr,C0040363;C0041260;C1883351
201,nmbr . nmbr to nmbr . nmbr %,C0040363;C0041260;C1883351
201,nmbr nmbr . nmbr ( nmbr . nmbr ) [nmbr ( nmbr . nmbr ) ] nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) [nmbr . nmbr ( - nmbr . nmbr to nmbr . nmbr ) ],C0040363;C0041260;C1883351
201,> nmbrto < nmbr uln,C0040363;C0041260;C1519815;C1883351
200,psoriasis ( n =,C0033860
200,psoriasis > nmbr % of bsa,C0033860
200,psoriasis duration,C0033860;C0449238;C2926735
200,previous exposure to systemic psoriasis therapyb ( yes ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
200,psoriasis duration ( years ),C0033860;C0439234;C0449238;C2926735
200,with psoriasis ( n = nmbr ),C0033860
200,without psoriasis ( n = nmbr,C0033860
200,£ nmbr % bsa psoriasis,C0033860
200,psoriasis bsa > nmbr %,C0033860
200,duration of psoriasis ( years ),C0033860;C0439234;C0449238;C2926735
200,without psoriasis ( n = nmbr ),C0033860
200,psoriasis characteristics,C0033860;C1521970
200,duration of psoriasis,C0033860;C0449238;C2926735
200,psoriasis,C0033860
200,psoriasis affecting > nmbr % of body - surface,C0033860;C0392760;C0489451;C1314939
200,psoriasis covering > nmbr % bsa,C0033860;C0180153;C0439844
199,ranolazine ( n nmbr nmbr ),C0073633
199,ranolazine vs . placebo km failure rate,C0073633
199,ranolazine n = nmbr,C0073633
199,ranolazine ( n = nmbr ),C0073633
199,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0073633;C1280500;C1518681;C2348382
199,ranolazine ( n = nmbr,C0073633
199,ranolazine,C0073633
198,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
198,on antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
198,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
198,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
197,individuals without diabetes,C0011847;C0011849;C0027361;C0237401
197,individuals with diabetes,C0011847;C0011849;C0027361;C0237401
197,people with diabetes n = nmbr,C0011847;C0011849;C0027361
197,people without diabetes n = nmbr,C0011847;C0011849;C0027361
196,percent stenosis [core lab],C0439165;C0678234;C1261287;C2632116;C4684837
196,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
196,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
196,prior known stenosis > nmbr %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
196,stenosis > nmbr %,C0678234;C1261287;C2632116
196,% stenosis,C0678234;C1261287;C2632116
196,diameter stenosis,C0678234;C1261287;C1301886;C2632116
196,stricturing,C1261287
195,use of antiplatelet agents — no . / total no . ( % ),C0085826;C1524063
195,antiplatelet drugs,C0085826;C2963157
195,other antiplatelet agent 一 no . ( % ),C0085826
195,antiplatelet agents,C0085826
195,nonaspirin antiplatelet agent,C0085826;C0722138
195,antiplatelet agents ( % ),C0085826
195,antiplatelet agent,C0085826
195,antiplatelets agents,C0085826
195,other antiplatelet agents,C0085826
195,antiplatelet agent n ( % ),C0085826
195,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
195,use of antiplatelet agents^,C0085826;C1524063
195,antiplatelet drug,C0085826
195,antiplatelet agent or anticoagulant,C0085826
195,use of antiplatelet agents,C0085826;C1524063
195,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
194,time from acs to randomization ( median,C0040223;C0742343;C3541383;C4318612
194,time from acs to randomization,C0040223;C0742343;C3541383;C4318612
193,daily dose > nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
193,feno nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,sfc nmbr / nmbr mg twice daily ( n = nmbr ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
193,nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,cana nmbr mg ( n - nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,< nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,cld nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,> nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,cana nmbr mg ( n = nmbr ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,toricoxib nmbr mg n = nmbr ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg / nmbr mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
193,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
193,saxa nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,> nmbr to < nmbr - nmbr mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
193,no . of nmbr - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
193,rosuva nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,eze nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,use of low - dose aspirin ( < nmbr mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
193,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
193,nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,sita nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr / nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,> nmbr - nmbr mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
193,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
193,nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg qd ( n = nmbr ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
193,cana nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,cana nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,aplxaban nmbr . nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,daily dose nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
193,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
193,alogliptin nmbr . nmbr mg + pioglitazone ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
193,cana nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
193,ato nmbr mg and sim nmbr^nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,daily dose nmbr - nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
193,ato nmbr mg and sim nmbr - nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
193,nmbr mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
193,nmbr . nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
193,crp — mg / liter^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
193,< nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,erlugliflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbrmg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg ( nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,lowest tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
193,nmbr mg eow n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,placebofigolimumab nmbr mg / nmbr mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,cana nmbr mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
193,nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbrmg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,rosuva nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg ew n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
193,ato nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,alogliptin nmbr mg + pioglitazone ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
193,glycopyrronium nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
193,nmbr mg twice daily n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
193,week nmbr — mg / liter^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,ertuglifldzin nmbr mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,saxa nmbr . nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,saxa nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,eze / simva nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,< nmbr . nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,azl - m nmbr mg ( n = nmbr ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
193,> nmbr . nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
193,nmbrmg / nmbr mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
193,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
193,mtx dose > nmbr mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
193,ertuglrflozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,fa nmbr mg ( « = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,crp > nmbr mg / nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
193,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
193,ratio of urinary albumin ( mg ) to creatinine ( g ),C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
193,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
193,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
193,p - value d nmbr mg vs . warfarin,C0024671;C0026410;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
193,nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg / kgf ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,empaglifiozin nmbr . nmbr mg ( w = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,empaglifiozin nmbr mg ( w = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,ami nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
193,ami nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
193,gly nmbr . nmbr mg b . i . d . n = nmbr,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
193,mean ± sd mg ( n = nmbr,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
193,t nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
193,nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
193,eduglinozin nmbr mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,llraglutide nmbr - nmbr mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
193,fa nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,> nmbr mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,empagiiflozin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,eze / simva nmbr / nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
193,eze nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,nmbrmg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
193,sfc nmbr / nmbr mg twice daily ( n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
193,week nmbr — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
193,highest tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
192,week nmbr ( itt population ),C0032659;C0332174;C0439230;C1257890
192,itt population,C0032659;C1257890
192,full population,C0032659;C0443225;C1257890
192,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
192,population,C0032659;C1257890
192,populations :,C0032659;C1257890
192,open - label population,C0032659;C1257890;C1709323
192,mitt population ( n = nmbr ),C0032659;C1257890
192,uplift ® population,C0032659;C1257890
192,mitt population,C0032659;C1257890
192,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
192,disease activity outcomes ( itt population ) week nmbr,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
192,bmi > = nmbr kg / mnmbr population ( n = nmbr ),C0032659;C0578022;C1257890;C1532718
191,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
191,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
191,cu index test,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
191,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
191,clinical indication at the index procedure,C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
191,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
191,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
191,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
191,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
191,cornell index,C0600653;C0918012;C1552854;C1637833;C2986546
191,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
191,tertile nmbr index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
191,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
191,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
191,insulinogenic index ( dinsulino_nmbro min / dglucoseo - nmbro min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
191,index mi ( n - nmbr,C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
191,health state index score,C0449820;C0600653;C0683314;C0918012;C1552854;C1637833;C2986546;C4050231
191,suit index,C0600653;C0918012;C1552854;C1637833;C2986546
191,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
191,leeds dactylitis index - basic,C0239161;C0600653;C0918012;C1552854;C1637833;C2986546
191,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
191,index event not confirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
191,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
191,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
191,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
191,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
191,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,lv mass index ( g / mnmbr - nmbr ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
191,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
191,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
190,enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr ),C0206460
190,enoxaparin only,C0205171;C0206460;C1720467
190,extended - duration enoxaparin ( n = nmbr ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
190,enoxaparin,C0206460
190,enoxaparin / vka,C0206460
190,extended - duration enoxaparin,C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
190,enoxaparin ( n = nmbr,C0206460
190,enoxaparin ( n = nmbr ),C0206460
189,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
189,apob ( week nmbr ),C0003593;C0332174;C0439230;C3252643
189,apob : apoal,C0003593;C3252643
189,apob ( mg / dl ),C0003593;C0439269;C3252643
189,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
189,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
189,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
189,apo - b,C0003593;C3252643
189,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
189,apo b,C0003593;C3252643
189,apob,C0003593;C3252643
189,apobnmbr,C0003593;C3252643
189,mean ( s . d . ) apob,C0003593;C0444504;C2347634;C2348143;C3252643
189,apo b *,C0003593;C3252643
189,apo b ( mg / dl ),C0003593;C0439269;C3252643
188,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
188,baseline heart rate ( beats / min ),C0018810;C0168634;C1442488
188,baseline heart rate,C0018810;C0168634;C1442488
188,heart rate at baseline,C0018810;C0168634;C1442488
187,total occlusion,C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
187,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
187,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
186,erythrocyte sedimentation rate,C1176468;C1619634
186,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
186,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
185,post - cabg,C0010055;C0687676;C1704687;C3469826
185,non - cabg or combined,C0010055;C1518422
185,treated with cabg — no . / total no . ( % ),C0010055;C0332293
185,history of cabg surgery,C0010055;C0455610
185,coronary - artery bypass grafting §,C0010055
185,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
185,previous cabg,C0010055;C0205156;C1552607
185,cabg or angioplasty,C0010055
185,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
185,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
185,prior aortocoronary bypass surgery,C0010055;C0455610
185,cabg — no . ( % ),C0010055
185,cabg or pci,C0010055
185,coronary bypass surgery,C0010055
185,cabg — no . { % ),C0010055
185,previous pci / cabg,C0010055;C0205156;C1552607;C4049621
185,coronary artery bypass,C0010055
185,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
185,coronary artery bypass graft — no . ( % ),C0010055;C1260596
185,coronary artery bypass grafting n ( % ),C0010055
185,coronary artery bypass grafting,C0010055
185,cabg or ptca ( % ),C0010055
185,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
185,cabg or ptca / pci,C0010055
185,non - cabg related bleeding at nmbr h,C0010055;C1518422
185,cabg :,C0010055
185,no prior cabg,C0010055;C0332152;C2826257
185,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
185,hx cabg,C0010055;C0262926;C3814444
185,cabg ( % ),C0010055
185,coronary bypass,C0010055
185,cabg performed during index hospitalization,C0010055
185,coronary artery bypass surgery,C0010055
185,coronary artery bypass graft,C0010055;C1260596
185,coronary - artery bypass grafting,C0010055
185,prior cabg,C0010055;C0332152;C2826257
185,cabg > nmbr month ago,C0010055;C0332177;C0439231
185,timi non - cabg major,C0010055;C1518422
185,multivessel coronary - artery bypass grafting,C0010055
185,cabg only,C0010055;C0205171;C1720467
185,cabg or valve,C0010055
185,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
185,cabg,C0010055
185,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
185,prior cabg surgery,C0010055;C0455610
184,nmbr mo to nmbr yr,C0026544;C0332177;C0439234
184,duration of disease — mo,C0026544;C0332177;C0872146
184,nmbrmo,C0026544;C0332177
184,nmbr - nmbr mo,C0026544;C0332177
184,nmbr to < nmbr mo,C0026544;C0332177
184,< nmbrmo,C0026544;C0332177
184,exacerbations in past nmbr mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
184,nmbr mo,C0026544;C0332177
184,> nmbr mo,C0026544;C0332177
184,exacerbation within nmbr mo,C0026544;C0332177;C4086268
184,nmbr mo - nmbr y,C0026544;C0332177
184,nmbr - < nmbrmo,C0026544;C0332177
184,< nmbr mo,C0026544;C0332177
184,exacerbations in previous nmbr mo ( n ),C0026544;C0205156;C0332177;C1552607;C4086268
184,at least nmbr / mo,C0026544;C0332177
184,left ventricular ejection fraction within previous nmbr mo — no . / total no . ( % ) nmbr,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
184,left ventricular ejection fraction within previous nmbr mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
184,lvef within nmbr mo,C0026544;C0332177;C0428772;C0488728
184,exacerbation within previous nmbr mo,C0026544;C0205156;C0332177;C1552607;C4086268
184,antiplatelet within nmbr mo before randomization,C0026544;C0332177
184,fall in last nmbr mo,C0026544;C0085639;C0238715;C0332177;C4553726
183,atorvastatin monotherapy ( n = nmbr * ),C0286651
183,atorvastatin,C0286651
183,concomitant atorvastatin dose,C0178602;C0286651;C0521115;C0869039;C1114758
183,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
183,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
183,atorvastatin ( n = nmbr,C0286651
183,atorvastatin { n = nmbr,C0286651
183,atorvastatin factorial study,C0286651;C2826344
182,pav,C0058890
182,change in pav,C0058890;C0392747;C0443172;C1705241;C4319952
181,time since as diagnosis ( years ),C0040223;C3541383
181,time from ld to pci  min  median ( qnmbr – qnmbr ),C0040223;C0694649;C3541383
181,at any time,C0040223;C3541383
181,time since start of fit,C0040223;C3541383
181,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
181,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4521986
181,time since asthma diagnosis [years],C0040223;C3541383
181,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
181,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
181,time since asthma diagnosis years,C0040223;C3541383
181,time since first psoriasis diagnosis ( y ),C0040223;C3541383
181,time from qualifying mi,C0040223;C1514624;C3541383;C3810814
181,time since asthma,C0040223;C3541383
181,time since diagnosis of pah — yrf,C0040223;C3541383
181,time sample drawn ( h ),C0040223;C3541383
181,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
181,time from longest event to randomisation,C0040223;C0441471;C1522425;C3541383;C4019010
181,time since diagnosis of ciu / csu ( years ) nmbr,C0040223;C3541383
181,time since bph diagnosis ( years ),C0040223;C3541383
181,time since as diagnosis,C0040223;C3541383
181,time since epilepsy diagnosis ( years ),C0040223;C3541383
181,time since end of fit,C0040223;C3541383
181,time since diagnosis,C0040223;C3541383
181,time since diagnosis of type nmbr diabetes mellitus,C0040223;C3541383
181,time since rheumatoid arthritis diagnosis,C0040223;C3541383
181,time since diagnosis of tnmbrdm,C0040223;C3541383
181,time since diagnosis of type nmbr diabetes,C0040223;C3541383
181,time since diagnosis of sle,C0040223;C3541383
181,time since psa onset,C0040223;C3541383
181,high titre ( > nmbr times of uln ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
181,nmbr min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
181,time since pah diagnosisc ( years ),C0040223;C3541383
181,time since diagnosis of psa ( years ),C0040223;C3541383
181,time since diagnosis of pah years #,C0040223;C3541383
181,cpk > nmbr times uln,C0040223;C1519815;C1632851
181,time since diagnosis of ln,C0040223;C3541383
181,time since diagnosis of diabetes ( years ) ( median,C0040223;C3541383
181,time since asthma diagnosis ( years ),C0040223;C3541383
181,time since start insulin ( years ),C0040223;C3541383
181,time since diagnosis of copd,C0040223;C3541383
181,time since diagnosis of ciu / csuf ( y ),C0040223;C3541383
181,time since prior alendronate use,C0040223;C3541383
181,time since diagnosis of diabetes — no . ( % ),C0040223;C3541383
181,time since first luts ( years ),C0040223;C3541383
181,time since primary diagnosis,C0040223;C3541383
181,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
181,time since cabg,C0040223;C3541383
181,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
181,time since cessation of full - dose warfarin therapy,C0040223;C3541383
181,time from event to randomization — days,C0040223;C0441471;C3541383;C4019010
181,time from symptom onset to balloon inflation,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
181,time since randomization,C0040223;C3541383
181,time from,C0040223;C3541383
181,time since psa diagnosis ( years ),C0040223;C3541383
181,time - to - first - infusion from hip surgery ( days ),C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
181,time from symptom onset to start of fibrinolytic therapy — hr,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
181,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
181,time ( sec ) *,C0040223;C0565930;C3541383
181,duration of ra ( time from symptom onset ),C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
181,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
181,mean time to first subcutaneous injectiong,C0040223;C0205435;C0443315;C0444504;C1279901;C2347634;C2348143;C3541383
181,mean time to first oral dose postsurgeryh,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
181,mean time since diagnosis,C0040223;C0444504;C2347634;C2348143;C3541383
181,time since ipf diagnosisa,C0040223;C3541383
181,mean time since diagnosis ( years ),C0040223;C0444504;C2347634;C2348143;C3541383
181,mean time since asthma,C0040223;C0444504;C2347634;C2348143;C3541383
181,mean time since as diagnosis,C0040223;C0444504;C2347634;C2348143;C3541383
181,percentage of time in therapeutic inr range,C0040223;C0439165;C1549488;C1561533;C3541383
181,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
181,time since diagnosis of heart failure,C0040223;C3541383
181,time from presentation to randomization — hr,C0040223;C0449450;C3541383
181,time since most recent myocardial,C0040223;C3541383
181,time since diagnosis of diabetes,C0040223;C3541383
181,time since onset ( h ),C0040223;C3541383
181,time since qualifying event,C0040223;C3541383
181,time since diagnosis of diabetesa,C0040223;C3541383
181,time since psoriasis diagnosis,C0040223;C3541383
181,time since diagnosis — mo,C0040223;C3541383
181,time since diagnosis of type nmbr diabetes - no . ( % ),C0040223;C3541383
181,time since first af diagnosis,C0040223;C3541383
181,time in trial,C0040223;C3541383
181,time since first copd diagnosis ( years ),C0040223;C3541383
181,time,C0040223;C3541383
181,daily “ off ” time,C0040223;C0332173;C3541383
181,time since pd diagnosis,C0040223;C3541383
181,median time since diagnosis * ( range ),C0040223;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383
181,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
181,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C3541383
181,time since copd diagnosis ( yrs ),C0040223;C3541383
181,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
180,anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),C0206578
180,ez / simva < % >,C0206578
180,anmbr + eznmbr,C0206578
180,ez / simva,C0206578
180,all ez / simva,C0206578
180,ez / simva n = nmbr n ( % ),C0206578
180,czech republic,C0206578
180,anmbr + ez n = nmbr anmbr n = nmbr,C0206578
180,ldl - cz,C0206578
180,anmbr + ez n = nmbr,C0206578
179,use of antiarrhythmic agent,C0003195;C0301380;C1524063
179,antiarrhythmic agent,C0003195;C0301380
179,antiarrhythmic,C0003195;C3537142
179,other antiarrhythmics^,C0003195
179,antiarrhythmic drug,C0003195;C0301380
179,class nmbr antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
179,anti arrhythmic,C0003195;C3537142
179,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
179,antiarrhythmics,C0003195
179,antiarrhythmic drugs,C0003195
179,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
178,nitrate,C0028125;C0699857;C3848573
178,nitrate — no . ( % ),C0028125;C0699857;C3848573
178,nitrates ( % ),C0028125;C0699857;C3848573
178,intravenous nitrates,C0028125;C0348016
178,nitrates,C0028125;C0699857;C3848573
178,nitrates ( oral or topical ),C0028125;C0699857;C3848573
178,nitrate ( oral or topical ),C0028125;C0699857;C3848573
178,nitrate ( oral or intravenous ),C0028125;C0699857;C3848573
177,bosentan,C0252643
177,concomitant use of bosentan,C0252643;C0521115;C1524063
177,bosentan ( n = nmbr ),C0252643
176,baseline ics use : no,C0168634;C0815320;C1442488;C4551720
176,baseline ics,C0168634;C0815320;C1442488;C4551720
176,baseline ics dose,C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
176,baseline ics use : yes,C0168634;C0815320;C1442488;C4551720
176,ics users at baseline,C0168634;C0815320;C1442488;C1706077;C4551720
176,baseline ics use,C0168634;C0815320;C1442488;C4551720
175,albuminuria ( g / g ),C0001925;C1319635
175,micro - / macro - albuminuria,C0001925;C0085672;C1553035;C2984010;C3811161;C4049106
175,albuminuria_p_interaction,C0001925;C1704675
175,normal albuminuria ( uacr < nmbr ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
175,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
175,any albuminuria — no . ( % ),C0001925
175,albuminuria,C0001925
175,any albuminuria,C0001925
175,macro - albuminuria,C0001925;C2984010
175,albuminuria and previous maerovaseular disease plus established renal disease ( egfr nmbr - nmbr ml / min / lnmbr in - with an uacr > nmbr mg / g or egfr nmbr - < nmbr ml / inin / lnmbr in - with any uacr mg / g ),C0001925
175,albuminuria and previous maerovaseular disease without established renal disease,C0001925
174,hispanic / non - hispanic,C0086409;C1518422
174,hispanic or latino ethnic group !,C0086409
174,hispanic or latino ( n — nmbr ),C0086409
174,hispanic or latino ethnic group *,C0086409
174,hispanic or latino,C0086409
174,mixed hispanic,C0086409;C0205430;C3160715
174,hispanic or latino ethnic groupb,C0086409
174,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409
174,hispanic,C0086409
174,hispanic or latino ethnic groupf,C0086409
174,hispanic or latino ( n = nmbr ),C0086409
174,hispanic ( n = nmbrlnmbr ),C0086409
174,hispanic — no . ( % ),C0086409
174,biack hispanic,C0086409
174,american hispanic ( n   = nmbr ),C0086409;C0596070
174,hispanic ( n = nmbr ),C0086409
174,ethnicitya hispanic or latino,C0086409
173,apob : apoa - nmbr ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
173,apob : apoanmbr,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
173,apob : apoanmbr ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
173,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
173,< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
172,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
172,cv event,C0441471;C3538987;C4019010;C4048877;C4318503
172,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
172,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
172,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
172,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
172,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
172,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
172,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
172,no cv event ( n = nmbr,C0441471;C3538987;C4019010;C4048877;C4318503
172,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
172,incidence rate of cv events,C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
172,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
172,cv,C3538987;C4048877;C4318503
172,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
172,qualifying cv event,C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
172,cv historya,C3538987;C4048877;C4318503
172,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
171,russia / georgia ( n = nmbr ),C0017452;C0017454;C0035970
171,russia / georgia,C0017452;C0017454;C0035970
170,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
170,time from symptoms to randomization,C0040223;C0683368;C1457887;C3541383
169,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
169,time from qualifying ecg to balloon inflation,C0040223;C1514624;C1623258;C3541383
168,coronary angiography and intervention,C0085532;C1548829
168,coronary angiography — no . ( % ),C0085532;C1548829
168,coronary angiography,C0085532;C1548829
167,non - steroidal anti - inflammatory drugs,C0003211
167,nsaid use — no . / total no . ( % ),C0003211;C3536840
167,prior nsaid,C0003211;C0332152;C2826257;C3536840
167,traditional nsaid use,C0003211;C3536840;C3897349
167,cumulative nsaid score,C0003211;C0449820;C1511559;C3536840;C4050231
167,traditional nsaid,C0003211;C0443324;C1548559;C3536840
167,nsaid,C0003211;C3536840
167,concomitant use of nsaids to week nmbr,C0003211;C0521115;C1524063
167,never nsaid,C0003211;C2003901;C3536840
167,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
167,nsaid   at   least   once,C0003211;C3536840
167,other nsaids,C0003211
166,pulmonary function tests,C0024119;C2598152
166,pulmonary function tests ( post - bronchodilator ),C0024119;C2598152
165,left atrial diameter,C0225860;C0225861;C1301886
165,left atrial diameter : < nmbr mm ( n = nmbr ),C0225860;C0225861;C1301886;C4330985;C4554674
165,size of left atrium normal — no . ( % ) £,C0225860;C0456389
165,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
164,crohn ' s disease duration,C0010346;C0449238;C2926735
164,crohn ' s disease,C0010346
164,location of crohn ' s disease,C0010346;C0450429;C1515974;C4284930;C4284931
164,crohn ’ s disease related surgery,C0010346
164,crohn ' s disease - related medication at baseline,C0010346
164,history of crohn ' s disease surgery,C0010346;C0455610
164,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
164,early crohn ' s disease *,C0010346;C1279919
164,median crohn ' s disease duration,C0010346;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
164,non - early crohn ' s disease,C0010346;C1279919;C1518422
164,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
163,indacaterol nmbr ug ( n = nmbr ),C0041573;C0439211;C1722260
163,indacaterol nmbr ug versus indacaterol nmbr ug,C0041573;C0439211;C1722260
163,indacaterol nmbr ug versus placebo,C0041573;C0439211;C1722260
162,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
162,weight ( kg ) bmi ( kg / mnmbr ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
162,weight ab,C0005910;C0043100;C1305866;C1705104
162,mean weight ( sd ),C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
162,normal weight ( bmi < nmbr ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
162,mean ± s . d . weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
162,weight ( median [iqr] ),C0005910;C0043100;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193
162,weight,C0005910;C0043100;C1305866;C1705104
162,weight nmbr - nmbr,C0005910;C0043100;C1305866;C1705104
162,weight nmbr +,C0005910;C0043100;C1305866;C1705104
162,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
162,mean weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
162,median weight,C0005910;C0043100;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193
162,weight < nmbr,C0005910;C0043100;C1305866;C1705104
162,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
162,mean ( sd ) weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
162,weight^ ,C0005910;C0043100;C1305866;C1705104
162,mean ( s . d . ) weight,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143
162,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
161,care use,C0042153;C0457083;C1947933;C1947944
161,rotablator use,C0042153;C0457083;C1260867;C1947944
161,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
161,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
161,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
161,oad use,C0042153;C0457083;C1947944
161,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
161,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
161,oam use [n ( % ) ],C0042153;C0457083;C1947944
161,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
161,hormone therapy use,C0042153;C0279025;C0457083;C1947944
161,saba use in past nmbr days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
161,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
161,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
161,low - dose aspirin use . strata *,C0042153;C0457083;C1947944;C2608320
161,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
161,any use,C0042153;C0457083;C1947944
161,other llt use,C0042153;C0457083;C1947944;C2347090
161,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
161,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
161,laba use,C0042153;C0457083;C1947944
161,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
161,anorexigen use,C0042153;C0457083;C1947944
161,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
161,background laba use,C0042153;C0457083;C1706907;C1947944
161,antiplatelet use,C0042153;C0457083;C1947944
161,antithrombotic use,C0042153;C0457083;C1947944
161,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
161,multivitamin use,C0042153;C0301532;C0457083;C1947944
161,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
161,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
161,use oforal glucose - lowering agent — no . ( % ),C0042153;C0457083;C1947944
161,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
161,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
161,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
161,use,C0042153;C0457083;C1947944
161,prior oma use ( n = nmbr ),C0042153;C0332152;C0457083;C1947944;C2826257
161,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
161,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
161,lama use,C0042153;C0457083;C0999593;C1416775;C1947944
161,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
161,antithrombotic use before enrollment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
161,prior vka use for > nmbr d,C0042153;C0332152;C0457083;C1947944;C2826257
161,use ( % ),C0042153;C0457083;C1947944
161,no use,C0042153;C0457083;C1947944
161,saba use,C0042153;C0457083;C1947944
161,rescue use : mean no . of inhalations / d,C0042153;C0444504;C0457083;C1947944;C2347634;C2348143
161,no prior oma use ( n = nmbr ),C0042153;C0332152;C0457083;C1947944;C2826257
161,cgm use,C0042153;C0457083;C1947944
161,background laba use - yes,C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
160,telmisartan ( n = nmbr,C0248719
160,telmisartan ( n = nmbr ),C0248719
160,telmisartan,C0248719
160,telmisartan group ( n = nmbr ),C0248719;C0441848
159,nice primary prevention onlyb,C0033144;C4087029
159,primary prevention subgroup,C0033144;C1079230;C1515021
158,nmbr mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
158,clopidogrel loading dose nmbr mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
158,intended clopidogrel dose nmbr mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
157,hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index,C0020261
157,hctz = hydrochlorothiazide . * based on a ' / _nmbr test,C0020261
157,v / hctz,C0020261
157,hctz * ( n = nmbr ),C0020261
157,hctz,C0020261
157,v alsartan / hctz,C0020261
157,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C1511726;C3245479;C3714741
157,azl - m + hctz ( n = nmbr ),C0020261;C0369637;C0441923
157,hydrochlorothiazide,C0020261
157,v / hctz ( n = nmbr ),C0020261
157,hctz *,C0020261
156,ticagrelor nmbr mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
156,ticagrelor nmbr mg nmbr year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
156,ticagrelor nmbr mg no diabetes n = nmbr,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
156,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
156,ticagrelor nmbr mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
156,ticagrelor nmbr mg nmbr yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
155,q wave in the infarct territory at baseline *,C0021308;C0429089;C1301808;C1305738;C2983136
155,nonfatai myocardiai infarction,C0021308
155,vertebrobasilar infarct,C0021308;C0545733
155,q waves in the infarct territory at baseline *,C0021308;C0429089;C1301808;C1305738;C2983136
155,infarct location anterior,C0021308;C0450429;C1515974;C4284930;C4284931
155,infarction > nmbr days previously,C0021308;C0439228
155,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
155,prior infarction,C0021308;C0332152;C2826257
155,infarct - related vessel ( % ),C0021308
155,infarct size,C0021308;C0456389
155,any relevant infarct,C0021308;C2347946
155,infarct territory ( % ),C0021308;C1301808;C2983136
155,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
155,infarction before age nmbr ( a ),C0001779;C0021308
155,any infarct,C0021308
155,nonfatal myocardiail infarction,C0021308
155,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
155,infarct localisation,C0021308;C0475264;C1744691
155,cardioembolic infarction,C0021308
155,infarct location — no . / total no . ( % ),C0021308;C0450429;C1515974;C4284930;C4284931
155,infarct location ( interactsn $ : p = nmbr . nmbr ),C0021308;C0450429;C1515974;C4284930;C4284931
155,infarction,C0021308
155,atherothrombotic infarction,C0021308
155,previous infarction,C0021308;C0205156;C1552607
155,carotid infarct,C0021308;C0741968
155,infarct localization,C0021308;C0475264;C1744691
155,no infarct visible,C0021308
155,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
155,myocardiai infarction,C0021308
155,infarction nmbr - nmbr days,C0021308;C0439228
155,infarct characteristics,C0021308;C1521970
154,risk categories,C0035647;C0683312;C4552904
154,timi risk score *,C0035647;C0449820;C4050231;C4552904
154,moderate risk ( nmbr - nmbr ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
154,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
154,timi risk score !,C0035647;C0449820;C4050231;C4552904
154,risk at,C0035647;C4552904
154,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
154,timi risk score > nmbr,C0035647;C0449820;C4050231;C4552904
154,timi risk score ( interaction : p = nmbr . nmbr ),C0035647;C0449820;C1704675;C4050231;C4552904
154,risk category ( points ),C0035647;C0683312;C3889287;C4552904
154,timi risk score — no . / total no . ( % ) f,C0035647;C0449820;C4050231;C4552904
154,> nmbr - nmbr ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
154,ukpds nmbr - year risk score < nmbr %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
154,ukpds nmbr - year risk score > nmbr %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
154,tlmi risk score,C0035647;C0449820;C4050231;C4552904
154,timi risk score — no . / total no . ( % ) : c,C0035647;C0449820;C4050231;C4552904
154,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
154,timi risk score nmbr - nmbr,C0035647;C0449820;C4050231;C4552904
154,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
154,moderate risk ( > nmbr - nmbr ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
154,timi risk score — %,C0035647;C0449820;C4050231;C4552904
154,ncep risk category at study entry,C0035647;C1705654;C2983287;C2983669;C4552904
154,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
154,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
154,risk difference,C0035647;C1705241;C1705242;C4552904
154,timi risk score,C0035647;C0449820;C4050231;C4552904
154,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
154,absolute risk difference ( nmbr % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
154,risk *,C0035647;C4552904
154,risk,C0035647;C4552904
154,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
154,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
154,risk stratum,C0035647;C4552904
153,gold nmbr ( « = nmbr ),C0018026;C1304897
153,mild ( gold nmbr ),C0018026;C1304897;C2945599
153,gold grade nmbr,C0018026;C0441800;C0919553;C1304897;C3244287
153,gold a,C0018026;C1304897
153,gold nmbr - nmbr ( n = nmbr ),C0018026;C1304897
153,gold group b,C0018026;C1304897;C4522078
153,gold grade nmbr and ics non - users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
153,gold grades nmbr - nmbr ( percent - predicted fev ( ),C0018026;C1304897
153,moderate ( gold nmbr ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
153,gold grade nmbr and ics users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
153,gold group a,C0018026;C0441835;C1304897;C4522145
153,gold nmbr - nmbr,C0018026;C1304897
153,gold nmbr,C0018026;C1304897
153,gold ii,C0018026;C1304897;C1710602;C4082587
153,severity of airflow limitation ( gold nmbr ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
153,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
153,severity ofcopd ( goldnmbr ),C0018026;C0439793;C0522510;C1304897
153,gold group c,C0018026;C0441837;C1304897
153,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
153,gold stage [n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
153,gold stage iii,C0018026;C0441771;C1304897
153,gold b,C0018026;C1304897
153,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
153,gold,C0018026;C1304897
153,gold stage — no . ( % ) * *,C0018026;C1304897
153,gold c,C0018026;C1304897
153,very severe ( gold nmbr ),C0018026;C1304897;C3641272;C4050419
153,severity of airflow limitation ( gold nmbr - nmbr ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
153,gold stage ii,C0018026;C0441767;C1304897
153,gold stage ( % ) : c,C0018026;C0441785;C1304897
153,gold groups a - d using mmrcb,C0018026;C1304897
153,gold nmbr - nmbr ( « = nmbr ),C0018026;C1304897
153,severity of the disease ( gold nmbr ),C0018026;C0521117;C1304897
153,gold d,C0018026;C1304897
153,severe ( gold nmbr ),C0018026;C0205082;C1304897;C4050465;C4050466
153,gold group d,C0018026;C0441838;C1304897
152,previous oral antidiabetic medication use,C0205156;C0935929;C1527415;C1552607
152,> nmbr oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
152,antidiabetic medications,C0935929
152,antidiabetic medication,C0935929
152,nmbr oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
152,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
152,no antidiabetic drug,C0935929
152,antidiabetic,C0935929
152,antidiabetic drug,C0935929
152,duration of oral antidiabetic treatment,C0442027;C0444921;C0935929;C4521986
152,antidiabetic medication | |,C0935929
152,antidiabetic agents,C0935929
152,antidiabetic agent,C0935929
151,% anti - ccp + ( > nmbr units ),C0439148;C1519795;C3853603;C4318437
151,anti - ccp antibody positive,C0741132;C4318437
151,anti - ccp antibody - positive,C0741132;C4318437
151,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
151,anti - ccp positive ( > nmbr u / ml ),C0439178;C0439340;C1446409;C1514241;C1880521;C2825490;C2945590;C3812269;C4318437
150,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
150,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
150,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
150,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
150,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
150,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
149,with any stent,C0038257
149,number of stent = l or nmbr or nmbr,C0038257;C0237753;C0449788
149,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
149,stent length per lesion,C0038257;C0221198;C1444754;C1546698;C1706316
149,other stent,C0038257
149,stent type,C0038257;C0332307;C1547052
149,stent plus medical therapy,C0038257;C0418981
149,no . of stents,C0038257
149,stent group ( n = nmbr ),C0038257;C0441848
149,number of stents,C0038257;C0237753;C0449788
149,stenting plus medical therapy ( n = nmbr ),C0038257;C0418981;C2348535
149,number of stents ( per patient ),C0038257;C0237753;C0449788
149,mean total stent length per lesion,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143
149,number stent > nmbr,C0038257;C0237753;C0449788
149,type of stent at index procedure,C0038257;C0332307;C1547052
149,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
149,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
149,mean stent diameter per lesion,C0038257;C0221198;C0552409;C1546698
149,multivessel stenting,C0038257;C2348535
149,prior stent,C0038257;C0332152;C2826257
149,total stent length ( mm ),C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
149,number of stent = nmbr,C0038257;C0237753;C0449788
149,stented lesions,C0038257;C0221198
149,stents per lesion,C0038257;C0221198;C1546698
149,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
149,long ( > nmbrmm ) stenting yes ( n = nmbr ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
149,minimum stent diameter,C0038257;C4054490
149,with stent,C0038257
149,stent diameter $ nmbr mm,C0038257;C1301886;C4330985;C4554674
149,number of stents implanted,C0038257;C0237753;C0449788
149,stent type implanted,C0038257;C0332307;C1547052
149,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
149,stent,C0038257
149,stent diameter < nmbr mm,C0038257;C1301886;C4330985;C4554674
149,stent ( n = nmbr ),C0038257
149,indication for stent,C0038257;C0392360;C3146298
149,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
149,without stent,C0038257
149,with stent^l,C0038257
148,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
148,ckd n,C1561643
148,no ckd,C1561643
148,ckd stage nmbr,C0205390;C1300072;C1306673;C1561643
148,no ckd n,C1561643
148,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
148,chronic kidney disease ( % ),C1561643;C4553188
148,ckd stage nmbr ( % ),C0205390;C1300072;C1306673;C1561643
148,ckd stages,C1306673;C1561643
148,without ckd ( nmbr ),C1561643
148,chronic kidney disease †,C1561643;C4553188
148,no - ckd standard ( n = nmbr ),C1442989;C1561643;C2828392
148,chronic kidney disease,C1561643;C4553188
148,ckd,C1561643
148,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
148,ckd *,C1561643
148,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
148,no ckd ( % ),C1561643
148,with ckd standard ( n = nmbr ),C1442989;C1561643;C2828392
148,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
148,with ckd ( nmbr ),C1561643
148,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
147,steroids § §,C0038317
147,steroids ( n = nmbr vs nmbr ),C0038317
147,no steroids ( n = nmbr vs nmbr ),C0038317
147,steroid - sparing remission *,C0038317;C0544452;C0687702
147,steroids ( inhaled ) a,C0038317
147,steroids ( other ),C0038317
147,other steroids,C0038317
147,steroids,C0038317
147,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
146,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
146,lev - exposed,C0023556
146,lev ( n   =   nmbr ),C0023556
146,prior lev treatment,C0023556;C1514463
146,lev - naive,C0023556
146,prior lev use,C0023556;C0332152;C2826257
146,prior lev,C0023556;C0332152;C2826257
146,never used lev,C0023556;C1273517;C2003901
146,lev status,C0023556;C0449438
145,canakinumab,C2718773
145,all canakinumab,C2718773
145,canakinumab dose,C0178602;C0869039;C1114758;C2718773
145,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
145,active canakinumab ( n   =   nmbr,C0205177;C2718773;C3853793;C3888249
144,formoterol nmbr gg ( n = nmbr ),C0017454;C0018370;C0060657
144,formoterol nmbr gg bid,C0017454;C0018370;C0060657
143,chondroitin sulfate ( n = nmbr ),C0008466
143,chondroitin sulfate,C0008466
142,gender ( female : male,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
142,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
142,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
141,non - lad artery,C0003842;C0226004;C1518422
141,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
141,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
141,lad artery,C0003842;C0226004
141,arterial access,C0003842;C0221464;C0444454;C1554204
141,arterial revascularization,C0003842;C0221464;C0581603
141,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
141,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
141,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
140,serum albumin,C0036773;C0728877
140,serum albumin - adjusted calcium ( mg / dl ),C0036773;C0728877
139,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
139,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
139,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
139,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
138,aldosterone blockers,C0002006
138,aldosterone blocker,C0002006
137,aggressive ( n = nmbr ),C0001807;C0580822
137,aggressive ( nmbr ),C0001807;C0580822
136,fasting c - peptide,C0006558;C0015663
136,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
136,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
135,non - european trial,C0008976;C0239307;C1518422;C1535514
135,end of trial,C0008976;C0444930;C2746065
135,european trial,C0008976;C0239307;C1535514
135,in - trial nonfatal or fatal stroke n = nmbr,C0008976;C0150312;C0332285;C1707101
135,pooled trials * n = nmbr,C0008976;C1709595;C2349200;C4522255
135,combined trials,C0008976;C0205195
135,in - trial and post - trial nmbr - year rates per nmbr ( se ) total events / number at risk,C0008976;C0150312;C0332285;C1707101
135,non - trial antiplatelet,C0008976;C1518422
135,non - trial p blocker,C0008976;C1518422
135,trial completers,C0008976
135,ended > nmbr days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
135,trial nmbr,C0008976
135,cure trial,C0008976;C1880198
135,completed trial,C0008976;C0205197;C3854010
135,all trials,C0008976
135,primary trial end point,C0008976;C2986535
135,trial,C0008976
135,follow - up in - trial at nmbr yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
134,baseline fevnmbr #,C0168634;C1442488;C3714541
134,baseline mean fevnmbr ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3714541
134,baseline fev,C0168634;C1442488;C3714541
134,baseline fvc,C0168634;C1442488;C3714541
134,baseline fevnmbr % predicted,C0168634;C1442488;C3714541
134,baseline pre - bronchodilator fevnmbr,C0168634;C1442488;C2599602;C3714541
134,baseline post - bronchodilator fevnmbr   ( sd ),C0168634;C1442488;C2599594;C2699239;C3714541
134,fevnmbr at baseline,C0168634;C1442488;C3714541
134,baseline fevnmbr,C0168634;C1442488;C3714541
133,rf positive and acpa negative,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
133,rf and acpa positive,C0035448;C0201660;C0748398;C1547111
133,rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111
133,rf and acpa negative,C0035448;C0201660;C0748398;C1547111
133,rf,C0035448;C0201660;C0748398;C1547111
133,rheumatoid factor !,C0035448;C0201660
133,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
133,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
133,positive for rheumatoid factor,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
133,rheumatoid factor or acpa positive,C0035448;C0201660
133,rheumatoid factor and acpa positive,C0035448;C0201660
133,rf - positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
133,rf negative and acpa positive,C0035448;C0201660;C0205160;C0748398;C1513916;C1547111;C2825415;C2825491;C3853545
133,rf positive ( > nmbr iu / ml ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
133,rheumatoid factor positive §,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
133,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
133,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
133,rf or acpa positive,C0035448;C0201660;C0748398;C1547111
133,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
133,% rf +,C0035448;C0201660;C0748398;C1547111
133,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
133,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
132,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
132,geometric cnmbr concentration,C0086045;C0449829;C1446561;C3827302
132,ldl - c concentration,C0086045;C1446561;C3827302
132,crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
132,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
132,crp concentration > nmbr mg / l,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
132,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
131,dipyridamole alone,C0012582
131,dipyridamole,C0012582
130,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
130,concentrations at baseline,C0086045;C0168634;C1442488
130,mean baseline ibdq score ( sd ) § crp concentration,C0086045;C0168634;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
129,total haq,C0102923;C0439175;C0439810;C0451208
129,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
129,haq pain scale,C0102923;C0451208;C1504479
129,haq,C0102923;C0451208
129,haq pain score,C0102923;C0451208;C0582148
129,haq score,C0102923;C0451208
128,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
128,fibrinogen,C0016006;C1167394;C2587184;C3540039
127,py = nmbr ),C0030428;C3538810
127,no pa,C0030428;C3541314
127,py = nmbr . nmbr ),C0030428;C3538810
127,py *,C0030428;C3538810
127,pa,C0030428;C3541314
127,nmbr . nmbr per nmbr py,C0030428;C3538810
127,standard care n ( % ) / nmbrpy,C0030428;C1442989;C1947933;C2828392;C3538810
126,egfr ( mdrd ),C1739039;C3811844;C3812682;C3839656
126,egfr nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
126,egfr nmbr - nmbr,C1739039;C3811844;C3812682
126,egfr using cg / mdrd formulae,C1739039;C3811844;C3812682
126,egfr nmbr to < nmbr ml / min / nmbr . nmbr m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,normal egfr ( nmbr < egfr < nmbr ml / min per nmbr . nmbr mnmbr ) at baseline to high egfr ( > nmbr ml / min per nmbr . nmbr mnmbr ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1739039;C2347086;C3811844;C3812682;C4553972
126,egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,renal function ( egfr ) according to mdrd,C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
126,egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr to < nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min / nmbr . nmbr mnmbr ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,> nmbr egfr,C1739039;C3811844;C3812682
126,egfr < nmbr,C1739039;C3811844;C3812682
126,egfr — mean ( sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
126,egfr via mdrd ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
126,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr - nmbr kg / m^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr - nmbr m^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min per nmbr · nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr - nmbr m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr,C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr^nmbr m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr in nmbr classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
126,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr + nmbr m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr · nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr,C0439445;C1739039;C3811844;C3812682
126,egfr ( median,C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr . nmbr ( vs egfr > nmbr ),C1739039;C3811844;C3812682
126,mean ( sd ) egfr,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
126,egfr ≥ nmbr ml / min per nmbr · nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr mnmbr *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr ml / min per nmbr^nmbr m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,renal function ( egfr,C0232804;C1739039;C3811844;C3812682
126,egfr ≥ nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,stage nmbrb : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0441781;C1739039;C3811844;C3812682
126,egfr ≥ nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,renal function < nmbr egfr,C0232804;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr mnmbr §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr £ nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min,C0439445;C1739039;C3811844;C3812682
126,egfr > nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr - nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr ml / min / nmbr - nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr > nmbr,C1739039;C3811844;C3812682
126,mdrd - egfr ( ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
126,mdrd egfr,C1739039;C3811844;C3812682;C3839656
126,egfr > nmbr ml / min,C0439445;C1739039;C3811844;C3812682
126,mild impairment ( egfr nmbr - nmbr ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
126,egfr ‡ ( ml / min per nmbr · nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr and albuminuria,C1739039;C3811844;C3812682
126,egfr snmbro ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,normal ( egfr > nmbr ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
126,mean ± sd egfr,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
126,egfr snmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr to < nmbr ml / min / nmbr . nmbr m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( mumin / nmbr . nmbr mnmbr ),C0369637;C0441923;C1739039;C3811844;C3812682
126,moderate impairment ( egfr nmbr – nmbr ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
126,moderate impairment ( egfr nmbr - nmbr ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
126,moderate impairment ( egfr nmbr - nmbr ml / min / m^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
126,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
126,egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr in ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr from the mdrd equation ( sd ),C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
126,egfr — ml / min / nmbr . nmbr m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr - nmbr mnmbr ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr ( ml / min per nmbr - nmbr mnmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
126,egfr nmbr . nmbr - nmbr . nmbr ( vs egfr > nmbr ),C1739039;C3811844;C3812682
126,severe impairment ( egfr < nmbr ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
126,egfr nmbr to < nmbr ml / min,C0439445;C1739039;C3811844;C3812682
126,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
126,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
126,egfr -,C1739039;C3811844;C3812682
126,normal ( egfr ≥ nmbr ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
126,egfr +,C1739039;C3811844;C3812682
126,egfr nmbr to < nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
126,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
126,severe impairment ( egfr < nmbr ml / min / m^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
126,egfr ( ml / min per nmbr - nmbr m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr   < nmbr   ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,mean ( s . d . ) egfr,C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
126,egfr nmbr – nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min per nmbr^nmbr m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr   ≥ nmbr   ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
126,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
126,egfr category ( ml / min / nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
126,egfr crcl ml · min − nmbr · nmbr . nmbr m − nmbr,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
126,mild impairment ( egfr nmbr - nmbr ml / min / m^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
126,mild impairment ( egfr nmbr – nmbr ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
125,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
125,ldl cholesterol,C0023824;C0202117
125,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
125,ldl cholesterol < nmbr - nmbr mmol / l,C0023824;C0202117;C1532563
125,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
125,low - density lipoprotein cholesterol,C0023824
125,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
125,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
125,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
125,ldl cholesterol > nmbr - nmbr mmol / l,C0023824;C0202117;C1532563
125,visit nmbr ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
125,ldl - cholesterol,C0023824;C0202117
125,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
125,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
125,ldl - cholesterol (,C0023824;C0202117
125,low density lipoprotein cholesterol,C0023824
125,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
125,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
125,calculated ldl cholesterol ( week nmbr ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
125,ldl cholesterol^ :,C0023824;C0202117
125,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
125,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
125,- ldl cholesterol,C0023824;C0202117
125,ldl cholesterol ( mmol / l ) ( median,C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
125,nmbr mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
125,ldl cholesterol ( sd ),C0023824;C0202117;C2699239
124,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0205225;C0439612;C0439631;C1305868;C4049621
124,fibrinolysis ( n = nmbr ),C0016017;C1305868
123,cause of death unknown,C0007465;C4050444
123,• death from any cause,C0007465
123,• nmbr : death from any cause,C0007465
123,death from any cause,C0007465
123,by cause of death,C0007465;C4050444
122,> nmbr additional cv risk factorsnmbr,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
122,ascvdor > nmbr cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
122,> nmbr cv risk factors^ or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
122,> nmbr cv risk factors 咐 or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
122,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
122,cv risk factors and history,C0035648;C1553898;C3538987;C4048877;C4318503
122,cv risk factor,C0035648;C3538987;C4048877;C4318503
122,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
122,no ascvd + additional cv risk factors,C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
121,participants with metabolic syndrome,C0524620;C0679646
121,with metabolic syndrome,C0524620
121,metabolic syndromenmbr *,C0524620
121,metabolic syndrome ( % ),C0524620
121,metabolic syndrome — no . ( % ) nmbr,C0524620
121,metabolic syndrome characteristics,C0524620;C1521970
121,the metabolic syndrome^,C0524620
121,participants without metabolic syndrome,C0524620;C0679646
121,metabolic syndrome visit nmbr low - density lipoprotein cholesterol strata,C0524620
121,metabolic syndrome * n = nmbr,C0524620
121,metabolic syndrome ( % ) b,C0524620
121,metabolic syndrome ( n = nmbr ),C0524620
121,without metabolic syndrome,C0524620
121,metabolic syndrome *,C0524620
121,no metabolic syndrome,C0524620
121,metabolic syndrome — no . ( % ) ^,C0524620
121,metabolic syndrome,C0524620
121,metabolic syndrome ( > nmbr of nmbr characteristics ),C0524620;C1521970
121,metabolic syndrome — no . ( % ) !,C0524620
120,renal subgroup,C0022646;C1079230;C1515021
120,renal functiona,C0022646
120,renal impairmentt,C0022646
120,renal functionb,C0022646
120,renal parameters,C0022646;C0449381
120,renal functionc,C0022646
120,renal events,C0022646;C0441471;C3541888
120,renal composite *,C0022646;C0205199;C1547335
120,primary renal endpoint or death,C0022646;C2986535
120,exploratory kidney and microvascular outcomes,C0022646;C0227665
120,renal impairmentf,C0022646
120,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
120,primary renal endpoint,C0022646;C2986535
120,renal,C0022646
119,> nmbr antihypertensive medications,C0003364
119,any blood - pressure - lowering drug 一 no . ( % ),C0003364
119,number of antihypertensive medications at study entry,C0003364;C1718138
119,no antihypertensive medication,C0003364
119,other blood - pressure drug,C0003364
119,number of antihypertensive medications used,C0003364;C1718138
119,antihypertensive drugs,C0003364
119,number of antihypertensive agent reported,C0003364;C0237753;C0449788
119,anti - hypertensive,C0003364
119,use of anti - hypertensive agents,C0003364;C1524063
119,anti - hypertensives,C0003364
119,one antihypertensive medication,C0003364;C0205447
119,antihypertensives ' *,C0003364
119,antihypertensive medicationnmbr ',C0003364
119,types of antihypertensive medications at last visit   §,C0003364;C0332307
119,number of antihypertensive medications,C0003364;C1718138
119,antihypertensive medication ),C0003364
119,antihypertensive medication or,C0003364
119,type of antihypertensive medication use among patients using antihypertensive medications,C0003364;C0332307;C1524063;C1547052
119,antihypertensive,C0003364
119,other antihypertensive drug,C0003364
119,> nmbr antihypertensive medication,C0003364
119,other anti - hypertensives,C0003364
119,other blood pressure - lowering drugs,C0003364
119,antihypertensive medication,C0003364
119,antihypertensive drug,C0003364
119,mean number of antihypertensive medications at nmbr year   *,C0003364;C0444504;C1718138;C2347634;C2348143
119,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C2347634;C2348143
119,antihypertensives,C0003364
119,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
119,use of antihypertensive drugs,C0003364;C1524063
119,any antihypertensive drug,C0003364
119,prior antihypertensive medication,C0003364;C0332152;C2826257
119,other antihypertensive agents,C0003364
119,types of antihypertensive medications at nmbr year   †,C0003364;C0332307
119,antihypertensive agents *,C0003364
119,nmbr antihypertensive medication,C0003364
119,any antihypertensive agent,C0003364
119,any anti - hypertensive agent,C0003364
119,antihypertensive agents,C0003364
119,received antihypertensive within last nmbr days,C0003364;C0439228;C1514756
119,other anti - hypertensive,C0003364
119,other antihypertensive medications,C0003364
119,other antihypertensive,C0003364
118,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
118,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
118,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
117,left ventricular hypertrophy * *,C0149721;C3484363
117,left ventricular hypertrophy ( % ),C0149721;C3484363
117,lvh,C0149721
117,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
117,lv hypertrophy,C0149721
117,lvh + n = nmbr,C0149721
117,lvh - n = nmbr,C0149721
117,left ventricular hypertrophy,C0149721;C3484363
116,physician ' s judgment that vka inappropriate],C0022423;C0031831;C0804815
116,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815
116,physician ' s judgment that vka,C0022423;C0031831;C0804815
115,hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),C0065879
115,hscrp > nmbr . nmbr mga .,C0065879
115,nmbr / nmbr mga ( n = nmbr ),C0065879
114,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
114,laboratory parameters,C0022877;C0449381;C3244292;C4283904
114,laboratory investigations,C0022877;C1261322;C3244292;C4283904
114,laboratory values,C0022877;C0042295;C3244292;C4283904
114,laboratory measures,C0022877;C3244292;C4283904
114,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
114,laboratory ae,C0022877;C3244292;C3887670;C4283904
114,laboratory variables,C0022877;C0439828;C3244292;C4283904
114,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
114,laboratory determinations,C0022877;C0680730;C3244292;C4283904
113,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
113,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
112,white race — no . ( % ) : t,C0007457;C0043157;C0220938
112,white ( n = nmbr,C0007457;C0043157;C0220938
112,non - caucasian eze / simva ( n = nmbr ),C0007457;C0043157;C1518422
112,non - caucasian simva ( n = nmbr ),C0007457;C0043157;C1518422
112,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
112,white ( n   = nmbr,C0007457;C0043157;C0220938
112,non - caucasian eze / simva ( „ = nmbr },C0007457;C0043157;C1518422
112,non - hispanic white,C0007457;C0043157;C0220938;C1518424
112,non - caucasian simva ( „ = nmbr },C0007457;C0043157;C1518422
112,non - caucasian,C0007457;C0043157;C1518422
112,caucasians,C0007457;C0043157
112,white ( n — nmbr ),C0007457;C0043157;C0220938
112,caucasian eze / simva,C0007457;C0043157
112,caucasian simva,C0007457;C0043157
112,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
112,non - caucasian simva,C0007457;C0043157;C1518422
112,white not of hispanic origin,C0007457;C0043157;C0220938
112,caucasian ( % ),C0007457;C0043157
112,non white,C0007457;C0043157;C0220938;C1518422
112,non - white,C0007457;C0043157;C0220938;C1518422
112,white race — no . / total no . ( % ) f,C0007457;C0043157;C0220938
112,white race — no . / total no . ( % ) $,C0007457;C0043157;C0220938
112,caucasian eze / simva ( „ = nmbr },C0007457;C0043157
112,white ( nmbr . nmbr % ),C0007457;C0043157;C0220938
112,non - caucasian eze / simva,C0007457;C0043157;C1518422
112,white / other,C0007457;C0043157;C0220938
112,white race — no . ( % ) f,C0007457;C0043157;C0220938
112,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
112,white race — no . ( % ) :,C0007457;C0043157;C0220938
112,white race — no . { % ) - i -,C0007457;C0043157;C0220938
112,white race — no . { % ) t,C0007457;C0043157;C0220938
112,white race — no . { % ) $,C0007457;C0043157;C0220938
112,caucasian n = nmbr,C0007457;C0043157
112,racea white,C0007457;C0043157;C0220938
112,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
112,white race — no . { % ) ' i ',C0007457;C0043157;C0220938
112,caucasian eze / simva ( n = nmbr ),C0007457;C0043157
112,caucasian simva ( „ = nmbr },C0007457;C0043157
112,caucasian simva ( n = nmbr ),C0007457;C0043157
112,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0043157;C0220938
112,non - white race,C0007457;C0043157;C1518422
112,non - white raceb,C0007457;C0043157;C0220938;C1518422
112,caucasians ( n = nmbr ),C0007457;C0043157
112,white race,C0007457;C0043157
112,caucasian,C0007457;C0043157
112,white race ( n = nmbr nmbr ),C0007457;C0043157
112,white,C0007457;C0043157;C0220938
112,white ( n = nmbr ),C0007457;C0043157;C0220938
112,white or caucasian,C0007457;C0043157;C0220938
112,caucasian nmbr,C0007457;C0043157
111,( nmbr % ci ) b,C0008107;C3259781
111,* ci denotes confidence interval .,C0008107;C3259781
111,[nmbr % ci] *,C0008107;C3259781
111,hr ( nmbr % ci ) p   value,C0008107;C1709380;C3259781
111,mean pasi score ( nmbr % ci ),C0008107;C3259781;C3533236;C4528685
111,( nmbr % ci ) c,C0008107;C3259781
111,( nmbr % ci ) p value,C0008107;C1709380;C3259781
111,( nmbr % ci ) a,C0008107;C3259781
111,( nmbr % ci ) ,C0008107;C3259781
111,stratified hazard ratio ( nmbr % ci ),C0008107;C0205363;C2985465;C3259781
111,rate ratio ( nmbr % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
111,% - point difference ( nmbr % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
111,nmbr % ci for difference,C0008107;C1705241;C1705242;C3259781
111,- nmbr . nmbr ( nmbr % ci : - nmbr . nmbr,C0008107;C3259781
111,etd ( % ) [nmbr % ci],C0008107;C1180255;C3259781
111,cmh rr ( nmbr % ci ),C0008107;C3259781;C4554402
111,( ci ) b,C0008107;C3259781
111,mean ( nmbr % ci ) change from nmbr . nmbr to nmbr . nmbr mg,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
111,nmbr % cinmbr,C0008107;C3259781
111,adjusted hr ( nmbr % ci ),C0008107;C0456081;C3259781
111,rate estimate ( nmbr % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
111,mean eq - nmbrd response ( nmbr % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
111,nmbr - y kaplan - meier rate ( nmbr % ci ),C0008107;C0871208;C1521828;C3259781
111,adjusted hazard ratio ≠ ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
111,hr ( nmbr % ci ) *,C0008107;C3259781
111,hazard ratio ( nmbr % ci ) for adjudicated type nmbr diabetes,C0008107;C1320657;C2985465;C3259781
111,multivariable adjusted hr ( nmbr % ci ),C0008107;C0456081;C3259781
111,adjusted mean difference ( nmbr % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
111,hazard ratio [nmbr % ci],C0008107;C2985465;C3259781
111,proportion ( nmbr % ci ) adjusted for baseline hbanmbrc,C0008107;C1709707;C3259781
111,hazard ratio ( nmbr % ci ) nmbr with vs . without psoriasis,C0008107;C2985465;C3259781
111,hazard ratio ( nmbr % ci ) vs . placebo,C0008107;C2985465;C3259781
111,hazard ratio ( nmbr % ci ) - j -,C0008107;C2985465;C3259781
111,estimated difference ( nmbr % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
111,harzard ratio ( nmbr % ci ),C0008107;C0456603;C1547037;C3259781
111,harzar ratio ( nmbr % ci ),C0008107;C0456603;C1547037;C3259781
111,nmbr . nmbr nmbr % ci : nmbr . nmbr - nmbr . nmbr p = nmbr . nmbr,C0008107;C3259781
111,nmbr . nmbr ( nmbr % ci nmbr . nmbr to nmbr . nmbr ) p = nmbr . nmbr,C0008107;C3259781
111,nmbr . nmbr ( nmbr % ci nmbr . nmbr to nmbr . nmbr ),C0008107;C3259781
111,adjusted ⁎ hazard ratio ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
111,median time to first exacerbation ( months [nmbr % ci] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
111,mean bmi ( nmbr % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
111,adjusted hr  nmbr % ci,C0008107;C0456081;C3259781
111,( nmbr % ci] nmbr,C0008107;C3259781
111,hradjusted ( nmbr % ci ) b,C0008107;C3259781
111,hradj ( nmbr % ci ),C0008107;C3259781
111,adjusted hr * ( nmbr % ci ),C0008107;C0456081;C3259781
111,hr [nmbr % ci ),C0008107;C3259781
111,hazard . ratio . ( nmbr % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
111,nmbr . nmbr ( nmbr % ci : nmbr . nmbr,C0008107;C3259781
111,adjusted hr ( nmbr % ci ) * compared with no diabetes at bl or at year nmbr,C0008107;C0456081;C3259781
111,adjusted hazard ratio ‡ ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
111,adjusted hazard ratio § ( nmbr % ci ),C0008107;C0456081;C2985465;C3259781
111,rr ( nmbr % ci ) c,C0008107;C3259781;C4554402
111,difference ( nmbr % ci ) *,C0008107;C1705241;C1705242;C3259781
111,hr ( nmbrs % ci ),C0008107;C3259781
111,adjusted hazard ratio ( nmbr % ci ) †,C0008107;C0456081;C2985465;C3259781
111,multivariable adjusted model hr ( nmbr % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
111,nmbr % ci nmbr . nmbr - nmbr . nmbr,C0008107;C3259781
111,crude model hr ( nmbr % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
111,etr : nmbr . nmbr [nmbr . nmbr  nmbr . nmbr]nmbr % ci  p     =   nmbr . nmbr,C0008107;C3259781
111,unadjusted hazard ratio ( nmbr % ci ),C0008107;C1439367;C2985465;C3259781
111,ratio ( nmbr % ci ) *,C0008107;C0456603;C1547037;C3259781
111,lsm ( nmbr % ci ),C0008107;C3259781
111,estimate ( nmbr % ci ),C0008107;C0750572;C3259781
111,arr ( nmbr % ci ),C0008107;C2170357;C3259781;C4084934
111,oradj ( nmbr % ci ),C0008107;C3259781
111,rr^ ( nmbr % ci ),C0008107;C3259781;C4554402
111,rr ( nmbr % ci ),C0008107;C3259781;C4554402
111,hr ( nmbr % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
111,unadjusted hr ( nmbr % ci ) for nmbr sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
111,% ( nmbr % ci ),C0008107;C3259781
111,( nmbr % ci ),C0008107;C3259781
111,lsms difference ( nmbr % ci ) nmbr,C0008107;C1705241;C1705242;C3259781
111,hazard ratio for event ( nmbr % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
111,cochranemantelehaenszel ( repeated nmbr . nmbr % ci ) c,C0008107;C0205341;C3259781
111,etd : − nmbr . nmbr [ − nmbr . nmbr  − nmbr . nmbr]nmbr % ci  p     <   nmbr . nmbr,C0008107;C1180255;C3259781
111,etd : − nmbr . nmbr [ − nmbr . nmbr  − nmbr . nmbr]nmbr % ci  p     <   nmbr . nmbr,C0008107;C1180255;C3259781
111,etd : − nmbr . nmbr [ − nmbr . nmbr  nmbr . nmbr]nmbr % ci  p     =   nmbr . nmbr,C0008107;C1180255;C3259781
111,rr ( nmbr % ci ) *,C0008107;C3259781;C4554402
111,nmbr % ci,C0008107;C3259781
111,ff – nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C3259781;C4554348
111,unadjusted hr ( nmbr % ci ) for nmbr standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
111,hazard ratio ( nmbr % ci ),C0008107;C2985465;C3259781
111,ff nmbr % ( nmbr % ci – nmbr – nmbr % ),C0008107;C3259781;C4554348
111,hazard ratio * ( nmbr % ci ),C0008107;C2985465;C3259781
111,hazard ratiof ( nmbr % ci ),C0008107;C0598697;C3259781
111,hr ( nmbr % ci ) “,C0008107;C3259781
111,unadjusted hr ( nmbr % ci ) a,C0008107;C1439367;C3259781
111,hazard ratio ( nmbr % ci ) *,C0008107;C2985465;C3259781
111,difference ( nmbr % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
111,etd ( nmbr % ci ),C0008107;C1180255;C3259781
111,hr nmbr % ci,C0008107;C3259781
111,mean ( nmbr % ci ) difference vs saxa + dapa + met,C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
111,hr ( nmbr % ci ),C0008107;C3259781
110,czp nmbr mg ( nnmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,week nmbr czp nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,week nmbr czp nmbr mg qnmbrw,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg ( n nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg ( n = nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg qnmbrw,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
110,czp nmbr mg every nmbr weeks ( n = nmbr ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
109,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
109,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
108,pain vas ( range nmbr - nmbr ),C0042815;C1514721;C2348147;C3542016
108,patient ' s assessment of pain ( nmbr - nmbr vas ),C0042815;C0679830
108,pain vas,C0042815
108,pain ( vas ),C0042815
108,pain ( nmbr - nmbr mm vas ),C0042815;C4330985;C4554674
108,pain ( nmbr mm vas ),C0042815;C4330985;C4554674
108,psa pain ( vas ),C0042815;C3810537;C3813209
108,patient global assessment of pain ( vas nmbr - nmbr mm ),C0042815;C4054229;C4330985;C4554674
108,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
107,mini - mental state examination,C0451306
107,mmse < nmbr,C0451306
107,mmse score *,C0449820;C0451306;C4050231
107,mmse score,C0449820;C0451306;C4050231
107,mean mmse score,C0451306;C3533236
107,a mini - mental state examination,C0451306
107,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
107,mmse > nmbr,C0451306
107,mmse nmbr - nmbr,C0451306
107,mmse ( points ),C0451306
106,risk reduction,C1137094
106,% risk reduction ( nmbr % cl ),C0596019;C1137094
106,risk reduction ( nmbr % cl ),C0596019;C1137094
105,one - third radius,C0034627;C0205437;C0205447;C1306504
105,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
104,£ nmbr kg,C0022718;C0439209;C4054209
104,> median ( nmbr kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
104,nmbr to < nmbrkg,C0022718;C0439209;C4054209
104,< nmbr kg,C0022718;C0439209;C4054209
104,> nmbr - nmbr kg,C0022718;C0439209;C4054209
104,kg,C0022718;C0439209;C4054209
104,onmbr kg,C0022718;C0439209;C0483204;C4054209
104,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
104,> nmbr kg,C0022718;C0439209;C4054209
104,# nmbr kg,C0022718;C0439209;C4054209
104,< nmbrkg,C0022718;C0439209;C4054209
104,> = nmbr kg,C0022718;C0439209;C4054209
104,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
104,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
104,nmbr kg,C0022718;C0439209;C4054209
104,qnmbr : > nmbr . nmbr kg ( n = nmbrvsnmbr ),C0022718;C0439209;C4054209
104,< median ( nmbr kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
104,nmbr - nmbr kg,C0022718;C0439209;C4054209
104,« nmbr kg,C0022718;C0439209;C4054209
104,> nmbr . nmbr - nmbr . nmbr kg,C0022718;C0439209;C4054209
104,> nmbrkg,C0022718;C0439209;C4054209
104,> nmbr kg — no . ( % ),C0022718;C0439209;C4054209
104,median m / kgnmbr ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
104,qnmbr : nmbr . nmbr to < nmbr . nmbr kg ( n = nmbr vs nmbr ),C0022718;C0439209;C4054209
104,. nmbr kg,C0022718;C0439209;C4054209
104,> = nmbrkg,C0022718;C0439209;C4054209
104,nmbr to < nmbr kg,C0022718;C0439209;C4054209
104,dose adjustment reason < nmbr kg,C0022718;C0439209;C2826286;C4054209
104,< = € nmbr kg,C0022718;C0439209;C4054209
104,< = nmbr kg,C0022718;C0439209;C4054209
104,weight in kg ( baseline : mean ( sd ) [n]  wk nmbr and change : mean ( se ) [n] ),C0022718;C0332174;C0439209;C0439230;C0444504;C1303013;C2347634;C2348143;C2699239;C4054209
104,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
104,< nmbr . nmbr kg,C0022718;C0439209;C4054209
104,nmbr - < nmbr kg,C0022718;C0439209;C4054209
104,> nmbr . nmbr kg,C0022718;C0439209;C4054209
104,qnmbr : < nmbr . nmbr kg ( n = nmbrvsnmbr ),C0022718;C0439209;C4054209
104,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
103,blood urea nitrogen,C0005845;C0600137
103,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
102,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
102,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
102,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
102,family history of coronary disease,C0018787;C0850707
102,hospitaiization for heart faiiure,C0018787
102,cardiac parameters,C0018787;C0449381;C1522601
102,coronary,C0018787
102,cardiac,C0018787;C1522601
102,symptomatic heart fail,C0018787;C0231220
102,heart failurea,C0018787
102,history of coronary heart disease,C0018787;C0683519;C0730226;C0850708;C0944983
102,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
102,native coronary,C0018787;C0302891
102,congestive heart,C0018787;C0742742
102,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
102,cardiac and echocardiography parameters,C0018787;C1522601
102,cardiac medications at discharge,C0018787;C0806915;C1522601
102,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
102,coronary end point,C0018787;C2349179;C2826544
102,coronary endpoint,C0018787;C2349179;C2826544
102,cardiac stretch,C0018787;C0600080;C1522601
102,cardiac failurec,C0018787;C1522601
102,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
102,cardiac enzyates raised,C0018787;C1522601
102,bmi ( kg / mnmbr ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
102,cardiac diseasec,C0018787;C1522601
101,estimated gfr,C0017654;C0750572;C1424601
101,by gfr stratum for all participants,C0017654;C0679646;C1424601
101,estimated gfr — ml / min / nmbr . nmbr m^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr — ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,glomerular filtration rate §,C0017654;C1561549
101,estimated gfr^,C0017654;C0750572;C1424601
101,by gfr stratum for diabetic participants,C0017654;C0241863;C0679646;C1424601
101,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr ( ml / min per nmbr . nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
101,estimated gfr ( ml / min / nmbr . nmbr mnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr — no . ( % ) nmbr,C0017654;C0750572;C1424601
101,gfr as assessed by mdrd,C0017654;C1424601
101,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
101,glomerular filtration rate,C0017654;C1561549
101,mild decrease in gfr ( nmbr - nmbr ml / mln per nmbr . nmbr m^ ),C0017654;C0392756;C0439526;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
101,estimated gfr ( ml / min / nmbr . nmbrmnmbr ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
101,estimated gfr < nmbr ml / min / nmbr . nmbr m^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr > nmbr ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,estimated gfr < nmbr ml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
101,gfr > nmbr,C0017654;C1424601
101,gfr < nmbrml / min / nmbr . nmbr mnmbr,C0017654;C0369637;C0439445;C0441923;C1424601
101,gfr nmbr nmbr,C0017654;C1424601
101,gfr < nmbr,C0017654;C1424601
101,gfr nmbr - nmbr,C0017654;C1424601
100,cigarette users,C0677453;C1704760;C1706077;C3890423
100,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
100,current cigarette,C0521116;C0677453;C1704760;C1705970;C3890423
100,current smoker ( > nmbr cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
100,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
99,pioglitazone dose,C0071097;C0178602;C0869039;C1114758
99,pioglitazone ( n = nmbr,C0071097
99,pioglitazone,C0071097
99,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
99,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
99,pioglitazone group ( n = nmbr ),C0071097;C0441848
99,pioglitazone ( n = nmbr ),C0071097
99,pioglitazone only,C0071097;C0205171;C1720467
98,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
98,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
98,cad and abi < nmbr - nmbr §,C1504769;C2239547;C3813548;C4284121
98,familv historv of cad,C1504769;C2239547;C3813548;C4284121
98,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
98,cad,C1504769;C2239547;C3813548;C4284121
98,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
98,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
98,multivessel cad,C1504769;C2239547;C3813548;C4284121
98,cad *,C1504769;C2239547;C3813548;C4284121
97,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
97,no statin vs statin alone vs any statin plus other llt,C0360714
97,ltt other than statin,C0360714
97,statin ( n - nmbr ),C0360714
97,no prior statin ( n = nmbr,C0332152;C0360714;C2826257
97,prior statin ( n = nmbr,C0332152;C0360714;C2826257
97,statin ( open ),C0360714
97,statin users,C0360714;C1706077
97,statin during admission,C0184666;C0360714;C0809949
97,statin,C0360714
97,statin and / or other lipid - lowering agent therapy,C0360714
97,statin monotherapy,C0360714
97,statin use at study entry,C0360714;C0869040;C1705654
97,combined statin and other lipid - lowering agent use,C0205195;C0360714
97,no statin ( + / - llt ),C0360714;C2347090
97,any statin + other llt,C0360714
97,statin or ezetimibe,C0360714
97,eze + statin n = nmbr,C0360714
97,ze + statin,C0360714
97,no statin during admission,C0184666;C0360714;C0809949
97,peri - op statins : no ( n = nmbr ),C0347985;C0360714
97,statin intensitynmbr * nmbr,C0360714;C0522510
97,statin without other llt,C0360714;C2347090
97,statin with other llt,C0360714;C2347090
97,duration of prior statin therapy^,C0332152;C0360714;C0444917;C2826257
97,non high dose statin ( n = nmbr,C0360714;C0444956;C1518422
97,high - intensity statin,C0360714;C4081854
97,statin + fibrate or niacin,C0360714
97,use of statins,C0360714;C1524063
97,no high - intensity statin,C0360714;C4081854
97,statin — no . / total no . ( % ),C0360714
97,statin + fibrate or,C0360714
97,any statin,C0360714
97,llt other than statin at randomization,C0360714;C2347090
97,moderate - dose statin,C0360714;C1709056
97,statin at enrollment,C0360714;C1516879;C1696073;C3888021
97,llv wlalil nmbr statin,C0360714
97,statin usage,C0360714;C0457083
97,any llt other than statins,C0360714;C2347090
97,statin use — no . { % ),C0360714
97,low - dose statin,C0360714;C0445550;C1708745
97,statin and / or ezetimibe,C0360714
97,eze + statin,C0360714
97,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
97,statins 一 no . ( % ),C0360714
97,statin alone,C0360714
97,high - intensity statin *,C0360714;C4081854
97,statins,C0360714
97,no statin,C0360714
97,statins used during follow - up,C0360714
97,baseiine statin,C0360714
97,high - dose statin,C0360714;C0444956
97,statin ( n = nmbr ),C0360714
97,statin potency stratum,C0360714;C3245505
97,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
97,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
97,statin ( s ),C0360714
97,statin intolerancenmbr,C0231199;C0360714;C1744706;C2355652
97,any statin ( with / without llt ),C0360714
97,statin users ( n = nmbr ),C0360714;C1706077
97,taking statins,C0360714;C1515187
97,statin non - users ( n = nmbr ),C0360714;C1518422;C1706077
97,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052
97,other statin,C0360714
97,moderate - intensity statin,C0360714;C4081855
97,high - dose statin pretreatment ( n = nmbr ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
97,statin ( % ),C0360714
97,statin intolerant *,C0231200;C0360714
97,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
97,statin only,C0205171;C0360714;C1720467
97,non - statin ( n = nmbr ),C0360714;C1518422
97,statin with fibrate,C0360714
97,statin only ( n = nmbr,C0205171;C0360714;C1720467
97,use of statin at any follow - up visit ( % ),C0360714;C1524063
97,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052
97,any statin versus no statin at randomization,C0360714
97,high dose statin ( n = nmbr,C0360714;C0444956
97,high ‐ intensity statins ‡,C0360714;C4081854
96,n - nmbr fatty acids,C0015684;C0369718;C0441922
96,omega - nmbr fatty acid,C0015684;C1719844
96,omega - nmbr fatty acids,C0015684;C1719844
96,n - nmbr fatty acids slope lsm ± se ( mm / year ),C0015684;C0369718;C0441922
96,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),C0015684;C1719844
96,fatty acid profile,C0015684;C1979963;C2003903
96,n - nmbr fatty acids ( n = nmbr ),C0015684;C0369718;C0441922
96,fatty acid group ( n = nmbr ),C0015684;C0441848
96,fatty acid composition,C0015684;C0486616;C1555710
96,omega - nmbr fatty acid ( n = nmbr ),C0015684;C1719844
96,number omega - nmbr number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
95,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking in the past year,C0037369;C0453996;C1881674;C4086728
95,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
95,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
95,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
95,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
95,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
95,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
95,smoking *,C0037369;C0453996;C1881674
95,no smoking,C0037369;C0453996;C1881674
95,smoking ( ever ),C0037369;C0453996;C1881674
95,smoking pack - yearsb,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
95,smoking * ( > nmbr pack - years ),C0037369;C0453996;C1277691;C1881674
95,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
95,smoking ( % ),C0037369;C0453996;C1881674
95,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
95,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking pack - years,C0037369;C0453996;C1277691;C1881674
95,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking : current smoker,C0037369;C0453996;C1881674
95,smoking ( a ),C0037369;C0453996;C1881674
95,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
95,current smoking — no . / total no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
95,smoking,C0037369;C0453996;C1881674
95,smoking ' ! ',C0037369;C0453996;C1881674
95,smoking : ex - smoker,C0037369;C0453996;C1881674
95,mean ( sd ) duration of smoking,C0037369;C0444504;C0449238;C0453996;C1881674;C2347634;C2348143;C2699239;C2926735
95,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
94,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
94,past cardiovascular history,C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
94,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
94,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
94,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
94,all cardiovascular,C0007226;C3887460
94,any cardiovascular diseased,C0007226;C3887460
94,cardiovascular status,C0007226;C0449438;C3887460
94,previous history of cardiovascular events,C0007226;C2004062;C3887460
94,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
94,recent cardiovascular eventf,C0007226;C0332185;C3887460
94,concomitant cardiovascular therapy ( taken > nmbr days ),C0007226;C0521115;C0587038;C1707479;C3887460
94,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
94,cardiovascular,C0007226;C3887460
94,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
94,cardiovascular and respiratory,C0007226;C3887460
94,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C3887460
94,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
94,exploratory cardiovascular and death outcomes,C0007226;C3887460
94,primary cardiovascular endpoint,C0007226;C2986535;C3887460
94,high cardiovascular risk,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
93,ethnicity,C0015031;C0243103
93,ethnicity ( % ),C0015031;C0243103
93,ethnicity t,C0015031;C0243103
93,othery ethnicity,C0015031;C0243103
93,ethnicitynmbr ',C0015031;C0243103
93,ethnicity - no . ( % ),C0015031;C0243103
92,intestinal area involved,C0017446;C0021853;C0205146
92,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146
91,mean treatment exposure,C0039798;C0087111;C0274281;C0332157;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
91,dpp - nmbr inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
91,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
91,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
91,treatment ( de vs warfarin ) by thrombophilia interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
91,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
91,treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
91,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
91,antithrombotic therapy,C0039798;C0087111;C1363945
91,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
91,month nmbr subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
91,interaction between treatment and baseline bmi category,C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
91,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
91,treatment difference % ( nmbr % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
91,noninsulin therapy,C0039798;C0087111;C1363945
91,events treatment ( nmbr ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
91,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
91,lcznmbr treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
91,no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
91,vka therapy,C0039798;C0087111;C1363945
91,type of insulin therapy — no . ( % ) nmbr,C0039798;C0087111;C0457592;C1363945
91,treatment diff . vs tio ( nmbr % ci ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,ed therapy,C0039798;C0087111;C1363945;C3538926
91,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
91,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
91,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
91,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
91,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
91,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
91,continuous lvef nmbr treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
91,epa treatment ( n = nmbr ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,acei / arb therapy,C0039798;C0087111;C1363945;C3888198
91,any therapy — no . ( % ),C0039798;C0087111;C1363945
91,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
91,background therapy,C0039798;C0087111;C1363945;C1706907
91,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
91,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
91,therapy,C0039798;C0087111;C1363945
91,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
91,treatment difference ( nmbr % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
91,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1552607
91,treatment stratum^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
91,previous treatment with a laba and / or lama,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
91,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
91,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
91,oab therapy,C0039798;C0087111;C1363945
91,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
91,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
91,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0039798;C0087111;C0178602;C0366686;C0682295;C0869039;C1114758;C1363945;C1880019;C4303340
91,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,background treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
91,long term vka therapy,C0039798;C0087111;C0443252;C1363945
91,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
91,topical therapy,C0039798;C0087111;C0332237;C1363945
91,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
91,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
91,pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,ineffective therapy,C0039798;C0087111;C1363945;C3242229
91,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
91,inadequate response / intolerance to prior therapy,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
90,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
90,fasting tgs,C0015663;C1156212;C1537574
90,fastest third,C0015663;C0205437;C0456962;C2985769
90,fasting serum glucose,C0015663;C0202041;C3534430
90,fasting plasma glucose *,C0015663;C0202042;C0455280
90,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
90,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
90,fasting triglyceride level,C0015663;C0428475
90,normal fasting glucose level ( n = nmbr ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
90,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
90,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
90,fasting tgs §,C0015663;C1156212;C1537574
90,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
90,fasting free fatty acids ( ^mol / liter ),C0015663
90,fasting plasma glucose ( mg / dl ) nmbr,C0015663;C0202042;C0439269;C0455280
90,fasting plasma glucose categories,C0015663;C0202042;C0455280;C0683312
90,faster aspart,C0015663;C0123677;C0456962;C2985769
90,fasting lipid levels,C0015663;C0428460
90,fasting plasma glucose nmbr medan,C0015663;C0202042;C0455280
90,fasting plasma glucose,C0015663;C0202042;C0455280
90,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
90,fasting,C0015663
90,fasting indices,C0015663;C4033634
90,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
90,fasting plasma glucose ( mmol / l ) nmbr,C0015663;C0202042;C0455280;C1532563
90,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
89,beta - adrenergic blocker,C0001645;C2757061;C3536830
89,without beta blocker,C0001645
89,beta - blocker,C0001645
89,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
89,beta blockers,C0001645
89,peri - op beta - blockers : no ( n = nmbr ),C0001645;C0347985
89,beta blocker,C0001645
89,use of beta - blockers,C0001645;C1524063
89,use of beta - blocker,C0001645;C1524063
89,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
89,beta - blocker — no . / total no . ( % ),C0001645
89,beta - blockers through hospital discharge or day nmbr — %,C0001645;C0586003
89,beta - blocker — no . ( % ),C0001645
89,with beta blocker,C0001645
89,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
89,beta blocker users,C0001645;C1706077
89,beta - blocker n ( % ),C0001645
89,beta - blocker !,C0001645
89,beta - blockers ( all ),C0001645
89,beta - blockers,C0001645
89,no beta - blocker,C0001645
89,betablocker,C0001645
88,insulin - naive,C0021641;C1533581;C1579433;C3714501
88,insulin + oad,C0021641;C1533581;C1579433;C3714501
88,insulin plus nmbr oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
88,insulin - treated dm,C0021641;C1533581;C1579433;C3714501
88,insulin alone,C0021641;C1533581;C1579433;C3714501
88,insulin,C0021641;C1533581;C1579433;C3714501
88,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
88,insulin ( % ),C0021641;C1533581;C1579433;C3714501
88,insulin plus > nmbr oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
88,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
88,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
88,insulin - treated diabetes,C0021641;C1533581;C1579433;C3714501
88,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
88,insulin treated,C0021641;C1533581;C1579433;C3714501
88,daily insulin dose,C0021641;C0332173;C0366513;C1533581;C1579433;C2348070;C3714501
88,insulin dependentc,C0021641;C1533581;C1579433;C3714501
88,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
88,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
88,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
88,insulin based,C0021641;C1533581;C1579433;C3714501
88,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
88,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
88,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
88,total daily insulin dose,C0021641;C1533581;C1579433;C2348070;C3714501
88,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
88,oad plus insulin,C0021641;C1533581;C1579433;C3714501
88,median ( qnmbr : qnmbr ) duration of insulin use,C0021641;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
88,insulin - requiring,C0021641;C1533581;C1579433;C3714501
88,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
88,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
88,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
88,insulin - treated,C0021641;C1533581;C1579433;C3714501
88,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
88,median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
88,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
87,heparin at randomization,C0019134;C0034656;C0770546
87,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
87,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
86,gly nmbr . nmbr gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
86,ff nmbr gg ( n = nmbr,C0017454;C0018370;C4554348
86,gg,C0017454;C0018370
86,ind nmbr gg q . d . n / n ( % ),C0017454;C0018370;C4049864
85,other dmards,C0242708
85,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
85,prior conventional synthetic dmards,C0242708;C0332152;C0439858;C1883254;C2826257
85,dmard | |,C0242708
85,concomitant use of conventional synthetic dmard up to nmbr mo — no . { % ) methotrexate,C0242708;C0439858;C0521115;C1524063;C1883254
85,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
85,dmard − ( n   =   nmbr ),C0242708
85,dmard user,C0242708;C1548600;C1706077
85,dmard + ( n   =   nmbr ),C0242708
85,dmard or corticosteroid,C0242708
85,no . previous dmard,C0205156;C0242708;C1552607
85,previous dmards,C0205156;C0242708;C1552607
85,previous dmards use,C0205156;C0242708;C1552607
84,previous disease — no . ( % ) f,C0012634;C0205156;C1552607
84,any condition,C0012634;C0348080;C1705253;C3864998
84,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
84,history of other medical conditions,C0012634;C0262926;C0348080;C1705253;C3864998
84,no multivessel disease,C0012634
84,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
84,disease location,C0012634;C0450429;C1515974;C4284930;C4284931
84,no polyvascular disease * ( n = nmbr nmbr ),C0012634
84,medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
84,established disease,C0012634;C0443211;C1272684
84,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
84,moderate disease activity : > nmbr . nmbr to < nmbr . nmbr,C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
84,coronarv arterv disease,C0012634
84,penetrating disease,C0012634;C0205321
84,left - sided disease only,C0012634;C3842976
84,priorbone disease,C0012634
84,multivessel disease,C0012634
84,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
84,disease extent,C0012634;C0439792
84,disorders ( soc ),C0012634
84,high disease activity : > nmbr . nmbr,C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
84,multivessel disease 一 no . ( % ),C0012634
84,disease site,C0012634;C0205145;C1515974;C2825164
84,microvascular disease *,C0012634;C0443258
84,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
84,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
84,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
84,disease localization,C0012634;C0475264;C1744691
84,physician global assessment of disease,C0012634;C4050369
84,any disease,C0012634
84,no polyvascular disease ( n = nmbr nmbr ),C0012634
84,disease localization ' ’,C0012634;C0475264;C1744691
84,peripherai arteriai disease,C0012634
84,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
84,site of disease — no . ( % ),C0012634;C2945843
84,disease hare . no . ( % ) i,C0012634
84,disease and quality - of - life scores,C0012634
84,previous disease and drug use,C0012634;C0205156;C1552607
84,underlying disease,C0012634;C4067746
84,atherosclerotic disease ( % ),C0012634;C0333482
84,disease,C0012634
84,uc disease durslion,C0012634
84,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
84,macrovascular disease,C0012634
84,condition nmbr ( nmbr . nmbr ),C0012634;C0348080;C1705253;C3864998
84,previous disease :,C0012634;C0205156;C1552607
84,presenting condition,C0012634;C0348080;C0449450;C1705253;C3864998
84,priorvascular disease,C0012634
84,multivessel disease — no . ( % ),C0012634
84,nmbr ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
84,patient ' s global assessment of disease,C0012634;C4054229
84,polyvascular disease ( n = nmbr ),C0012634
84,patient global assessment of disease,C0012634;C4054229
84,established maerovaseular disease and albuminuria,C0012634;C0443211;C1272684
84,polyvascular disease and no type nmbr diabetes ( n = nmbr ),C0012634
84,atherosclerotic disease *,C0012634;C0333482
84,disease site — no . of patients ( % ) |,C0012634;C0205145;C1515974;C2825164
84,cerebrovascuiar disease,C0012634
84,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
84,prior disease,C0012634;C0332152;C2826257
84,polyvascular disease * and type nmbr diabetes status,C0012634
84,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
84,location of disease,C0012634;C0450429;C1515974;C4284930;C4284931
84,microvascular disease,C0012634;C0443258
84,polyvascular disease * ( n = nmbr ),C0012634
84,prespecified medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
84,polyvascular disease and type nmbr diabetes ( n = nmbr ),C0012634
83,nmbr % < hbanmbrc < = nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc nmbr weeks,C0019016;C0439230;C1825777;C3538758
83,qualifying hbanmbrc ( % ),C0019016;C1514624;C1825777;C3538758
83,hbanmbrc category,C0019016;C0683312;C1825777;C3538758;C3889287
83,hbanmbrc > nmbr · nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc > = nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc > nmbr % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
83,hbanmbrc in % ( median ( qnmbr,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
83,hbanmbrc > nmbr . nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc categories,C0019016;C0683312;C1825777;C3538758
83,normal hbanmbrc,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
83,hbanmbrc month nmbr ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
83,hbanmbrc strata,C0019016;C1825777;C3538758
83,hbanmbrc > nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc ≤ nmbr . nmbr % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
83,hbanmbrc < nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc < = nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,hbanmbrc nmbr - < = nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc   ( % ),C0019016;C1825777;C3538758
83,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
83,hbanmbrc ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
83,% hbanmbrc ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
83,serum haemoglobin anmbrc concentration ( % ),C0019016;C0683149
83,hbanmbrc subgroups,C0019016;C1079230;C1825777;C3538758
83,hbanmbrc at week nmbr,C0019016;C0332174;C0439230;C1825777;C3538758
83,hbanmbrc,C0019016;C1825777;C3538758
83,mean hbanmbrc ± s . d .,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
83,hbanmbrc levels,C0019016;C0441889;C1825777;C3538758
83,hbanmbrc at nmbr weeks *,C0019016;C0439230;C1825777;C3538758
83,hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0019016;C1825777;C3538758
83,mean ( sd ) hbanmbrc level,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
83,hbanmbrc < = nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
83,hba „ ( % ),C0019016;C1825777;C3538758
83,hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,hbanmbrc > nmbr % ( n nmbr nmbr ),C0019016;C1825777;C3538758
83,mean ( sd ) hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
83,mean hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
83,hbanmbrc ( % ) all countries,C0019016;C0454664;C1825777;C3538758
83,hemoglobin a,C0019016
83,reduction of hbanmbrc from baseline ≥ nmbr . nmbr %,C0019016;C0301630;C0392756;C1293152;C1825777;C3538758;C4551656
83,mean ± s . d . hbanmbrc,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
83,hbanmbrc ( n ),C0019016;C1825777;C3538758
83,hbanmbrc ≤ nmbr . nmbr %,C0019016;C1825777;C3538758
83,hbanmbrc < nmbr % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
83,change in hbanmbrc nmbr to month nmbr ( % ),C0019016;C0392747;C0443172;C1705241;C1825777;C3538758;C4319952
83,hbanmbrc < nmbr . nmbr %,C0019016;C1825777;C3538758
83,hba,C0019016;C1825777;C3538758
83,any hbanmbrc,C0019016;C1825777;C3538758
83,hbanmbrc \n ,C0019016;C1825777;C3538758
83,hbanmbrc ( sd ),C0019016;C1825777;C2699239;C3538758
83,hbanmbrc % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
83,hbanmbrc ( % ) *,C0019016;C1825777;C3538758
83,hbanmbrc ( % ),C0019016;C1825777;C3538758
83,hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,hba]c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,hbanmbrc ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
83,week nmbr hbanmbrc,C0019016;C0332174;C0439230;C1825777;C3538758
83,hbanmbrc < nmbr % ( n - nmbr ),C0019016;C1825777;C3538758
82,n o diabetes,C0011847;C0011849;C0369718;C0441922
82,no diabetes,C0011847;C0011849
82,diabetes ( % ),C0011847;C0011849
82,diabetes *,C0011847;C0011849
82,non - diabetes,C0011847;C0011849;C1518422
82,diabetesnmbr,C0011847;C0011849
82,diabetes,C0011847;C0011849
82,duration of diabetes,C0011847;C0011849;C0449238;C2926735
82,known duration of diabetes,C0011847;C0011849;C0205309;C0449238;C2926735
82,mean ± s . d . duration of diabetes,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2926735
82,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849
82,diabetes mellitus duration ( sd ),C0011849;C0449238;C2699239;C2926735
82,diabetes mellitus 一 no . ( % ),C0011849
82,diabetes mellitus [n ( % ) ],C0011849
82,diabetes mellitus — no . / total no . ( % ),C0011849
82,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
82,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
82,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
82,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
82,diabetes melitus,C0011847;C0011849
82,undiagnosed diabetes mellitus,C0011849;C1408353
82,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
82,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
82,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
82,diabetes classificationa,C0011847;C0011849
82,diabetes ( p = . oonmbr ),C0011847;C0011849
82,diabetes ( p = . onmbr ),C0011847;C0011849
82,diabetes - related medication use,C0011847;C0011849;C0240320;C0439849;C0445223
82,diabetes ( p = . nmbr ),C0011847;C0011849
82,diabetes ( n [ % ] ) *,C0011847;C0011849
82,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
82,diabetes ( n = nmbr ),C0011847;C0011849
82,diabetes mellitus duration,C0011849;C0449238;C2926735
82,diabetes mellitus n = nmbr,C0011849
82,diabetes mellitus yes ( n,C0011849;C1549445;C1705108;C1710701
82,diabetes duration,C0011847;C0011849;C0449238;C2926735
82,other ( % ) diabetes ( interaction : p = nmbr . nmbr ),C0011847;C0011849;C1704675
82,duration of diabetes < nmbr years,C0011847;C0011849;C0439234;C0449238;C2926735
82,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
82,with diabetes,C0011847;C0011849
82,duration of diabetes > nmbr years,C0011847;C0011849;C0439234;C0449238;C2926735
82,prior diabetes,C0011847;C0011849;C0332152;C2826257
82,long ( > nmbr years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
82,new diabetes — no . ( % ),C0011847;C0011849;C0205314
82,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
82,high risk of diabetes,C0011847;C0011849;C0332167
82,diabetes mellitust,C0011847;C0011849
82,median duration oftype nmbr diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
82,"high risk of diabetes """,C0011847;C0011849;C0332167
82,without diabetes,C0011847;C0011849
82,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
82,diabetes | |,C0011847;C0011849
82,diabetes^,C0011847;C0011849
82,diabetesnmbr ( % ),C0011847;C0011849
82,diabetes t,C0011847;C0011849
82,diabetes n ( % ),C0011847;C0011849
82,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
82,diabetes present nmbr ( nmbr . nmbr ),C0011847;C0011849;C0150312;C0449450
82,undiagnosed diabetes ( n = nmbr ),C0011847;C0011849;C1408353
82,new - onset diabetes,C0011847;C0011849;C0746890
82,duration of diabetes mellitus,C0011849;C0449238;C2926735
82,no previous diagnosis of diabetes mellitus,C0011849;C0332132
82,new diabetes,C0011847;C0011849;C0205314
82,diabetes duration ( known ),C0011847;C0011849;C0449238;C2926735
82,diabetes mellitus — no . ( % ),C0011849
82,duration of diabetes — yr^,C0011847;C0011849;C0439234;C0449238;C2926735
82,previous diabetes,C0011847;C0011849;C0205156;C1552607
82,diabetes and untreated hypertension,C0011847;C0011849
82,previous diabetes mellitus,C0011849;C0205156;C1552607
82,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
82,no diabetes ( p = . onmbr ),C0011847;C0011849
82,no diabetes ( p = . nmbr ),C0011847;C0011849
82,no diabetes ( n = nmbr,C0011847;C0011849
82,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
82,no diabetes ( n - nmbr,C0011847;C0011849
82,diabetes ( n - nmbr,C0011847;C0011849
82,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
82,diabetes mellitus ( % ),C0011849
82,diabetes mellitus !,C0011849
82,no diabetes mellitus,C0011849
82,diabetes mellitus,C0011849
82,diabetes mellitus :,C0011849
82,hx of diabetes,C0011847;C0011849;C0262926;C3814444
82,new - onset diabetes §,C0011847;C0011849;C0746890
82,median ( qnmbr : qnmbr ) duration of diabetes,C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
82,diabetes absent nmbr ( nmbr . nmbr ),C0011847;C0011849
82,short ( < nmbr years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
82,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
82,diabetes — no . ( % ),C0011847;C0011849
82,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
82,duration of diabetes in years,C0011847;C0011849;C0449238;C2926735
82,all without diabetes ( n = nmbr ),C0011847;C0011849
82,all with diabetes ( n = nmbr ),C0011847;C0011849
82,duration of diabetes < nmbr yrs,C0011847;C0011849;C0449238;C2926735
82,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
81,total updrs score ( range,C0439175;C0439810;C3639721
81,first primary ( change in updrs score / wk,C0205225;C0205435;C0392747;C0439612;C0439631;C0443172;C1279901;C1705241;C3639721;C4319952
81,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
81,mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0439175;C0439810;C0443172;C0444504;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
81,total updrs score ( baseline ),C0439175;C0439810;C3639721
81,updrs,C3639721
81,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
81,updrs score,C3639721
81,second primary ( estimated change in total updrs score from baseline to wk nmbr ),C0205225;C0205436;C0392747;C0439175;C0439612;C0439631;C0439810;C0443172;C0457385;C0565930;C0750572;C1561503;C1705190;C1705241;C3639721;C4319952
81,third primary ( change in updrs score / wk,C0205225;C0205437;C0392747;C0439612;C0439631;C0443172;C1705241;C3639721;C4319952
80,waist circumference,C0455829
80,waist circumference .,C0455829
80,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
80,increased waist circumference,C0205217;C0442805;C0455829
80,waist circumference — cm,C0455829
80,mean ± sd waist circumference,C0444504;C0455829;C2347634;C2348143;C2699239
80,waist circumference — cmj,C0455829
80,waist circumference ( cm ),C0455829
79,both ptca and cabg,C2936173
79,percutaneous transluminal coronary angioplasty,C2936173
79,ptca or pci,C2936173
79,prior ptca or pci,C0332152;C2826257;C2936173
79,previous ptca,C0205156;C1552607;C2936173
79,prior ptca or cabg,C0332152;C2826257;C2936173
79,ptca,C2936173
79,ptca only,C0205171;C1720467;C2936173
79,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
78,copd — no . ( % ) medication use,C0024117;C1412502;C3714496
78,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
78,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
78,severity of copd — no . ( % ) f,C0024117;C0439793;C0522510;C1412502;C3714496
78,chronic obstructive lung disease,C0024117
78,copd disease severity,C0024117;C0521117;C1412502;C3714496
78,severity of copd *,C0024117;C0439793;C0522510;C1412502;C3714496
78,copd ( n = nmbr ),C0024117;C1412502;C3714496
78,mean ( sd ) duration of copd,C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
78,copd severitya,C0024117;C1412502;C3714496
78,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
78,copd ( % ),C0024117;C1412502;C3714496
78,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
78,duration of copd — days^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
78,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
78,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
78,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
78,mean copd duration,C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2926735;C3714496
78,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
78,copd,C0024117;C1412502;C3714496
78,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
78,copd severityy,C0024117;C1412502;C3714496
78,copd or asthma,C0024117;C1412502;C3714496
78,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1412502;C3714496
78,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
78,prior copd medicationa,C0024117;C0332152;C1412502;C2826257;C3714496
78,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
78,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
78,chronic obstructive pulmonary disease,C0024117
78,copd duration,C0024117;C0449238;C1412502;C2926735;C3714496
78,chronic obstructive pulmonary disease — no . ( % ),C0024117
77,cholesterol,C0008377
77,cholesterol ( % ),C0008377
77,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
77,cholesterol — mmol / liter,C0008377;C0439190;C0475211
77,kdl cholesterol ( mmol / ),C0008377;C0439190
77,cholesterol ( mmol / l ),C0008377;C1532563
77,aldl cholesterol,C0008377
77,csf cholesterol,C0008377;C3540512;C3889436
77,cholesterol — mg / dl,C0008377;C0439269
77,cholesterol ( mg / dl ),C0008377;C0439269
77,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
77,cholesterol - mean ( sd,C0008377;C0444504;C2347634;C2348143;C2699239
77,ldl - to - hdl cholesterol ratio,C0008377;C0428621;C1171408
77,cholesterol ( ng / ml ),C0008377;C0439275
77,cholesterol ( nmol / l ),C0008377;C0439282
76,responder analyses ( achieving alc < nmbr . nmbr % ),C0002778;C0936012;C1524024
76,included in analysis,C0002778;C0332257;C0936012;C1524024
76,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
76,nmbr days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
76,crude analysis,C0002778;C0936012;C1524024
76,stratified analyses,C0002778;C0205363;C0936012;C1524024
76,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0936012;C1524024
76,analysis,C0002778;C0936012;C1524024
76,pooled analysis of sustain nmbr — nmbr trials,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
76,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
76,final analysis ( all patients ),C0002778;C0205088;C0936012;C1524024;C1546485;C3853528
76,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
76,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
76,prespecified analysis,C0002778;C0936012;C1524024
76,integrated analysis set ( n = nmbr ),C0002778;C0936012;C1158478;C1524024;C1705422
75,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
75,peripheral arterial disease — no . ( % ),C0085096;C1704436
75,peripheral arterial disease,C0085096;C1704436
75,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
75,any peripheral arterial disease,C0085096;C1704436
75,peripheral arterial disease §,C0085096;C1704436
75,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
75,peripheral arterial disease ( n = nmbr nmbr ),C0085096;C1704436
74,aspirin - erdp ( n = nmbr,C0004057
74,aspirin < nmbr day,C0004057;C0332173;C0439228;C0439505
74,acetyl - salicylic acid,C0004057
74,combinations of aspirin and ppi use ( p = nmbr . nmbrt ),C0004057;C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036
74,acetylsalicylic acid,C0004057
74,prior aspirin,C0004057;C0332152;C2826257
74,no use of nmbr - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
74,aspirin 一 no . ( % ),C0004057
74,aspirin — no . ( % ),C0004057
74,aspirin alone ( n = nmbr ) nmbr . nmbr,C0004057;C0205171;C0439044;C0679994
74,without aspirin ( n = nmbr,C0004057
74,aspirin but no ppi,C0004057
74,no prior aspirin,C0004057;C0332152;C2826257
74,aspirin / antiplatelet,C0004057
74,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
74,no aspirin,C0004057
74,asa,C0004057;C3853627
74,aspirin only,C0004057;C0205171;C1720467
74,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
74,pfo + asa,C0004057;C3853627
74,aspirin / other antiplatelet agents,C0004057
74,aspirin and other antiplatelet,C0004057
74,asa or antiplatelet agent,C0004057;C3853627
74,aspirin and ppi,C0004057
74,aspirin or other antiplatelet or anticoagulant agent,C0004057
74,aspirin ( % ),C0004057
74,aspirin ( any dose ),C0004057
74,aspirin ( n,C0004057
74,no aspirin or ppi,C0004057
74,aspirin ( n = nmbr ) no . of participants with events ( % ),C0004057
74,aspirin alone ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0004057;C0205171;C0439044;C0679994
74,aspirin before admission,C0004057;C0184666;C0809949
74,medication use ( % ) aspirin,C0004057;C0240320
74,use of aspirin at time of qualifying event ( % ),C0004057;C1524063
74,long - term aspirin,C0004057;C0443252
74,aspirin group ( n = nmbr ),C0004057;C0441848
74,aspirin or other antiplatelet drug,C0004057
74,nmbr - asa compounds,C0004057;C0205198;C1706082;C3853627
74,aspirin alone,C0004057
74,aspirin < nmbr hours,C0004057;C0439227
74,aspirin ( n = nmbr ),C0004057
74,aspirin and thienopyridine therapy,C0004057
74,nmbr aspirin ( n = nmbr nmbr ),C0004057
74,aspirin or thienopyridines ( % ),C0004057
74,aspirin nmbr,C0004057
74,aspirin only ( n = nmbr,C0004057;C0205171;C1720467
74,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
74,with aspirin ( n = nmbr,C0004057
74,aspirin ( asa ) ( » = nmbr nmbr ),C0004057;C3853627
74,aspirin ( n = nmbr nmbr ),C0004057
74,aspirin ( n = nmbr,C0004057
74,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
74,high - dose aspirin,C0004057;C0444956
74,baseiine aspirin,C0004057
74,aspirin or other antiplatelet agent,C0004057
74,aspirin,C0004057
74,asas nmbr / nmbr,C0004057;C3853627
74,no asa,C0004057;C3853627
74,aspirin or other antiplatelet agents,C0004057
74,aspirin alone ( n = nmbr ),C0004057;C0205171;C0439044;C0679994
74,aspirin alone group no of events / total n ( % ),C0004057;C2826346
74,asas partial remission,C0004057;C1521726;C3853627;C4552913;C4552914
74,asasnmbr,C0004057;C3853627
73,acetaminophen,C0000970;C2917659
73,paracetamol,C0000970
72,mean ( sd ) postbronchodilator fevnmbr % predicted,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
72,post - bronchodilator fevnmbr ( % predicted * ),C2599594;C3714541
72,pre - bronchodilation fevnmbr,C0439566;C3714541
72,absolute decline in fvc > nmbr % predicted,C0205344;C3714541
72,fevnmbr % predicted,C3714541
72,% predicted fevnmbr,C0681842;C1882327;C3714541
72,post - bronchodilation fevnmbr,C0439576;C3714541
72,post - bronchodilator fev,C2599594;C3714541
72,mean ( sd ) postbronchodilator fevnmbr reversibility,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
72,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
72,% predicted fev^,C0681842;C1882327;C3714541
72,% predicted fev,C0681842;C1882327;C3714541
72,pre fevnmbr   % pred,C0332152;C0740175;C2257086;C3669034;C3714541
72,change in fevnmbr at week nmbr,C0392747;C0443172;C1705241;C3714541;C4319952
72,mean ( sd ) postbronchodilator fevnmbr / fvc,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
72,pre fevnmbr,C0332152;C0740175;C2257086;C3669034;C3714541
72,predose fevnmbr ( l ) *,C0439565;C3714541;C3812758
72,post - bronchodilator fevnmbr — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
72,fevnmbr / fvc %,C3714541
72,% reversibility in fev^ at,C0449261;C3714541
72,pre - bronchodilator fevnmbr,C2599602;C3714541
72,post - bronchodilator ratio of fevnmbr to fvc — %,C0456603;C1547037;C2599594;C3714541
72,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
72,post - bronchodilator fevnmbr ( l ),C2599594;C3714541
72,prebronchodilator fevnmbr,C2599602;C3714541
72,fevnmbr post - bronchodilator,C3714541
72,nmbr ( fevnmbr < nmbr % pred ),C3714541
72,absolute reversibility in fevnmbr,C0205344;C0449261;C3714541
72,prebronchodilator fevnmbr ( l ),C2599602;C3714541
72,% predicted prebronchodilator fevnmbr,C0681842;C1882327;C2599602;C3714541
72,fvc post - bronchodilator,C3714541
72,fvc pre - bronchodilator,C2599602;C3714541
72,post - bronchodilator fevnmbr ( l ) *,C2599594;C3714541
72,post - bronchodilator fvc ( l ) a,C2599594;C3714541
72,post - bronchodilator fevnmbr ( l ) a,C2599594;C3714541
72,prebronchodilator fevnmbr ( l ) t,C2599602;C3714541
72,postbronchodilator fevnmbr,C2599594;C3714541
72,pre - bronchodilator fevnmbr ( l ),C2599602;C3714541
72,ratio of fevnmbrto fvc ( % ),C0456603;C1547037;C3714541
72,fevnmbr / fvc ( post - albuterol ),C3714541
72,pre - bronchodilator fevnmbr ( % predicted normal ),C2599602;C3714541
72,mean ( sd ) fevnmbr,C0444504;C2347634;C2348143;C2699239;C3714541
72,absolute decline in fvc > nmbr % predicted or death,C0205344;C3714541
72,fevnmbr / fvc ratio *,C0456603;C1547037;C3714541
72,mean prebronchodilator fevnmbr ( sd ),C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
72,predose fev -,C0439565;C3714541;C3812758
72,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
72,predose fev / fvc,C0439565;C3714541;C3812758
72,iii : fevnmbr > nmbr % - < nmbr % predicted,C0439070;C1705160;C3714541
72,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
72,mean change in fevnmbr,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
72,fvc < nmbr % predicted,C3714541
72,fvc > nmbr % predicted,C3714541
72,fevnmbr : fvc ratio ,C0456603;C1547037;C3714541
72,pre - bronchodilator fevnmbr / fvc ( % ),C2599602;C3714541
72,pre - bronchodilator fvc ’ % pred,C2599602;C3714541
72,fevnmbr : fvc ratio,C0456603;C1547037;C3714541
72,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
72,postbronchodilator fevnmbr / fvc,C2599594;C3714541
72,fevnmbr reversibility,C0449261;C3714541
72,fvc ∗,C3714541
72,pre - bronchodilator mean ( sd ) fevnmbr,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
72,fevnmbr ( % predicted ),C3714541
72,% predicted ” fev,C0681842;C1882327;C3714541
72,fvc % predicted !,C3714541
72,pre - bronchodilator fev^ ( l ),C2599602;C3714541
72,mean ( sd ) fevnmbr / fvc,C0444504;C2347634;C2348143;C2699239;C3714541
72,mean ( sd ) change from pre - to post - bronchodilator fevnmbr,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
72,severe ( fev,C0205082;C3714541;C4050465;C4050466
72,post - bronchodilator fevnmbr / fvc,C2599594;C3714541
72,mean ( sd ) fevnmbr postbronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
72,mean ( sd ) fev nmbr / fvc,C0444504;C2347634;C2348143;C2699239;C3714541
72,post - bronchodilator fevnmbr / fvc ( % ) a,C2599594;C3714541
72,mean ( sd ) fev nmbr,C0444504;C2347634;C2348143;C2699239;C3714541
72,mean ( sd ) post - bronchodilator fevnmbr reversibility,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
72,mean fevnmbr,C0444504;C2347634;C2348143;C3714541
72,pre fvc % pred,C0332152;C0740175;C2257086;C3669034;C3714541
72,prebronchodilator fevnmbr ( %,C2599602;C3714541
72,fevnmbr ( l ),C3714541
72,mean ( sd ) % reversibility fevnmbr at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
72,predose fvc ( l ) *,C0439565;C3714541;C3812758
72,predose fvc ( l ),C0439565;C3714541;C3812758
72,pre - bronchodilator fev,C2599602;C3714541
72,mean postbronchodilatora fevnmbr,C0444504;C2347634;C2348143;C3714541
72,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
72,fevnmbr / fvc prebronchodilatort,C3714541
72,fevnmbr — liters,C0475211;C3714541
72,fevnmbr ( liters ),C0475211;C3714541
72,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
72,mean ( sd ) post - bronchodilator fevnmbr percentage predicted,C0439165;C0444504;C1549488;C1561533;C2347634;C2348143;C2599594;C2699239;C3714541
72,fvc ( l ),C3714541
72,reversibility of fevnmbr ( % ),C0449261;C3714541
72,fevnmbr,C3714541
72,fev_ ( l ) :,C3714541
72,fvc,C3714541
72,fvc ( l ) ,C3714541
72,fvc ( l ) *,C3714541
72,fvc ( l ) proportion taking pulmonary medications ( % ) b,C1709707;C3714541
72,post - bronchodilator fevnmbr  % predicted,C2599594;C3714541
72,post - bronchodilator fevnmbr / fvc ratio,C0456603;C1547037;C2599594;C3714541
72,post - bronchodilator fevnmbr reversibility,C0449261;C2599594;C3714541
72,postbronchodilator fevnmbr reversibility,C0449261;C2599594;C3714541
72,fvc — liters,C0475211;C3714541
72,fvc ( liters ),C0475211;C3714541
72,post - bronchodilator fevnmbr % predictedb,C2599594;C3714541
72,prebronchodilator fevnmbr / fvc,C2599602;C3714541
72,post - bronchodilator fevnmbr ml,C0439526;C1705224;C2599594;C3714541;C3887665
72,fevnmbr ( % predicted normal ),C3714541
72,fvc ( % predicted ),C3714541
72,fevnmbr at week nmbr,C0332174;C0439230;C3714541
72,fevnmbr % reversibility,C0449261;C3714541
72,post fevnmbr   % pred,C0687676;C1704687;C3469826;C3714541
72,post - bronchodilator fevnmbr ( % predicted normal ) a,C2599594;C3714541
72,percentage of predicted pre - bronchodilator fev^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
72,post fevnmbr,C0687676;C1704687;C3469826;C3714541
72,trough fevnmbr   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
72,fevnmbr % predicted at baseline,C3714541
72,fevnmbr / fvc,C3714541
72,fevnmbr % predicted normal,C3714541
72,fevnmbr percent predicted ( sd ),C0439165;C3714541
72,post - bronchodilator fevnmbr — liters,C0475211;C2599594;C3714541
72,moderate ( nmbr % < fev,C0205081;C1881878;C3714541;C4049705;C4049706;C4085643;C4321335
72,fevnmbr % predicted ( post salbutamol ),C3714541
72,fevnmbr ( l ) pre - bronchodilator,C2599602;C3714541
72,fevnmbr / fvc ratio,C0456603;C1547037;C3714541
72,fev,C3714541
72,absolute fvc decrease > nmbr %,C0205344;C0392756;C0547047;C3714541
72,post fvc % pred,C0687676;C1704687;C3469826;C3714541
72,cnmbr ml decrease in trough fevnmbr,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
72,fevnmbr pre - bronchodilator,C2599602;C3714541
72,pre - bronchodilator fvc ( l ),C2599602;C3714541
72,fevnmbr — % of predicted value,C0681842;C1522609;C1882327;C3714541
72,fevnmbr ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
72,mean ( sd ) post - bronchodilator fevnmbr / fvc,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
72,fevnmbr % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
72,fevnmbr % predicted < nmbr %,C3714541
72,mean ( sd ) fevnmbr ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
72,mean ( sd ) fevnmbr ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
72,fevnmbr % predicted ≥ nmbr %,C3714541
72,ratio of fevnmbr to fvc,C0456603;C1547037;C3714541
72,fevnmbr % pred,C3714541
72,fevnmbr % reversibility ( sd ),C0449261;C2699239;C3714541
72,mean - sd change in pre - bronchodilator fevnmbr,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
72,trough fevnmbr,C0444506;C3714541
72,fevnmbr / fvc prebronchodilator,C2599602;C3714541
72,post - bronchodilator percent of predicted fevnmbr,C1882327;C2599594;C3714541
72,post fvc,C0687676;C1704687;C3469826;C3714541
72,fevnmbr ( post - albuterol ),C3714541
72,% predicted pre - bronchodilator fevnmbr,C0681842;C1882327;C2599602;C3714541
72,fevnmbr pre - bronchodilator ( % predicted normal ),C2599602;C3714541
72,trough fev,C0444506;C3714541
72,mild ( fev,C2945599;C3714541
72,percent of predicted fevnmbr,C1882327;C3714541
72,prebronchodilator fevnmbr ( % predicted normal ) t,C2599602;C3714541
72,post - bronchodilator fevnmbr,C2599594;C3714541
72,fevnmbr pre - bronchodilator ( l ),C2599602;C3714541
72,pre - bronchodilator fevnmbr / fvc ratio *,C0456603;C1547037;C2599602;C3714541
72,fevnmbr prebronchodilator [l],C2599602;C3714541
72,post - bronchodilation fvc,C0439576;C3714541
72,pre - bronchodilation fvc,C0439566;C3714541
71,sacubitril / valsartan,C4033631
71,sacubitril / valsartan ( n = nmbr ),C4033631
70,screening % reversibility fevnmbr,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
70,pre - bronchodilator screening fevnmbr ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
70,fevnmbr   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
70,screening fevnmbr   % predicted,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
70,post - bronchodilator fevnmbr at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
70,post - bronchodilator screening fevnmbr ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
70,screening prebronchodilator fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
70,predose fev^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
70,screening % predicted fevnmbr,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
70,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
69,stroke ( vs tia ),C0038454;C4554100
69,stroke — no . / total no . ( % ),C0038454;C4554100
69,previous stroke or tia,C0038454;C0205156;C1552607;C4554100
69,no stroke n = nmbr nmbr,C0038454;C4554100
69,stroke n = nmbr,C0038454;C4554100
69,hemispheric stroke n = nmbr,C0038454;C0205139;C4554100
69,previous stroke or tia ( % ),C0038454;C0205156;C1552607;C4554100
69,stroke at entry,C0038454;C1705654;C4554100
69,stroke / transient ischemic attack,C0038454;C4554100
69,any stroke,C0038454;C4554100
69,nonfatal stroke ®,C0038454;C4554100
69,stroke or systemic embolism,C0038454;C4554100
69,prior stroke,C0038454;C0332152;C2826257;C4554100
69,no prior stroke,C0038454;C0332152;C2826257;C4554100
69,stroke any,C0038454;C4554100
69,nonfatal stroke,C0038454;C4554100
69,stroke or systemic,C0038454;C4554100
69,stroke n ( % ),C0038454;C4554100
69,stroke thought due to atherothrombotic disease,C0038454;C4554100
69,stroke or see,C0038454;C4554100
69,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
69,time from onset of qualifying stroke to randomization,C0038454;C0449244;C1514624;C4554100
69,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
69,previous stroke ortia nmbr - nmbr,C0038454;C0205156;C1552607;C4554100
69,qualifying stroke,C0038454;C1514624;C4554100
69,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
69,stroke — no . ( % ),C0038454;C4554100
69,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
69,stroke or se ( s / se ),C0038454;C4554100
69,stroke subtype,C0038454;C0449560;C4554100
69,previous stroke or transient ischemic attack,C0038454;C0205156;C1552607;C4554100
69,fatal stroke,C0038454;C1302234;C1705232;C4554100
69,previous stroke or transient ischemic attack — no . / total,C0038454;C0205156;C1552607;C4554100
69,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
69,any stroke ( n = nmbr ),C0038454;C4554100
69,stroke or tia,C0038454;C4554100
69,prior stroke / mi,C0038454;C0332152;C2826257;C3810814;C4554100
69,stroke and tia,C0038454;C4554100
69,previous stroke,C0038454;C0205156;C1552607;C4554100
69,previous stroke *,C0038454;C0205156;C1552607;C4554100
69,no prior stroke ( n = nmbr ),C0038454;C0332152;C2826257;C4554100
69,stroke ( fatal / nonfatal ),C0038454;C4554100
69,atherothrombotic stroke,C0038454;C4554100
69,prior stroke or tza,C0038454;C0332152;C2826257;C4554100
69,no stroke ( n = nmbr ),C0038454;C4554100
69,prior stroke ( n = nmbr ),C0038454;C0332152;C2826257;C4554100
69,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
69,a stroke,C0038454;C4554100
69,cerebrovascular accident,C0038454
69,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
69,stroke at entry ( vs transient ischemic attack ),C0038454;C1705654;C4554100
69,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
69,stroke,C0038454;C4554100
69,stroke or tia — no . ( % ),C0038454;C4554100
69,stroke / see,C0038454;C4554100
69,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
69,sensorimotor stroke,C0038454;C4554100
69,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
69,stroke / non -,C0038454;C4554100
69,previous clinical stroke or tia,C0038454;C0205156;C0205210;C1552607;C4554100
69,previous clinical stroke or transient ischemic attack ( % ),C0038454;C0205156;C0205210;C1552607;C4554100
69,stroke / m nmbr,C0038454;C0369637;C0441923;C4554100
69,stroke ortia,C0038454;C4554100
69,disabling stroke,C0038454;C4554100
69,stroke or pvd,C0038454;C4554100
69,new stroke *,C0038454;C0205314;C4554100
69,stroke or transient ischemic attack,C0038454;C4554100
69,no previous stroke or tia ( n = nmbr ),C0038454;C0205156;C1552607;C4554100
69,stroke ortiab,C0038454;C4554100
69,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
69,nonfatal stroke ( n = nmbr ),C0038454;C4554100
69,no . of strokes ( % ),C0038454
69,previous stroke or tl a,C0038454;C0205156;C1552607;C4554100
69,prior stroke or tia,C0038454;C0332152;C2826257;C4554100
69,• any stroke,C0038454;C4554100
69,with prior mi / stroke ( n = nmbr ),C0038454;C0332152;C2826257;C3810814;C4554100
69,all stroke,C0038454;C4554100
69,stroke or,C0038454;C4554100
69,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
69,no . of strokes / no . of patients in category ( and % ),C0038454
69,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
69,previous stroke or tia ( n = nmbr ),C0038454;C0205156;C1552607;C4554100
69,previous stroke or tl a nmbr - nmbr,C0038454;C0205156;C1552607;C4554100
69,stroke non - fatal,C0038454;C4554100
69,stroke or cerebrovascular disease,C0038454;C4554100
69,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
69,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
68,previous cardiovascular disease !,C0007222;C0205156;C1552607
68,established cvd ( age > nmbr ),C0001779;C0007222;C0443211;C1272684
68,no cvd,C0007222
68,cardiovascular disease n ( % ),C0007222
68,medical history of cv disease or heart failure,C0007222;C0262926
68,atherosclerotic cvd,C0007222;C0333482
68,atherosclerotic cvd §,C0007222;C0333482
68,chronic cvd,C0007222;C0205191
68,cardiovascular disease *,C0007222
68,prior cvd,C0007222;C0332152;C2826257
68,cvd events,C0007222;C0441471;C3541888
68,cardiovascular disease,C0007222
68,cardiovascular disorder,C0007222
68,cvd or mi,C0007222
68,cvd / mi / stroke / urgent vascular hospitalization,C0007222;C3810814
68,high - risk cvd,C0007222;C0332167;C3272283;C4050568;C4319571
68,established cardiovascular disease,C0007222;C0443211;C1272684
68,combined nmbr - year cvd,C0007222;C0205195;C0439234;C0439508
68,no cardiovascular disease ( n = nmbr ),C0007222
68,cvd,C0007222
68,previous cvd^,C0007222;C0205156;C1552607
68,other atherosclerotic cvd,C0007222;C0333482
68,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
68,prior cardiovascular disease,C0007222;C0332152;C2826257
68,combined cvd,C0007222;C0205195
68,cardiovascular disease ( n = nmbr ),C0007222
68,nmbr - nmbr with cv disease ( n = nmbr ),C0007222
68,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
68,cvd without miatroke,C0007222
68,cvd without ml^troke,C0007222;C0439526;C1705224;C3887665
68,any cardiovascular disease,C0007222
68,no prior cvd,C0007222;C0332152;C2826257
68,cvd / mi / stroke / urgent coronary revascularization,C0007222;C3810814
68,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
68,cvd without mi or stroke ( n = nmbr ),C0007222;C3810814
68,other atherosclerotic cvd * *,C0007222;C0333482
68,no cardiovascular disordernmbr ',C0007222
68,cv disease,C0007222
68,cvd subjects,C0007222
67,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
67,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
67,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
67,blood pressure eontrolt,C0005823;C1271104;C1272641
67,blood pressure while seated — mm hg,C0005823;C1271104;C1272641
67,blood pressure in mm hg,C0005823;C0439475;C1271104;C1272641
67,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
67,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
67,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
67,bloodpressure,C0005823;C1271104;C1272641
67,blood pressure < nmbr / nmbr mmhg,C0005823;C0439475;C1271104;C1272641
67,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
67,blood pressure > nmbr mm hg,C0005823;C0439475;C1271104;C1272641
67,blood pressure systolic,C0005823;C1271104;C1272641
67,blood pressure ( % ),C0005823;C1271104;C1272641
67,blood pressure ( mm hg ) systolic,C0005823;C0439475;C1271104;C1272641
67,blood pressure < nmbr mm hg,C0005823;C0439475;C1271104;C1272641
67,blood pressure,C0005823;C1271104;C1272641
67,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
66,"b . benralizumab nmbr mg qnmbrw """,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
66,benralizumab nmbr mg qnmbrw,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
66,benralizumab nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
65,ccbs,C0006684
65,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
65,calcium antagonist,C0006684
65,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
65,ccb,C0006684
65,calcium antagonist strategy ( n = nmbr nmbr ),C0006684;C0679199
65,calcium antagonists,C0006684
65,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
65,calcium channel blocker ( % ),C0006684;C3536851;C4521885
65,baseiine ccb,C0006684
65,calcium - channel blockers,C0006684;C2757014
65,calcium - channel antagonists,C0006684;C2757014
65,calcium antagonist — no . ( % ),C0006684
65,calcium channel antagonists,C0006684;C2757014
65,calcium channel blocker,C0006684;C3536851;C4521885
65,non - calcium antagonist strategy ( n = nmbr nmbr ),C0006684;C0679199;C1518422
65,calcium - channel blocker,C0006684;C3536851;C4521885
65,calcium channel blockers,C0006684;C2757014
65,arb - arb / ccb,C0006684;C3888198
65,arb + ccb ( n = nmbr ),C0006684;C3888198
65,caleium ehannel bloekers ( ccb ),C0006684
65,calcium - channel blockers ( % ),C0006684;C2757014
65,calcium - channel blocker *,C0006684;C3536851;C4521885
64,valsartan / hctz,C0020261;C0216784
64,valsartan / hctz ( n = nmbr ),C0020261;C0216784
63,nmbr . nmbr - nmbr . nmbr % f,C0016327
63,nmbr fnmbrq % ),C0016327
63,p value f,C0016327;C1709380
63,nmbr . nmbrfnmbr . nmbr,C0016327
63,f * >,C0016327
63,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
63,f emale,C0016327
63,f - plasma glucose,C0016327;C0202042;C0455280
63,? f ? n,C0016327
63,p int . f,C0016327;C0369773;C2603361;C3272375
63,f,C0016327
63,fnmbr vs placebo,C0016327
63,nmbr fnmbrl % nmbr,C0016327
63,ancestry ( % ) f,C0016327
63,all ( n = nmbrf ),C0016327;C0369718;C0441922
63,glycemic status f,C0016327;C1320980
63,nmbrs fnmbr ),C0016327;C0565930;C2603362
62,clopidogrel n / n ( % ),C0070166
62,clopidogrel n / n { % ),C0070166
62,hours from clopidogrel loading,C0070166;C0439227;C1708715
62,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
62,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
62,clopidogrel no . of patients % ),C0070166
62,clopidogrel ( n = nmbr ),C0070166
62,clopidogrel or ticlopidine,C0070166
62,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
62,clopidogrel ( n = nmbr ) n / n ( % ),C0070166
62,clopidogrel ( n = nmbr nmbr ),C0070166
62,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
62,clopidogrel ( n = nmbr,C0070166
62,clopidogrel given before procedure,C0070166
62,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
62,loading dose of clopidogrel or ticlopidine,C0070166;C3714444
62,early clopidogrel intended,C0070166;C1279919
62,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
62,use of clopidogrel,C0070166;C1524063
62,clopidogrel %,C0070166
62,clopidogrel / total no . of patients % %,C0070166;C0439175;C0439810
62,interval from clopidogrel loading,C0070166;C1272706;C1552654;C1552713;C1708715
62,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
62,clopidogrel,C0070166
61,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
61,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
61,mri substudy ( n = nmbr ),C0024485;C1824234;C3890166
60,mean ( sd ) dasnmbr - nmbr ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
60,change in dasnmbr > nmbr . nmbr,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
60,dasnmbr - esr lda,C0051767;C0057671;C3811131;C4553195
60,dasnmbr,C0051767;C0057671
60,dasnmbr - esr,C0051767;C0057671;C3811131
60,dasnmbr - crp,C0051767;C0057671;C3890735;C4048285
60,c . dasnmbr - crp < nmbr . nmbr,C0051767;C0057671;C3890735;C4048285
60,das - nmbr ( crp ) < nmbr . nmbr,C0051767;C0057671;C3890735;C4048285
60,dasnmbr ( crp ),C0051767;C0057671;C3890735;C4048285
60,dasnmbr ‐ crp,C0051767;C0057671;C3890735;C4048285
60,dasnmbr - crp §,C0051767;C0057671;C3890735;C4048285
60,dasnmbr - hscrp,C0051767;C0057671
60,dasnmbr - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
60,das - nmbr ( crp ),C0051767;C0057671;C3890735;C4048285
60,dasnmbr - nmbr ( esr ) nmbr,C0051767;C0057671;C3811131
60,dasnmbr ( esr ),C0051767;C0057671;C3811131
60,dasnmbr - nmbr ( esr ),C0051767;C0057671;C3811131
60,dasnmbr - nmbr ( esr ) < nmbr . nmbrt,C0051767;C0057671;C3811131
60,mean score on dasnmbr - nmbr ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
60,dasnmbr score,C0051767;C0057671
60,dasnmbr - nmbr ( esr ) < nmbr . nmbr *,C0051767;C0057671;C3811131
59,prior cerebrovascular disease,C0007820;C0332152;C2826257
59,cerebrovascular disease n ( % ),C0007820
59,cerebrovascular disease,C0007820
59,only cerebrovascular disease,C0007820;C0205171;C1720467
59,without cerebrovascular disease,C0007820
59,cerebrovascular disorders,C0007820
59,ischemic cerebrovascular disease,C0007820;C0475224
59,cerebral vascular disease,C0007820
59,with cerebrovascular disease,C0007820
58,etoricoxib ( n = nmbr ),C0972314
58,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
58,etoricoxib group ( n = nmbr nmbr ),C0441848;C0972314
58,etoricoxib,C0972314
58,etoricoxib ( n = nmbr nmbr ),C0972314
58,etoricoxib ( n = nmbr,C0972314
57,ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021
57,ace inhibitors or angiotensin receptor blockers,C0003015
57,ace inhibitors / arbs,C0003015;C3888198
57,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
57,ace inhibitors,C0003015
57,ace inhibitor,C0003015;C4541021
57,ace - inhibitor or arb ( % ),C0003015;C4541021
57,ace inhibitor / arb,C0003015;C3888198;C4541021
57,ace inhibitor and / or arb,C0003015;C4541021
57,ace inhibitor or arb use,C0003015;C4541021
57,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C4541021
57,no ace inhibitor / arb,C0003015;C3888198;C4541021
57,ace inhibitors or angiotensin - receptor blockers,C0003015
57,dipeptidyl peptidase nmbr inhibitors,C0003015
57,dipeptidyl peptidase nmbr inhibitor,C0003015;C2757044;C3536837
57,ace inhibitors / arb,C0003015
57,ace inhibitors or angiotensin ii blockers,C0003015
57,ace inhibitor or arb at last follow - up,C0003015;C4541021
57,ace inhibitor or arb,C0003015;C4541021
57,ace inhibitor monotherapy,C0003015;C4541021
57,ace inhibitors and arb,C0003015
57,ace inhibitors or arb,C0003015
57,both ace inhibitor and arb,C0003015;C4541021
57,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
57,use of ace inhibitor,C0003015;C1524063;C4541021
57,ace inhibitors or arbs,C0003015
57,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
57,ace - inhibitors,C0003015
57,use of ace inhibitors / arbs,C0003015;C1524063;C3888198
57,neither ace inhibitor nor arb,C0003015;C4541021
57,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C2757044;C3536837;C4541021
57,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
57,angiotensin - converting enzyme inhibitors,C0003015;C2757044
57,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
57,angiotensin - converting enzyme inhibitors^,C0003015;C2757044
57,ace inhibitor — no . ( % ),C0003015;C4541021
57,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
57,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
57,ace inhibitor or angiotensin ii receptor,C0003015;C4541021
57,ace inhibitors through hospital discharge or day nmbr — %,C0003015;C0586003
57,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C2757044;C3536837;C4541021
57,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
57,ace inhibitors or angiotensin - receptor blockers^,C0003015
57,ace - inhibitors / arbs,C0003015;C3888198
57,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
57,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
57,ace inhibitor or arb at enrollment,C0003015;C4541021
57,ace inhibitors or angiotensin ii,C0003015
57,peri - op ace - inhibitors / arbs : no ( n = nmbr ),C0003015;C0347985;C3888198
57,dipeptidyl peptidase - nmbr inhibitor,C0003015;C2757044;C3536837
57,ace inhibitor or angiotensin receptor blocker,C0003015;C4541021
56,cardiovascular medications,C0007220
56,cardiovascular medication usage,C0007220;C0457083
55,placebo analysed ( % ),C0032042;C1696465;C1706408
55,placebo nmbr . nmbr,C0032042;C1696465;C1706408
55,placebo nmbr year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
55,placebo ( lsm ),C0032042;C1696465;C1706408
55,snmbr vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
55,placebo n = nmbr n ( % ),C0032042;C1696465;C1706408
55,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
55,placebo estimated mean,C0032042;C1696465;C1706408
55,placebo - adjusted mean difference in % hbanmbrc ( nmbr % ci  [ p value] ),C0032042;C1696465;C1706408
55,placebo ( n = nmbro ),C0032042;C1696465;C1706408
55,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
55,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
55,canvas ( n = nmbr ) : placebo ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
55,placebo %,C0032042;C1696465;C1706408
55,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
55,snmbr - nmbr vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
55,placebo ( n = nmbr ) i -,C0032042;C1696465;C1706408
55,nmbr placebo n = nmbr,C0032042;C1696465;C1706408
55,nmbr placebo ( n = nmbr nmbr ),C0032042;C1696465;C1706408
55,placebo monthly ( n = nmbr ),C0032042;C0332177;C1696465;C1706408
55,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
55,placebo ( n - nmbr ),C0032042;C1696465;C1706408
55,placebo no . / total no .,C0032042;C1696465;C1706408
55,placebo nmbr / nmbr,C0032042;C1696465;C1706408
55,placebo n,C0032042;C1696465;C1706408
55,placebo ( n = nmbr ) †,C0032042;C1696465;C1706408
55,placebo n ( rate ) nmbr,C0032042;C0871208;C1521828;C1696465;C1706408
55,placebo n / n,C0032042;C1696465;C1706408
55,placebo ( n = nmbrl ),C0032042;C1696465;C1706408
55,placebo no diabetes n = nmbr,C0032042;C1696465;C1706408
55,placebo no . ( nmbr - y km % ),C0032042;C1696465;C1706408
55,nmbr mg / day - placebo,C0032042;C0439422;C1696465;C1706408
55,placebo [n = nmbr],C0032042;C1696465;C1706408
55,with placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408
55,placebo ( n nmbr ),C0032042;C1696465;C1706408
55,placebo §,C0032042;C1696465;C1706408
55,placebo / simva,C0032042;C1696465;C1706408
55,placebo allocation,C0032042;C1696465;C1706408;C1706778
55,placebo group ( n = nmbr ),C0032042;C0441848;C1696465;C1706408
55,difference from placebo ( nmbr % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
55,placebo n = nmbr subjects,C0032042;C1696465;C1706408
55,placebo ( n = nmbr * ),C0032042;C1696465;C1706408
55,placebo ( n[nmbr ),C0032042;C1696465;C1706408
55,placebo no . / total ( % ),C0032042;C1696465;C1706408
55,nmbr placebo,C0032042;C1696465;C1706408
55,placebo nmbr,C0032042;C1696465;C1706408
55,placebo ( % ),C0032042;C1696465;C1706408
55,placebo dn = nmbr ),C0032042;C1333964;C1696465;C1706408;C1707618
55,- nmbr placebo,C0032042;C1696465;C1706408
55,placebo group ( n = nmbr ) ’ j ',C0032042;C0441844;C1696465;C1706408
55,placebo km %,C0032042;C1696465;C1706408;C3887676
55,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
55,placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408
55,placebo [n z nmbr],C0032042;C1696465;C1706408
55,any placebo,C0032042;C1696465;C1706408
55,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
55,placebo nmbr yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
55,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
55,placebo,C0032042;C1696465;C1706408
55,placebo /,C0032042;C1696465;C1706408
55,placebo ( n   =   nmbr ),C0032042;C1696465;C1706408
55,placebo no . of events / no .,C0032042;C1696465;C1706408
55,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
55,comparison with placebo,C0032042;C1696465;C1706408;C1707455
55,placebo event rate ( n = nmbr ),C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
55,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
55,with placebo,C0032042;C1696465;C1706408
55,placebo ( » = nmbr ),C0032042;C1696465;C1706408
55,placebo ( n   =   nmbr,C0032042;C1696465;C1706408
55,placebo ( n   =   nmbr ),C0032042;C1696465;C1706408
55,placebo ( nmbr = nmbr ),C0032042;C1696465;C1706408
55,placebo ( nmbr,C0032042;C1696465;C1706408
55,placebo ( n   =   nmbr ) a,C0032042;C1696465;C1706408
55,placebo n / n ( % ),C0032042;C1696465;C1706408
55,placebo ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0032042;C1696465;C1706408
55,placebo n[nmbr,C0032042;C1696465;C1706408
55,placebo n ( % ),C0032042;C1696465;C1706408
55,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
55,placebo ( n   = nmbr ),C0032042;C1696465;C1706408
55,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
55,placebo ( n = nmbr nmbr ),C0032042;C1696465;C1706408
55,placebo |,C0032042;C1696465;C1706408
55,placebo ( n = nmbr ) n ( % ),C0032042;C1696465;C1706408
55,placebo ( n = nmbr ) ',C0032042;C1696465;C1706408
55,placebo nmbronmbr,C0032042;C1696465;C1706408
55,placebo ( n = nmbrinmbr ),C0032042;C1696465;C1706408
55,placebo ( n nmbr nmbr,C0032042;C1696465;C1706408
55,placebo ( n   = nmbr,C0032042;C1696465;C1706408
55,placebo [n = nmbr |,C0032042;C1696465;C1706408
55,"placebo "" ( n = nmbr )",C0032042;C1696465;C1706408
55,placebo ( n = nmbr,C0032042;C1696465;C1706408
55,placebo ( n = nmbr ),C0032042;C1696465;C1706408
55,placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408
55,placebo n = nmbr,C0032042;C1696465;C1706408
55,placebo ( « = nmbr ),C0032042;C1696465;C1706408
55,placebo ( n - nmbr . nmbr ),C0032042;C1696465;C1706408
55,placebo ( n   =   nmbr ) b,C0032042;C1696465;C1706408
55,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
55,placebo ( symptom days a week ),C0032042;C0439228;C1457887;C1696465;C1706408;C3854129
55,placebo ( n = lnmbr ),C0032042;C1696465;C1706408
55,placebo ( n : nmbr ),C0032042;C1696465;C1706408
55,placebo ( n — nmbr ),C0032042;C1696465;C1706408
55,placebo ( w = nmbr ),C0032042;C1696465;C1706408
55,placebo ( n [ nmbr ),C0032042;C1696465;C1706408
55,feno placebo ( lsm ),C0032042;C1696465;C1706408
55,placebo ( n z nmbr ),C0032042;C1696465;C1706408
55,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
54,triglycerides nmbrnd third,C0041004;C0205437
54,triglyceride,C0041004
54,triglyceride ( mmol / l ) t,C0041004;C1532563
54,triglycerides *,C0041004
54,triglycerides,C0041004
54,triacylglycerol,C0041004
54,mean ± sd triglycerides,C0041004;C0444504;C2347634;C2348143;C2699239
54,triglycerides — mmol / liter,C0041004;C0439190;C0475211
54,triglycerides > nmbr mg / dl ( > nmbr . nmbr mmol / l ),C0041004;C0439269;C1532563
54,- triglycerides,C0041004
54,triglycerides ( week nmbr ) a,C0041004;C0332174;C0439230
54,triglycerides < nmbr - nmbr mmol / l,C0041004;C1532563
54,triglyceride a,C0041004
54,triglycerides ( mmol / l ) :,C0041004;C1532563
54,triglycerides ( mg / dl ) * *,C0041004;C0439269
54,triglycerides - mg / dl * *,C0041004;C0439269
54,triglycerides > nmbr - nmbr mmol / l,C0041004;C1532563
54,triglycerides nmbr,C0041004
54,triglyceride ( mm,C0041004;C4330985;C4554674
54,triglycerides ( mmol / l ),C0041004;C1532563
54,nmbr . nmbr mg / dl triglycerides^,C0041004;C0439269
54,triglyceride ( mmol / l ),C0041004;C1532563
54,triglycerides * ( mg / dl ),C0041004;C0439269
54,triglycerides mean,C0041004;C0444504;C2347634;C2348143
54,triglycerides — mmol / l,C0041004;C1532563
54,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
54,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
54,triglycerides — mg / dl,C0041004;C0439269
54,triglyceride ( mg / dl ),C0041004;C0439269
54,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
54,triglycerides — mg / dl | |,C0041004;C0439269
54,triglycerides — mg / dl^,C0041004;C0439269
54,triglyceride ( mg / dl ) nmbr,C0041004;C0439269
54,triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l ),C0041004;C0439269;C1532563
54,triglycerides * *,C0041004
54,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
54,± standard deviation . triglyceride,C0041004;C0871420
54,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
54,triglycerides ( mmol / l ) ( median,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
54,triglycerides ( sd ),C0041004;C2699239
54,triglyceride ( median  mg / dl ) - nmbr [nmbr - nmbr percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
54,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
54,triglycerides ( median,C0041004
54,triglycerides ( mg / dl ),C0041004;C0439269
54,triglycerides > nmbr mg / dl,C0041004;C0439269
53,cdr - sob,C0013404;C4521843
53,dyspnea t,C0013404;C1963100
53,dyspnoea - mmrc grade,C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
53,without dyspnoea,C0013404;C1963100
53,no dyspnoea ( n = nmbr ),C0013404;C1963100
53,dyspnea,C0013404;C1963100
53,borg dyspnea score who functional class,C0013404;C0449820;C1963100;C4050231
53,dyspnea – mmrc grade,C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
53,with dyspnoea,C0013404;C1963100
53,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
53,dyspnoea ( n = nmbr ),C0013404;C1963100
52,all with coenzyme qnmbr ( n = nmbr,C0041536
52,coenzyme qnmbr,C0041536
52,coenzyme qnmbr p,C0041536
51,varespladib ( n = nmbr ),C2713485
51,varespladib,C2713485
50,implantable cardioverter - defibrillator,C0162589;C2825184
50,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
49,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
49,simvastatin,C0074554
49,simvastatin monotherapy ( n = nmbr,C0074554
49,exetimibe / simvastatin,C0074554
49,simvastatin ( n = nmbr ),C0074554
49,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),C0074554;C0439422
49,simvastatin ( n = nmbr . nmbr ),C0074554
49,simvastatin ( n = nmbr,C0074554
49,simvastatin ( nmbr / nmbr mg / d ),C0074554;C0439422
48,american indian /,C0002460
48,american indian,C0002460
48,american indian or alaska,C0002460
48,american indian or alaskan native,C0002460
48,american indian or native alaskan,C0002460
48,american indian / alaska native,C0002460
48,american ‐ indian / alaska native,C0002460
48,american indian or,C0002460
48,american indian / alaskan native,C0002460;C0238611
48,"american indian or alaska native "" :",C0002460
48,american indian or alaskan,C0002460
48,american indian or alaska native,C0002460
47,amiodarone vs . placebo,C0002598
47,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598
47,peri - op amiodarone : no ( n = nmbr ),C0002598;C0347985
47,amiodarone,C0002598
47,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
47,amiodarone ( n = nmbr ),C0002598
47,amiodarone ( n,C0002598
47,no amiodarone,C0002598
46,atrial fibrillation or flutter — no . ( % ),C0004238;C0344434;C1963067
46,atrial fibrillation alone ) ,C0004238;C0344434;C1963067
46,atrial fibrillation ( % ),C0004238;C0344434;C1963067
46,type of atrial fibrillation ( n = nmbr nmbr ),C0004238;C0332307;C0344434;C1547052;C1963067
46,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
46,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0205435;C0332189;C0344434;C1279901;C1963067
46,> nmbr episodes of atrial fibrillation in previous nmbr mo,C0004238;C0332189;C0344434;C1963067
46,atrial fibrillation type,C0004238;C0332307;C0344434;C1547052;C1963067
46,duration of qualifying atrial fibrillation » nmbr days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
46,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
46,atrial fibrillation,C0004238;C0344434;C1963067
46,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
46,atrial fibrillation or flutter,C0004238;C0344434;C1963067
46,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
46,no atrial fibrillation,C0004238;C0344434;C1963067
46,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C1963067
46,atrial fibrillation or flutter ( ecg ) §,C0004238;C0344434;C1963067
46,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
46,duration of last qualifying episode of atrial fibrillation > nmbr days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
46,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
46,atrial fibrillation !,C0004238;C0344434;C1963067
46,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
46,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
46,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
45,latin america hr ( nmbr % cl ),C0023122;C0596019
45,latin america,C0023122
45,latin america ( n = nmbr ),C0023122
45,latin america or south africa,C0023122
44,bnp o nmbr pg / ml or nt pro - bnp o nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
44,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
44,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
44,elevated bnp ( nmbr pg / ml ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
44,nesiritide,C0054015
44,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
44,nesiritide ( n = nmbr ),C0054015
44,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
44,bnp ( n = nmbr ),C0054015;C1095989;C1417808;C2982014
44,bnp,C0054015;C1095989;C1417808;C2982014
44,bnp < nmbr pg / ml n = nmbr,C0054015;C0439297;C1095989;C1417808;C2982014
44,bnp > nmbr pg / ml or nt pro - bnp > nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
44,bnp > nmbr pg / ml n = nmbr,C0054015;C0439297;C1095989;C1417808;C2982014
44,nptercilenmbr ( bnpnmbr - nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
44,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0054015;C1095989;C1417808;C2982014
44,bnp > nmbr pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
44,bnp / ntbnp ( n = nmbr ),C0054015;C1095989;C1417808;C2982014
44,normal bnp,C0054015;C0205307;C0231683;C0439166;C1095989;C1417808;C2347086;C2982014;C4553972
43,lipid - lowering,C0023779;C0441994;C2003888
43,prior lipid - modifying therapy,C0023779;C0392747;C1514463
43,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
43,mean lipid values,C0023779;C0042295;C0444504;C2347634;C2348143
43,lipid profile,C0023779;C1979963;C2003903
43,lipid and lipoprotein values ( mg / dl ),C0023779
43,lipid,C0023779
43,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
43,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
43,lipids,C0023779
43,lipid values,C0023779;C0042295
43,lipid lowering,C0023779;C0441994;C2003888
43,plasma lipids ( mg / dl ) nmbr total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
43,lipid trial participants #,C0023779;C1997894;C2242969
43,other lipid parameters,C0023779;C0449381
43,lipid - lowerinq druq,C0023779
43,lipids — mg / dl,C0023779;C0439269
43,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
43,lipid measures at baseline — mg / dl,C0023779
43,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
43,lipid modifiers,C0023779;C4284280
43,lipid parameters,C0023779;C0449381
43,lipid trial participants,C0023779;C1997894;C2242969
43,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
42,no prior hf hospitalization ( n   = nmbr,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
42,hospitalization for hf previous year,C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
42,prior hospitalization for hf,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,prior hf hospitalization ( n = nmbr ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
42,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
42,hf hospitalizations,C0018488;C0019993;C1313497;C1538440;C3273279
42,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279
42,no prior hf hospitalization ( n = nmbr,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,previous hf hospitalization,C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
42,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
42,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
42,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
41,lipid - lowering medications^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
41,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
41,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
41,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
41,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
41,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
41,lipid medication,C0013227;C0023779;C3244316;C4284232
41,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
41,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
40,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
40,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
39,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
39,adjudicated macenmbr,C0349381;C0949745;C1445339
39,mace,C0349381;C0949745;C1445339
39,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
39,primary outcome ( nmbr - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
39,nmbr - polnt mace,C0349381;C0949745;C1445339
39,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
39,expanded mace,C0205229;C0349381;C0949745;C1445339
39,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
39,mace category,C0349381;C0683312;C0949745;C1445339;C3889287
39,b mace,C0349381;C0949745;C1445339
39,mace +,C0349381;C0949745;C1445339
38,seizure types reported during baseline,C0036572;C0332307;C1959629;C4553401
38,seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401
38,age at first seizure,C0001779;C0036572;C0205435;C1279901;C1959629;C4553401
38,cluster seizures,C0036572;C1555715;C1704332
38,seizure worry,C0036572;C0233481;C1959629;C4553401
37,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
37,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
36,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
36,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
35,family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
35,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
34,nontrial ppi,C0358591;C0871125;C3811894
34,ppi use,C0358591;C0871125;C3811894
34,ppi,C0358591;C0871125;C3811894
34,ppi use ( p = nmbr . nmbrt ),C0358591;C0871125;C3811894
34,ppi use at baseline,C0358591;C0871125;C3811894
34,ppi use within nmbr months of randomization,C0358591;C0871125;C3811894
34,ppi use ( p = nmbr - nmbrt ),C0358591;C0871125;C3811894
34,ppi or hnmbr receptor antagonist,C0358591;C0871125;C3811894
34,no ppi,C0358591;C0871125;C3811894
34,ppi but no aspirin,C0358591;C0871125;C3811894
34,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
34,no regular ppi use,C0205272;C0358591;C0871125;C3811894
34,regular ppi use,C0205272;C0358591;C0871125;C3811894
33,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
33,any secukinumab ( n   = nmbr ),C3179547
33,secukinumab pooled †   ( n   = nmbr ),C1709595;C2349200;C3179547;C4522255
33,secukinumab,C3179547
32,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
32,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
31,atenolol ( n = nmbr,C0004147
31,atenolol n = nmbr,C0004147
31,atenolol *,C0004147
31,atenolol strategy,C0004147;C0679199
31,atenolol ( no . = nmbr ),C0004147
31,atenolol ( n = nmbr ),C0004147
31,atenolol strategy ( n = nmbr ),C0004147;C0679199
31,atenolol strategy ( n = nmbr,C0004147;C0679199
31,atenolol,C0004147
31,atenolol ( « = nmbr nmbr ),C0004147
31,treated with atenolol ( n = nmbr ),C0004147;C0332293
31,atenolol n = nmbr no . ( % ),C0004147
30,• iii : death from cv causes,C0011065;C0439070;C1306577;C1705160;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death or hf hospitalization n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,• death from cv causes,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death or hf hosp .,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
30,cv death or ml,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
29,baseline ldl - c nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C0439190;C1442488
29,baseline ldl - c > nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C0439190;C1442488
29,iee at baseline : < nmbriu / l,C0168634;C0439457;C1442488
29,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
29,baseline crp < nmbrmg / l,C0168634;C0439268;C1442488;C3890735;C4048285
29,baseline bmi ( kg / m^ ),C0168634;C0578022;C1442488;C1532718
29,baseline bmi ( kg / mnmbr ),C0168634;C0578022;C1442488;C1532718
29,baseline % bsa involvement,C0168634;C1314939;C1442488
29,improvement from baseline ≥   nmbr,C0168634;C1442488;C2986411
29,baseline anmbrc ( % ),C0168634;C1442488
29,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
29,baseline bmi,C0168634;C0578022;C1442488
29,baseline bii,C0168634;C1413059;C1442488
29,baseline age,C0001779;C0168634;C1442488
29,baseline alc < nmbr . nmbr %,C0168634;C1424945;C1442488;C3811058
29,nmbr year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,baseline bmi < nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
29,baseline basfi,C0168634;C1442488
29,baseline chanmbrdsnmbr - vascb,C0168634;C1420648;C1442488;C3714751
29,baseline basdai,C0168634;C1442488;C1998004
29,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
29,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
29,nmbr med at baseline,C0168634;C1442488;C4321267
29,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
29,baseline bsa,C0168634;C1442488
29,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
29,baseline crcl,C0168634;C1442488;C1846718
29,baseline daytime nasal symptoms score,C0168634;C0231918;C0332169;C1442488
29,baseline ibdq total score,C0168634;C1442488;C2964552
29,baseline diabetes mellitus therapy,C0168634;C0948092;C1442488
29,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
29,db baseline ( week nmbr ),C0168634;C0332174;C0439230;C1418892;C1442488
29,coiticosieroids at baseline,C0168634;C1442488
29,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
29,baseline free pcsknmbr level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
29,> nmbr mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
29,baseline dlqi,C0168634;C1442488;C3899393
29,baseline corticosteroidst ( mean dose : nmbr . nmbr mg / day ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
29,baseline ecg with lvh,C0168634;C0232306;C1442488
29,baseline ecrcl nmbr nmbr ml / min,C0168634;C0439445;C1442488
29,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline ecrcl k nmbr to < nmbr ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
29,baseline ecro < nmbr mumin,C0168634;C1442488
29,geometric mean of baseline,C0168634;C1442488;C2986759
29,baseline ecrq nmbr nmbr to < nmbr ml / min,C0168634;C0439445;C1442488
29,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
29,mean percentage change from baseline to final visit,C0168634;C0392747;C0439165;C0443172;C0444504;C1442488;C1549488;C1561533;C1705241;C2347634;C2348143;C4319952
29,ldl - c at baseline :,C0168634;C1442488
29,ldl - c in mmol / l ( baseline : mean ( sd ) [n]  wk nmbr and change : mean ( se ) [n] ),C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
29,hscrp at baseline,C0168634;C1442488
29,hscrp ( post - baseline / baseline ratio ),C0168634;C0456603;C0687676;C1442488;C1547037;C1704687;C3469826
29,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
29,flex baseline bmd,C0168634;C1442488
29,change from baseline to eos,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,hypertension severity at baseline,C0168634;C1442488;C4013784
29,crcl at baseline < nmbr ml / min,C0168634;C0439445;C1442488;C1846718
29,baseline measurements,C0168634;C0242485;C1442488
29,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
29,bmi at baseline ( kg / mnmbr ),C0168634;C0578022;C1442488;C1532718
29,baseline crp,C0168634;C1442488;C3890735;C4048285
29,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
29,change from baseline in hbanmbrc ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline £ std,C0168634;C1442488
29,age at baseline ( years ),C0168634;C1442488;C1510829
29,mean ( sd ) baseline scores,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
29,age at baseline in years,C0001779;C0168634;C1442488
29,baseline crp levels < nmbr mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
29,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
29,hyponatremic ( < nmbr meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
29,haq - di improvement from baseline to week nmbr,C0168634;C1442488;C2986411;C3826998;C4321476
29,for baseline hemoglobin < nmbr g nmbr ',C0168634;C1319312;C1442488
29,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
29,> nmbr years baseline ldl - c,C0168634;C0439234;C1442488
29,for baseline hemoglobin nmbr g nmbr ’,C0168634;C1319312;C1442488
29,baseline crp levels ≥ nmbr mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
29,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
29,sinus rhythm at baseline,C0168634;C0232201;C1442488
29,baseline dad ( n   = nmbr + nmbr ),C0168634;C1442488;C3641946
29,baseline nmbr - mlnute walk distance :,C0168634;C0429886;C1442488
29,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
29,baseline ^ste,C0168634;C1420459;C1442488;C3811127
29,change from baseline to final apbm,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline to week nmbr in uasnmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline to week nmbr in weekly iss,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,elevated baseline crp,C0168634;C0742906;C1442488
29,baseline hdl - c in nmbr classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
29,change from baseline to week nmbr in weekly no . of hives score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline trl - c in nmbr classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
29,change from baseline to week nmbr in weekly size of largest hive score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline to week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline trig > nmbr millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
29,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
29,( baseline ),C0168634;C1442488
29,baseline bmi > nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
29,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
29,baseline lvef,C0168634;C0428772;C0488728;C1442488
29,mean ( sd ) improvement from baseline to week nmbr in basdai questions *,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
29,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
29,ratio to baseline in eosinophil count at week nmbr,C0168634;C0456603;C1442488;C1547037
29,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
29,baseline scales,C0168634;C1442488
29,mean ( sd ) improvement from baseline to week nmbr in basdai,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
29,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
29,changes at baseline,C0168634;C0392747;C0443172;C1442488
29,no chd at baseline,C0168634;C0280604;C1442488;C3542407
29,ratio to baseline in total ige at week nmbr,C0168634;C0456603;C1442488;C1547037
29,mean baseline ucdai score,C0168634;C0444504;C1442488;C2347634;C2348143
29,change from baseline to week nmbr in dlqi scorez,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
29,change from baseline in rescue medication use ( puffs per day ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline ( n ),C0168634;C1442488
29,baseline ( mean,C0168634;C0444504;C1442488;C2347634;C2348143
29,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,enthesitis score at baseline,C0168634;C0449820;C1282952;C1442488;C4050231
29,change from baseline in acq - nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,insulin use at baseline,C0168634;C0240016;C1442488
29,week nmbr - baseline,C0168634;C0332174;C0439230;C1442488
29,baseline cdai score,C0168634;C0683448;C1413248;C1442488;C3273706
29,change from baseline in acq - nmbr score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,at baseline — no . ( % ),C0168634;C1442488
29,baseline acq - nmbr score,C0168634;C1442488;C2919686
29,baseline,C0168634;C1442488
29,change from baseline in fevj ( mb ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,at baseline,C0168634;C1442488
29,change from baseline in mean nmbr - h dbp,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline in mean nmbr - h sbp,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
29,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
29,seizure frequency during nmbr ‐ week baseline,C0149775;C0168634;C0332174;C0439230;C1442488
29,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline in morning pef during weeks nmbr - nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,ccv history / condition at baseline,C0168634;C0683519;C1442488
29,change from baseline in post - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,change from baseline in pre - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline killip class,C0168634;C1442488;C1881332
29,atrial fibrillation on baseline ecg,C0168634;C0344434;C1442488
29,baseline ( sd ),C0168634;C1442488;C2699239
29,fbg baseline,C0168634;C1442488
29,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488
29,adjusted for all baseline variables,C0168634;C0439828;C0456081;C1442488
29,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,adjusted for all baseline variablesnmbr,C0168634;C0439828;C0456081;C1442488
29,baseline total pcsknmbr level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
29,chd at baseline,C0168634;C0280604;C1442488;C3542407
29,current smoker at baseline,C0168634;C1442488;C3173209;C3241966
29,baseline who functional class,C0168634;C1442488
29,age at baseline years,C0168634;C1442488;C1510829
29,baseline tav - < median ( n = nmbr,C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
29,parameters at baseline,C0168634;C0449381;C1442488
29,baseline tav - > = median ( n = nmbr,C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
29,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
29,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
29,normonatremic ( > nmbr meq / l ) at baseline,C0168634;C0439375;C1442488
29,mtss at baseline observed case,C0168634;C1442488
29,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
29,baseline eosinophil < nmbr cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
29,high ( > nmbr % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
29,high ( > nmbr kg / m^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
29,baseline - adjusted hr,C0168634;C1442488
29,mean ( s . d . ) baseline fpg,C0168634;C0444504;C1442488;C2347634;C2348143
29,baseline - - mdrd,C0168634;C1442488;C3839656
29,baseline ( mmol / l ),C0168634;C1442488;C1532563
29,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
29,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
29,participants at baseline,C0168634;C0679646;C1442488
29,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p nmbr . nmbr vs nmbr y .,C0168634;C0392747;C0443172;C1442488
29,baseline ldl - c strata,C0168634;C1442488
29,intensified baseline ( n - nmbr ),C0168634;C1442488
29,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
29,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
29,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
29,baseline . mean _ sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
29,anmbrc at baseline ≥ nmbr . nmbr %,C0168634;C1442488
29,anmbrc at baseline < nmbr . nmbr %,C0168634;C1442488
29,baseline sgrq score,C0168634;C1442488
29,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
29,aspirin dose at baseline,C0168634;C1442488;C4696290
29,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr,C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
29,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr,C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
29,mean change from baseline in acq overall score ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,characteristic at baseline,C0168634;C1442488;C1521970
29,mean change from baseline in fevnmbr % predicted,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,mean change from baseline in the number of,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,nmbrbaseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
29,baseline trl - c by quintiles,C0168634;C1442488;C1508496
29,mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,baseline value,C0168634;C1442488;C1522609
29,b - blockers at baseline,C0168634;C1442488
29,baseline nmbr - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
29,change from baseline in dasnmbr - esr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,untreated at baseline,C0168634;C0332155;C1442488
29,> nmbr years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
29,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
29,baseline adas - cog nmbr,C0168634;C1442488;C3539026
29,baseline outcomes,C0168634;C1274040;C1442488
29,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
29,subgroup analysis : change from baseline in hbanmbrc at week nmbr per baseline hbanmbrc category,C0168634;C0392747;C0443172;C1442488;C1705241;C2986480;C4319952
29,baseline tg level { n = nmbr,C0168634;C0337445;C0441889;C0456079;C1442488;C1547707;C2946261
29,baseline hdl - c level ( n = nmbr » nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
29,baseline mssbp ( mmhg ),C0168634;C0439475;C1442488
29,% change from baseline to week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,comparison with baseline,C0168634;C1442488;C1707455
29,baseline hdl - c level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
29,hdl - c at baseline .,C0168634;C1442488;C3715113
29,change from baseline in % predicted fevnmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline hdl - c level ( n = nmbr,C0168634;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
29,baseline tjc,C0168634;C1442488
29,baseline to year nmbr,C0168634;C0439234;C0439508;C1442488
29,baseline tophusa,C0168634;C1442488
29,baseline hdl - c level ( n = snmbr,C0168634;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
29,baseline mean serum uric acid,C0168634;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143
29,low ( < nmbr % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
29,baseline hdl ‐ c,C0168634;C1442488;C3715113
29,baseline height ( cm ),C0168634;C0489786;C1442488
29,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
29,baseline tg level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
29,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
29,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
29,baseline tg level ( n = nmbr,C0168634;C0337445;C0441889;C0456079;C1442488;C1547707;C2946261
29,baseline hbalc > nmbr %,C0168634;C1442488
29,baseline hbalc^,C0168634;C1442488
29,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
29,baseline tbp,C0168634;C1442488
29,baseline medical therapy,C0168634;C0418981;C1442488
29,baseline hbalc ’,C0168634;C1442488
29,baseline tg,C0168634;C0337445;C1442488
29,baseline pcsi < nmbra,C0168634;C1442488
29,baseline creatinine clearance,C0168634;C0812399;C1442488
29,baseline hbi,C0168634;C1442488
29,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
29,baseline tg < nmbr . nmbr mmol / l,C0168634;C0337445;C1442488;C1532563
29,baseline uacr > nmbr mg / g,C0168634;C1300563;C1442488
29,baseline hdl - c,C0168634;C1442488;C3715113
29,baseline msdbp ( mmhg ),C0168634;C0439475;C1442488
29,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
29,baseline tg > nmbr . nmbr mmol / l,C0168634;C0337445;C1442488;C1532563
29,baseline post - bronchodilator % predicted fev,C0168634;C1442488
29,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
29,baseline hstni,C0168634;C1442488
29,baseline uacr < nmbr mg / g,C0168634;C1300563;C1442488
29,baseline who function class,C0168634;C1442488
29,baseline total pcsknmbr level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
29,< nmbr baseline killip class,C0168634;C1442488;C1881332
29,corticosteroid use at baseline,C0168634;C0239126;C1442488
29,baseline ldl ‐ c,C0168634;C1442488
29,baseline ldlc level ( n = nmbr,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
29,baseline ldlc level ( n = nmbr . nmbr ) > nmbr . nmbr mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
29,baseline ldl - c > nmbr mg / dl,C0168634;C0439269;C1442488
29,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
29,baseline characteristic,C0168634;C1442488
29,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
29,baseline % predicted fevnmbr,C0168634;C1442488
29,ocs at baseline,C0168634;C1442488
29,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
29,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
29,baseline variable,C0168634;C0439828;C1442488;C4553760
29,baseline vfx,C0168634;C1442488
29,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
29,baseline fpg,C0168634;C1442488
29,baseline ecrcl,C0168634;C1442488
29,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
29,baseline ppasi score,C0168634;C1442488
29,baseline upgr,C0168634;C1442488
29,baseline uasnmbr,C0168634;C1442488
29,baseline ifg ( fpg nmbr . nmbr - nmbr . nmbr mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
29,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
29,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
29,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
29,normal acr ( < nmbr mg / mg ) at baseline to albuminuria ( acr > nmbr mg / g ),C0168634;C0205307;C0231683;C0439166;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
29,baseline nihss score,C0168634;C1442488;C1697238
29,mental status ( baseline spmsq scores ),C0168634;C0278060;C1442488
29,baseline if have nmbr yr follow - up *,C0168634;C1442488
29,difference nmbr years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
29,none at baseline,C0168634;C1442488
29,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
29,low ( < nmbr kg / mnmbr ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
29,low ( < nmbr kg / m^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
29,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
29,difference nmbr years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
29,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
29,diabetes therapy at baseline ( alone or in combination ),C0168634;C1442488;C3274787;C3539002
29,medication use at baseline,C0168634;C0240320;C1442488
29,hoehn and yahr stage ( baseline ),C0168634;C0205390;C1300072;C1306673;C1442488
29,baseline microalbumin : < nmbr,C0168634;C0201838;C1442488;C2362049
29,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
29,killip at baseline,C0168634;C1442488
29,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
29,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
29,baseline sedbp,C0168634;C1442488
29,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
29,baseline spga,C0168634;C1442488
29,median ( iqr ) change from baseline to week nmbr in psa - modified total shs score,C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
29,baseline fc - ldl - c,C0168634;C1442488;C2983605
29,baseline rst - segment elevation,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488
29,baseline albumin / creatinine ratio in nmbr classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
29,baseline normoglycemia,C0168634;C0580545;C1442488
29,dlqi improvement from baseline to week nmbr,C0168634;C1442488;C2986411;C3899393
29,baseline normoglycaemia ( fpg < nmbr . nmbr mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
29,nihss at baseline,C0168634;C1442488;C1697238
29,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
29,baseline / concomitant therapies,C0168634;C1442488;C1707479
29,baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488;C3829066
29,baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488;C3829066
29,alc < nmbr . nmbr % at baseline,C0168634;C1424945;C1442488;C3811058
29,baseline pssi score,C0168634;C1442488
29,baseline ste in worst lead,C0168634;C1420459;C1442488;C1522166;C3811127
29,baseline ocs use : yes,C0168634;C1442488
29,baseline smoking status,C0168634;C1442488;C1519386
29,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0168634;C0201976;C0205173;C0600061;C1442488;C1705764
29,baseline sjc,C0168634;C1442488
29,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
29,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
29,baseline nihss,C0168634;C1442488;C1697238
29,baseline of induction ),C0168634;C0205263;C0857127;C1442488
29,baseline eosinophil nmbr cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
29,baseline sesbp,C0168634;C1442488
29,baseline shs ( nmbr - nmbr ),C0168634;C1442488
29,baseline sgrq total score,C0168634;C1442488;C2964552
29,baseline ( geometric mean,C0168634;C1442488;C2986759
29,a from baseline,C0168634;C1442488
29,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
29,baseline serum calcium level,C0036785;C0168634;C0728876;C1442488
29,baseline estimated gfr,C0168634;C1442488
29,open - label phase ( baseline = week nmbr ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
29,baseline factor,C0168634;C1442488;C1521761;C2827422
29,baseline pasi,C0168634;C1442488;C4528685
29,mean change from baseline bp at week nmbr,C0168634;C0392747;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
29,baseline of induction,C0168634;C0205263;C0857127;C1442488
29,dactylitis score at baseline,C0168634;C0239161;C0449820;C1442488;C4050231
29,baseline sua,C0168634;C1442488
29,change from baseline at week nmbr,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
29,baseline free pcsknmbr level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
29,baseline hbalc > nmbr mmol / mol ( > nmbr . nmbr % ),C0168634;C1442488;C3829066
29,baseline hbalc,C0168634;C1442488
29,crcl at baseline,C0168634;C1442488;C1846718
29,factor at baseline,C0168634;C1442488;C1521761;C2827422
29,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
29,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
29,baseline mean ( mg / dl],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
29,baseline hbalc < nmbr %,C0168634;C1442488
29,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
29,steroid use at baseline,C0168634;C0281991;C1442488
29,baseline median [mg / l],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
29,baseline mwd,C0168634;C1442488
29,baseline ptga,C0168634;C1442488
29,treated at baseline,C0168634;C1442488;C1522326
29,baseline tava,C0168634;C1442488
29,baseline hbalc > nmbr % to < nmbr %,C0168634;C1442488
29,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
29,median ( iqr ) meannmbrsdchange from baseline to week nmbr by weight group and mtx use : weight,C0168634;C0444504;C0549183;C0876920;C1442488;C2347634;C2347635;C2348143;C2348144;C2939193
29,baseline bmi nmbr to < nmbr kg / mnmbr,C0168634;C0578022;C1442488;C1532718
29,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
29,baseline mssbp / msdbp,C0168634;C1442488
29,baseline ldl - c,C0168634;C1442488
29,one at baseline,C0168634;C0205447;C1442488
29,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
29,baseline ldl - c :,C0168634;C1442488
29,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
29,mmrc at baseline,C0168634;C1442488;C3826977
29,asthma control test score at baseline,C0168634;C1442488;C2733224
29,baseline glycated,C0168634;C1442488
29,baseline subgroup,C0168634;C1079230;C1442488;C1515021
29,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
29,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
29,baseline nbp,C0168634;C1442488
29,baseline serum k +,C0168634;C0302353;C1442488
29,baseline geometric mean ( nmbr ® / l ),C0168634;C1442488;C2986759
28,azathioprine monotherapy,C0004482
28,azathioprine,C0004482
28,aza ( n = nmbr ),C0004482
28,azathioprine ( n = nmbr ),C0004482
27,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
27,fatigue,C0015672;C3463815;C4050243;C4554645
27,fatigue ( range nmbr - nmbr ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
27,facit - fatigue . mean nmbrsd ( range nmbr - nmbr ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
27,question nmbr ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
26,gastrointestinal area involved,C0017446;C0205146;C0521362
26,area,C0017446;C0205146
26,geographic region — no . ( % ),C0017446
26,geographic region — number ( % ),C0017446;C0237753;C0449788
26,geographic region,C0017446
26,geographic location,C0017446
26,region :,C0017446;C0205147
26,region — no . ( % ),C0017446;C0205147
26,region ofenrollment — %,C0017446;C0205147
26,geographical region ( % ),C0017446
26,regions,C0017446;C0205147
26,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
26,region of residence ( p = nmbr nmbr ),C0017446;C0205147;C0237096
26,region of the world,C0017446;C0205147;C2700280
26,region of world — no . ( % ),C0017446;C0205147;C2700280
26,region latin american,C0017446;C0205147
26,other ® region — no . ( % ),C0017446;C0205147
26,age years geographic region,C0017446;C1510829
26,geographic region - other,C0017446
26,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
26,region ofthe world,C0017446;C0205147;C2700280
26,region *,C0017446;C0205147
26,region - no . ( % ),C0017446;C0205147
26,mean — ml / min / nmbr . nmbr mnmbr of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
26,region n ( % ),C0017446;C0205147
26,area of retinal thickening within the grid,C0017446;C0205146;C1302690
26,region,C0017446;C0205147
26,geographic region ?,C0017446
26,geographic region^,C0017446
26,area of fluorescein leakage within the grid,C0017446;C0205146;C4476700
26,region ( pooled ),C0017446;C0205147
26,grouped region,C0017446;C0205147;C0439745;C4319846
26,enrollment by region,C0017446;C0205147;C1516879;C1696073;C3888021
26,region - n ( % ),C0017446;C0205147
26,region 一 no . ( % ),C0017446;C0205147
26,region ( % ),C0017446;C0205147
26,geographical region,C0017446
26,geographic site,C0017446
26,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
26,estimated glomerular filtration rate — ml / min / nmbr . nmbr mnmbr of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
26,region ( us ),C0017446;C0205147
26,region — no . { % ),C0017446;C0205147
25,single vessel disease,C0037179;C0042373;C0087136;C0205171
25,single - vessel disease,C0037179;C0042373;C0087136;C0205171
24,thienopyridine,C1120149
24,prior thienopyridine ( + ),C0332152;C1120149;C2826257
24,continued thienopyridine n = nmbr subjects,C0549178;C1120149
24,continued thienopyridine n ( % ),C0549178;C1120149
24,planned thienopyridine at enrollment,C1120149;C1709561
24,continued thienopyridine ( n = nmbr ),C0549178;C1120149
24,continued thienopyridine ( n nmbr nmbr ),C0549178;C1120149
24,+ thienopyridine,C1120149
24,no thienopyridine,C1120149
24,thienopyridine type,C0332307;C1120149;C1547052
24,thienopyridine ( n = nmbr ),C1120149
24,prior thienopyridine ( - ),C0332152;C1120149;C2826257
24,thienopyridine n = nmbr,C1120149
24,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
24,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
24,- thienopyridine,C1120149
24,thienopyridine alone,C1120149
24,continued thienopyridine %,C0549178;C1120149
23,cyclosporine ( n = nmbr ),C0010592;C0010594
23,cyclosporin,C0010592;C0010594
22,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
22,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
21,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
21,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
21,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
20,europe ( zone nmbr ),C0015176;C1710706
20,e . europe,C0015176
20,europe and russia,C0015176
20,east europe,C0015176;C1707877
20,west europe,C0015176;C1705493
20,europe ii,C0015176;C1710602;C4082587
20,europe nmbr +,C0015176
20,w . europe,C0015176
20,w est europe,C0015176;C3811127;C3890902
20,europe nmbr ¶,C0015176
20,* other - europe ( n = nmbr ),C0015176
20,europe and australia,C0015176
20,europe nmbr ( n = nmbr,C0015176
20,europe ( including south africa ),C0015176
20,e europe,C0015176
20,europe nmbr,C0015176
20,europe and canada,C0015176
20,europe n z nmbr,C0015176
20,europe nmbr ( n = nmbr ),C0015176
20,non europe,C0015176;C1518422
20,europe / lsrael,C0015176
20,w europe,C0015176
20,europenmbr,C0015176
20,europe,C0015176
19,ssz + mtx ( n = nmbr ),C0025677;C1417487
19,csdmards + mtx ( n = nmbr ),C0025677;C1417487
19,mtx + non - mtx,C0025677;C1417487;C1518422
19,nmbr non - mtx,C0025677;C1417487;C1518422
19,concomitant csdmards other than methotrexate,C0025677;C0521115
19,lef + mtx ( n = nmbr ),C0025677;C1417487
19,mtx n = nmbr,C0025677;C1417487
19,methotrexate user,C0025677;C1548600;C1706077
19,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
19,mtx ( n = nmbr ),C0025677;C1417487
19,concomitant methotrexate,C0025677;C0521115
19,non - mtx,C0025677;C1417487;C1518422
19,mtx + other csdmards,C0025677;C1417487
19,mtx > nmbr and £ nmbr mg / week,C0025677;C1417487
19,mtx,C0025677;C1417487
19,mtx only,C0025677;C0205171;C1417487;C1720467
19,mtx naive or free,C0025677;C1417487
19,use of methotrexate at randomization —,C0025677;C1524063
19,mtx > nmbr and si nmbr mg / week,C0025677;C1417487
19,concomitant use of mtx to week nmbr,C0025677;C0521115;C1417487;C1524063
19,no methotrexate,C0025677
19,nmbr tcz + mtx mtx,C0025677;C1417487
19,mtx + othetcsdmards,C0025677;C1417487
19,mtx + other csomards,C0025677;C1417487
19,non - mtx csdmards,C0025677;C1417487;C1518422
19,mtx ( n ),C0025677;C1417487
19,methotrexate plus other csdmardfl,C0025677
19,nmbr tcz + mtx,C0025677;C1417487
19,methotrexate,C0025677
19,csdmard otherthan methotrexate,C0025677
19,concomitant mtx —,C0025677;C0521115;C1417487
19,tcz + mtx ( n ),C0025677;C1417487
19,methotrexate dose | |,C0025677;C0178602;C0869039;C1114758
19,methotrexate dose on day nmbr — mg per wl < nmbr,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
19,methotrexate alone^,C0025677
18,total patients n = nmbr,C0030705;C0439175;C0439810
18,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
18,percentage patients reaching target,C0030705;C0439165;C1549488;C1561533
18,patients with > nmbr exacerbations resulting in hospital admission,C0030705;C4086268
18,aii patients ( n = nmbr ),C0030705;C1424250;C2698414
18,subset of patients on metformin,C0030705;C1515021
18,no . ( % ) with event [incidence rate per nmbr patient - y],C0030705;C0441471;C1708485;C4019010
18,patients not receiving immunosuppressive agents at baseline,C0030705
18,patients who received positive results on test for antibodies to infliximabt,C0030705
18,patients treated for > nmbr weeks ( % ),C0030705
18,all patients n = nmbr,C0030705
18,patients without ra,C0030705;C3538806;C4048756
18,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
18,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
18,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
18,patients with previous loss of response to infliximab,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
18,percent of patients,C0030705;C0439165
18,patients receiving corticosteroids at baseline,C0030705
18,all patients with opg n - nmbr,C0030705;C1262886;C1336645;C1412836;C1710303
18,patients not receiving corticosteroids at baseline,C0030705
18,ard ( nmbr % cl ) per nmbr patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
18,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0030705;C1709707
18,patients treated with statins ( n = nmbr ),C0030705
18,all patients n = nmbr nmbr,C0030705
18,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
18,all patients ( p < nmbr . nmbr ),C0030705
18,all patients ( n   =   nmbr ) b,C0030705
18,all patients ( n nmbr nmbr ),C0030705
18,vents / patients,C0030705
18,patients who received negative results on test for antibodies to infliximabt,C0030705
18,patients with any clinical,C0030705;C0205210
18,patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C3887665
18,for patients using personal cgm,C0030705
18,no . of patients / total no . ( % ),C0030705
18,for patients not using personal cgm,C0030705
18,patients with event / patients analyzed,C0030705;C0441471;C4019010
18,patients randomized,C0030705
18,all patients ( p = nmbr . nmbr ),C0030705
18,patients treated with atenoloi ( n = nmbr ),C0030705
18,patients with supplemental vitamin d dose of nmbr iu / day starting at screeningc,C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
18,n ( % of patients ),C0030705;C0369718;C0441922
18,no . of patients with as,C0030705
18,patients with dactylitis at baseline,C0030705;C0239161
18,no . ( % ) of patients with atrial tachyarrhythmia,C0030705
18,patients with dactylitis at week nmbr,C0030705;C0239161
18,no . of patients with ra,C0030705
18,no . of patients with psa,C0030705
18,no . ( % ) of patients with fingernail involvement,C0030705
18,patients with dactylitisa,C0030705
18,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
18,no . ( % ) of patients with stroke,C0030705
18,patients with digits with dactylitis,C0030705;C0582802
18,patients with enthesitis at week nmbr radiographic progression § change from baseline to week nmbr in psa - modified total shs score,C0030705;C1282952
18,patients not treated with statins ( n = nmbr ),C0030705
18,patients with draining fistulae at baseline[n = nmbr],C0030705;C0544791
18,no . of patients / no . of events,C0030705
18,patients receiving lcz,C0030705
18,patients receiving enl,C0030705
18,proportion of patients in corticosteroid - free clinical remission at week nmbr,C0030705;C1709707
18,patients with endpoin t,C0030705
18,patients with normoalbuminuria at baseline,C0030705
18,patients with enthesitis,C0030705;C1282952
18,patients with enthesitis at baseline,C0030705;C1282952
18,patients with dactylitis,C0030705;C0239161
18,patients with diabetesb,C0030705
18,patients receiving immunosuppressive agents at baseline,C0030705
18,rate per nmbr patient - years,C0030705;C0439234;C0871208;C1521828
18,patients with prior ml hr ( nmbr % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
18,all patients ( n = nmbr ),C0030705
18,patient presentation,C0030705;C0449450
18,patients with > nmbr % bsa,C0030705
18,no . of patients ( % ),C0030705
18,patients with uncomplicated events ( p = o - nmbr 十 ),C0030705;C0441471;C0443334;C3541888
18,patients with complicated events,C0030705;C0231242;C0441471;C3541888
18,patients treated,C0030705
18,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
18,no . of patients,C0030705
18,patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
18,patients with an event per nmbr patient - years,C0030705;C0441471;C4019010
18,patients,C0030705
18,of patients,C0030705
18,patients with ascvd but no prior ml hr ( nmbr % cl ),C0030705;C3665365
18,no . ( % ) of patients with ≥ nmbr % bsa affected,C0030705
18,patients with change from baseline in psa - modified total shs score # nmbr,C0030705;C0392747;C0443172;C1705241;C4319952
18,rate / nmbr patient - years,C0030705;C0439234;C0871208;C1521828
18,patients with change from baseline in total psa ‐ modified shs ≤ nmbr,C0030705;C0392747;C0443172;C1705241;C4319952
18,rate per nmbr - patient - years ( control vs alirocumab ) *,C0030705;C0439234;C0871208;C1521828
18,rate per nmbr - patient - years ( control vs alirocumab ) i,C0030705;C0439234;C0871208;C1521828
18,total patients,C0030705;C0439175;C0439810
18,patients with enthesitis at week nmbr,C0030705;C1282952
18,patients with > nmbr exacerbation in previous nmbr months,C0030705;C4086268
18,no . patients with,C0030705
18,no . patients ( % ),C0030705
18,patients with only mrf hr ( nmbr % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
18,percentage of patients with event,C0030705;C0439165;C1549488;C1561533
18,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
18,patients with level > nmbr pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
18,patients with end point,C0030705;C2349179;C2826544
18,% of patients nmbr . nmbr nmbr . nmbr,C0030705
18,patients with nail psoriasis ( mnapsi > nmbr ),C0030705;C0406322
18,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
18,% patients,C0030705
18,patients with moderate - to - severe pain ( womac pain score,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
18,patient,C0030705
18,proportion of patients with trough fevi > nmbr ml above baseline,C0030705;C1709707
18,proportion of patients who achieved acrnmbr n / n ( % ),C0030705;C1709707
18,( nmbr patients ),C0030705
18,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C1549488;C1561533
18,patients with mild pain ( womac pain score,C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
18,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
18,patients with low ( < nmbr mg / dl ) cnmbr,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
18,patients with measurement,C0030705;C0242485
18,percentages of patients with event,C0030705;C0439165;C1549488;C1561533
18,of patients meeting criterion / total no . of patients,C0030705
18,remaining patients,C0030705;C1527428
18,patients with improvement $ nmbr . nmbr,C0030705;C2986411
18,all patients ( « = nmbr nmbr ),C0030705
18,all patients ( n = nmbr,C0030705
18,patients with > nmbr exacerbations resulting in emergency department visit,C0030705;C4086268
18,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
18,itt patients,C0030705
18,patients with weekly iss mid response,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
18,patients with event ( n,C0030705;C0441471;C4019010
18,patients with chronic,C0030705;C0205191
18,patients without chronic,C0030705;C0205191
18,patients with event / patients analysed,C0030705;C0441471;C4019010
18,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0337051;C0443252;C1509144;C1720467;C2349200
18,patients with ra,C0030705;C3538806;C4048756
18,patients ( ft ),C0030705
18,number ol ( % ) patients > nmbr years,C0030705;C0237753;C0439234;C0449788
18,no . of hospitalised patients,C0030705
18,patients with event / analyzed,C0030705;C0441471;C4019010
18,week nmbr % of patients,C0030705;C0332174;C0439230
18,no . of patients with events ( % ),C0030705
18,no . of patients / no . of events ( % ) nmbr / nmbr ( nmbr ) nmbr / nmbr ( nmbr ),C0030705
18,percentage of patients receiving dose adjustment,C0030705;C0439165;C1549488;C1561533
18,patients with perianal fistulae,C0030705;C0267561
18,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
18,younger patients ( agednmbr years ),C0030705;C0332239
18,patients with syndesmophytes at baseline,C0030705;C0221690
18,patients without diabetesb,C0030705
18,patients without syndesmophytes at baseline,C0030705;C0221690
18,patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
18,older patients ( aged > nmbr years ),C0030705;C0580836
18,patients / events n,C0030705;C0441471;C3541888
18,no new erosions among patients with ≥ nmbr uninvolved joint at baseline ¶,C0030705;C0205314;C0333307;C1959609
18,subset of patients not on metformin,C0030705;C1515021
18,no new jsn among patients with ≥ nmbr uninvolved joint at baseline ¶,C0030705;C0205314
18,patients using concurrent tiotropium,C0030705
18,patients with radiographic erosion,C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
18,patients ( n ),C0030705
18,patients per nmbr patient - years,C0030705;C0439234
18,all patients,C0030705
18,patients with $ nmbr % bsa at baseline,C0030705
18,patients who did not use insulin pump,C0030705
18,patients not receiving statin,C0030705
18,patients with complicated events ( p = nmbr - nmbr 十 ),C0030705;C0231242;C0441471;C3541888
18,patients not receiving mtx,C0030705
18,patients who had ulcerations at,C0030705
18,patients with > nmbr exacerbations resulting in ed visit,C0030705;C4086268
18,patients without draining fistulae at baseline[n = nmbr],C0030705;C0544791
18,patients randomised,C0030705
18,patients meeting the criteria to receive nmbr mg of,C0030705
18,patients randomly assigned,C0030705
18,patients < nmbr %,C0030705
18,patients treated with losartan ( n = nmbr ),C0030705
18,patients > nmbr %,C0030705
18,patients total no .,C0030705
18,diabetic patients,C0030705;C0241863
18,rates per nmbr patient - years,C0030705;C0439234;C0871208;C1521828
18,randomised patients ( n ),C0030705
18,patients taking oral corticosteroids at baseline,C0030705
18,patients taking mtx,C0030705
18,patients receiving statin,C0030705
18,patients receiving mtx,C0030705
18,patients without,C0030705
18,patients receiving immunotherapy,C0030705
18,patients receiving any uc medication,C0030705
18,randomised patients with dactylitis at baseline,C0030705;C0239161
18,randomised patients with enthesitis at baselinet,C0030705;C1282952
18,patients receiving nmbr mg of edoxaban at randomization — no . ( % ) f,C0030705
18,patients with macroalbuminuria at baseline,C0030705
18,patients treated and operated,C0030705
18,patients included in analysis,C0030705
18,patients who used insulin pump,C0030705
18,patients analyzed,C0030705
18,patients aged > nmbr y,C0030705
18,patients > nmbr y *,C0030705
18,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
18,patients who received nmbr or nmbr drugs,C0030705
18,patients > nmbr y,C0030705
18,patients < nmbr y *,C0030705
18,patients ( treated set * ),C0030705
18,patient years,C0030705;C0439234
18,patients who received indeterminate results on test for antibodies to infliximabt,C0030705
18,patients assessed,C0030705
18,no . of events / patients,C0030705;C0441471;C3541888
18,patient characteristic,C0030705
18,patients having exacerbation,C0030705
18,patients n,C0030705
18,patients treated with insulin,C0030705
18,patient - years ) hr ( unadjusted ),C0030705;C0439234
18,patients with $ nmbr dactylitis digit at week nmbr enthesitis,C0030705;C3863761
18,patient - reported hypertension — no . { % ),C0030705
18,patients entering pt period n = nmbr,C0030705
18,patients with microalbuminuria at baseline,C0030705;C0730345
18,patients < nmbr y,C0030705
18,patients who received nmbr drug,C0030705
17,country : argentina ( n = nmbr ),C0003761;C0454664;C1504311;C1511538
17,argentina,C0003761;C1504311
16,emphysema ( % ),C0013990;C0034067
16,emphysema ( n = nmbr ),C0013990;C0034067
16,emphysema,C0013990;C0034067
16,emphysema ( itt ) ( n = nmbr ),C0013990;C0034067
15,females ( itt ) ( n = nmbr ),C0086287
15,female sex — %,C0086287
15,female sex ( % ),C0086287
15,percentage of females,C0086287;C0439165;C1549488;C1561533
15,females ( n = nmbr ),C0086287
15,females,C0086287
15,female sex — no . ( % ) race — no . ( % ) f,C0086287
15,females only,C0086287;C0205171;C1720467
15,female sex — number ( % ),C0086287;C0237753;C0449788
15,female sex — no . ( % ),C0086287
15,female sex,C0086287
15,female sex — no . { % ),C0086287
15,female gender,C0086287
15,female gender ( % ),C0086287
15,number of females n ( % ),C0086287;C0237753;C0449788
15,female gender n ( % ),C0086287
15,sex : female,C0086287
15,number of ( % ) females,C0086287;C0237753;C0449788
15,sex ( female ),C0086287
14,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
14,th ( nmbr % ),C0039725;C0039738;C1420718;C4282123;C4285344
14,median ( nmbrth,C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
14,age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
14,th c,C0039725;C0039738;C1420718;C4282123;C4285344
14,nmbrth — nmbrth percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
14,nmbrth - nmbrth percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
14,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
14,nmbrth : nmbr . nmbr - nmbr pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
13,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
13,relative decrease > nmbr %,C0080103;C0205345;C0392756;C0547047;C1547039
12,alteplase,C0032143
12,alteplase group ( n = nmbr ),C0032143;C0441848
12,alteplase ( n = nmbr ),C0032143
12,r - tpa,C0032143
11,nmbr antianginal drugs,C0013227;C1874267;C3537168;C3687832
11,medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
11,use of medication from randomization through nmbr hr — no . / total no . ( % ),C0013227;C1524063;C3244316;C4284232
11,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
11,use of medication for pah,C0013227;C1524063;C3244316;C4284232
11,nmbr antianginal drug,C0013227;C1254351;C1874267;C3537168
11,drug - related teaes,C0013227;C0439849;C0445223;C1254351
11,medications at baselinet,C0013227;C0802604;C2598133;C4284232
11,medications in use at baseline — no . ( % ),C0013227;C0802604;C2598133;C4284232
11,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
11,other medications,C0013227;C0802604;C2598133;C4284232
11,medications in use at baseline,C0013227;C0802604;C2598133;C4284232
11,medications in use at baseline — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
11,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
11,medication within nmbr days before enrolment,C0013227;C0439228;C3244316;C4284232
11,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
11,study medication,C0013227;C0557651;C2603343;C3244316;C4284232
11,any medication,C0013227;C3244316;C4284232
11,> nmbr drug - related,C0013227;C0439849;C0445223;C1254351
11,medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232
11,other drugs,C0013227;C3687832
11,> nmbr drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
11,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
11,concomitant drugs,C0013227;C0521115;C3687832
11,due to drug - relateda ae,C0013227;C1254351;C3887670
11,drugs and toxins,C0013227;C3687832
11,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
11,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
11,drug naive,C0013227;C1254351
11,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
11,drug ‐ relateda,C0013227;C1254351
11,drug discontinuation not due to death,C0013227;C0457454;C1254351;C1444662;C4552847
11,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
11,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
11,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
11,use of medications for pah — no . ( % ),C0013227;C0802604;C1524063;C2598133;C4284232
11,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
11,medication taken alone or in combination,C0013227;C3244316;C4284232
11,drug and insulint,C0013227;C1254351
11,drug - relateda,C0013227;C1254351
11,periprocedural medications,C0013227;C0802604;C2598133;C4284232
11,on step - nmbr drug,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
11,annanginal drugs ( nmbr / l / s » nmbr ) ^,C0013227;C3687832
11,no . of drugs,C0013227;C3687832
11,concomitant medication — no . { % ) | ace inhibitor,C0013227;C0521115;C3244316;C4284232
11,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
11,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
11,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
11,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
11,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
11,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
11,ipah / fpah / drug and toxin,C0013227;C0152171;C1254351;C1419079
11,drugs used in diabetes,C0013227;C3687832
11,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
11,medication — no . ( % ),C0013227;C3244316;C4284232
11,medications,C0013227;C0802604;C2598133;C4284232
11,use of medication at baseline — no . ( % ),C0013227;C1524063;C3244316;C4284232
11,medication,C0013227;C3244316;C4284232
11,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
11,medications through day nmbr,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
11,other medication usage,C0013227;C0457083;C3244316;C4284232
11,concomitant medication ( > nmbr % ),C0013227;C0521115;C3244316;C4284232
11,other drugs — no . ( % ),C0013227;C3687832
11,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
11,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
11,concomitant medications ( yes ),C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
11,drug eluting,C0013227;C1254351
11,concomitant medications in > nmbr % of subjects,C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
11,medications ( % ),C0013227;C0802604;C2598133;C4284232
11,drug - eluting,C0013227;C1254351
11,medications on admission,C0013227;C0802604;C2598133;C4284232
11,number of antidiabetes drugs at screening,C0013227;C0237753;C0449788;C3687832
11,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
11,drug - related teaesnmbr,C0013227;C0439849;C0445223;C1254351
11,medications *,C0013227;C0802604;C2598133;C4284232
11,immunomodulatory drugs,C0013227;C3687832
11,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
11,lowering drugs,C0013227;C0441994;C2003888;C3687832
11,medication prior to admission,C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
11,no antianginal drug,C0013227;C1254351;C1874267;C3537168
11,medication use — no . ( % ) ^ |,C0013227;C3244316;C4284232
11,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
11,concurrent medication,C0013227;C0205420;C3244316;C4284232
11,concomitant medication,C0013227;C0521115;C3244316;C4284232
11,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
11,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
11,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
11,antithrombotic medications,C0013227;C0802604;C2598133;C4284232
11,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
11,> nmbr concomitant medication,C0013227;C0521115;C3244316;C4284232
11,medication useb,C0013227;C3244316;C4284232
11,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
11,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
11,associated with drug or toxin exposure,C0013227;C0332281;C1254351
11,medication use — no . { % ),C0013227;C3244316;C4284232
11,medication in use at the baseline,C0013227;C3244316;C4284232
11,any drug - related ae,C0013227;C0439849;C0445223;C1254351;C3887670
11,medication continued into double - blind treatment period,C0013227;C3244316;C4284232
11,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
11,medication nmbr ( nmbr . nmbr ),C0013227;C3244316;C4284232
11,medication use — no . ( % ),C0013227;C3244316;C4284232
11,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
11,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
11,previous medications,C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
10,apixaban vs . placebo,C1831808
10,apixaban,C1831808
10,apixaban dose ( or matching placebo ),C0178602;C0869039;C1114758;C1831808
10,apixaban ( n = nmbr ),C1831808
9,nihss at randomization,C0034656;C1697238
9,crcl at randomization - ml / min,C0034656;C0439445;C1846718
9,randomized < nmbr hr after presentation — %,C0034656;C0449450;C3815594
9,interval from randomization to angiography,C0034656;C1272706;C1552654;C1552713
9,randomization ),C0034656
9,randomization to end of study,C0034656
9,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
9,crcl at randomization,C0034656;C1846718
9,randomization to,C0034656
9,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981
9,no . randomized,C0034656;C3815594
9,to randomization,C0034656
9,randomized to receive aspirin yes,C0034656;C3815594
9,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
9,randomization,C0034656
9,renal function at randomization,C0034656;C0232804
9,at randomization,C0034656
9,p - blocker intake at randomisation ( n = nmbr ),C0034656;C0369773;C1512806;C2603361
9,antiplatelet at randomization,C0034656
9,corticosteroid use at randomization,C0034656;C0239126
9,age at randomization ( years ),C0034656;C1510829
9,treatmentofpulmonary embolismpriorto randomization,C0034656
9,randomized to canakinumab nmbr mg,C0034656;C3815594
9,randomized to receiveaspirin,C0034656;C3815594
9,index stroke > nmbr days before randomization — no . ( % ),C0034656;C0439228;C0456712
9,randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079
9,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
9,aspirin dose at randomization,C0034656;C4696290
9,year from randomization,C0034656;C0439234;C0439508
9,symptom onset to randomization,C0034656;C4086878
9,other llt at randomization,C0034656;C2347090
9,mar imputation ( random . ) ( n = nmbr ),C0034656;C0439605;C2699638;C3829202;C4255469
9,randomized to receive beta carotene,C0034656;C3815594
9,coronary revascularization nmbr days after randomization,C0034656;C0439228;C0877341
9,no vka at randomization,C0034656
9,randomisation,C0034656
9,vka at randomization,C0034656
9,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
9,biochemical parameters at randomization,C0034656;C0205474;C0449381
9,age at randomisation,C0001779;C0034656
9,age at randomization,C0001779;C0034656
9,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
9,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
9,creatinine clearance at randomization,C0034656;C0812399
9,randomisation scheme,C0034656;C1519193
9,no p - blocker intake at randomisation ( n = nmbr ),C0034656;C0369773;C1512806;C2603361
9,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
9,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
9,bocf - iike imputation ( random . ) ( n = nmbr ),C0034656;C0439605;C2699638;C2984917
9,symptom onset - to - randomization,C0034656;C4086878
9,randomized,C0034656;C3815594
9,patient characteristics at randomization,C0034656;C0815172
9,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
9,dose reduction at randomization — no . ( % )  i ,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
9,asastoppedat randomization,C0034656
9,electrocardiographic findings at randomization,C0034656;C0438154
9,randomized to receive vitamin e,C0034656;C3815594
9,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
9,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
9,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
9,randomization stratum,C0034656
9,labs at randomization,C0034656;C0587081
9,randomization - to -,C0034656
9,p lace of randomization ( interaction : p = nmbr . nmbr ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
9,medications at timing of randomization,C0034656;C2359859
9,killip class iv at randomization,C0034656;C2697847
9,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
9,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
9,p - blocker intake at randomisation ( n = nmbro ),C0034656;C0369773;C1512806;C2603361
9,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
8,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C1532338
8,percutaneous coronary intervention or coronary artery bypass graft surgery,C1532338
8,percutaneous coronary intervention,C1532338
8,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
8,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
8,percutaneous coronary intervention §,C1532338
8,percutaneous coronary revascularization,C1532338
8,percutaneous coronary intervention n ( % ),C1532338
8,percutaneous coronary intervention done *,C1532338
8,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C1532338;C2826257
8,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
7,race - non - white ( n = nmbr,C0034510;C1706779;C3853635
7,race ( % ) ) ',C0034510;C1706779;C3853635
7,race or ethnic group — no . / total no . ( % ) f,C0034510;C1706779;C3853635
7,race white,C0034510;C1706779;C3853635
7,race - white ( n = nmbr,C0034510;C1706779;C3853635
7,race — no . ( % ),C0034510;C1706779;C3853635
7,racial group,C0034510
7,nonwhite race !,C0034510;C1706779;C3853635
7,race or ethnic background — no . ( % ) f,C0034510;C1706779;C3853635
7,race or ethnic origin,C0034510;C1706779;C3853635
7,race ( % ),C0034510;C1706779;C3853635
7,race — no . ( % ) |,C0034510;C1706779;C3853635
7,race - no . ( % ),C0034510;C1706779;C3853635
7,nonwhite race,C0034510;C1706779;C3853635
7,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
7,race n ( % ),C0034510;C1706779;C3853635
7,race,C0034510;C1706779;C3853635
7,race *,C0034510;C1706779;C3853635
7,race or ethnic group ( % ) f,C0034510;C1706779;C3853635
7,race or ethnic group — no . f,C0034510;C1706779;C3853635
7,race — no . ( % ) f,C0034510;C1706779;C3853635
7,race — no . ( % ) ' (,C0034510;C1706779;C3853635
7,race or ethnic group ( % ),C0034510;C1706779;C3853635
7,$ race was determined by the investigator during the patient ' s interview .,C0034510;C1706779;C3853635
7,race — no . ( % ) : c,C0034510;C1706779;C3853635
7,race — no . ( % ) 卞,C0034510;C1706779;C3853635
7,race : white,C0034510;C1706779;C3853635
7,racenmbr,C0034510;C1706779;C3853635
7,race or ethnic group,C0034510;C1706779;C3853635
7,race :,C0034510;C1706779;C3853635
7,race or ethnic group — no . { % ) ■ ' ( white,C0034510;C1706779;C3853635
7,race or ethnicity,C0034510;C1706779;C3853635
7,race and ss at baseline,C0034510;C1706779;C3853635
7,race — no . { % ) - i -,C0034510;C1706779;C3853635
7,race — no . { % ) ' i ',C0034510;C1706779;C3853635
7,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
7,race — no . ( % ) : t,C0034510;C1706779;C3853635
7,range race,C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
7,race nonwhitet,C0034510;C1706779;C3853635
7,race §,C0034510;C1706779;C3853635
7,race - n ( % ),C0034510;C1706779;C3853635
7,race ( p = o - nmbr ),C0034510;C1706779;C3853635
7,race ( % ) $,C0034510;C1706779;C3853635
7,race ( % ) white,C0034510;C1706779;C3853635
7,race - nonwhite,C0034510;C1706779;C3853635
7,race ( % white ),C0034510;C1706779;C3853635
7,race — no . / total no . ( % ) f,C0034510;C1706779;C3853635
7,race ( white,C0034510;C1706779;C3853635
7,race ( % ) *,C0034510;C1706779;C3853635
7,other race,C0034510;C1706779;C3853635
7,race ( non - white ) ( % ),C0034510;C1706779;C3853635
7,race : non - white,C0034510;C1706779;C3853635
7,race_white,C0034510;C1706779;C3853635
7,race or ethnic group — no . ( % ) : t,C0034510;C1706779;C3853635
7,race - non - white,C0034510;C1706779;C3853635
7,race or ethnic group — no . ( % ) f,C0034510;C1706779;C3853635
6,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
6,dead ( n = nmbr ),C0011065
6,death from,C0011065;C1306577;C4082313;C4552775
6,macce ( death,C0011065;C1306577;C4082313;C4552775
6,any death,C0011065;C1306577;C4082313;C4552775
6,no . of deaths,C0011065;C1306577
6,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
6,death,C0011065;C1306577;C4082313;C4552775
6,death or disabling stroke,C0011065;C1306577;C4082313;C4552775
6,deaths,C0011065;C1306577
6,death *,C0011065;C1306577;C4082313;C4552775
6,death or mi at nmbr days,C0011065;C1306577;C4082313;C4552775
6,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
6,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
6,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
6,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
6,death or nmbrmwd decrease > nmbr m,C0011065;C1306577;C4082313;C4552775
6,chd deaths,C0011065;C0280604;C1306577;C3542407
6,death or ich,C0011065;C1306577;C4082313;C4552775
6,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
6,death ( all - cause ),C0011065;C1306577;C4082313;C4552775
6,total deaths,C0011065;C0439175;C0439810;C1306577
6,death ( all cause ),C0011065;C1306577;C4082313;C4552775
6,death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775
6,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
6,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
6,all death,C0011065;C1306577;C4082313;C4552775
6,nmbr days composite of death / new mi / urgent revascularization and definite st,C0011065;C0205199;C0439609;C0581603;C1306577;C1547335;C3272275;C3810814;C4082313;C4552775;C4689466
6,noncardiac death,C0011065;C1306577;C4082313;C4552775
6,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
5,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
5,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
5,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
5,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C2603343
5,study drug loading days ( actual ) : nmbr ( n = nmbr ),C0013175;C0237400;C0439228;C1708715
5,exposure to study drug — days,C0013175;C0332157;C0439228
5,study drug,C0013175
5,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
5,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
5,duration of study - drug administration — hr,C0013175;C2348354
5,medications at study entry — no . / total no . ( % ),C0013175;C1705654
5,daily dose of study medication prescribed,C0013175;C2348070
4,hdl cholesterol > nmbr - nmbr mmol / l,C0023822;C0392885;C1532563
4,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
4,hdl - cholesterol,C0023822;C0392885
4,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
4,hdl cholesterol < nmbr - nmbr mmol / l,C0023822;C0392885;C1532563
4,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
4,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
4,hdl cholesterol,C0023822;C0392885
4,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
4,hdl cholesterol *,C0023822;C0392885
4,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
4,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
4,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
4,hdl cholesterol ( week nmbr ) a,C0023822;C0332174;C0392885;C0439230
4,- hdl cholesterol,C0023822;C0392885
4,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
4,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
4,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
4,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
4,hdl cholesterol < nmbr mg / dl *,C0023822;C0392885;C0439269
4,high - density lipoprotein cholesterol,C0023822
4,hdl cholesterol §,C0023822;C0392885
4,> nmbr . nmbr hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
4,high density lipoprotein cholesterol,C0023822
4,hdl cholesterol ( mmol / l ) ( median,C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
4,terol  hdl - c  high - density lipoprotein cholesterol ,C0023822
4,hdl cholesterol ( sd ),C0023822;C0392885;C2699239
4,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
4,hdl cholesterol^ :,C0023822;C0392885
4,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
3,tofacitinib nmbr mg twice daily n = nmbr,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
3,tofacitinib nmbr mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
3,tofacitinib nmbr mg bid [n = nmbr |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
3,tofacitinib nmbr mg bid ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
3,tofacitinib nmbr mg bid ( n   = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
3,tofacitinib nmbr mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
2,previous hospitalization for heart failure,C0205156;C1552607;C3898876
2,glycemic status,C1320980
2,plasma glucose nmbr hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
2,prebronchodilator fevj ( % predicted ),C2599602
2,symptomatic localization - related,C0231220;C0475264;C1744691
2,fpg data ',C1511726;C3245479;C3714741
2,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
2,multivitamins,C0301532;C3714835
2,fevnmbr   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
2,mycophenolate ( any derivative ),C0883242
2,cardiothoracic ratio,C0456603;C1547037;C4055270
2,previous events,C0205156;C0441471;C1552607;C3541888
2,n - nmbr allocation,C0369718;C0441922;C1706778
2,usual care,C1947933;C3538928
2,upper respiratory tract inflammation,C0877266
2,fpg month nmbr ( mg / dl ),C0332177;C0439231;C0439269
2,post svc,C0231957;C0687676;C1704687;C3469826
2,nonfatal mi ( n = nmbr ),C3810814
2,postbronchodilator nmbr . nmbr ( nmbr . nmbr ),C2599594
2,none ( n = nmbr ),C0369718;C0441922
2,nondiabetic participants !,C0679646
2,fpg ( mg / dl ) x,C0439269
2,noncompliant,C0457432
2,upper abdominal pain,C0232492
2,no prior mi ( n = nmbr,C0332152;C2826257;C3810814
2,no prior mi n = nmbr,C0332152;C2826257;C3810814
2,multiracial or other,C1881928
2,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
2,plasma cholesterol — mg / dl,C0439269;C0858034
2,no prior revascularization ( n = nmbr,C0332152;C0581603;C2826257
2,no revascularisation,C0581603
2,pre - specified trial endpoints,C2826245
2,total macular volume,C0332574;C0449468
2,t - wave inversion only,C0205171;C0520888;C1720467
2,nonblack participants,C0679646
2,total events,C0439175;C0439810;C0441471;C3541888
2,nonblack ( n = nmbr )  adjusted hazard ratio *,C0456081;C2985465
2,n - nmbr fatty acit,C0369718;C0441922
2,fpg ( mmol / nmbr ),C0439190
2,symptomatic remissionb n / n ( % ),C0231220
2,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
2,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
2,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
2,n ( lesions ),C0369718;C0441922
2,pleased,C3829994;C4264468
2,tender joint count ( nmbr - nmbr  per tender joint ),C0451530
2,n ( stented lesions ),C0369718;C0441922
2,n = nmbrt,C0369718;C0441922
2,total length of implanted stents,C0021102;C0439175;C0439810;C0449462;C2828363
2,tender - or painful - joint count ( of nmbr joints assessed ) — no .,C0234234
2,non - mets,C0812270;C1518422;C1705694;C2939420
2,previous mi and tnmbrdm,C0205156;C1552607;C3810814
2,fevi reversibility — %,C3830088
2,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
2,n events ( % ),C0369718;C0441471;C0441922;C3541888
2,no concomitant antiplatelet,C0521115
2, † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by nmbr . nmbr . to convert values for triglycerides to millimoles per liter  multiply by nmbr . nmbr .,C0042295;C0332288
2,cadillac score,C0449820;C4050231
2,t - jj ( nmbr - nmbr ),C2603360
2,tender joint count ( nmbr - nmbr joints ),C0451530
2,n ( iqr ),C0369718;C0441922
2,non stent thrombosis - related mi,C1518422;C3897493
2,non - q - wave myocardial infarction,C0542269;C3537181
2,glycohemoglobin,C0202054;C0696092
2,non - user nmbr,C1518422;C1548600;C1706077
2,non - us,C1518422
2,n ( % ) responders,C0369718;C0441922
2,n ( % ) unless otherwise specified,C0369718;C0441922
2,pre - treatedforhypertension [n ( % ) ],C0332152;C0740175;C2257086;C3669034
2,tender joints ( nmbr - joint count ),C0451530
2,tender joint count of nmbr joints,C0451530
2,tender joint count ( range nmbr - nmbr joints ),C0451530;C1514721;C2348147;C3542016
2,tender joint count ( nmbr ),C0451530
2,non - st - segment elevation,C0520886;C1518422
2,upper tertile : > nmbr . nmbr,C1282910
2,no stsd > nmbr mm on admission ( n = nmbr,C0184666;C0809949;C4330985;C4554674
2,tender joint count ( nmbr – nmbr joints ),C0451530
2,non - rollover,C0517067;C0543436;C1518422
2,t - wave inversion,C0520888
2,fevi percent predicted ( % ),C0429706;C0439165;C0849974;C1561566;C4528367
2,pre - treatment[n ( % ) ]c,C1550147;C2709094;C3539075;C3539076
2,non - rheumatic valvular heart disease,C0264757;C1518422
2,treatment throughout study,C1521826;C3161471
2,symptom onset to pci,C4049621;C4086878
2,total ige — lu / ml,C0439175;C0439810;C2697941
2,tnmbrd duration,C0449238;C2603360;C2926735
2,previous smokers,C0337671
2,no new a or and no more than nmbr new bilag b domain score,C0205314
2,no ef data | |,C1511726;C3245479;C3714741
2,mssbp > nmbr mmhg,C0439475
2,fsn score,C0449820;C4050231
2,mssbp ± sd,C2699239
2,previous smoker,C0337671
2,tertiary endpoints :,C0205372;C2349179
2,values were reported for nmbr patients in the spironolactone group and nmbr,C0042295
2,normal ( > nmbr ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
2,symptomatic,C0231220
2,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
2,no dysglycaemia or mets pbo ( n = nmbr ) vs evomab ( n = nmbr ),C1960636
2,values were calculated using t tests for continuous variables and chi - square,C0042295
2,tertiary end points,C0205372;C2349179
2,fsg ( mg / dl ),C0439269
2,frequent or continuous,C0332183
2,no draining fistulas *,C0544791
2,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
2,feno — ppb,C1415800
2,symmetric t - wave inversions,C0332516;C0520888;C2699744
2,swollen joints > nmbr,C0152031
2,tertile of total cholesterol at baseline,C0201950;C0543421
2,urine albumin / creatinine ratio,C0455271;C1318330
2,g,C0439267
2,us site,C0205145;C1515974;C2825164
2,swollen joints ( nmbr - joint count ),C0451521
2,g - blockers,C0439267
2,pre - bronchodilator fevr l,C1708033;C2599602
2,pre - bronchodilator fevr % pred,C1708033;C2599602
2,pre - bronchodilator fevj,C2599602
2,tnmbr ( nmbr . nmbr - nmbr . nmbr ng / ml ),C0439275;C2603360
2,g + c,C0439267
2,normal cognitive,C2712133
2,"pre - bronchodilator fevi / fvc "" %",C0802741;C2599602;C3815113
2,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
2,no gi bleed,C1708130;C3539617;C4050121
2,t wave inversion,C0520888
2,pre - bronchodilator fevi change,C0849974;C1561566;C2599602;C4528367
2,gained bmd,C1517378
2,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
2,normal ( bmi < nmbr ),C4229017
2,normal ( > nmbr mlvmin per nmbr . nmbr mnmbr ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
2,tertiary amines,C3653356
2,triglycerides level,C0428475
2,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
2,previous mi ( % ),C0205156;C1552607;C3810814
2,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
2,t ( n = nmbr,C2986835
2,pre - procedure,C3272300
2,no prior admc,C0332152;C2826257
2,ppbc score,C0449820;C4050231
2,values are mean ± sd  median [quartile range]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0042295
2,total ige levelx ( iu / ml ),C0439175;C0439458;C0439810
2,normal ( ≤   uln ) n   =   nmbr,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
2,normal ( < nmbr . nmbr u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
2,normal ( £ nmbr ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
2,potential predictor,C2698872;C3245505
2,nordic,C0331873
2,nonglycemic cardiovascular risk factors,C0850624
2,value for nteraction,C1522609
2,previous infliximab therapy | |,C0205156;C1552607;C4076075
2,terrible,C3827840
2,temporal data and management strategy,C0442043;C1511726;C2362314;C3245479;C3714741
2,postbronchodilator fevj ( % predicted ),C2599594
2,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
2,no diuretic therapy,C0948575
2,gastrointestinal event,C0441471;C0521362;C4019010
2,total included in combined analysis,C0439175;C0439810
2,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from nmbr patients in the aliskiren group and nmbr patients in the hydrochlorothiazide group . † obesity was defined as body mass index nmbr kg / mnmbr . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criterianmbr as any nmbr of the following : waist circumference nmbr cm for men or nmbr cm for women  triglycerides nmbr mg / dl  high - density lipoprotein cholesterol nmbr mg / dl for men or nmbr mg / dl for women  mssbp nmbr mm hg or msdbp nmbr mm hg  fasting glucose nmbr mg / dl . § by medical history . aliskiren  n nmbr  hydrochlorothiazide  n nmbr .,C0042295
2,symmetric t wave inversions,C0332516;C0520888;C2699744
2,total ige,C0439175;C0439810
2,previous segments resection ( s ) *,C0205156;C1552607;C2987624
2,frequent exacerbator,C0332183
2,freqency of events,C0441471;C3541888
2,previous revascularization,C0205156;C0581603;C1552607
2, blood pressure nmbr / nmbr mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0042295
2,normal ( ≥ nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
2,symptom - free days in the past nmbr weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
2,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
2,previous myocardiaunfarction,C0205156;C1552607
2,mtx average weekly dose,C0332174;C0366550;C1510992;C2825518
2,tertiary,C0205372
2,pre - dose,C0439565;C3812758
2,no pretreatment,C1550147;C2709094;C3539075;C3539076
2,symptom bother,C1457887;C3854129
2,freedom from gtc seizures,C1299590
2,previous ml or abnormal angiogram,C0205156;C0439526;C1552607;C1705224;C3887665
2,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
2,former / current smoker ( n = nmbr nmbr ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
2,n events / n subjects,C0369718;C0441471;C0441922;C3541888
2,systemic corticosteroids — no . ( % ),C4053960
2,no . with visit,C0545082;C1512346;C2826704
2,never been on a vka,C2003901
2,never drink,C2003901
2,never or past,C2003901
2,never smoked — no . ( % ),C2003901
2,final,C0205088;C1546485;C3853528
2,never took alendronate,C2003901
2,new - onset atrial fibrillation,C0741281
2,no . of events / sample size i i,C0441471;C3541888
2,no . / total,C0439175;C0439810
2,no . of events / total no . nmbr % ),C0441471;C3541888
2,neurologicai events,C0441471;C3541888
2,use of cgm interaction test p - value^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
2,follow - up,C0589120;C1522577;C1704685;C3274571
2,geographical location,C4545686
2,no . of events / totol no . ( % ),C0441471;C3541888
2,no . of exacerbations in past year,C4086268
2,prebronchodilator fevi ( % predicted ),C0849974;C1561566;C2599602;C4528367
2,focal,C0205234
2,tah ( n = nmbr ),C0404079
2,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
2,neuropathy — no . ( % ),C0442874
2,prerandomization pci,C4049621
2,glucose in urine,C0004076
2,prespecified subgroups,C1079230
2,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
2,kilip class,C0456387;C1518526;C1705943
2,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
2,non - / ex - drinker,C0457801
2,prestudy treatment status,C0749659
2,nominal change,C0392747;C0443172;C1705241;C4319952
2,nocturnal back pain,C1970122
2,nocad / mi,C3810814
2,no . / total 	 no . ( % ),C0439175;C0439810
2,total hipc,C0439175;C0439810
2,no . / total no . ( % ),C0439175;C0439810
2,negative ctnl ( n = nmbr,C0205160;C1513916;C2825415;C2825491;C3853545
2,prespecified subgroup analyses,C2986480
2,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
2,no . / total no . ( % ) t,C0439175;C0439810
2,presentation *,C0449450
2,presentation to tertiary care hospital — %,C0337954;C0449450
2,no . of events / sample size,C0441471;C3541888
2,presence of tophi,C0150312;C0221248;C0392148;C3854307
2,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
2,new or worsenina neohrodathv,C0205314
2,final anmbrc ( % ),C0205088;C1546485;C3853528
2,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
2,no atopy ( n = nmbr ),C0392707;C3539705
2,post - bronchodilator fevx ( l ),C2599594
2,geometric mean uacr,C2986759
2,first serum creatinine,C0201976;C0205435;C0600061;C1279901
2,no . of prior aedsd,C0332152;C2826257
2,first year *,C0205435;C0439234;C0439508;C1279901
2,no . of previous csdmards,C0205156;C1552607
2,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
2,predictive factor,C0683956
2,fl ( nmbr . nmbr ),C1300812;C1708024
2,fl ( nmbrb ),C1300812;C1708024
2,urinary albumin - to - creatinine ratio §,C0455271;C1318330
2,no . of participants,C0679646
2,no . of participants ( % ),C0679646
2,no baseline characteristics,C4684572
2,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
2,flex ain ' ’,C0347129
2,flex aln^,C0729594;C2681220
2,t,C2603360
2,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
2,vessels with stenosis > nmbr %,C0679403
2,post - bronchodilator fevinmbr % predicted,C0849974;C1561566;C2599594;C4528367
2,no ( reference ),C1514811;C1706462
2,use of high - dose inhaled glucocorticoid — no . { % ),C0444956;C1524063
2,stent placement,C0522776
2,taking antihypertensive medication at baseline,C1515187
2,new or worsentna neohrodathv,C0205314
2,new york heart association class,C1882083
2,taking antihypertensive treatment at,C1515187
2,no . of infusions,C0574032
2,nfs < - nmbr . nmbr ( low ),C1555018
2,no . of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,nfs > nmbr . nmbr ( high ),C1555018
2,arterial access site,C3272298
2,use of low - dose aspirin ( < nmbr,C1524063;C2608320
2,night - time awakenings in past nmbr weeks ( sd ) *,C0860510;C2699239;C2987125
2,final timi flow grade < nmbr,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
2,post - bronchodilator fevi,C0849974;C1561566;C2599594;C4528367
2,first diagnosed,C0205435;C1279901
2,urinary albumin : creatinine ratio^,C0455271;C1318330
2,night - time awakenings in past nmbr weeks prior to baseline,C0860510;C2987125
2,preferred term,C1709637;C2347664
2,nih stroke scale,C1697238;C3484372
2,nihss score,C1697238
2,use of pci or thrombolysis within one day of randomization,C1524063;C4049621
2,previous nmbr - ari use ( % ),C0205156;C1412533;C1552607;C4521376
2,previous nmbrari use,C0205156;C1412533;C1552607;C4521376
2,non - hispanic and latino,C1518424
2,ff nmbr   µ g,C0439267;C4554348
2,non - hispanicwhite,C1518422
2,non - hispanic or latino,C1518424
2,using hrt or raloxifene at baseline ( % ),C1524063
2,pooled itt,C1709595;C2349200;C4522255
2,former smoker — no . { % ),C0337671
2,tcz nmbr mg / kg n = nmbr,C0439272
2,pooled non - canvas studies ( n = nmbr ) : non - cana ( n = nmbr )  cana nmbr mg ( n = nmbr )  cana nmbr mg ( n = nmbr ),C1518422;C1709595;C2349200;C3281223;C4522255
2,using alendronate at baseline ( % ),C1524063
2,non - hishnic,C1518422
2,previous coronary artery bypass grafting,C2144990
2,n / n   ( % ),C0369718;C0441922
2,n / n ( % / yr ),C0369718;C0439234;C0441922
2,non - hdl cholesterol j,C0729627;C1535899
2,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
2,non ‐ hdl cholesterol,C0729627;C1535899
2,previous coronary artery bypass surgery,C2144990
2,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
2,former smoker — no . ( % ),C0337671
2,user,C1548600;C1706077
2,non - inhaled steroid use,C0586793;C1518422
2,ff nmbr % ( - nmbr %,C4554348
2,non - ischaemic ( n = nmbr ),C0475224;C1518422
2,n / a,C1272460
2,former smokers,C0337671
2,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
2,n events / n at risk,C0369718;C0441471;C0441922;C3541888
2,fevi / fvc ( % ),C0802741;C3815113
2,previous diagnosis,C0332132
2,n observed,C0369718;C0441922
2,non - ischemic,C0475224;C1518422
2,fevinmbr l,C0429706;C0849974;C1561566;C4528367
2,no chd simva ( „ = nmbr ),C0280604;C3542407
2,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
2,n participants,C0369718;C0441922;C0679646
2,teaes of special interest,C0205555;C0543488
2,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
2,former smoker ( n = nmbr,C0337671
2,n t % ),C0369718;C0441922
2,ff - nmbr % ( - nmbr %,C4554348
2,polyvascular disease * status,C3176928
2,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
2,n . a .,C1272460
2,non ‐ haemorrhagic stroke — no . ( % ),C0333275;C1518422
2,previous coronary artery bypass graft,C2144990
2,previous a - blocker,C0205156;C1552607
2,non - carrier ( n = nmbr ),C2986416
2,target vessel,C0449618
2,fibrillation / flutter ),C0016385;C0232197;C2242390
2,no cases,C0868928;C1533148
2,us n = nmbr,C0369718;C0441922
2,post - procedure,C3272301
2,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
2,positive vs . negative,C0439178;C1446409;C1514241;C2825490;C3812269
2,previous bdmard received,C0205156;C1552607
2,previous af,C0205156;C0344434;C1552607;C4049859
2,post - dose,C0439568
2,general health ( self - reported ),C0424575;C4018875
2,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
2,non - cana ( n = nmbr ),C1418845;C1518422
2,previous a - blocker use,C0205156;C1552607
2,non - biological systemic,C0205373;C0445097
2,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C1333400
2,gi bleed,C1708130;C3539617;C4050121
2,ggt increased,C1415053
2,non - / ex - tobacco user,C1518422;C3853727
2,pnmbrynmbr inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
2,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
2,positive ctnl ( n = nmbr ),C0439178;C1446409;C1514241;C2825490;C3812269
2,urgent surgery,C2188405
2,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
2,n + v ( n = nmbr ),C0369718;C0441922
2,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
2,non - east asianf,C1518422;C1707877
2,former ( n   = nmbr,C0205156;C0750523
2,poor outcome at nmbr months,C0439231;C3806166
2,no . of agents,C0450442;C1254351;C1521826
2,n = nmbr lesions,C0369718;C0441922
2,generalized,C0205246
2,clinical dementia rating score,C4304227
2,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
2,used,C1273517
2,urgent revascularizati on,C0439609;C3272275
2,non - diabetics ( n = nmbr ),C0241863;C1518422
2,nap,C0870935;C1423800;C4283878
2,triglyceride level,C0428475
2,no chd eze / simva ( n = nmbr ),C0280604;C3542407
2,non - diabetic subjects,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
2,non - diabetic ( n = nmbr ),C0241863;C1518422
2,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
2,no history of heart failure at baseline,C0455531
2,insulin dose ( u ),C0366513;C0439148
2,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
2,normal coronary angiography,C0853522
2,p - value ( vs placebo ),C1709380
2,p - value for,C1709380
2,p - value for interactionnmbr :,C1704675;C1709380
2,p - value for trend across categories,C1521798;C1709380;C4554533
2,p - value low vs . high nfs^,C1709380
2,p - value n / n ( % ),C1709380
2,p - value vs . placebo,C1709380
2,p ‐ value *,C1709380
2,p - value },C1709380
2,p - value ‘ ’,C1709380
2,p - value ¶,C1709380
2,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931
2,p - valuenmbr,C1709380
2,p - valueb,C0369773;C2603361
2,p ( nmbr % cl ),C0369773;C0596019;C2603361
2,european or arab,C0239307;C1535514
2,evening,C0587117
2,evening mealb,C0587117
2,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
2,event { n ( % ),C0441471;C4019010
2,< mild,C2945599
2,p - inte faction,C0369773;C2603361
2,p - inter,C0369773;C2603361
2,patients with remission,C1277626
2,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2,event rate ( per nmbr,C0441471;C0871208;C1521828;C4019010
2,event ( p = nmbr . nmbro + ),C0441471;C4019010
2,event number,C0237753;C0441471;C0449788;C4019010
2,p ‐ value,C1709380
2,ugt induction status : as randomizeda,C0205263;C0449438;C0857127;C1420188;C4284131
2,p - value ( interaction ) ≠,C1704675;C1709380
2,event during on -,C0441471;C4019010
2,p - value ( trend ),C1521798;C1709380;C4554533
2,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
2,p . b * int,C1539794;C3272375
2,p . b “ int,C1539794;C3272375
2,uacr *  mg / g ( qnmbr  qnmbr ),C1300563
2,p value ( nominal ),C1709380
2,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
2,p value ( vs . previous time point ),C1709380
2,p value for,C1709380
2,p value for dm vs . no dm,C4086240
2,uc disease duration ( y ),C0872146
2,p value for interaction - dosage with dabigatran,C0178602;C1704675;C1709380;C2986497
2,moderate - < severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,p value for interaction ( age continuous ),C0001779;C1704675;C1709380
2,p value for interaction by region,C1704675;C1709380
2,p value for interaction ®,C1704675;C1709380
2,< nmbrmmhg,C0439475
2,p value for trend *,C1521798;C1709380;C4554533
2,p value interaction,C1704675;C1709380
2,p value ( interaction ),C1704675;C1709380
2,p value ( inter ),C1709380
2,p blocker before admission,C0184666;C0369773;C0809949;C2603361
2,p for trend -,C0369773;C1521798;C2603361;C4554533
2,p blocker *,C0369773;C2603361
2,p blockersubgroup,C0369773;C2603361
2,p for inter - act,C0369773;C2603361
2,ufh only,C0205171;C1720467
2,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
2,p for trend,C0369773;C1521798;C2603361;C4554533
2,p inter,C0369773;C2603361
2,p vaiue ( interaction ),C0369773;C1704675;C2603361
2,udy entry,C1705654
2,mild - < moderate,C1299392
2,timi flow ‡,C3272266
2,p interaction = nmbr . nmbr,C0369773;C1704675;C2603361
2,p j nmbr * trend,C1518835;C1521798;C4554533
2,p vaiue,C0369773;C2603361
2,events consistent with genital infection,C0441471;C3541888
2,p - int .,C0369773;C2603361;C3272375
2,events consistent with uti,C0441471;C3541888
2,pci performed,C4049621
2,other medical history,C0262926;C1704706
2,other n ( % ),C0369718;C0441922
2,other outcomes,C1274040
2,pci postindex event,C0441471;C4019010;C4049621
2,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C4086268
2,exacerbations requiring hospitalisation ( past year ) ( % ),C4086268
2,other prespecified end points,C2349179
2,pci :,C4049621
2,exacerbations in the year before study,C0439234;C0439508;C4086268
2,exacerbations in the prev . year : nmbr,C0439234;C0439508;C1552852;C4086268
2,exacerbations in the past nmbr months n,C4086268;C4331910
2,other selected aes,C1412268;C1707391;C2699274
2,unadjusted hazard ratio ( nmbr % cl ),C0596019;C1439367;C2985465
2,pci indication,C0392360;C3146298;C4049621
2,type nmbr diabetes . n ( % ),C1320657
2,type nmbr diabetes *,C1320657
2,other / mixed ( n = nmbr ),C0205430;C3160715
2,other atherosclerotic,C0333482
2,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
2,other ( n   = nmbr ),C0369718;C0441922
2,other ( n = nmbr,C0369718;C0441922
2,other { n = nmbr ),C0369718;C0441922
2,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
2,other ascvd,C3665365
2,pedal edema,C0574002
2,exact ( b ),C2828393;C4050514
2,other clinical characteristics,C0683325
2,other combination,C0205195;C1947911;C3811910
2,non - lad,C1518422
2,other diagnostic procedure *,C0430022;C1546908
2,type nmbr diabetes mellitusa,C1320657
2,other end points,C2349179
2,other * ( n = nmbr ),C0369718;C0441922
2,other / multiple,C0439064
2,patients with specific disease characteris -,C0205369;C0683521;C1552740
2,p - blockers ( % ),C0369773;C2603361
2,pb,C1415801;C3819255
2,time since last dose of,C0946444
2,ex - drinker,C0337679
2,ugt induction status : per aeda,C0205263;C0449438;C0857127;C1420188;C4284131
2,type of af,C0332307;C0344434;C1547052;C4049859
2,p ' value,C1709380
2,p - blocking agents,C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C2603361
2,type bnmbr / c lesions,C4264484
2,> nmbryears,C0439234
2,every day,C0332173;C0439228;C0439505
2,p - for interaetion,C0369773;C2603361
2,events requiring assistance,C0441471;C3541888
2,events consistent with volume depletion,C0441471;C3541888
2,p - gp inhibitor,C3898062
2,umec nmbr . nmbr mcg ( n = nmbr ),C0439211;C3463985
2,pci — no . { % ),C4049621
2,outcome - variant,C0205419;C1274040
2,outcomes,C1274040
2,outcome ( n,C1274040
2,outcome according to primary cancer site — no . / total no . ( % ),C0680240;C0872338;C1274040
2,outcome and metabolizer phenotype,C1274040
2,outcome severity,C0439793;C0522510;C1274040
2,outcome type,C0332307;C1274040;C1547052
2,outcome_subgroup,C1079230;C1274040;C1515021
2,outcomes during accord,C0680240;C1274040
2,pci alone ( n = nmbr ),C0205171;C0439044;C0679994;C4049621
2,over past nmbr years,C4086728
2,overal event rate,C0441471;C0871208;C1521828;C4019010
2,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
2,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
2,exacerbation historyh,C4086268
2,pci duration,C0449238;C2926735;C4049621
2,estimated proportions ( % ) and odds ratios,C0750572;C1709707
2,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
2,p value within category,C0683312;C1709380;C3889287
2,type of ml,C0332307;C0439526;C1547052;C1705224;C3887665
2,topical,C0332237
2,pasi response by baseline weight,C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
2,pasi score ( nmbr - nmbr ),C0449820;C4050231;C4528685
2,pasi score ( nmbr - nmbr ) d,C0449820;C4050231;C4528685
2,type of intervention,C3274412
2,pasi scorenmbr,C0449820;C4050231;C4528685
2,pasinmbra,C4528685
2,took prior antihyperglycemic agent ( any ),C1515187
2,pasinmbr,C4528685
2,passive smoker,C0425309
2,past or nonsmoker ( n = nmbr ),C1444637;C4284302
2,patients with > nmbr exacerbation requiring er visit or admission to hospital in the nmbr months before screening,C1512346;C3810541;C3811131;C4086268
2,past treatment for paod,C2945691
2,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
2,tophi present,C0221248
2,tonic – clonic,C3543842
2,patient ' s history of :,C0679831;C1369882
2,partner,C0682323;C3887537
2,yes  non - proliferative,C1549445;C1705108;C1710701
2,yes  unknown,C1549445;C1705108;C1710701
2,participants taking insulin,C0679646
2,participants with an event per nmbr patient - years,C0441471;C0679646;C4019010
2,type of insulin,C0457592
2,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
2,pasi,C4528685
2,tonic,C3543842
2,tobacco user,C3853727
2,pasi # nmbr at week nmbr,C0332174;C0439230;C4528685
2,pasi [c],C4528685
2,eq - nmbrd - nmbr   l,C0205163;C0439185
2,pasi nmbr,C4528685
2,"total cholesterol  mg / dl "" ^",C0201950;C0439269;C0543421
2,patient ' s global assessment of response to therapy score,C0871261;C1704632;C1706817;C2911692;C4054229
2,patient assessment of arthritis pain,C0679830;C4317006
2,participants randomized,C0679646
2,entocort ec ( n = nmbr ),C1170256
2,environmental stimuli,C0450025
2,entry hip fracture location,C1705654;C3260017
2,total > atients,C0439175;C0439810
2,total nmbr,C0439175;C0439810
2,entry category,C0683312;C1705654;C3889287
2,total basdai score,C0439175;C0439810;C1998004
2,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
2,eo severity by la classification at baseline ( baseline of the healing study ),C0332120;C0439793;C0522510;C1881447
2,total cholesterol ( sd ),C0201950;C0543421;C2699239
2,total carmelina population,C3258257
2,enthesitis score *,C0449820;C1282952;C4050231
2,enthesitis score ( mases,C0449820;C1282952;C4050231
2,total c ( mg / dl ) *,C0439175;C0439269;C0439810
2,enrolled into osler,C4684790
2,eo,C0332120
2,eosinoohil count,C0750480;C1705566
2,patient assessment of disease activity,C0679830;C1292728
2,total ( n [ nmbr ),C0439175;C0439810
2,type / no . of valves repaired / replaced mitral,C0332307;C1547052
2,total cholesterol level,C0878805;C1445957
2,patient global assessment of disease activity ( nmbr - nmbr cm,C4054228
2,patient global assessment of disease activity,C4054228
2,patient status after wake - up,C0449437;C1170730
2,total - c,C0439175;C0439810
2,total ( n nmbr nmbr ),C0439175;C0439810
2,eosinophil counf cells pl ',C0682547;C3897966;C4049765
2,eosinophils ( cells / ll ) inclusion criteria,C0682547
2,total ( n   = nmbr ),C0439175;C0439810
2,total ( n ),C0439175;C0439810
2,total ( n   =   nmbr ),C0439175;C0439810
2,total ( v = nmbr,C0439175;C0439810
2,eosinophil count,C0200638;C0750879
2,yes  proliferative,C1549445;C1705108;C1710701
2,participants,C0679646
2,estimated means and treatment differences ( % ),C0750572;C1704970
2,p / interaction,C0369773;C1704675;C2603361
2,p   values for interaction,C1704675;C1709380
2,p   values of interaction,C1704675;C1709380
2,p   vs . placebo,C0369773;C2603361
2,p ( inter ),C0369773;C2603361
2,p ) atients with > nmbr exacerbations resulting in emergency department visit,C0369773;C2603361;C4086268
2,p . o ),C0369773;C2603361
2,p < nmbr . nmbr ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1959644;C2603343;C2603361
2,p   value,C1709380
2,> nmbr . nmbrmm,C4330985;C4554674
2,pnmbr vs no treatment nmbr,C0369773;C2603361
2,pnmbrynmbr antagonist,C0231491;C0369773;C2603361
2,"estimated creatinine clearance "" ! """,C0750572;C0812399
2,pnmbr min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
2,pnmbrznmbr ( n = nmbr ),C0369773;C2603361
2,p   value for interaction,C1704675;C1709380
2,estimated glomerular filtration rate — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C3811844
2,pnmbr vs usual care,C0369773;C2603361
2,p value § ® ( w,C1709380
2,p value ∥,C1709380
2,estimated mean nmbr % cl,C0444504;C0596019;C0750572;C2347634;C2348143
2,estimated mean,C0444504;C0750572;C2347634;C2348143
2,estimated glomerular filtration rate §,C3811844
2,estimated glomerular filtration rate | |,C3811844
2,estimated glomerular filtration rate^,C3811844
2,estimated glomerular filtration rate < nmbr,C3811844
2,p valuer,C0369773;C0401806;C2603361
2,estimated glomerular filtration rate — no . ( % ),C3811844
2,> nmbrmmhg,C0439475
2,p valueb,C0369773;C2603361
2,p valuec,C0369773;C2603361
2,p valuej ',C0369773;C2603361
2,estimated glomerular filtration rate — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C3811844
2,pnmbr vs placebo,C0369773;C2603361
2,type of basal insulin,C0205112;C0332307;C0457592;C0650607;C1547052
2,participant - reported hypertension — no . { % ),C0679646;C2698741;C4554048
2,total cholesterol^,C0201950;C0543421
2,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
2,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
2,parameter statistics,C0681933
2,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
2,parameters,C0449381
2,total cigarette pack - years,C0439175;C0439810;C1303175
2,type of hospital care,C0259945;C0332307;C1547052
2,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
2,> = nmbrmg / dl,C0439269
2,type of hospitalization,C3177060
2,patients with eot data,C2707520
2,pre - mixed insulin,C0205430;C0332152;C0740175;C2257086;C3160715;C3669034
2,paroxysmal ( n,C0205311
2,paroxysmal !,C0205311
2,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
2,< = nmbr ml / min,C0439445
2,< = nmbr . nmbrmm,C4330985;C4554674
2,estimate,C0750572
2,pack - years ( iqr ),C1277691
2,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
2,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
2,pack years,C1277691
2,estimate ( nmbr % cl ),C0596019;C0750572
2,pad details,C0182158;C0332568;C1522508;C3540603;C3669270;C3814046;C4319657
2,uacr   ≥ nmbr   mg / mmol ∗,C0567349;C2348885
2,panel b,C0441833;C1706365;C1999270
2,uacr   < nmbr   mg / mmol ∗,C0567349;C2348885
2,type of event :,C1561488
2,uacr ( mg / g,C1300563
2,uacr — mg / g,C1300563
2,pairwise comparison,C1707455
2,panel a,C0441833;C1706365;C1999270
2,penetrating no . of resections,C0205321
2,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
2,experience ( n,C0237607;C0596545
2,number of exacerbations in the last nmbr months,C0237753;C0449788;C4086268
2,favors favors amlodipine chlorthalidone,C0309049
2,number of exacerbations in previous nmbr months,C0237753;C0449788;C4086268
2,number of exacerbations in previous nmbr   months,C0237753;C0449788;C4086268
2,number of exacerbations in previous year,C0237753;C0449788;C4086268
2,number of exacerbations in the nmbr months before screening,C0237753;C0449788;C4086268
2,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
2,type of reflux disease,C0232483;C0457464;C1882919;C4317146
2,number of events ( annualised rate [ % ] ),C4330837
2,number of hospitalizations in last year prior to baseline,C4086639
2,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
2,fatal / nonfatal mi,C1302234;C1705232;C3810814
2,three or more lesions,C0205449
2,number of implanted stents,C0237753;C0449788;C0522776
2,fatal or nonlatal stroke,C1302234;C1705232
2,favors favors lisinopril chlorthalidone,C0309049
2,favors comparator,C0309049;C1707454;C4553389;C4553390
2,number of medications,C1718138
2,fbg ( mg / dl ),C0439269
2,disease stage,C0699749
2,physician global assessment of disease activity,C4050369
2,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
2,physician global assessment of disease activity ( nmbr - nmbr cm,C4050369
2,number of concomitant aedsc,C0237753;C0449788;C0521115
2,fbg ( mmol / l ),C1532563
2,third yeart,C0205437
2,number of events,C4330837
2,ttf - fv,C1332112;C1705840;C4087167
2,number of copd exacerbations within nmbr months,C0237753;C0449788;C0740304
2,unknown / missing,C0439673;C3541433;C4050014
2,number of draining fistulae per patient,C0237753;C0449788;C0544791
2,this study,C0557651;C2603343
2,number of er visits in last year prior to baseline,C0237753;C0449788;C3810541;C3811131
2,number of lesions,C0449791
2,number of pack years,C0237753;C0449788;C1277691
2,pifr l / min,C0702093;C1524029;C3813700
2,fatal chd and nonfatal mia,C0280604;C1302234;C1705232;C3542407
2,fatal or non - fatal myocardial infarction,C1302234;C1705232
2,number of swollen joints ( nmbr assessed ),C0038999;C0449813
2,number of target vessels,C0237753;C0449618;C0449788
2,number of tender joints ( nmbr - nmbr ),C0234234;C0449813
2,number of tender joints ( nmbr assessed ),C0234234;C0449813
2,number of treated lesions ( per patient ),C0449791;C1522326
2,stage nmbr ( cockcroft - gault ),C0205390;C1300072;C1306673
2,fatal or non - fatal stroke,C1302234;C1705232
2,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
2,number of treated patients,C1522326;C2360800
2,number of visits,C1549755
2,stage nmbr ( four - variable modification of diet in kidney disease ),C0205390;C1300072;C1306673
2,fatal aes,C1302234;C1412268;C1705232;C2699274
2,number randomized,C0237753;C0449788
2,number of swollen joints ( nmbr - nmbr ),C0038999;C0449813
2,thrombolysis,C0520997
2,number of participants with an event,C0237753;C0449788;C0679646
2,number of patients with events,C2360800
2,number of patients ( % ) or mean ± sd,C2360800
2,fatal or nonlatal myocardial inlarctlon,C1302234;C1705232
2,number of patients randomized,C2360800
2,number of patients with available data,C2360800
2,number of patients with dose available,C2360800
2,number of symptom days per week,C0237753;C0439228;C0449788;C1457887;C3854129
2,number of patients with exacerbations in the previous nmbr months,C2360800
2,fatal or nonfatal myocardial infarction,C1302234;C1705232
2,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
2,h . pylori infection,C0850666
2,fatal or nonfatal stroke,C1302234;C1705232
2,unknown ( % ),C0439673;C3541433;C4050014
2,unknown — no . { % ),C0439673;C3541433;C4050014
2,number of subjects in analysis,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
2,fc > nmbr mg / dl ( > _ nmbr . nmbr mmol / l ) or history of diabetes,C0439269;C1532563;C2983605
2,number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0237881;C0349790;C0449788;C0750502;C1546944
2,numbers of events ( % ) :,C4330837
2,normoalbuminuria ( uacr < nmbr mg / g ),C1300563
2,female patients^,C0150905
2,normal responder ( n = nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,normal responders ( n = nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
2,normalized volume measures,C0449468;C1690016;C1705102;C1882115;C2700258
2,normalized womac score,C0449820;C1882115;C4050231
2,target vessel diameter,C0449618;C1301886
2,normal or mild ( iief - ef nmbr - nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,normoglycemia,C0580545
2,normoglycemic,C0580545
2,normoglycemic^,C0580545
2,upadacitinib nmbr mg ( n = lnmbr ),C0439268
2,normoglycemic {,C0580545
2,received pci,C1514756;C4049621
2,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
2,normal or increased gfr ( > nmbr ml / mln per nmbr . nmbr m^ ),C0205307;C0231683;C0439166;C2347086;C4553972
2,acei / arb and bb after randomisation,C3888198
2,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
2,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
2,test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
2,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
2,normal function ( crcl > nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C4296962
2,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
2,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
2,tests for categoric,C0589061
2,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from nmbr to nmbr . scores for the western,C0205120;C0489786;C1552595
2,normal function or mild impairment,C4296962
2,type of mi,C0332307;C1547052;C3810814
2,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
2,normal or high egfr ( > nmbr ml / min per nmbr . nmbr mnmbr ) at baseline to low egfr ( < nmbr ml / min per nmbr . nmbr mnmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,normal or increased baseline gfr ( > nmbr ml / min / nmbr . nmbr mnmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972
2,normotensive ( n = nmbr ),C2712122
2,north,C1709269
2,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
2,nerd grade,C0441800;C0919553;C3244287
2,notes :,C1317574
2,nt probnp > nmbr ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
2,nteraction p value,C1709380
2,placebo ‐ controlled period,C0439531;C1706408;C1948053
2,placebo - control study,C0683952
2,place !,C0442504;C1533810;C1704765;C1882509
2,pla n = nmbr,C0456170
2,not tested,C1518422
2,unstable,C0443343;C1883468
2,pla « = nmbr,C0456170
2,number ( % ) of patients,C2360800
2,number and % of participants with events,C0237753;C0449788
2,number of “ off ” periods,C0237753;C0449788
2,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
2,notatincreased fall risk ( n - nmbr,C1268740
2,not severe,C4316743
2,north ameriea,C1709269
2,not estimable,C1518422
2,nosnmbr nmbr c . t,C0326287;C1518425
2,nosnmbr nmbr a . g,C0326287;C1518425
2,untreated,C0332155
2,not assessable,C1883425
2,unstable but no rest angina,C0443343;C1883468
2,not collected^,C1518422
2,not hispanic,C1518424
2,not receiving,C1518422
2,pulsed blood pressure,C0232108
2,admission crcl,C0184666;C0809949;C1846718
2,not perfused,C1518422
2,not present at screening,C1518422
2,admission k,C0184666;C0597277;C0809949;C1708601
2,feature,C1521970;C1706388;C2346469;C2348519
2,two lesions,C0205448;C0221198
2,ii - iii,C0439070;C1705160;C1710602;C4082587
2,unadjusted model hr,C1439367;C3161035;C3274659;C3714583;C3853906
2,uncontrolled : acq - nmbr > nmbr . nmbr,C0205318;C2919686
2,one or more exacerbations,C0205447
2,one or more medications,C0205447
2,facit - f score,C0449820;C3272505;C4050231
2,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178
2,facit - f,C3272505
2,percentage of p,C0439165;C1549488;C1561533
2,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
2,factor,C1521761;C2827422
2,type nmbr diabetes — no . { % ) §,C1320657
2,facilitated pci ( n = nmbr ),C4049621
2,percentage of bsa involved,C0439165;C1549488;C1561533
2,percentage,C0439165;C1549488;C1561533
2,option,C1518601;C1550456
2,uncontrolled on oad ( s ),C0205318
2,one lesion,C0205447;C0221198;C1546698
2,type nmbr diabetes — no . ( % ) §,C1320657
2,facial psoriasis,C1276112
2,on - pump,C3842462
2,fair or poor,C2911689
2,percentages,C0439165;C1549488;C1561533
2,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < nmbr mg / dl . tbased on participant history or review of chart .,C0439165;C1549488;C1561533
2,omega - nmbr fa ( n = nmbr ),C1719844
2,percentage points,C0439165;C1549488;C1561533
2,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
2,failure,C0231174;C0680095
2,factor absent,C1521761;C2827422
2,intermediate risk,C3640764
2,factors that confer a,C1521761;C2827422
2,factor *,C1521761;C2827422
2,factor present,C0150312;C0449450;C1521761;C2827422
2,type,C0332307;C1547052
2,type nmbr diabetes — no . ( % ),C1320657
2,or for cana vs pbo ( nmbr % ci ) | |,C1418845
2,time point,C2348792
2,fall in last nmbr months ( % ),C0085639;C0238715;C0439231;C4553726
2,percent change from baseline at week nmbr,C3272907
2,extracranial,C0580586
2,oral hypoglycemic agents,C0359086
2,percent change from baseline to week nmbr in auc ( mean,C3272907
2,extensive / pancolitis,C0205231;C0868908
2,oral hypoglycemic agentsj,C0359086
2,oral or other systemic corticosteroid,C0442027;C4521986
2,exposed,C0332157
2,percent improvement,C0439165;C2986411
2,unadjusted p value,C1439367;C1709380
2,organic,C0747055
2,origin [n ( % ) ],C0079946;C0439659;C1550512
2,oropharyngeal pain,C2363731;C4554669
2,type nmbr diabetes mellitus ' nmbr ',C1320657
2,experienced,C0237607;C0596545
2,percent impairment while working due to asthma,C0221099;C0439165;C0684336
2,oral fi - blockers,C0442027;C4050619;C4521986
2,or for cana vs pbo ( nmbr % ci ) §,C1418845
2,unclassified,C0205426;C1546437;C2347854;C4085229
2,or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
2,oral ( % ),C0442027;C4521986
2,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
2,oral agent and / or insulin therapy,C0442027;C0450442;C1254351;C1521826;C4521986
2,type nmbr diabetes meiiitus,C1320657
2,uncontrolled on basal insulin,C0205318;C0650607
2,oral anticoagulant n ( % ),C0354604
2,all bare metal stents,C2825200
2,oral antihyperglycaemic,C0359086
2,type nmbr diabetes mellitus,C1320657
2,percent overall work impairment due to asthma,C0439165
2,percent of predicted value before bronchodilation^,C1882327
2,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
2,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
2,two or more at baseline,C0205448
2,unfractionated only,C0205171;C1720467
2,nx *,C0445085
2,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
2,nyha functional classification — no . ( % ) i,C0205245;C0542341;C1275491;C2700217
2,tier nmbraes,C1412268;C2699274
2,recent,C0332185
2,nyha iii or iv § ( n = nmbr nmbr ),C0439070;C1275491;C1705160
2,inadequate,C0205412;C0439856
2,pfor trend,C1151635;C1521798;C4554533
2,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
2,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
2,persistent / permanent,C0205322;C0205355;C0332996
2,persistent *,C0205322;C0332996
2,fasting plasma glucose in mmol / l ( median ( qnmbr,C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
2,nyha ll / lll patients with lvef < nmbr . nmbr at baseline,C1275491
2,nyha_class,C1882083
2,persistent faol ( n [ nmbr ),C0205322;C0332996
2,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
2,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
2,persistent ( n,C0205322;C0332996
2,nyha class iii / iv,C0278962
2,nyha,C1275491
2,non - european,C0239307;C1518422;C1535514
2,nyha class ( when patient was last in stable condition,C1882083
2,nyha class ii ( n = nmbr ),C1882085
2,nyha class iii or iv,C1882086
2,< nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,fatal & nonfatal ccvd,C1302234;C1705232
2,tier nmbr aes,C1412268;C2699274
2,nyha classes iii - iv,C0278962
2,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
2,nyha functional class nmbr,C0205245;C0542341;C1882083;C2700217
2,fatal,C1302234;C1705232
2,past or nonsmoker,C1444637;C4284302
2,nyha functional class i,C0205245;C0542341;C1882084;C2700217
2,persistent faod ( n [ nmbr ),C0205322;C0332996
2,o,C0483204
2,perianal,C0442158
2,peripheral - artery stenosis,C4025272
2,oct center point thickness,C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732
2,octi & matenmbr,C0682323;C1260875
2,time from onset of symptoms to presentation — hr,C1320528
2,unhappy,C1688635
2,family history of myocardial infarction prior to age nmbr,C0455406
2,time from onset of symptoms to start of fibrinolytic therapy — hr,C1320528
2,period ii,C0439531;C1710602;C1948053;C4082587
2,ocn,C1412791;C2347392
2,family history of diabetes mellitus — no . { % ),C0260526;C1313937
2,of variation ),C0205419
2,off - pump,C0182537;C1518543
2,older subjects ( aged > nmbr years ',C0580836
2,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
2,time from symptom onset of ra,C1320528;C3538806;C4048756
2,ocs dose *,C0178602;C0869039;C1114758
2,obstructive subscore,C0549186
2,permanent users,C0205355;C1706077
2,fasting blood glucose > nmbr mg / dl ( > nmbr . nmbr mmol / l ),C0428568;C0439269;C1261430;C1532563
2,o - oonmbr ( - nmbr - nmbr to nmbr - nmbr ),C0483204
2,onmbro ( oonmbr - o - nmbro ),C0483204
2,fasting glucose level,C0202045
2,permanent af,C0205355;C0344434;C4049859
2,oab - q score,C0449820;C3641332;C4050231
2,permanent ( n,C0205355
2,two or more,C0205448
2,observed case,C0868928;C1441672;C1706255;C1706256
2,peripheral sensory neuropathy,C0151313;C4554142
2,peripheral revascularisation,C0205100;C0581603
2,two or more antihypertensive medications,C0205448
2,peripheral artery diseaseb,C0489868
2,peripheral arterial stenosis,C4025272
2,observed,C1441672
2,previous stroke 一 no . ( % ),C0205156;C1552607
2,primary endpoint ’,C2986535
2,swollen joint count of nmbr joints,C0451521
2,lmnmbr bid ( n = nmbr ),C1261082;C1551056
2,xi = nmbr - nmbr,C1720296
2,weight at baseline,C1303013
2,xi = nmbr,C1720296
2,xi = nmbr - nmbr  p = nmbr - l,C1720296
2,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
2,risk factor for venous thromboembolism,C1521761;C2827422;C3495424;C3496592
2,lmnmbr nmbr,C1261082;C1551056
2,local eosinophil count,C0200638;C0205276;C0750879
2,xi = nmbr - nmbr  p = nmbr - nmbr,C1720296
2,local eosinophil count [cells / µ l],C0200638;C0205276;C0347983;C0750879
2,local eosinophil count [cells / ml],C0200638;C0205276;C0750879;C2699156
2,sokolow - lyon ( mm ) *,C4330985;C4554674
2,locally advanced,C1517927
2,xi = nmbr - nmbr  p = o - l,C1720296
2,lone atrial fibrillation — no . ( % ) §,C0340489
2,xi = nmbr - nmbr  p = nmbr,C1720296
2,xi = nmbr . nmbr,C1720296
2,lis,C2247545
2,years modified hoehn and yahr stage,C0439234
2,lioid trial participants,C1997894;C2242969
2,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
2,lieum only,C0205171;C1720467
2,life - threatening,C1546953;C2826244;C3537125
2,hospitalized,C0701159
2,limb amputation,C0002689
2,limited,C0439801;C2674459;C3542948;C4050251
2,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
2,lipc,C1416867
2,risk level at admission,C0184666;C0809949;C2923839
2,lipid ‐ lowering therapies,C0585943
2,xho  p = o - nmbr,C4050013
2,xi = ° - ° nmbr,C1720296
2,lipid lowering therapy,C0585943
2,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
2,lira,C1555441
2,risk marker and model,C1519104
2,hospitalization for heart failure or cv death,C3898876
2,hospitalization for heart failure or cv,C3898876
2,hospitalization for heart failure n ( % ),C3898876
2,low ( n = nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,low - ceiling diuretic,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
2,years ( sd ),C0439234;C2699239
2,some college / tech,C0557806;C1826596
2,low ( < nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,low ( > nmbr . nmbr and < nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,low ( nmbr - nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
2,xi = nmbr - l  p = nmbr - nmbr,C1720296
2,source,C0449416;C1705919;C4521696
2,low { < nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,low cnmbr ( < nmbr . nmbr g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
2,reversible to albuterolc,C0205343
2,low cnmbr ( < nmbr mg / dl ),C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
2,south or central america,C1710133
2,south or central american,C1710133
2,lost bmd,C0745777;C3815882
2,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
2,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
2,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
2,xi = l ’ nmbr  p = nmbr - nmbr,C1720296
2,hospitalisation for heart failure,C3898876
2,xi = o - nmbr  p = o - nmbr,C1720296
2,xi = oo  p = o - nmbr,C1720296
2,sokolow - lyon voltage,C0598352
2,year - nmbr,C0439234;C0439508
2,trait,C0599883
2,long - term vitamin k antagonist,C0443252;C1096489;C2267235
2,long term ( n = nmbr ) +,C0443252
2,long term *,C0443252
2,loop diureties,C0445022
2,loop or thiazide diuretic^,C0445022
2,some college,C0557806
2,year,C0439234;C0439508
2,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
2,hospitalized for an exacerbation,C0701159;C4086268
2,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
2,less than high school,C0439092;C0599395;C0683862;C0870649
2,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
2,rr ( nmbraci ) [p value],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
2,ldl / hdl cholesterol ratio,C2938854
2,hs - crp _ = nmbr . nmbr mg / l,C0439268;C3890735;C4048285
2,hs - crp mg / l,C0439268;C3890735;C4048285
2,ldl : hdl ratio,C0428621
2,ldlc,C1416822
2,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
2,leading to study drug discontinuation,C0332152;C1522538
2,left,C0205091;C0443246;C1552822
2,leading to study withdrawal,C0332152;C1522538
2,rr reduction,C0301630;C0392756;C1293152;C4551656;C4554402
2,rr ( nmbr % cl ) [ / ’ value],C0596019;C1522609;C4554402
2,leeds enthesitis index,C0451148
2,leeds enthesitis index^ score > nmbr — no . { % ),C0451148
2, ( nmbr % cl : nmbr . nmbr - nmbr . nmbr ) p = nmbr . nmbr,C0596019
2, p = nmbr . nmbr,C0596019
2,hs - crp < nmbr . nmbr nlg l,C3890735;C4048285
2,hs - crp jnmbr . nmbr mg / l,C0439268;C3890735;C4048285
2,hs - crp jnmbr . nmbrmg / l,C0439268;C3890735;C4048285
2,hs graduate / ged,C0588053;C1547183;C1880947
2,smoking ( during the previous month ),C0332177;C0439231;C2114448
2,smoking consumption pack - years,C0425291;C1277691
2,ldl - c ( mg / dl ) * *,C0439269
2,hx mi or stroke,C0262926;C3810814;C3814444
2,ldl - c < nmbr mg / dl ( nmbr . nmbr mmol / l ),C0439269;C1532563
2,hscrp range,C1514721;C2348147;C3542016
2,ldl - c > nmbr mg / dl,C0439269
2,ldl - c nmbr - nmbr mg / dl,C0439269
2,smoking history ( pack - years ) ∗,C1277691;C1519384
2,ldl - c goal attainment,C0680230
2,ldl - c in mmol / l ( mean ± sd for baseline [n]  mean ± se for week nmbr [n] ),C0444504;C1532563;C2347634;C2348143;C2699239
2,hscrp level,C0441889;C0456079;C1547707;C2946261
2,ldl - c level,C0441889;C0456079;C1547707;C2946261
2,ldl - c   *   ( mmol / l ),C1532563
2,ldl - c < nmbrmg / dl,C0439269
2,hr nmbr . nmbr ( nmbr % cl nmbr . nmbr,C0596019
2,left main coronary artery bifurcation,C3898614
2,smoking status . no . ( % ),C1519386
2,less than nmbr,C0439092
2,lesions treated per patient,C0221198
2,hr ( nmbr % cl ) = nmbr . nmbr ( nmbr nmbr,C0596019
2,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
2,smoking status current,C0521116;C1519386;C1705970
2,hr ( nmbr % cl ) = nmbr . nmbr ( nmbr . nmbr,C0596019
2,smoking status current smoker ( n = nmbr ),C1519386;C3173209;C3241966
2,wt,C1883559;C2700323
2,hr ( nmbr % cl ) = nmbr . nmbrb ( nmbr,C0596019
2,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
2,xnmbr years,C0439234
2,hr ( nmbr % cl ) = nmbr nmbr ( nmbr . nmbr . nmbr,C0596019
2,less than nmbr kg / mnmbr,C0439092;C1532718
2,less than nmbr . nmbr %,C0439092
2,hot climate subset,C0178683;C1515021
2,hospitalized !,C0701159
2,hospitalized without airway compromise,C0701159;C4055482
2,lesion ( s ),C0221198;C1546698
2,lesion length ≥ nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
2,hr ( nmbr % cl ) pvalue,C0596019
2,lelt ventricular hypertrophy *,C0340279
2,hr nmbr - nmbr ( nmbr % cl nmbr - nmbr - nmbr - nmbr ),C0596019
2,hr nmbr - nmbr ( nmbr % cl nmbr - nmbr - nmbr ),C0596019
2,left shoulder,C0524469
2,left side,C0205091
2,rr ( nmbr % cl ) p value,C0596019;C1709380;C4554402
2,row §,C1552840;C1552846
2,smoking status — no . { % ),C1519386
2,smoking status ( ongoing ) ( n ),C0549178;C1519386
2,row * n = nmbr,C1552840;C1552846
2,left ventricular ejection fraction — % §,C0428772;C0488728
2,hr ( b . p . m . ),C0369637;C0441923
2,left ventricular ejection fraction ( % ),C0428772;C0488728
2,left ventricular systolic dysfunction,C1277187;C1963159;C4553199
2,legend,C2729544
2,western,C1705493
2,low cnmbr / cnmbr and anti - dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
2,lce,C1423759;C3273355
2,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
2,major amputationsb,C0205082;C0205164;C4318856;C4521762
2,ssomgdayp . eq .,C0205163;C0439185
2,week nmbr / et,C0332174;C0439230
2,major and crnm bleeds,C0205082;C0205164;C4318856;C4521762
2,history of hypertension . no . ( % ),C0455527
2,history of hypertension - n ( % ),C0455527
2,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
2,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
2,history of hypertension^,C0455527
2,history of heart failure at baseline,C0455531
2,history of heart failure — no . { % ),C0455531
2,history of fistullzing disease,C0683519;C0730226;C0850708;C0944983
2,major or clinically relevant non - major bleed,C0205082;C0205164;C4318856;C4521762
2,st - depression and t - wave inversion,C0520887
2,years since symptom onset,C0439234
2,st - depression only,C0205171;C0520887;C1720467
2,renal biopsy class,C0194073;C0456387;C1518526;C1705943
2,week nmbra,C0332174;C0439230
2,low dose,C0445550;C1708745
2,sri ‐ nmbr response rate,C0237629;C1420401
2,lvef ≤ nmbr %,C0428772;C0488728
2,sprint acr > nmbr - nmbr,C1412134;C1515941
2,lvef^nmbr . nmbr and nyha class ii,C0428772;C0488728
2,lvesv ( ml ),C0439526;C1705224;C3887665
2,week and,C0332174;C0439230
2,lvh by ecg,C0232306
2,renal function ( ml / min ),C0232804;C0439445
2,lvh by ecg or echo . n ( % ),C0232306
2,history of macrovascular disease at baseline,C0683519;C0730226;C0850708;C0944983
2,lvh by ecg or echocardiography,C0232306
2,lvh by ecg or echocardiographyd,C0232306
2,ss years,C0439234;C2699257;C3891295;C4551874
2,lvh on ecg,C0232306
2,mnmbrs,C0439493;C1513009
2,total no . of events / participants,C0439175;C0439810
2,years since pd diagnosis,C0439234
2,major or clinically relevant non - major bleeding,C0205082;C0205164;C4318856;C4521762
2,st - segment depression > nmbr mm,C0520887;C4330985;C4554674
2,week nmbr * ’ ’,C0332174;C0439230
2,history of diabetes mellitus ( n = nmbr ),C0455488
2,yes ( n,C1549445;C1705108;C1710701
2,week nmbr ( mmol / l ),C0332174;C0439230;C1532563
2,mar ( itt ) ( n = nmbr ),C3829202;C4255469
2,st segment elevation,C0520886
2,yes vs . no,C1549445;C1705108;C1710701
2,week nmbr mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
2,younger subjects ( aged < nmbr years ),C0332239
2,mate !,C0682323;C1260875
2,st - segment depression > nmbr mm — no . ( % ),C0520887;C4330985;C4554674
2,maximum,C0806909;C1552615;C2826546
2,mayo score ( nmbr - nmbr ),C0449820;C0454788;C1077578;C4050231
2,mean — %,C0444504;C2347634;C2348143
2,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
2,mean — ml / min,C0439445;C0444504;C2347634;C2348143
2,mean — ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
2,mean — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
2,yes ( any ),C1549445;C1705108;C1710701
2,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0683519;C0730226;C0850708;C0944983
2,st segment depression,C0520887
2,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
2,st - segment depression or t - wave inversion on ecg,C0520887
2,st - segment elevation,C0520886
2,week nmbr *,C0332174;C0439230
2,"week nmbr  % ( n ) "" """,C0332174;C0439230
2,history of fistulizing disease,C0683519;C0730226;C0850708;C0944983
2,history of fistulising disease,C0683519;C0730226;C0850708;C0944983
2,history of falls in year before randomization,C1561668;C2919132
2,history of falls,C1561668;C2919132
2,related to study druga,C0439849;C0445223
2,years ),C0439234
2,major surgery,C0679637
2,st depression > nmbr mm,C0520887;C4330985;C4554674
2,st elevation,C0520886
2,major / crnm bleed,C0205082;C0205164;C4318856;C4521762
2,male patients *,C0150904
2,sprint acr < nmbr - nmbr,C1412134;C1515941
2,lvef < nmbr . nmbr,C0428772;C0488728
2,renal function *,C0232804
2,total randomized,C0439175;C0439810
2,reversibility < nmbr % ( n = nmbr ),C0449261
2,reversibility < nmbr % ( itt ) ( n = nmbr ),C0449261
2,lower - dose,C0445550;C1708745
2,lower - limb angioplasty or bypass surgery,C0745788
2,special interest categories,C0205555;C0543488;C0683312
2,lower - target group ( n = nmbr ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
2,years since diagnosis,C0439234
2,lower dose,C0445550;C1708745
2,total phase nmbr pooled ( n = nmbr ),C0205390;C0439175;C0439810;C1710475
2,reversibility [ % ],C0449261
2,total randomised ( n ),C0439175;C0439810
2,hit - nmbr score,C0272285;C0332159;C0449820;C1708373;C4050231
2,reversibility — %,C0449261
2,lower risk ( n = nmbr ),C3272281;C3538919
2,lower tertile : b nmbr . nmbr,C0441994;C1548802;C2003888
2,revascularization in nmbr days,C0439228;C0581603
2,low risk ( n nmbr nmbr ),C3272281;C3538919
2,reversibility > nmbr % ( itt ) ( n = nmbr ),C0449261
2,reversibility > nmbr % ( n = nmbr ),C0449261
2,reversibility snmbr % ( itt ) ( n = nmbr ),C0449261
2,reversible,C0205343
2,reversibility ’ ' %,C0449261
2,low hdl - c,C0151691
2,south,C1710133
2,hoehn & yahr stage ( “ on ” ),C0205390;C1300072;C1306673
2,hoehn & yahr stage ( “ off ” ),C0205390;C1300072;C1306673
2,hoehn & yahr stage,C0205390;C1300072;C1306673
2,southern hemisphere,C0205139;C1710133
2,low hdl cholesterol * |,C0151691
2,reversibility to salbutamolc,C0449261
2,reversibility stratum *,C0449261
2,low nfs nfs < - nmbr . nmbr ( n = nmbr ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
2,years of follow - up,C0439234;C0589120;C1522577;C1704685;C3274571
2,low normal ( n = nmbr ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
2,low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,total psa ‐ modified shs,C0392747;C2986589;C3889737
2,lowest,C1708760
2,lvef ( u ),C0428772;C0439148;C0488728
2,weekly issnmbr,C0332174;C1740819;C1845118
2,renin inhibitor,C1960108;C3537174;C4521920
2,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
2,ltg - exposed,C1420817;C4521367;C4521846
2,ltg - naive,C1420817;C4521367;C4521846
2,ltg subgroup,C1079230;C1420817;C1515021;C4521367;C4521846
2,lue for interaction,C1704675
2,lung infection,C0876973;C4552950
2,weekly iss {,C0332174;C1740819;C1845118
2,lowest normal ( n = nmbr ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
2,lv hypertrophy per ecg,C0232306
2,lvedv ( ml ),C0439526;C1705224;C3887665
2,week   nmbr,C0332174;C0439230
2,history of osteoporotic fracture,C4075937
2,lvef — no . ( % )  i ,C0428772;C0488728
2,renal function : ! : n ( % ),C0232804
2,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
2,lsm difference ( nmbr % cl ),C0596019;C1705241;C1705242
2,weeko mean + sem,C0444504;C2347634;C2348143
2,years since mi ( median,C0439234
2,years since last gout flare,C0439234
2,lpa,C1096202;C1439335;C3539666;C4049711;C4553379
2,lrg,C1428862
2,revascularisation,C0581603
2,restriction in normal activities in the past nmbr weeks,C0443288;C4697852
2,respiratory medication taken at baseline,C0418986
2,total number of patients,C0439175;C0439810;C2360800
2,total number of events / participants,C0439175;C0439810;C0679646;C4330837
2,years since diagnosis of type nmbr diabetes,C0439234
2,history of smoking,C1519384
2,resection performed — no . { % ),C0015252;C0728940
2,history of postmenopausal fracture *,C0232970;C1272071
2,weeks_measured,C0439230
2,rescue medication use,C0240320
2,required hospitalization,C1708385
2,repaired s - p shunts,C0205340
2,ld,C0694649
2,lavolta ii,C1710602;C4082587
2,mean % predicted value prebronchodilation,C0444504;C2347634;C2348143
2,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
2,ipss,C1019118;C1998280;C2827405;C3811063
2,serum creatinine . mg / dl,C0201976;C0439269;C0600061
2,ipss - s,C1019118;C1998280;C2827405;C3811063
2,ipss - v,C1019118;C1998280;C2827405;C3811063
2,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
2,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
2,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
2,increase in serum creatinine,C0201976;C0442805;C0600061
2,serum creatinine level,C0600061
2,serum phosphate,C0036820
2,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
2,ipss hrql,C1019118;C1998280;C2827405;C3811063
2,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
2,inconsistent fao ( n [ nmbr ),C0016457;C0442809
2,inclusion criteria,C1512693
2,included in this study ( n = nmbr ),C0332257;C0557651;C2603343
2,iop,C0578862
2,with higher classes indicating greater limitations on physical activity owing to,C0205250;C0456387;C1518526;C1705943;C4019422
2,ischemic stroke or see,C0948008
2,intravenous vasoactive drugs,C0683092;C1980011
2,intracerebral,C0442111
2,intracranial,C0524466
2,score ( > nmbr ) at nmbr monthsb unadjusted or,C0449820;C4050231
2,serious teaes,C0205404
2,seropositivity status,C0449438;C0521143
2,intravenous ( n = nmbr ),C0348016
2,indication,C0392360;C3146298
2,with events ( % ),C0441471;C3541888
2,serum creatinine > nmbr / xmol / l,C0201976;C0600061
2,serum calcium,C0036785;C0728876
2,investigations,C1261322
2,scalp psoriasis,C0406326
2,serum creatinine - mean ( sd,C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
2,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
2,involved gastrointestinal,C0521362;C1314939
2,indeterminate nfs - nmbr . nmbr < nfs < nmbr . nmbr ! n = nmbr ),C0205258;C1513839
2,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
2,incident or worsening nephropathy,C1551358
2,serum potassium level,C0302353;C0543465
2,in extension study,C0231448;C0557651;C1880641;C2603343
2,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,ischaemic ( n = nmbr ),C0475224
2,in previous year,C0205156;C0439234;C0439508;C1552607
2,total score < nmbr,C2964552
2,ischaemic dilated cardiomyopathy,C1960867
2,ischaemic or unknown stroke,C0475224
2,ischaemic skin lesions,C0037284;C0475224
2,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
2,ischaemic stroke,C0948008
2,ischemic,C0475224
2,total scores ( total score range : nmbr - nmbr ),C1514721;C2348147;C2964552;C3542016
2,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
2,sample statistics,C2348149
2,ischemic outcomes,C0475224;C1274040
2,ischemic stroke ( % ),C0948008
2,with mets,C0812270;C1705694;C2939420
2,inadequate response or intolerance to > nmbr anti - tnfdrug,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,irritative subscore,C0441723;C1706307;C2700617
2,inappropriate,C1548788;C3537135;C3542467
2,incidence rate *,C1708485
2,serum sodium — mmol / liter,C0439190;C0475211;C0523891
2,incidence rate no . ( / nmbrperson - years ),C1708485
2,incidence rate difference,C1705241;C1705242;C1708485
2,serum sodium,C0523891
2,serum sodium . meq / l,C0439375;C0523891
2,serum total ige,C1441420
2,serum urate ( mg / dl ),C0439269;C0455272
2,incidence rate ( n ) a,C1708485
2,incidence rate ( n ),C1708485
2,with lowest bwb,C1708760
2,serum uric acid,C0455272;C0700634
2,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
2,ipss voiding subscore,C1019118;C1998280;C2827405;C3811063
2,irregular or ulcerated ica plaquef,C0205271
2,score > nmbr . nmbr,C0449820;C4050231
2,intolerance ®,C0231199;C1744706;C2355652
2,intolerance ',C0231199;C1744706;C2355652
2,interaction,C1704675
2,sedbp ( mmhg ) [mean _sd]d,C0439475;C0444504;C2347634;C2348143;C2699239
2,sdc ( nmbr . nmbr - nmbr . nmbr ng / ml ),C0439275;C1419891;C3273112
2,sedbp ( mmhg ) [mean_ sd]a,C0439475;C0444504;C2347634;C2348143;C2699239
2,sdai ( nmbr - nmbr ),C3871128
2,injectable anti ‐ hyperglycaemic,C1272883
2,inter . p - value,C0205103;C1548610
2,sd or %,C2699239
2,initial timi flow grade nmbr,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
2,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
2,interaction jnmbr - valuet,C1704675
2,interaction p - vaiue,C1704675
2,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
2,interaction p - value *,C1704675;C1709380
2,selena - sledai > nmbr,C0451528
2,interaction p - valuef,C1704675
2,selena - sledai activity,C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
2,sdc ( ng / ml ),C0439275;C1419891;C3273112
2,inotropic agent,C0304509
2,intensitynmbr,C0522510
2,intensity of statin therapy at baseline — no . { % ),C0522510;C1278454
2,insulin dose,C0366513
2,secondary endpoints :,C4528314
2,insulin dose ( iu / day ),C0366513;C0439465
2,section nmbra,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
2,section nmbrb,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
2,insulin administration,C0199782
2,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
2,insulin treatment,C0745343
2,insulin type,C0457592
2,section nmbrc,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
2,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
2,intensification of antianginal therapy,C1511484;C1874267;C3537168
2,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
2,insufficient,C0205412;C0231180;C0439856
2,intensity of statin therapy,C0522510;C1278454
2,inhibitor,C1999216
2,selena - sledai total score,C0451528;C2964552
2,intolerance,C0231199;C1744706;C2355652
2,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1552654;C1552713;C4086878
2,intermediate ( nmbr ),C0205103;C1550465;C2827755;C3889971
2,serious,C0205404
2,intermediate ( nmbr - nmbr ),C0205103;C1550465;C2827755;C3889971
2,score improvement,C0449820;C2986411;C4050231
2,interquartile range — ml / min,C0439445;C1711350
2,intertrochanteric,C0745355
2,interval between clinical evaluation and initiation of treatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
2,interval of > nmbr yr since diagnosis of type nmbr diabetes — no . ( % ),C0439234;C1272706;C1552654;C1552713
2,score on st . george ' s respiratory questionnaire^^,C3472502
2,serious aes,C0205404;C1412268;C2699274
2,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
2,score at week nmbr,C0332174;C0439230;C0449820;C4050231
2,serious decline in kidney function *,C0205404;C0232804
2,serious decline in kidney functionnmbr,C0205404;C0232804
2,score nmbr . nmbr,C0449820;C4050231
2,inducing,C0205263
2,score on asthma control questionnaire * *,C4706265
2,intermediate - acting,C0205103;C1550465;C2827755;C3889971
2,infected,C0439663
2,interim analysis ( all patients ),C4684691
2,interaction p = nmbr . nmbr,C1704675
2,interaction p vaiue,C1704675
2,interaction p value nmbr . nmbr,C1704675;C1709380
2,inguinal hernia repair,C0021446
2,infrequent exacerbator,C0521114
2,inflotmas io mgluj versus piecew,C1046794;C3146236
2,interaction p value !,C1704675;C1709380
2,interaction p value ∗,C1704675;C1709380
2,total score §,C2964552
2,interaction p value *,C1704675;C1709380
2,total score > nmbr,C2964552
2,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = nmbr . nmbr  gender  p = nmbr . nmbr  race  p = nmbr . nmbr  history of chd  p = nmbr . nmbr  history of diabetes  p = nmbr . nmbr . lisinopril vs . chlorthalidone : age  p = nmbr . nmbr  gender  p = nmbr . nmbr  race  p = nmbr . nmbr  history of chd  p = nmbr . nmbr  history of diabetes  p = nmbr . nmbr . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C1704675;C1709380
2,interaction pf,C1704675;C3815179
2,interaction : treatment by psoriasis p valueb,C1704675;C3258078
2,interim analysis,C4684691
2,ischemic stroke ( incl . uncertain ),C0948008
2,ischemic stroke subtype,C0449560;C0948008
2,latin american subgroup,C1079230;C1515021;C1553378
2,shs ( nmbr - nmbr  per nmbr score ),C0449820;C4050231
2,sgrq total scorenmbr,C2964552
2,snmbr kg / m^,C0565930;C1532718;C2603362
2,known duration,C0205309;C0449238;C2926735
2,snmbr mg / mmol,C0565930;C0567349;C2348885;C2603362
2,short term ( n = nmbr ) +,C0443303
2,total vdh - s score,C2964552
2,short term^,C0443303
2,significant worsening in kccq clinical,C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
2,sgrq - c total scoreb,C0439175;C0439810;C3826872
2,significant worsening in kccq clinical score ( ≥ nmbr ) at nmbr mo †,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
2,known duration of type nmbr diabetes,C0205309;C0449238;C1320657;C2926735
2,l,C0439394;C1706495;C3642217
2,l ( < l ),C3539687
2,single vessel coronary artery disease †,C0581374
2,s wave in vnmbr ( mm ),C0456681;C4301968
2,sinus tracts / perforation,C0544791;C0549099;C0854572;C1185740;C1881710
2,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
2,km rates { % ) e / s,C0871208;C1521828;C3887676
2,ish status,C0449438
2,snmbr exacerbations,C0565930;C2603362;C4086268
2,icsa plus laba,C0332287
2,severity of copda,C0439793;C0522510
2,severity of heartburnb,C0439793;C0522510
2,severity ofhypertension [n ( % ) ]b,C0439793;C0522510
2,killip class nmbr,C1881332
2,killip class nmbr / nmbr,C1881332
2,snmbr . nmbr mg / mmol,C0565930;C0567349;C2348885;C2603362
2,killip class ii,C2697845
2,sfc ( n   = nmbr,C4521536
2,white hispanic - n ( % ),C1533020;C1533021
2,sexually active,C0241028
2,sexually activenmbr ( % ),C0241028
2,killip class *,C1881332
2,kl nmbr ( % ),C1366480;C1416656;C1704887
2,km event ( % ) at nmbr y,C0441471;C3887676;C4019010
2,km rate ( % ),C0871208;C1521828;C3887676
2,l compared wit,C0439394;C1706495;C3642217
2,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
2,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
2,laboratory tests,C0022885
2,rvalue for interaction,C1704675
2,total vdh - s score ( nmbr - nmbr ) ( n ),C2964552
2,ruled out non - fatal pe with or,C1446409
2,total !,C0439175;C0439810
2,slnmbr mm hg,C0439475
2,hypertension requiring treatment,C0578998
2,laboratory testing,C0022885
2,lack of effectiveness,C0235828
2,without mets,C0812270;C1705694;C2939420
2,lack of efficacy,C0235828
2,total sample = nmbr ( % ),C0370003;C0439175;C0439810;C2347026
2,lack of efficacy with > nmbr anti - interleukin nmbr,C0235828
2,lack of efficacy with > nmbr bdmard,C0235828
2,large / very large,C0442824;C0549177;C2984081
2,last study visit,C1517741
2,late load,C0205087
2,size ( cmnmbr ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
2,laa closure ( n = nmbr ),C0185003;C1521802
2,womac stiffness score,C0427008;C0449820;C4050231
2,la grade b,C1881342
2,s fs nmbr,C0565930;C1517317;C2603362;C3814419
2,l vs . c,C0439394;C1706495;C3642217
2,s nmbr yrs,C0565930;C2603362
2,l . l ± nmbr . nmbr,C3539687
2,sitting blood pressure — mmhg,C0439475;C0580946
2,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
2,s nmbr mmhg,C0439475;C0565930;C2603362
2,s ( snmbr,C0565930;C2603362
2,six - minute walk distance,C0012751;C3900196
2,l / c,C0439394;C1706495;C3642217
2,lnmbr - nmbr vs placebo,C0439394;C1706495;C3642217
2,hzard ratio,C0456603;C1547037
2,lnmbr - nmbr vs lnmbr - nmbr - nmbr,C0439394;C1706495;C3642217
2,white hispanic,C1533020;C1533021
2,womac pain score,C0582148
2,killip class > i,C2697844
2,idm,C0270221
2,killip class > nmbr,C1881332
2,impaired fasting glucose §,C1272092
2,severe ( ipss > nmbr ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
2,jnmbr coefficient,C1707429
2,snmbr months,C0439231;C0565930;C2603362
2,jugular venous distension,C0425687
2,severe ( ipss > nmbr ) ( n = nmbr ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
2,severe ( itt ) ( n = nmbr ),C0205082;C4050465;C4050466
2,impaired fasting glucosex,C0221099
2,impaired fasting glucose ( > nmbr mg / dl ) ( % ),C0439269;C1272092
2,withdrawals,C1710677;C2349954;C2825032;C3812880;C4049634
2,impaired fasting glucose,C1272092
2,impaired fasting giucose levei ( n = nmbr ),C0221099
2,jugular venous distention > nmbr cm,C0425687
2,impacts,C1825598;C4049986
2,jvd $ nmbr cm hnmbro,C0425687;C0455483
2,jvp $ nmbr cm hnmbro,C0455483
2,severe ( nnmbr = nmbr ),C0205082;C4050465;C4050466
2,severe ( iief - ef nmbr - nmbr ),C0205082;C3641331;C4050465;C4050466
2,severe ( iief - ef < nmbr ),C0205082;C3641331;C4050465;C4050466
2,ivc ( n = nmbr ),C4085887
2,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
2,isolated systolic hypertension^,C0745133
2,isolated systolic hypertension ⁎,C0745133
2,sample sizea,C0370003;C2347026
2,sesbp ( mmhg ) [mean - sd]d,C0439475;C0444504;C2347634;C2348143;C2699239
2,total sgrq score,C0439175;C0439810
2,sesbp ( mmhg ) [mean _sd]a,C0439475;C0444504;C2347634;C2348143;C2699239
2,severe ( < nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
2,severe ( > nmbr ),C0205082;C4050465;C4050466
2,total study itt population ( n = nmbr ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2,item,C1551338;C4554251
2,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
2,saes,C1519255;C1622657;C4553214
2,iuss score,C0439453
2,imputed,C2699638
2,iv inotropic drug,C1971835
2,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
2,imm only,C0205171;C0205470;C1720467
2,severe / moderate,C1299393
2,igg ( > nmbr . nmbr g / l ),C0439294;C0456615
2,snmbr ( nmbr . s ),C0565930;C2603362
2,snmbr ml / min,C0439445;C0565930;C2603362
2,severe to end - stage impairment ( nmbr ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
2,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
2,ii chiorthaiidone amiodipine,C1710602;C4082587
2,kg / mnmbr,C1532718
2,igt / ifg,C1334085;C1708411
2,kg / mnmbr ),C1532718
2,imm,C0205470
2,igelow ( < nmbrku / l  n = nmbr  nmbr ),C0439340
2,snmbr years,C0439234;C0565930;C2603362
2,ige high ( > nmbr ku / l  n = nmbr  nmbr ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,ige ( ku / l ),C0439340
2,killip class — no . / total no . ( % ) i,C1881332
2,iga nmbr / nmbr,C2825347
2,severe / lite threatening,C0205082;C4050465;C4050466
2,ii / iii,C0439070;C1705160;C1710602;C4082587
2,severe or very severe smoking status,C0205082;C4050465;C4050466
2,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
2,snmbr - nmbr - snmbr . nmbr %,C0565930;C2603362
2,k - m % n,C0369637;C0441923;C0597277;C1708601
2,image only,C0205171;C1704254;C1704922;C1720467;C3542466
2,withdrew consent,C2349954
2,ill -,C0231218
2,k,C0597277;C1708601
2,kaplan - meier rates,C0871208;C1521828
2,iii or iv,C0439070;C1705160
2,iii and iv,C0439070;C1705160
2,iii ( nmbr ),C0439070;C1705160
2,iief - ef domain score,C0449820;C1880389;C1883221;C3541951;C3641331;C4050231
2,iinmbr ( ii . nmbr ),C1710602;C4082587
2,severe disease,C1836348
2,severe ed,C0205082;C3538926;C4050465;C4050466
2,severe episodes in previous year — no . / patient,C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
2,severe exacerbations,C0205082;C4050465;C4050466;C4086268
2,mean — mm hg,C0439475;C0444504;C2347634;C2348143
2,referent,C1706462
2,swollen joint count ( range nmbr - nmbr joints ),C0451521;C1514721;C2348147;C3542016
2,prior ed therapy,C1514463;C3538926
2,mild - to - moderate ( ipss < nmbr ),C1019118;C1299392;C1998280;C2827405;C3811063
2,mild ( < nmbr ),C2945599
2,mild ( nmbr - nmbr ),C2945599
2,subgroup levels,C0441889;C1079230;C1515021
2,mild ( nmbr – nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0369637;C0439445;C0441923;C2945599
2,mild ( iief - ef nmbr - nmbr ),C2945599;C3641331
2,very high vs . normal,C0442804;C4321397
2,mild ( ipss < nmbr ),C1019118;C1998280;C2827405;C2945599;C3811063
2,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2,mild ( n = nmbr ),C2945599
2,mild ( nnmbr = nmbr ) nmbr,C2945599
2,mild decrease ( nmbr - < nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
2,mild dysfunction ( crcl > nmbr - nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C3274775
2,mild ed,C2945599;C3538926
2,subgroup no .,C1079230;C1515021
2,subgroup p - valuenmbr,C1079230;C1515021;C1709380
2,middle tertile : > nmbr . nmbr to b nmbr . nmbr,C0444598;C0549183;C1552826
2,very high vs . normalb,C0442804;C4321397
2,missing *,C1551393;C1705492;C3272743
2,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
2,hbalc £ nmbr mmol / mol ( > nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,hbalc £ nmbr mmol / mol ( < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,hbalc £ nmbr mmol / mol ( £ nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,hbalc ( mmol / mol ),C3829066
2,microalbuminuria or macroalbuminuria §,C0730345
2,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
2,hbaj ( - ( %  mmol / mol ),C3829066
2,subgroup analyses,C2986480
2,very severe ( itt ) ( n = nmbr ),C3641272;C4050419
2,microvascular complicationsb,C0443258
2,microvascular disease history,C0443258;C0683519
2,prior medication use,C0240320;C0332152;C2826257
2,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
2,microvascular outcome,C0443258;C1274040
2,middle,C0444598;C0549183;C1552826
2,subgroup based on :,C1079230;C1515021
2,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
2,hazard rationmbr,C2985465
2,mild impairment,C0221099;C0684336;C2945599
2,minimum,C1524031;C1552614;C2826545
2,mineralcorticoid receptor antagonist,C4543207
2,prior cardiovascular event,C0332152;C1320716;C2826257
2,subject disposition,C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
2,subjects ( n ),C0681850;C1550501;C1706203;C2349001;C2697811
2,hazard ratio with high ( nmbr % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
2,subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
2,subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811
2,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2,mild impairment ( £ nmbr to,C0221099;C0684336;C2945599
2,subjects who did not receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
2,subjects who did receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
2,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2,minutes from symptom onset to prehospital ecg,C0439232;C0700321;C0702093;C1282918;C2347166;C4086878
2,hazard ratio with,C2985465
2,subjects with imputed value for end ‐ of ‐ treatment body weight,C0681850;C1522609;C1550501;C1706203;C2349001;C2697811;C2699638
2,hazard ratio vs . placebo,C2985465
2,min per nmbr . nmbr mnmbr,C0369637;C0441923;C0702093;C1524029;C3813700
2,very elderly patients ( n - nmbr ),C0442824;C0870602;C2984081
2,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
2,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
2,hazard ratio * ( and nmbr % ci ),C2985465
2,mild impairment ( nmbr tonmbrml / min ),C0221099;C0439445;C0684336;C2945599
2,mild or no dysfunction ( crcl > nmbr ml / min  n = nmbr nmbr  [nmbr . nmbr % ] ),C2945599
2,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
2,mild / moderate ( ipss < nmbr ),C1019118;C1299392;C1998280;C2827405;C3811063
2,very high ( >   nmbrxuln ) n   =   nmbr,C0442804;C4321397
2,hazard ratio with low ( nmbr % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
2,min - ’,C0702093;C1524029;C3813700
2,subgroup p value !,C1079230;C1515021;C1709380
2,total mayo score,C0454788;C1077578;C2964552
2,min - max,C0702093;C1524029;C3813700
2,min – max,C0702093;C1524029;C3813700
2,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
2,very high,C0442804;C4321397
2,very good or excellent,C3641222
2,hbalc < nmbr mmol / mol ( < nmbr . nmbr % ) at week nmbr,C0332174;C0439230;C3829066
2,hbalc < nmbr % ( nmbr mmol / mol ),C3829066
2,hbalc < nmbr mmol / mol ( £ nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,prior oac,C0332152;C2826257
2,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
2,"met atopy and ige nmbr - nmbr ku / l criteria "" ( n = nmbr )",C0392707;C0428210;C1550543;C3539705;C4317104
2,heart failure hospitalisation or cv death,C3898876
2,met / tzd,C0428210;C1550543;C4317104
2,metabolic syndromeb,C0311400;C1524026;C2707259
2,study population,C2348561
2,prior oad :,C0332152;C2826257
2,prior oabg surgery,C0455610
2,total n,C0439175;C0439810
2,health - care use rate ( peryear ),C0814514;C0871208;C1521828
2,hdlnmbr,C3715113
2,study treatment,C1521826
2,study treatment — no . / total no . ( % ),C1521826
2,total nnmbr,C0439175;C0439810
2,total n   =   nmbr,C0439175;C0439810
2,metformin ? pioglitazone,C1635037
2,heart failure hospitalizations,C3898876
2,study druga,C0557651;C2603343
2,prior pci or cabg,C0332152;C2826257;C4049621
2,study nmbr . nmbr,C0557651;C2603343
2,prior vka experience,C0237607;C0332152;C0596545;C2826257
2,height ',C0489786
2,prior treatment — no . ( % ),C1514463
2,structural,C0678594
2,visit,C0545082;C1512346;C2826704
2,adcs - adl,C3641947
2,prior revascularization ( n = nmbr,C0332152;C0581603;C2826257
2,prior revascularization ( % ),C0332152;C0581603;C2826257
2,structural heart disease — no . ( % ) f,C1290384
2,menopausal status and hormone therapy use,C1513126
2,stsd > nmbr mm on admission ( n = nmbr,C0184666;C0809949;C4330985;C4554674
2,menopausal status and hormone therapy use premenopausal,C1513126
2,mental status,C0278060
2,npi,C1412208;C1549728;C3539727
2,proportion of > = nmbr % responder rates,C0871208;C1521828;C1709707
2,prior myocardial infarction ( % ),C0155668
2,metformin • pioglitazone,C1635037
2,hbalc < nmbr mmol / mol ( < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,hdl - c < nmbr mg / dl_,C0439269;C3715113
2,micral test result,C0456984;C0587081
2,micro - or macroalbuminuria,C0085672;C1553035;C3811161;C4049106
2,hdl - c < nmbrmg / dl . n ( % ),C0439269;C3715113
2,subgroup nmbr,C1079230;C1515021
2,hdl - c level,C0441889;C0456079;C1547707;C2946261;C3715113
2,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
2,hdl - c > nmbr mg / dl ( nmbr . nmbr mmol / l ),C0439269;C1532563;C3715113
2,hdl - c < nmbr mg / dl,C0439269;C3715113
2,subcutaneous ( n = nmbr ),C0443315
2,hdl - c ( mg / dl ) *,C0439269;C3715113
2,hder *,C3898895
2,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
2,microalbuminuria — no . ( % ),C0730345
2,microalbuminuria ( uacr nmbr – nmbr ),C0730345
2,hbalc > nmbr mmol / mol ( > nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,hbalc > nmbr - < nmbr mmol / mol ( > nmbr . nmbr - < nmbr . nmbr % ) ( n = nmbr / nmbr ),C3829066
2,mi *,C3810814
2,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
2,mi — no . ( % ),C3810814
2,mg / mmol,C0567349;C2348885
2,subcutaneous unfractionated heparin,C0353681
2,prior myocardial infarction — no . / total no . ( % ),C0155668
2,prior myocardial infarction — no . { % ),C0155668
2,prior ml or stroke at baseline,C0332152;C0439526;C1705224;C2826257;C3887665
2,prior mi within nmbr y,C0332152;C2826257;C3810814
2,prior mi n = nmbr,C0332152;C2826257;C3810814
2,prior mi diagnosis :,C0332132;C3810814
2,prior mi ( n = nmbr,C0332152;C2826257;C3810814
2,methotrexate treatment !,C0746573
2,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2,hdl < nmbr mg / dl,C0439269;C3715113
2,mexican,C0240339
2,mg / day,C0439422
2,mg / dl fpg ( mmol / l ),C0439269;C1532563
2,mg / g,C1300563
2,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
2,complete ulcer healing at week nmbr,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
2,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
2,sustain nmbr : semaglutide add ‐ on to insulin vs . placebo,C0443318;C2732140
2,grip strength < meidan,C0429271;C2598165
2,grade nmbr ( severe copd ),C0441800;C0919553;C3244287
2,grade nmbr ( moderate copd ),C0441800;C0919553;C3244287
2,grade > nmbr,C0441800;C0919553;C3244287
2,primary endpoint at nmbr months,C0439231;C2986535
2,moderate / severe reduction in egfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,modified has - bled > nmbr,C0392747;C3889737
2,modified has - bled score,C0392747;C3889737
2,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
2,sustained decrease of > nmbr % in egfr ®,C0392756;C0443318;C0547047
2,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
2,monoamine oxidase b inhibitors,C2917290;C3653412
2,morning,C0332170
2,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
2,morning stiffness duration,C0449238;C0457086;C2926735
2,swollen - joint count ( of nmbr joints assessed ) — no .,C0451521
2,primary composite end point ‡,C0205199;C1547335;C2986535
2,moderate / severe exacerbations  patient subgroups  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,mitral valve disease ( n = nmbr nmbr ),C0026265;C4553832
2,primary composite^,C0205199;C0205225;C0439612;C0439631;C1547335
2,sustain nmbr : semaglutide vs . iglar,C0443318;C2732140
2,moderate or severe decrease in gfr ( < nmbr ml / min / nmbr . nmbr mnmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,gusto severe / moderate,C1299393
2,moderate or severe decrease in gfr { < nmbr ml / mln per nmbr . nmbr m^ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate or severe renal disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
2,grs,C1412761;C3539564
2,moderate / severe exacerbation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,group d ( high risk,C0441838
2,group b ( low risk,C3272281;C3538919;C4522078
2,primary composite endpoint ‡,C0205199;C1547335;C2986535
2,primary endpoint at nmbr days,C0439228;C2986535
2,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
2,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate / low,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  nmbr % cl  nmbr % confidence interval  tia  transient ischemic attack .,C0205225;C0439612;C0439631
2,morning stiffness severity,C0439793;C0457086;C0522510
2,variablesnmbr,C0439828
2,variable ' ! ',C0439828;C4553760
2,mostly dissatisfied,C0205393;C0750554
2,mostly satisfied,C0205393;C0750554
2,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
2,previous use of nonbiologic systemic therapy,C0205156;C1515119;C1524063;C1552607
2,mrf,C0312443;C1412879
2,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
2,variable demographic characteristics,C0439828;C0683970;C4553760
2,msdbp ( mm hg ),C0439475
2,good / moderate response,C0205170;C4085643
2,msdbp ± sd,C2699239
2,previous systemic treatment,C0205156;C0678812;C1552607
2,previous stroke yes ( n,C0205156;C1552607;C3841753
2,percentage of days without heartburn,C0439165;C0439228;C1549488;C1561533
2,treatment effect ( hr ),C1518681
2,mssbp ( mm hg ),C0439475
2,mssbp < nmbr mmhg,C0439475
2,most frequent serious teaes,C0205393;C0205404;C0332183
2,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
2,swollen joint count ( nmbr ),C0451521
2,most frequent infections,C0205393;C0239998
2,previously untreated isolated systolic hypertension,C0332155;C0745133
2,swollen joint count ( nmbr - nmbr joints ),C0451521
2,good,C0205170
2,variables .,C0439828
2,swollen joint count ( nmbr – nmbr joints ),C0451521
2,variables *,C0439828
2,previous use of vitamin k antagonist for > nmbr days — no . ( % ),C0205156;C1096489;C1524063;C1552607;C2267235
2,previous use of systemic steroids,C0205156;C0205373;C0281991;C1552607
2,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
2,swollen joint count ( nmbr — nmbr  per swollen joint ),C0451521
2,proportion of days without heartburn at week nmbr,C0439228;C1709707
2,variables,C0439828
2,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C1552607
2,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
2,most frequent aesa,C0205393;C0332183
2,sustain nmbr : semaglutide vs . exenatide er nmbr . nmbr mg,C0443318;C2732140
2,sustain nmbr : semaglutide vs . sitagliptin nmbr mg,C0443318;C2732140
2,moderate impairment ( nmbr tonmbrml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
2,hazard interaction,C0598697;C1704675
2,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
2,primary pcit,C0205225;C0439612;C0439631
2,suit quartile nmbr ( b nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
2,primary outcome : nmbr % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
2,vdz / pla n = nmbr,C0456170
2,model,C3161035;C3274659;C3714583;C3853906
2,hazard ratio ( nmbr % c,C2985465
2,model nmbr,C3161035;C3274659;C3714583;C3853906
2,moderate - to -,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,hazard inleraction,C0598697
2,model nmbr +,C3161035;C3274659;C3714583;C3853906
2,suit quartile nmbr ( > nmbr . nmbr - < nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
2,model nmbrt,C3161035;C3274659;C3714583;C3853906
2,model nmbr §,C3161035;C3274659;C3714583;C3853906
2,primary outcome ! ( n = nmbr ),C0205225;C0439612;C0439631;C1274040
2,primary outcome plus revascularization or nonfatal hf,C0205225;C0332287;C0439612;C0439631;C0581603;C1274040
2,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
2,prior a - blocker use,C0332152;C2826257
2,prior acbi or arb use,C0332152;C2826257
2,mmol / l ),C1532563
2,mixed,C0205430;C3160715
2,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
2,subsets,C1515021
2,hazard ratio and nmbr % confidence interval,C2985465
2,hazard ratio nmbr ),C2985465
2,mixed ( itt ) ( n = nmbr ),C0205430;C3160715
2,hazard ratio [nmbr % cl],C0596019;C2985465
2,hazard ratio ( nmbr % cl],C0596019;C2985465
2,sufficient,C0205410
2,mixed ( n = nmbr ),C0205430;C3160715
2,prior admb,C0332152;C2826257
2,hazard ratio ( nmbr % cl ) *,C0596019;C2985465
2,mmol / l [n],C1532563
2,verapamil sr ( no . = nmbr ),C1527129
2,"hazard ratio ( nmbr % cl ) """,C0596019;C2985465
2,suit quartile nmbr ( > nmbr . nmbr nmol / mmol ) ( n = nmbr ),C1532564;C1533073;C2828255
2,moderate - to - severe copd exacerbation,C0740304;C1299393
2,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
2,sustain nmbr : semaglutide vs . placebo,C0443318;C2732140
2,moderate ( iief - ef nmbr - nmbr ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
2,moderate ( ipss < nmbr ) ( n = nmbr ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
2,moderate ( n = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,sustain nmbr,C0443318;C2732140
2,new or worsening vertebral fracture at nmbr months,C0205314
2,moderate ( nnmbr = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,primary endpoint :,C2986535
2,moderate ( snmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate severe ( n = nmbr ) ( n = nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate chronic kidney disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,primary end points,C0205225;C0439612;C0439631;C2349179
2,primary end point *,C2986535
2,primary end point |,C2986535
2,primary end - point,C2986535
2,moderate decrease ( nmbr - < nmbr mlymin per nmbr . nmbr mnmbr ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate dysfunction ( crcl nmbr - nmbr ml / min  n = nmbr [nmbr . nmbr % ] ),C0439445;C1846718;C3274776
2,haq - di ( range nmbr - nmbr ),C1514721;C2348147;C3542016;C3826998;C4321476
2,primary endpoint^,C2986535
2,haq - di mcide,C3826998;C4321476
2,primary endpointnmbr,C2986535
2,primary nonresponse,C0205225;C0439612;C0439631
2,moderate ( > nmbr and < nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,mean percentage of nights without heartburn,C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
2,moderate ( > nmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate ( nmbr % . < nmbr % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,haq di score ( range nmbr - nmbr ),C0449820;C1514721;C2348147;C3542016;C3826998;C4050231;C4321476
2,haq di score ( nmbr - nmbr ),C0449820;C3826998;C4050231;C4321476
2,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
2,haq di ( range nmbr - nmbr ),C1514721;C2348147;C3542016;C3826998;C4321476
2,haq di,C3826998;C4321476
2,primary indication,C1549995
2,moderate ( nmbr – nmbr ml · min − nmbr · nmbr . nmbr m − nmbr ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
2,moderate ( nmbr - nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,sustain,C0443318;C2732140
2,moderate ( nmbr < ipss < nmbr ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
2,progression to diabetes,C1735364
2,adas - cog,C3539026
2,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
2,highest,C1522410
2,highly sensitive responder ( n = nmbr ),C0439822
2,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
2,highly sensitive,C0439822
2,rate ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C0871208;C1521828
2,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
2,mean bmd ( = sd ),C0444504;C2347634;C2348143;C2699239
2,rate - control group ( n = nmbr ),C0441848;C0489879
2,higher risk ( n = nmbr ),C0332167;C3272283;C4050568;C4319571
2,budesonide - budesonide / formoterol,C1276807
2,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
2,higher dose,C0444956
2,higher - target group ( n = nmbr ),C0205250;C0441848;C1521840;C2986546
2,mean bmi ± s . d .,C0444504;C0578022;C2347634;C2348143
2,mean bmi ± sd ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,mean bmii 士 s . d .,C0444504;C2347634;C2348143
2,rate,C0871208;C1521828
2,highly sensitive responders ( n = nmbr ),C0439822
2,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
2,treated with laba,C0332293
2,mean age ( years,C0444504;C1510829;C2347634;C2348143
2,mean acq - nmbr scores,C0444504;C2347634;C2348143;C2919686
2,rate of sares,C0871208;C1521828
2,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4521986
2,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
2,rate of non - progression ( defined as cfb in mtss £ nmbr . nmbr ),C0871208;C1521828;C3839460
2,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
2,mean age ( y ),C0001779;C0444504;C2347634;C2348143
2,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
2,rate in all participants,C0679646;C0871208;C1521828
2,mean age 士 s . d .,C0001779;C0444504;C2347634;C2348143
2,mean age ± s . d .,C0001779;C0444504;C2347634;C2348143
2,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
2,mean alc,C0444504;C1424945;C2347634;C2348143;C3811058
2,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
2,mean asui scored,C0444504;C2347634;C2348143
2,rate of non - progression ( defined as cfb in mtss £ nmbr ),C0871208;C1521828;C3839460
2,higher - dose,C0444956
2,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2,stating,C1301808;C1442792;C3148680
2,high dose,C0444956
2,high crp or esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2,high crp and esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
2,high ( n = nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high ( nmbr - nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high ( nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high ( > nmbr . nmbr u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
2,week - nmbr changea,C0332174;C0439230;C4349366
2,mean doseb,C0444504;C2347634;C2348143
2,high ( > nmbr ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,high ( > nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,mean duration of pd,C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
2,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
2,randomised patients with basdai assessment at baseline and week nmbr,C0679830;C1998004
2,high ( >   uln and   ≤   nmbrxuln ) ( n   =   nmbr ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
2,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
2,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
2,high microalbuminuria to macroalbuminuria ( n = nmbr ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,mean difference ( nmbr % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
2,week,C0332174;C0439230
2,rankin scale ≥ nmbr,C0451405
2,range iga modified nmbr score,C1514721;C2348147;C2825347;C3542016
2,high risk *,C0332167;C3272283;C4050568;C4319571
2,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
2,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
2,mean change in radiographic end points shs,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
2,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,high risk ( n nmbr nmbr ),C0332167;C3272283;C4050568;C4319571
2,high risk ( > nmbr ),C0332167;C3272283;C4050568;C4319571
2,mean change ‘ s in fasting blood glucose [mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
2,sdc nmbr . nmbr - nmbr . nmbr ng / ml,C0439275;C1419891;C3273112
2,mean crp level,C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261;C3890735;C4048285
2,high normal ( n = nmbr ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
2,high nfs nfs > nmbr . nmbr ( n = nmbr ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
2,mean acq - nmbr score at randomization  ! ,C0444504;C2347634;C2348143;C2919686
2,week nmbr mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
2,mean ±   sd,C0444504;C2347634;C2348143;C2699239
2,stage ii,C0441767
2,received first loading dose,C0205435;C1279901;C1514756;C3714444
2,stage nmbra ckd cohort ( post hoc analysis excluding metformin users ),C0205390;C1300072;C1306673
2,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
2,stage nmbra ckd cohort ( secondary analysis ),C0205390;C1300072;C1306673
2,history of cerebrovascular disease — no . { % ),C0585890
2,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
2,history of cardiovascular disease — no . { % ),C0455539
2,mean ( sd ) % of predicted normal fevnmbr,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
2,mean ( sd ) change from pre - to post - bronchodilator fevi,C0332152;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
2,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
2,week nmbr ( non - ee responders ),C0332174;C0439230;C1518422
2,week nmbr crp,C0332174;C0439230;C3890735;C4048285
2,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
2,mean ( sd ) nmbr . nmbr ( nmbr . nmbr ),C0444504;C2347634;C2348143;C2699239
2,re - medy,C0556581;C2986904
2,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
2,receiving antihypertensive,C1514756
2,stage nmbr ckd egfr nmbr to nmbr ml / min ( n = nmbr ),C0205390;C1300072;C1306673
2,stage nmbr ckd egfr > nmbr ml / ( n = nmbr ),C0205390;C1300072;C1306673
2,receiving antihypertensive treatment -,C1514756
2,mean ( ± s . d . ),C0444504;C2347634;C2348143
2,history of coronary artery disease — no . { % ),C1881055
2,history of coronary artery disease - n ( % ),C1881055
2,history of coronary artery disease,C1881055
2,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
2,mean ( median ) mtx dose,C0366550;C0444504;C0549183;C0876920;C2347634;C2347635;C2348143;C2348144;C2939193
2,reference,C1514811;C1706462
2,ref §,C1425988
2,history of clinical fracture ( > nmbr years ),C0205210;C0439234;C1272071
2,history of clinical fracture ( > nmbr years old ),C0205210;C0439234;C1272071
2,ref .,C1425988
2,reduction in odds %,C0301630;C0392756;C1293152;C4551656
2,reduced hdl cholesterol,C0151691
2,receptor blocker,C0597357
2,receiving antihypertensive treatment,C1514756
2,mean ( sd ) bmd in g / cmnmbr,C0439267;C0444504;C2347634;C2348143;C2699239
2,mean ( sd ) eevi,C0444504;C2347634;C2348143;C2699239
2,week nmbr mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
2,rate †,C0871208;C1521828
2,treated lesions ‡,C0221198;C1522326
2,rates,C0871208;C1521828
2,week nmbr outcomes,C0332174;C0439230;C1274040
2,standard treatment ( n - nmbr ),C4684780
2,week nmbr outcome,C0332174;C0439230;C1274040
2,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
2,rate ‡,C0871208;C1521828
2,mean ± s . d .,C0444504;C2347634;C2348143
2,stage iii,C0441771
2,total no . of events / total no . of participants,C0439175;C0439810
2,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
2,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
2,mean ± sd unless otherwise indicated,C0444504;C2347634;C2348143;C2699239
2,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
2,rate ratio vs placebo ( nmbr % ci ),C0456603;C0871208;C1521828;C1547037
2,rate ratio { nmbr % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
2,ratio of ldl to hdl cholesterol,C0456603;C1547037
2,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
2,history of asthma - related intubation — no . ( % ),C0455544
2,history of atrial fibrillation and / or flutter,C0729790
2,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
2,mean ( sd ) fevi,C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
2,stage iv,C0205390;C1300072;C1306673
2,standard,C1442989;C2828392
2,mean ( sd ) fevi / fvc,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
2,re - cover nmbr warfarin,C0180153;C0556581;C1999244;C2986904;C3888055
2,history of cardiovascular disease — no . ( % ),C0455539
2,standard allocation,C1442989;C1706778;C2828392
2,re - cover nmbr dabigatran,C0180153;C0556581;C1999244;C2986904;C3888055
2,week nmbr ( before ee ),C0332174;C0439230
2,mean ( sd ) values are presented for all variables,C0042295;C0444504;C2347634;C2348143;C2699239
2,week nmbr responders,C0332174;C0439230
2,mean ( sd ) years daily ocs use,C0332173;C0439234;C0444504;C2347634;C2348143;C2699239
2,mean ( sd ) % predicted normal fevnmbr,C0444504;C2347634;C2348143;C2699239
2,history of atrial fibrillation or flutter,C0729790
2,mean fpg,C0444504;C2347634;C2348143
2,mean hbaic = • = s . d .,C0444504;C2347634;C2348143
2,height in meters .,C0441074;C0489786
2,volume change,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952
2,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
2,median ( range ) total ige level ( iuml ~ ’ ) nmbr,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
2,median ( range ) treatment duration,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
2,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
2,median age [interquartile range] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
2,median age,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
2,fatal / nonfatal mi ( excluding silent mi ),C1302234;C1705232;C3810814
2,median ( qnmbr – qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,psa subtypes,C0449560;C3810537;C3813209
2,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
2,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
2,psa reported,C3810537;C3813209
2,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2,vldl - c,C0523560
2,heparin use,C0239945
2,psychogenic,C0458006
2,ramus,C3538818
2,pts,C1419129;C2698747
2,pvaluefor interaction nmbr - nmbr,C1704675
2,pump,C0182537
2,heterozygous familial hypercholesterolemia †,C0342882
2,meddra smq,C1140263
2,heterozygous familial hypercholesterolemia,C0342882
2,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
2,median — ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
2,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
2,psycholeptics,C3653516
2,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
2,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
2,ptrend across doses,C0178602
2,ptga of disease activity ( nmbr ‒ nmbr mm ),C1292728;C4330985;C4554674
2,voluntary,C0439656;C3543419
2,volumetric bmd by qct,C0412669;C0445383
2,median infusions — no . ( range ),C0549183;C0574032;C0876920;C2347635;C2348144;C2939193
2,combined efficacy and safety endpoint,C0205195;C1280519;C1707887
2,psa level,C4086720
2,proportion of responders n / n ( % ),C1709707
2,prostate biopsy,C0194804
2,vitamin k antagonist experiencedk ( n = nmbr nmbr ),C1096489;C2267235
2,proportions,C1709707
2,medication use ( % ),C0240320
2,vitamin k antagonist experienced,C1096489;C2267235
2,medication use at entry ( % ),C0240320;C1705654
2,proportion taking pulmonary medications ( % ) b,C1709707
2,medication use before enrollment,C0240320;C1516879;C1696073;C3888021
2,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
2,proportion,C1709707
2,hemoglobin level,C0019029;C1314664
2,complete clinical response at week nmbr,C0205197;C3853530;C4283785
2,helicobacter pylori infection ( + ) ( n ),C0850666
2,helicobacter pylori - negative,C4688581
2,height loss ( cm ),C0424641
2,height loss,C0424641
2,prostate volume ( cmnmbr ),C1441416
2,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
2,vitamin k antagonist naive,C1096489;C2267235
2,medical therapy before admission,C0184666;C0418981;C0809949
2,hemorrhagic,C0333275
2,psa ( ng / ml ),C0439275;C3810537;C3813209
2,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
2,psa - modified shs ( nmbr - nmbr ),C0392747;C3810537;C3813209;C3889737
2,psa ‐ modified mases score ( nmbr – nmbr scale ),C0392747;C3810537;C3813209;C3889737
2,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
2,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
2,psa - modified mases score ( nmbr - nmbr ),C0392747;C3810537;C3813209;C3889737
2,median §,C0549183;C0876920;C2347635;C2348144;C2939193
2,medians ( iqr ),C0549183
2,medical and lifestyle history,C0199168;C0205476
2,medical historv,C0199168;C0205476
2,medical history — %,C0262926;C1704706
2,medical history . no . ( % ),C0262926;C1704706
2,proximal,C0205107;C4489236
2,pvaluefor trend,C1521798;C4554533
2,qids - srnmbr,C4331197
2,qmax ( ml / s ),C0439390
2,ra duration ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
2,mean number of puffs per day,C0237753;C0444504;C0449788;C1533107;C2347634;C2348143
2,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
2,mean of maximum cimt,C0444504;C0806909;C1552615;C2347634;C2348143;C2826546
2,stent thrombosis or mi,C3897493
2,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
2,mean of mean cimt,C0444504;C2347634;C2348143
2,raas inhibitor,C1999216
2,stented vessel,C0183521
2,mean qmax score by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0578022;C3533236
2,mean or n,C0444504;C2347634;C2348143
2,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
2,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
2,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
2,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
2,mean pulmonary artery pressure,C3854605
2,quintile,C1508496
2,mean number of exacerbations in previous y ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2,high - risk,C0332167;C3272283;C4050568;C4319571
2,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
2,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
2,mean iief ef score mean iief domain score by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0578022;C1880389;C1883221;C3533236;C3541951;C3641331
2,radiate,C0332301
2,racec,C4287599
2,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
2,mean ipss,C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
2,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
2,mean mmrc grade,C0441800;C0444504;C0919553;C2347634;C2348143;C3244287;C3826977
2,statistic * *,C2348149;C2828391
2,mean no . agents ( sd ) other medications,C0444504;C2347634;C2348143
2,status ( spmsq < nmbr,C0449438
2,status ( spmsq > nmbr,C0449438
2,high - school graduate or ged,C0870649;C1549971
2,high - school graduate,C0870649;C1549971
2,mean number of caes in past nmbr months ( number per patient ) ] |,C0237753;C0444504;C0449788;C2347634;C2348143
2,stent thrombosis - related mi,C3897493
2,quintile nmbr ( nmbr . nmbr % - nmbr . nmbr % ) ( n = nmbr ),C1508496
2,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
2,qmax category,C0683312;C3889287
2,qol,C0518214
2,qualifying events,C0441471;C1514624;C3541888
2,qrs width,C0487742
2,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
2,mean total ipss mean ipss by bmi ( < nmbr / < nmbr to < nmbr / < nmbr kg / mnmbr ),C0439175;C0439810;C0444504;C0578022;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
2,qrs duration,C0429025;C0488377
2,qol due to urinary symptoms,C0426359;C0518214;C0678226
2,mean wall thickness ( cm ),C0677535;C4054557
2,mean years since menopause,C0439234;C0444504;C2347634;C2348143
2,quintile ( n ),C1508496
2,total no . nmbr,C0439175;C0439810
2,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
2,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
2,stratum nmbr : inadequate response or intolerance to nmbr - nmbr bdmards of same moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
2,stratum nmbr : inadequate response or intolerance to > nmbr bdmards of same moa or > nmbr of multiple moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,qmaxi rn l / s,C2827110;C3540639;C4281819
2,mean sitting systolic blood pressure,C0444504;C2347634;C2348143
2,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
2,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810
2,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
2,high - dose arb ( n = nmbr ),C0444956;C3888198
2,question nmbr ( length of morning stiffness since arising ),C0457086;C1444754;C1522634;C1706316
2,question nmbr ( morning stiffness since arising ),C0457086;C1522634
2,steroid use,C0281991
2,storage subscore,C0337174;C1698986;C1753314
2,stratification factor : menopausal status,C1513126;C1514984
2,stratification factors,C1514984
2,qualifying symptomatic event,C1514624
2,stratified by,C0205363
2,mean score ( min,C0702093;C1524029;C3533236;C3813700
2,qualifying high - risk features — %,C1514624
2,mean selena - sledai score ± sd,C0444504;C0451528;C2347634;C2348143
2,mean serum cholesterol,C0444504;C0587184;C2347634;C2348143
2,mean serum creatinine,C0201976;C0444504;C0600061;C2347634;C2348143
2,mean serum potassium,C0302353;C0444504;C0543465;C2347634;C2348143
2,weeks,C0439230
2,nmbr . nmbr ( reference ),C1514811;C1706462
2,enrolled from re - cover study — no . ( % ),C4684790
2,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0542331;C1299392;C1442858
2,number of ( % ) patients > nmbr years,C0439234;C2360800
2,current / past smoker,C1444637;C3173209;C3241966;C4284302
2,< nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,number of e,C0237753;C0449788
2,continued treatment study,C0549178;C3161471
2,p value for trend,C1521798;C1709380;C4554533
2,mean ( s . d . ) ldl particle size,C0444504;C2347634;C2348143;C3641256
2,total ( n = nmbr ),C0439175;C0439810
2,ada nmbr / nmbr ( n[nmbr ),C1060325;C3811629
2,< nmbr mm,C4330985;C4554674
2,snmbr %,C0565930;C2603362
2,age ' ^nmbr yrs,C0001779
2,acrnmbr,C1412134;C1515941
2,age ( years ) *,C1510829
2,tg < = nmbr . nmbr,C0337445
2,rate * ( n ),C0871208;C1521828
2,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
2,no persistent wrf ( n = nmbr,C0205322;C0332996
2,nmbr to < nmbrmmhg,C0439475
2,mean ( sd ) disease duration,C0444504;C0872146;C2347634;C2348143;C2699239
2,age - years,C1510829
2,total no . of patients,C0439175;C0439810
2,selena - sledai ( range u - nmbrunmbr ) t,C0439148;C0451528;C1514721;C2348147;C3542016
2,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
2,isolated impaired glucose tolerance — no .,C0205409;C1548221
2,airflow reversibility — no . ( % ) |,C0231999;C0449261
2,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
2,pci duration in min ( median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
2,killip class lll - iv,C1261077;C2697847
2,age > nmbr years,C1510829
2,nmbr - aminosalicylates {,C0368663
2,antibodies to infliximab,C3533054
2,creatinine clearance < nmbr ml / min ( % ),C0439445;C0812399
2,total comparators ( n = nmbr ),C0439175;C0439810;C1707454;C4553389;C4553390
2,high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2,us site of enrollment,C1516879;C1696073;C2945843;C3888021
2,« snmbr - nmbr,C0565930;C2603362
2,> median,C0549183;C0876920;C2347635;C2348144;C2939193
2,non - hdl - c,C1518422;C3715113
2,motor,C1513492;C1705994
2,≥ nmbr . nmbr years,C0439234
2,anmbr n = nmbr,C0369718;C0441922
2,p valued,C0369773;C2603361
2,study,C0557651;C2603343
2,no pci,C4049621
2,pooled,C1709595;C2349200;C4522255
2,nmbr . nmbr min,C0702093;C1524029;C3813700
2,age < nmbr yr,C0001779;C0439234
2,daily,C0332173
2,hr nmbr % cl,C0596019
2,frail,C0871754
2,> lnmbr years,C0439234;C0439394;C1706495;C3642217
2,( nmbr % cl ),C0596019
2,* p value,C1709380
2,arb,C3888198
2,nmbr enmbr years,C0439234
2,p - valuec,C0369773;C2603361
2,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
2,n ( % ),C0369718;C0441922
2,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
2,number,C0237753;C0449788
2,> nmbr years ( n = nmbr ),C0439234
2,> nmbr to < nmbr mm hg,C0439475
2,uvb,C0454530;C0564461
2,p - int,C0369773;C2603361;C3272375
2,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
2,abnormal,C0205161;C2347472;C2699333
2,nmbr - nmbr ft,C1881534;C3890579
2,age > = nmbr years,C1510829
2,hs - crp,C3890735;C4048285
2,no prior llt,C0332152;C2347090;C2826257
2,range,C1514721;C2348147;C3542016
2,> nmbr - < nmbr years,C0439234
2,> nmbr ug / g,C0439272
2,cdai,C0683448;C1413248;C3273706
2,age nmbr,C0001779
2,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
2,no . of treated lesions,C0221198;C1522326
2,worsened,C1457868;C4084902
2,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2,pharmaco - invasive ( n = nmbr ),C0205281;C1334278
2,uac nmbr - nmbr mg / g,C1300563
2,mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143
2,history of hypertension — no . ( % ),C0455527
2,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
2,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
2,pci data,C1511726;C3245479;C3714741;C4049621
2,handihaler only,C0205171;C1720467
2,pci > nmbr month ago,C0332177;C0439231;C4049621
2,mean — ml / min / nmbr . nmbr mnmbr level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
2,mean cdai score ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
2,prior diagnosis - no . ( % ),C0332132
2,elevated cardiac markers,C0205250;C1271630;C3163633
2,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
2,n / n nmbr / nmbr,C0369718;C0441922
2,previous cardiovascular events,C0205156;C1320716;C1552607
2,> nmbr years nmbr / nmbr ( nmbr . nmbr ),C0439234
2,no estimate,C0750572
2,interquartile range,C1711350
2,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
2,p - value * ' ',C1709380
2,high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571
2,history of microalbuminuria — no . ( % ),C3532606
2,nmbr mg / day delayed - start,C0439422
2,documented symptomatic chdb,C0231220;C1301725;C1609436
2,middle tg tertile,C0337445;C0444598;C0549183;C1552826
2,non - epa number of <,C0237753;C0449788;C1518422
2,eq - nmbrd ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
2,no use ofdiabetes drugs — no . ( % ),C0240320
2,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
2,angina class iii or iv — no . ( % ),C0264677
2,n ( nmbryr km event rate,C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
2,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
2,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
2,serum potassium,C0302353;C0543465
2,never smoked,C2003901
2,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
2,proadm ( ng / ml ),C0439275
2,associated with ctd,C0332281;C1335071;C1442905
2,cerebrovascular,C1880018
2,esr,C3811131
2,total mayo score $ | |,C0454788;C1077578;C2964552
2,habitual fish intake : < nmbr servings / wk ( n = nmbr ),C0205353;C0332174;C0439230;C0556216;C1519269
2,number resulting in hospital admission,C0237753;C0449788
2,pasi score ( nmbr - nmbr ) t,C0449820;C4050231;C4528685
2,number of concomitant csdmards,C0237753;C0449788;C0521115
2,radiographic characteristics at baseline and randomization,C0444708;C4684572
2,method of identification ofstenosis ( % ),C1301921
2,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
2,saba puffs per day at baseline,C0332173;C0439228;C0439505;C1533107
2,joint space narrowing score,C0449820;C1859695;C4050231
2,less than nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439092;C0439445;C0441923
2,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
2,laa ostium,C0444567
2,laa length,C1444754;C1706316
2,pasi score > nmbr *,C0449820;C4050231;C4528685
2,motor subscale ( range,C1513492;C1514721;C1705994;C2348147;C3542016
2,not treated,C1518422
2,number of patients > nmbr years ( % ),C0439234;C2360800
2,after amendment,C0680532;C2346732
2,elevated crp ( > ulnt ),C0742906
2,symptom onset to arrival in catheterization laboratory,C1555577;C1706079;C4086878
2,coronary heart disease risk equivalents,C0439185;C1277690;C4049980
2,microalbuminuria or macroalbuminuria,C0730345
2,uac > nmbr mg / g,C1300563
2,health assessment questionnaire score,C2960025
2,antidiabetes drug usage [ % ( n ) ],C0242510
2,ibdq total score,C2964552
2,current smoker ( n = nmbr,C3173209;C3241966
2,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
2,new or suspected thrombus,C0205314
2,median feno,C0549183;C0876920;C2347635;C2348144;C2939193
2,primary enrollment diagnoses,C0332137;C0801658;C1516879;C1696073;C3888021
2,unspecified,C0205370;C1549663;C2983689;C4048188
2,participation in phase a,C0205390;C0679823;C1710475
2,missing,C1551393;C1705492;C3272743
2,events ( % ),C0441471;C3541888
2,s,C0565930;C2603362
2,paci,C1165245
2,nmbr mmhg,C0439475
2,> nmbr mg / dl,C0439269
2,age nmbr y,C0001779
2,> nmbr / day,C0332173;C0439228;C0439505
2,< median,C0549183;C0876920;C2347635;C2348144;C2939193
2,≥ nmbr years,C0439234
2,> nmbr to < nmbr years,C0439234
2,age :,C0001779
2,p +,C0369773;C2603361
2,vldl,C0523560
2,mi,C3810814
2,n *,C0369718;C0441922
2,present,C0150312;C0449450
2,pci,C4049621
2,monthnmbr,C0332177;C0439231
2,primary,C0205225;C0439612;C0439631
2,yes *,C1549445;C1705108;C1710701
2,second ( n = nmbr ),C0205436;C0457385;C0565930;C1561503;C1705190
2,age — y £,C0001779
2,n / n ( % ),C0369718;C0441922
2,open,C0175566
2,mild,C2945599
2,nmbr mg / day,C0439422
2,lateral,C0205093
2,age ^nmbr,C0001779
2,> nmbr mm hg,C0439475
2,< nmbr mg / dl,C0439269
2,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
2,rrr ( nmbr % cl ),C0596019
2,> nmbr ( n = nmbr ),C0369718;C0441922
2,nmbr — nmbr years,C0439234
2,£ nmbr to < nmbr years,C0439234
2,never,C2003901
2,p - blocker,C0369773;C2603361
2,age > nmbr,C0001779
2,swollen,C0038999
2,< nmbr years,C0439234
2,nmbr to < nmbr yr,C0439234
2,edge,C0205154;C2697523
2,peace ( n = nmbr ),C0680443
2,pci ( % ),C4049621
2,bmi^,C0578022
2,p blocker,C0369773;C2603361
2,p trend,C0369773;C1521798;C2603361;C4554533
2,ada,C1060325;C3811629
2,> nmbr type,C0332307;C1547052
2,us ( n = nmbr ),C0369718;C0441922
2,< nmbr mg / g,C1300563
2,bmi < = nmbr,C0578022
2,mental,C0229992
2,> nmbr ft,C1881534;C3890579
2,class > nmbr,C0456387;C1518526;C1705943
2,"/ ’ - value """,C1522609
2,prior mi,C0332152;C2826257;C3810814
2,age > = nmbr,C0001779
2,alone,C0205171;C0439044;C0679994
2,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
2,value *,C1522609
2,p - value *,C1709380
2,age £ nmbr,C0001779
2,mean ( sd ),C0444504;C2347634;C2348143;C2699239
2,sd,C2699239
2,pfor,C1151635
2,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
2,nmbr to < nmbr mm hg,C0439475
2,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
2,af alone,C0344434;C4049859
2,other ( n,C0369718;C0441922
2,monthly,C0332177
2,state,C1301808;C1442792;C3148680
2,lsm ( nmbr % cl ),C0596019
2,≥ nmbr to < nmbr years,C0439234
2,» nmbr yr,C0439234
2,mean — yr,C0439234;C0444504;C2347634;C2348143
2,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,< nmbr week,C0332174;C0439230
2,vitality,C0424589
2,< nmbr ng / ml,C0439275
2,nmbrto < nmbrmmhg,C0439475
2,# nmbr year,C0439234;C0439508
2,changenmbr,C0392747;C0443172;C1705241;C4319952
2,< lnmbr years,C0439234;C0439394;C1706495;C3642217
2,treated,C1522326
2,tnmbrd,C2603360
2,pasi *,C4528685
2,> nmbr - < nmbr mmhg,C0439475
2,< nmbr ( n — nmbr ),C0369718;C0441922
2,< nmbr yr,C0439234
2,bmi > nmbr,C0578022
2,dd,C3538867;C3814791
2,age yrs,C0001779
2,sfc ( n [nmbr ),C4521536
2,> nmbr / > nmbr mm hg,C0439475
2,< nmbr ft,C1881534;C3890579
2,■ nmbr years,C0439234
2,af,C0344434;C4049859
2,bmi < nmbr,C0578022
2,all ( n = nmbr ),C0369718;C0441922
2,age ( years ) +,C1510829
2,result,C1274040;C1546471;C2825142
2,nmbr % cl,C0596019
2,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
2,> = nmbr years,C0439234
2,nmbr mg / g,C1300563
2,ascvd,C3665365
2,loop,C0445022
2,l ( % ),C0439394;C1706495;C3642217
2,pla,C0456170
2,( n = nmbr ),C0369718;C0441922
2,former,C0205156;C0750523
2,b lack,C0332268
2,median,C0549183;C0876920;C2347635;C2348144;C2939193
2,nmbr — < nmbr years,C0439234
2,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,> nmbr ( n — nmbr ),C0369718;C0441922
2,nmbr - nmbr years,C0439234
2,p value *,C1709380
2,< nmbr years ( n = nmbr ),C0439234
2,total *,C0439175;C0439810
2,grade nmbr,C0441800;C0919553;C3244287
2,no ascvd,C3665365
2,> = nmbr - < nmbr mmhg,C0439475
2,group d,C0441838
2,= snmbr,C0565930;C2603362
2,nmbr - nmbr min,C0702093;C1524029;C3813700
2,ii ( n = nmbr ),C1710602;C4082587
2,age : < nmbr years,C1510829
2,primary pci,C0205225;C0439612;C0439631;C4049621
2,past,C1444637;C4284302
2,< nmbr mm hg,C0439475
2,known chd,C0205309;C0280604;C3542407
2,nnt,C1417750
2,locf ),C2825507
2,< nmbr days,C0439228
2,erosion,C0333307;C1880549;C1959609;C3887524
2,psa ( n = nmbr ),C3810537;C3813209
2,age : > nmbr years,C1510829
2,n / pyr,C0369718;C0441922
2,never smoking,C2003901
2,n,C0369718;C0441922
2,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,igm ( n = nmbr ),C1706005
2,< nmbr ml,C0439526;C1705224;C3887665
2,strategy,C0679199
2,age > nmbr y * *,C0001779
2,hdl - c,C3715113
2,> nmbr - nmbr years,C0439234
2,snmbr,C0565930;C2603362
2,nmbr ( n = nmbr ),C0369718;C0441922
2,ale,C0678386;C2632076
2,p valuea,C0369773;C2603361
2,mean *,C0444504;C2347634;C2348143
2,open — no . ( % ),C0175566
2,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
2,laa closure ( n - nmbr ),C0185003;C1521802
2,night - time awakenings / week,C0332174;C0439230;C0860510
2,paci ( n = nmbr ),C1165245
2,bmi,C0578022
2,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2,number of participants,C0237753;C0449788;C0679646
2,low ( nmbr - nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,peripheral revascularization,C0205100;C0581603
2,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
2,betanmbr selective,C0330390;C0439096;C2004068
2,iii and iv ejection fraction,C0439070;C1705160
2,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
2,score nmbr - nmbr,C0449820;C4050231
2,nyha class nmbr or higher,C1882083
2,history of major cardiovascular disease,C0205082;C0205164;C0455539;C4318856;C4521762
2,no pci or cabg — no . ( % ),C4049621
2,non - diabetic patients,C0241863;C1829939
2,evidence or thombus,C3887511
2,events / n,C0441471;C3541888
2,anti - coagulants - no . ( % ),C0848112
2,radial access site,C0442038;C0589360;C0920847
2,controllednmbr — no . ( % ),C2587213;C2911690
2,serum total cholesterol ( mmol / l ),C0587184;C1287371;C1532563
2,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
2,modified rankin score,C0392747;C0449820;C3889737;C4050231
2,mean involved bsa,C0444504;C2347634;C2348143
2,other defined,C1704788;C3539106
2,without ( n = nmbr nmbr ),C0369718;C0441922
2,nmbr - nmbr ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,non - extensive,C0205231;C1518422
2,electrocardiographic findings — no . ( % ),C0438154
2,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
2,bmi ( kg / mnmbr ) cardiovascular history,C0578022;C1532718;C1880008
2,< nmbr regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
2,tg ( mg / dl ),C0337445;C0439269
2,time from onset to medication,C0449244
2,total cholesterol ( mmo nmbr / nmbr ),C0201950;C0543421
2,more than nmbr lesions per vessel,C0205172
2,no . of events / total no . ( % ),C0441471;C3541888
2,ind nmbr mg q . d . n = nmbr,C0439422;C4049864
2,sgrq total score ( week,C0332174;C0439230;C2964552
2,creatinine level,C0428279
2,exercise category ( % ),C3669314
2,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
2,non - reversible ( % ),C0205343;C1518422
2,acuity major,C0750509
2,standard therapyy ( n = nmbr ),C1442989;C2828392
2,acqnmbr score,C2919686
2,albumin / creatinine ratio - mg / mmol,C0486293;C0567349;C1318293;C2348885
2,current medication,C0746467
2,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2,months ( log - transformed ),C0439231
2,total c ( mmol / l,C0439175;C0439810;C1532563
2,saba reversibility,C0449261
2,stratification variables,C0439828;C1514983
2,simplified disease activity index score,C0449820;C3869582;C4050231
2,toast classification,C1710306;C4521230
2,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
2,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
2,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
2,left ventricular ejection fraction — %,C0428772;C0488728
2,ischaemic ( n = nmbrlnmbr ),C0475224
2,time intervals,C0872291
2,age > nmbr y,C0001779
2,nmbr - point mace,C1552961;C2347617;C3714763
2,moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,weekly,C0332174
2,> nmbr ( high risk ),C0332167;C3272283;C4050568;C4319571
2,> nmbr prior myocardial infarction — no . ( % ),C0155668
2,prior therapy,C1514463
2,duration of pci ( min ),C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2,van der heijde mtss,C0557775;C1511780
2,nyha class ( when patient was last in stable condition before admission ),C1882083
2,left ventricular ejection fraction < nmbr %,C0428772;C0488728
2,mestizos,C0682082
2,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
2,history of a transient ischaemic attack,C0455536
2,known tiromtcch * c ccndifeon,C0205309
2,swollen joint count ( nmbr - nmbr possible joints ),C0332149;C0451521;C1705910;C2362652
2,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
2,previous ml ( interaction : p = nmbr . nmbr ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
2,no hemoconcentration hemoconcentration,C0549409;C0854379
2,< nmbr . nmbr mmol / liter estimated gfr,C0439190;C0475211
2,nyha class ii ( n = nmbrlnmbr ),C1882085
2,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
2,duration of ra,C0449238;C2926735;C3538806;C4048756
2,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
2,• ? sd ml / min,C0439445;C2699239
2,first - recorded event  no . ( and % ) of patients,C0205435;C1279901
2,unknown ( none of the above ),C0439673;C3541433;C4050014
2,spacer use during the study,C0221874;C0869040
2,nmbr - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
2,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
2,other medical history — no . ( % ),C0262926;C1704706
2,sfc nmbr mg / nmbr mg,C1319635;C4521536
2,nmbr - nmbr ( low risk ),C3272281;C3538919
2,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
2,reversibility : > nmbr - < nmbr %,C0449261
2,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
2,target - vessel revascularization,C0449618;C0581603
2,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
2,after amendment ( % ),C0680532;C2346732
2,respiratory - related^,C0439849;C0445223;C0521346;C1546767
2,stented vessels,C0183521
2,sedentary,C0205254
2,age category ( years ),C0683312;C1510829;C3889287
2,bifurcation lesion with side branch $ nmbr . nmbr mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
2,feno nmbr mg / eze nmbr mg ( n = nmbr ),C1319635
2,mean ( s . d . ) total pcsknmbr,C0439175;C0439810;C0444504;C2347634;C2348143
2,estimated means and difference,C0750572;C1704970
2,ada impaired fasting glucose,C1060325;C1272092;C3811629
2,tender - joint count,C0451530
2,in - stent restenosis,C3272317
2,verapamil sr,C1527129
2,swollen - joint count,C0451521
2,nmbr to < nmbr ml per nmbr - nmbr mnmbr,C0369637;C0439526;C0441923;C1705224;C3887665
2,within last nmbr d,C1517741
2,intermediate,C0205103;C1550465;C2827755;C3889971
2,wapnmbrc ( ng / ml ),C0439275
2,total cholesterol > nmbr mg / dl,C0201950;C0439269;C0543421
2,lvef,C0428772;C0488728
2,right coronary artery,C1261316
2,difference vs . pbof mean ( s . e . ) t,C1705241;C1705242
2,treatment arm,C1522541
2,continuous variables,C0439828;C0549178
2,intensified nmbr months ( n - nmbr ),C0439231
2,smoking history : current smoker,C1519384;C3173209;C3241966
2,not reported,C1518422
2,mildly impaired,C0750532;C2945599
2,egfrmdrd ， ml - min - nmbr - nmbr . nmbr m_nmbr,C0369637;C0439445;C0441923
2,> nmbr erosion,C0333307;C1880549;C1959609;C3887524
2,concomitant therapies at hospital discharge,C0586003;C1707479
2,oral hypoglycaemics only,C0205171;C0359086;C1720467
2,specific risk of bleeding^,C0205369;C1552740;C3251812
2,number resulting in emergency department visit,C0237753;C0449788
2,number of exacerbations,C0237753;C0449788;C4086268
2,lvef within nmbr months,C0428772;C0439231;C0488728
2,> nmbr mg / dl eze / simva nmbr = nmbr },C0439269
2,greater than or equal to nmbr mm hg,C0439093
2,orthopnea,C0085619
2,nmbr - wk kaplan - meier rate,C0332174;C0439230;C0871208;C1521828
2,improved,C0184511;C0332272;C1561611;C4084203
2,> nmbr previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
2,duplex ultrasonography,C3825392
2,use of supplemental oxygen,C4067893;C4554557
2,unadjusted or ( nmbr % ci ) p value,C1439367
2,rarely / never,C4035880
2,age ( yrs ),C0001779
2,non - ischaemic cardiomyopathy,C0349782;C1518422
2,history of myocardial infarction,C1275835
2,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
2,endovascular,C0524425
2,hormone - refractory prostate carcinoma,C1328504
2,experience,C0237607;C0596545
2,physician ' s global assessment . mean nmbr sd,C0444504;C2347634;C2348143;C2699239;C4050369
2,age ( yrs ) nmbr - nmbr,C0001779
2,presence of erosions,C0150312;C0333307;C0392148;C1959609;C3854307
2,nmbr - nmbr / nmbr - nmbr mm hg,C0439475
2,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
2,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
2,medication effects,C1319171
2,uae ( p,C1519789
2,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
2,aliskiren / valsartan ( n = nmbr ),C2733073
2,urinary protein - to - creatinine ratio | |,C1096054
2,( b ) concomitant respiratory medications [n ( % ) ],C0418986;C0521115
2,glycated hemoglobin level,C0202054
2,albumin creatinine ratio,C0486293;C1318293
2,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
2,csf a ( nmbr ( pm ),C3540512;C3889436
2,prior treatment — %,C1514463
2,history of atrial fibrillation or flutter treatment at randomisation,C0729790
2,interquartile range height — cm,C0489786;C1711350
2,mild thrombocytopenia ( < nmbrx nmbr / l ),C1856453
2,reversibility ( anticholinergic ),C0449261
2,number of exacerbation in the previous nmbr months,C0237753;C0449788;C4086268
2,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
2,( n nmbr nmbr ),C0369718;C0441922
2,before pci,C4049621
2,medical history ( % ),C0262926;C1704706
2,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
2,elevated bun ( > nmbr . nmbr meq / l ),C0151539;C0439375
2,mean ( sd ) bmi ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,% difference,C1705241;C1705242
2,non - frail,C0871754;C1518422
2,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,prerandomization statin therapy,C1278454
2,previous loss of response to infliximab,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2,exposed ( n = nmbr ),C0332157
2,primary composite end point,C0205199;C1547335;C2986535
2,lean ( < nmbr kg / mnmbr ),C1532718
2,event rate,C0441471;C0871208;C1521828;C4019010
2,prior use of systemic,C0205373;C0332152;C1524063;C2826257
2,ibdq domain scores,C1880389;C1883221;C3541951
2,patella fracture,C0159849
2,medical history and risk factors,C0262926;C1704706
2,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
2,antihypertensive therapy — no . ( % ),C0585941
2,fixed triple ( n = nmbr ),C0205174;C0443218;C2827483;C3714578
2,us resident,C1320928;C1549439;C2347958;C3835651
2,less than nmbr mm hg,C0439092;C0439475
2,bmi > nmbr — no . ( % ) f,C0578022
2,tender and swollen joints — mean no . : :,C0234234
2,category nmbr,C0683312;C3889287
2,type of event,C1561488
2,persistent or permanent immobilization,C0205322;C0332996
2,diet controlled or no,C0743195
2,persistent or paroxysmal,C0205322;C0332996
2,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
2,prior or new diabetes,C0332152;C2826257
2,swollen joint count ( nmbr joints ),C0451521
2,nmbr - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
2,mean nmbr sd,C0444504;C2347634;C2348143;C2699239
2,other cardiovascular risk factors,C0850624
2,severe copdc [n z nmbr],C0205082;C4050465;C4050466
2,any coronary revascularization,C0877341
2,current n z nmbr,C0521116;C1705970
2,age ( years ),C1510829
2,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
2,fasting blood glucose > nmbr mg / dl,C0428568;C0439269;C1261430
2,multivessel ( two vessel,C4012475;C4037954
2,non - hdl - c / hdl - c,C1518422;C3715113
2,mean serum glucose,C0202041;C0444504;C2347634;C2348143;C3534430
2,euroscore logistic,C3164744
2,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
2,cerebrovascular or peripheral arterial disease,C1880018
2,low feno subgroup (,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
2,number of copd exacerbations in the previous year,C0237753;C0449788;C0740304
2,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
2,non - stenotic vessels,C0679403;C1518422
2,> nmbr . nmbr bpm current smoker,C3173209;C3241966
2,hospitalization for heart failure,C3898876
2,any history of congestive heart failure,C0455531;C0742742
2,treatment satisfaction,C3476649
2,pathologic q waves — no . ( % ),C0429090
2,total periventricular wml score,C2964552
2,corticosteroid use,C0239126
2,tender joint count ( n / nmbr ),C0451530
2,slowest third,C0205437;C0439834
2,fasting blood glucose,C0428568;C1261430
2,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0042295
2,absent ( < nmbr mg / dl ),C0332197;C0439269;C4285062
2,nmbr mg / day early - start,C0439422
2,acute ( < nmbr hr ),C0205178
2,total ldl - c *,C0439175;C0439810
2,a - glucosidase inhibitor,C1512211
2,% with haq - di decrease > nmbr . nmbr,C0392756;C0547047;C3826998;C4321476
2,monitoring ( n = nmbr ),C0150369;C1283169
2,reduced ef,C0392756
2,sgrq total score * *,C2964552
2,dip involvement,C1314939;C3539618
2,forearm fracture,C1305215
2,significant worsening in kccq clinical score ( > nmbr ) at nmbr monthsnmbr,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
2,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
2,> nmbr . nmbr to < nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
2,ccsc at nmbr month before enrollment,C0332177;C0439231;C1516705
2,total,C0439175;C0439810
2,moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,erosion score ( nmbr - nmbr ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
2,who / idf impaired fasting glucose,C1272092
2,( sd ),C2699239
2,acrnmbr response at week nmbr,C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2,aminosalicylates,C0368663
2,brain volume,C1113695
2,swollen joint count ( nmbr - nmbr ),C0451521
2,jsn score ( nmbr - nmbr ),C0449820;C4050231
2,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
2,daily iglar dose at week nmbr ( u ),C0560588;C2348070
2,> nmbr mg / dl simva nmbr = nmbr],C0439269
2,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
2,coronary revascularization procedure,C0877341
2,middle third,C0442050
2,symptom score ( sd ),C2699239;C3476546
2,former / non - drinker,C0205156;C0457801;C0750523
2,multiple ( nmbr + ) chd risk,C0439064;C1282512
2,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
2,lm bifurcation treated,C0184906;C1261082;C1551056;C3146289
2,> nmbr failure,C0231174;C0680095
2,hscrp > nmbr mg / l,C0439268
2,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
2,dose ( n ),C0178602;C0869039;C1114758
2,smoking status,C1519386
2,time from last dose of pnmbrynmbr inhibitor,C0946444;C1999216
2,snmbr gallop,C0565930;C2603362
2,no . of target vessels,C0449618
2,> nmbr / tmol / liter — no . ( % ),C0475211
2,renin inhibitors,C2917241;C3653375
2,not localized,C1518422
2,constitutional,C1511487
2,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
2,proximal - mainleft,C0205107;C4489236
2,prior anti - tnf therapy,C0281481;C0332152;C2826257
2,sgrq total score,C2964552
2,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
2,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
2,composite endpoint of doubling of serum creatinine,C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2349179;C2826544
2,statin therapy,C1278454
2,former / current smoker,C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
2,qualifying myocardial infarction,C1514624
2,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
2,delayed reaction,C0205421;C0443286;C1545665;C3272602
2,standard care,C1442989;C1947933;C2828392
2,pharmaco - invasive n = nmbr,C0205281;C1334278
2,nmbr % c . i .,C1547546
2,moderate ( > nmbr to < nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,antiplatelet therapy dual,C1096021
2,number of patients with fractures,C2360800
2,before amendment ( % ),C0680532;C2346732
2,( haq - di,C3826998;C4321476
2,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
2,bmi > nmbr ( % ),C0578022
2,high risk ( nmbr - nmbr ),C0332167;C3272283;C4050568;C4319571
2,functional outcome ( mrs nmbr - nmbr ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
2,mean number of exacerbations in previous nmbr months ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2,serum triglycerides,C0542495
2,previously on acei + arb,C3888198
2,menopausal status and use of ht,C1513126
2,ultra,C0728475
2,age < nmbr,C0001779
2,pentraxin - nmbr ( ng / ml ),C0439275
2,> nmbr - nmbr mmol / l,C1532563
2,< nmbr - nmbr mmol / l,C1532563
2,nmbr to nmbr mg / g,C1300563
2,nmbr to < nmbr mg / dl,C0439269
2,> nmbr . nmbr mg / dl,C0439269
2,< nmbr . nmbr l - g / l,C0439267;C3539687
2,> nmbr . nmbr ng / ml,C0439275
2,> nmbr ' nmbr mmol / l,C1532563
2,< nmbr . nmbrmg / l,C0439268
2,nmbr - nmbr mg / dl,C0439269
2,mean ( s . e . ),C0444504;C2347634;C2348143
2,mean ( s . e . ) t,C0444504;C2347634;C2348143
2,mean ( s . d . ),C0444504;C2347634;C2348143
2,mean bmi ( kg / mnmbr ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,gastroduodenum,C0391900
2,gastroduodenal,C0450199
2,primary endpoint,C2986535
2,. nmbr . nmbr mg / mmol,C0567349;C2348885
2,> nmbr + nmbr mmol / l,C1532563
2,mean ( s . d . ) age,C0001779;C0444504;C2347634;C2348143
2,nmbr nmbr mg / dl,C0439269
2,< nmbr years eze / simva ( n = nmbr },C0439234
2,> nmbr drinks,C0452428
2,nmbr drinks,C0452428
2,< nmbr . nmbr mg / dl,C0439269
2,> nmbr . nmbr mg / mmol,C0567349;C2348885
2,> nmbr . nmbr - g / l,C0439294;C0456615
2,nmbr - nmbr mg / g,C1300563
2,≥ nmbr to < nmbr mg / g,C1300563
2,< nmbr . nmbr ng / ml,C0439275
2,> nmbr . nmbr mg / l,C0439268
2,> nmbr . nmbr mmol / l,C1532563
2,≥ nmbr to < nmbr mg / dl,C0439269
2,< nmbr . nmbr mmol / l,C1532563
2,< nmbr . nmbr mg / mmol,C0567349;C2348885
2,> nmbr & < nmbr mg / dl,C0439269
2,> nmbr to nmbr mg / g,C1300563
2,"primary end point """,C2986535
2,mean ± s . d . age,C0001779;C0444504;C2347634;C2348143
2,medical therapies,C0418981
2,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
2,body mass indexc,C0518010
2,previous mi,C0205156;C1552607;C3810814
2,previous pci,C0205156;C1552607;C4049621
2,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
2,previous ami,C0205156;C1552607;C4319936
2,previous,C0205156;C1552607
2,w event ( rate ),C0441471;C0871208;C1521828;C4019010
2,type nmbr diabetes ( n = nmbr,C1320657
2,body - mass indexj,C0518010
2,no type nmbr diabetes ( n = nmbr,C1320657
2,with p blockers,C0369773;C2603361
2,without p blockers,C0369773;C2603361
2,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
2,lesion length $ nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
2,lesion length > nmbr mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
2,> median ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,body - mass indexf,C0518010
2,height ( cm ),C0489786
2,nmbr mg / day early - start - delayed - start,C0439422
2,< nmbr kg / mnmbr,C1532718
2,nmbr mg / day early - start - delayed start,C0439422
2,£ nmbr kg / mnmbr,C1532718
2,anmbr kg / mnmbr,C1532718
2,< nmbr kg / m nmbr,C1532718
2,> nmbrkg / mnmbr,C1532718
2,< nmbrkg / mnmbr,C1532718
2,snmbr kg / mnmbr,C0565930;C1532718;C2603362
2,≥ nmbr kg / mnmbr,C1532718
2,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
2,> nmbr kg / mnmbr,C1532718
2,< nmbr years n z nmbr,C0439234
2,> nmbr years n z nmbr,C0439234
2,age < nmbr y ( n = nmbr ),C0001779
2,age ' nmbr y ( n nmbr ),C0001779
2,age > nmbr y ( n = nmbr ),C0001779
2,height — cm,C0489786
2,> nmbr years eze / simva ( „ = nmbr },C0439234
2,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
2,serum creatinine ( gmol / ),C0201976;C0600061
2,hs - crp ( mg / l ),C0439268;C3890735;C4048285
2,mhis score,C0449820;C4050231
2,kccq score,C3476798
2,aqlq score,C4055434
2,accp score,C0449820;C4050231
2,esr — mm / hr,C3811131;C4330985;C4554674
2,"esr ( mm / hour ) git config - - global user . name "" your name """,C0205246;C0439227;C0564385;C1418224;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4554674
2,premenopausal,C0279752
2,fpg ( mg / dl ),C0439269
2,edss score,C0451246;C3887783
2,crp — mg / l,C0439268;C3890735;C4048285
2,crp ( ng / ml ),C0439275;C3890735;C4048285
2,bun ( mg / dl ),C0439269
2,tgs ( mg / dl ),C0439269;C1156212;C1537574
2,hdl ( mg / dl ),C0439269;C3715113
2,crp ( mg / dl ),C0439269;C3890735;C4048285
2,mpo ( ng / ml ),C0439275
2,mean score,C3533236
2,gds score *,C0451184;C1149049;C1418244
2,fibula fracture,C0149699
2,> median ( nmbr mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
2,> nmbr yr — no . ( % ),C0439234
2,< nmbr vr — no . ( % ),C3476815
2,< nmbr yr — no . ( % ),C0439234
2,> nmbr yr ( % ),C0439234
2,< nmbr days ( % ),C0439228
2,£ median ( nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,> median ( nmbr % ),C0549183;C0876920;C2347635;C2348144;C2939193
2,> median ( nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,rope score,C0449820;C1563164;C4050231
2,previous mi — no . ( % ),C0205156;C1552607;C3810814
2,diabetes status,C1317301
2,diabetic status,C0241863;C0449438
2,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
2,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
2,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
2,mean acrn,C0444504;C2347634;C2348143
2,hscrp ( mg / l ),C0439268
2,hscrp ( mg / l ) c,C0439268
2,hscrp ( nmol / l ),C0439282
2,nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,inflammatory,C0333348
2,previous or current use of im or cs : no,C0205156;C1552607
2,previous or current use of im and cs : no,C0205156;C1552607
2,nmbr to < nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,nmbr to o nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0483204
2,nmbr to onmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C0483204
2,≥ nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,aspirin dose,C4696290
2,troy ( ng / ml ),C0439275;C1420811;C1883402
2,hypertensive,C0857121
2,unstable anginad,C0443343;C1883468
2,unstable anginat,C0443343;C1883468
2,arb monotherapy,C3888198
2,age category >,C0001779;C0683312;C3889287
2,bmi category,C0578022;C0683312;C3889287
2,age category,C0001779;C0683312;C3889287
2,age range,C0001779;C1514721;C2348147;C3542016
2,age range ( years ),C1510829;C1514721;C2348147;C3542016
2,< median ( nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,> median ( nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
2,fascng plasma glucose a medan,C0202042;C0455280
2,dissatisfied with / stopped $ nmbr prior systemic therapies because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
2,dissatisfied with / stopped $ nmbr prior systemic therapy because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
2,current smoker 一 no . ( % ),C3173209;C3241966
2,current smoker — no . ( % ),C3173209;C3241966
2,gdf - nmbr ( ng / ml ),C0439275;C1418244
2,anmbrc < nmbr . nmbr % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
2,anmbr = nmbr . nmbr % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
2,hazard ratio ( nmbr % cl ),C0596019;C2985465
2,pci orcabg,C4049621
2,very severe,C3641272;C4050419
2,more severe^,C0205082;C0205172;C4050465;C4050466
2,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
2,more severe,C0205082;C0205172;C4050465;C4050466
2,< median ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,chanmbrdsnmbr - vasc $ nmbr,C1420648;C3714751
2,chanmbrdsnmbr - vasc # nmbr,C1420648;C3714751
2,bmi ( kg / mnmbr ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
2,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
2,< nmbr mmol / l,C1532563
2,> nmbr mmol / l,C1532563
2,bmi ( kg / mnmbr ),C0578022;C1532718
2,bmi ( kg / mnmbr ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,bmi in kg / mnmbr,C0578022;C1532718
2,hazard ratio or differencenmbr * ( nmbr % cl ) p - value,C2985465
2,peripheral artery diseasef,C0489868
2,hazard ratio or differencenmbr ( nmbr % cl ) p - value,C2985465
2,history of hypertension ( a ) c,C0455527
2,history of hypertension ( % ),C0455527
2,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
2,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
2,£ median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,< median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,history of pvd,C4534349
2,end points,C2349179
2,nyha class iv,C1882087
2,prior peripheralarterialdisease,C0332152;C2826257
2,nyha class ii,C1882085
2,nyha class > ii,C1882085
2,nyha class i,C1882084
2,prior lgi event,C0332152;C0441471;C2826257;C4019010
2,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
2,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
2,no prior lgi event,C0332152;C0441471;C2826257;C4019010
2,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
2,endpoint,C2349179;C2826544
2,saphenous vein graft,C0729538
2,saphenous - vein graft,C0729538
2,one tnfi and,C0205447
2,one tnfi *,C0205447
2,postmenopausal and current hrt,C0232970
2,postmenopausal and current ht,C0232970
2,end point,C2349179;C2826544
2,> median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,full po pulatio n,C0443225;C0946289
2,no epa group n = nmbr,C0441848
2,mean age ( years ),C0444504;C1510829;C2347634;C2348143
2,intense,C0522510
2,< nmbr . nmbr kg / mnmbr,C1532718
2,nmbr - nmbr kg / mnmbr,C1532718
2,> nmbr . nmbr kg / mnmbr,C1532718
2,usual care ( n = nmbra ),C1947933;C3538928
2,usual care ( n = nmbr ),C1947933;C3538928
2,total population ( n = nmbr ),C3258257
2,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
2,epa group n = nmbr,C0441848
2,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
2,duration of tnmbrd ( years ),C0439234;C0449238;C2926735
2,no antiplatelet therapy,C1096021
2,antiplatelet therapy,C1096021
2,antiplatelet therapy §,C1096021
2,haq - di scoreff,C3826998;C4321476
2,haq - di scored,C3826998;C4321476
2,inter .,C0205103;C1548610
2,p value * nmbr,C1709380
2,p valuenmbr,C1709380
2,> qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
2,vitamin k antagonists,C3653316
2,vitamin k antagonist,C1096489;C2267235
2,modified acc - aha lesion class bnmbr or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
2,modified acc / aha lesion class bnmbr or cj,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
2,oad only,C0205171;C1720467
2,past only,C0205171;C1444637;C1720467;C4284302
2,< nmbr ml / min per nmbr - nmbr mnmbr,C0369637;C0439445;C0441923
2,> nmbr ml / min per nmbr - nmbr mnmbr,C0369637;C0439445;C0441923
2,australia / new zealand,C4289954
2,subjects $ nmbr years of age,C0681850;C1550501;C1706203;C2349001;C2697811
2,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
2,nmbr - nmbr vr — no . ( % ),C3476815
2,nmbr - nmbr yr — no . ( % ),C0439234
2,nmbr = nmbr yr — no . ( % ),C0439234
2,< qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
2,nyha class,C1882083
2,nyha class iii,C1882086
2,chanmbrdsnmbr - vasc > nmbr,C1420648;C3714751
2,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2,any mi ( n - nmbr,C3810814
2,no pad ( n - nmbr,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2,ldl - c ( mmol / l ),C1532563
2,hdl - c ( mmol / l ),C1532563;C3715113
2,ldl - c * ( mmol / l ),C1532563
2,anti - hypertensive therapy,C0585941
2,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2,age ( years ) ( mean,C0444504;C1510829;C2347634;C2348143
2,no mvd ( n - nmbr,C1417507;C3272839
2,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2,one of the above,C0205447
2,two of the above,C0205448
2,all of the above,C1282910;C1552828
2,none of the above,C1282910;C1552828
2,any of the above,C1282910;C1552828
2,no . of events,C0441471;C3541888
2,mvd ( n - nmbr,C1417507;C3272839
2,pad ( n - nmbr,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2,no readmission ( n = nmbr ),C1548168;C4489276
2,present ( > nmbr mg / dl ),C0150312;C0439269;C0449450
2,reversibility to,C0449261
2,reversibility ( % ) t,C0449261
2,reversibility *,C0449261
2,reversibility,C0449261
2,reversibility ( % ),C0449261
2,reversibility %,C0449261
2,present ( £ nmbr mg / dl ),C0150312;C0439269;C0449450
2,nmbr . nmbr to # nmbr . nmbr mg / mmol,C0567349;C2348885
2,no mi ( n - nmbr,C3810814
2,nmbr . nmbr - < nmbr . nmbr mg / mmol,C0567349;C2348885
2,ifg / igt,C1334085;C1708411
2,ifg and igt,C1334085;C1708411
2,< nmbr % ( < nmbr mmol / mol ),C3829066
2,> nmbr % ( > nmbr mmol / mol ),C3829066
2,> = nmbr % ( nmbr mmol / mol ),C3829066
2,< nmbr % ( nmbr mmol / mol ),C3829066
2,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
2,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
2,serum creatinine — mg / dl,C0201976;C0439269;C0600061
2,post - bronchodilator,C2599594
2,p . interaction,C0369773;C1704675;C2603361
2,p : interaction,C0369773;C1704675;C2603361
2,p - interactio n,C0369773;C2603361
2,creat clearance < nmbr ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
2,creat clearance > nmbr ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
2,pre - bronchodilator,C2599602
2,prebronchodilator,C2599602
2,postbronchodilator,C2599594
2,final median,C0205088;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
2,heritable,C0439660
2,variable,C0439828;C4553760
2,nyha iii,C0439070;C1275491;C1705160
2,stage nmbrb : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441781;C0441923
2,stage nmbra : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C1300072;C1306673
2,stage nmbr : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
2,readmission ( n = nmbr ),C1548168;C4489276
2,p - interaction,C0369773;C1704675;C2603361
2,interaction - p,C1704675
2,age - interaction,C0001779;C1704675
2,interaction p,C1704675
2,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
2,latin american,C1553378
2,medical history — no . ( % ),C0262926;C1704706
2,> nmbr months,C0439231
2,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
2,controlled,C2587213;C2911690
2,uncontrolled,C0205318
2,currently,C0521116
2,p inleraclion,C0369773;C2603361
2,p nmbr interaction,C0369773;C1704675;C2603361
2,p for interaction,C0369773;C1704675;C2603361
2,pfor interaction,C1151635;C1704675
2,p interaction,C0369773;C1704675;C2603361
2,p for interaction *,C0369773;C1704675;C2603361
2,> nmbr days ( % ),C0439228
2,medical therapy,C0418981
2,stage nmbr,C0205390;C1300072;C1306673
2,yes ( % ),C1549445;C1705108;C1710701
2,prior pci,C0332152;C2826257;C4049621
2,( n = nmbr,C0369718;C0441922
2,oradj ( nmbr % cl ),C0596019
2,v total ( n = nmbr ),C0439175;C0439810
2,event ( % ),C0441471;C4019010
2,general,C0205246;C3812897;C3891294;C4521767
2,≤ nmbr ug / g,C0439272
2,post - mi,C0856742
2,> nmbr days,C0439228
2,sdai,C3871128
2,p value,C1709380
2,< nmbr ( n z nmbr ),C0369718;C0441922
2,> nmbr mm ( n = nmbr ),C4330985;C4554674
2,all n = nmbr,C0369718;C0441922
2,tg > nmbr . nmbr,C0337445
2,p value c,C1709380
2,ebria,C1917247
2,m / f,C1306057
2,< nmbr min,C0702093;C1524029;C3813700
2,age < nmbryrs,C0001779
2,age ( yr ),C0001779;C0439234
2,ale < nmbr,C0678386;C2632076
2,chd *,C0280604;C3542407
2,arbs,C3888198
2,age in years,C1510829
2,l / ll,C0439394;C1706495;C3642217
2,tg ’,C0337445
2,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2,others,C1955473;C3539125
2,arr ( nmbr % cl ),C0596019;C2170357;C4084934
2,> nmbr . nmbr mm hg,C0439475
2,lama,C0999593;C1416775
2,chd,C0280604;C3542407
2,p - value,C1709380
2,edge ii,C0205154;C1710602;C2697523;C4082587
2,ml,C0439526;C1705224;C3887665
2,mets,C0812270;C1705694;C2939420
2,n .,C0369718;C0441922
2,hdl choleslerol,C3715113
2,mate,C0682323;C1260875
2,canvas,C3281223
2,study nmbr,C0557651;C2603343
2,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,ml ),C0439526;C1705224;C3887665
2,ff - blocker,C4554348
2,< nmbr . nmbr years,C0439234
2,total n = nmbr,C0439175;C0439810
2,met ( n = nmbr ),C0428210;C1550543;C4317104
2,> nmbr mm,C4330985;C4554674
2,other chd,C0280604;C3542407
2,lda,C4553195
2,nmbr - nmbr days,C0439228
2,hr ( nmbr % cl ),C0596019
2,n nmbr,C0369718;C0441922
2,age > = nmbr yrs,C0001779
2,m being,C0369637;C0441923
2,nmbr min,C0702093;C1524029;C3813700
2,age ( year ),C0001779;C0439234;C0439508
2,enrolled from re - cover ii study — no . ( % ),C4684790
2,upper,C1282910
2,< nmbr year,C0439234;C0439508
2,stage nmbrb,C0441781
2,pint,C0560012;C3811619;C3890014;C3890556
2,hdl,C3715113
2,age # nmbr yrs,C0001779
2,provoked,C1444748
2,> nmbr years,C0439234
2,mean a ± sdt,C0444504;C2347634;C2348143
2,qd,C0332173
2,no prior mi,C0332152;C2826257;C3810814
2,mean ± sd,C0444504;C2347634;C2348143;C2699239
2,stage nmbra,C0205390;C1300072;C1306673
2,lesions,C0221198
2,total c,C0439175;C0439810
2,p [int],C0369773;C2603361;C3272375
2,rarely,C0522498
2,nmbryr,C0439234
2,month nmbr,C0332177;C0439231
2,brachial,C0445456
2,nmbr - nmbr yr,C0439234
2,< nmbr % ( n = nmbr ),C0369718;C0441922
2,> nmbr ml,C0439526;C1705224;C3887665
2,age $ nmbr yrs,C0001779
2,rr ( nmbr % cl ),C0596019;C4554402
2,whitea,C1021495
2,age > : nmbr,C0001779
2,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,p blockers,C0369773;C2603361
2,sama,C1075468
2,£ nmbr years,C0439234
2,> nmbr / week,C0332174;C0439230
2,non - c,C1518422
2,group a,C0441835;C4522145
2,$ nmbr ( n = nmbr ),C0369718;C0441922
2,≥ nmbr mg / dl,C0439269
2,> nmbr % ( n = nmbr ),C0369718;C0441922
2,age > nmbr yrs,C0001779
2,yes ( n = nmbr ),C1549445;C1705108;C1710701
2,orc ( nmbr % cl ),C0596019;C1167125
2,m,C0369637;C0441923
2,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2,nnmbr yrs,C0369718;C0441922
2,psa,C3810537;C3813209
2,nmbr years,C0439234
2,nmbr yr,C0439234
2,n = nmbr,C0369718;C0441922
2,lower,C0441994;C1548802;C2003888
2,mg / dl,C0439269
2,p - valuea,C0369773;C2603361
2,ml c,C0439526;C1705224;C3887665
2,tg +,C0337445
2,cdai < nmbrt,C0683448;C1413248;C3273706
2,tg §,C0337445
2,rate *,C0871208;C1521828
2,$ nmbr years,C0439234
2,dd ( n = nmbr ),C3538867;C3814791
2,nyha ii,C1275491;C1710602;C4082587
2,£ nmbr yo ( n = nmbr ),C1413296
2,> nmbr mmhg,C0439475
2,< nmbr days ( n = nmbr ),C0439228
2,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
2,> = nmbr mmhg,C0439475
2,age — yrf,C0001779
2,fragile,C0302113
2,n o,C0369718;C0441922
2,csf,C3540512;C3889436
2,sites,C0205145
2,first ( n = nmbr ),C0205435;C1279901
2,age > nmbr yr,C0001779;C0439234
2,value,C1522609
2,> nmbr to < nmbr yr,C0439234
2,age < nmbr y,C0001779
2,p value 十,C1709380
2,spinal,C0521329
2,arr,C2170357;C4084934
2,age > nmbr yrs *,C0001779
2,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
2,no psa,C3810537;C3813209
2,< nmbr mmhg,C0439475
2,level nmbr,C0441889;C0456079;C1547707;C2946261
2,european,C0239307;C1535514
2,bmi > = nmbr,C0578022
2,onmbr,C0483204
2,severity,C0439793;C0522510
2,normal,C0205307;C0231683;C0439166;C2347086;C4553972
2,sdai < nmbr t,C3871128
2,age years,C1510829
2,row,C1552840;C1552846
2,care,C1947933
2,n %,C0369718;C0441922
2,early ( n = nmbr ),C1279919
2,mm hg,C0439475
2,cl nmbr %,C0596019
2,$ nmbr years ( n = nmbr ),C0439234
2,< nmbr ( n = nmbr ),C0369718;C0441922
2,oral,C0442027;C4521986
2,tgt,C1421391;C1428265;C4321338
2,sfc ( n = nmbr ),C4521536
2,current smoker ( % ),C3173209;C3241966
2,hdl ( mmol / l ),C1532563;C3715113
2,mrf subjects,C0312443;C1412879
2,history of hypertension ( n = nmbr ),C0455527
2,no history of hypertension ( n = nmbr ),C0455527
2,current smoker,C3173209;C3241966
2,current smokers,C3173209;C3241966
2,current smokers ( % ),C3173209;C3241966
2,current non - smoker,C0425311
2,tg ( mmol / l ),C0337445;C1532563
2,current smokers *,C3173209;C3241966
2,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
2,interactior p - value,C1709380
2,interaction p - value,C1704675;C1709380
2,interaction p value 中,C1704675;C1709380
2,interaction p value §,C1704675;C1709380
2,interaction p value,C1704675;C1709380
2,ppg,C1418888
2,ldl ( mmol / l ),C1532563
2,active ( n = nmbr ),C0205177;C3853793;C3888249
2,yes ',C1549445;C1705108;C1710701
2,with ( n = nmbr ),C0369718;C0441922
2,radial,C0442038;C0920847
2,nnmbr / nnmbr,C0369718;C0441922
2,> = nmbr yr,C0439234
2,sfc ( n[nmbr ),C4521536
2,ra,C3538806;C4048756
2,pci — no . ( % ),C4049621
2,ratio,C0456603;C1547037
2,k ( mmol / l ),C0597277;C1532563;C1708601
2,smoking status — no . ( % ),C1519386
2,unadjusted,C1439367
2,unadjusted hr,C1439367
2,adjusted,C0456081
2,unadjusted hr .,C1439367
2,tg ( mmol / l ) c,C0337445;C1532563
2,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
2,duration of pd,C0449238;C2926735;C4553228;C4553229
2,multivariate p - value,C1709380
2,univariate p - value,C1709380
2,class i,C0441885;C1319793;C2698967
2,stage nmbra : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0205390;C1300072;C1306673
2,nmbrrd > nmbr . nmbr,C0694666;C4553350
2,oral hypoglycemic,C0359086
2,oral hypoglycemics,C0359086
2,disease activity],C1292728
2,disease activity,C1292728
2,ease activity],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
2,class iii,C0441887;C2698969
2,group b ( n = nmbr ),C0441848
2,class ii,C0441886;C2698968
2,class iv,C0441888;C2698970
2,smoking status *,C1519386
2,smokinq status,C0449438
2,nyha iii or iv,C0439070;C1275491;C1705160
2,total cholesterol *,C0201950;C0543421
2,total cholesterol,C0201950;C0543421
2,diabetic,C0241863
2,diabetics,C0241863
2,non - diabetics,C0241863;C1518422
2,diabeticnmbr,C0241863
2,group c ( n = nmbr ),C0441848
2,group a ( n = nmbr ),C0441848
2,ltbr ( ng / ml ),C0439275;C1416931
2,pigr ( ng / ml ),C0439275;C1418569
2,haq - di *,C3826998;C4321476
2,haq - di * *,C3826998;C4321476
2,nmbr - hour madbp,C0439227;C0564385
2,nmbr - hour masbp,C0439227;C0564385
2,nmbr to < nmbr ( n = nmbr ),C0369718;C0441922
2,nmbr to < nmbr ( n z nmbr ),C0369718;C0441922
2,aceis / arbs,C3888198
2,acei / arb,C3888198
2,diabetic yes,C0241863;C1549445;C1705108;C1710701
2,diabetic no,C0241863
2,non - diabetic,C0241863;C1518422
2,group c,C0441837
2,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,prior llt,C0332152;C2347090;C2826257
2,nmbr to < nmbr years,C0439234
2,year nmbr,C0439234;C0439508
2,no prior pci,C0332152;C2826257;C4049621
2,hr ( nmbr % cl ) *,C0596019
2,^median,C0549183;C0876920;C2347635;C2348144;C2939193
2,> nmbr min,C0702093;C1524029;C3813700
2,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
2,nnmbr,C0369718;C0441922
2,> nmbr mg / g,C1300563
2,nmbr mg / dl,C0439269
2,p values,C1709380
2,> nmbr to nmbr years,C0439234
2,age > nmbr yr 十,C0001779;C0439234
2,site,C0205145;C1515974;C2825164
2,> = nmbr years ( n = nmbr ),C0439234
2,ifg,C1334085;C1708411
2,s £ nmbr,C0565930;C2603362
2,hdl *,C3715113
2,< nmbr yo ( n = nmbr ),C1413296
2,samanmbr,C1075468
2,no mi,C3810814
2,"p - value """,C1709380
2,never smoker,C0425293
2,≥ nmbr mg / g,C1300563
2,≥ nmbr ng / ml,C0439275
2,no psa ( n = nmbr ),C3810537;C3813209
2,lama +,C0999593;C1416775
2,primary *,C0205225;C0439612;C0439631
2,age < nmbr yrs,C0001779
2,lnmbr,C0439394;C1706495;C3642217
2,n_,C0369718;C0441922
2,< nmbr / < nmbr mm hg,C0439475
2,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
2,crcl < nmbr,C1846718
2,age — yr,C0001779;C0439234
2,mean = sd,C0444504;C2347634;C2348143;C2699239
2,avr,C0449217
2,age ( years ) :,C1510829
2,lvef > nmbr %,C0428772;C0488728
2,group b,C4522078
2,laci ( n = nmbr ),C1420705;C3273314;C4281721
2,hazard,C0598697
2,p valuey,C0369773;C2603361
2,age ( yij,C0001779
2,tender,C0234234
2,p *,C0369773;C2603361
2,iii ( n z nmbr ),C0439070;C1705160
2,non - hdl,C1518422;C3715113
2,puva,C0853073;C1704892
2,off pump,C0182537;C1518543
2,event,C0441471;C4019010
2,iii,C0439070;C1705160
2,glinide,C2266929
2,indian,C1524069
2,week nmbr,C0332174;C0439230
2,right,C0205090;C0444532
2,tg *,C0337445
2,mean,C0444504;C2347634;C2348143
2,on pump,C3842462
2,> nmbr yr,C0439234
2,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
2,n =,C0369718;C0441922
2,no chd,C0280604;C3542407
2,sfc,C4521536
2,[nmbr % cl],C0596019
2,age < nmbr years,C1510829
2,n / n,C0369718;C0441922
2,> nmbr . nmbr min,C0702093;C1524029;C3813700
2,aicd,C0972395;C2611803;C3537205;C3546309
2,major,C0205082;C0205164;C4318856;C4521762
2,prior,C0332152;C2826257
2,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
2,no ( n = nmbr ),C0369718;C0441922
2,absent,C0332197;C4285062
2,age $ nmbr years § *,C1510829
2,laci,C1420705;C3273314;C4281721
2,ischemic stroke ( vs . tia ),C0948008
2,bone erosion ( judged by physician ),C0587240
2,nmbr . nmbr - nmbr . nmbr mg / l,C0439268
2,genotyping,C1285573
2,events,C0441471;C3541888
2,event / total,C0439175;C0439810;C0441471;C4019010
2,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
2,total comparators,C0439175;C0439810;C1707454;C4553389;C4553390
2,estimated glomerular filtration rate,C3811844
2,duration,C0449238;C2926735
2,arb at enrollment,C1516879;C1696073;C3888021;C3888198
2,remission,C0544452;C0687702
2,week nmbr mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
2,seropositivity,C0521143
2,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
2,bmi ( kg / mnmbr ) < nmbr,C0578022;C1532718
2,severe hyperkalemiac,C0205082;C4050465;C4050466
2,non - hdl - c ( mmol / l,C1518422;C1532563;C3715113
2,yes,C1549445;C1705108;C1710701
2,nmbr - nmbr . nmbr kg / mnmbr,C1532718
2,history of congestive heart failure,C0455531;C0742742
2,medical history — no . / total no . ( % ),C0262926;C1704706
2,south asian,C1519427
2,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
2,history of currently treated hypertension,C0455527;C0521116;C1522326
2,tg,C0337445
2,terminal ileum,C0227327
2,prior tnfi,C0332152;C2826257
2,established ascvd,C0443211;C1272684;C3665365
2,emergent / urgent surgery,C0750573;C2188405
2,laboratory measurements,C0681902
2,tender joint count ( nmbr - nmbr ),C0451530
2,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
2,ldl - c < nmbr . nmbr mmol / l,C1532563
2,years [range],C0439234;C1514721;C2348147;C3542016
2,modmy al randcnxzaton,C0202311
2,additional investigations,C2359834
2,ejection fraction,C0489482;C2700378
2,class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967
2,hormonal status,C0449438;C0458083
2,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
2,anticoagulant therapy,C0150457
2,> nmbr servings / wk ( n = nmbr ),C0332174;C0439230;C1519269
2,total group ( n = nmbr ),C0439175;C0439810;C0441848
2,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
2,managed medically — no . / total no . ( % ),C1273870
2,alt,C1266129;C4553172
2,scr,C1539487;C4050416
2,median ( sd ),C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
2,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
2,hormone therapy,C0279025
2,( nmbr % ell ' ll,C1427925;C3273466
2,circumflex,C1880089
2,treatment duration,C0444921;C3259042
2,before bronchodilation,C1371299;C3537072
2,bmi ( nmbr . nmbr  nmbr . nmbr ),C0578022
2,physical function ( nmbr - nmbr,C0516981;C4049916
2,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
2,medical characteristics,C0199168;C0205476;C1521970
2,age < nmbr years — no . ( % ),C1510829
2,serum sodium — meq / liter,C0439152;C0475211;C0523891
2,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
2,dactylitis,C0239161
2,acute and delayed reaction,C0205178
2,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
2,reversibility ( bnmbr - agonist ),C0449261;C2987634
2,medical history,C0262926;C1704706
2,current / past,C0521116;C1444637;C1705970;C4284302
2,no . of days to homa - ir testing — median ( iqr ),C0439228
2,nmbr - nmbr / week,C0332174;C0439230
2,pnmbrynmbr inhibitor,C0369773;C1999216;C2603361
2,history of paroxysmal atrial fibrillation,C0205311;C0729790
2,< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0369637;C0439445;C0441923
2,biomarker status,C0449442
2,≥ nmbr . nmbr to < nmbr . nmbr years,C0439234
2,nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0439590;C1550147;C2709094;C3539075;C3539076
2,isolated igt,C0205409;C1548221
2,pasi < nmbr *,C4528685
2,nmbr locf ),C2825507
2,distal anastomosis ( % ),C0448964
2,elevated creatinine ( > nmbr pmol / l ),C0151578;C0439284;C0700225
2,calculated ldl - c in nmbr classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
2,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
2,oral hypoglycemic agent,C0359086
2,very severe n z nmbr,C3641272;C4050419
2,years since pah diagnosis,C0439234
2,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
2,severity n ( % ),C0439793;C0522510
2,history of hypercholesterolemia,C1533076
2,current (,C0521116;C1705970
2,prior pci or cabg surgery,C0332152;C2826257;C4049621
2,unacceptable adverse events,C0877248;C1705413;C1883420
2,standard care ( n = nmbr ),C1442989;C1947933;C2828392
2,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2,ldl particle size ( week nmbr ),C0332174;C0439230;C3641256
2,parameter,C0549193;C1704769;C2350001
2,week nmbr ( geometric mean,C0332174;C0439230;C2986759
2,cardiac rhythm,C0232187
2,patients ' characteristics age ( years ),C0815172;C1510829
2,acc / aha lesion class bnmbr or c,C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
2,presence of honeycombing,C0150312;C0332468;C0349384;C0392148;C3854307
2,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
2,dpi ( other than diskus ),C1553480
2,fpg ( mmol / l ),C1532563
2,lipid levels — mg / dl,C0428460;C0439269
2,open triple ( n = nmbr ),C0175566
2,mean ( sd ) extent of exposure,C0274281;C0332157;C0439792;C0444504;C2347634;C2348143;C2699239
2,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
2,pfo closure group ( n = nmbr ),C0185003;C0441848;C1521802
2,cardiovascular risk factors — no . / total no . ( % ),C0850624
2,percentage difference ( nmbr % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
2,combined n = nmbr,C0205195
2,urinary albumin - to - creatinine ratio^,C0455271;C1318330
2,simplified disease activity index,C3869582
2,ratio of ldl to hdl,C0456603;C1547037
2,total study population ( n = nmbr,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2,who / idf ifg,C1334085;C1708411
2,cardiovascular history 一 no . ( % ),C1880008
2,postmenopausal,C0232970
2,difference vs placebo,C1705241;C1705242
2,> nmbr : obese class iii,C1319441
2,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
2,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
2,mean hscrp,C0444504;C2347634;C2348143
2,native latin,C0302891
2,in ibdq total score at week nmbr,C0332174;C0439230;C2964552
2,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,triple - vessel disease,C0856738
2,mean ( sd ) crp,C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
2,one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,C0205447
2,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
2,carotid revascularization,C0581603;C0741968
2,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
2,time from onset to randomization,C0449244
2,class l / ll heart failure,C0456387;C1518526;C1705943
2,sglt - nmbr inhibitors^,C3665045
2,any type,C0332307;C1547052
2,left anterior descending artery,C0226032
2,anyantianginal agent,C0450442;C1254351;C1521826
2,concomitant therapy,C1707479
2,indication for pci,C0392360;C3146298;C4049621
2,median ( iqr ) age,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,established ascvd or > nmbr cv risk factors,C0443211;C1272684;C3665365
2,abx - facil . pci,C4049621
2,combined end points,C0205195;C2349179
2,elevated tg,C0205250;C0337445;C3163633
2,formal education,C0681344
2,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
2,angina class iii or iv prior myocardial infarction,C0264677
2,multiple,C0439064
2,emotional well - being,C2984554;C3641833
2,prior surgery : no,C0455610
2,smoking history,C1519384
2,isolated systolic hypertension,C0745133
2,no . of prior tnfi,C0332152;C2826257
2,discontinuations teaes,C0457454
2,adverse outcome,C1274040
2,prior ischemic stroke,C0332152;C0948008;C2826257
2,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
2,haq - di score ( nmbr - nmbr ),C0449820;C3826998;C4050231;C4321476
2,nmbr year or more,C0439234;C0439508
2,crcb - ( ml / min ),C0439445
2,active or previous cancer,C0205177;C3853793;C3888249
2,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
2,nmbr no . of events,C0441471;C3541888
2,( nmbr % cl ) interaction,C0596019;C1704675
2,responders of three - item end point at nmbr weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
2,fatal and nonfatal stroke,C1302234;C1705232
2,conventional treatment ( n = nmbr ),C2945704
2,dual antiplatelet,C0205173;C1554184
2,intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205103;C1550465;C2827755;C3889971
2,microalbuminuria or proteinuria,C0730345
2,primary end point kaplan - meier rate,C0871208;C1521828;C2986535
2,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
2,p value for adjusted hr,C0456081;C1709380
2,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
2,a / v ( n = nmbr ),C1272460
2,unknown,C0439673;C3541433;C4050014
2,laba / lama,C0999593;C1416775
2,elevated at wk nmbr — no . ( % ) nmbr,C0205250;C0332174;C0439230;C3163633
2,ccv history / condition,C0683519
2,type nmbr diabetes mellitus ’,C1320657
2,perianal or anus,C0442158
2,prior implantable cardiodefibrillator,C0021102;C0332152;C2826257
2,crp ( mg / l ),C0439268;C3890735;C4048285
2,nmbr - nmbr ( severe ),C0205082;C4050465;C4050466
2,history of percutaneous coronary intervention,C1320647;C4554713
2,current or previous atrial fibrillation,C0521116;C1705970
2,repaired chd,C0205340;C0280604;C3542407
2,peripheral vasodilators,C0724804
2,current drinker,C0556297
2,former or never,C0205156;C0750523
2,musculoskeletal,C0497254;C2707260
2,received an oral aha within nmbr weeks prior to screening,C1514756
2,stiffness subscale,C0427008
2,oral aminosalicylates,C0368663;C0442027;C4521986
2,bmi kg - m - nmbr,C0578022;C1532718
2,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
2,stroke risk score,C0449820;C1277291;C4050231
2,< nmbr years eze / simva,C0439234
2,o total randomized,C0439175;C0439810;C0483204
2,left circumflex artery,C0226037
2,current ( % ),C0521116;C1705970
2,any clinical ae,C0205210;C3887670
2,mean ( sd ) feno,C0444504;C2347634;C2348143;C2699239
2,cdai score §,C0683448;C1413248;C3273706
2,medications at discharge or day nmbr,C0806915
2,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
2,arterial graft,C0450140
2,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),C0302353;C0543465;C1532563
2,concomitant therapies n ( % ),C1707479
2,disease duration,C0872146
2,previous ischemic stroke,C0205156;C0948008;C1552607
2,glucose metabolism,C0596620
2,nmbr . nmbr - nmbr . nmbr kg / mnmbr,C1532718
2,primary pci no .,C0205225;C0439612;C0439631;C4049621
2,radial access — no . / total no . ( % ),C0442038;C0920847
2,age nmbr + yrs,C0001779
2,> nmbr . nmbr pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
2,health assessment questionnaire - disability index,C4321476
2,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2,medically important infectionsa,C3898777;C4084912
2,time of symptom onset to randomization ( hrs ),C1320528
2,( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0439269;C1532563
2,difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242
2,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,demographic characteristics,C0683970
2,past or current angina pectoris,C1444637;C4284302
2,history of peripheral vascular disease,C1881056
2,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
2,lipid - lowering therapy,C0585943
2,dlqi,C3899393
2,st - segment elevation mi,C0520886;C3810814
2,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
2,chanmbrdsnmbr - vasc score ( median,C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
2,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
2,type of event — no . ( % ),C1561488
2,coexisting conditions,C0679225
2,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
2,total n = nmbr n ( % ),C0439175;C0439810
2,three - vessel disease,C3272265
2,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
2,nace ( primary endpoint ),C2986535
2,interaction : treatment by psoriasis p valuenmbr,C1704675;C1709380;C3258078
2,score > nmbr %,C0449820;C4050231
2,any aes,C1412268;C2699274
2,mean ( s . d . ) hbalc,C0444504;C2347634;C2348143
2,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
2,estimated glomerular filtration rate - ml / min,C0439445;C3811844
2,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
2,< nmbr months,C0439231
2,nmbr degree of ica stenosis 丰,C0201519;C4034225
2,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
2,min,C0702093;C1524029;C3813700
2,highest tg tertile,C0337445;C1522410
2,days of study - drug administration ( % ) * * nmbr day,C0150270;C2826182;C3469597
2,kim nmbr ( pg / ml ),C0439297
2,mi or cad,C3810814
2,right ventriculardysfunction atinclusion,C0205090;C0444532
2,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
2,urine albumin - to - creatinine ratio,C0455271;C1318330
2,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
2,planned treatment duration,C4528394
2,mild or moderate copd,C2945599
2,creatinine clearance ， : : nmbr ml / min,C0439445;C0812399
2,joint swelling,C0152031
2,nmbrmwd decrease > nmbr m,C0369637;C0392756;C0441923;C0547047
2,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
2,peripheral edema,C0085649
2,anatomic complexity characteristics,C0439855;C0502371;C1704241
2,serum creatinine > nmbr pmol / l . n ( % ) |,C0201976;C0439284;C0600061
2,conventional treatment,C2945704
2,left circumflex,C0205091;C0443246;C1552822;C1880089
2,number of pack - years,C0237753;C0449788;C1277691
2,type nmbr diabetes duration,C0449238;C1320657;C2926735
2,bilateral disease ( % ) ' j ' ' j ',C1511113
2,pathological q waves,C0429090
2,former n z nmbr,C0205156;C0750523
2,tender joint count,C0451530
2,high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,unbound pcsknmbr ( nmol / l ),C0439282
2,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,percentage with disease duration < nmbr years,C0439165;C0439234;C0872146;C1549488;C1561533
2,systemic corticosteroids,C4053960
2,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
2,mean eosinophil count,C0200638;C0444504;C0750879;C2347634;C2348143
2,clinical and laboratory measurements,C0205210
2,current medication — no . ( % ),C0746467
2,low hdl cholesterol,C0151691
2,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0683610;C4553947
2,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
2,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
2,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
2,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
2,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
2,lvef ( % ),C0428772;C0488728
2,menopausal status and use of hrt ( % ) y,C1513126
2,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
2,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
2,type nmbr diabetes,C1320657
2,months since ra was first diagnosed,C0439231
2,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C0205267;C2315493
2,enthesitis count,C0750480;C1282952;C1705566
2,history of alcohol use,C0551571;C0552479
2,week nmbr fpg,C0332174;C0439230
2,post - menopausal ( a ),C0232970
2,small vessel,C0225988
2,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
2,severe n z nmbr,C0205082;C4050465;C4050466
2,extensive,C0205231
2,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
2,clinical presentation,C2708283
2,cardiovascular history — no . / total no . ( % ),C1880008
2,cardiac therapy,C3654025
2,nmbr - aminosalicylates | | | |,C0368663
2,coronary bypass graft,C1260596
2,acr,C1412134;C1515941
2,mean yearly decline,C0444504;C2347634;C2348143
2,bare - metal stent — no . ( % ),C2825200
2,standard care n ( % ),C1442989;C1947933;C2828392
2,number ( % ) of patients with event,C2360800
2,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
2,oral medications,C0304289
2,no . of nmbr - mg acetaminophen tablets / day,C0439422;C1243102
2,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
2,timi major / minor,C4441842
2,pooled simva,C1709595;C2349200;C4522255
2,baseline dyspnea index,C1511069
2,family history of diabetes — no . ( % ),C1313937
2,nyha class nmbr - nmbr : no { n = llll ),C1882083
2,large mi,C0549177;C3810814
2,never / rarely,C0522498;C2003901
2,severity of hypertensionb,C0439793;C0522510
2,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
2,intravenous vasodilators ( % ),C0443081
2,total cholesterol ( week nmbr ),C0201950;C0332174;C0439230;C0543421
2,at least nmbr severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
2,verapamil sr n = nmbr no . ( % ),C1527129
2,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
2,crp ( mg / dl ) < nmbr . nmbr,C0439269;C3890735;C4048285
2,no peripheral revascularization ( n = nmbr,C0205100;C0581603
2,pancolitis,C0868908
2,diabetes mellitus status,C1317301
2,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
2,positive,C0439178;C1446409;C1514241;C2825490;C3812269
2,age [years] ( interaction : p = nmbr . nmbr ),C1510829;C1704675
2,decreased appetite,C0232462
2,duration of morning,C0332170;C0449238;C2926735
2,time to admission,C3854258;C3854259
2,established,C0443211;C1272684
2,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
2,radial access,C0442038;C0444454;C0920847;C1554204
2,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
2,negative,C0205160;C1513916;C2825415;C2825491;C3853545
2,severe dysfunction,C3274777
2,> nmbrmg / dl chd status,C0280604;C0439269;C0449438;C3542407
2,intraperitoneal,C0442120
2,chd eze / simva ( n = nmbr],C0280604;C3542407
2,fatal and nonfatal ml,C1302234;C1705232
2,smoking status ( % ),C1519386
2,mean age,C0001779;C0444504;C2347634;C2348143
2,duration of disease,C0872146
2,laboratory findings,C0587081
2,crp,C3890735;C4048285
2,resection performed,C0015252;C0728940
2,ada ifg,C1060325;C1334085;C1708411;C3811629
2,median change,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
2,combined estimated gfr and albuminuria status,C0205195
2,oral antidiabetes monotherapya,C0442027;C4521986
2,oral hypoglycemic drug,C0359086
2,age at diagnosis,C1828181;C3173302
2,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,number of exacerbations in last nmbr months,C0237753;C0449788;C4086268
2,former smoker ( n = nmbr ),C0337671
2,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,any event,C0441471;C4019010
2,pain in extremity,C0030196;C4553007
2,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
2,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
2,age ( yrs ) < nmbr,C0001779
2,serum hdl cholesterol ( mmol / l ),C0428472;C1532563
2,former smoker,C0337671
2,less than nmbr %,C0439092
2,ischemic tvr,C0475224
2,third heart sound,C0232237;C0232278
2,psa duration,C0449238;C2926735;C3810537;C3813209
2,atrial fibrillation / atrial flutter,C0155709
2,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
2,prior biologic therapy ( including anti - tnfs ),C0278947
2,measured at home with automated device,C0444706;C3541902
2,dose of aspirin,C4696290
2,efficacy,C1280519;C1707887
2,non - stemi,C3537184
2,serum total cholesterol,C0587184;C1287371
2,visits nmbrenmbr,C0545082;C1512346;C2826704
2,serum creatinine > nmbr mmol / l,C0201976;C0600061;C1532563
2,lesions bnmbr / c,C0221198;C1546698
2,other oral hypoglycemic drug ( s ),C0359086
2,mean duration of disease,C0444504;C0872146;C2347634;C2348143
2,years,C0439234
2,invasive,C0205281;C1334278
2,trend / het . test,C1521798;C4554533
2,medical therapy only ( n = nmbr ),C0205171;C0418981;C1720467
2,elevated hscrp > nmbr mg / l,C0205250;C0439268;C3163633
2,median total cholesterol,C0201950;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
2,mean ± sd bmi,C0444504;C0578022;C2347634;C2348143;C2699239
2,disease duration nmbr to bnmbr years ( n = nmbr ),C0439234;C0872146
2,prior years taking warfarin,C0332152;C0439234;C2826257
2,estimated glomerular filtration,C0232809;C0750572
2,mean a ± sem ( % ),C0444504;C2347634;C2348143
2,pasi score ! * *,C0449820;C4050231;C4528685
2,acute coronary event,C0205178;C0741923
2,ntpro - cnp ( ng / ml ),C0439275;C3889729
2,cardiovascular history,C1880008
2,after bronchodilation,C1371299;C3537072
2,mean nmbrmwd *,C0444504;C2347634;C2348143
2,bare metal stent,C2825200
2,nmbr mg / kg ( n = nmbr ),C0439272
2,after pci,C4049621
2,standard ( n = nmbr ),C1442989;C2828392
2,indian ( indian subcontinent ),C0454693
2,type nmbr diabetes 一 no . ( % ),C1320657
2,high intensity,C4081854
2,p,C0369773;C2603361
2,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
2,total invasive cancer,C0439175;C0439810;C0677898
2,acute stent thrombosis,C0205178;C3897493
2,number of patients with,C2360800
2,lesion length,C0221198;C1444754;C1546698;C1706316
2,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
2,non - q wave,C0429089;C1305738;C1518422
2,left ventricular ejection fraction,C0428772;C0488728
2,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
2,bmi > nmbr kg / mnmbr ( % ),C0578022;C1532718
2,total gadolinium - enhancing lesion count,C0439175;C0439810;C0750480;C1333400;C1705566
2,nmbr to < nmbr kg / mnmbr,C1532718
2,st - elevation mi,C0520886;C3810814
2,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
2,absolute,C0205344
2,> nmbr oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
2,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
2,risk of bleeding,C3251812
2,dactylitis count,C0239161;C0750480;C1705566
2,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
2,cognitive functioning,C0392334;C0392335
2,history of hyperlipidemia ( % ),C4695788
2,diskus only,C0205171;C1553480;C1720467
2,jsn score,C0449820;C4050231
2,current smoker — no . of patients ( % ),C3173209;C3241966
2,total chol,C0201950;C0439175;C0439810
2,non - hdl - c in nmbr classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
2,family history ol diabetes ?,C1313937
2,age ( years ) : nmbr - < nmbr,C1510829
2,extent of disease,C0449279;C4553144
2,urgent coronary revascularization,C0439609;C0877341;C3272275
2,serious ae,C0205404;C3887670
2,smoking history ( ever ),C1519384;C3887636
2,hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr,C0596019;C2985465
2,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
2,prior myocardial infarction,C0155668
2,health habits,C0679786
2,type of mi ( % ),C0332307;C1547052;C3810814
2,concomitant corticosteroid use,C0239126;C0521115
2,estimated glomerular filtration rate ( mdrd ),C3811844;C3839656
2,mild impairment ( nmbr to < nmbr ),C0221099;C0684336;C2945599
2,years since menopause,C0439234
2,medical therapy ( n = nmbr ),C0418981
2,haemorrhagic,C0333275
2,no . of prior bdmards,C0332152;C2826257
2,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
2,primary end point,C2986535
2,lvdd ( mm ),C4330985;C4554674
2,tg < nmbr,C0337445
2,bypass surgery,C1536078
2,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
2,right coronary,C0225808
2,three or more drugs,C0205449
2,data missing,C1511726;C3245479;C3714741
2,factor xa inhibitor,C2825027;C4553708
2,allhat - llt,C2347090
2,with revascularisation,C0581603
2,level nmbr immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
2,serum creatinine,C0201976;C0600061
2,not reported in ecrf,C1518422
2,laba users,C1706077
2,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
2,severe impairment ( < nmbr ),C0205082;C0221099;C0684336;C4050465;C4050466
2,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
2,final timi flow,C0205088;C1546485;C3272266;C3853528
2,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
2,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
2,active a,C0205177;C3853793;C3888249
2,qualifying mi type,C0332307;C1514624;C1547052;C3810814
2,planned treatment strategy,C0599880;C0679199
2,/ ’ - valuenmbr ’,C1522609
2,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
2,patient ' s global assessment of disease activity,C4054228
2,opg,C1262886;C1336645;C1412836;C1710303
2,severely impaired,C0205082
2,missing data — no . / total no . ( % ),C4684714
2,anticyclic citrullinated peptide positive^,C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
2,wrist fracture,C0435630;C4553927
2,ischaemic,C0475224
2,< nmbr . nmbr mmol / liter triglyceride level,C0428475;C0439190;C0475211
2,> nmbr . nmbrmmol / l ( n = nmbr ),C1532563
2,impaired fasting glucose level ( n = nmbr ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
2,selected clinical characteristics,C0683325;C1707391
2,endovascular — no . ( % ),C0524425
2,primary pci ( n = nmbr ),C0205225;C0439612;C0439631;C4049621
2,glucose test,C0337438;C0595310
2,mean number of exacerbations ( per patient - year [nmbr % ci] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2,prior history of cardiovascular disease,C0332152;C0455539;C2826257
2,history of systemic hypertension,C0205373;C0455527
2,diabetes therapy,C3274787;C3539002
2,age,C0001779
2,mean ( s . d . ) free pcsknmbr,C0332296;C0444504;C1880497;C1996904;C2347634;C2348143
2,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
2,medical history and risk factors — no . ( % ),C0262926;C1704706
2,rankin grade,C0441800;C0919553;C3244287
2,crp ( mg / l ) : < nmbr,C0439268;C3890735;C4048285
2,mean score on haq - di §,C3533236;C3826998;C4321476
2,history of cardiovascular disease,C0455539
2,intervention in complex lesions,C0221198;C1292781
2,type of treatment,C0455708
2,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
2,int . p *,C3272375
2,aspirin at any dose,C4696290
2,carotid,C0741968
2,inflammatory disease,C1290884
2,blood eosinophil count ( nmbr cells per l ),C0200638
2,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
2,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
2,qualifying event — no . ( % ),C0441471;C1514624;C4019010
2,killip class,C1881332
2,respiratory medication ( % ),C0418986
2,concomitant lipid - lowering therapy,C0521115;C0585943
2,receptor blockers,C0597357
2,fc - ldl - c,C2983605
2,receiving concomitant corticosteroids,C1514756
2,ascvd including tia,C3665365
2,exacerbations,C4086268
2,history of cardiovascular disease — no . ( % ) ^ |,C0455539
2,normoglycemicnmbr,C0580545
2,fevi,C0849974;C1561566;C4528367
2,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
2,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
2,other ( nmbr . nmbr % ) t,C2603360
2,revascularization,C0581603
2,hoehn and yahr stage ( range,C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
2,low risk and fewer symptoms ( group a ),C3272281;C3538919
2,alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172
2,nmbr yr km % ( n ),C0439234;C3887676
2,time of symptom onset to balloon inflation ( hrs ),C1320528
2,no dysglycaemia or mets,C1960636
2,moderate impairment ( nmbr to < nmbr ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
2,estimated creatinine clearance < nmbr ml / min *,C0439445;C0750572;C0812399
2,history of myocardial infarction ( % ),C1275835
2,mean bmi,C0444504;C0578022;C2347634;C2348143
2,electrophysiological study — no . ( % ) weight — ibj,C0850293
2,body mass,C0518010
2,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
2,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
2,left anterior descending,C0205386;C0441998;C1547177
2,measurements,C0242485
2,receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756
2,b digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
2,nmbr bmi,C0578022
2,history of cardiac arrhythmia,C3494593
2,number of prior csdmards,C0237753;C0332152;C0449788;C2826257
2,efficacy and safety : net adverse clinical events *,C1280519;C1707887
2,heart disease risk factors,C0741920
2,current smoker : ex - smoker ( % ),C3173209;C3241966
2,dx at presentation,C0449450;C3538936
2,device group,C1706365
2,permanent,C0205355
2,n analysed,C0369718;C0441922
2,p value versus placebo,C1709380
2,> nmbr vessels with > nmbr % stenosis,C0679403
2,atrial fibrillation / flutter,C0155709
2,exposure,C0274281;C0332157
2,age when diabetes first diagnosed — yr,C0001779
2,chd risk equivalents,C0439185;C1282512;C4049980
2,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
2,peri - or postmenopausal,C0347985
2,indeterminate or unknown,C0205258
2,ratet ( nmbr % cl ),C0596019
2,evaluable for acrnmbr at week nmbr,C1412134;C1515941;C1516986
2,discontinuations,C0457454
2,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0439297
2,event rates,C0441471;C0871208;C1521828;C4019010
2,nyha class iii or iv ( n = nmbr ),C1882086
2,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
2,median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
2,score of > nmbr . nmbr — %,C0449820;C4050231
2,nmbr - nmbr ( n = nmbr,C0369718;C0441922
2,nmbr = help needed  still independent,C1269765;C1552861
2,non - metsyn,C1518422
2,mi type unknown ( % ),C0332307;C1547052;C3810814
2,one or more blood pressure medications,C0205447
2,pasi score,C0449820;C4050231;C4528685
2,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
2,csf nmbrs - hydroxy -,C3540512;C3889436
2,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
2,not reported / unknown,C1518422
2,difference from baselinea,C1705241;C1705242
2,single vessel coronary artery disease *,C0581374
2,crohn ' s disease activity index score],C0449820;C0451071;C4050231
2,prior coronary revascularization,C0332152;C0877341;C2826257
2,nmbr - aminosalicylic compounds — no . ( % ),C0205198;C1706082
2,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
2,estimated * creatinine clearance < nmbr mlvmin,C0750572;C0812399
2,other countries,C0454664
2,smoking history — no . ( % ),C1519384
2,mean — g / dl,C0439267;C0444504;C2347634;C2348143
2,outcome,C1274040
2,egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr,C0369637;C0439445;C0441923
2,verapamil sr n = nmbr,C1527129
2,dactylitis count ( nmbr - nmbr ),C0239161;C0750480;C1705566
2,tnl ultrapositive > nmbr . nmbr pg / l,C0439278;C1540071
2,severe teaes,C0205082;C4050465;C4050466
2,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
2,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
2,multivessel pci,C4049621
2,oral anticoagulant — no . / total no . ( % ),C0354604
2,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
2,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
2,rentrop score,C0449820;C4050231
2,multiple tnfi *,C0439064
2,missing data,C4684714
2,chanmbrdsnmbr - vasc,C1420648;C3714751
2,incidence rate,C1708485
2,urinary albumin / creatinine ratio,C0455271;C1318330
2,family history of coronary artery disease,C2317524
2,valvular disease ( % ),C3258293
2,received > nmbr prior anti - tnf therapies,C0281481;C0332152;C1514756;C2826257
2,acr deciles,C1412134;C1515941
2,prior bypass graft surgery,C0185098;C0455610
2,average maximum common and bifurcation cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546
2,oral anticoagulant,C0354604
2,p - value for interaction nmbr . nmbr,C1704675;C1709380
2,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
2,type of end point,C0332307;C1547052;C2349179;C2826544
2,mean ( sd ) esr,C0444504;C2347634;C2348143;C2699239;C3811131
2,mild to moderate,C1299392
2,degree of stenosis,C4034225
2,location,C0450429;C1515974;C4284930;C4284931
2,pci or cabg surgery for index event,C4049621
2,glinide 一 no . ( % ),C2266929
2,symptom duration,C0449238;C1457887;C2926735;C3854129
2,history of hypertension for nmbr mo or more,C0455527
2,elevated fasting glucose,C0205250;C3163633
2,symptom onset - to -,C4086878
2,no . ( % ) of participants,C0679646
2,received nmbr prior anti - tnf therapy,C0281481;C0332152;C1514756;C2826257
2,cardiac therapy §,C3654025
2,ultrasound carotid arteries,C0948945
2,ada nmbr / nmbr n[nmbr,C1060325;C3811629
2,pack - years smoked,C1277691
2,height,C0489786
2,chd risk - no . ( % ),C0280604;C3542407
2,infusion administered — no . / total no . ( % ),C0574032;C1827465
2,non - hdl cholesterol ( week nmbr ),C0332174;C0439230;C0729627;C1535899
2,type of vessel involved,C1282017
2,mean ( sd ) mtx dose,C0366550;C0444504;C2347634;C2348143;C2699239
2,age ( y ),C0001779
2,disease duration ( yr ),C0439234;C0872146
2,linagliptin / metformin,C3264599
2,duration of disease — yr : t,C0439234;C0872146
2,pelvic fractures,C0149531
2,standard care allocation,C1442989;C1706778;C1947933;C2828392
2,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
2,number ( % ),C0237753;C0449788
2,age subgroups,C0001779;C1079230
2,no . of events / no . of patients,C0441471;C3541888
2,clinical ae,C0205210;C3887670
2,serious adverse events,C1519255
2,nmbr - nmbr ( mild ),C2945599
2,lowzmedium intensity,C0522510
2,moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,major diabetic eye disease,C0205082;C0205164;C0342245;C4318856;C4521762
2,all participants,C0679646
2,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
2,symptom onset,C4086878
2,hormonal therapy — no . ( % ),C0279025
2,gpi used during pci,C1415351
2,antihypertensive therapy,C0585941
2,change from,C0392747;C0443172;C1705241;C4319952
2,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
2,chd simva nmbr = nmbr],C0280604;C3542407
2,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
2,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
2,peripheral artery occlusive disease ( stage nmbr / nmbr / nmbr / nmbr / nmbr ),C0205390;C1300072;C1306673;C1306889
2,age nmbr years or more,C1510829
2,treated with pci — no . / total no . ( % ),C0332293;C4049621
2,% change,C0392747;C0443172;C1705241;C4319952
2,lifestyle modifications,C0870811;C2960841
2,nmbr nmbr years,C0439234
2,low risk ( nmbr - nmbr ),C3272281;C3538919
2,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
2,lesion characteristics,C1286326
2,baseline dyspnea index score,C0449820;C1511069;C4050231
2,creatinine clearance — no . ( % ),C0812399
2,any oral hypoglycemic drug 一 no . ( % ),C0359086
2,elevated at wk nmbr — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
2,habnmbrc ( mean ± sem ),C0444504;C2347634;C2348143
2,nmbr - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
2,subject completion status,C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
2,total cholesterol - to - hdl cholesterol ratio,C0428619
2,oral anticoagulant drugs,C0354604
2,definite,C0439544;C1704787
2,intravenous heparin,C0354566
2,nmbr - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
2,biventricular pacemaker,C1719274
2,p value § ( < nmbr vs . > = nmbr years ),C1709380
2,non - hispanic,C1518424
2,country,C0454664;C1511538
2,clinical characteristics,C0683325
2,prior af ablation,C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
2,rsg nmbr mg / day,C0439422
2,former or current smokers ( % ),C0205156;C0750523
2,history of diabetes mellitus,C0455488
2,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
2,not provided,C1518422
2,vasoprotectives,C0304533
2,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
2,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
2,swollen joint count ( n / nmbr ),C0451521
2,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
2,coronary risk factors — no . ( % ),C2024776
2,cardiovascular risk factors,C0850624
2,less than nmbr year,C0439092;C0439234;C0439508
2,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C1279901
2,medical therapy only,C0205171;C0418981;C1720467
2,normal renal function,C0232805
2,postmenopausal ( % ),C0232970
2,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
2,normal > nmbr - nmbr,C0205307;C0231683;C0439166;C2347086;C4553972
2,elevated hscrp,C0205250;C3163633
2,cardiac troponin t level,C0441889;C0456079;C1547707;C2946261;C3538889
2,on drug treatment ( % ),C0150270;C3469597
2,pre - specified hr ( nmbr % cl ),C2826245
2,albumin / creatinine ratio,C0486293;C1318293
2,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
2,discontinuations due to ae,C0457454;C0678226;C3887670
2,creatinine clearance,C0812399
2,renal function,C0232804
2,preoperative serum creatinine > nmbr pmol / l,C0201976;C0439284;C0445204;C0600061
2,all others,C1955473;C3539125
2,median age ( nmbr %,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,history of cerebrovascular disease,C0585890
2,haq - di,C3826998;C4321476
2,negative ( < nmbr . nmbr ),C0205160;C1513916;C2825415;C2825491;C3853545
2,endpoint week nmbr,C0332174;C0439230;C2349179;C2826544
2,mild ( > nmbr to < nmbr ),C2945599
2,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
2,modified rankin scale — no . ( % ) |,C2984908;C3854213
2,penetrating,C0205321
2,baseline weight,C1303013
2,years since myocardial infarction,C0439234
2,hoehn and yahr stage,C0205390;C1300072;C1306673
2,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C3163633
2,scores for global and pain assessments §,C0205246;C0449820;C2348867
2,hbalc < nmbr % ( < nmbr mmol / mol ),C3829066
2,geometric mean,C2986759
2,haq - di ( nmbr - nmbr ),C3826998;C4321476
2,bifurcation,C0184906;C3146289
2,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C1705241;C4319952
2,differencenmbr,C1705241;C1705242
2,serum cholesterol ( mg / l ) *,C0439268;C0587184
2,angina symptoms^,C0858277
2,previous pci or cabg,C0205156;C1552607;C4049621
2,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
2,peripheral artery occlusive disease,C1306889
2,established ( n = nmbr ),C0443211;C1272684
2,nmbr years or older,C0439234
2,af pattern,C0344434;C0449774;C4049859
2,early - start group ( n = nmbr ),C1279919
2,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
2,tg ( mmol / l,C0337445;C1532563
2,verapamil sr strategy ( n = nmbr,C0679199;C1527129
2,on - treatment,C4684449
2,killip class i — no . ( % ),C2697844
2,killip class ( interaction : p = nmbr . nmbr ),C1704675;C1881332
2,adjusted hr ( enl vs lcz ) ( nmbr % cl ),C0456081
2,total basdai,C0439175;C0439810;C1998004
2,no . of days to randomization — median ( iqr ),C0439228
2,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
2,angiogenesis,C0302600;C1519670
2,non - fatal mi,C1302234;C1518422;C1705232;C3810814
2,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
2,type nmbr,C0332307;C1547052
2,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
2,s . e .,C0565930;C2603362
2,history of atrial fibrillation,C0729790
2,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
2,prior coronary revascularization ( pci or cabg ),C0332152;C0877341;C2826257;C4049621
2,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
2,renal function : creatinine clearance,C0232804;C0812399
2,nyha functional class,C0205245;C0542341;C1882083;C2700217
2,bmi ( median,C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
2,alternative disability,C0231170;C1523987
2,p - value for variance,C1709380;C1711260;C2348152
2,k ( rate ),C0597277;C0871208;C1521828;C1708601
2,score,C0449820;C4050231
2,selected clinical characteristics — no . / total no . ( % ),C0683325;C1707391
2,pci delay due to low risk,C4049621
2,. nmbr . nmbr ml / s / mnmbr ( nmbr ml / min / nmbr . nmbr mnmbr ),C0439390;C0702093;C1524029;C1709500;C3813700
2,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
2,reason for enrollment in active a,C0392360;C1516879;C1696073;C3888021
2,octave induction nmbr,C0205263;C0857127
2,supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833
2,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
2,nmbr ( fevi ^nmbr % pred ),C0849974;C1561566;C4528367
2,oral anticoagulant agent,C0354604
2,nonfatal ischemic stroke,C0948008
2,current prescribed medications,C0521116;C1705970;C3166216;C3202967
2,atopic ( based on phadiatop test ),C0392707
2,not available,C0686905
2,estimated response rate and odds ratio,C0237629;C0750572
2,first loading dose,C0205435;C1279901;C3714444
2,duration of,C0449238;C2926735
2,loop at enrollment,C0445022;C1516879;C1696073;C3888021
2,current cigarette use,C0521116;C0694535;C1705970
2,central europe,C0682369
2,kccq ( nmbr months ),C0439231;C3476798
2,change in bp,C1268766
2,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2,subacute ( nmbr - nmbr days ),C0205365;C0439228
2,low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,tnmbr lesion volume,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258
2,new anti - anginal therapy,C1874267;C3242274;C3537168
2,total cataract,C3665439
2,> nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,mental component,C0229992;C0449432;C1705248
2,pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
2,pooled eze / simva,C1709595;C2349200;C4522255
2,unknown or missing,C0439673;C3541433;C4050014
2,concomitant aminosalicylates,C0368663;C0521115
2,qualifying peripheral arterial disease,C1514624
2,previous bypass surgery,C0205156;C1536078;C1552607
2,surgical technique,C0683469
2,revascularisation but no antiplatelets,C0581603
2,pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
2,clinical and patient - reported characteristics at baseline and randomization,C0205210
2,swollen - joint count ( of nmbr joints ),C0451521
2,other sglt - nmbr inhibitor,C1999216
2,psa - modified total shs,C3810537;C3813209
2,mean change at week nmbr,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,acpa positive ( > nmbr iu / ml ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
2,not hospitalized for heart failure in the year prior to study enrollment,C1518422
2,all ischemic stroke,C0948008
2,older than nmbr years,C0439234;C0580836
2,long - term antiplatelet therapy,C0443252;C1096021
2,nmbr - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
2,stage > nmbr chronic kidney disease ( % ),C0205390;C1300072;C1306673
2,history of gestational diabetes mellitus — no . ( % of women ),C2183115
2,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),C0337445;C0439269;C3715113
2,clavicle fracture,C0159658
2,musculoskeletal stiffness,C0427008;C0497254;C2707260
2,laboratory examination,C0260877
2,organ system involvement,C0460002;C1314939
2,peripheral,C0205100
2,nmbr - nmbr drinks,C0452428
2,aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470
2,fraction ( % ),C1264633;C1554103
2,inclusion criteria — no . ( % ),C1512693
2,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
2,mtss units,C0439148;C1519795;C3853603
2,mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143
2,nyha class not reported,C1882083
2,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
2,glycatedhemoglobin category,C0683312;C3889287
2,age at enrolment,C0001779;C1516879;C1696073;C3888021
2,chronic respiratory failure,C0264492
2,idiopathic,C0332240
2,estimated glomerular filtration rate - no . ( % ) : :,C3811844
2,serum creatinine ( pmol / l ),C0201976;C0439284;C0600061
2,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
2,dihydropyridine calcium - channel blocker,C2945601
2,tg mg / dl,C0337445;C0439269
2,clinical details,C0205210;C1522508
2,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
2,no chd eze / simva nmbr = nmbr },C0280604;C3542407
2,moderate n z nmbr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,a / v ( n = nmbr ) v ( n = nmbr ),C0560268;C1272460;C3887614
2,verapamil - sr strategy,C0679199;C1527129
2,albumin measurements^^,C0201838
2,before amendment,C0680532;C2346732
2,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
2,ldl particle numbers ( week nmbr ),C0237753;C0332174;C0439230;C0449788;C2612459
2,serum ldl cholesterol,C0428474
2,first hhf,C0205435;C1279901
2,nmbr - year framingham chd risk ( % ) nmbr mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
2,< nmbr mg / dl eze / simva ( n = nmbr },C0439269
2,laba non - users,C1518422;C1706077
2,euroscore additive,C0442796;C1550602;C3164744
2,mean ( sd ) [range],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
2,watchman ( n = nmbr ),C0335390
2,normal ( > nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972
2,persistent wrf ( n = nmbr ),C0205322;C0332996
2,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
2,adcs - adl score *,C0449820;C3641947;C4050231
2,left side of colon,C0227388
2,clinical disease activity index score ( nmbr - nmbr ),C0449820;C3869583;C4050231
2,combination - facilitated pci ( n = nmbr ),C0205195;C1947911;C3811910
2,history of claudication,C2315493
2,rope score * *,C0449820;C1563164;C4050231
2,inter p - value,C0205103;C1548610
2,discontinued,C1444662
2,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
2,peripheral revascularization ( n = nmbr ),C0205100;C0581603
2,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,prothrombin mutation ( % ),C1610621
2,cardiovascular risk factors and medical history,C0850624
2,difference,C1705241;C1705242
2,reversibility to salbutamol,C1271924
2,mean ucsd - sobq score * ( sd ),C2699239;C3533236
2,albumin - to - creatinine ratio,C0486293;C1318293
2,medical therapy alone,C0418981
2,nmbr ( fevi nmbr - < nmbr % pred ),C0849974;C1561566;C4528367
2,anmbrs - hydroxy -,C0700307
2,qrs interval > nmbr msec — no . ( % ),C0439223;C0520880
2,haq - di improvement > nmbr . nmbr,C2986411;C3826998;C4321476
2,nmbr p value,C1709380
2,participants n,C0679646
2,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
2,time from onset of symptoms to randomization — days,C1320528
2,% change median baseline crp > nmbrmg / l,C0392747;C0443172;C1705241;C4319952
2,interactionnmbr,C1704675
2,no history of migraine,C0455512
2,duration of symptoms,C0436359
2,normoglycemia^,C0580545
2,edss stratification,C0451246;C1514983;C3887783
2,highest killip classiciation pre - pci,C1522410
2,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
2,urinary albumin : creatinine ratio *,C0455271;C1318330
2,associated with corrected,C0205202;C0332281
2,medical treatment,C0679624
2,indeterminate ! !,C0205258
2,select lipids and lipoproteins,C1707391
2,nmbr - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
2,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
2,estrogen therapy,C0279494
2,haq - di total score,C2964552;C3826998;C4321476
2,> qnmbr ( nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),C0237753;C0449788
2,hscrp > nmbr to < nmbr mg / l,C0439268
2,ra symptom duration < nmbr months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
2,ldl - c < nmbr mg / dl,C0439269
2,positive family history of type nmbr diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
2,urinary albumimcreatinine ratio,C1273442
2,chronic pulmonary disease,C0746102
2,atio - pla,C0456170
2,adjusted * or ( nmbr % ci ) p value,C0456081
2,change at week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
2,stent implanted,C0522776
2,estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923;C3811844
2,nmbrlnmbrmmhg,C0439394;C0439475;C1706495;C3642217
2,european subcategories,C0239307;C1515010;C1535514
2,use of other medications — no . ( % ),C0240320
2,total - c : hdl - c,C0439175;C0439810;C3715113
2,reversibility ( % predicted fevnmbr ) *,C0449261
2,conversion to sinus rhythm in < nmbr days,C1321500
2,vein bypass graft stented,C0398147
2,mild dysfunction or normal,C3274775
2,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
2,prior treatment,C1514463
2,mean ( s . d . ) ldl particle number,C0237753;C0444504;C0449788;C2347634;C2348143;C2612459
2,number of treated lesions,C0449791;C1522326
2,any recurrent stroke,C2242682
2,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
2,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
2,recurrent infections ( > nmbr per year ),C0239998;C0439234;C0439508
2,p - value ( lnteraction ),C1709380
2,renal fmclicn : creatntoe clearance,C0232813;C0699829
2,left side only,C3842976
2,bmi — mean ( sd ) ( kg / mnmbr ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,all countries,C0454664
2,serum cholesterol,C0587184
2,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
2,af or atrial flutter 卞,C0344434;C4049859
2,ejection fraction based on local reading,C0489482;C2700378
2,moderately impaired,C0205081;C1881878;C4085643;C4321491
2,past or never,C1444637;C4284302
2,number resulting in ed visit,C0237753;C0449788
2,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
2,peripheral artery,C0489868
2,anti - hypertensive therapy - no . ( % ),C0585941
2,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
2,no . of participants with events ( % ),C0679646
2,mean a ± sd,C0444504;C2347634;C2348143
2,> nmbr months ( n = nmbr,C0439231
2,lowest tg tertile,C0337445;C1708760
2,prior mi ( n - nmbr,C0332152;C2826257;C3810814
2,> nmbr mg / dl — %,C0439269
2,esr ( mm / h ),C0456680;C3811131
2,neither n = nmbr,C0369718;C0441922
2,months since first ra symptom,C0439231
2,established atherosclerotic,C0333482;C0443211;C1272684
2,omega - nmbr fa,C1719844
2,ejection fraction : < nmbr % ( n = nmbr ),C0489482;C2700378
2,known duration of type nmbr diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
2,number of exacerbations nmbr months before randomisation,C0237753;C0439231;C0449788;C4086268
2,units per week,C0560588
2,other atherosclerotic event,C0333482;C0441471;C4019010
2,non - u . s .,C1518422
2,acuity - defined bleeding,C0750509
2,other / multiracial,C1881928
2,previous coronary - artery bypass grafting,C2144990
2,median ( min,C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
2,large shunt,C0232180;C0542331;C0549177;C1442858
2,history of hypertension,C0455527
2,mean — ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
2,swollen joint count,C0451521
2,multiple tnfi and other bdmards §,C0439064
2,previous infliximab therapy — no . of patients ( % ) * *,C0205156;C1552607;C4076075
2,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
2,duration of initial anticoagulation,C0003281;C0205265;C0449238;C1279901;C1555582;C1705685;C2917212;C2919015;C2926735;C3537050
2,undetermined etiology,C0478157
2,at least two cardiovascular risk factors,C0205448;C0850624
2,previous oad ( % ),C0205156;C1552607
2,antialdosterone agents,C0450442;C1254351;C1521826
2,history of heart failure — no . ( % ),C0455531
2,week nmbr ( mean,C0332174;C0439230;C0444504;C2347634;C2348143
2,level nmbr immobility^,C0231441;C0441889;C0456079;C1547707;C2946261
2,tender joint count ( nmbr - nmbr possible joints ),C0240094;C4554549;C4696258
2,hs - crp ( median,C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
2,hospitalization for heart failure within nmbr mo,C3898876
2,yes ( stopped for trial ),C1549445;C1705108;C1710701
2,delayed - start group ( n = nmbr ),C0205421;C0439659;C0441848;C1545665;C3272602
2,cdai score < nmbr,C0683448;C1413248;C3273706
2,complex lesions^,C0221198;C0439855;C1704241
2,n - terminal pro - brain natriuretic peptide,C3272900
2,lvef < nmbr %,C0428772;C0488728
2,hip circumference — cm,C0562350
2,geographic distribution - no . ( % ),C0681686
2,number of exacerbations in the past nmbr months,C0237753;C0449788;C4086268
2,potassium supplement,C0304475
2,rate ratio,C0456603;C0871208;C1521828;C1547037
2,irregular or ulcerated ica p ) laque : [ :,C0205271
2,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
2,p value nmbr . nmbr,C1709380
2,nonaspirin antiplatelet,C0722138
2,at six weeks,C0205452;C0439230
2,less severenmbr,C0205082;C0439092;C0547044;C4050465;C4050466
2,concomitant drug treatment,C0150270;C0521115;C3469597
2,implanted pacemaker,C0848753
2,mean % predicted dlco * ( sd ),C0444504;C2347634;C2348143
2,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
2,overall quality of life,C3641830
2,urinary albumin : creatinine ratio ( pg / mg ),C0455271;C1318330;C1627892
2,left circumflex coronary artery,C0226037
2,symptom onset to hospital admission,C0184666;C4086878
2,< nmbr % predicted arr ( n = nmbr,C0681842;C1882327;C2170357;C4084934
2,duration of type nmbr diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
2,one or more copd exacerbations ( n / n [ % ] ),C0205447
2,personal relationships,C1552027
2,moderate dysfunction,C3274776
2,tnf - rnmbra ( ng / ml ),C1363984;C1706001
2,plaque score ( nmbr - nmbr ),C0429153
2,mean sd fpg,C0444504;C2347634;C2348143;C2699239
2,previous anti - tnf therapy,C0205156;C0281481;C1552607
2,standard ( nmbr ),C1442989;C2828392
2,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
2,daily activities,C0871707
2,p value ( on vs off omt ),C1709380
2,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
2,metsyn with ldl > nmbr . nmbr mg / dl,C0439269
2,severe or worse airflow limitation,C0205082;C4050465;C4050466
2,ff nmbr pgod,C4554348
2,low risk and more symptoms ( group b ),C3272281;C3538919
2,high risk,C0332167;C3272283;C4050568;C4319571
2,creatinine clearance category,C0683312;C0812399;C3889287
2,tg > nmbr mg / dl,C0337445;C0439269
2,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
2,ldl - c ( mg / dl ) < nmbr,C0439269
2,western friroce,C1705493
2,large vessel,C0225990
2,ccs class §,C1879987
2,mean % predicted fvc ( sd ),C0444504;C2347634;C2348143
2,three or more agents,C0205449
2,ascot - lla,C0718674
2,diabetes mellitus ( type nmbr or nmbr ),C1320657
2,total study population ( n = nmbr ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2,absolute change,C1549031
2,duration of type nmbr diabetes ( years ),C0439234;C0449238;C1320657;C2926735
2,alt ( units / l ),C0439339;C1266129;C4553172
2,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
2,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
2,killip class — no . ( % ) i,C1881332
2,prior ml or abnormal angiogram,C0332152;C0439526;C1705224;C2826257;C3887665
2,verapamil - sr ( « = nmbr nmbr ),C1527129
2,number of patients ( % ) or mean 士 sd,C2360800
2,prior stroke — no . ( % ),C0332152;C2826257
2,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
2,acute reaction,C0205178;C0443286
2,stent implanted — no . ( % ),C0522776
2,number ( s ) of features present,C0237753;C0449788;C1521970;C1706388;C2346469;C2348519
2,extent of disease — no . / total no . ( % ) § ^ |,C0449279;C4553144
2,simplified disease activity index score ( nmbr - nmbr ),C0449820;C3869582;C4050231
2,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
2,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
2,cardiovascu lar subg roup,C0276828;C1419115;C3814448
2,greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr,C0439093
2,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
2,maintenance dose,C3714445
2,miami k antagonist received,C0231491;C0597277;C1551421;C1708601
2,nmbr - nmbr ( very severe ),C3641272;C4050419
2,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
2,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
2,# of prior bdmards,C0332152;C2826257
2,age y,C0001779
2,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
2,medical history and risk factors ( % ),C0262926;C1704706
2,non - ischaemic,C0475224;C1518422
2,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
2,tender joint count ( nmbr joints ),C0451530
2,duration of full - dose warfarin therapy before enrollment ( mo ),C0366686;C0443225;C0444917
2,severe or very severe copd,C0205082;C4050465;C4050466
2,waist ( cm ),C0230097
2,mean disease duration,C0444504;C0872146;C2347634;C2348143
2,lv mass,C0455825
2,omega nmbr allocation,C1706778;C1719844
2,congenital heart disease,C0152021
2,combined ( n = nmbr ),C0205195
2,"prior cardiovascular event "" ' """,C0332152;C1320716;C2826257
2,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
2,aqlq ( s ) score,C0449820;C4050231;C4055434
2,non - hdl ( mg / dl ) < nmbr,C0439269;C1518422;C3715113
2,prior use of $ nmbr systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
2,health assessment questionnaire ( nmbr - nmbr range ),C0451208;C1514721;C2348147;C3542016
2,clinical,C0205210
2,number of individuals,C1549735
2,left main coronary artery,C1261082
2,background csdmard category,C0683312;C1706907;C3889287
2,% predicted,C0681842;C1882327
2,total cholesterol ( median,C0201950;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
2,loop or thiazide diuretic : ! :,C0445022
2,monitoring group ( n = nmbr ),C0150369;C0441848;C1283169
2,ischemic coronary artery disease,C0852149
2,blood eosinophil count > nmbr / mmnmbr at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
2,no known frtrontxtfufoc cond aon,C0205309
2,previous coronary angioplasty,C2114427
2,extensive disease other,C0849867
2,octave induction nmbr and nmbr,C0205263;C0857127
2,single vessel coronary artery diseasenmbr,C0581374
2,greater than or equal to nmbr %,C0439093
2,st - segment depression,C0520887
2,ascvd as per protocol,C1698058;C3665365
2,interquartile range — yr,C0439234;C1711350
2,residual perfusion defect > nmbr % on lung scan,C1457869;C1518040;C1609982
2,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
2,history of heart failure,C0455531
2,prior cardiovascular history,C0332152;C1880008;C2826257
2,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
2,p - value for trend *,C1521798;C1709380;C4554533
2,at entry,C1705654
2,nmbr - nmbr months ( n = nmbr ),C0439231
2,valvular disease,C3258293
2,pack - years,C1277691
2,epa hr events ( % ),C0441471;C3541888
2,pciperformed for qualifying event,C0441471;C1514624;C4019010
2,nmbr week to nmbr month,C0332174;C0332177;C0439230;C0439231
2,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
2,current,C0521116;C1705970
2,syndesmophyte present,C0221690
2,bypass graft,C0185098
2,severe,C0205082;C4050465;C4050466
2,hospitalization for heart failure within previous nmbr mo — no . ( % ),C3898876
2,p value for trend across tertiles,C1521798;C1709380;C4554533
2,nmbr - nmbr drinks / wk,C0452428
2,mmrc grade,C0441800;C0919553;C3244287;C3826977
2,bodily pain,C3890602
2,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
2,p - blockers,C0369773;C2603361
2,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
2,absolute decrease > nmbr %,C0205344;C0392756;C0547047
2,intrathoracic or intraperitoneal surgery,C0595836
2,former or never diabetes,C0205156;C0750523
2,current other ( predefined ) medical conditions,C0521116;C1705970
2,center location,C0205099
2,use of rescue medication,C0240320
2,p vs placebo,C0369773;C2603361
2,cardiac troponin t level > nmbr . nmbr pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
2,composite events,C0205199;C0441471;C1547335;C3541888
2,foot fracture,C0272774
2,high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571
2,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,baseline systolic blood pressure,C4274438
2,ventricular tachyarrhythmias,C3827656
2,a ngina > nmbr day s previously *,C0332173;C0439228;C0439505
2,age ^nmbr yrs,C0001779
2,creatinine clearance < nmbr ml / min,C0439445;C0812399
2,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
2,primary pci n = nmbr,C0205225;C0439612;C0439631;C4049621
2,prior tnfi treatment,C1514463
2,pasinmbr response },C0871261;C1704632;C1706817;C2911692;C4528685
2,sinus rhythm,C0232201
2,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
2,^median > median,C0549183;C0876920;C2347635;C2348144;C2939193
2,motor weakness,C1513492;C1705994;C3714552
2,tender - joint count ( of nmbr joints ),C0451530
2,total ( n = nmbr,C0439175;C0439810
2,median duration of symptoms ( range ),C0436359;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2,uacr ( mg / g ),C1300563
2,acrnmbr response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2,past or current,C1444637;C4284302
2,enthesitis,C1282952
2,previous stroke — no . ( % ),C0205156;C1552607
2,slo days,C0439228;C1416602;C3539661
2,baseline body weight quartile,C1303013;C2828255
2,k - m %,C0369637;C0441923;C0597277;C1708601
2,( pg / mg ),C1627892
2,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr — no . / total no . ( % ) §,C0369637;C0439445;C0441923;C3811844
2,elevated serum potassium,C0553704
2,endpoint rate,C0871208;C1521828;C2349179;C2826544
2,no chd simva ( n = nmbr],C0280604;C3542407
2,previous ischemic stroke ortia,C0205156;C0948008;C1552607
2,lumbar epidural,C0581283
2,no . of events / total,C0441471;C3541888
2,no . of participants per nmbr patient - yr,C0679646
2,negative for helicobacter pylori — no . / total no . ( % ),C4688581
2,mtx ( mean dose : nmbr . nmbr mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
2,other medical history — no . / total no . ( % ),C0262926;C1704706
2,serum k + level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261
2,chronic inflammatory disease,C1290886
2,no . of non - tnfi,C1518422
2,interaction p - valuenmbr,C1704675;C1709380
2,ipah,C0152171
2,< nmbr mg / dl simva ( n = nmbr],C0439269
2,mnmbr subgroup,C0369637;C0441923;C1079230;C1515021
2,p - value interaction,C1704675;C1709380
2,undetermined,C0205258;C3536725;C4082977
2,uc duration,C0449238;C2926735
2,other / missing,C1551393;C1705492;C3272743
2,severe or moderate,C0205082;C4050465;C4050466
2,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0205156;C1552607
2,acute respiratory insufficiency,C0865850
2,> nmbr % predicted arr ( n = nmbr ),C0681842;C1882327;C2170357;C4084934
2,reversible ( % ),C0205343
2,left atrial dimension,C3275097
2,ejection fraction category,C0489482;C0683312;C2700378;C3889287
2,modified has - bled,C0392747;C3889737
2,min - max age,C0001779;C0702093;C1524029;C3813700
2,ischemic stroke,C0948008
2,medications at discharge,C0806915
2,multiracial,C1881928
2,concomitant aedsa,C0521115
2,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
2,nmbr = some restrictions  no help needed,C0443288
2,previous loss of response to and intolerance of infliximab,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
2,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0488728
2,left ventricular ejection,C2733342
2,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
2,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
2,> nmbr years to < nmbr years ( n = nmbr ),C0439234
2,pathologic q waves,C0429090
2,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
2,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
2,subject characteristics,C0681884;C1519021;C1706465
2,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
2,category nmbr and nmbr,C0683312;C3889287
2,renal function subgroups,C0232804;C1079230
2,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
2,class nmbr or no symptoms,C0456387;C1518526;C1705943
2,moderate copdb [n z nmbr],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,hs - crp ( mg / l,C0439268;C3890735;C4048285
2,non - ischaemic ( n = nmbronmbr ),C0475224;C1518422
2,normalized,C1882115
2,haq - di score,C0449820;C3826998;C4050231;C4321476
2,all ( n = nmbr * ),C0369718;C0441922
2,nmbr . nmbr - nmbr . nmbr mmol / l,C1532563
2,age < nmbr yr or > nmbr yr,C0001779;C0439234
2,age > nmbr yr and st - segment changes,C0001779;C0439234
2,age > nmbr yr and elevated biomarkers,C0001779;C0439234
2,age > nmbr yr ( % ),C0001779;C0439234
2,age > nmbr gd lesion = nmbr n = nmbr,C0001779;C0221198;C1546698
2,age > nmbr gd lesion > nmbr n = nmbr,C0001779;C0221198;C1546698
2,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,age >,C0001779
2,age ≥ nmbr yearsa,C0001779
2,age ≥ nmbr years,C1510829
2,age ≥ nmbr years and bmi ≥ nmbr kg / mnmbr,C1510829
2,age ≥ nmbr years and bmi < nmbr kg / mnmbr,C1510829
2,age < nmbr years ( n =,C1510829
2,age < nmbryears,C1510829
2,age < nmbr : qvainmbr - sfc,C0001779;C4521536
2,age < nmbr years ( n = nmbr,C1510829
2,age ( y ) ∗,C0001779
2,age < nmbr years ( itt ) ( n = nmbr ),C1510829
2,age < nmbr vears n = nmbr,C0001779
2,age < nmbr years and bmi ≥ nmbr kg / mnmbr,C1510829
2,age < nmbr years and bmi < nmbr kg / mnmbr,C1510829
2,age < nmbr gd lesion = nmbr n = nmbr,C0001779;C0221198;C1546698
2,age < nmbr gd lesion > nmbr n = nmbr,C0001779;C0221198;C1546698
2,age £ nmbr years ( itt ) ( n = nmbr ),C1510829
2,age [years],C1510829
2,age [year],C0001779;C0439234;C0439508
2,age ( yr ) *,C0001779;C0439234
2,age ( years  sd ),C1510829;C2699239
2,age ( years ) a,C1510829
2,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
2,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2,age > nmbr ( years ) t,C1510829
2,age > nmbr vears n = nmbr,C0001779
2,age > nmbr y ( % ),C0001779
2,age > nmbr y *,C0001779
2,age group ( y ),C0001779;C0441858
2,age groiro : < nmbr years,C1510829
2,age cohort,C2348001
2,age categories ( y ),C2916832
2,age categories,C2916832
2,age bnmbr y ( n = nmbr ),C0001779
2,age at menopause ( yr ),C0439234;C1625754;C1629609
2,age at entry ( years ),C1510829;C1705654
2,microalbuminuria,C0730345
2,age at diagnosis of ln,C0861352;C1428884;C1828181;C3173302;C3714709
2,age at diagnosis < nmbr years,C0439234;C1828181;C3173302
2,age a nmbr,C0001779
2,age nmbr + years,C1510829
2,age nmbr + y,C0001779
2,age nmbr +,C0001779
2,age nmbr - nmbr years ( n = nmbr ),C1510829
2,age nmbr - nmbr years ( itt ) ( n = nmbr ),C1510829
2,age nmbr - nmbr,C0001779
2,age nmbr - nmbr y ( n = nmbr ),C0001779
2,age nmbr - nmbr yr,C0001779;C0439234
2,age nmbr * nmbr yr,C0001779;C0439234
2,age nmbr years ( n = nmbr ),C1510829
2,age nmbryears,C1510829
2,age nmbr nmbr y,C0001779
2,age ± sd ( yrs ),C0001779;C2699239
2,age > nmbr years ( n = nmbr ),C1510829
2,age > nmbr years ( itt ) ( n = nmbr ),C1510829
2,age > nmbr : qvainmbr - sfc,C0001779;C4521536
2,age > nmbr yr — no . ( % ),C0001779;C0439234
2,age ( years ( s . d . ) ),C1510829
2,age ( y ) [mean - sd],C0001779;C0444504;C2347634;C2348143;C2699239
2,age mean age,C0001779;C0444504;C2347634;C2348143
2,acuity - bleeding major / minor,C0750509
2,adjusted nmbr or ( nmbr % cl ),C0456081
2,adiusted hazard ratio *,C2985465
2,adherence to study regimen — no . ( % ) ff,C1510802
2,adherence to study regimen — no . ( % ),C1510802
2,adherence > nmbr %,C1510802
2,adhere,C3714578
2,additional subgroup analyses,C1524062;C2986480
2,additional endpoints,C1524062;C2349179
2,add - on to metnmbr,C0428210;C1550543;C1883712;C4317104
2,add - on to met,C0428210;C1550543;C1883712;C4317104
2,adamantane derivatives,C3653470
2,acute stent thrombosis ( definite or probable ),C0205178;C3897493
2,acuity minor,C0750509
2,acuity major or,C0750509
2,actual or estimated weight,C0237400
2,age ( sd ),C0001779;C2699239
2,actual ( l ),C0237400
2,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
2,activity ( range nmbr - nmbr ),C0205177;C0439167;C0441655;C1514721;C1561536;C2348147;C3542016;C3668946;C4049938;C4049939
2,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
2,active   versus   placebo,C0205177;C3853793;C3888249
2,active vs placebo,C0205177;C3853793;C3888249
2,active treatment,C1704532
2,active comparatorb,C0205177;C3853793;C3888249
2,active,C0205177;C3853793;C3888249
2,action tested is between the continuous variable and treatment .,C0441472;C3266814
2,acrnmbr week nmbr responders,C0332174;C0439230;C1412134;C1515941
2,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
2,acr functional class,C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
2,acr > nmbr mg / g,C1300563;C1412134;C1515941
2,adjusted hazard ratio ( nmbr % cl ) *,C0456081;C0596019;C2985465
2,adjusted hazard ratio *,C0456081;C2985465
2,adjusted hr * ( nmbr % cl ) pvalue,C0456081;C0596019
2,adjusted modelc hr,C0456081
2,age ( per nmbr years ),C1510829
2,age ( p = o - nmbr ),C0001779
2,age ( median [iqr] ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,age & nmbr,C0001779
2,age — yr race — no . ( % ) f,C0001779;C0439234
2,age — y,C0001779
2,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
2,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
2,af type,C0332307;C0344434;C1547052;C4049859
2,af or atrial flutter !,C0344434;C4049859
2,af duration,C0344434;C0449238;C2926735;C4049859
2,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme,C0344434;C4049859
2,aes *,C1412268;C2699274
2,aes related to,C1412268;C2699274
2,aes leading to dose reduction of study drugb,C1412268;C2699274
2,aes leading to discontinuation of study drugb,C1412268;C2699274
2,aes leading to,C1412268;C2699274
2,ae / e ' ratio ( per nmbr unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
2,ae / a ratio ( per nmbr . nmbr unit ),C3887670
2,ae ' ( per cm / s ),C0439392;C3887670
2,adverse events leading to premature treatment discontinuation,C0877248;C1705413
2,adverse events ( any grade ),C0877248;C1705413
2,adverse event,C0877248
2,advanced,C0205179
2,admission grace score,C0184666;C0809949
2,adjusted *   hr,C0456081
2,adjusted or ( nmbr % cl ),C0456081
2,adjusted or ( nmbr % ci ) c,C0456081
2,adjusted or ( nmbr % ci ) b,C0456081
2,age is > nmbr vrs,C0001779
2,age s * nmbr yr,C0001779;C0439234
2,autonomic neuropathy,C0259749
2,any site,C0205145;C1515974;C2825164
2,as duration,C0449238;C2926735
2,arthritis mutilans,C0702102
2,arr ( % ),C2170357;C4084934
2,areas,C0205146;C4319729
2,arbs or ace inhibitors,C3888198
2,arb or ace inhibitor,C3888198
2,arb ( n,C3888198
2,aqlq ( si + nmbr score ’,C0449820;C4050231;C4055434
2,aqlq ( s ) + nmbr score : §,C0449820;C4050231;C4055434
2,aqlq ( s ) + nmbr score,C0449820;C4050231;C4055434
2,apoal ( mg / dl ) *,C0439269
2,apasp ( per mmhg ),C0439475
2,aortic valve disease ( n = nmbr nmbr ),C1260873;C4553103
2,aortic - valve replacement,C0003506
2,any severity,C0439793;C0522510
2,anti - gad positive ( n = nmbr ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
2,any serious teaes,C0205404
2,any serious ae,C0205404;C3887670
2,any sae,C1519255;C1622657;C4553214
2,any revascularization,C0581603
2,any peripheral revascularization,C0205100;C0581603
2,any mi,C3810814
2,any electrocardiographic abnormality — no . ( % ),C0522055
2,any early adverse event,C0877248;C1279919
2,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
2,any ae leading to discontinuation,C3887670
2,any ae,C3887670
2,any adverse event leading to study drug discontinuation,C0877248
2,any adverse event ( ae ),C0877248;C3887670
2,any acuity bleeding,C0333276
2,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
2,ascvd no prior ml,C3665365
2,"ascvd """,C3665365
2,ascvd * . n ( % ),C3665365
2,atypical absence,C0595948
2,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
2,attack ( % ),C0277793;C1261512;C1304680
2,atopy by phadiatop test,C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
2,atopy ( specific ige ) c,C0205369;C0392707;C1552740;C3539705
2,atopy ( n = nmbr,C0392707;C3539705
2,atopic,C0392707
2,atonic,C0541791
2,atients with event,C0441471;C4019010
2,atherosclerotic cvdj,C0333482
2,at weeks nmbr and nmbr,C0439230
2,at week nmbr,C0332174;C0439230
2,at increased fall risk ( n - nmbr ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
2,at end of follow - up — no . / total no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
2,at c data,C1511726;C3245479;C3714741
2,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
2,at nmbr years,C0439234
2,asymmetric peripheral arthritis,C0238694;C0332514
2,asubset of the ≥ nmbr years subgroup .,C0439234;C1079230;C1515021
2,asthma exacerbations,C0349790
2,ast increased,C1415181;C3891303
2,ast > nmbrx uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
2,assigned to topiramate,C1516050;C1552601
2,asdas inactive disease,C0544452
2,asdas - crp   <   nmbr . nmbr,C3890735;C4048285
2,asdas - crp *,C3890735;C4048285
2,asdas - crp δ   ≥   nmbr . nmbr,C3890735;C4048285
2,anti ‐ hyperglycaemic agent,C1321567
2,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
2,age snmbr years ( n = nmbr,C1510829
2,airway compromise,C4055482
2,all doses,C0178602
2,all ( n = nmbr ) nmbr . nmbr ± nmbr . nmbr,C0369718;C0441922
2,all ( n = nmbr,C0369718;C0441922
2,alive ( n = nmbr ),C2584946;C4551704
2,alcohol users,C0556297
2,alcohol > nmbr drinks per week,C0332174;C0439230;C0556297
2,alc at weeko ( % ),C1424945;C3811058
2,alc at week nmbr ( % ),C0332174;C0439230;C1424945;C3811058
2,alc > nmbr . nmbr - nmbr . nmbr %,C1424945;C3811058
2,alc ( mmol / mol ),C1424945;C3811058;C3829066
2,alc ( % ),C1424945;C3811058
2,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
2,alav ( per ml ),C0439526;C1705224;C3887665
2,airway reversibility,C0178987;C0449261;C0458827
2,ain,C0347129
2,anti - gad negative ( n = nmbr ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
2,aii participants ( n = nmbr ),C0679646;C1424250;C2698414
2,age   ≥ nmbr   y,C0001779
2,age\\yr,C0001779;C0439234
2,age / gd lesion,C0001779;C0221198;C1546698
2,age . . . . . . . . y ( n = nmbr ),C0001779
2,age . years,C1510829
2,age . y,C0001779
2,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
2,age  y  median ( qnmbr – qnmbr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,age *,C0001779
2,age yr,C0001779;C0439234
2,age when diabetes first diagnosed ( years ),C0001779
2,age subgroup,C0001779;C1079230;C1515021
2,age snmbr,C0001779
2,all doses ( n = nmbr ),C0178602
2,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
2,all mis,C0687670;C1333208;C1412384;C3538735
2,all mis *,C0687670;C1333208;C1412384;C3538735
2,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
2,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
2,anti - dsdna ( > nmbr iu / ml ),C0439458;C0741099
2,anti - anaemics,C0857322
2,anterior or non - anterior ml,C0205094
2,anterior mi,C3536746
2,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
2,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
2,ankle edema,C0235439
2,angina class iii or iv prior,C0264677
2,and after pci,C4049621
2,ancova result,C0814908;C1274040;C1546471;C2825142
2,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C4019010
2,anatomic extent of qualifying event,C0220784;C0439792;C0441471;C1514624;C4019010
2,amputation due to diabetes — no . ( % ),C0598284;C0678226
2,aminosalicylate,C0368663;C2825094
2,american,C0596070
2,ambition,C0870128
2,alvmi ( per g / mnmbr ),C0456715
2,alvesv ( per ml ),C0439526;C1705224;C3887665
2,alvedv ( per ml ),C0439526;C1705224;C3887665
2,alt or ast > nmbr x ulnnmbr,C1266129;C4553172
2,alt increased,C1266129;C4553172
2,alt > nmbrx uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
2,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
2,all recurrent strokes,C1836785
2,all participants^^ ( n = nmbr / nmbr ),C0679646
2,all participants * ( n = nmbr / nmbr ),C0679646
2,all participants ( n = nmbr ),C0679646
2,acr ( mg / g ),C1300563;C1412134;C1515941
2,acq score,C2919686
2,acq - nmbr total score ∗,C2919686;C2964552
2,nmbr - nmbr { o - nmbr - nmbr - onmbr ),C0483204
2,nmbr cl ),C0596019
2,nmbr ( ref ),C1425988
2,nmbr ( $ nmbr ml / min ),C0439445
2,nmbr - nmbr / day,C0332173;C0439228;C0439505
2,nmbr - nmbr / week ( n = nmbr ),C0332174;C0439230
2,nmbr - nmbr drinks / dav,C0452428
2,nmbrtob nmbr months,C0439231;C1420851
2,nmbr ( o - nmbr - o - nmbr ),C0483204
2,nmbr ( o - onmbr - o - nmbr ),C0483204
2,nmbr . nmbr ( nmbr % cl nmbr . nmbr to nmbr . nmbr ) p = nmbr . nmbr,C0596019
2,nmbr . nmbr ( nmbr . nmbr - l . l ),C3539687
2,nmbr to nmbr symptom days per week,C0677547;C1457887;C3854129
2,nmbr — nmbr days,C0439228
2,nmbr - nmbr ( snmbr - nmbr ) t,C0718146
2,nmbr - nmbr ( o - nmbr - nmbr - oo ),C0483204
2,± sd .,C2699239
2,nmbr - nmbr ( o - nmbr - o - nmbro ),C0483204
2,nmbr - nmbr ( o - nmbrs - o - nmbr ),C0483204
2,nmbr - nmbr ( o - nmbro - o - nmbr ),C0483204
2,nmbr - nmbr mm,C4330985;C4554674
2,nmbr - nmbr ( o - nmbr - o - nmbr ),C0483204
2,nmbr - nmbr ( nmbr % cl nmbr - nmbr to nmbr - nmbr ),C0596019
2,nmbr - nmbr ( onmbr - o - nmbr ),C0483204
2,nmbr - nmbr hours,C0439227
2,• urgent coronaiy revascularization > nmbr days,C0439228;C0439609;C0581603;C3272275
2,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
2,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2,• ischemic stroke,C0948008
2,• any mi,C3810814
2,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least nmbr . nmbr % of the patients in the any secukinumab group during the nmbr ‐ week placebo ‐ controlled period and events with an eair of at least nmbr . nmbr cases per nmbr patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version nmbr . nmbr )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week nmbr visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0332257;C1552866;C2700399
2,nmbr day l,C0332173;C0439228;C0439505
2,nmbr event,C0441471;C4019010
2,nmbr exacerbation in prev nmbr m ( n = nmbr ),C0369637;C0441923;C1552852;C4086268
2,nmbr low ( n = nmbr ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
2,nmbr events,C0441471;C3541888
2,nmbr to < nmbr mm hg — no . { % ),C0439475
2,nmbr to nmbr mm hg,C0439475
2,nmbr ml ( nmbr to nmbr ) ( n = nmbr / nmbr ) §,C0439526;C1705224;C3887665
2,nmbr ml ( nmbr to nmbr ) ( n - nmbr / nmbr ),C0439526;C1705224;C3887665
2,nmbr ( nmbr % cl nmbr to nmbr ),C0596019
2,nmbr ( mono ),C1551432;C1551969
2,nmbr ml ( nmbr to nmbr ) ( n = nmbr / nmbr ),C0439526;C1705224;C3887665
2,nmbr - nmbr mg / dl *,C0439269
2,nmbr % participants,C0679646
2,nmbr years or more,C0439234
2,nmbr ml / min,C0439445
2,nmbr mg / kg,C0439272
2,nmbr mg / d ( n = nmbr ),C0439422
2,nmbr μ g ( n = nmbr ),C0439267
2,nmbr - yr rate / nmbr participants,C0439234;C0679646;C0871208;C1521828
2,nmbr - year risk of chd,C0439234;C0439508;C1282512
2,nmbr - year risk for chd,C0439234;C0439508;C1282512
2,nmbr - < nmbr ng / l ( n = nmbr ),C0439297
2,nmbr . nmbr - < nmbr ng / l ( n = nmbr ),C0439297
2,nmbr . nmbr ( fi . nmbr ),C4050619
2,nmbr . nmbr ( ref . ),C1425988
2,nmbr . nmbr ( referent ),C1706462
2,nmbr to nmbr mg / l ( n = nmbr ),C0439268
2,nmbr to nmbr years,C0439234
2,nmbr standard ( n = nmbr ),C1442989;C2828392
2,nmbr parameter,C0549193;C1704769;C2350001
2,nmbr n / n,C0369718;C0441922
2,nmbr month l,C0332177;C0439231
2,» nmbr years,C0439234
2,> year nmbr,C0439234;C0439508
2,acq - nmbr score 本,C2919686
2,> nmbr . nmbr pmol / liter,C0439192;C0475211
2,> nmbr . nmbr to < nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
2,> nmbr per pl in nmbr months before screening,C0439231;C3897966;C4049765
2,> nmbr in previous,C0205156;C1552607
2,> nmbr % predicted to < nmbr % predicted,C0681842;C1882327
2,> nmbr to < nmbr iu / l,C0439457
2,> nmbr to < nmbrml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,> nmbr to < nmbr mg dl,C0439269
2,> nmbr kg / mnmbr ( n = nmbr ),C1532718
2,> nmbr kg / m ’,C1532718
2,> nmbr kg / m^,C1532718
2,> nmbr days to nmbr year ( n = nmbr ),C0556972
2,> nmbr ( moderate or high bleeding risk ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,> nmbr mg / l ( n = nmbr ),C0439268
2,> nmbr drinks / dav,C0452428
2,> nmbr to < nmbr ppb,C1415800
2,> ulnand < nmbr ng / l,C0439297
2,> nmbr - < snmbr kg / m ’,C0565930;C1532718;C2603362
2,> nmbr - < nmbrkg / mnmbr ( n = nmbr ),C1532718
2,> nmbr - snmbr kg / m ’,C0565930;C1532718;C2603362
2,> nmbr - ^nmbr kg / m ’,C1532718
2,> nmbr mg / day,C0439422
2,> nmbr mg / d peq,C0439422
2,> nmbr ( n = nmbrlnmbr ),C0369718;C0441922
2,> nmbr ( nmbr ) drinks / day if male ( female ),C0452428
2,〉 nmbr years,C0439234
2,> nmbr symptom days per week,C0677547;C1457887;C3854129
2,> nmbr ml / s,C0439390
2,> nmbr mm hg — no . ( % ),C0439475
2,〉 nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,> nmbr ^mol / liter — no . ( % ),C0347982
2,> nmbr - nmbr yr,C0439234
2,> nmbr ppb,C1415800
2,> nmbr % predicted,C0681842;C1882327
2,> nmbr % responder rate,C0871208;C1521828
2,> mean,C0444504;C2347634;C2348143
2,> lto £ nmbr symptom days per week,C0677547;C1457887;C3854129
2,> nmbrml / min / nmbr . nmbr,C0439445
2,> nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
2,> nmbr ml / min / nmbr . nmbr,C0439445
2,> nmbr ml / min per nmbr . nmbr m^,C0369637;C0439445;C0441923
2,> nmbr ml min - nmbr nmbr . nmbr m ' nmbr,C0369637;C0439445;C0441923
2,> nmbr mg dl,C0439269
2,> nmbr ml / min ( n = nmbr ),C0439445
2,> nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
2,> nmbr yr — %,C0439234
2,> nmbr years or < nmbr crcl,C0439234
2,> nmbr ( n,C0369718;C0441922
2,> nmbr iu / l,C0439457
2,> nmbr yr — no . { % ),C0439234
2,> nmbr . nmbr mg / day,C0439422
2,> nmbr to < nmbr mg / dl,C0439269
2,> nmbr yrs of age ( n = nmbr,C0001779
2,> nmbr yr ( n = nmbr ),C0439234
2,> nmbr to < nmbriiil / iiim / nmbr . nmbr mnmbr,C0369637;C0441923
2,> nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
2,> nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0369637;C0439445;C0441923
2,> nmbr mi / min,C0702093;C1524029;C3810814;C3813700
2,> nmbr mg / dl ( > nmbr . nmbr mmol / l ) + +,C0439269;C1532563
2,> nmbr crcl,C1846718
2,> nmbr weeks,C0439230
2,> nmbr mg / l,C0439268
2,> nmbruln,C1519815
2,> nmbr % stenosis of major artery,C0038449;C0205082;C0205164;C4318856;C4521762
2,nmbr . nmbr to < nmbr . nmbr mmhg,C0439475
2,nmbr [nmbr - nmbrjs,C1552154
2,nmbr . nmbr to < nmbr . nmbr mm hg,C0439475
2,nmbr to < nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
2,nmbr % clf,C3540486;C4553190
2,nmbr mg / nmbr wk ( n = nmbr ),C1881833
2,nmbr - day cce,C0332173;C0439228;C0439505
2,nmbr . ' ^ / nmbrtnmbrc } u,C0439148;C2603360
2,nmbr - nmbr . nmbr mm,C4330985;C4554674
2,nmbr . l ( nmbrl . nmbr ),C3539687
2,nmbr nil,C0442734
2,nmbr years ( n = nmbr ),C0439234
2,nmbr / nmbr ( nmbr . nmbr ) ( continued ),C0549178
2,nmbrmwt ( m ),C0369637;C0441923
2,nmbrmoto < nmbr yr,C0439234
2,nmbr to nmbr yr,C0439234
2,nmbr to < nmbr yr — no . ( % ),C0439234
2,nmbr to nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,nmbr to < nmbr ml / min / nmbr - nmbr,C0439445
2,nmbr - year predicted risk ( % ) of,C0439234;C0439508
2,nmbr to < nmbr ml min ’ nmbr nmbr . nmbr m ' nmbr,C0369637;C0439445;C0441923
2,nmbr to < nmbr yr — no . { % ),C0439234
2,nmbr - nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,nmbr . nmbr ( g . l ),C0439294;C0456615
2,nmbr days,C0439228
2,nmbr - year km %,C0439234;C0439508;C3887676
2,nmbr - min walk distance,C0429886;C0702093;C1524029;C3813700
2,nmbr - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
2,nmbrl . nmbr ( lnmbr . nmbr ),C3539687
2,nmbrl ( lnmbr ),C3539687
2,nmbr . nmbr ( nmbr l . l ),C3539687
2,nmbr kg / m ’,C1532718
2,nmbr % decrease in womac pain score,C0392756;C0547047;C0582148
2,nmbr to < nmbr ml / min ( n = nmbr nmbr ),C0439445
2,α - glucosidase inhibitor,C1512211
2,a - glucosidase inhibitors,C1512211
2,a - glucosidase inhibitors ' nmbr,C1512211
2,a nmbr years,C0439234
2,acq - nmbr score ' ! ',C2919686
2,acq - nmbr score,C2919686
2,aclidinium nmbr   μ g bid ( n   =   nmbr ),C0439267;C2699757
2,aclidinium nmbr   μ g ( n   =   nmbr ),C0439267;C2699757
2,aclidinium nmbr   μ g ( n   =   nmbr ) b,C0439267;C2699757
2,aclidinium nmbr   μ g ( n   =   nmbr ) a,C0439267;C2699757
2,ace inhibitor / arb therapy,C1444755;C3888198
2,acd,C4554601
2,accord primary,C0680240
2,accord acr > nmbr - nmbr,C0680240;C1412134;C1515941
2,accord acr < nmbr - nmbr,C0680240;C1412134;C1515941
2,access site,C0589360
2,absolute time spent “ on ”,C0439546
2,absolute time spent “ on ” without troublesome dyskinesia,C0439546
2,absolute time spent “ on ” with troublesome dyskinesia,C0439546
2,absolute difference estimate vs placebo ( nmbr % ci ),C0750572;C1549031
2,absolute ( l ),C0205344
2,absence,C0332197;C1689985
2,about nmbr mg / l,C0439268
2,about nmbr mg / l or more,C0439268
2,anmbrc > = median,C0549183;C0876920;C2347635;C2348144;C2939193
2,anmbrc < median,C0549183;C0876920;C2347635;C2348144;C2939193
2,anmbrc [n ( % ) ],C1272460
2,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
2,a . acr nmbr,C1412134;C1515941
2,a prebronchodilator fevl ( % predicted ),C2599602
2,a median,C0549183;C0876920;C2347635;C2348144;C2939193
2,a decrease of > nmbr points in the cdai score,C0392756;C0547047;C2924612
2,a compared w,C1707455
2,nmbr to < nmbr m um in,C0369637;C0441923
2,nmbr - < nmbrml / min,C0439445
2,nmbr – < nmbr ml / min,C0439445
2,nmbr − nmbr mg / g,C1300563
2,nmbr – nmbr months,C0439231
2,nmbr - yr %,C0439234
2,nmbr - nmbr — no . / total no . ( % ),C0439175;C0439810
2,nmbrs . nmbr ± s . nmbr,C0565930;C2603362
2,nmbrnd : nmbr . nmbr - nmbr . nmbr pmol / l,C0439284
2,nmbrnd tertile ( > nmbr to < = nmbr mg / dl [ > nmbr . nmbr to < = nmbr . nmbr mmol / l] ) c,C0439269
2,nmbrl . nmbr ( lnmbr . nmbrl ),C3539687
2,nmbr a . g,C0439267
2,nmbr ( io - nmbr % ),C1046794;C3146236
2,nmbr < bmi < nmbr,C0578022
2,nmbr μ g bid ( n = nmbr ),C0439267
2,nmbr - < nmbr kg / mnmbr,C1532718
2,nmbr kg / mnmbr,C1532718
2,nmbr mm hg,C0439475
2,nmbr - nmbr mmol / l,C1532563
2,nmbr . nmbr range nmbr - nmbr,C1514721;C2348147;C3542016
2,nmbr yr . km rate,C0439234;C0871208;C1521828;C3887676
2,nmbr hr after glucose challenge,C3840385
2,nmbr nmbr to < nmbr kg / mnmbr,C1532718
2,nmbr ( nmbr to < nmbr ml / min ),C0439445
2,nmbr — no . / total no . ( % ),C0439175;C0439810
2,nmbr - hour ppg,C0439227;C0564385;C1418888
2,nmbr - h pmg ( mmol / l ),C2827804
2,nmbr - gi,C1708130;C3539617;C4050121
2,nmbr - < nmbr years,C0439234
2,nmbr ( nmbrs . s ),C0565930;C2603362
2,nmbro / nmbronmbr ( nmbr - nmbr % ),C0483204
2,nmbr ( only nmbr distal ),C0205108;C0205171;C1720467;C4522154
2,nmbr ( nmbr . nmbr ) ( continued ),C0549178
2,nmbr blocker before admission,C0184666;C0809949
2,nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,"nmbr - nmbr ml min "" nmbr",C0439445
2,nmbr - nmbr ml min ) nmbr,C0439445
2,nmbr . nmbr - nmbr . nmbr mm,C4330985;C4554674
2,nmbr . nmbr ± l . l,C3539687
2,nmbr . nmbr ( nmbr . o - nmbr . o ),C0483204
2,nmbr - nmbr / week ( n = nmbr ) nmbr - nmbr / week ( n = nmbr ),C0332174;C0439230
2,nmbr ( nmbr cl ),C0596019
2,nmbr to < nmbr ml / min / nmbr,C0439445
2,nmbr min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
2,nmbr / day,C0332173;C0439228;C0439505
2,nmbr / week ( n = nmbr ),C0332174;C0439230
2,nmbr . nmbr ± nmbr . lf,C1416933;C2986618;C4554443
2,nmbr week,C0332174;C0439230
2,nmbr ( severe disease ),C1836348
2,nmbr ‐ point reduction in selena – sledai score,C0301630;C0392756;C0451528;C1293152;C1552961;C2347617;C3714763;C4551656
2,nmbr - point mace ( nmbr - point mace plus hospitalization for unstable angina ),C1552961;C2347617;C3714763
2,nmbr - nmbr ( < nmbr ml / min ),C0439445
2,nmbrrd : nmbr . nmbr - nmbr . nmbr pmol / l,C0439284;C0694666;C4553350
2,nmbrrd tertile ( > nmbr mg / dl [ > nmbr . nmbr mmol / l] ) d,C0439190;C0439269;C0567349;C0694666;C2348885;C3642216;C4553350
2,nmbr . l ( nmbr . l ),C3539687
2,nmbr events[nmbr . nmbr],C0441471;C3541888
2,nmbr wk,C0332174;C0439230
2,nmbr to < nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
2,nmbr to < nmbr ml / min per nmbr . nmbr m^,C0369637;C0439445;C0441923
2,nmbr kg / mnmbr or more,C1532718
2,nmbr days urgent revascularization,C0439228;C0439609;C0581603;C3272275
2,nmbr days stroke ( ischemic ),C0439228
2,nmbr days new mi or definite acute st,C0205314;C0439228;C3810814
2,nmbr days new mi,C0205314;C0439228;C3810814
2,nmbr – ≤ nmbr ml / min,C0439445
2,nmbr - nmbr crcl,C1846718
2,augment copd,C0205217
2,available data,C0470187;C1511726;C3245479;C3714741
2,> nmbrmonths,C0439231
2, chf = congestive heart failure . * any use in nmbr h before surgery except for aspirin which only required any use in the nmbr days before surgery .,C1511726;C3245479;C3714741
2,daytime nasal symptoms score change from baseline,C0231918;C0332169
2,days with heartburna ( days ),C0439228
2,data,C1511726;C3245479;C3714741
2, median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C1511726;C3245479;C3714741
2,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold nmbr criteria [nmbr]  gold nmbr [nmbr]    bon a scale of nmbr – nmbr  with higher scores indicating worse health status  the mcid is a change of nmbr   units  on a scale of nmbr – nmbr  with higher scores indicating more severe dyspnea  on a scale of nmbr – nmbr  with higher scores indicating worse health status,C1511726;C3245479;C3714741
2,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < nmbr . nmbr vs . non - epa . § p < nmbr . nmbr vs . non - epa,C1511726;C3245479;C3714741
2,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < nmbr . nmbr vs . ng . † p < nmbr . nmbr vs . ng .,C1511726;C3245479;C3714741
2,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at nmbr year . * cardiovascular ( cv ) death,C1511726;C3245479;C3714741
2, signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p nmbr . nmbr .,C1511726;C3245479;C3714741
2,data are number of patients ( % ) or mean ( sd ),C1511726;C3245479;C3714741
2,data are number of patients ( % ) or hazard ratio ( nmbr % cl ),C1511726;C3245479;C3714741
2,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C1511726;C3245479;C3714741
2,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids,C1511726;C3245479;C3714741
2, hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for nmbr patients ( nmbr rosuvastatin  nmbr placebo ) .,C1511726;C3245479;C3714741
2,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by nmbr . nmbr . * estimated with cockroft - gault equation ,C1511726;C3245479;C3714741
2,current smoker — no . / total no . ( % ),C3173209;C3241966
2, ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C1511726;C3245479;C3714741
2,daily exercise ( % ),C0332173
2,dactylitis severity score ) score > nmbr — no . { % ),C0239161;C0457451
2,dactylitis score ( nmbr - nmbr ),C0239161;C0449820;C4050231
2,dactylitis score,C0239161;C0449820;C4050231
2,dactylitis in > nmbr digit,C3863761
2,d - value,C1522609
2,czech repumc,C0337799
2,cypnmbranmbr,C1418793;C2634343
2,cutoffs,C1442160
2,currently smokes,C0521116
2,current smokers ( n = nmbr ),C3173209;C3241966
2,current smokers ( itt ) ( n = nmbr ),C3173209;C3241966
2,current smoker at screeninga,C3173209;C3241966
2,decline #   ml · yr − nmbr,C0439234;C0439526;C1705224;C3887665
2,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
2,definite stent thrombosis,C0439544;C1704787;C3897493
2,delayed,C0205421;C1545665;C3272602
2,difference vs placebo ( nmbr % ci ),C1705241;C1705242
2,difference vs pbo ( nmbr % ci ),C1705241;C1705242
2,difference vs pbo,C1705241;C1705242
2,difference vs ff nmbr pg ( nmbr % ci ),C1705241;C1705242
2,difference in means ( nmbr % cl ),C0596019;C1704970;C1705241;C1705242
2,difference in means,C1704970;C1705241;C1705242
2,dietary calcium intake,C0489458
2,diet - controlled ( % ),C0743195
2,diagnostic catheterization,C0596429
2,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
2,diabetics • no ( n = nmbr,C0241863
2,diabetics ( n = nmbr ),C0241863
2,diabetics - yes ( n = nmbr,C0241863;C1549445;C1705108;C1710701
2,diabetics - no ( n = nmbr,C0241863
2,diabetic subjects,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
2,diabetic participants !,C0241863;C0679646
2,diabetic participants,C0241863;C0679646
2,diabetic eye disease,C0342245
2,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
2,diabetic ( no ),C0241863
2,diabetesh yes,C1549445;C1705108;C1710701
2,diabetes mellitus ( type nmbr ),C1320657
2,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
2,device = watchman filter,C0180860;C0335390
2,deviation,C0012727;C0205419;C1705236
2,descent,C0205386;C0680043
2,dermal,C0221928;C1522447
2,demographic data,C4684639
2,delighted,C3830544
2,current smoker »,C3173209;C3241966
2,current smoker — no . ( % ) blood pressure — mm hg,C3173209;C3241966
2,direction of hr,C0449738
2,controllertreatment before entry *,C1705654
2,crcl < nmbrml / min,C0439445;C1846718
2,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
2,crcl ( ml / min ),C0439445;C1846718
2,cortteosterom relrsclory status,C0449438
2,coronary revascularisation §,C0877341
2,coronary eventsnmbr,C0741923
2,coronar y artery disease,C0852949
2,coronar y - artery bypass grafting,C0450140;C0741847
2,cornell voltage x duration product,C0449238;C0598352;C1514468;C1704444;C2926735
2,cornell voltage - duration product,C0449238;C0598352;C1514468;C1704444;C2926735
2,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
2,corneii product,C1514468;C1704444
2,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
2,conventional agents *,C0439858;C0450442;C1254351;C1521826
2,controlled : acq - nmbr < nmbr . nmbr,C2587213;C2911690;C2919686
2,current smoker — no . { % ),C3173209;C3241966
2,continuous,C0549178
2,continue thienopyridine n = nmbr,C0549178
2,conservative strategy ( n = nmbr,C0679199
2,congestion *,C0700148;C2826600
2,concurrent illness,C0205420;C0221423
2,concomitant oads,C0521115
2,concomitant medication use,C0240320;C0521115
2,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
2,concomitant antiplatelet,C0521115
2,concomitant aedsb,C0521115
2,concomitant,C0521115
2,concern,C2699424
2,composite of doubling of serum creatinine,C0201976;C0205173;C0205199;C0600061;C1547335;C1705764
2,composite of nmbr % reduction in egfr,C0205199;C0301630;C0392756;C1293152;C1547335;C4551656
2,crcl > nmbr - < nmbrml / min,C0439445;C1846718
2,crcl > nmbrml / min,C0439445;C1846718
2,crcl nmbr - nmbr,C1846718
2,crcl of nmbr - nmbr ml min ',C0439445;C1846718
2,current or prior smoking,C0521116;C1705970
2,current or former smoker,C0521116;C1705970
2,current lra use,C0521116;C1705970
2,current enthesitis,C0521116;C1282952;C1705970
2,current dactylitis,C0239161;C0521116;C1705970
2,current corticosteroid use,C0239126;C0521116;C1705970
2,current ( n   = nmbr,C0521116;C1705970
2,cumulative events,C0441471;C1511559;C3541888
2,cuban,C1553379
2,cryptogenic localization - related,C0332240;C0475264;C1744691
2,cryptogenic,C0332240
2,crusade score,C0449820;C4050231
2,crude rate,C0871208;C1521828
2,crp   >   uln,C1519815;C3890735;C4048285
2,crp   ≤   uln,C1519815;C3890735;C4048285
2,crp level,C0441889;C0456079;C1547707;C2946261;C3890735;C4048285
2,crp > nmbr . nmbr mg / dl,C0439269;C3890735;C4048285
2,crp [mg / l],C0439268;C3890735;C4048285
2,crp ( normal < nmbr . nmbr mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
2,crp ( mg / l ) [b],C0439268;C3890735;C4048285
2,cross - clamp,C0175721;C1883710;C2828360;C3810601
2,critical site,C0205145;C1511545;C1515974;C2825164
2,creatinine clearance category [ml / min],C0439445;C0683312;C0812399;C3889287
2,creatinine clearance > nmbr to < nmbr ml / min — no . ( % ) f,C0151280
2,creatinine clearance < nmbr ml / min — no . ( % ) weight < nmbr kg — no . ( % ),C0439445;C0812399
2,creatinine clearance — ml / min,C0439445;C0812399
2,creatine clearance category nmbr to < nmbr ml / min nmbr / nmbr,C0373595;C0439445;C0683312;C3889287
2,creatine clearance category,C0373595;C0683312;C3889287
2,crcl,C1846718
2,diffusion capacity of the lung for carbon monoxide,C0231971
2,discontinuation of lama prior to baseline,C0457454;C0999593;C1416775;C1444662;C4552847
2,average daily dose,C1510992;C2348070;C2825518
2,eastern and central europe,C1707877
2,effect estimate,C0750572;C1280500;C1518681;C2348382
2,ef domain,C1880389;C1883221;C3541951
2,edss stratification . no . ( % ),C0451246;C1514983;C3887783
2,ed visit related to exacerbation,C0545082;C1512346;C2826704;C3538926
2,ed severity,C0439793;C0522510;C3538926
2,ed severity * *,C0439793;C0522510;C3538926
2,ed duration > nmbr yr,C0439234;C0449238;C2926735;C3538926
2,ed duration,C0449238;C2926735;C3538926
2,ed characteristics,C1521970;C3538926
2,ed > nmbr yr,C0439234;C3538926
2,ecg abnormality at entry,C0522055;C1705654
2,ecg - lvh ( sokolow - lyon ),C0232306
2,ecg - lvh ( cornell ),C0232306
2,ecfr ( ml / min per nmbr - nmbr m ’ ),C0369637;C0439445;C0441923
2,ease - nmbr,C1331418
2,dysglycaemia or mets,C1960636
2,early use intended,C1279919
2,early routine,C0205547;C1279919
2,early load,C1279919
2,"early invasivenmbr """,C0205281;C1279919;C1334278
2,early invasive *,C0205281;C1279919;C1334278
2,early invasive strategy ( n = nmbr,C0205281;C0679199;C1279919;C1334278
2,early death,C1836407
2,early,C1279919
2,eacit - e total score ) |,C2964552
2,enmbr / snmbr vs snmbr,C3846405
2,enmbr / snmbr vs enmbr,C3846405
2,enmbr / snmbr ( n = nmbr ),C3846405
2,e / a ratio,C0456603;C1547037
2,e ( characteristic n,C1521970
2,effect of covariates on slopes,C1280500;C1518681;C2348382
2,effect size !,C0814843
2,effect size^,C0814843
2,efficacy end points,C1280519;C1707887;C2349179
2,enox,C3147679
2,endpoints,C2349179
2,endpoint *,C2349179;C2826544
2,end - point ( sd ),C2349179;C2699239;C2826544
2,empty,C1880497
2,empa,C2699863
2,elevation of cardiac biomarker levels or st - seg - ment deviation > nmbr mm — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
2,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
2,elevated vs . normalc,C0205250;C3163633
2,elevated vs . normalb,C0205250;C3163633
2,elevated vs normalb,C0205250;C3163633
2,elevated symptomatic serum creatinine,C0231220;C0700225
2,elevated serum creatinine,C0700225
2,elevated serum creatinine ( > nmbr . nmbr mg / dl_ ),C0439269;C0700225
2,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
2,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
2,elevated crp,C0742906
2,elective procedure,C0747973
2,elderly patients ( n — nmbr ),C0870602
2,ejection fraction *,C0489482;C2700378
2,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
2,ejection fraction ( % ),C0489482;C2700378
2,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
2,either ocs use,C3844638
2,efficacy variable,C0439828;C1280519;C1707887;C4553760
2,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
2,efficacy measures,C1280519;C1707887
2,efficacy endpoints *,C1280519;C1707887;C2349179
2,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
2,dysglycemic categories,C0683312;C1960636
2,duration since diagnosis ( years ),C0449238;C2926735
2,disease activity ( n ( % ) ),C1292728
2,door - to - balloon time — hr,C4296144
2,drinker ( nmbr to nmbr drinks / week ),C0332174;C0439230;C0452428;C0556338
2,drinker ( nmbr - nmbr drinks / week ),C0556338
2,draining fistulae,C0544791
2,dpp - nmbr,C1414174
2,doubling of creatinine level,C0205173;C0428279;C1705764
2,double - dummy phase * *,C0205390;C1710475;C4684647
2,dose,C0178602;C0869039;C1114758
2,dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
2,dose reduced at randomization *,C0178602;C0869039;C1114758
2,dose ratio at week nmbr ( nmbr % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
2,dose equivalent,C0178602;C0205163;C0439185;C0869039;C1114758
2,dose adjustment n ( % ),C2826232
2,dose adjusted,C0178602;C0869039;C1114758
2,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
2,documented mi,C1301725;C1609436;C3810814
2,duration of type nmbr diabetes mellitus,C0449238;C1320657;C2926735
2,documented hypoglycaemiac,C1301725;C1609436
2,dlqi §,C3899393
2,dlqi score,C3899393
2,dlqi ( nmbr - nmbr ),C3899393
2,diuretic therapy,C0948575
2,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
2,distal forearm,C0588203
2,distal,C0205108;C4522154
2,disseminated tuberculosis,C0152915
2,disease severity,C0521117
2,disease history,C0683519
2,disease duration > nmbr years,C0439234;C0872146
2,disease duration [year],C0439234;C0439508;C0872146
2,disease duration ( y ),C0872146
2,drinker,C0556338
2,dual antiplatelet therapy,C0205173;C1096021;C1554184
2,dual ii,C0205173;C1554184;C1710602;C4082587
2,due to ae,C3887670
2,duration of type nmbr diabetes categories,C1320657;C1547660
2,duration of type nmbr diabetes,C0449238;C1320657;C2926735
2,duration of treatment in the healing study,C0444921
2,duration of total exposure to study treatment,C0439175;C0439810;C2826870
2,duration of tnmbrd,C0449238;C2926735
2,duration of symptoms > nmbr min,C0436359;C0702093;C1524029;C3813700
2,duration of procedure,C2346509
2,duration of previous use of vka,C0205156;C1552607;C1881378;C2826775
2,duration of paod ( years ),C0439234;C0449238;C2926735
2,duration of infusion during medical management — hr,C0449238;C0574032;C1827465;C2926735
2,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735
2,duration of infusion before cabg — hr,C0449238;C0574032;C1827465;C2926735
2,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735
2,duration of disease since,C0872146
2,duration of disease before baseline,C0872146
2,duration of disease ( yr ),C0439234;C0872146
2,duration of disease ( years ),C0439234;C0872146
2,duration of disease ( y ),C0872146
2,duration of disease — yr^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
2,duration of current flare,C0449238;C0521116;C1517205;C1705970;C2926735;C3540542
2,duration of as,C0449238;C2926735
2,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
2,duration > nmbr years,C0439234;C0449238;C2926735
2,duration > nmbr to < nmbr years,C0439234;C0449238;C2926735
2,duration < nmbr year,C0439234;C0439508;C0449238;C2926735
2,duration — yr,C0439234;C0449238;C2926735
2,durable clinical responseg,C0205210
2,durable clinical remissionh,C0205210
2,due to sae,C1519255;C1622657;C4553214
2,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
2,composite endpoint ( anmbrc < nmbr . nmbr %,C0205199;C1547335;C2349179;C2826544
2,composite endpoint,C0205199;C1547335;C2349179;C2826544
2,bmi kg · m − nmbr,C0578022;C1532718
2,bolus alone,C1186706;C1511237;C1705509;C3812160
2,bolus,C1186706;C1511237;C1705509;C3812160
2,body mass indext,C0518010
2,body mass indexf  < nmbr,C0518010
2,body mass indexf,C0518010
2,body mass indexb,C0518010
2,body mass indexa,C0518010
2,bmi > nmbrkg / mnmbr ( n = nmbr / nmbr ),C0578022;C1532718
2,bmi > nmbrkg / m * ( n = nmbr / nmbr ),C0578022;C1532718
2,bmi  kg / mnmbr  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
2,bmi * ( kg / mnmbr ),C0578022;C1532718
2,bmi # kg - m “ nmbr,C0578022;C1532718
2,bmi   kg · m − nmbr,C0578022;C1532718
2,bmi onmbr kg / mnmbr,C0578022;C1532718
2,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0578022
2,bmi > nmbrkg / mnmbr,C0578022;C1532718
2,bmi category ( kg / mnmbr ),C0578022;C0683312;C1532718;C3889287
2,bmi categories,C0578022;C0683312
2,bmi anmbr,C0578022
2,bmi nmbr,C0578022
2,bmi nmbr - nmbr - nmbr nmbr,C0578022
2,bmi nmbr nmbr - nmbr nmbr,C0578022
2,bmi nmbr - nmbr - nmbr - nmbr,C0578022
2,bmi nmbr - < nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
2,bmi nmbr - < nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
2,"bmi nmbr - < nmbr kg / m "" ( n = nmbr / nmbr )",C0578022;C1532718
2,bmi nmbr - < nmbr kg / m - ( n = nmbr / nmbr ),C0578022;C1532718
2,bmi > nmbr obese,C0578022
2,bmi > nmbr kg / mnmbr *,C0578022;C1532718
2,bmi > nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
2,bolus and corrections,C1186706;C1511237;C1705509;C3812160
2,bolus and infusion,C1186706;C1511237;C1705509;C3812160
2,bone erosion score,C0449820;C0587240;C4050231
2,bonferroni - adjusted p value,C1709380;C1879894
2,cardiac biomarker,C1271630
2,cardiac biomarker elevation,C0439775;C0702240;C1271630
2,cancer surgery,C0920424
2,cananmbr / met ( n = nmbr ),C1418845
2,cananmbr ( n = nmbr ),C1418845
2,cana,C1418845
2,calculated annual decline,C0332181;C0444686;C1441506
2,calcium level,C0201925;C0428302
2,caffeine users,C3532939
2,caffeine user,C3532939
2,caffeine consumption *,C0948365
2,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
2,cnmbrenmbr fab bolus and infusion ( n = nmbr ),C1186706;C1511237;C1705509;C3812160
2,cnmbrenmbr fab bolus ( n = nmbr ),C1186706;C1511237;C1705509;C3812160
2,cnmbrenmbr fab bolus,C1186706;C1511237;C1705509;C3812160
2,cnmbr - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
2,c group ( n = nmbr ),C0441848
2,c - reactive proteinc,C0205332
2,bypass graft §,C0185098
2,by treatment arm,C1522541
2,by genotyping,C1285573
2,budesonide - formoterol nmbr + nmbr . nmbr ^g ( n = nmbr ),C0439267;C1276807
2,budesonide - formoterol nmbr ^g + nmbr . nmbr ^g ( n = nmbr ),C1276807;C1319635
2,budesonide - formoterol ( n = nmbr ),C1276807
2,bud / fm nmbr / nmbr atg n = ^nmbr,C2700462;C2945744;C3540627;C3815109
2,bronchial reversibility %,C0205039;C0449261;C1442216
2,bowel stricturing,C0267465
2,boost intensify premix i ( global patient population ),C1511253;C1874596
2,boost intensify all ( pan - asian patient population ),C1511253;C1874596
2,bmi > nmbr — no . { % ) $,C0578022
2,bmi < nmbr kg / mnmbr ( n = nmbr / nmbr ),C0578022;C1532718
2,composite,C0205199;C1547335
2,basal only,C0205112;C0205171;C1720467
2,because of sae,C1519255;C1622657;C4553214
2,because of ae,C3887670
2,beam   <   nmbr   mg / dl at week nmbr,C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
2,beam values ( mg / dl ),C0042295;C0338248;C0439269;C2347880;C4521565
2,baseline diastolic blood pressure,C4274392
2,baseiine acei / arb,C3888198
2,basdainmbr,C1998004
2,basdai ⁎ ⁎,C1998004
2,basdai,C1998004
2,basdai score,C1998004
2,basdai score ( nmbr - nmbr ),C1998004
2,basdai responses at week nmbr,C0332174;C0439230;C0871261;C1998004
2,basdai question nmbr score ( nmbr - nmbr ),C1998004
2,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
2,basal insulin doset,C0650607
2,bmi < nmbr kg / m^ ( n = nmbr / nmbr ),C0578022;C1532718
2,basal insulin,C0650607
2,basal alone,C0205112;C0205171;C0439044;C0679994
2,basal,C0205112
2,barc types nmbr,C0332307
2,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0175673
2,background lipid - lowering therapy,C0585943;C1706907
2,b . acr nmbr,C1412134;C1515941
2,b postbronchodilator fevl ( % predicted ),C2599594
2,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
2,azl - m + cldb,C0369637;C0441923
2,azl - m / cld ( n = nmbr ),C0369637;C0441923
2,azl - m nmbr mg nmbr - cld nmbr mg ( n = lnmbr ),C0369637;C0441923;C2827881
2,azl - m nmbr mg + cld nmbr mg,C0369637;C0441923;C1319635
2,azl - m,C0369637;C0441923
2,before admission ),C0184666;C0809949
2,before bronchodilation — liters §,C0475211;C1371299;C3537072
2,below median,C0549183;C0876920;C2347635;C2348144;C2939193
2,benazepril - hydrochlorothiazide group ( n = nmbr ),C0441848;C0717481
2,bmi < nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
2,"bmi < nmbr kg / m "" ( n = nmbr / nmbr )",C0578022;C1532718
2,bmi £ nmbr kg / m * ( n = nmbr / nmbr ),C0578022;C1532718
2,bmi [kg / mnmbr],C0578022;C1532718
2,bmi ( sd ),C0578022;C2699239
2,bmi ( kg = mnmbr ),C0578022;C1532718
2,bmi ( kg / mnmbr ) a,C0578022;C1532718
2,bmi ( kg / mnmbr ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,bmi ( kg / mnmbr ) [mean - sd],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,bmi ( kg / mnmbr ) ( sd ),C0578022;C1532718;C2699239
2,bmi ( kg / mnmbr ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
2,bmi ( kg / m ’ ),C0578022;C1532718
2,bmi ( kg / m^ ),C0578022;C1532718
2,bmi ( kg / ( m ) nmbr ),C0578022;C1532718
2,bmi ( kg / m nmbr ),C0578022;C1532718
2,bmi ( . kg / m - ) *,C0578022;C1532718
2,bmi - kg / mnmbr,C0578022;C1532718
2,blood pressure : systolic / diastolic ( mm hg ) ( mean,C0439475;C0444504;C2347634;C2348143;C2704328
2,blood - glucose control,C3267174
2,black / african,C0337824
2,black hispanic - n ( % ),C1533017;C1533018
2,black hispanic,C1533017;C1533018
2,biochemical events,C0205474;C0441471;C3541888
2,bii score,C1413059
2,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
2,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
2,bifurcation lesion with side branch ≥ nmbr . nmbr mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
2,between - treatment comparison of percentage change from baseline in total hip bmd,C0439165;C1299575;C1549488;C1561533;C1707455
2,beta bloekers,C0330390;C0439096;C2004068
2,cardiac index,C0428776
2,cardiac procedure :,C1279986
2,cardiothoracic ratio > nmbr . nmbr,C0456603;C1547037;C4055270
2,chronic cardiovascular disease,C1290380
2,clinical characteristics ( % ),C0683325
2,clinical and patient reported outcomes,C0205210
2,clean,C1947930
2,cld nmbr mg ( n = lnmbr ),C0439268
2,class v only,C0205171;C0457166;C1720467;C1880098
2,class ll - iv,C0456387;C1518526;C1705943
2,class iv only,C0205171;C0441888;C1720467;C2698970
2,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
2,class ii ( b - blockers ),C0441886;C2698968
2,class i or no symptoms,C0441885;C1319793;C2698967
2,class nmbr,C0456387;C1518526;C1705943
2,class > ii,C0441886;C2698968
2,cl - nmbr],C0596019
2,cigarette smoker *,C0337667
2,chronic bronchitist,C0205191
2,cardiovascular disease risk category,C0683312;C1113685;C3889287
2,chlor,C0308648
2,chi - square p value,C1552646;C1709380
2,chest x - ray,C0039985
2,chest discomfort,C0235710
2,chd simva ( „ = nmbr ),C0280604;C3542407
2,chd eze / simva ( „ = nmbr ),C0280604;C3542407
2,chd + cl all,C0280604;C0596019;C3542407
2,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
2,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
2,charm,C0849759
2,charlson comorbidity index,C4546361
2,charlson comobility score,C0449820;C4050231
2,characteristics *,C1521970
2,characteristics no . of participants,C1521970
2,clinical disease activity index,C3869583
2,clinical endpoint,C2347784
2,clinical or lesion rf for st,C0205210
2,clinical outcome,C0205210;C1274040
2,components of the first cid,C0205435;C0449432;C1279901;C1707433
2,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
2,components,C0449432
2,complete healinga,C0205197;C0725685;C3853530;C4283785
2,comparison,C1707455
2,comparator,C1707454;C4553389;C4553390
2,combo - facilitated pci,C4049621
2,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
2,combined major macrovascular events,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
2,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
2,combined end poir,C0205195;C0444930;C2746065
2,combined end point,C0205195;C2349179;C2826544
2,combined chd,C0205195;C0280604;C3542407
2,combined,C0205195
2,combination ( n = nmbr ),C0205195;C1947911;C3811910
2,combination,C0205195;C1947911;C3811910
2,college graduate or more,C0682187
2,college degree or higher,C0441889;C0449286;C0542560;C0557806;C2348088
2,cognitive subscale on alzheimer ' s disease assessment scale,C0450989;C1516691
2,cognitive,C1516691
2,coefficient,C1707429
2,cluster nmbr : not reversible,C1555715;C1704332
2,cluster nmbr : reversible,C1555715;C1704332
2,cluster nmbr : diuretic ( n = nmbr ),C1555715;C1704332
2,closure,C0185003;C1521802
2,clinically relevant non,C1518422;C2347946
2,clinical variables,C0205210;C0439828
2,clinical responsed,C0205210
2,clinical remissione,C0205210
2,characteristic †,C1521970
2,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
2,characteristic^,C1521970
2,centrally acting sympathomimetics,C3653511
2,central / eastern,C0205099;C1707877;C1879652
2,central or south america,C0205099;C1879652
2,central eosinophil count,C0200638;C0205099;C0750879;C1879652
2,central and south america and mexico,C0205099;C1879652
2,central and south america,C0205099;C1879652
2,central and eastern europe,C0205099;C1879652
2,center,C0205099;C3810851
2,cdmard experience,C0237607;C0596545
2,cdai §,C0683448;C1413248;C3273706
2,cdai score,C0683448;C1413248;C3273706
2,cdai > nmbr,C0683448;C1413248;C3273706
2,cdai ( nmbr - nmbr ),C0683448;C1413248;C3273706
2,ccq total score,C2964552
2,catheter site — femoral,C0449652
2,category — no . / total no . ( % ),C0683312;C3889287
2,category,C0683312;C3889287
2,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
2,categorical variables,C0439828;C0683312;C3889287
2,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
2,cases,C0868928;C1533148
2,cardiovascular therapies — no . { % ),C0587038
2,cardiovascular risk factors and history ( % ),C0850624
2,cardiovascular risk factors and history — no . ( % ),C0850624
2,cardiovascular risk factors and history,C0850624
2,cardiovascular risk factors alone ( n = nmbr ),C0205171;C0439044;C0679994;C0850624
2,cardiovascular risk factors — no . { % ),C0850624
2,cardiovascular risk factor — no . { % ),C0850624
2,cardiovascular history — no . ( % ),C1880008
2,cardiovascular events,C1320716
2,central / south,C0205099;C1710133;C1879652
2,centre,C0205099;C3810851
2,characteristic / outcome,C1274040;C1521970
2,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
2,characteristic *,C1521970
2,characteristic and treatment,C1521970
2,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
2,characteristic age — yr,C0001779;C0439234;C1521970
2,characteristic age,C0001779;C1521970
2,characteristic ( a ),C1521970
2,changes in shs,C0392747;C0443172
2,changes in serum creatinine,C0201976;C0392747;C0443172;C0600061
2,change to   week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
2,change to week nmbr * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
2,change to week nmbr *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
2,change to week nmbr,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
2,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
2,change in sesbp,C0392747;C0443172;C1705241;C4319952
2,change in sedbp,C0392747;C0443172;C1705241;C4319952
2,change in psa ‐ modified shs,C0392747;C0443172;C1705241;C3810537;C3813209;C3889737;C4319952
2,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
2,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
2,change in hbalc after nmbr weeks etd ( nmbr % cl ),C0392747;C0443172;C1705241;C4319952
2,change in fpg nmbr to month nmbr ( mg / dl ),C0392747;C0443172;C1705241;C4319952
2,change,C0392747;C0443172;C1705241;C4319952
2,chanmbrdsnmbrvasc score ( % ),C0449820;C1420648;C3714751;C4050231
2,chanmbrdsnmbrvasc score,C0449820;C1420648;C3714751;C4050231
2,chanmbrdsnmbr - vasc score,C0449820;C1420648;C3714751;C4050231
2,chanmbrdsnmbr - vasc nmbr nmbr,C1420648;C3714751
2,chanmbrdsnmbr - vasc nmbr - nmbr,C1420648;C3714751
2,chanmbrdsnmbr - vasc < nmbr,C1420648;C3714751
2,chanmbrsnmbr score,C0449820;C1420648;C4050231
2,cgi - s,C4526016
2,> nmbr . nmbr mm,C4330985;C4554674
2,age at diagnosis snmbr years,C0439234;C1828181;C3173302
2,ptgada ( mm ),C4330985;C4554674
2,indian ( american ) or alaska native,C0596070;C1524069
2,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
2,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
2,stage nmbr : < nmbr,C0205390;C1300072;C1306673
2,stage nmbr : > = nmbr,C0205390;C1300072;C1306673
2,non - hdl choleslerol,C1518422;C3715113
2,non - hdl cholesterol,C0729627;C1535899
2,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
2,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
2,> nmbr yr since menopause,C0439234
2,paroxysmal,C0205311
2,laba ( only monotherapy ),C0205171;C1720467
2,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
2,< nmbr yr since menopause,C0439234
2,prior myocardial infarction 一 no . ( % ),C0155668
2,phgada ( mm ),C4330985;C4554674
2,ss > nmbr ( n = nmbrvs nmbr ),C2699257;C3891295;C4551874
2,( mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
2,( mean % difference,C0444504;C1705241;C1705242;C2347634;C2348143
2,ss < nmbr ( n = nmbrvsnmbr ),C2699257;C3891295;C4551874
2,reversibility : < nmbr %,C0449261
2,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
2,reversibility : > nmbr %,C0449261
2,left anterior descending coronary artery,C0226032
2,endpoint / baselinec,C2349179;C2826544
2,acr response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
2,anmbrc ( mmol / mol ),C3829066
2,subgroup p value 本,C1079230;C1515021;C1709380
2,subgroup p valuef,C1079230;C1515021
2,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
2,- - - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -,C0332174;C0439230
2,% change ( median  qnmbr  qnmbr ),C0392747;C0443172;C1705241;C4319952
2,p - blocker ( % ),C0369773;C2603361
2,severe or very severe,C0205082;C4050465;C4050466
2,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
2,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
2,difference ( nmbr % cl ),C0596019;C1705241;C1705242
2,nmbr months,C0439231
2,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
2,maternal history,C0559473
2,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
2,paternal history,C0424909
2,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
2,# pts,C1419129;C2698747
2,- onmbro ( - nmbr - loto - nmbr - nmbr ),C0483204
2,nmbr drinks / wk,C0452428
2,> nmbr drinks / week,C0452428
2,- o . os,C2673162
2,nmbr + drinks / wk,C0452428
2,- o - oonmbr ( - nmbr - nmbr to nmbr - nmbr ),C0483204
2,- nmbr - nmbr ( nmbr % cl - nmbr - nmbr to nmbr - nmbr ),C0596019
2,- nmbr - nmbr ( nmbr % cl - nmbr - nmbr to - nmbr - nmbr ),C0596019
2,- [the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C4684719
2,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
2,> nmbr drinks / wk,C0452428
2,- - - - - - - - - - - - week nmbr - - - - - - - - - - - - - - - - -,C0332174;C0439230
2,sri response,C0871261;C1420401;C1704632;C1706817;C2911692
2,interruption,C0332453;C1512900
2,"number ste "" t > nmbr",C0237753;C0449788;C1420459;C3811127
2,> nmbr . nmbr mmol / liter,C0439190;C0475211
2,structural heart disease §,C1290384
2,< nmbr . nmbr mmol / liter,C0439190;C0475211
2,< nmbr . nmbr pmol / liter,C0439192;C0475211
2,male patients,C0150904
2,female patients,C0150905
2,age ( years ) - < median ( n = nmbr,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
2,age ( years ) - > = median ( n = nmbr,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
2,lsm difference,C1705241;C1705242
2,p value ( int ),C1709380;C3272375
2,p - value ( int ),C1709380;C3272375
2,present smokerc,C0150312;C0449450
2,prior revascularization,C0332152;C0581603;C2826257
2,lower risk,C3272281;C3538919
2,pci revascularization,C0581603;C4049621
2,low risk,C3272281;C3538919
2,old stroke *,C1536121
2,subgroups,C1079230
2,subgroup,C1079230;C1515021
2,ldl - c : hdl - c,C3715113
2,ldl - c / hdl - c,C3715113
2,ldl - c / hdl - cx,C3715113
2,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
2,two agents,C0205448;C0450442;C1254351;C1521826
2,< nmbr years simva ( n = nmbr },C0439234
2,modified has - bled < nmbr,C0392747;C3889737
2,structural heart disease,C1290384
2,subcortical wml load diameter,C0815275;C1301886;C1550025;C1704782;C1708715
2,nmbr - nmbr yr ( % ),C0439234
2,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
2,nmbr - nmbr days ( % ),C0439228
2,difference ( % ),C1705241;C1705242
2,total cholesterol — mg / dl,C0201950;C0439269;C0543421
2,non - us ( n = nmbr ),C1518422
2,non - epa ( n = nmbr ),C1518422
2,demographic feature,C0683970
2,demographic features,C0683970
2,no of events womenmen *,C0441471;C3541888
2,nonfatal ml,C0439526;C1705224;C3887665
2,toial cholcsierol ( mg / dl ),C0439269
2,nontatal ml,C0439526;C1705224;C3887665
2,ischemic cardiomyopathy,C0349782
2,ischaemic cardiomyopathy,C0349782
2,hdl - c ( median,C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
2,ldl - c ( median,C0549183;C0876920;C2347635;C2348144;C2939193
2,no change,C0392747;C0443172;C1705241;C4319952
2,> nmbr ml / min,C0439445
2,£ nmbr ml / min,C0439445
2,no . pts,C1419129;C2698747
2,< nmbr ml / min,C0439445
2,age < nmbr years ( median ),C1510829
2,age > nmbr years ( median ),C1510829
2,without acei / arb,C3888198
2,smoking history ( pack - years ),C1277691;C1519384
2,with acei / arb,C3888198
2,% improvement in dactylitis score at week nmbr,C0239161;C0449820;C2986411;C4050231
2,p blockers ( % ),C0369773;C2603361
2,% improvement in enthesitis score at week nmbr,C0449820;C1282952;C2986411;C4050231
2,nmbr - < nmbr ml / min,C0439445
2,cigarette smoker,C0337667
2,hemoglobin ( g nmbr ! ),C1319312
2,( subgroup ),C1079230;C1515021
2,( sd ) l / min acq - nmbr score,C0702093;C1524029;C2699239;C2919686;C3813700
2,microalbuminuria — no . / total no . ( % ),C0730345
2,( ref ),C1425988
2,chd simva,C0280604;C3542407
2,( range ),C1514721;C2348147;C3542016
2,( points ),C1552961;C2347617;C3714763
2,( nyha grade iii or iv ),C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4283820;C4283821;C4283822
2,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
2,no chd simva,C0280604;C3542407
2,( n = lnmbr ),C0369718;C0441922
2,( n = nmbrlnmbr ),C0369718;C0441922
2,> nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
2,< nmbr . nmbr mu / l $ mmol / l,C0439190;C0439342
2,"( n = nmbr ) "" ' ( n = nmbr )",C0369718;C0441922
2,stage nmbra : > = nmbr and < nmbr,C0205390;C1300072;C1306673
2,stage nmbrb : > = nmbr and < nmbr,C0441781
2,< nmbr with no historical count > nmbr,C0750480;C1552658;C1552723;C1705566;C2004062
2,( n = nmbr ) ( n = nmbr ),C0369718;C0441922
2,( mu / l $ mmol / l ) b,C0439190;C0439342
2,( mmol / l ),C1532563
2,< nmbr with historical count > nmbr,C0750480;C1552658;C1552723;C1705566;C2004062
2,prior smoker,C0337671
2,nmbr - nmbr ml / min,C0439445
2,> nmbr to < nmbr ml / min,C0439445
2,mean ± s . d . fpg,C0444504;C2347634;C2348143
2,nmbr to < nmbr ml / min,C0439445
2,fbs > = nmbr mg / dl,C0439269;C3812213
2,* p < nmbr . nmbr for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0369773;C2603361
2,* p < nmbr . nmbr for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0369773;C2603361
2,* interquartile range,C1711350
2,* data reported as n ( % ) or median ( quartiles nmbr,C1511726;C3245479;C3714741
2,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by nmbr . nmbr . to convert triglycerides to micromoles per liter  multiply by nmbr . nmbr . to convert fpg to micromoles per liter  multiply by nmbr . nmbr . to convert fpi to picomoles per liter  multiply by nmbr . nmbr .,C1511726;C3245479;C3714741
2,* data are expressed as median ± sd,C1511726;C3245479;C3714741
2,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C1709380
2,* plus – minus values are means ± sd . percentages may not total nmbr because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter,C0042295;C0332288
2,anti - coagulants,C0848112
2,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
2,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0332288
2,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
2,all cana,C1418845
2,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0042295;C0332288
2,physician ' s global assessment,C4050369
2,* patient characterization data are reproduced from morrow et al . ( nmbr ) .,C1880022;C2707520
2,* nonfatal ml,C0439526;C1705224;C3887665
2,physician ' s global assessment !,C4050369
2,* data are expr,C1511726;C3245479;C3714741
2,( yes / no ),C1512698
2,previous or current im use : no,C0205156;C1552607
2,( years ),C0439234
2,previous or current cs use : no,C0205156;C1552607
2,( week ),C0332174;C0439230
2,( min ) *,C0702093;C1524029;C3813700
2,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
2,previous cancerc,C0205156;C1552607
2,( ≥ nmbr mg / l ),C0439268
2,( < nmbr ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
2,not hispanic or latino,C1518424
2,north american,C0425358;C2700615
2,south american,C0425359
2,( < nmbr mg / l ),C0439268
2,( < nmbr . nmbr mmol / l ),C1532563
2,preamendment,C1548596
2,( % of target ) ∗,C1521840;C2986546
2,( $ nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923
2,& median,C0549183;C0876920;C2347635;C2348144;C2939193
2,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
2,% / yr,C0439234
2,% / year,C0439234;C0439508
2,% reversibility,C0449261
2,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
2,age > nmbr yearsnmbr,C1510829
2,% reduction,C0301630;C0392756;C1293152;C4551656
2,age < nmbr yearsnmbr,C1510829
2,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
2,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
2,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
2,adp antagonist,C0231491;C0523452
2,% predicted post - bronchodilator fevnmbr,C0681842;C1882327
2,% predicted post - bronchodilator fev,C0681842;C1882327
2,% of predicted,C0681842;C1882327
2,ind / glyb n = nmbr,C1415124;C4049864
2,( nmbr subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
2,> nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,( nmbr - nmbr ml / min per nmbr . nmbr mnmbr ),C0369637;C0439445;C0441923
2,≥ nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,( mg / dl ),C0439269
2,< nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,( mg / dl ± sd ),C0439269;C2699239
2,> nmbr ml / min / nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,( median,C0549183;C0876920;C2347635;C2348144;C2939193
2,history of major microvascular disease,C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
2,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
2,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
2,( l ) t,C0439394;C1706495;C3642217
2,( iqr ) — days,C0439228
2,history of major macrovascular disease,C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
2,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
2,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
2,patient characteristics,C0815172
2,patients ' characteristics,C0815172
2,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
2,treatment with antiplatelet drugs,C3469597
2,( including hypertension ),C0332257
2,one - vessel disease,C3275121
2,two - vessel disease,C0581375
2,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
2,( b ) age subgroups,C0001779;C1304659
2,( a ) bmi subgroups,C0578022;C1079230
2,( nmbr . nmbr % )  values were not collected for nmbr patients ( nmbr . nmbr % ) who were enrolled,C0042295
2,> nmbr years simva ( „ = nmbr },C0439234
2,modified has - bled $ nmbr,C0392747;C3889737
2,bmi > nmbr kg / mnmbr,C0578022;C1532718
2,mayo score,C0449820;C0454788;C1077578;C4050231
2,total ( n = nmbr nmbr ),C0439175;C0439810
2,> median ( nmbr . nmbr years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,< median ( nmbr . nmbr years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
2,difference vs placebo * *,C1705241;C1705242
2,difference vs placebo ',C1705241;C1705242
2,difference vs . placebo,C1705241;C1705242
2,chronic kidney diseased,C2364010
2,estimated difference %,C0750572;C1705241;C1705242
2,> nmbr . nmbr ( n — nmbr ),C0369718;C0441922
2,estimated difference,C0750572;C1705241;C1705242
2,insulin use,C0240016
2,family history of diabetes ( % ) *,C1313937
2,family history of diabetes ( - ),C1313937
2,interruption ( n = nmbr ),C0332453;C1512900
2,family history of diabetes ( + ),C1313937
2,total population n,C3258257
2,total population,C3258257
2,duration ofdiabetes — yr,C0439234;C0449238;C2926735
2,loop or thiazide diuretic #,C0445022
2,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
2,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
2,loop or thiazide diuretic,C0445022
2,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
2,disease duration ( years ),C0439234;C0872146
2,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
2,bmi : > nmbr . nmbr kg / mnmbr,C0578022;C1532718
2,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
2,bmi : < nmbr . nmbr kg / mnmbr,C0578022;C1532718
2,$ nmbr exacerbations,C4086268
2,nmbr exacerbation,C4086268
2,< nmbr years simva,C0439234
2,> nmbr years simva,C0439234
2,hdlnmbr - c,C3715113
2,am △ 士 s . e .,C3813124;C3890196;C4520798
2,neuropathy,C0442874
2,no clinical or lesion rfs for st,C0205210
2,any clinical or lesion rf for st,C0205210
2,> nmbr exacerbations,C4086268
2,all n = nmbr nmbr,C0369718;C0441922
2,< nmbr months — number / n ( % ),C0237753;C0439231;C0449788
2,> nmbr months — number / n ( % ),C0237753;C0439231;C0449788
2,nmbr exacerbations,C4086268
2,mi < nmbr months *,C0439231;C3810814
2,mi > nmbr months *,C0439231;C3810814
2,ldl - c ( mmol / l,C1532563
2,hdl - c ( mmol / l,C1532563;C3715113
2,previous coronary revascularization,C0205156;C0877341;C1552607
2,previous coronary revascularisation,C0205156;C0877341;C1552607
2,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
2,< nmbr . nmbr ( n — nmbr ),C0369718;C0441922
2,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
2,alc > = nmbr . nmbr %,C1424945;C3811058
2,alc < nmbr . nmbr %,C1424945;C3811058
2,baseline characteristics,C4684572
2,symptomatic padt,C0231220
2,> nmbr years of age,C1510829
2,nmbr ( n = nmbr,C0369718;C0441922
2,nyha class — no . ( % ),C1882083
2,nyha class — no . ( % ) $,C1882083
2,sdai < nmbr . nmbr *,C3871128
2,cdai < nmbr . nmbr *,C0683448;C1413248;C3273706
2,pfo closure,C0185003;C1521802
2,laa closure,C0185003;C1521802
2,mean sd hdl - c,C0444504;C2347634;C2348143;C2699239;C3715113
2,mean sd ldl - c,C0444504;C2347634;C2348143;C2699239
2,nmbr - h ppg ( mmol / l ) *,C1418888;C2827804
2,nmbr - h ppg ( mmol / l ),C1418888;C2827804
2,acq - nmbr scoret,C2919686
2,npi - nmbr score *,C1412208;C1549728;C3539727
2,acq - nmbr score *,C2919686
2,history myocardial infarction,C0155668;C1275835
2,teaes ( > nmbr % in any treatment group ),C0374505
2,teaes ( > nmbr % in any treatment group ) *,C0374505
2,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
2,disease characteristics *,C0599878
2,history of hypertension *,C0455527
2,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
2,disease characteristics,C0599878
2,oral anticoagulants,C0354604
2,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
2,mssbp > nmbrmmhg,C0439475
2,mssbp < nmbrmmhg,C0439475
2,no ( n = nmbr,C0369718;C0441922
2,persistent,C0205322;C0332996
2,mild teaes,C2945599
2,persistent af,C0205322;C0332996;C0344434;C4049859
2,inferior,C0542339;C0678975
2,non - anterior,C0205094;C1518422
2,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
2,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
2,ast,C1415181;C3891303
2,not anterior,C0205094;C1518422
2,anterior,C0205094
2,hand fracture,C0435632
2,left - sided colitisz,C0205091;C0443246
2,q - wave mi,C0861151
2,q wave mi,C0861151
2,q wave,C0429089;C1305738
2,age ( median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
2,left sided colitis,C2887821
2,qrs < nmbr msec,C0439223
2,killip class > ii ( % ),C2697845
2,score of # nmbr,C0449820;C4050231
2,score of $ nmbr,C0449820;C4050231
2,left - sided colitis,C2887821
2,total body,C0229960
2,antagonist,C0231491
2,total no .,C0439175;C0439810
2,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
2,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
2,medication use,C0240320
2,< nmbr years of age,C1510829
2,supplemental oxygen,C4534306
2,bmi < nmbr kg / mnmbr,C0578022;C1532718
2,antiplatelet - onl group ( n = nmbr ),C0441848
2,hs - crp < nmbr . nmbr mg / l,C0439268;C3890735;C4048285
2,age in nmbr classes,C0001779;C0456387;C1518526;C1705943;C4019422
2,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
2,mean sd mssbp,C0444504;C2347634;C2348143;C2699239
2,mean ± sd msdbp,C0444504;C2347634;C2348143;C2699239
2,multi - vessel coronary artery disease,C1299432
2,nmbr - nmbr . nmbr : obese class i,C3853264
2,hs - crp < nmbr . nmbr g / l,C0439294;C0456615;C3890735;C4048285
2,creatine clearance,C0373595
2,nmbr - nmbr . nmbr : obese class ii,C3853263
2,qualifying event,C0441471;C1514624;C4019010
2,at qualifying event,C0441471;C1514624;C4019010
2,creatinine clearance ( ml / min ),C0439445;C0812399
2,age < nmbr years ( n = nmbr ),C1510829
2,age : < nmbr years ( n = nmbr ),C1510829
2,total cholesterolnmbr < nmbr mg / dl,C0201950;C0439269;C0543421
2,total cholesterolnmbr > nmbr mg / dl,C0201950;C0439269;C0543421
2,esam ( ng / ml ),C0439275;C1424976
2,no / unknown,C0439673;C3541433;C4050014
2,qualifying mi $ nmbr yrs prior,C1514624;C3810814
2,qualifying mi < nmbr yrs prior,C1514624;C3810814
2,anterior { % ),C0205094
2,inferior ( % ),C0542339;C0678975
2,≥ nmbr . nmbr % ( ≥ nmbr mmol / mol ),C3829066
2,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
2,naive : yes,C1549445;C1705108;C1710701
2,antiplatelet - only group ( n = nmbr ),C0205171;C0441848;C1720467
2,mean ± s . d . bmi,C0444504;C0578022;C2347634;C2348143
2,estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr ),C0369637;C0439445;C0441923;C3811844
2,ldl - c : hdl - c ratio,C0428621
2,bmi < nmbrkg / mnmbr,C0578022;C1532718
2,bmi > = nmbrkg / mnmbr,C0578022;C1532718
2,ldl - c / hdl - c ratio,C0428621
2,dpp - nmbr inhibitor,C1414174;C1999216
2,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
2,hazard ratio,C2985465
2,hazard ratiof,C0598697
2,( mean % change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,physical function,C0516981;C4049916
2,( mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
2,number of patients,C2360800
2,physical functioning,C0516981;C4049916
2,ldl - c ( mg / dl ),C0439269
2,hdl - c ( mg / dl ),C0439269;C3715113
2,characteristics,C1521970
2,nmbr . nmbr - nmbr . nmbr % t,C2603360
2,characteristic,C1521970
2,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,C0439275
2,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,C0439297
2,hscrp < nmbr . nmbr mg / l,C0439268
2,hscrp > nmbr . nmbr mg / l,C0439268
2,inferior / posterior,C0205095;C0542339;C0678975
2,hs - crp > nmbr . nmbr mg / l,C0439268;C3890735;C4048285
2,inferior or posterior,C0542339;C0678975
2,< nmbr . nmbr % ( nmbr mmol / mol ),C3829066
2,mean ( s . d . ) bmi,C0444504;C0578022;C2347634;C2348143
2,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
2,difference from placeboa,C1705241;C1705242
2,adjusted hr ( nmbr % cl ),C0456081;C0596019
2,range ( min,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
2,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
2,coronary revascularisation,C0877341
2,coronary revascularization,C0877341
2,patient ' s global assessment of,C4054229
2,patient ' s global assessment !,C4054229
2,patient ' s global assessment,C4054229
2,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
2,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
2,stage nmbr : > nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
2,stage nmbr : < nmbr ml / min / nmbr . nmbr mnmbr,C0439445;C0456533
2,rr ( cl ),C0596019;C4554402
2,median ( qnmbr,C0549183;C0876920;C2347635;C2348144;C2939193
2,mmol / l,C1532563
2,mmol / mol,C3829066
2,median ( qnmbr : qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193
2,bmi category ( % ),C0578022;C0683312;C3889287
2,( mmol / l],C1532563
2,chd eze / simva,C0280604;C3542407
2,no chd eze / simva,C0280604;C3542407
2,age category ( % ),C0001779;C0683312;C3889287
2,unadjusted p - value for interaction,C1439367;C1704675;C1709380
2,adjusted p - value for interaction,C0456081;C1704675;C1709380
2,copd exacerbation : no,C0740304
2,range : min,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
2,aqlq ( s ) + nmbr scored,C4055434
2,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
2,aqlq ( s ) + nmbr scorets,C4055434
2,duration of pci,C0449238;C2926735;C4049621
2,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
2,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2,non - hdl - c *,C1518422;C3715113
2,nmbr - < nmbr months,C0439231
2,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
2,received nmbr prior biologic therapies,C0278947;C1514756
2,received nmbr prior biologic therapy,C0278947;C1514756
2,left main,C0205091;C0205225;C0443246;C1542147;C1552822
2,rest pain,C0234253
2,< nmbr mg / dl eze / simva,C0439269
2,> nmbr mg / dl eze / simva,C0439269
2,nmbr ( n nmbr nmbr ),C0369718;C0441922
2,no st depression or elevation,C0520887
2,st depression or elevation,C0520887
2,> o - nmbr - ii,C0483204;C1710602;C4082587
2,coronaiy artery disease,C0852949
2,history of atrial fibrillation or fl utter,C0729790
2,stratum ii,C1710602;C4082587
2,< qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
2,> nmbr u / kg / day,C1532634
2,≤ nmbr u / kg / day,C1532634
2,ecg findings,C0438154
2,> qnmbr ( nmbr ) — number / n ( % ),C0237753;C0449788
2,hazard ratio ( nmbr % confi dence interval ),C1272706;C1552654;C1552713;C2985465
2,fbs < nmbr mg / dl,C0439269;C3812213
2,indian ( american ) or alaskan native,C0596070;C1524069
2,prior myocardial infarction — no . ( % ),C0155668
2,* rate is number of events per nmbr patient - years of follow - up . fthe p value for number of patients from log - rank,C0871208;C1521828
2,£ nmbr m b ' m in,C1709500
2,bare - metal stent,C2825200
2,other ( n = nmbr ),C0369718;C0441922
2,other ( n — nmbr ),C0369718;C0441922
2,p — value for interaction,C1704675;C1709380
2,p - value for interaction *,C1704675;C1709380
2,p value for interactiont,C1709380
2,p value for interaction,C1704675;C1709380
2,£ nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
2,p - value for interaction,C1704675;C1709380
2,£ l nmbr kg,C1637390
2,赛 nmbr years,C0439234
2,p value for interaction^,C1704675;C1709380
2,< nmbr cells / ul nmbr nmbr,C0439378
2,= international prostate symptom score ,C1998280
2,< median { nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2,< median ( nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2,< median ( nmbr year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
2,stent thrombosis *,C3897493
2,< mean,C0444504;C2347634;C2348143
2,< nmbr ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
2,< nmbr mg / dl eze / simva ( n = nmbr ),C0439269
2,< nmbr . nmbr % ( < nmbr mmol / mol ),C3829066
2,< nmbr yrs of age ( n = nmbr,C0001779
2,< nmbr yr ( n = nmbr ),C0439234
2,crp < nmbr mg / l,C0439268;C3890735;C4048285
2,< nmbr mg / dl simva ( n = nmbr ),C0439269
2,crp $ nmbr mg / l,C0439268;C3890735;C4048285
2,stent thrombosis,C3897493
2,> nmbr kg / mnmbr ( n — nmbr ),C1532718
2,p value fo interactio,C1709380
2,≥ nmbr ml / min,C0439445
2,chd status §,C0280604;C0449438;C3542407
2,chd status,C0280604;C0449438;C3542407
2,> nmbr cells / ul,C0439378
2,> nmbr to   ≤   nmbr years vs .   ≤   nmbr years,C0439234
2,bmi ( kg / mnmbr ) *,C0578022;C1532718
2,£ nmbr min,C0702093;C1524029;C3813700
2,< nmbr mg / dl simva,C0439269
2,not hispanic or latino ( n — nmbr ),C1518424
2,> nmbr mg / dl simva ( „ = nmbr ),C0439269
2,> nmbr mg / dl eze / simva ( „ = nmbr ),C0439269
2,not hispanic or latino ( n = nmbr ),C1518424
2,> nmbr years vs .   ≤   nmbr years,C0439234
2,= sia,C1225105;C1551538
2,£ nmbr . nmbr min,C0702093;C1524029;C3813700
2,< nmbr kg / mnmbr ( n — nmbr ),C1532718
2,≥ nmbra ( n = nmbr ),C0369718;C0441922
2,≤ nmbr mg / l,C0439268
2,£ nmbr . nmbr mmol / l,C1532563
2,≤ nmbr years,C0439234
2,< nmbr mm hg — no . ( % ),C0439475
2,no aminosalicylates,C0368663
2,≥ nmbr sae,C1519255;C1622657;C4553214
2,≥ nmbr ae,C3887670
2,£ nmbr mg / dl,C0439269
2,≥   nmbr   mmol / mol ( nmbr . nmbr % ),C3829066
2,≤   nmbr   mmol / mol ( nmbr . nmbr % ),C3829066
2,£ nmbr yr,C0439234
2,aminosalicylates * *,C0368663
2,< nmbr yr — no . { % ),C0439234
2,< nmbr mgday p . eq .,C0205163;C0439185
2,^numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^hypertension was defined as a self - reported systolic blood pressure > nmbr mm hg,C0237753;C0449788
2,< nmbr kg / mnmbr ( n = nmbr ),C1532718
2,< median nmbr . nmbr,C0549183;C0876920;C2347635;C2348144;C2939193
2,disease duration b nmbr years ( n = nmbr ),C0439234;C0872146
2,no history of cancer,C0455471
2,< = nmbr yr,C0439234
2,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
2,< nmbr kg / m^,C1532718
2,< = nmbr year,C0439234;C0439508
2,< nmbr . nmbr ld,C0694649
2,< nmbr mg / l ( n = nmbr ),C0439268
2,< nmbr crcl,C1846718
2,non - st — elevation mi,C0520886;C1518422;C3810814
2,non - st - elevation mi,C0520886;C1518422;C3810814
2,< nmbr ppb,C1415800
2,< nmbr mg / day,C0439422
2,disease duration > nmbr years ( n = nmbr ),C0439234;C0872146
2,bmi ( kg / m ),C0578022;C1532718
2,< nmbr . nmbr ng / ml ( n = nmbr ),C0439275
2,< nmbr . nmbr ng / l ( n = nmbr ) n ( % ),C0439297
2,< nmbr mg / d peq,C0439422
2,< nmbryear,C0439234;C0439508
2,inferior ( n,C0542339;C0678975
2,< nmbr . nmbr ng / l ( n = nmbr ),C0439297
2,anterior ( n,C0205094
2,< nmbr ml / s,C0439390
2,< nmbr / nmbr mm hg,C0439475
2,< nmbr mg / dl *,C0439269
2,< nmbr / nmbr mmhg,C0439475
2,< nmbr . nmbr mm hg,C0439475
2,< nmbr . nmbr min,C0702093;C1524029;C3813700
2,history of cancer,C0455471
2,< nmbr ml / min / nmbr . nmbr m^ — no . { % ),C0369637;C0439445;C0441923
2,< nmbr ml / min — %,C0439445
2,< nmbr month n = nmbr,C0332177;C0439231
2,< nmbr ml / min / nmbr . nmbr m^,C0369637;C0439445;C0441923
2,< nmbr l / min,C0439393
2,drinker ( % ) a,C0556338
2,drinker ( % ),C0556338
2,< nmbr ml / min per nmbr . nmbr mnmbr,C0369637;C0439445;C0441923
2,"< nmbr ml min ’ nmbr nmbr . nmbr m "" nmbr",C0369637;C0439445;C0441923
2,< nmbr mi / min,C0702093;C1524029;C3810814;C3813700
2,age < nmbr years old,C1510829
2,< nmbr weeks,C0439230
2,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
2,< nmbr mg / l,C0439268
2,< nmbr ml / min ( n = nmbr ),C0439445
2,maximum cimt a med an,C0806909;C1552615;C2826546
2,< nmbr years simva ( n = nmbr ),C0439234
2,< nmbr years ( % ),C0439234
2,< nmbr ml / min / nmbr,C0439445
2,crcl < nmbr ml / min,C0439445;C1846718
2,< nmbr mg / dl ( < nmbr . nmbr mmol / l ),C0439269;C1532563
2,< nmbr . nmbr mu / l - mmol / l,C0439190;C0439342
2,< nmbr meters,C0441074
2,< nmbr % predicted,C0681842;C1882327
2,< nmbr ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
2,crcl > nmbr ml / min,C0439445;C1846718
2,< nmbr years eze / simva ( n = nmbr ),C0439234
2,age > = nmbr years old,C1510829
2,< nmbr mg dl ( reference ),C0439269;C1514811;C1706462
2,ecrcl < nmbr ml / min,C0439445
2,| : s blocker,C0565930;C2603362
2,≤ nmbr   year,C0439234;C0439508
2,lipid - lowering therapy - no . ( % ),C0585943
2,> = medion ( nmbr days ),C0439228
2,/ \ge category,C0683312;C1292300;C3538705;C3889287
2,/ ’ interaction,C1704675
2,non - st - segment elevation mi,C0520886;C1518422;C3810814
2,postmenopausal and no ht,C0232970
2,rate ratio ( nmbr % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
2,extensive colitisy,C0205231
2,nmbr - nmbr months,C0439231
2,nmbr - nmbr / month,C0332177;C0439231
2,/ pl nmbr nmbr,C3897966;C4049765
2,: mi,C3810814
2,[nmbr . nmbr mmol / l] ),C1532563
2,[kg / m^],C1532718
2,nmbr - nmbr ( n = nmbr ),C0369718;C0441922
2,> = median ( nmbr days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2,. nmbr step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463
2,> = medan ( nmbr year - old ),C0439234;C0439508;C0580836
2,lipid - lowering therapy — no . ( % ),C0585943
2,> nmbrrd quartile,C0694666;C2828255;C4553350
2,duration of disease — yr,C0439234;C0872146
2,score 一 no . ( % ),C0449820;C4050231
2,[min,C0702093;C1524029;C3813700
2,adas — cog score,C0449820;C3539026;C4050231
2,[no / yes] ( % ),C1549445;C1705108;C1710701
2,> = nmbr ml / min / nmbr . nmbrmnmbr,C0369637;C0439445;C0441923
2,> = nmbr . nmbr % ( > = nmbr mmol / mol ),C3829066
2,[sd],C2699239
2,> = nmbr years and < nmbr years,C0439234
2,> = nmbr meters,C0441074
2,primary outcome,C0205225;C0439612;C0439631;C1274040
2,primary outcome !,C0205225;C0439612;C0439631;C1274040
2,> = nmbr ng / l ( n = nmbr ),C0439297
2,atrial flutter / fibrillation,C0155709
2,> nmbr ng / l,C0439297
2,mayo $ nmbr,C0454788;C1077578
2,womac score,C0449820;C4050231
2,> nmbr   years,C0439234
2,> nmbr years to < nmbr years,C0439234
2,total score,C2964552
2,lacunar,C0241970;C1459585
2,> nmbr / nmbr lung fields,C0225759
2,> nmbr . nmbr ng / ml ( n = nmbr ),C0439275
2,mean dlqi score ( nmbr % ci ),C0444504;C2347634;C2348143;C3899393
2,arial flutter or fibrillation,C0016385;C2242390
2,> nmbr year,C0439234;C0439508
2,mayo < nmbr,C0454788;C1077578
2,current smoker ( n z nmbr ),C3173209;C3241966
2,> nmbr aes,C1412268;C2699274
2,current smoker ( n = nmbr ),C3173209;C3241966
2,omega - nmbr fa intake nmbrnd third,C0205437;C1512806;C1719844
2,> nmbr to nmbr   years,C0439234
2,> nmbr to < = nmbr years,C0439234
2,omega - nmbr fa intake nmbr,C1512806;C1719844
2,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by nmbr . nmbr  to convert values for triglycerides to millimoles per liter  multiply by nmbr . nmbr . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » nmbr . nmbr ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C1079230
2,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
2,> nmbr serious aes,C0205404;C1412268;C2699274
2,> nmbr exacerbation in prev nmbr m ( n = nmbr ),C0369637;C0441923;C1552852;C4086268
2,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239
2,> nmbr aes leading to discontinuation,C1412268;C2699274
2,primary outcomes,C0205225;C0439612;C0439631;C1274040
2,postmenopausal and no hrt,C0232970
2,> = nmbr mg / g,C1300563
2,< nmbr / nmbr mm hg +,C0439475
2,> nmbr mg / dl simva,C0439269
2,age ( years ) : < nmbr,C1510829
2,> nmbr month n = nmbr,C0332177;C0439231
2,> nmbr years ( % ),C0439234
2,^nmbr ml / min,C0439445
2,> = nmbr ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
2,^nmbr months,C0439231
2,> = nmbr l_ / min,C0439393
2,> = nmbr l / min,C0439393
2,anmbr + enmbr ( n = nmbr ),C1272460
2,> = nmbr ng / l ( n = nmbr ) n ( % ),C0439297
2,> = nmbr kg / mnmbr,C1532718
2,>   nmbr – <   nmbr   mmol / mol ( nmbr . nmbr – nmbr . nmbr % ),C3829066
2,> = nmbr . nmbr to < nmbr ng / l ( n = nmbr ) n ( % ),C0439297
2,upper limb fracture,C0178316
2,> nmbr years eze / simva ( n = nmbr ),C0439234
2,> nmbr years old,C0439234
2,> median nmbr . nmbr,C0549183;C0876920;C2347635;C2348144;C2939193
2,> nmbr ml min ) nmbr,C0439445
2,> nmbr years bmi,C0439234;C0578022
2,^nmbr mm hg,C0439475
2,^nmbr mg / g,C1300563
2,eastern european,C0239309
2,> nmbr years simva ( n = nmbr ),C0439234
2,adas - cog score *,C0449820;C3539026;C4050231
2,^nmbr days,C0439228
2,age ( years ) : > nmbr,C1510829
2,anmbr / nmbr ( n = nmbr ),C0369718;C0441922
2,> = nmbr to < nmbr ng / l ( n = nmbr ) n ( % ),C0439297
2,> = nmbr days,C0439228
2,general health,C0424575;C4018875
1,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
1,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
1,hypertension ( > nmbr / nmbr mm hg or taking,C0020538;C0439475;C1963138
1,no hypertension ( n = nmbr ),C0020538;C1963138
1,hypertension 一 no . ( % ),C0020538;C1963138
1,arterial hypertension,C0020538
1,hypertension n ( % ),C0020538;C1963138
1,hypertension requiring medical treatment,C0020538;C1963138
1,hypertension absent,C0020538;C1963138
1,hypertension severity,C0020538;C0439793;C0522510;C1963138
1,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
1,hypertension^,C0020538;C1963138
1,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
1,high blood pressure,C0020538;C2926615
1,arterial hypertension — no . ( % ),C0020538
1,elevated blood pressure,C0020538;C0497247
1,htn,C0020538
1,hypertension — no . ( % ),C0020538;C1963138
1,prior hypertension,C0020538;C0332152;C1963138;C2826257
1,previous hypertension,C0020538;C0205156;C1552607;C1963138
1,no resistant htn n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
1,systemic arterial hypertension,C0020538
1,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
1,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
1,isoiated systoiic hypertension *,C0020538;C1963138
1,hypertension and left ventricular hypertrophy,C0020538;C1963138
1,arterial hypertension *,C0020538
1,systemic hypertension,C0020538
1,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
1,hypertension !,C0020538;C1963138
1,hypertension §,C0020538;C1963138
1,hypertension — no . ( % ) |,C0020538;C1963138
1,treated hypertension :,C0020538;C1522326;C1963138
1,no htn,C0020538
1,hyper - tension,C0020538;C1963138
1,htn hx,C0020538;C0262926;C3814444
1,hypertension — no . / total no . ( % ),C0020538;C1963138
1,> nmbr . nmbr kg / mnmbr hypertension :,C0020538;C1532718;C1963138
1,duration of hypertension,C0020538;C0449238;C1963138;C2926735
1,hypertension : no ( n = nmbr ),C0020538;C1963138
1,hypertension ( n 二 nmbr ),C0020538;C1963138
1,treated for hypertension,C0020538;C1522326;C1963138
1,hypertension ( % ) : t,C0020538;C1963138
1,hypertension,C0020538;C1963138
1,no prior htn ( n = nmbr,C0020538;C0332152;C2826257
1,hypertension ( % ),C0020538;C1963138
1,no hypertension,C0020538;C1963138
1,hypertensionnmbr ( % ),C0020538;C1963138
1,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
1,resistant htn : spiro n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
1,resistant htn n = nmbr,C0020538;C0332325;C1514892;C1550464;C2827757
1,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
1,previous htn,C0020538;C0205156;C1552607
1,hypertension *,C0020538;C1963138
1,prior htn ( n = nmbr,C0020538;C0332152;C2826257
1,hypertension 本,C0020538;C1963138
0,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
0,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
0,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
0,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
0,heart failure *,C0018801;C0018802;C4554158
0,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
0,heart failure nmbr month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
0,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
0,heart failure,C0018801;C0018802;C4554158
0,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
0,heart failure or lvef < nmbr % associated with index acs event,C0018801;C0018802;C4554158
0,combined cardiac failure,C0018801;C0018802;C0205195
0,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
0,cardiac failure —,C0018801;C0018802
0,heart failure ‡,C0018801;C0018802;C4554158
0,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
0,prior heart failure ( n = nmbr,C0018801;C0018802;C0332152;C2826257;C4554158
0,heart failure at entry,C0018801;C0018802;C1705654;C4554158
0,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
0,heart failure nmbr yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
0,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C4554158
0,heart failure ( nyha ii ‐ iii ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
0,heart failure — no . / total no . ( % ),C0018801;C0018802;C4554158
0,cardiac failure *,C0018801;C0018802
0,cardiac failure §,C0018801;C0018802
0,no prior heart failure ( n = nmbr,C0018801;C0018802;C0332152;C2826257;C4554158
0,histor y of heart failure,C0018801;C0018802;C4554158
0,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
0,cardiac failure,C0018801;C0018802
0,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
0,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
0,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
0,heart failure — no . ( % ),C0018801;C0018802;C4554158
0,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
0,participants without heart failure,C0018801;C0018802;C0679646;C4554158
0,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
0,no heart failure,C0018801;C0018802;C4554158
0,participants with heart failure,C0018801;C0018802;C0679646;C4554158
0,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
0,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
0,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
-1,tiotropium + olodaterol nmbr / nmbr,C4032878
-1,tiotropium nmbr meg ( n = nmbr ),C0024489;C0025175;C0072225;C0213771
-1,classification of af,C0008902;C0008903;C0344434;C0678229;C4049859
-1,rasagiline,C0525678
-1,haemodynamics and lv function,C0019010;C4281788
-1,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
-1,salmeterol nmbr gg bid,C0017454;C0018370;C0073992
-1,hypokalemia ‡   ( potassium < nmbr . nmbr mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
-1,serum pnmbrnp ( ^g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
-1,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
-1,comorbidities other than diabetes,C0009488;C0011847;C0011849
-1,minor surgery,C0038904
-1,sss score,C0037052;C0723181
-1,ff / vi nmbr / nmbr pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
-1,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,eqnmbrda health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
-1,demographic factors,C0011292;C0011298
-1,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
-1,draining cutaneous fistula at baseline,C0013103;C0180499;C4265177
-1,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
-1,tiotropium salmeterol no . of patients / total no .,C0073992;C0213771
-1,digitalis,C0012252;C0304520
-1,cerebral ischemia,C0007785;C0917798
-1,glatiramer acetate,C0289884
-1,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
-1,glimepiride,C0061323
-1,eda,C0162359;C1539327;C3539920;C3887494
-1,tnf antagonist - failure population ( n - nmbr ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
-1,absolute risk difference ( ci ),C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
-1,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
-1,proctosigmoiditis,C0033252
-1,edoxaban at randomization,C0034656;C2975435
-1,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
-1,centrilobular emphysema,C0221227
-1,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0040223;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
-1,edoxaban warfarin,C0043031;C2975435
-1,left ventricular ef,C0225897
-1,bronchitis,C0006277
-1,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
-1,tk,C0041405;C0220928;C4050092
-1,synovitis,C0039103
-1,metabolic syndromenmbr baseline lipids,C0023779;C0168634;C0524620;C1442488
-1,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
-1,sinusitis,C0037199;C4553555
-1,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
-1,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
-1,glycaemic control ( hbanmbrc ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
-1,lipoprotein ( a ) tx difference vs pbo,C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
-1,carotid artery disease,C0007273
-1,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
-1,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
-1,eplerenone ( n   = nmbr ),C0961485
-1,dental procedure,C0011331
-1,carvedilol,C0054836
-1,aspirin use ( > nmbr mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
-1,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
-1,carrier ( n = nmbr ),C0007294;C0560175;C1325398;C1706209;C3273162
-1,carotid endarterectomy,C0014099
-1,carotid bulb sites,C0007281;C0205145
-1,carisbamate nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
-1,cataract,C0086543;C4555209
-1,carisbamate nmbr,C1871983
-1,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
-1,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : nmbr x ( nmbr — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0017480;C0042027;C0168634;C0301630;C0392756;C0456603;C1293152;C1442488;C1522544;C1524119;C1547037;C1704695;C2986759;C3854019;C4551656
-1,caribbean,C0043122;C0206155;C1331005
-1,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
-1,gmr,C1522544;C1704695
-1,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
-1,magnetic resonance angiography,C0243032
-1,id genotype,C0009450;C0017431;C0600091;C1441613
-1,cardiac rhythm disorders,C0264886
-1,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
-1,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
-1,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
-1,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
-1,education level,C0013621;C0013658
-1,cgfrby ckd - epi,C0162734;C1561643;C4281721
-1,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0040223;C0205435;C0220880;C0441471;C1279901;C3541383;C4019010
-1,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
-1,glycaemic control group,C0005802;C0009932
-1,time to first cv hospitalization or death from any cause,C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
-1,cc,C0008318;C3538933
-1,time to angiography — hr,C0002978;C0040223;C3541383
-1,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C1301931;C1524003;C3541383
-1,ezetimibe use,C0042153;C0457083;C1142985;C1947944
-1,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
-1,catecholamines or corticosteroids without hospitalization,C0007412
-1,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
-1,nontraumatic leg or foot amputation,C0023216;C1140621
-1,nilvadipine,C0132512
-1,glycemic indexes,C1136206
-1,immunomodulatory agents,C0005525
-1,endothelin - receptor antagonists,C1134681;C2266875
-1,alcohol use ( > nmbr drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
-1,nordic countries,C0036273
-1,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
-1,women ethnic origin,C0015031;C0043210
-1,erectile dysfunction,C0242350;C1961100
-1,mras,C1335594;C1367476
-1,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
-1,baseline nmbr - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
-1,fevnmbr reversibilityz ( pre / post ipratropium ),C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
-1,east asia,C0015631
-1,dmard - ir,C0022065;C0022071;C0242708;C1448132
-1,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
-1,dmab ( n = nmbr ),C0012411
-1,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0202177;C0441889;C1719844
-1,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
-1,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
-1,general anaesthesia,C0002915;C2930406
-1,wrist,C0043262;C1322271
-1,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
-1,dates of recruitment,C0011008;C2348077;C2949735
-1,erysipelas,C0014733
-1,genetic subgroup,C0017296;C0314603;C1079230;C1515021
-1,triglycerides nmbrst third,C0036056;C0041004;C0205437;C3272372
-1,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
-1,thienopyridine use,C0042153;C0457083;C1120149;C1947944
-1,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
-1,emotional status,C0013987;C0449438;C0849912
-1,microvascular eye diseased,C0015392;C0443258;C0700042
-1,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
-1,genotype - specific treatment effect hazard ratio ( nmbr % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
-1,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
-1,xanthine,C0043314;C0043318
-1,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
-1,patent foramen ovale,C0016522;C0344724
-1,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
-1,first - generation stentt,C0079411;C0205435;C1279901;C3146294
-1,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
-1,length of stay ( randomization to discharge,C0023303;C0034656
-1,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
-1,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
-1,dmard at baseline,C0168634;C0242708;C1442488
-1,vascular disease indicator no ( n = nmbr ),C0021212;C0042373;C1235732;C1522602
-1,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
-1,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
-1,naproxen,C0027396
-1,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
-1,val / hctz ( n = nmbr ),C0020261;C0042285;C0523975
-1,microvascular complications,C0009566;C0443258;C1171258
-1,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
-1,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
-1,event / patients in group ( incidence / nmbr person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
-1,odds ratio adj ( nmbr % cl ),C0001552;C0028873;C0596019;C2826286
-1,glp - nmbr receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
-1,gene,C0017337
-1,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
-1,digital clubbing,C0009080;C0149651
-1,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
-1,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
-1,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
-1,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
-1,supplementary oxygen,C0030054
-1,ertugliflozin,C4079805
-1,chadsnmbr risk factors,C0007928;C0035648;C1413373;C1553898
-1,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
-1,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
-1,glycemic drugs,C0005802;C0013227;C3687832
-1,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
-1,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
-1,dbp nmbr . nmbr ( nmbr . nmbr ) baseline lipid profile,C0023779;C0168634;C0536221;C1442488;C1979963;C2003903;C3813197;C4281799
-1,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
-1,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
-1,baseline uric acid,C0041980;C0168634;C1442488
-1,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
-1,history of microvascular eye disease 本,C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
-1,de nmbr mg bid ( n - nmbr,C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
-1,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
-1,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
-1,persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
-1,apolipoprotein b tx difference vs pbo,C0003593;C0041403;C1705241;C1705242
-1,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
-1,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
-1,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
-1,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
-1,modified acc or aha lesion class bnmbr or c,C0175754;C0282160;C0392747;C3541413;C3889737
-1,mra regimen ( n - nmbr ),C0040808;C0243032;C1609165;C2945654;C3891069
-1,famotidine nmbr mg ( n = nmbr ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
-1,family history ot chd,C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
-1,mental health,C0025353
-1,accp bleeding risk at inclusion,C0007637;C1512693;C3251812
-1,bursitis,C0006444
-1,total back pain score ( nmbr – nmbr   mm scale ),C0004604;C0175659;C0349674;C1947916;C1963071;C2964552;C4330985;C4553945;C4554674
-1,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
-1,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
-1,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
-1,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
-1,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
-1,ecg atrial fibrillation,C0004238;C0344434;C1623258;C1963067
-1,orthostatic hypotension,C0020651
-1,onset of chest pain,C0024902;C0206132;C0332162
-1,non - transient risk factors for recurrent vte,C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
-1,eczema,C0013595;C4553957
-1,enalapril + aliskiren dm = nmbr non - dm = nmbr,C0011816;C0014025;C1120110;C3250443
-1,bb after randomisation,C0004739;C0034656;C0332297
-1,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
-1,modified acc / aha lesion class bnmbr / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
-1,mouth ulceration,C0149745
-1,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
-1,time from sx onset to baseline ecg,C0449244;C1519428;C3539997;C3815196
-1,detemir / insulin glargine,C0537270;C0907402
-1,avm % △ ( se ),C0003857;C0036919;C0279476
-1,montelukast ( n = nmbr ),C0298130
-1,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
-1,bundle branch block,C0006384;C1879286
-1,tass ’,C0559483
-1,budesonide mmx nmbr mg,C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
-1,perfusion defectsatinclusion,C0031001;C4281794
-1,diuretic use,C0012798;C0042153;C0457083;C1947944
-1,europa ( n = nmbrlnmbr ),C0242751
-1,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
-1,lung function,C0035245
-1,phenytoin,C0031507;C0202454
-1,measures of lung function,C0035245;C0079809;C1879489
-1,indacaterol nmbr pg,C0030827;C0072225;C1266240;C1722260
-1,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
-1,haplotype,C0018591
-1,bud nmbr ptg n = nmbr,C0039512;C1418830;C2700462;C2945744
-1,with dm ( n proactive intervention ( n = nmbra ),C0011816;C0184661;C0886296;C1273869;C3250443
-1,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
-1,ulcers / gangrene,C0017086;C0041582
-1,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
-1,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per nmbr patient - years of follow - up  rrr  relative risk reduction  yr  year . ^treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < nmbr or > nmbrg i - nmbr ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year nmbr as covariates .,C0009667;C0019046;C0022661;C0168634;C0441471;C0596019;C0871208;C1442488;C1521828;C3541888
-1,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per nmbr patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0026538;C0035078;C0168634;C0205088;C0441471;C0699829;C1442488;C2316810;C2985465;C3541888
-1,russia / ukraine / belarus,C0006539;C0035970;C0041580
-1,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
-1,diet diet + pravastatin event / patients ( nmbrooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
-1,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
-1,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
-1,indacaterol nmbr gg qd,C0017454;C0018370;C0332173;C1722260
-1,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
-1,notable abnormalities,C0000768;C0000769;C4288581
-1,electrocardiograph results,C0013798;C0180600;C1623258
-1,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
-1,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
-1,alaska native,C0682125
-1,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ nmbr mg / dl [ > nmbr . nmbr mmol / l] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < nmbr . nmbr  § p = nmbr . nmbr  * p = nmbr . nmbr . nteractions were not statistically significant ( p > nmbr . nmbr ) .,C0005507;C0006560;C0243073;C1413716;C1441604;C1510438;C4048285
-1,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
-1,h dl cholesterol < nmbr mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
-1,h pylori serology *,C0036745;C0079488;C0220911;C0455278
-1,diet - i - pravastatin ( n = nmbr ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
-1,h . pylori status,C0079488;C0449438
-1,diary variables,C0376660;C0439828
-1,no regular consumption,C0009830;C0205272;C1947907
-1,amlodipine / wlsartan inmbr / nmbr mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
-1,mepolizumab,C0969324
-1,post - fibrinolysis angioplasty ( n = nmbr ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
-1,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
-1,hydralazine,C0020223
-1,tcz - sc nmbr mg every other week ( n = nmbr ),C0024671;C0026410;C0282380;C0439269;C1960952;C2346927;C4321396;C4521761
-1,medal,C0524670
-1,brv overall ( n = nmbr ),C0155502;C0282416;C1561607
-1,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
-1,fluvastatin ( n = nmbr ),C0082608
-1,subarachnoid hemorrhage,C0038525
-1,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
-1,heart failure ( hf ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
-1,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
-1,haq score ( nmbr – nmbr scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
-1,laser or vitrectomy,C0023089;C0458142;C1023865;C1706315
-1,hard mace,C0018599;C0349381;C0949745;C1445339
-1,safety population,C0032659;C0036043;C1257890;C1705187
-1,bp - lowering treatment ( n = nmbr ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
-1,with lowest hbanmbrcd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
-1,bosentan use :,C0042153;C0252643;C0457083;C1947944
-1,famotidine nmbr - famotidine nmbr,C0015620
-1,tadalafil,C1176316
-1,systolic blood pressurea,C0005767;C0005768;C0039155;C0229664
-1,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
-1,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
-1,enoxaparin nmbr mg ( n = nmbr,C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
-1,coumadin,C0699129
-1,ptca < nmbr h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
-1,bone mineral density ( g / cmnmbr ),C0005938;C0177804;C0439267
-1,ezetimibe nmbr mg + statin ( n = nmbr,C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
-1,central america and south america,C0007674
-1,north america / oceania,C0028405;C0282279;C4085681
-1,bp - lowering treatments,C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
-1,entacapone,C0165921
-1,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
-1,abdominal or perianal fistula at baseline,C0000726
-1,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
-1,clopidogrel / ticlopidine,C0040207;C0070166
-1,elms,C0330531;C2980688
-1,cardiac mediations,C0018787;C0680727;C1522601
-1,diff_measure ( dm added this as table had multiple headings ),C0011816;C0079809;C0242485;C3250443
-1,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
-1,with highest bwa,C0006041;C1522410
-1,within nmbr h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
-1,bph - related health status,C0005001;C1704272
-1,geographic region - europe,C0015176;C0017446
-1,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
-1,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0332152;C0392747;C2826257;C3687832
-1,diastolic blood pressurea,C0005767;C0005768;C0012000;C0229664
-1,with highest hbanmbrcc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
-1,ipah / hpah,C0152171;C0340543;C0637939;C1150929
-1,end - stage renal disease,C0022661;C2316810
-1,bpearson ' s chi ‐ square test .,C0008041
-1, pre - specified analysis and adjusted for time - varying bp,C0005823;C0008107;C0009667;C0022661;C2985465;C3259781
-1,exact - pro total score,C0033382;C0523852;C2828393;C2964552;C2987124;C4050514
-1,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
-1,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : nmbr en : nmbr x cr nmbr . nmbr x age nmbr . nmbr x nmbr . nmbr )  hdl = high - density lipoprotein .,C0005823;C1739039;C3811844;C3812682
-1,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023823;C0039411;C0040642;C0041004;C0041405;C0041698;C1824670;C2744579;C2983605;C3272447;C3890735;C4048285;C4522122;C4552600
-1,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
-1,anti - inflammatory drugs,C0003209
-1,chf on losartan ( % ),C0018802;C0126174
-1,canrenone ( n z nmbr ),C0006882
-1,jejunum,C0022378
-1,gfr ( ml / min per nmbr . nmbr nr ),C0017654;C0027496;C0439445;C1424601;C3844738
-1,weight group,C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
-1,hbanmbrc distribution,C0019016;C0520511;C1704711;C1825777;C3538758
-1,dha intake on food frequency questionnaire,C0034394;C0142831;C1286336;C1512806;C2348308;C2986698
-1,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
-1,vldl cholesterol,C0023826;C0523560
-1,corticosteroid - azathioprine / nmbr - mercaptopurine,C0000618;C0001617;C0004482;C3536709
-1,golimumab nmbr mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
-1,cardiac arrhythmia,C0003811;C0264886;C1560249
-1,ticagrelor nmbr mg diabetes n = nmbr,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
-1,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
-1,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
-1,thyroid hormone,C0040135;C4522017
-1,thyroid disease,C0040128
-1,diagnosed diabetes ( n = nmbr ),C0011847;C0011849;C0011900
-1,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
-1,canakinumab nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
-1,thromboembolism,C0040038
-1,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
-1,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
-1,canagliflozin nmbr mg vs sitagliptin nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2974540;C4321396;C4521761
-1,epilepsy drug,C0013227;C0014544;C1254351
-1,epilepsy with grand mal seizures on awakening,C0014549;C0494475
-1,n ( % ) patients with risk faetors for cv disease aged > nmbr,C0030705;C0035647;C0369718;C0441922;C4552904
-1,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
-1,metabolizer phenotype ( % ) §,C0031437;C1285572
-1,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
-1,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
-1,epistaxis,C0014591;C4554627
-1,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
-1,dermatitis atopic,C0011603
-1,time from ra diagnosis,C0011900;C0040223;C1704338;C1704656;C3538806;C3541383;C4048756
-1,cardiovascular mortality ( per nmbr person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
-1,des implantation for restenosis,C0011702;C0021107;C0029976;C0333186;C4551552
-1,time from psoriatic arthritis diagnosis [a],C0003872;C0011900;C0040223;C1704338;C1704656;C3541383
-1,time from parkinson ’ s disease diagnosis in months,C0011900;C0030567;C0040223;C1704338;C1704656;C3541383
-1,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
-1,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
-1,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
-1,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
-1,minority,C0026192
-1,distribution of metformin dose at randomization,C0025598;C0178602;C0520511;C0869039;C1114758;C1704711
-1,time from hospitalization to randomization — hr,C0019993;C0040223;C3541383
-1,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
-1,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
-1,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
-1,time from acute coronary syndrome to randomization ( days ),C0040223;C0948089;C3541383
-1,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
-1,gout history,C0018099;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
-1,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
-1,cabg surgery by no . of vessels nmbr,C0010055;C0042381;C3714645
-1,pbo / simva - nmbryr km rale ( % ),C0031962;C0034642;C0439234;C3887676
-1,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
-1,testosterone ( nmol / l ),C0039601;C0439282
-1,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
-1,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0181074;C0332835;C0917805;C1054154;C1532338;C1961139
-1,antithrombotic / coagulant,C0009117
-1,caffeine,C0006644;C0236734
-1,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
-1,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
-1,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
-1,concomitant asthma medications,C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
-1,egfr by cystatin c ( ml / min per nmbr · nmbrmnmbr,C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
-1,ret / abx - facil . pci,C0389252;C4049621
-1,ca - channel blockers,C0870261;C3887642
-1,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
-1,el,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
-1,median ( nmbr % ci ) time to weekly iss mid response up to week nmbr ( wk ) f,C0008107;C0034746;C0332174;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
-1,hbanmbrca,C0019016;C1825777;C3538758;C3887642
-1,pm pef ( sd ),C0030266;C0030771;C1518922;C1542834;C2699239;C4049155
-1,cilostazol,C0055729
-1,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
-1,diagnosis of diabetes,C0011847;C0011849;C0011900;C1704338;C1704656
-1,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
-1,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
-1,thienopyridine + dipyridamole,C0012582;C1120149
-1,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
-1,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
-1,baseline albumin : < nmbr,C0001924;C0168634;C1442488
-1,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
-1,pro / pro homozygotes,C0019904;C1120626
-1,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
-1,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
-1,blood eosinophil concentration,C0014467;C0086045;C0427728;C0699870;C1313904;C1446561;C3827302
-1,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
-1,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
-1,therapy - fatigue ( facit - f,C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
-1,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
-1,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1947944;C2945760
-1,mean ± sd nmbr - h adbp,C0033727;C0168370;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
-1,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
-1,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
-1,platelet count,C0032181;C1287267
-1,other supraventricular tachycardia,C0039240;C1963244;C3815188
-1,the netherlands,C0027778
-1,angiotensin receptor blockers,C0521942;C0815017
-1,n ( % ) liraglutide nmbr placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
-1,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
-1,the american college of rheumatology ) .,C0035452;C0557806;C0596070
-1,neck pain,C0007859;C1963180;C4553909
-1,gaviscon da ( n = nmbr ),C0011318;C0061146;C3668815
-1,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
-1,previous copd treatment,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
-1,phosphorus,C0031705;C0080014;C3714498
-1,ctn - i,C0021966;C0221138;C0917591
-1,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,midas score,C1309950;C1423498;C4049617
-1,patients with diabetic nephropathy,C0011881;C0030705;C1442864
-1,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
-1,median change in atheroma volume,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
-1,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
-1,migraine with aura,C0154723
-1,middle east,C0026068
-1,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
-1,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
-1,concomitant drug therapies,C0013216;C0521115
-1,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
-1,family history of vte,C0241889;C0630906
-1,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
-1,concomitant antibiotic use,C0003232;C0042153;C0457083;C0521115;C1947944
-1,net clinical benefit : on - treatment vte or major bleeding,C0039798;C0087111;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4684590
-1,uric acid fertile nmbr ( > nmbr . nmbr mg / dl ),C0015895;C0041980;C0439269
-1,net clinical benefit : cv death,C0011065;C1306577;C1456447;C3538987;C3853572;C3887809;C3890893;C4048877;C4082313;C4318503;C4552775;C4684590
-1,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
-1,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
-1,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
-1,network,C0150775;C1513822;C1705739;C1882071
-1,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
-1,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
-1,mdi / hfa,C0015458;C0993596;C1839839;C4049613
-1,contrast angiography,C0002978;C0009924;C1979874
-1,migraine without aura,C0338480
-1,vedolizumab cohort nmbr ( n = nmbr ),C0009247;C0599755;C2742797
-1,neurocognitive disorders,C0029227;C4041080
-1,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
-1,tiotropium ( nznmbr ),C0027978;C0213771
-1,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
-1,triple therapy use at screening,C0039798;C0042153;C0087111;C0205174;C0220908;C0220909;C0457083;C1363945;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
-1,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
-1,metformin + sulphonylureas,C0025598;C0038766
-1,smoking habit,C4505437
-1,micturitions / nmbrh,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
-1,congestive heart failure at randomisation,C0018802;C0034656
-1,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  hnmbr  histamine nmbr  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C1739039;C3538987;C3811844;C3812682;C3887460;C4048877;C4318503
-1,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
-1,concurrent prednisolone,C0032950;C0205420
-1,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
-1,thoracic cage fractures,C0222762
-1,obesity ( body mass index > nmbr kg / mnmbr ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
-1,inhaled anticholinergic §,C0004048;C0242896;C3537004
-1,nmbr - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
-1,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
-1,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
-1,vasp pri - defined hpr ( % patients ),C0034044;C0255567;C1421428;C1826843;C3539761;C3539762
-1,fibrinolytic agent before randomisation,C0016018;C0034656
-1,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,viidagliptin nmbr mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
-1,doxazosin,C0114873
-1,vildagliptin + metformin ( vldm ),C0025598;C1570906
-1,torsemide,C0076840
-1,duration of macular edema,C0024440;C0271051;C0449238;C2926735
-1,pancreatic cancer,C0235974;C0346647;C2984259
-1,vildagliptin nmbr mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
-1,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
-1,leisure,C0086542
-1,proportion of predicted normal fevnmbr value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
-1,europe ( plus south africa ),C0015176;C0037712;C0332287
-1,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
-1,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
-1,apremilast nmbr mg bid n = nmbr,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
-1,antithrombotic agents,C1704311
-1,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
-1,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
-1,secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
-1,vital signs,C0150404;C0518766
-1,fibrous,C0016059;C0439709
-1,radius fracture,C0034628
-1,component . for all instruments,C0449432;C1705248;C4551823
-1,ulcer,C0041582;C3887532
-1,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
-1,ratio fp / sal : sal ( nmbr % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
-1,oxidative stress,C0242606
-1,frailty status,C0424594;C0449438
-1,no p value for ischemia ischemia hr ( nmbr % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
-1,composite ocular end point^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
-1,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
-1,western european includinq australia,C0004340;C0043128;C0239307;C0239312;C1535514
-1,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
-1,ffa / i,C0015688;C0021966;C0221138
-1,fg > nmbr,C0016703;C0439214;C2348814
-1,uncertain,C0087130;C4085655
-1,metastatic,C0036525;C1522484;C4085632
-1,ratio of hrs ( nmbr % ci ),C0008107;C0456603;C1547037;C1568891;C3259781
-1,years with gouty arthritis,C0003868;C0439234
-1,functional assessment of chronic illness,C0008679;C0278372
-1,rheumatic heart disease,C0035439
-1,unadjusted nmbr - y risk per nmbr population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
-1,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
-1,metabolism and nutrition,C0025519;C0025520
-1,years with gout,C0018099;C0439234
-1,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
-1,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
-1,tofacitinib,C2930696
-1,liraglutide nmbr . nmbr mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
-1,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
-1,baseline hematocrit,C0018935;C0168634;C0518014;C1442488
-1,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
-1,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
-1,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
-1,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
-1,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
-1,mh + crpnorr,C0026514;C2930980
-1,associated with hiv infection,C0019693;C0332281
-1,muscle spasms,C0037763
-1,rivaroxaban nmbr mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
-1,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
-1,methylxanthines,C0066447
-1,creatinine nmbr . nmbr mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
-1,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
-1,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
-1,plp - c,C0034266;C1175541;C1257874;C1705623
-1,tiotropium nmbr gg qd,C0017454;C0018370;C0213771;C0332173
-1,tirofiban ( n = nmbr ),C0247025
-1,aml / val nmbr / nmbr mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
-1,atv nmbr mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
-1,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
-1,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
-1,fenofibrate ( n = nmbr ),C0033228
-1,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
-1,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
-1,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
-1,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
-1,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
-1,mean pulse pressure,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347634;C2348143
-1,ustekinumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
-1,philippines,C0031529
-1,atenolol - losartan,C0004147;C0126174
-1,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
-1,uveitis,C0042164;C1963266
-1,atorvastatin - pravastatin,C0085542;C0286651
-1,dulaglutide nmbr . nmbr mgf,C1366394;C3179549;C3712803;C3887684
-1,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
-1,neuropilin ( ng / ml ),C0287275;C0439275
-1,cr imputation ( random . ) ( n = nmbr ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
-1,use of proton inhibitors,C0033727;C0243077;C1524063
-1,valdecoxib,C0913246
-1,dupilumab nmbr,C3660996
-1,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
-1,angiographic complications,C0002978;C0009566;C1171258
-1,cox - nmbr selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
-1,nmbr = minor symptoms  no limitations,C0026193;C0205165;C0683368;C1457887
-1,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
-1,cough ( investigator reported ),C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727
-1,placebo - carisbamate nmbrmg - carisbamate nmbrmg,C0032042;C1319635;C1696465;C1706408;C1871983
-1,hyperkalemia ‡   ( potassium ≥ nmbr . nmbr mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
-1,cromoglicate,C0010347
-1,prior cardiac surgery,C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
-1,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
-1,p - val . ( nmbr ),C0042285;C0369773;C0523975;C2603361
-1,difference ( tiotropium - placebo ) ml ( nmbr % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
-1,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
-1,fevnmbr aucnmbrminenmbrh,C0376690;C3714541
-1,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
-1,filtration rate nmbr - nmbr,C0016107;C0871208;C1521828
-1,placebo secukinumab nmbr mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
-1,sf - nmbr physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
-1,no . copies glynmbr - glunmbr - nmbrc,C0068000;C1948062
-1,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
-1,tim nmbr nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
-1,no . fingernails,C0222001
-1,contusion,C0009938
-1,ups score,C0334463;C3542434
-1,fevnmbr prebronchodilator [ % pn],C0219433;C1549735;C2599602;C3541307;C3714541;C4049640;C4049767
-1,mean platelet volume,C0200665;C0344388
-1,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,psoriasis body surface area > nmbr %,C0005902;C0033860
-1,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
-1,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
-1,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
-1,ezetimibe,C1142985
-1,psoriatic arthritis pain],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
-1,other lipid - modifying drug use at study entry,C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
-1,neutropenia,C0023530;C0027947;C0853697
-1,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
-1,fev auc i nmbrh,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
-1,alcohol abuse,C0085762;C4050601
-1,placebo - ezetimibe nmbr / simvastatin nmbr - fenofibrate nmbr - ezetimibe nmbr / simvastatin nmbr / ezetimibe nmbr,C0032042;C0033228;C1532737;C1696465;C1706408
-1,coping,C0009967
-1,puerperium,C0034042;C0086839;C1879329
-1,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
-1,usa / canada,C0006823;C0041703
-1,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
-1,involved intestinal area,C0021853;C1879646
-1,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
-1,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
-1,copd - rosuvastatin ( nmbr pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
-1,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
-1,left bundle - branch block,C0023211;C0344420;C2828132
-1,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
-1,olmesartan nmbr - olmesartan nmbr / hydrochlorothiazide nmbr . nmbr,C0020261;C1098320
-1,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
-1,copd - rosuvastatin ( n = nmbr ),C0024117;C0965129;C1412502;C3714496
-1,copd - placebo ( nmbr pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
-1,urine acr geometric mean ( cv % ),C0042036;C0042037;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
-1,ff / vi nmbr / nmbr gg ( n = nmbr,C0017454;C0018370;C0205999;C4554348
-1,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0027361;C0439234;C0441848;C2347489
-1,vascular accidents,C0000924;C0005847;C1558950;C1801960
-1,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
-1,mepolizumab nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
-1,combined fatal / nonfatal outcomes,C0205195;C0206277
-1,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
-1,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
-1,diltiazem or verapamil,C0012373
-1,waist circumference women : > nmbr in ( nmbr cm ) men : > nmbr in ( nmbr cm ) tc nmbrc nmbr mg / dl,C0025266;C0043210;C0455829
-1,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
-1,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
-1,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
-1,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
-1,leukocytes,C0023516
-1,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
-1,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the nmbr genotype groups ) .,C0008107;C0009667;C0022661;C2360800;C3259781
-1,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
-1,dabigatran nmbr   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
-1,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C1272460;C1546968;C1879645;C3259781;C4049872;C4552882
-1,chylomicron triglycerides,C0008731;C0041004;C1325761
-1,supine after nmbr minutes change from baseline,C0038846;C0439232;C0700321;C0702093;C1282918;C2347166
-1,shock risk indext,C0035647;C0036974;C4552904
-1,transfusion ≥ nmbr units rbcs or whole blood,C0005841;C0014792;C0199960;C0439148;C1519795;C1879316;C3853603
-1,chylomicron cholesterol,C0008377;C0008731;C1325761
-1,transaminases increased,C0002594;C0919834
-1,chronic sinusitis + nasal polypsd,C0028429;C0149516;C4520890
-1,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
-1,chronic renal insufficiency,C0403447;C1561643
-1,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0802604;C2598133;C4284232
-1,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
-1,anti - ischaemia agents *,C0022116;C0040616;C4321499
-1,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
-1,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
-1,treatment for latent tuberculosis^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
-1,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
-1,formoterol nmbr   μ g ( n   =   nmbr ),C0060657;C0439267
-1,baseline hb < nmbr g nmbr nmbr n = nmbr,C0062408;C0168634;C0439267;C1442488
-1,formoterol tiotropium n = nmbr non - tiotropium n = nmbr,C0060657;C0213771;C1518422
-1,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
-1,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
-1,class iv glomerulonephritis,C0017658;C0441888;C2698970
-1,nice classification of copd severity of obstruction,C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
-1,tendonitis,C0039503
-1,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
-1,d non - vertebral fragility fractures ( fas ),C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
-1,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
-1,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
-1,sirolimus eluting stent,C0038257;C0072980
-1,nmbr mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
-1,> nmbr to < nmbr egfr,C0040363;C0041260;C1739039;C1883351;C3811844;C3812682
-1,oral contraceptives,C0009905
-1,headache,C0018681;C4553197
-1,d population,C0032659;C0073187;C0332173;C1257890;C4484261
-1,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
-1,dopamine agonist use,C0042153;C0178601;C0457083;C1947944;C3536925
-1,medication adherence,C2364172
-1,initiation of dialysis,C0011945;C0011946;C0589507;C1059964;C1158830;C1704686;C4551529
-1,mycophenolate mofetil,C0209368
-1,cross - damp time : < l : llhrs : min ( n = nmbr ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
-1,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
-1,gait,C0016928
-1,gamma glutamyltransferase,C0017040
-1,gastroenteritis,C0017160
-1,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
-1,dopa and dopa derivativese,C0013023
-1,atrial flutter,C0004239;C0344423;C1963068
-1,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
-1,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
-1,established cvd / chronic kidney disease ( age > nmbr ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
-1,endothelin nmbr ( pg / ml ),C0079284;C0439297
-1,treatment difference ( nmbr % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
-1,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
-1,fasting lipids ( mmol / nmbr ),C0015663;C0023779;C0439190
-1,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
-1,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
-1,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
-1,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
-1,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
-1,cohort nmbr ( n = nmbr ) f,C0009247;C0016327;C0599755
-1,dapagliflozin placebo no . of events / no . of patients,C0032042;C1696465;C1706408;C2353951
-1,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
-1,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
-1,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
-1,chondroitin,C0008454
-1,control baseline ( n - nmbr ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
-1,cholinesterase inhibitor use at baseline,C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
-1,walking,C0080331;C4283795;C4321241;C4321242
-1,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,war,C0043027
-1,chloroquine,C0008269
-1,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,established renal disease ( egfr nmbr - < nmbr ml / min / nmbr . nmbr m^ with any uacr mg / g or egfr > nmbr - nmbr ml / inin / lnmbr mnmbr with an uacr > nmbr mg / g ) without previous maerovaseular and albuminuria disease,C0022658;C0369637;C0441923;C0443211;C1272684;C1739039;C3811844;C3812682;C3829050
-1,beta - blocker ( except sotalol ),C0001645;C0037707
-1,no in - trial stroke n = nmbr,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
-1,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease ,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
-1,chl,C0019829
-1,china / japan,C0008115;C0022341
-1,fasting serum glucose level,C0015663;C0202045;C0229671;C0583332;C1546774;C1550100
-1,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
-1,ctn - l,C0917591
-1,hbanmbrc distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
-1,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
-1,inflammation,C0021368
-1,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
-1,dalteparin ( n = nmbr ),C0206461
-1,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
-1,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
-1,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
-1,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
-1,colon ' ses - cd score,C0007928;C0009368;C0034283;C0449820;C3888384;C4050231;C4552032
-1,blood oxygenation,C0005767;C0005768;C0229664;C0231940;C0282636
-1,sf - nmbr ( health transition score ),C0037712;C0376627;C0449820;C4050231
-1,fistula,C0016169
-1,lovastatin nmbr mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
-1,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
-1,flecainide,C0016229
-1,nationality,C0027473
-1,cv disease history,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
-1,colesevelam hydrochloride group ( n = nmbr ),C0441848;C0541154
-1,colesevelam ( n = nmbr ),C0541155
-1,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
-1,nicotine pack - years,C0028040;C1277691
-1,colectomy ( partial or total ),C0009274
-1,fluvastatin nmbr mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
-1,therapy ( asa nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
-1,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
-1,hcq + mtx ( n = nmbr ),C0020336;C0025677;C1417487
-1,type nmbr collagen,C0009325;C0332307;C1547052
-1,need for nmbr ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
-1,etn + mtx ( n = nmbr ),C0014758;C0025677;C0717758;C1417487
-1,cystitis,C0010692;C0600041;C1963088
-1,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
-1,colonic area involved,C0009368;C0017446;C0205146
-1,d nmbr mg vs . warfarin,C0024671;C0026410;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
-1,ment,C0084844;C1538994
-1,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
-1,abdominal aortic — no . ( % ),C0003484
-1,olmesartan ( n = nmbr ),C1098320
-1,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
-1,history of bone disease ( predefined ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
-1,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
-1,vitamin c,C0003968;C2349136;C3714687;C4522080
-1,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
-1,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
-1,dyspepsia,C0013395;C4552968
-1,duration of rat,C0034693;C0034721;C0449238;C2926735
-1,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
-1,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
-1,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
-1,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
-1,heart failure nmbr mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
-1,intravenous dobutamine,C0012963;C0348016
-1,colonoscopy,C0009378;C1548837
-1,dual i extension - end of trial hbanmbrc,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
-1,galectin - nmbr ( ng / ml ),C0439275;C0607430
-1,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
-1,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
-1,modified hachinski ischemia scale,C0022116;C0175659;C0349674;C0392747;C1947916;C3889737;C4321499
-1,serum ua < nmbrmg / dl by month nmbr,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
-1,fluticasone alone ( n = nmbr ),C0082607;C0205171;C0439044;C0679994
-1,blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0347983;C0427512
-1,acute rheumatic disorders,C0001314
-1,nebivolol ( n = nmbr ),C0068475
-1,pravastatin nmbr mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
-1,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
-1,clinical efficacy at week nmbr,C0087113;C0332174;C0439230
-1,vonoprazan nmbr mg n = nmbr,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
-1,pitavastatin nmbr mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
-1,forearm,C0016536
-1,clinical dementia rating sum of boxes,C0179400;C0451074;C1515051;C1638312
-1,ncep atp - iii metabolic syndrome features,C0439070;C0524620;C1705160;C2744579;C4552600
-1,clinic research experience,C0008972;C0237607;C0596545
-1,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
-1,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0242485;C0392747;C0443172;C0729333;C1705241;C4319952
-1,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
-1,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
-1,d ( nmbr % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
-1,treatment with sulphonylurea,C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
-1,treatment with sulphonylurea + biguanide,C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
-1,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
-1,study protocol,C1507394;C2348563;C2599718
-1,dihydropyridine,C0012315;C0220821
-1,classification of epilepsy type,C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
-1,osteoporosis,C0029456;C4554622
-1,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
-1,glomerular,C0022663;C0268731
-1,meloxicam,C0083381
-1,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
-1,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
-1,aortic stenosis,C0003507
-1,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
-1,czp combined arms ( n = nmbr ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
-1,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
-1,clow - potency stratum : simvastatin nmbrmg  pravastatin nmbr mg  fluvastatin nmbr mg  atorvastatin nmbr mg  high - potency stratum : simvastatin nmbr mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
-1,tibia fracture,C0040185
-1,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
-1,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
-1,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
-1,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
-1,control of sitting bp at week nmbr,C0037623;C0243148;C0277814;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
-1,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
-1,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
-1,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
-1,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0008107;C0023668;C0024671;C0026410;C0286651;C0439269;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
-1,nocturia episodes / nmbrh,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
-1,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
-1,hungary,C0020174
-1,memantine use at baseline,C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
-1,two - dimensional echocardiography,C0013524
-1,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
-1,systolic pressure at ankle level ( mmhg ),C0003086;C0003087;C0439475;C0441889;C0456079;C0871470;C1547707;C2946261
-1,cause of dvt or pe — no . ( % ),C0015127;C0149871;C1524003;C2926618;C3899446
-1,dasnmbr ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
-1,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
-1,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
-1,all randomized women,C0034656;C0043210;C3815594
-1,pace,C0287990;C1552930;C4048252
-1,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
-1,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
-1,cardiac glycosides,C0007158
-1,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
-1,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
-1,baseline hemoglobin,C0019046;C0168634;C1442488
-1,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
-1,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
-1,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0220938;C0439541;C1533017;C1533018;C1533020;C1533021
-1,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
-1,( phase nmbr dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
-1,indomethacin,C0021246
-1,prior gestational diabetes,C0085207;C0332152;C2826257
-1,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
-1,thienopyridine at randomization,C0034656;C1120149
-1, geometric mean with nmbr % confidence interval in parenthesis .,C0000723;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0731033;C0871472;C1256463;C1280412;C1704614;C1707455;C1739039;C1881413;C2347026;C3811844;C3812682;C4318736
-1,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
-1,belgium,C0004950
-1,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
-1,risk factors for recurrent vte — no . ( % ) f,C0035648;C0630906;C1455761;C1553898;C2945760
-1,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
-1,influenza,C0021400;C0021403
-1,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C1947916;C1963185
-1,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
-1,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
-1,absolute risk reduction ( nmbr % ci ),C0008107;C3179139;C3259781
-1,inferior mi *,C0340305;C3542426
-1,uric acid ( mg / dl ) creatinine clearance ( ml / min per nmbr . nmbr mnmbr ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
-1,sex ( male ) ethnic origin,C0015031;C0086582
-1,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal nmbr due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^history of or currently have elevated serum creatinine level but less than nmbr mg / dl_ ( < nmbr pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = nmbr for calcium antagonist strategy and n = nmbr for non - calcium antagonist strategy ) .,C0000723;C0003211;C0010055;C0042295;C1305855;C1532338;C3536840
-1,acs management,C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
-1,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
-1,sitting pulse,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
-1,probenecid,C0033209
-1,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
-1,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
-1,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
-1,propafenone,C0033429
-1,prior urate lowering therapies,C0441994;C0729829;C0935936;C1514463;C2003888
-1,propionic acid derivatives,C0033482;C0695274;C3540752
-1,work and school,C0043227
-1,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
-1,lv heart structure,C0018787;C0023128;C0731033;C1881413
-1,fh ii,C1854107
-1,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
-1,triglycerides tx difference vs pbo,C0041004;C0041403;C1705241;C1705242
-1,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
-1,serum trap - nmbrb ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
-1,oxcarbazepine,C0069751
-1,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0717550;C1322815;C1739039;C2757044;C3811844;C3812682;C4551552
-1,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
-1,individuals with tnmbrdm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
-1,( minimum - maximum ) focal seizure fre - quency / nmbr days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
-1,benign prostatic hyperplasia,C1704272
-1,lung neoplasm malignant,C0024121
-1,apremilast,C1678805
-1,red blood cell counting,C0014772;C1287262
-1,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
-1,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
-1,baseline hs - crp tertiles ( mg / i],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
-1,jbs - nmbr primary prevention onlynmbr,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
-1,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
-1,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
-1,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . nmbr for major cardiovascular event . no other interactions are significant . ^calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > nmbr mm hg  a diastolic blood pressure > nmbr mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > nmbr mg / dl_ ( nmbr . nmbr mmol / l ) or physician - diagnosed high cholesterol . ^diabetes defined by self - report . # calculated using the framingham risk score among nmbr nmbr women who provided a blood sample at baseline .,C0000723;C0009667;C0010068;C0027051;C0242492;C0428953;C0439526;C0596019;C1705224;C2926063;C3810814;C3887665;C4552959;C4554402
-1,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > nmbr and < nmbr mm hg / > nmbr and < nmbr mm hg  less severe  > nmbr and < nmbr mm hg / > nmbr and < nmbr mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0597357;C2757044;C3536837;C3888198;C4541021
-1,drinking,C0001948;C0684271
-1,baseline cardiovascular disease,C0007222;C0168634;C1442488
-1,nmbr . nmbr ( lo . i ),C0021966;C0206579;C0221138;C1232424
-1,previous use of biologic systemic therapy,C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
-1,venous insufficiency,C0042485
-1,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
-1,* per nmbr participant years . composite of first occurrence death ( all cause ),C0011065;C0205199;C0205435;C0243132;C0439234;C0679646;C1279901;C1306577;C1547335;C1554210;C2698741;C2745955;C4082313;C4552775;C4554048
-1,myalgia,C0231528;C4552646
-1,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
-1, ¿ ldl cholesterol levels are shown according to the median value ( nmbr mg per deciliter [nmbr . nmbr mmol per liter] ) and according to the values that divide the subjects into three equal groups ( < nmbr  nmbr to nmbr  and > nmbr mg per deciliter [ < nmbr . nmbr  nmbr . nmbr to nmbr . nmbr  and > nmbr . nmbr mmol per liter] ) .,C0008107;C0009667;C0439165;C1137094;C3259781
-1,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
-1,peripheral neuropathy,C0031117
-1,nmbrmw distance,C0012751;C0024548;C0026385;C0556966
-1,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
-1,primary - prevention cohort,C0009247;C0033144;C0599755
-1,hdl cholesterol < nmbr ( men ) or < nmbr mg / dl ( women ),C0023822;C0025266;C0392885
-1,previous treatment in the healing study,C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
-1,humerus fracture,C0020162
-1,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
-1,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
-1,australia / nz,C0004340;C0027978
-1,nmbr - y rate per nmbr persons ( se ),C0027361;C0036919;C0871208;C1521828
-1,previous pdenmbr - i therapy,C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
-1,adalimumab group ( n = nmbr ) t,C0036669;C1122087
-1,nmbr mq / kq *,C0024853
-1,diagnoses / risk factors,C0011900;C0035648;C1553898
-1,intensive therapy ( n = nmbr ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
-1,high - density lipoprotein cholesterol tx difference vs pbo,C0023822;C0041403;C1705241;C1705242
-1,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
-1,intensive bp lowering,C0037623;C0162425;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
-1,diabetic kidney disease,C0011881
-1,. nmbr kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
-1,acitretin,C0050559
-1,* the nmbr substrata with baseline ( bl ) ldl cholesterol nmbr to nmbr mg / dl and nmbr to nmbr mg / dl were combined to make nmbr group with bl ldl cholesterol nmbr to nmbr mg / dl because of small numbers of patients included in the substrata with nmbr to nmbr mg / dl . † bl hdl cholesterol cutoffs were nmbr or nmbr mg / dl for men and nmbr or nmbr mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe nmbr mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023824;C0168634;C0202117;C1442488;C1552663;C2827109
-1,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
-1,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C3273373;C3665488
-1,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
-1,prior antiinflammatory / antirheumatic products,C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
-1,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
-1,associated with drug / toxin,C0013221;C0332281
-1,acid,C0001128;C0202406
-1,korean,C1556095
-1,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
-1,fp / sal nmbr / nmbr pg ( n = nmbr ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
-1,enalapril dm = nmbr non - dm = nmbr,C0011816;C0014025;C3250443
-1,regional anaesthesia,C0002911
-1,abaloparatide - sc,C0282380;C4042342
-1,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
-1,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
-1,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
-1,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hbanmbrc  hemoglobin anmbrc  hmg - coa  nmbr - hydroxy - nmbr - methylglutaryl coenzyme a . asome subjects took more than nmbr oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0022709;C1305855
-1,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by nmbr . nmbr . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( nmbr - nmbr )  intermediate ( nmbr - nmbr )  and high ( nmbr - nmbr ) risk . nmbr,C0000723;C0022709;C0027051;C0428953;C0439526;C0439836;C1705224;C1711350;C2926063;C3810814;C3887665;C4552959
-1,reported in ecrf,C0684224;C0700287;C4319718;C4551412
-1,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
-1,arterial area ( mmnmbr ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
-1,* atherosclerotic coronary heart disease,C0010054;C0010068;C0018787;C0333482;C1956346
-1,nmbr . nmbr ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
-1,p - value ( anova ),C0753802;C1709380
-1,insulin glargine dose at screening visit,C0178602;C0220908;C0220909;C0366513;C0869039;C0907402;C1114758;C1698960;C1710031;C1710032;C1710477;C2348164
-1,insulin glargine + insulin lispro ( award - nmbr  n = nmbr ),C0004446;C0293359;C0907402
-1,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
-1,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
-1,australasia,C0282279;C1257882
-1,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
-1,fp nmbr mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
-1,insulin detemir,C0537270
-1,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
-1,insulin aspart,C0123677;C1708521
-1,hub,C0063034;C1414372;C1708389
-1,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
-1,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
-1,lv mass index ( mg / mnmbr ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
-1,taiwan,C0039260
-1,tachyarrhythmias,C0080203
-1,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
-1,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
-1,apo a - l ( g / l ),C0628062
-1,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0680240;C1274040
-1,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
-1,randomised patients with spondylitis at baseline,C0030705;C0038012
-1,- fnmbr . nmbr ( - i - nmbr . nmbr ),C0016327;C0021966;C0221138
-1,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,- nmbr . nmbr ± nmbr . nmbr § ti,C0039247;C0040302;C1553045;C1704756
-1,randomization to first balloon inflation,C0021398;C0034656;C0205435;C0336867;C0441144;C1279901;C1318493
-1,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
-1,ptca / cabg,C0010055;C2936173
-1,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
-1,r | r ' ' ' ( nmbr % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
-1,radionuclide ventriculography,C0017200;C0034610
-1,outcome measure,C0086749
-1,other vascular disease ( cvd or pad ),C0007222;C0042373
-1,previous tnf - antagonist use,C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
-1,ag,C0002037;C0051080;C0152305;C3888235
-1,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
-1,overall ( pp ) ( n = nmbr ),C0030375;C0063017;C0282416;C1561607;C4319755
-1,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
-1,ihd,C0151744
-1,acute infection without septic shock,C0036983;C0275518
-1,^nmbr - cell function — % §,C0007613
-1,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
-1,igl ( n = nmbr ),C0021037;C0314619;C2247518
-1,index event to randomization,C0034656;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
-1,catheterization performed for qualifying event,C0007430
-1,ovary,C0029939;C0227898
-1,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
-1,outcomes by treatment ( spironolactone vs placebo ),C0037982;C0085415
-1,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
-1,india,C0021201;C2700456
-1,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
-1,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
-1,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
-1,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
-1,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
-1,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
-1,married,C0024841;C0555047
-1,cerebral embolism,C0007780
-1,mass index ,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
-1,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
-1,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,C0005910;C0006041;C0030705;C0392756;C0547047;C2986891
-1,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
-1,other climate subset,C0008946;C1515021
-1,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
-1,recent treatment ( < nmbr months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
-1,adalimumab croup,C0010380;C1122087
-1,hiv,C0019682;C0019699
-1,ibs ( nmbr . nmbr ),C0022104;C0432306
-1,ala carriers,C0007294;C0523459;C3888236
-1,iv : fevnmbr < nmbr % predicted,C0022326;C3714541;C4265176
-1,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
-1,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
-1,rash,C0015230
-1,transient monocular blindness,C0149793
-1,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
-1,male sex ( % ) race or ethnic group ( % ) f,C0034510;C0086582;C1706779;C3853635
-1,acm,C0001143;C1549040
-1,ibuprofen,C0020740
-1,event / patients ( nmbr / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
-1,rec . ischemia due to ecg changes,C0022116;C0678226;C1424025;C1623258;C2606415;C4321499
-1,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
-1,tp vs no tp,C0036183;C3541334
-1,ica stenosis nmbr % - nmbr % f,C0016327;C0201519;C0678234;C1261287;C2632116
-1,rate / nmbr pyo,C0033809;C0871208;C1521828
-1,affected body - surface area > nmbr % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
-1,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
-1,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
-1,puerto rican,C0034043
-1,vi nmbr mg ( n = nmbr ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
-1,in the spironolactone group and nmbr patients in the placebo group .,C0037982;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
-1,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
-1,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
-1,ptxnmbr ( ng / ml ),C0030899;C0439275
-1,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
-1,additional radiographic findings at week nmbr,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
-1,adj . hr ( nmbr % cl ) a,C0001552;C0596019;C2826286
-1,oxypurinol ( n = nmbr ),C0030086
-1,reteplase / abciximab - facilitated pci ( n = nmbr ),C0256103;C0288672;C4049621
-1,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
-1,pulmonary vascular resistance,C0456261;C0488644
-1,in - trial nmbr - year rates per nmbr ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1521828;C1707101;C3541888;C4288115
-1,bm i < nmbr,C0006416;C0021966;C0221138
-1,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
-1,pulse rate ( mean nmbr h ),C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
-1,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
-1,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
-1,activities of daily living updrs subscore ( baseline ),C0001288;C0168634;C1442488;C3639721;C4050548
-1,( incl . uncertain ),C0268281;C1418854
-1,direct thrombin inhibitors,C0003440;C3541936
-1,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
-1,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
-1,( fxs ),C0016667
-1,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
-1,sotalol,C0037707
-1,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
-1,psa - modified shs of hands & feetnmbr ( nmbr - nmbr ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
-1,esrd saxa nmbr . nmbr mg ( n = nmbr ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
-1,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
-1,austria,C0004348
-1,adjusted hr ( nmbr % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
-1,lvh by ecg / echo,C0058928;C0232306;C1655045
-1,baseline fecal caicrctectin,C0015733;C0168634;C1442488
-1,question nmbr ( discomfort from any areas tender to touch / pressure ),C0152054;C0205146;C0234234;C0439815;C0702221;C1522634;C2364135;C4319729
-1,mab,C0003250;C0369637
-1,imaging data,C0011923;C0079595;C1511726;C3245479;C3714741
-1,quartiles of fgf - nmbr ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
-1,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
-1,question nmbr ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
-1,question nmbr ( pain / swelling in joints other than neck / back / hips ),C0003862;C0013604;C0038999;C1522634
-1,syndecan - nmbr ( ng / ml ),C0075691;C0439275;C1419891
-1,immunomodulators,C0001551;C0005525;C1527392
-1,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
-1,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
-1,ileum ses - cd score,C0007928;C0020885;C0034283;C0449820;C4050231;C4552032
-1,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
-1,af on baseline ecg,C0168634;C0344434;C1442488;C1623258;C4049859
-1,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
-1,overall freedom population ( n = nmbr ),C0016694;C0032659;C0282416;C1257890;C1561607
-1,aes in ≥ nmbr japanese patients in a study arm,C0030705;C0376247;C1412268;C1556094;C2699274
-1,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
-1,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
-1,lvh by ecgt blood pressure,C0005823;C0149721;C1271104;C1272641
-1,pv,C0030840;C0032463
-1,adjusted rate of fevnmbr   decline ( se ),C0036919;C0456081;C0871208;C1521828;C3714541
-1,pyrexia,C0015967
-1,adolescents ( aged nmbr - nmbr y ),C0205653
-1,adults ( aged   ≥ nmbr y ),C0001675
-1,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
-1,aed inducer status,C0449438;C0887457;C3898767
-1,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
-1,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
-1,impaired cognitive,C0338656
-1,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
-1,lymphadenopathy,C0497156;C4282165
-1,overall mortality,C0026565;C0026566;C0282416;C1561607
-1,nmbr tq - fi ' i,C0021966;C0221138;C3555502;C4050619
-1,pnmbrynmbr antagonists,C0243076;C0369773;C2603361
-1,streptokinase,C0038418
-1,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
-1,physician ' s ga,C0016993;C0031831;C0804815
-1,ifx + aza ( n = nmbr ),C0004482;C0020823
-1,sal nmbr mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
-1,jbs - nmbr secondary prevention onlynmbr,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
-1,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
-1,pi,C0122626;C0429863;C3537219;C3539772
-1,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
-1,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
-1,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
-1,piroxicam,C0031990
-1,patients with cardiac disorders,C0012634;C0018799;C0030705;C0741926
-1,laboratory values in patients with history of diabetes,C0022877;C0030705;C0042295;C3244292;C4283904
-1,patients with bp $ nmbr / nmbr mmhg ( abpm ) at baseline,C0030705;C0037623;C0439475;C1415692;C1708288;C4318478
-1,ankle fracture,C0159877;C4552974
-1,physician ' s assessment of disease activity ( vas ),C0031831;C0042815;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
-1,insulin tx difference vs pbo,C0021641;C0041403;C1533581;C1579433;C1705241;C1705242;C3714501
-1,time to end - of - study ivus,C0040227;C0444930;C1456025;C2746065
-1,previous warfarin use,C0042153;C0043031;C0205156;C0457083;C1552607;C1947944
-1,lansoprazole nmbr mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
-1,ls - mean change from baseline ( nmbr % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
-1,valproate,C0080356
-1,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
-1,physical exam oedema,C0013604;C0031809;C1717255
-1,lansoprazole ( n = nmbr ),C0050940
-1,lacunar infarction,C0333559
-1,trochanter,C0162370
-1,treatment groups [n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
-1,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
-1,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
-1,pharyngitis,C0031350;C4553308
-1,phenobarbital,C0031412
-1,phosphatase,C0031678;C1149880;C4522024
-1,enalapril + aliskiren ( n = nmbr ),C0014025;C1120110
-1,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
-1,laparoscopic cholecystectomy,C0162522
-1,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
-1,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0524620;C1142985;C1696465;C1706408
-1,= placebo  eze : tes ( fc j > nmbr rr nmbr definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
-1,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
-1,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > nmbr . nmbr mmol / l] ) . to qualify as having,C0023128;C0039411;C0040642;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C3272447;C3642216;C4522122
-1,nmbr . nmbrto . nmbr . i . iot,C0006196;C0021966;C0221138
-1,placebo mortality rate,C0026565;C0032042;C0205848;C1696465;C1706408
-1,knees ( n ),C0022742
-1,placebo diabetes n = nmbr,C0011847;C0011849;C0032042;C1696465;C1706408
-1,= cerebrospinal fluid .,C0007806;C0007807
-1,anaesthesia / analgesia,C0002905
-1,nmbr ix,C0015491
-1,fluindione,C0117899
-1,plac,C0048838
-1,cardiac valve surgery : no ( n = nmbr ),C0018821;C0018826;C0038894;C0038895;C0184252;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
-1,placebo dr = nmbr ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
-1,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
-1,fema le,C0023190;C0439090;C1423767;C2697858
-1,patients with > nmbr exacerbation requiring admission to hospital in the nmbr months before screening,C0030673;C4086268
-1,patients with nmbr co - aed,C0030705;C0887457;C3245499
-1,lipid measure *,C0023779;C0079809;C0242485
-1,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
-1,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
-1,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0037455;C0175659;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460
-1,single,C0037179;C0087136;C0205171
-1,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
-1,placebo + pioglitazone ( n = nmbr ),C0032042;C0071097;C1696465;C1706408
-1,> nmbr med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
-1,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
-1,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
-1,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
-1,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
-1,placebo + insulin glargine ( award - nmbr  n = nmbr ),C0004446;C0032042;C0907402;C1696465;C1706408
-1,cardiac medications during index hospital stay and / or discharge,C0013227;C0428776;C0802604;C2598133;C3489408;C4284232
-1,type of drug - eluting stent,C0038257;C0332307;C0457591;C1322815;C1547052
-1,placebo to ustekinumab nmbr mgt,C0032042;C1608841;C1696465;C1706408
-1,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
-1,neutrophils,C0027950
-1,inspiratory capacity ( l ),C0021610;C0802663
-1,safety : non - cabg - related bleeding,C0010055;C0036043;C1518422;C1705187
-1,lips,C0023759
-1,skull,C0037303;C2951888
-1,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > nmbr mg / l  for europa > nmbr mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0184661;C0189695;C0392347;C0439268;C0522523;C0545743;C0886296;C1273869;C4049621
-1,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
-1,cg / ld,C0043444;C0694649;C1567075;C3540479
-1,least squares mean between - treatment difference ( nmbr % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
-1,devices,C0025080;C0220819;C0699733
-1,least - squares mean difference ( nmbr % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
-1,least - squares mean difference ( nmbr % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
-1,peak fevnmbr ( nmbr - nmbrh )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
-1,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
-1,waist circumference snmbr ( men ) or > nmbr cm ( women ),C0025266;C0455829
-1,pbo to czp week nmbr dose combined,C0031962;C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
-1,patients with microvascular complications,C0009566;C0030705;C0443258;C1171258
-1,patients with psoriasis > nmbr % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
-1,n - nmbr pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
-1,patients with serum nmbr ( oh ) d ≥   nmbr . nmbr and <   nmbr   ng / ml,C0030705;C0220853;C0229671;C1546774;C1550100
-1,aml / val,C0023465;C0023467;C0042285;C0523975
-1,on - pump time : < l : nmbrhrs : min ( n = nmbr ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
-1,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
-1,patients with pulmonary embolism,C0030705;C0034065
-1,placebo croup,C0010380;C0032042;C1696465;C1706408
-1,pbo czp nmbr mg qnmbrw week nmbr ( n = nmbr ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
-1,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
-1,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
-1,pbo - sc every other week ( n = nmbr ),C0031962;C0282380
-1,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
-1,patients with prior dmard use,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
-1,> nmbr da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
-1,pef at baseline,C0030771;C0168634;C1442488;C1518922;C1542834
-1,cholecystectomy ( n = nmbr ),C0008320
-1,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
-1,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
-1,> nmbr kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
-1,patients with enthesitis ( lei > nmbr ),C0023401;C0030705;C0428209;C1282952
-1,dilated cardiomyopathy,C0007193;C2984282
-1,lcl,C3658298
-1,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - nmbr — parkinson disease questionnaire .,C0001288;C0030567;C0165921;C0353697;C0441655;C0681889;C1420005;C1423759;C3273355;C3639721
-1,perindopril - indapamide,C1273169
-1,natalizumab ( n = nmbr ) f,C0016327;C1172734
-1,li nmbr ( nmbr . nmbr ),C0023617;C3495095
-1,lacosamide,C0893761
-1,lav ( ml ),C0019682;C0439526;C1705224;C3887665
-1,linear regression,C0023733;C2346679
-1,etn,C0014758;C0717758
-1,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
-1,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
-1,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
-1,levosimendan ( n   = nmbr ),C0246904
-1,leukopenia,C0023530;C0750394
-1,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
-1,prostate cancer,C0376358;C0600139;C2984325;C3541264
-1,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
-1,> nmbr to < nmbr ml / min / lnmbrnr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
-1,> nmbr % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
-1,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
-1,n - nmbr fatty acids - placebo lsm ( nmbr % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
-1,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
-1,patients with fingernail involvement,C0030705;C0222001;C1314939
-1,mean ham - d score ( nmbr % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
-1,level of thyroperoxidase antibody at baseline,C0021965;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1547707;C2946261;C3272921
-1,levodopa dose,C0023570;C0178602;C0869039;C1114758
-1,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
-1,percent work time missed due to asthma,C0040223;C0043227;C0439165;C3541383
-1,> nmbr y pathogenesis,C0543483;C0699748
-1,mexico,C0025885
-1,placebo tolvaptan ( nmbr mg ) ( n nmbr nmbr ) ( n nmbr nmbr ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
-1,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
-1,nmbr - nmbr ml / rain,C0034640;C0439526;C1705224;C3887665
-1,pregnancy,C0032961
-1,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
-1,nmbr coenzyme qnmbr subgroups for time to first hospitalization ( number of patients variable ) .,C0040223;C0041536;C1079230;C3541383
-1,paresthesia,C0030554;C4553220
-1,> < nmbr . nmbr  < nmbr . nmbr  r < mmse = mini - mental ,C0205090;C0451306;C0684010;C2603358
-1,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
-1,duration from clopidogrel / placebo to pci,C0032042;C0070166;C0449238;C1696465;C1706408;C2926735
-1,ischemic heart disease indicator no ( n = nmbrl ),C0010054;C0021212;C0151744;C1235732;C1522602
-1,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
-1,inversion,C0021943;C0021945;C1705687;C2349984
-1,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
-1,avm ( n = nmbr ),C0003857;C0279476
-1,stroke of undetermined cause,C0015127;C0038454;C1524003
-1,low - trauma fracture since age nmbr,C0521170
-1,nmbr - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
-1,adjusted mean ± se ( nmbr % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
-1,prevalent cvd,C0007222;C0033105;C0220900
-1,left ventricular dysfunction,C0242698
-1,pin /,C0175718;C1168556;C1704584
-1,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
-1,medical history of diabetic retinopathy §,C0011884;C0262926
-1,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
-1,prednisone use,C0032952;C0042153;C0457083;C1947944
-1,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
-1,number ( % ) reporting migraine on nmbr - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
-1,albuminuria < nmbr gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
-1,nmbr i - nmbr - nmbrai,C0003504;C0021966;C0221138;C4551710
-1,nmbr ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
-1,mae,C0286540;C4085238
-1,nmbrhr prandial glucose ' * ’,C0017725;C1998602;C4553624
-1,hdl - cy,C0010622;C0332298;C2239193;C3715113
-1,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
-1,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
-1,prevalent kidney disease ( egfr < nmbr ml / min / usm^ or maeroalbuminuria uacr > nmbr mg / g ),C0022658;C0033105;C0220900;C0439445;C1739039;C3811844;C3812682
-1,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
-1,intercourse satisfac -,C0009253
-1,obese patients,C0028754;C0030705
-1,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
-1,oral treprostinil ( n = nmbr ),C0442027;C1145760;C4521986
-1, l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  nmbrs  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step nmbr diet and care intensi ﬁ ed to step nmbr diet if ldl cholesterol nmbr · nmbr mmol / l ( nmbr mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0008377;C0036453;C0038952;C0074554;C0150158;C0220921;C0240951;C0489835;C0557651;C0565930;C1705493;C1706420;C1947933;C2603343;C2603362
-1,paclitaxel - eluting stent use,C0038257;C0042153;C0144576;C0457083;C1947944
-1,low complement / anti - dsdna positive ( n = nmbr ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
-1,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0597277;C1552607;C1708601;C2825076;C3714656
-1,internal carotid artery sites,C0007276;C0205145
-1,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
-1,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
-1,distribution time,C0040223;C0520511;C1704711;C3541383
-1,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
-1,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
-1,[zi = nmbr] nmbr ( nmbr . nmbr ),C0043476
-1,immunologic,C0152036;C0205470
-1,pah - sle,C0024141;C0030123;C3203102;C4284467
-1,< nmbr . nmbr tng > cll,C0023434
-1,glycoprotein llb / llla inhibitors,C0017968;C0243077
-1,bdp / ff / g ( n = nmbr ),C0004906;C0439267;C1422585;C1538710;C4554348
-1,romania,C0035826
-1,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
-1,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
-1,fevi aucnmbr - nmbrl,C0376690;C0429706;C0849974;C1561566;C4528367
-1,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
-1,previous antiparkinson medication,C0003405;C0205156;C1552607
-1,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
-1,pancreas,C0030274
-1,clinical copd phenotype^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
-1,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
-1,low body weight ( < nmbr kg ),C0022718;C0041667;C0439209;C4054209
-1,no . in the nmbr mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
-1,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
-1,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
-1,nmbr - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
-1,patients on atorvastatin,C0030705;C0286651
-1,nmbr early intervention ( n = nmbr ),C0242687;C1964029
-1,polyarticular arthritis,C0162323
-1,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
-1,atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr ),C0286651;C1142985;C1319635
-1,key : fc = fasting glucose  bp = * this category did not include ar have nmbr of the indicated charac,C0015663;C0017725;C0037623;C1415692;C1708288;C2983605;C4318478
-1,pool of fh i and ii studies,C0337051;C1260386;C1509144;C2349200
-1,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
-1,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
-1,body weight index ( kg / mnmbr ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
-1,time from study drug administration to coronary revascularization,C0013175;C0040227;C0150270;C0206209;C2349982;C3469597
-1,mmrc dyspnea scale,C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
-1,juvenile myoclonic epilepsy,C0270853
-1,patient population,C0030705;C0032659;C1257890
-1,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
-1,japanese subpopulation,C0376247;C1257890;C1556094
-1,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
-1,procalcitonin ( ng / ml ),C0072027;C0439275
-1,simvastatin nmbr mg plus fenofibrate nmbr mg ( n = nmbr /,C0033228;C0074554;C0332287;C1319635
-1,plasma creatine,C0010286;C0032105;C1550098;C4521445
-1,nmbr % cit,C0008864;C0523573;C1427027;C4553421
-1,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
-1,nmbr — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
-1,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
-1,placebo → golimumab nmbr mg / nmbr mga,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
-1,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
-1,plasma dha,C0032105;C0142831;C1550098;C2348308;C4521445
-1,nmbr n qi,C0369718;C0376586;C0441922
-1,metabolic syndrome w / o tnmbrdm,C0011816;C0524620;C3250443
-1,卞 at discharge .,C0012621;C0030685;C2926602
-1,plasma lipoproteins,C0023820;C0032105;C1550098;C4521445
-1,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
-1,patients in the placebo group  nt - probnp values were reported for nmbr patients,C0030705;C0032042;C0042295;C0441833;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
-1,placebo nmbr . nmbr pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
-1,< nmbr kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
-1,ixekizumab every nmbr weeks ( n = nmbr ),C3489764
-1,pre - bronchodilator fefnmbr . nmbr ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
-1,risk group,C0242444
-1,copd population ( n = nmbr ),C0024117;C0032659;C1257890;C1412502;C3714496
-1,itca nmbr nmbr mg / day ( n = nmbr ),C0165330;C0439422
-1,isolated upper gastrointestinal disease behavior,C0004927;C0205409;C0810300;C1548221;C2707008
-1,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
-1,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977
-1,nmbr to < nmbr cel,C0208736;C0346421;C0439237;C1413336
-1,long ( inmbr years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
-1,lifestyle,C0023676
-1,pr / virgin islands,C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
-1,anakinra,C0245109
-1,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
-1,pravastatin sodium,C0700474
-1,nmbr - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
-1,nmbr - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
-1,potassium - sparing diuretic,C0304490;C3536751
-1,postoperative use of p - blocker,C0032790;C1524063
-1,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151
-1,aphasia,C0003537
-1,patient classification,C0008902;C0008903;C0030705;C0678229
-1,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
-1,unstable angina > nmbr mo ago,C0002965;C0026544;C0332177
-1,elevated troponin t ( > nmbr . nmbr / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
-1,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
-1,iv - nmbr mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
-1,patient - reported outcomes,C2987124
-1,cardiac pacemaker — no . ( % ),C0030163;C0037189
-1,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
-1,mca,C0149566
-1,patient ' s ga,C0016993;C0030705
-1,postbaseline binding antibodies,C0003241;C1145667;C1167622
-1,asthma population ( n = nmbr ),C0004096;C0032659;C1257890;C2984299
-1,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
-1,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
-1,i rosuvastatin ( n = nmbr ),C0021966;C0221138;C0965129
-1,bumetanide,C0006376
-1,baseline lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0168634;C0439282;C1096202;C1439335;C1442488
-1,hf symptoms and signs,C0018488;C0683368;C1313497;C1457887;C1538440;C3273279
-1,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C1313497;C1538440;C3273279
-1,baseline ics > nmbr pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0815320;C1442488;C2827928;C4551720
-1,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
-1,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
-1,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
-1,baseline los angeles grade of eo,C0024015;C0168634;C1442488
-1,baseline hemoglobin aj^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
-1,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
-1,baseline mean seated sbp,C0085805;C0168634;C0277814;C0444504;C1283233;C1442488;C2347634;C2348143
-1,baseline metformin,C0025598;C0168634;C1442488
-1,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
-1,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
-1,cox - nmbr selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
-1,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
-1,baseline hbanmbrc concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
-1,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
-1,south asia,C0037723;C1519427
-1,somnolence,C0013144;C2830004;C4553740
-1,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
-1,sotagliflozin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
-1,baseline dipeptidyl peptidase nmbr,C0022709;C0168634;C1442488
-1,south africa / south america,C0001737;C0002454;C0037712;C0037713
-1,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
-1,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
-1,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
-1,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
-1,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
-1,high - density lipoprotein cholesterol metabolic syndrome,C0023822;C0524620
-1,southern europe,C0037724
-1,squamous cell carcinoma,C0007137;C1302853
-1,time to balloon / needle,C0027551;C0040223;C0336867;C0441144;C1882041;C3541383
-1,new zealand,C0027978;C0324547
-1,baseline pava,C0135567;C0168634;C1442488
-1,baseline dasnmbr,C0051767;C0057671;C0168634;C1442488
-1,baseline tc,C0039411;C0040642;C0041405;C0041698;C0168634;C1442488;C1824670;C3272447;C4522122
-1,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
-1,baseline sitting sbp,C0085805;C0168634;C0277814;C1442488;C2584297;C4050224
-1,orthopaedic,C0029355
-1,baseline skin pain vas,C0042815;C0168634;C0241136;C0444099;C1123023;C1442488;C1963195;C3536884;C3827561;C4520765
-1,stage i ( gfr > nmbr ml / min per nmbr . nmbr mnmbr ) and stage v ( gfr < nmbr ml / min per nmbr . nmbr mnmbr ) were not considered because they included only nmbr and nmbr patient,C0007591;C0017654;C0021966;C0023806;C0221138;C0369637;C0439445;C0441766;C0441923;C0456533;C0702093;C1424601;C1524029;C3813700
-1,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
-1,baseline to eom placebo ( n = nmbr ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
-1,muscle twitching,C0015644;C0231530
-1,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
-1,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
-1,hemoglobin aj^ ( % ),C0004486;C0019046;C0230613
-1,baseline upgr > nmbr gm / gm ( nmbr mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
-1,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
-1,israel,C0022271
-1,baseline sitting dbp,C0168634;C0277814;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
-1,qvanmbr nmbr / nmbr | ig od n = nmbr,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
-1,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
-1,baseline risk factors,C0035648;C0168634;C1442488;C1553898
-1,st - segment deviation timi risk score,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
-1,baseline pfd,C0016065;C0168634;C1442488;C1839454;C2827389;C3889643
-1,baseline prediabetes,C0168634;C0362046;C1442488
-1,st ‐ str ≥ nmbr % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
-1,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C1442488
-1,baseline procedure,C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
-1,progestins,C0033306
-1,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
-1,legs only,C0205171;C1140621;C1720467
-1,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
-1,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
-1,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
-1,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
-1,fistula at baseline,C0016169;C0168634;C1442488
-1,baseline demographics,C0011298;C0168634;C1442488;C1704791
-1,solifenacin ( n = nmbr ),C1099677
-1,criteria for subcortical vad ( by mri ),C0077973;C0243161;C0815275
-1,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
-1,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
-1,sf ‐ nmbr health survey,C0018762;C0037712
-1,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
-1,history of high cholesterol ( a ) nmbr,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
-1,avp pg / ml,C0439297;C1098706;C1568204;C1708407
-1,shared epitope,C0003316;C0237876;C1522138
-1,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
-1,wc ( cm ),C0013123;C2825512
-1,% pred,C0032952;C0044955
-1,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
-1,sildenafil ( n = nmbr ),C0529793
-1,silodosin nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
-1,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fevnmbr    forced expiratory volume in nmbr   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0007450;C0018026;C0024117;C0152277;C0178628;C0205246;C0231958;C0325090;C0424093;C0524517;C0585361;C1304897;C1443200;C2348867;C3665481;C4050461;C4284282
-1,nvf at flex baseline - nmbr < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
-1,time from qualifying stroke to randomization,C0038454;C0040223;C1514624;C3541383;C4554100
-1,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
-1,ras - aldosterone inhibitor^,C0002006;C0002007;C0034678;C0525678;C1514727
-1,acarbose 一 no . ( % ),C0050393
-1,atherectomy,C0162513
-1,o - oinmbr ( - nmbr - nmbr to nmbr - nmbr ),C0029118;C0029434;C0483204
-1,r nmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
-1,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
-1,hip + nmbr vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
-1,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
-1,cox hr ( nmbr % ci ),C0008107;C1565830;C3259781
-1,arthralgia,C0003862;C4551938
-1,atorvastatin nmbr mg ( zi = nmbr ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
-1,"atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment  "" [expressed as number of patients reaching ldl - c goal at week nmbr / number of patients above goal at baseline  ^treatment stratum was defined by intake of atv nmbr or nmbr mg .",C0023824;C0210243;C0286651;C0674679;C1145759;C1334862;C1709380
-1,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
-1,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
-1,hmgcoa rl,C0047420;C1419337;C3539667
-1,sex ( women,C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
-1,ethacrynic acid,C0014963
-1,bacterial pneumonia,C0004626
-1,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
-1,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
-1,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
-1,base,C0002055;C0178499;C1880279
-1,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),C0007820;C0025266;C0280604;C3542407
-1,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
-1,baseline abi,C0168634;C1328319;C1442488;C3888326
-1,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
-1,snp,C0752046;C1527094
-1,sodium,C0037473;C0597484;C3541959;C3714642
-1,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
-1,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0231174;C0680095;C0699733;C2024216;C4554158
-1,social interaction,C0037420
-1,sodium - glucose cotransporter nmbr inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
-1,baseline cdr - sb ( n   = nmbr + nmbr ),C0038111;C0168634;C1442488;C3811240;C4521843
-1,baseline chadsnmbra,C0007928;C0168634;C1413373;C1442488
-1,korea,C0022771
-1,smoking classification,C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
-1,sirolimus - eluting stent use,C0038257;C0042153;C0072980;C0457083;C1947944
-1,sle markers,C0005516;C0024141
-1,sitagliptin nmbr nmbr . nmbr 士 nmbr . nmbr nmbr - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
-1,sitagliptin nmbr nmbr . nmbr 士 nmbr . nmbr fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
-1,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),C0126174;C0456081;C1137094
-1,ama 士 s . e .,C0002461;C0279755;C2825862
-1,sitting systolic blood pressure ( mm hg ),C0277814;C2584297;C4050224
-1,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
-1,sleep,C0037313
-1,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
-1,sleeping problems in the past nmbr weeks ( % ),C0700201;C2987125
-1,all - cause hospitalization,C0015127;C0019993;C1524003
-1,glomerular filtration rate ( ml / min / nmbr . nmbrma,C0017654;C0024443;C0439445;C1561549;C3887485
-1,high ( inmbr % ) baseline hbanmbrc,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
-1,high ( inmbr kg / mnmbr ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
-1,cyclo,C1172566
-1,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0444504;C0815320;C2347634;C2348143;C4551720
-1,monocytes,C0026473
-1,ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446
-1,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
-1,c - peptide tx difference vs pbo,C0006558;C0041403;C1705241;C1705242
-1,sudden cardiac death §,C0085298
-1,sudden death,C0011071;C1964022;C4554103
-1,shoulder pain,C0037011
-1,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
-1,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
-1,hc,C0020268;C0262499;C1413512
-1,sulphonamides,C0038760
-1,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
-1,sun - nmbr ( nmbr ),C0038817;C0376223
-1,surgical repair of vsd or pda > nmbr - year duration,C0018818;C0374711
-1,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
-1,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
-1,subpopulation analyses according to baseline hbanmbrc,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
-1,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
-1,hospitalization for acs,C0019993;C0742343;C4318612
-1,sal nmbr pg ( n = nmbr ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
-1,companion : nmbr - nmbr hours,C0031268;C0335343;C0439227;C0682323
-1,blood bilirubin increased,C0005437;C0005767;C0005768;C0229664
-1,blood glucose - lowering treatments,C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
-1,ranolazine ( n = nmbr ) placebo ( n = nmbr ),C0032042;C0073633;C1696465;C1706408
-1,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
-1,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
-1,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
-1,omeprazole,C0028978
-1,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
-1,number of co - aeds,C0180309;C0237753;C0449788;C3245499
-1,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C1121991
-1,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788
-1,pt baseline ( week nmbr ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
-1,nasopharyngitis,C0027441
-1,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0017654;C0018810;C0054015;C0085805;C0205088;C0332126;C0428883;C0459867;C0488055;C0871470;C1095989;C1275491;C1305855;C1306620;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3889152;C4050156;C4283901;C4284038
-1,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
-1,blisibimod ( n = nmbr ),C3713826
-1,body mass index ( kg / mnmbr ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
-1,bnp — pg / ml  i ,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
-1,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
-1,cardiac death,C0376297
-1,infarct ion w ithin previous nmbr day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
-1,body height ( cm ),C0005890;C0487985
-1,systemic sle medications,C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
-1,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
-1,symptoms onset to first balloon inflation,C0021398;C0205435;C0336867;C0441144;C1279901;C1318493;C4086878
-1,arteriosclerosis,C0003850
-1,body mass index ( mg / mnmbr ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
-1,vegfr ( ng / ml ),C0439275;C1568520
-1,white / caucasian,C0043157
-1,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
-1,body weight reduction > nmbr %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
-1,bmp kg - m “ nmbr,C0053932;C0279266;C1532718;C4281808
-1,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
-1,+ ics / + laba nz nmbr,C0027978;C0815320;C4551720
-1,nph,C0020258;C0027442
-1,< nmbr months in - nmbr kill,C0162388;C0439231;C0681205;C1550555
-1,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
-1,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0020261;C0444504;C1305855;C1319894;C2347634;C2348143
-1,hbanmbrc   at randomization,C0019016;C0034656;C1825777;C3538758
-1,hbanmbrc tx difference vs pbo,C0019016;C0041403;C1705241;C1705242;C1825777;C3538758
-1,bmi nmbr - < nmbr kg / ni - ( n = nmbr / nmbr ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
-1,bmi group ( kg / m^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
-1,left ventricular systolic or diastolic dysfunction,C0039155;C0225897
-1,hbanmbrc ( mmol / mol [se] ),C0019016;C0036919;C1825777;C3538758;C3829066
-1,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < nmbr . nmbr for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than nmbr mg / dl . dblood pressure control defined as < nmbr / nmbr or < nmbr / nmbr in patients with diabetes or a history of renal insufficiency .,C0003211;C0007787;C0085096;C0149721;C0282402;C1305855;C3536840
-1,hbanmbrc ( % patients < nmbr . nmbr % ),C0019016;C0030705;C1825777;C3538758
-1,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
-1,hbanmbrc — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
-1,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom nmbr h urine was collected ( see materials and methods section ) .,C0017480;C0085805;C0428883;C0488055;C0871470;C1305855;C1306620;C2986759;C3854019
-1,subdural / epidural,C0038541;C0228134;C0812144
-1,subcutaneous injections,C0021499
-1,brazil,C0006137
-1,steroid - free cr - nmbr,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
-1,ace inhibitors / sartans,C0003015;C1563745
-1,mean nmbr - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
-1,> nmbr . nmbr mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
-1,patient - reported outcome measures,C4277735
-1,hope ( n = nmbr ),C0392347
-1,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
-1,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
-1,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
-1,vascular history,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
-1,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
-1,cerebral hemorrhage,C2937358
-1,total body ( without head ),C0018670;C0229960;C1706305
-1,stomach,C0038351;C3714551
-1,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
-1,heat failure,C0018837;C0231174;C0680095
-1,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
-1,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
-1,proximal to the splenic flexure,C0205107;C0227387;C4489236
-1,hemoglobin ( < nmbr men,C0019046;C0025266
-1,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
-1,europe i,C0015176;C0021966;C0221138
-1,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0168634;C0449381;C1442488;C4281788
-1,high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
-1,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
-1,statin medication,C0013227;C0360714;C3244316;C4284232
-1,blood leucocyte concentration ( nmbr cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
-1,hematocrit,C0018935;C0518014
-1,statin potency medium ( n = nmbr ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
-1,ifx ( n = nmbr ),C0020823
-1,r elative risk ( nmbr % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
-1,bempedoic acid ( n = nmbr ),C3659310
-1,benazepril - amlodipine group ( n = nmbr ),C0051696;C0053091;C0441848
-1,strain ( % ),C0080194;C0456178;C1518614;C2987481
-1,pctindopnl - indapamide ( n = nmbr ),C0021186
-1,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
-1,study eye characteristics,C0015392;C0700042;C1568011
-1,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
-1,cardiac risk,C0018787;C0035647;C1522601;C4552904
-1,bl bml > nmbr ke / m^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
-1,health practices,C0018684
-1,study nmbr - item short - form general health survey ( sf - nmbr ) can range from nmbr to nmbr for the physical component and from nmbr to nmbr for the mental,C0037712;C0348078;C0376315;C0557651;C1282927;C1522492;C1551338;C1806781;C2350002;C2603343;C3481509;C4255237;C4554251
-1,insulin glargine n ( % ) / nmbrpy,C0030428;C0907402;C3538810
-1,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
-1,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
-1,malaysia,C0024552
-1,eos serum k +,C0302353;C1623465;C1861303
-1,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
-1,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541
-1,intravenous inotropes or vasopressors ( % ),C0348016;C1258199
-1,bladder,C0005682;C4319531
-1,stroke / se,C0036919;C0038454;C4554100
-1,ukraine,C0041580
-1,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
-1,stroke deaths,C0011065;C0038454;C1306577;C4554100
-1,biological,C0005532;C0205460
-1,cox - nmbr selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
-1,biomarkers at baseline,C0005516;C0168634;C1442488
-1,baseline dyslipidemia,C0168634;C0242339;C1442488
-1,biometric parameters,C0005544;C0449381;C2718322
-1,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
-1,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = nmbr ),C0016011;C0168273;C0243077
-1,stroke / embolism,C0013922;C0038454;C1704212;C4554100
-1,duration of dementia symptoms,C0011265;C0436359;C0497327
-1,current cvd / diabetes,C0007222;C0011847;C0011849;C0521116;C1705970
-1,bl bmnmbr < nmbr kg / m^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
-1,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
-1,rituximab,C0393022
-1,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
-1,atenolol use at nmbr month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
-1,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
-1,other atherosclerotic cvdd,C0333482;C1859330
-1,roflumilast ( n = nmbr,C0965618
-1,rivaroxaban nmbr . nmbr mg bid + aspirin nmbr mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
-1,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
-1,computed tomographic angiography,C1536105
-1,all non - mn,C0026327;C0026405;C1518422;C4285072
-1,operative procedure,C0543467;C0677612
-1,rofecoxib,C0762662
-1,rolofylline nmbr mg ( n = nmbr ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
-1,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
-1,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
-1,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
-1,all patients on maximally tolerated statin ± other llt,C0030705;C0360714
-1,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
-1,uti,C0042029;C0077906;C1412376
-1,rosuva  rosuvastatin  sd  standard deviation  tnmbrdm  type nmbr diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
-1,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
-1,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
-1,pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
-1,all - cause mortality ( per nmbr person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
-1,alcohol consumption at baseline,C0001948;C0168634;C1442488
-1,rhinitis,C0035455
-1,rib,C0035561
-1,aldosterone use,C0002006;C0042153;C0457083;C1947944
-1,algorithm nmbr,C0002045;C1553907
-1,all - cause death / stroke / see,C0011065;C0015127;C0038454;C1306577;C1524003;C4082313;C4552775;C4554100
-1,risk ratio [nmbr % cl],C0028873;C0242492;C0596019
-1,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
-1,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
-1,all dulaglutide nmbr . nmbr mg + insulin lispro / insulin glargine ( n = nmbr ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
-1,insulin sensitivity — % §,C0920563;C4049919
-1,femur fracture,C0015802
-1,death from cardiovascular causes,C0007226;C0007465;C3887460
-1,coronary angioplasty or stenting,C0002997;C0190211
-1,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
-1,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
-1,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
-1,homa_ir tx difference vs pbo,C0022065;C0022071;C0041403;C1448132;C1705241;C1705242
-1,% patients with no progression,C0030705;C0242656;C0449258
-1,amiodarone ote at baseline,C0002598;C0168634;C1442488
-1,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
-1,hong kong,C0019907;C2987742
-1,osteitis,C0029400
-1,amlodipine / lisinopril nmbr,C0051696;C0065374
-1,abatacept plus mtx ( n = nmbr ),C0025677;C1417487;C1619966
-1,rv and pulmonary vascular,C0035190;C3889272
-1,no po,C0032729;C0442027
-1,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
-1,vilanterol,C2935023
-1,y es,C0013754;C0205944
-1,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
-1,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
-1,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
-1,digitalis glycoside,C0012253
-1,rosuvastatin + fenofibric acid,C0060179;C0965129
-1,mean ( sd ) fevi / evc,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
-1,sfcnmbr / nmbr pg b . i . d . n = nmbr,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
-1,alleles,C0002085
-1,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
-1,ontario and mcmaster universities osteoarthritis index ( womac ) can range from nmbr to nmbr for the pain subscale,C0029040
-1,copd - placebo ( n = nmbr ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
-1,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
-1,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
-1,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
-1,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
-1,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
-1,rsnmbr ( aa ) & rsnmbr,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
-1,rsnmbr ( ac ) & rsnmbr,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
-1,rsnmbr ( cc ) & rsnmbr,C0008318;C0035970;C3538933;C3714753;C3813325
-1,american indian / native alaskan,C0002460;C0682125
-1,alcohol consumption ( % ) < nmbr drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
-1,hr with edoxaban ( nmbr % ci ),C0008107;C2975435;C3259781
-1,on metformin ir or metformin xr nmbr   mg / d,C0022065;C0022071;C0025598;C1448132
-1,qrs > nmbr msec nmbr - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
-1,egfr ( ckd - epi,C0162734;C1561643;C1739039;C3811844;C3812682;C4281721
-1,age distribution,C0001782
-1,poland,C0032356
-1,hypertrophy,C0020564
-1,hypertrophy per ecg ( n = nmbr nmbr ),C0020564;C1623258
-1,immobilization at randomization,C0020944;C0034656;C4048292
-1,hypertension ( bp > nmbr / nmbr mmhg or using antihypertensive medication ),C0020538;C0037623;C0439475;C1415692;C1708288;C1963138;C4318478
-1,region united states,C0017446;C0041703;C0205147
-1,renal failure,C0035078;C1963154
-1,age of asthma onset,C0004096;C0206132;C2984299;C3175530
-1,osteoprotegerin decreased,C0538161;C1308614;C1336645
-1,hyperlipidaemia therapy use,C0020473;C0039798;C0042153;C0087111;C0428465;C0457083;C1363945;C1947944;C4555212
-1,germany,C0017480
-1,low - density lipoprotein cholesterol tx difference vs pbo,C0023824;C0041403;C1705241;C1705242
-1,hyponatremia,C0020625;C4553967
-1,systolic pulmonary arterial pressure,C0024109;C0039155;C0871470;C1168098;C2707265;C2709248;C4522268
-1,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
-1,age at disease onset,C0012634;C0206132;C3870509
-1,mdrd egfr geometric mean ( cv % ),C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C4048877;C4318503
-1,age at diagnosis of sle,C0024141;C1828181;C3173302
-1,i moderate  nmbr mg of pravastatin ( n = nmbr ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
-1,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
-1,i intensive  nmbr mg of atorvastatin ( n = nmbr ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
-1,i amiodarone,C0002598;C0021966;C0221138
-1,cholecystitis chronic,C0008325;C1963083;C4553186
-1,atv n ( % ),C0210243;C0674679;C1145759;C1334862
-1,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
-1,age at lipid randomization ( y ),C0001779;C0034656;C0065033
-1,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
-1,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
-1,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
-1,renin - angiotensin - aldosterone system blocker,C0086907
-1,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
-1,reteplase,C0256103
-1,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
-1,mean sfnmbr score ( nmbr % ci ),C0008107;C0037712;C3259781;C3533236
-1,air + ig ( n = nmbr ),C0001861;C0021027;C0305052;C0360506;C3536832
-1,estonia,C0014908
-1,albiglutide ( n = nmbr ),C2607479
-1,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
-1,hps,C0242994
-1,hrg,C1437978;C1705020
-1,no smo king,C1311076;C1364142;C1423784
-1,total diuretic dose ( iv + oral ) on day nmbr,C0012798;C0022326;C2986497;C4265176
-1,lipid disorder,C0154251
-1,device group ( n = nmbr ),C0025080;C0441848;C0699733
-1,western europe / australia,C0004340;C0015176;C0043128;C0043129
-1,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
-1,diabetes at randomization,C0011847;C0011849;C0034656
-1,air ( n = nmbr ),C0001861;C3536832
-1,chronic coxnmbr inhibitors,C0085387;C0205191
-1,ors ( nmbr % cis ) :,C0069590;C1963718
-1,nmbr mg qw nmbr . nmbr pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
-1,any cv history / risk factors,C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
-1,mean ( nmbrth tonmbrthquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
-1,hyperkalaemia ( investigator reported ),C0020461;C0035173;C4552983
-1,hypertrophic cardiomyopathy,C0007194;C4551472
-1,requiring assistance,C0018896;C1269765
-1,nmbr mg biw nmbr . nmbr pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
-1,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
-1,no . of coronary vessels with > nmbr % diameter stenosis,C0010075
-1,resistant htn : placebo n = nmbr,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
-1,hydroxychloroquine,C0020336
-1,oral β - adrenergics,C0001637;C0442027;C4521986
-1,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
-1,ainmbr,C0003504;C4551710
-1,rest angina past nmbr h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
-1,baseline hb nmbrg i nmbr n = nmbr,C0062408;C0086706;C0168634;C1442488
-1,on maximum tolerated medications ( % ) median ( nmbrth to nmbrth quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
-1,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
-1,cards,C2930619;C3275277
-1,semuloparin ( n = nmbr ),C2700104
-1,area of retinal hemorrhage within the grid,C0017446;C0035317;C0205146
-1,discharge medication,C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
-1,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
-1,stent plus abciximab,C0038257;C0288672;C0332287
-1,current bone disease,C0005940;C0521116;C1705970
-1,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
-1,semaglutide nmbr . nmbr mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
-1,serms,C0732611
-1,sertraline,C0074393;C0524265
-1,serum nmbr - hydroxyvitamin d,C0020337;C0229671;C1546774;C1550100
-1,serum nmbr ( oh ) d concentrations,C0220853;C0683149
-1,coronary disease,C0010068;C1956346
-1,serum albumin concentration,C0001924;C0036773;C0086045;C0229671;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
-1,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
-1,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
-1,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
-1,plaque ( n,C0011389;C0241148;C0332461;C0333463;C4316797
-1,history of elms,C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
-1,dm medication,C0011816;C0013227;C3244316;C3250443;C4284232
-1,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol ,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
-1,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [standard deviation for medians calculated by ( qnmbr qnmbr ) / nmbr . nmbr] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041004;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C4522122
-1,ohs graduate,C0268353;C1861455
-1,screening hbanmbrc ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
-1,seizure history,C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
-1,self - rated health status,C0018759;C0036588;C0871208;C1551994
-1,apoe enmbr carriers,C0003595;C0007294;C0523511;C1412481
-1,apolipoprotein,C0003591
-1,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
-1,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
-1,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
-1,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
-1,serum biochemistry potassium,C0005477;C0302353;C0543465
-1,observation,C0302523;C0700325;C1964257;C3889687
-1, abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0002680;C0006938;C0037623;C1415692;C1708288;C3887950;C4050020;C4318478
-1,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
-1,associated with an atrial septal defect,C0018817;C0332281
-1,mean baseline ei score,C0022067;C0168634;C0444504;C1414370;C1442488;C2347634;C2348143;C2348481
-1,serum urea nitrogen,C0028158;C0229671;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
-1,history of > nmbr previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
-1,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
-1,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
-1,fevnmbr % pred . ( post - albuterol ),C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
-1,multi vessel ( or left main ),C0005847;C0439064;C3266262
-1,lymphocytes,C0024264;C4018897
-1,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
-1,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
-1,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
-1,prior brachytherapy,C0006098;C0332152;C2826257
-1,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
-1,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
-1,assessment of physical function ( nmbr - nmbr,C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C4049916
-1,mean ( s . d . ) apoc - ll nmbr,C0003594;C0444504;C2347634;C2348143
-1,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
-1,obesity * ( bmnmbr > nmbr kg / mnmbr ),C0006416;C0028754;C1532718;C1963185
-1,serum creatinine concentration and randomization to losartan,C0010294;C0086045;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
-1,asia - pacific region and south africa,C0003980;C0017446;C0205147
-1,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
-1,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
-1,serum fg,C0016703;C0229671;C0439214;C1546774;C1550100;C2348814
-1,digoxin / digitalis glycoside,C0012253;C0012265
-1,aspirin + thienopyridine,C0004057;C1120149
-1,asian itt population total ( n = nmbr ),C0032659;C0078988;C0439175;C0439810;C1257890
-1,serum mg < nmbr . nmbr mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
-1,asian / pacific islander,C0078988;C0242191
-1,serum n - propeptide of type nmbr collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
-1,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
-1,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
-1,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
-1,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0814908;C1522609;C3887950
-1,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
-1,baseline pos frequency per nmbr days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
-1,saxa nmbr mg nmbr metformin ( n nmbr nmbr ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
-1,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
-1,score on the minnesota living with heart failure scaled,C0026183;C0449820;C0595998;C4050231;C4520849;C4551704
-1,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
-1,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
-1,history of upper gl events ( perforations,C0018229;C0019664;C0019665;C0262512;C0262926;C0441471;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
-1,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
-1,saudi arabia,C0036243
-1,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
-1,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
-1,history of thyroid disease,C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
-1,pramlintide,C0537551
-1,omalizumab nmbr mg ( n [ nmbr ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
-1,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0085805;C0369637;C0428883;C0441923;C0488055;C0871420;C0871470;C1306620;C2699239
-1,aspirin i clopidogrel ( n = nmbr,C0004057;C0021966;C0070166;C0221138
-1,etn nmbr mg + mtx n = nmbr,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
-1,anti - hypertensive treatment history,C0003364;C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
-1,hope patients with coronary - artery disease ( n = nmbr ),C0010054;C0010068;C0030705;C0392347;C1956346
-1,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
-1,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
-1,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
-1,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
-1,sacral and / or lumbar,C0036037
-1,hla - bnmbr positive at baseline,C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
-1,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
-1,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
-1,hl 土 nmbr . nmbr,C1453952;C4085347
-1,fibrates,C1449704;C3540783
-1,salmeterol / fluticasone nmbr / nmbr pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
-1,salmeterol / fluticasone nmbr / nmbr   μ g b . i . d .,C0086706;C0939232
-1,history ot chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
-1,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
-1,myopathy,C0026848
-1,mra ( spironolactone or eplerenone ),C0037982;C0243032;C1609165;C3891069
-1,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
-1,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
-1,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
-1,olodaterol nmbrpg,C0030827;C0072225;C1266240;C2934193
-1,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
-1,secondary - prevention cohort,C0009247;C0599755;C0679699
-1,baseline treatments,C0087111;C0168634;C1442488
-1,olodaterol nmbr gg ( n = nmbr ),C0017454;C0018370;C2934193
-1,olmesartan medoxomil nmbrmg / hctznmbr . nmbrmg ( n = nmbr ),C0020261;C0386393;C1319635
-1,any blood,C0005767;C0005768;C0229664
-1,olmesartan medoxomil nmbr mg ( n = nmbr ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
-1,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
-1,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
-1,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
-1,marital status,C0024819;C1716536;C3172566
-1,olmesartan along with diuretic ( n - nmbr ),C0012798;C1098320
-1,( nmbr % ci]h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
-1,chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
-1,ff / vi nmbr / nmbr | ig ( n = nmbr ),C0021027;C0205999;C0305052;C0360506;C4554348
-1,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
-1,anticholinergic use,C0042153;C0242896;C0457083;C1947944;C3537004
-1,antidepressant,C0003289
-1,sbp > nmbrmnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
-1,relative risk ( nmbr % confidence interval ),C0009667;C0242492
-1,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
-1,background aha therapy at screening,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
-1,schwab & england score,C0014282
-1,antithrombin,C0003438;C0003440;C4521254
-1,cerebral thrombosis,C0079102;C0151945;C0795687
-1,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
-1,dilatative,C0002940;C0012359;C0700124;C1322279
-1,history of oxygen use - yes,C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
-1,antihypertensive randomization,C0003364;C0034656
-1,antihypertensive treatments,C0003364;C0087111
-1,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
